8EHQ- 1003- 15228

American Chemistry Council

October 17, 2003

Contain No CBI

RECEIVED OPPT CBIC 03 OCT 20 AM 10: 52

Document Control Office (7407W)
U.S. Environmental Protection Agency
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
1200 Pennsylvania Avenue, NW
Washington, D.C. 20460

RE: TSCA Section 8(e) Follow Up. 8EHQ# 1102-15228A and 1202-15228B

Dear Madam or Sir:

On November 27, 2002 and December 17, 2002, the American Chemistry Council Ethylbenzene Panel submitted, on behalf of its members,[1] two letters pursuant to Section 8(e) of the Toxic Substances Control Act, to inform EPA of preliminary findings on a rat reproductive toxicity range-finding study for ethylbenzene. In the November 27, 2002 letter, the Panel notified EPA of preliminary findings consisting of statistically significant lower body weight on postnatal day 1 for male and female pups of dams that received 1,000 ppm ethylbenzene by inhalation. The December 17, 2002 letter described some additional preliminary findings from the post-weaning phase.

The final report for this study is now available and an electronic copy is enclosed.

If you have any questions, please contact me at 301 924 2006 or Elizabeth_Moran@americanchemistry.com.

RECEIVED OPPT NCIC 2003 OCT 24 PM 3: 40

Yours truly,

Shelby J. Jones for E. Moran

8EHQ-02-15228

Elizabeth J. Moran, Ph.D.
Manager, Ethylbenzene Panel

attachment

8904000002 2

MR 270396

[1] The members of the Ethylbenzene Panel are: ATOFINA Petrochemicals, Inc., BP Amoco Chemical Company, Chevron Phillips Chemical Company, The Dow Chemical Company, GE Plastics, Lyondell Chemical Company, Nova Chemicals, Inc. and Sterling Chemicals Inc.

FINAL REPORT

Volume 1 of 4
(Text and Summary Tables 1-104)

STUDY TITLE

A PILOT INHALATION STUDY FOR A
REPRODUCTIVE TOXICITY STUDY OF
ETHYLBENZENE IN RATS

STUDY NUMBER

WIL-186028

STUDY DIRECTOR

Donald G. Stump, Ph.D., D.A.B.T.

STUDY INITIATION DATE

August 27, 2002

STUDY COMPLETION DATE

August 1, 2003

PERFORMING LABORATORY

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

AMERICAN CHEMISTRY COUNCIL CONTRACT NUMBER

EB-13.0-VCCEP-Research-WIL

SPONSOR

American Chemistry Council
Ethylbenzene Panel
1300 Wilson Boulevard
Arlington, VA 22209

COMPLIANCE STATEMENT

This study, designated WIL-186028, was conducted in compliance with the United States Environmental Protection Agency (EPA) Good Laboratory Practice Standards (40 CFR Part 792), September 18, 1989; the Organisation for Economic Cooperation and Development (OECD) Principles of Good Laboratory Practice [C (97) 186/Final], November 26, 1997; the Japanese Ministry of International Trade and Industry (MITI) Directive 31, March 1984, Kanpogyo No. 39 Environmental Agency, Kikoyoko No. 85; the standard operating procedures of WIL Research Laboratories, Inc., and the protocol as approved by the sponsor. A Certificate of Analysis was provided by the sponsor (presented in Appendix A); the characterization analyses were conducted according to Good Laboratory Practices (GLP).

Donald G. Stump

Donald G. Stump, Ph.D., D.A.B.T.
Associate Director, Developmental and
Reproductive Toxicology
Study Director

8/1/03
Date

TABLE OF CONTENTS

VOLUME 1 Page

Compliance Statement **2**
Table Of Contents **3**
Index Of Figures **6**
Index Of Tables **7**
Index Of Appendices **21**
1. Summary **22**
1.1. Objective 22
1.2. Study Design 22
1.3. Results 24
1.4. Conclusions 25
2. General Study Information And Key Study Dates **26**
2.1. General Study Information 26
2.2. Key Study Dates 27
3. Study Design **28**
4. Experimental Procedures – Materials And Methods **30**
4.1. Test And Control Articles 30
4.1.1. Test Article Identification 30
4.1.2. Vehicle Identification 31
4.1.3. Test Atmosphere Monitoring 31
4.1.4. Exposure Methods 31
4.1.5. Preparation Of Dosing Formulations 34
4.1.6. Sampling And Analyses 34
4.1.6.1. Test Article Characterization And Stability 35
4.1.6.2. Homogeneity And Stability Of The Test Article Formulations 35
4.2. F_0 Animal Receipt And Acclimation 35
4.3. F_0 And F_1 Animal Housing 36
4.4. Diet, Drinking Water And Maintenance Of F_0 And F_1 Animals 36

VOLUME 1 (continued) Page

4.5. Environmental Conditions 37
4.6. Assignment Of F_0 Animals To Treatment Groups 38
5. Parameters Evaluated 40
5.1. F_0 And Selected F_1 Offspring Observations 40
5.1.1. Clinical Observations And Mortality 40
5.1.2. Body Weights 40
5.1.3. Food Consumption 41
5.2. F_0 Reproductive Performance 41
5.2.1. Breeding Procedures 41
5.3. F_0 Parturition 42
5.4. F_1 Litter Data 42
5.4.1. Litter Viability And Deaths 42
5.4.2. Litter Reduction 43
5.4.3. Clinical Observations 43
5.4.4. Body Weights 43
5.4.5. Sex Determination 43
5.4.6. Calculation Of Litter Parameters 44
5.4.7. Weaning And Selection 44
5.5. Anatomic Pathology 45
5.5.1. Macroscopic Examinations 45
5.5.1.1. F_0 Generation 45
5.5.1.2. F_1 Pups 45
5.5.2. Organ Weights 46
5.6. Statistical Methods 46
5.7. Data Retention 47
6. Results 48
6.1. Analytical Chemistry 48
6.2. F_0 Generation 50
6.2.1. Clinical Observations And Survival 50

VOLUME 1 (continued) Page

6.2.2. Body Weights And Food Consumption 50
6.2.2.1. Males 50
6.2.2.2. Females 51
6.2.3. Reproductive Performance 52
6.3. F_1 Litter Data 52
6.4. Macroscopic Examinations And Organ Weight Data 55
6.4.1. F_0 Generation 55
6.4.2. F_1 Pups Found Dead 56
6.5. F_1 Generation - PND 22-33 56
6.5.1. Clinical Observations And Survival 56
6.5.2. Body Weights 57
6.5.3. Macroscopic Examination - Unscheduled Necropsies 58
6.6. F_1 Generation - PND 29-33 58
6.6.1. Clinical Observations And Survival 58
6.6.2. Body Weights 59
7. Discussion 60
7.1. Conclusions 61
8. Key Study Personnel and Report Submission 62
9. Quality Assurance Unit Statement 64
9.1. Phases Inspected 64
9.2. Approval 66
10. References 67
11. Deviations From The Protocol 68

INDEX OF FIGURES

VOLUME 1 (continued) Page

1. Summary Of Body Weights [G] (F_0 Males) 71
2. Summary Of Body Weights [G] (F_0 Females - Pre-Mating) 72
3. Summary Of Body Weights During Gestation (F_0 Females) 73
4. Summary Of Body Weights During Lactation (F_0 Females - Inhalation Phase) 74
5. Summary Of Body Weights During Lactation (F_0 Females - Inhalation/Gavage Phase) 75
6. Summary Of Offspring Weights [G] (F_1 Males - Inhalation Phase) 76
7. Summary Of Offspring Weights [G] (F_1 Females - Inhalation Phase) 77
8. Summary Of Offspring Weights [G] (F_1 Males - Inhalation/Gavage Phase) 78
9. Summary Of Offspring Weights [G] (F_1 Females - Inhalation/Gavage Phase) 79
10. Summary Of Body Weights [G] (F_1 Males - Inhalation Phase - PND 22-33) 80
11. Summary Of Body Weights [G] (F_1 Females - Inhalation Phase - PND 22-33) 81
12. Summary Of Body Weights [G] (F_1 Males - Inhalation/Gavage Phase - PND 22-33) 82
13. Summary Of Body Weights [G] (F_1 Females - Inhalation/Gavage Phase - PND 22-33) 83
14. Summary Of Body Weights [G] (F_1 Males - Inhalation Phase - PND 29-33) 84
15. Summary Of Body Weights [G] (F_1 Females - Inhalation Phase - PND 29-33) 85
16. Summary Of Body Weights [G] (F_1 Males - Inhalation/Gavage Phase - PND 29-33) 86
17. Summary Of Body Weights [G] (F_1 Females - Inhalation/Gavage Phase - PND 29-33) 87

INDEX OF TABLES

VOLUME 1 (continued) Page

SUMMARY DATA - F_0 GENERATION

1. Summary Of Survival And Disposition (F_0 Males) 89

2. Summary Of Survival And Disposition (F_0 Females - Pre-Mating/Gestation) 90

3. Summary Of Survival And Disposition
(F_0 Females - Lactation - Inhalation Phase) 91

4. Summary Of Survival And Disposition
(F_0 Females - Lactation - Inhalation/Gavage Phase) 92

5. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Males - Detailed Physical Examinations) 93

6. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Males - Prior To Exposure) 94

7. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Males - Midpoint Of Exposure) 95

8. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Males - 1-Hour Post-Exposure) 96

9. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Females - Pre-Mating/Gestation - Detailed Physical Examinations) 97

10. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Females - Pre-Mating/Gestation - Prior To Exposure) 98

11. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0
Females - Pre-Mating/Gestation - Midpoint Of Exposure) 99

12. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Females - Pre-Mating/Gestation - 1-Hour Post-Exposure) 100

13. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_0 Females - Lactation - Inhalation Phase - Detailed Physical Examinations) 101

VOLUME 1 (continued) Page

14. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation Phase - Prior To Exposure) 103

15. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation Phase - Midpoint Of Exposure) 104

16. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation Phase - 1-Hour Post-Exposure) 105

17. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - Detailed Physical Examinations) 106

18. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - Prior To Gavage Dosing) 107

19. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - 1-Hour Post-Gavage Dosing) 108

20. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - Prior To Exposure) 109

21. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - Midpoint Of Exposure) 110

22. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_0 Females - Lactation - Inhalation/Gavage Phase - 1-Hour Post-Exposure) 111

23. Summary Of Body Weights [G] (F_0 Males) 112

24. Summary Of Body Weight Changes [G] (F_0 Males) 113

25. Summary Of Cumulative Body Weight Changes [G] (F_0 Males) 114

26. Summary Of Weekly Food Consumption [G/Animal/Day] (F_0 Males) 115

27. Summary Of Weekly Food Consumption [G/Kg/Day] (F_0 Males) 116

28. Summary Of Food Efficiency (F_0 Males) 117

29. Summary Of Body Weights [G] (F_0 Females - Pre-Mating) 118

VOLUME 1 (continued) Page

30. Summary Of Body Weight Changes [G] (F_0 Females - Pre-Mating) 119

31. Summary Of Cumulative Body Weight Changes [G]
(F_0 Females - Pre-Mating) 120

32. Summary Of Weekly Food Consumption [G/Animal/Day]
(F_0 Females - Pre-Mating) 121

33. Summary Of Weekly Food Consumption [G/Kg/Day]
(F_0 Females - Pre-Mating) 122

34. Summary Of Food Efficiency (F_0 Females - Pre-Mating) 123

35. Summary Of Body Weights During Gestation [G] (F_0 Females) 124

36. Summary Of Body Weight Changes During Gestation [G] (F_0 Females) 125

37. Summary Of Food Consumption During Gestation [G/Animal/Day]
(F_0 Females) 126

38. Summary Of Food Consumption During Gestation [G/Kg/Day] (F_0 Females) 127

39. Summary Of Food Efficiency During Gestation (F_0 Females) 128

40. Summary Of Body Weights During Lactation [G]
(F_0 Females - Inhalation Phase) 129

41. Summary Of Body Weight Changes During Lactation [G]
(F_0 Females - Inhalation Phase) 130

42. Summary Of Food Consumption During Lactation [G/Animal/Day]
(F_0 Females - Inhalation Phase) 131

43. Summary Of Food Consumption During Lactation [G/Kg/Day]
(F_0 Females - Inhalation Phase) 132

44. Summary Of Food Efficiency During Lactation
(F_0 Females - Inhalation Phase) 133

45. Summary Of Body Weights During Lactation [G]
(F_0 Females - Inhalation/Gavage Phase) 134

VOLUME 1 (continued) Page

46. Summary Of Body Weight Changes During Lactation [G] (F_0 Females - Inhalation/Gavage Phase) 135

47. Summary Of Food Consumption During Lactation [G/Animal/Day] (F_0 Females - Inhalation/Gavage Phase) 136

48. Summary Of Food Consumption During Lactation [G/Kg/Day] (F_0 Females - Inhalation/Gavage Phase) 137

49. Summary Of Food Efficiency During Lactation (F_0 Females - Inhalation/Gavage Phase) 138

50. Summary Of Reproductive Performance (F_0) 139

51. Summary Of Gestation Lengths [Days] (F_0 Females) 142

52. Summary Of Implantation Sites (F_0 Females) 143

SUMMARY DATA - F_1 LITTERS

53. Summary Of PND 0 Litter Data (F_1 - Combined Phases) 144

54. Summary Of Offspring Weights [G] (F_1 - Combined Phases) 145

55. Summary Of Postnatal Survival [% Per Litter] (F_1 - Inhalation Phase) 146

56. Summary Of Pup Clinical Observations (F_1 - Inhalation Phase) 148

57. Summary Of Offspring Weights [G] (F_1 - Inhalation Phase) 150

58. Summary Of Offspring Weight Changes [G] (F_1 - Inhalation Phase) 152

59. Summary Of Postnatal Survival [% Per Litter] (F_1 - Inhalation/Gavage Phase) 154

60. Summary Of Pup Clinical Observations (F_1 - Inhalation/Gavage Phase) 156

61. Summary Of Offspring Weights [G] (F_1 - Inhalation/Gavage Phase) 158

62. Summary Of Offspring Weight Changes [G] (F_1 - Inhalation/Gavage Phase) 160

VOLUME 1 (continued) Page

SUMMARY DATA - PATHOLOGY

63. Summary Of Macroscopic Findings (F_0 Males - Scheduled Necropsy) 162

64. Summary Of Organ Weights [G] (F_0 Males - Scheduled Necropsy) 163

65. Summary Of Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Males - Scheduled Necropsy) 164

66. Summary Of Macroscopic Findings (F_0 Females - Inhalation Phase - Scheduled Necropsy) 165

67. Summary Of Organ Weights [G] (F_0 Females - Inhalation Phase - Scheduled Necropsy) 166

68. Summary Of Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Inhalation Phase - Scheduled Necropsy) 167

69. Summary Of Macroscopic Findings (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 168

70. Summary Of Organ Weights [G] (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 169

71. Summary Of Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 170

72. Summary Of Pup Necropsy Findings - Found Dead Pups (F_1 - Inhalation Phase) 171

73. Summary Of Pup Necropsy Findings - Found Dead Pups (F_1 - Inhalation/Gavage Phase) 172

SUMMARY DATA - F_1 GENERATION - PND 22-33

74. Summary Of Survival And Disposition (F_1 - Inhalation Phase - PND 22-33) 173

75. Summary Of Survival And Disposition (F_1 - Inhalation/Gavage Phase - PND 22-33) 175

VOLUME 1 (continued) Page

76. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation Phase - Detailed Physical Examinations - PND 22-33) 177

77. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation Phase - Prior To Exposure - PND 22-33) 179

78. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation Phase - Midpoint Of Exposure - PND 22-33) 181

79. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation Phase - 1-Hour Post-Exposure - PND 22-33) 183

80. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation/Gavage Phase - Detailed Physical Examinations - PND 22-33) 185

81. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation/Gavage Phase - Prior To Exposure - PND 22-33) 187

82. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation/Gavage Phase - Midpoint Of Exposure - PND 22-33) 189

83. Summary Of Clinical Findings: Total Occurrence/No. Of Animals (F_1 - Inhalation/Gavage Phase - 1-Hour Post-Exposure - PND 22-33) 191

84. Summary Of Body Weights [G] (F_1 - Inhalation Phase - PND 22-33) 193

85. Summary Of Body Weight Changes [G] (F_1 - Inhalation Phase - PND 22-33) 197

86. Summary Of Body Weights [G] (F_1 - Inhalation/Gavage Phase - PND 22-33) 201

87. Summary Of Body Weight Changes [G] (F_1 - Inhalation/Gavage Phase - PND 22-33) 205

88. Summary Of Macroscopic Findings (F_1 - Inhalation Phase - Unscheduled Deaths - PND 22-33) 209

89. Summary Of Macroscopic Findings (F_1 - Inhalation/Gavage Phase - Unscheduled Deaths - PND 22-33) 210

VOLUME 1 (continued) Page

90. Summary Of Macroscopic Findings
(F_1 - Inhalation/Gavage Phase - Pups Removed From Animal Room - PND 22-33) 211

SUMMARY DATA - F_1 GENERATION - PND 29-33

91. Summary Of Survival And Disposition (F_1 - Inhalation Phase - PND 29-33) 212

92. Summary Of Survival And Disposition
(F_1 - Inhalation/Gavage Phase - PND 29-33) 214

93. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation Phase - Detailed Physical Examinations - PND 29-33) 216

94. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation Phase - Prior To Exposure - PND 29-33) 218

95. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation Phase - Midpoint Of Exposure - PND 29-33) 220

96. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation Phase - 1-Hour Post-Exposure - PND 29-33) 222

97. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation/Gavage Phase - Detailed Physical Examinations - PND 29-33) 224

98. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation/Gavage Phase - Prior To Exposure - PND 29-33) 226

99. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation/Gavage Phase - Midpoint Of Exposure - PND 29-33) 228

100. Summary Of Clinical Findings: Total Occurrence/No. Of Animals
(F_1 - Inhalation/Gavage Phase - 1-Hour Post-Exposure - PND 29-33) 230

101. Summary Of Body Weights [G] (F_1 - Inhalation Phase - PND 29-33) 232

102. Summary Of Body Weight Changes [G]
(F_1 - Inhalation Phase - PND 29-33) 234

VOLUME 1 (continued) Page

103. Summary Of Body Weights [G]
(F_1 - Inhalation/Gavage Phase - PND 29-33) 236

104. Summary Of Body Weight Changes [G]
(F_1 - Inhalation/Gavage Phase - PND 29-33) 238

VOLUME 2

INDIVIDUAL DATA - F_0 GENERATION

105. Individual Survival And Disposition (F_0 Males) 242

106. Individual Survival And Disposition (F_0 Females - Pre-Mating/Gestation) 245

107. Individual Survival And Disposition
(F_0 Females - Lactation - Inhalation Phase) 246

108. Individual Survival And Disposition
(F_0 Females - Lactation - Inhalation/Gavage Phase) 248

109. Individual Clinical Observations [Positive Findings Only]
(F_0 Males - Detailed Physical Examinations) 250

110. Individual Clinical Observations [Positive Findings Only]
(F_0 Males - Prior To Exposure) 255

111. Individual Clinical Observations (F_0 Males - 1-Hour Post-Exposure) 256

112. Individual Clinical Observations [Positive Findings Only]
(F_0 Females - Pre-Mating/Gestation - Detailed Physical Examinations) 257

113. Individual Clinical Observations
(F_0 Females - Pre-Mating/Gestation - Prior To Exposure) 263

114. Individual Clinical Observations
(F_0 Females - Pre-Mating/Gestation - Midpoint Of Exposure) 264

115. Individual Clinical Observations
(F_0 Females - Pre-Mating/Gestation - 1-Hour Post-Exposure) 265

VOLUME 2 (continued) Page

116. Individual Clinical Observations [Positive Findings Only] (F_0 Females - Lactation - Inhalation Phase - Detailed Physical Examinations) 266

117. Individual Clinical Observations (F_0 Females - Lactation - Inhalation Phase - Prior To Exposure) 272

118. Individual Clinical Observations [Positive Findings Only] (F_0 Females - Lactation - Inhalation/Gavage Phase - Detailed Physical Examinations) 273

119. Individual Clinical Observations (F_0 Females - Lactation - Inhalation/Gavage Phase - Prior To Gavage Dosing) 279

120. Individual Clinical Observations (F_0 Females - Lactation - Inhalation/Gavage Phase - 1-Hour Post-Gavage Dosing) 280

121. Individual Clinical Observations (F_0 Females - Lactation - Inhalation/Gavage Phase - Prior To Exposure) 281

122. Individual Body Weights [G] (F_0 Males) 282

123. Individual Body Weight Changes [G] (F_0 Males) 286

123A. Individual Cumulative Body Weight Changes [G] (F_0 Males) 290

124. Individual Food Consumption [G/Animal/Day] (F_0 Males) 294

125. Individual Food Consumption [G/Kg/Day] (F_0 Males) 298

126. Individual Food Efficiency (F_0 Males) 302

127. Individual Body Weights [G] (F_0 Females - Pre-Mating) 306

128. Individual Body Weight Changes [G] (F_0 Females - Pre-Mating) 314

128A. Individual Cumulative Body Weight Changes [G] (F_0 Females - Pre-Mating) 318

129. Individual Food Consumption [G/Animal/Day] (F_0 Females - Pre-Mating) 322

130. Individual Food Consumption [G/Kg/Day] (F_0 Females - Pre-Mating) 326

VOLUME 2 (continued) Page

131. Individual Food Efficiency (F_0 Females - Pre-Mating) 330

132. Individual Body Weights During Gestation [G] (F_0 Females) 334

133. Individual Body Weight Changes During Gestation [G] (F_0 Females) 338

134. Individual Food Consumption During Gestation [G/Animal/Day] (F_0 Females) 342

135. Individual Food Consumption During Gestation [G/Kg/Day] (F_0 Females) 346

136. Individual Food Efficiency During Gestation (F_0 Females) 350

137. Individual Body Weights During Lactation [G] (F_0 Females - Inhalation Phase) 354

138. Individual Body Weight Changes During Lactation [G] (F_0 Females - Inhalation Phase) 358

139. Individual Food Consumption During Lactation [G/Animal/Day] (F_0 Females - Inhalation Phase) 362

140. Individual Food Consumption During Lactation [G/Kg/Day] (F_0 Females - Inhalation Phase) 366

141. Individual Food Efficiency During Lactation (F_0 Females - Inhalation Phase) 370

142. Individual Body Weights During Lactation [G] (F_0 Females - Inhalation/Gavage Phase) 374

143. Individual Body Weight Changes During Lactation [G] (F_0 Females - Inhalation/Gavage Phase) 378

144. Individual Food Consumption During Lactation [G/Animal/Day] (F_0 Females - Inhalation/Gavage Phase) 382

145. Individual Food Consumption During Lactation [G/Kg/Day] (F_0 Females - Inhalation/Gavage Phase) 386

146. Individual Food Efficiency During Lactation (F_0 Females - Inhalation/Gavage Phase) 390

147. Individual Reproductive Performance (F_0) 394

VOLUME 2 (continued) Page

148. Individual Gestation Lengths [Days] (F_0 Females) 398

149. Individual Implantation Sites (F_0 Females) 399

INDIVIDUAL DATA - F_1 LITTERS

150. Individual Litter Viability (F_1 - Inhalation Phase) 403

151. Individual Pup Viability (F_1 - Inhalation Phase) 407

152. Individual Pup Clinical Observations (F_1 - Inhalation Phase) 412

153. Individual Offspring Weights [G] (F_1 - Inhalation Phase) 441

154. Individual Offspring Weight Changes [G] (F_1 - Inhalation Phase) 467

155. Individual Litter Viability (F_1 - Inhalation/Gavage Phase) 493

156. Individual Pup Viability (F_1 - Inhalation/Gavage Phase) 497

157. Individual Pup Clinical Observations (F_1 - Inhalation/Gavage Phase) 503

158. Individual Offspring Weights [G] (F_1 - Inhalation/Gavage Phase) 529

159. Individual Offspring Weight Changes [G] (F_1 - Inhalation/Gavage Phase) 557

VOLUME 3

INDIVIDUAL DATA - PATHOLOGY

160. Individual Macroscopic Findings (F_0 Males - Scheduled Necropsy) 586

161. Individual Organ Weights And Final Body Weights [G]
(F_0 Males - Scheduled Necropsy) 666

162. Individual Organ Weights Relative To Final Body Weights [G/100 G]
(F_0 Males - Scheduled Necropsy) 670

163. Individual Macroscopic Findings
(F_0 Females - Inhalation Phase - Scheduled Necropsy) 674

164. Individual Organ Weights And Final Body Weights [G]
(F_0 Females - Inhalation Phase - Scheduled Necropsy) 708

VOLUME 3 (continued) Page

165. Individual Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Inhalation Phase - Scheduled Necropsy) 712

166. Individual Macroscopic Findings (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 716

167. Individual Organ Weights And Final Body Weights [G] (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 752

168. Individual Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Inhalation/Gavage Phase - Scheduled Necropsy) 756

169. Individual Macroscopic Findings (F_0 Females - Failed To Deliver) 760

170. Individual Organ Weights And Final Body Weights [G] (F_0 Females - Failed To Deliver) 769

171. Individual Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Failed To Deliver) 772

172. Individual Macroscopic Findings (F_0 Females - Inhalation Phase - Total Litter Loss) 775

173. Individual Organ Weights And Final Body Weights [G] (F_0 Females - Inhalation Phase - Total Litter Loss) 777

174. Individual Organ Weights Relative To Final Body Weights [G/100 G] (F_0 Females - Inhalation Phase - Total Litter Loss) 779

175. Individual Pup Necropsy Findings (F_1 - Inhalation Phase) 781

176. Individual Pup Necropsy Findings (F_1 - Inhalation/Gavage Phase) 785

INDIVIDUAL DATA - F_1 GENERATION - PND 22-33

177. Individual Survival And Disposition (F_1 - Inhalation Phase - PND 22-33) 789

178. Individual Survival And Disposition (F_1 - Inhalation/Gavage Phase - PND 22-33) 793

179. Individual Clinical Observations [Positive Findings Only] (F_1 - Inhalation Phase - Detailed Physical Examinations - PND 22-33) 797

VOLUME 3 (continued) Page

180. Individual Clinical Observations
(F_1 - Inhalation Phase - Prior To Exposure - PND 22-33) 800

181. Individual Clinical Observations
(F_1 - Inhalation Phase - 1-Hour Post-Exposure - PND 22-33) 801

182. Individual Clinical Observations [Positive Findings Only]
(F_1 - Inhalation/Gavage Phase - Detailed Physical Examinations - PND 22-33) 803

183. Individual Clinical Observations
(F_1 - Inhalation/Gavage Phase - Prior To Exposure - PND 22-33) 806

184. Individual Clinical Observations
(F_1 - Inhalation/Gavage Phase - Midpoint Of Exposure - PND 22-33) 807

185. Individual Clinical Observations
(F_1 - Inhalation/Gavage Phase - 1-Hour Post-Exposure - PND 22-33) 808

186. Individual Body Weights [G] (F_1 - Inhalation Phase - PND 22-33) 810

187. Individual Body Weight Changes [G] (F_1 - Inhalation Phase - PND 22-33) 826

188. Individual Body Weights [G] (F_1 - Inhalation/Gavage Phase - PND 22-33) 834

189. Individual Body Weight Changes [G]
(F_1 - Inhalation/Gavage Phase - PND 22-33) 850

190. Individual Macroscopic Findings
(F_1 - Inhalation Phase - Unscheduled Deaths - PND 22-33) 866

191. Individual Macroscopic Findings
(F_1 - Inhalation/Gavage Phase - Unscheduled Deaths - PND 22-33) 870

192. Individual Macroscopic Findings
(F_1 - Inhalation/Gavage Phase - Pups Removed From Animal Room - PND 22-33) 876

INDIVIDUAL DATA - F_1 GENERATION - PND 22-33

193. Individual Survival And Disposition (F_1 - Inhalation Phase - PND 29-33) 878

VOLUME 3 (continued) Page

194. Individual Survival And Disposition
(F_1 - Inhalation/Gavage Phase - PND 29-33) 882

195. Individual Clinical Observations [Positive Findings Only]
(F_1 - Inhalation Phase - Detailed Physical Examinations - PND 29-33) 886

196. Individual Clinical Observations [Positive Findings Only]
(F_1 - Inhalation/Gavage Phase - Detailed Physical Examinations -
PND 29-33) 889

197. Individual Body Weights [G] (F_1 - Inhalation Phase - PND 29-33) 892

198. Individual Body Weight Changes [G] (F_1 - Inhalation Phase - PND 29-33) 900

199. Individual Body Weights [G] (F_1 - Inhalation/Gavage Phase - PND 29-33) 908

200. Individual Body Weight Changes [G] (F_1 - Inhalation/Gavage Phase -
PND 29-33) 916

INDEX OF APPENDICES

VOLUME 4 Page

A. Certificate Of Analysis (Sponsor-Provided Data) 925

B. Analytical Chemistry Report (WIL Research Laboratories, Inc.) 937

C. Inhalation Report (WIL Research Laboratories, Inc.) 1009

D. Estimation Of Oral Doses Report (Sponsor-Provided Data) 1066

E. Nesting Material Analyses (Provided by the Manufacturer) 1072

F. Certified Feed Analyses (Provided by the Manufacturer) 1078

G. Water Analyses 1084

H. Animal Room Environmental Conditions 1088

I. WIL Reproductive Historical Control Data [Crl:CD®(SD)IGS BR Rats] 1096

J. Study Protocol 1121

1. SUMMARY

1.1. OBJECTIVE

This study was conducted to determine the exposure levels of the test article, ethylbenzene, that will generate minimal maternal and weanling toxicity but allow complete gestation, parturition and successful lactation, to determine the feasibility of gavage dosing of dams during lactation days 1-4, and to determine whether to begin inhalation exposures of F_1 weanlings on PND 22 or PND 29 in a subsequent two-generation reproductive toxicity study.

1.2. STUDY DESIGN

Four groups of male and female Crl:CD®(SD)IGS BR rats (20/sex/group) were exposed to either clean filtered air or vapor atmospheres of the test article. Target test article concentrations were 100, 500 and 1000 ppm (parts per million) for the F_0 generation and selected F_1 weanlings. Mean measured inhalation exposure concentrations were 99, 500 and 1008 ppm for the F_0 generation and 101, 498 and 1002 ppm for the F_1 generation. F_0 males were exposed to the test atmospheres for a minimum of four weeks. F_0 females were exposed to the test atmospheres for a minimum of two weeks prior to mating, throughout the mating period and from gestation day 0 through gestation day 20. At this time, one-half of the F_0 females were selected for the inhalation/gavage phase and the remaining females were selected for the inhalation only phase. Inhalation exposure of the F_0 females in both phases was suspended from gestation day 21 through lactation day 4. In the inhalation/gavage phase, F_0 females received the vehicle, corn oil, or the test article in the vehicle via oral gavage at dose levels of 0, 90, 342 and 621 mg/kg/day (divided into three equal doses, approximately two hours apart) at a dose volume of 1 mL/kg/dose during lactation days 1 through 4. Inhalation exposure of the F_0 females in both phases was re-initiated on lactation day 5 and continued through the day prior to euthanasia. The F_1 offspring were potentially exposed to the test article *in utero* (placental transfer), through nursing during lactation until weaning. On lactation days 21 and 28, pups were weaned and selected (one pup/sex/litter) for exposure to the same concentration of the

test article as their dam beginning on PND 22 or 29 and lasting through PND 33. Pups not selected for post-weaning exposures were necropsied following weaning on PND 28. For reporting purposes, the F_0 male exposure group designations were 100 ppm, 500 ppm and 1000 ppm. Exposure group designations for all F_0 females through the pre-mating and gestation periods were 100 ppm, 500 ppm and 1000 ppm. Exposure group designations for F_0 females that also received gavage doses of the test article and for all the F_1 offspring of these dams were 100 ppm/90 mg/kg, 500 ppm/342 mg/kg and 1000 ppm/621 mg/kg.

All animals were observed twice daily for moribundity and mortality, appearance, behavior and pharmacotoxic signs (prior to inhalation exposure and/or gavage dosing, at the midpoint of inhalation exposure and approximately one hour after completion of administration of the test article). Clinical observations, body weights and food consumption were recorded at appropriate intervals prior to mating and during gestation and lactation. All F_0 and F_1 females were allowed to deliver and rear their pups until weaning on lactation day 28, except for one pup/sex/litter that was weaned on PND 21. Ten pups per litter (of equal sex distribution, if possible) were selected on PND 4 to reduce the variability among the litters. Pups were observed daily for general appearance and behavior, and survival. Detailed physical examinations and body weights were recorded at appropriate intervals.

All F_0 males were necropsied following the breeding period. F_0 females were necropsied on lactation day 28; F_0 females which failed to deliver were necropsied on post-mating day 25 (females with evidence of mating) or post-cohabitation day 25 (females without evidence of mating) and F_0 females with total litter losses were euthanized within 24 hours of litter loss. Selected organs were weighed. All surviving pups were euthanized on PND 28 or 34 and received a gross external exam prior to being discarded.

1.3. RESULTS

No adverse exposure-related survival, clinical signs or macroscopic findings were noted at any exposure level in the F_0 generation. Increased mean liver (males and females) and kidney (males only) weights were observed in the 500 and 1000 ppm groups.

Body weight gain was decreased in the 500 and 1000 ppm group males and females during the first week of exposure and continued to be reduced in the 1000 ppm group males during the second week of exposure. Body weight parameters were unaffected in the low exposure group (100 ppm or 100 ppm/90 mg/kg).

There were no indications of adverse effects on reproductive performance in the F_0 generation. Male and female mating and fertility indices, pre-coital intervals, gestation lengths and live litter size were similar at all exposure levels. Postnatal survival was slightly reduced from birth to PND 4 in the 500 and 1000 ppm groups (inhalation phase) and in the 1000 ppm/621 mg/kg group (inhalation/gavage phase) as a result of large numbers of pup loss in single litters. Mean pup weights (male and female) in the 1000 ppm group were significantly decreased on PND 1 (11.1% and 9.0%, respectively). These reductions continued throughout the pre-weaning period in the 1000 ppm/621 mg/kg group (inhalation/gavage phase). In the inhalation phase, mean male pup body weights in the 500 and 1000 ppm groups were slightly lower than the control group on PND 14 and 21 (9.2-10.9% and 8.4-12.6%, respectively). Mean male and female offspring body weights in the 100 and 500 ppm groups for both the inhalation and inhalation/gavage phases were similar to the control group on PND 1.

Several exposure-related deaths were observed in the 500 and 1000 ppm group (inhalation phase) weanlings and the 1000 ppm/621 mg/kg group (inhalation/gavage phase) weanlings that initiated exposure on PND 22. Exposure-related clinical signs observed one hour following dosing included labored respiration, eyelids half-closed, prostrate, animal unable to right itself, and rocking, lurching and swaying while ambulating. Mean body weight gain was reduced in the F_1 weanlings exposed to 500 and 1000 ppm beginning on PND 22 in both the inhalation and inhalation/gavage phases.

Slightly reduced mean body weights were noted for the F_1 weanlings exposed to 100 ppm beginning on PND 22 in both the inhalation and inhalation/gavage phases.

No deaths or exposure-related clinical signs were noted in the F_1 weanlings exposed to the test article beginning on PND 29. Mean body weight gain was reduced in these weanlings exposed to 500 or 1000 ppm beginning on PND 29 in both the inhalation and inhalation/gavage phases.

No adverse effects were observed on clinical signs or body weights in the F_1 weanlings exposed to 100 ppm of test article beginning on PND 22 or 29.

1.4. CONCLUSIONS

Based on the results of this study, gavage dosing of dams on lactation days 1-4 will be performed and weanling inhalation exposure will initiate on PND 22 in a definitive two-generation reproductive toxicity study of ethylbenzene via whole-body inhalation. Exposure levels for this study will be 25, 100 and 500 ppm, and gavage dose levels on lactation days 1-4 will be 26, 90 and 342 mg/kg/day.

2. GENERAL STUDY INFORMATION AND KEY STUDY DATES

2.1. GENERAL STUDY INFORMATION

This report presents the data from "A Pilot Inhalation Study for a Reproductive Toxicity Study of Ethylbenzene in Rats." Due to software spacing constraints, the study title is presented as "Pilot Inh. Study for Repro. Tox. Study of Ethylbenzene in Rats" on the report tables. For clarification of the terminology used to differentiate the generations in the report text, the offspring of the F_0 generation were defined as the F_1 litters; pups from the F_1 litters were selected to constitute the F_1 generation. For reporting purposes, exposure group designations were 0 ppm, 100 ppm, 500 ppm and 1000 ppm for F_0 males, F_0 females selected for the inhalation only phase and for F_1 offspring from these females selected for exposure from PND 22-33 or 29-33. Exposure group designations were 0 ppm/0 mg/kg, 100 ppm/90 mg/kg, 500 ppm/342 mg/kg and 100 ppm/621 mg/kg for F_0 females selected for the inhalation/gavage phase and for F_1 offspring from these females selected for exposure from PND 22-33 or 29-33.

The following computer protocols (computer files containing data for protocol-scheduled events) were used for data collection during the study:

Computer Protocol	Type of Data Collected
WIL-186028M	F_0 parental (paternal) data
WIL-186028F	F_0 parental (maternal - combined phases) data
WIL-186028I	F_0 parental (maternal - inhalation only phase) and F_1 litter data
WIL-186028G	F_0 parental (maternal - inhalation/gavage phase) and F_1 litter data
WIL-186028A	F_1 PND 22-33 weanlings (inhalation only exposure)
WIL-186028D	F_1 PND 22-33 weanlings (inhalation/gavage exposure)
WIL-186028B	F_1 PND 29-33 weanlings (inhalation only exposure)
WIL-186028E	F_1 PND 29-33 weanlings (inhalation/gavage exposure)

2.2. KEY STUDY DATES

Date(s)	Event(s)
August 20, 2002	Experimental starting date (animal receipt)
September 6, 2002	Initiation of F_0 exposures
September 22, 2002	F_0 breeding
November 24, 2002	Last external exam of non-selected F_1 pups
November 24, 2002	Last necropsy of F_0 generation
November 5-23, 2002	F_1 inhalation phase exposures (PND 22-33)
November 5-29, 2002	F_1 inhalation/gavage phase exposure (PND 22-33)
November 12-23, 2002	F_1 inhalation phase exposures (PND 29-33)
November 12-29, 2002	F_1 inhalation/gavage phase exposures (PND 29-33)
November 30, 2002	Last external exam of F_1 generation

3. STUDY DESIGN



STUDY DESIGN (CONTINUED)



4. EXPERIMENTAL PROCEDURES – MATERIALS AND METHODS

4.1. TEST AND CONTROL ARTICLES

4.1.1. TEST ARTICLE IDENTIFICATION

The test article, ethylbenzene, was received from Ashland Chemical, Morrisville, Pennsylvania, for the American Chemistry Council Ethylbenzene Panel, Arlington, Virginia, on August 1, 2002 as follows:

Identification	No. of Containers Received	Description
Ethylbenzene, 99% CAS No.: 100-41-4 Lot No. C2A0E01423 [WIL Log No.: 5478A]	9 Drums[a] Total gross weight: 1759.7 kg Drum #1: 195.8 kg Drum #2: 195.6 kg Drum #3: 195.6 kg Drum #4: 195.5 kg Drum #5: 196.8 kg Drum #6: 194.4 kg Drum #7: 194.5 kg Drum #8: 195.6 kg Drum #9: 195.9 kg	Clear, colorless liquid

[a] = Drum no. 1 used for the F_0 and F_1 generation in this study

Stability data for the test article was the responsibility of the sponsor. Purity data was the responsibility of Dow Chemical Company. The test article was 99.9% pure. A Certificate of Analysis is presented in Appendix A. The bulk test article was stored refrigerated and was considered stable under this condition. Stability and purity of the test article for the drum used were confirmed by the Analytical Chemistry Department of WIL Research Laboratories, Inc. (see Section 4.1.6.2.). The results of these analyses are presented in Appendix B. A reserve sample (5.1 grams, 5478A #1) of the test article was collected and stored under refrigerated conditions in the Archives at WIL Research Laboratories, Inc.

4.1.2. VEHICLE IDENTIFICATION

The vehicle utilized in preparation of the gavage concentrations and for administration to the control group was 100% Pure Mazola Corn Oil, distributed by Bestfoods, Englewood Cliffs, New Jersey (6 bottles; exp. date: 06/25/03; WIL Log No. V1298) and purchased locally.

4.1.3. TEST ATMOSPHERE MONITORING

Exposure concentrations within each chamber were measured at least 10 times each exposure day by a validated gas chromatographic method. At least one standard was analyzed each day prior to exposure to confirm gas chromatographic calibration. Chamber temperature, relative humidity, ventilation rate, and negative pressure within the chambers were monitored and recorded automatically through the use of the LabVIEW® data acquisition virtual instrument device (DAVID). Measurements of ethylbenzene concentration commenced after the t_{90} start-up period (time required to reach 90% of the target chamber concentration). Oxygen content within the chamber was at least 19% and was measured during pre-study method development. Nominal chamber concentrations were determined daily for each chamber by weighing the amount of test article used during atmosphere generation, converting this mass to volume using standard gas laws, and dividing this test article volume by the total volume of air displaced through the chamber during the exposure. Total air volume was calculated by multiplying mean chamber ventilation rate (in liters per minute) by the exposure duration (in minutes). During the method development phase of the study, test atmosphere homogeneity was demonstrated. In addition, test atmospheres were evaluated for the presence of aerosols; there were no detectable aerosols at any evaluation interval. The methodology and results of these analyses are presented in Appendix C.

4.1.4. EXPOSURE METHODS

Each group of animals was exposed in a 2.0-m^3 stainless steel and glass whole-body inhalation chamber. Three chambers were dedicated for the test article exposure groups, while the fourth chamber was dedicated to the control group. The chambers were

operated under dynamic conditions at a slight negative pressure (approximately 0.5 inch of water) with at least 12 air changes per hour. Temperature and relative humidity were monitored at 35-minute intervals during the exposure periods and were between 18°C and 26°C and 30% to 70%, respectively. The daily exposure duration was six hours. Appropriate equipment and procedures for generation of the ethylbenzene vapor test atmospheres at the required concentrations were determined during the pre-study method development. The exposure methods and conditions are detailed in Appendix C.

All animals were housed in normal animal colony rooms during non-exposure hours. For each day's exposure, the animals were transferred to exposure caging, transported to the exposure chamber room, exposed for the requisite duration and returned to their home cages. Exposure cage batteries consisted of 24 individual (11-inch x 3.8-inch x 8-inch) compartments suitable for six-hour exposure periods. Animal cage batteries were rotated on a daily basis through various chamber locations in order to reduce the potential differences in exposure due to any residual non-homogeneity in chamber concentrations. Individual animals from the F_0 generation were placed in the same cage battery compartment for all exposures; the F_1 weanlings were group-housed with their littermates in the same cage battery compartment for all exposures. The rotation procedures used are maintained in the data records.

The F_0 males were exposed to the test article for a minimum of four weeks that encompassed the pre-mating and mating periods through the day prior to euthanasia. All F_0 females were exposed to the test atmosphere for two weeks prior to mating, throughout the mating period and from gestation day 0 through gestation day 20. At that time, one-half of the females were selected for the inhalation only phase and the remaining animals were selected for the inhalation/gavage phase. For the inhalation only females, inhalation exposure was suspended from gestation day 21 through lactation day 4 to avoid confounding effects on nursing. For the inhalation/gavage females, oral gavage doses of the test article or the vehicle (corn oil) were administered in three equal daily doses (approximately two hours between each dose) during lactation day 1-4 at a dose volume

of 1 mL/kg/dose. Inhalation exposures for both phases were re-initiated on lactation day 5 and continued through lactation day 27. Beginning on lactation day 5, the dams were removed from their litters during each daily six-hour exposure period. The control group, for the inhalation portion of the study, was exposed to clean, filtered air under conditions identical to those used for the groups exposed to the test article. All animals were exposed to the test article or to filtered air at approximately the same time each day.

The F_0 parental animals were assigned to study groups as follows:

Group Number	Test Article	Inhalation Exposure Level (ppm)	Gavage Dose Level[a] (mg/kg/day)	Gavage Dose Concentration (mg/mL)	Number of Males	Number of Females: Inhalation Only	Number of Females: Inhalation and Gavage
1	Control	0	0	0	20	10	10
2	Ethylbenzene	100	90	30	20	10	10
3	Ethylbenzene	500	342	114	20	10	10
4	Ethylbenzene	1000	621	207	20	10	10

[a] = Administered in three equal doses (approximately two hours apart) at a dose volume of 1 mL/kg/dose (3 mL/kg/day)

Inhalation exposure levels were determined from the results of previous studies and were provided by the sponsor representative. The total gavage doses, administered as three partial doses over a six-hour period each day, were estimated by physiologically-based pharmacokinetic (PBPK) modeling (Appendix D). The basis for this estimation provided blood area under the curve (AUC) values similar to those AUC values predicted to occur with daily six-hour inhalation exposure.

The offspring of the F_0 generation (F_1 litters) were potentially exposed to the test article *in utero*, through nursing during lactation. The F_1 pups remained with their dams until weaning on PND 28 with the exception of one male and one female from each litter, which were weaned on PND 21. Beginning on PND 22 or on PND 29, one F_1 male and female per litter from each of the weaning date cohorts were directly exposed to the same concentration of the test article as their dam through PND 33. Because rats are often more sensitive to test article exposure immediately following weaning, post-weaning

exposure of the F_1 pups began on PND 22 or 29 in order to determine the earliest age at which direct exposure of the F_1 pups can begin without producing excessive toxicity.

The selected route of administration was whole-body inhalation exposure because inhalation is the most likely route of human exposure. The oral gavage dosing during lactation days 1-4 was conducted because significant neurological development occurs in pups during this time period, when females typically are not removed from the pups due to concerns for the effect of such stress on the pups. The animal model selected, the Crl:CD®(SD)IGS BR rat, is recognized as appropriate for reproduction studies. WIL Research Laboratories, Inc. has reproductive historical control data for the Crl:CD®(SD)IGS BR rat.

4.1.5. PREPARATION OF DOSING FORMULATIONS

Appropriate amounts of the test article were weighed into tared, calibrated storage containers; the test article was 99.9 % pure (Appendix A). Approximately 70% of the vehicle, corn oil, was added to each container and mixed with a magnetic stirrer until uniform. An appropriate amount of the vehicle was then added to bring the mixture to the desired volume. The mixture was then stirred until uniform and throughout use using a magnetic stirrer. Oral dosing formulations were prepared weekly and aliquots were dispensed for daily dosing on lactation days 1-4 and chemical analyses. Dosing formulations were stored at room temperature for a period not to exceed one week in duration. The formulations were visually inspected by the study director on October 14, 2002, and were found to be visibly homogeneous and acceptable for dosing.

4.1.6. SAMPLING AND ANALYSES

All analyses were performed by the Analytical Chemistry Department at WIL Research Laboratories, Inc. The methodology and results of those analyses are presented in Appendix B. The results of these analyses confirmed the purity and stability of the bulk test article. In addition, the dosing formulations were found to be homogeneous,

contained the amounts of test article specified in the protocol and were stable for 10 days at room temperature.

4.1.6.1. TEST ARTICLE CHARACTERIZATION AND STABILITY

An approximate 5-mL sample of the test article was collected from the drum of test article used for this study prior to initial use. This sample was assessed for purity (expressed as "area percent") using GC/FID (gas chromotography equipped with a flame ionization detector) analysis of at least duplicate injections of the undiluted sample. A sample (5 mL) was collected following completion of the container's use during the exposure phase. This sample was used for confirmatory stability analysis; the resulting area percent purity was compared to the time zero value.

4.1.6.2. HOMOGENEITY AND STABILITY OF THE TEST ARTICLE FORMULATIONS

Homogeneity for both bulk oral dosing preparations and aliquots was established on the first preparation. One 10-mL sample from the middle of the control formulation and from the top, middle and bottom strata of each of the test article formulations were analyzed to confirm homogeneity. The aliquots dispensed for homogeneity were representative of the size of the aliquots dispensed for daily dosing procedures. One 10-mL sample from the control formulation and one 10-mL sample from the top and bottom strata were withdrawn from each of the aliquots dispensed for the first day of administration and for the tenth day after formulation to confirm homogeneity and re-suspension of the test article over the longest period of aliquot storage (10 days). Samples collected from the bulk preparation and the aliquots dispensed for the first day of dose administration were analyzed on the day collected. In addition, one 10-mL sample was collected from the middle of each dosing formulation prepared during the in-life phase of the study for concentration analyses.

4.2. F_0 ANIMAL RECEIPT AND ACCLIMATION

Ninety-five male and 96 female Crl:CD®(SD)IGS BR rats were received from Charles River Laboratories, Inc., Raleigh, North Carolina, on August 20, 2002. The animals were

56 days old upon receipt. The animals were individually housed except during mating. Each animal was examined by a qualified technician upon receipt and weighed the day following receipt (August 21, 2002). All animals were uniquely identified by a Monel® metal eartag displaying the animal number. During the acclimation period (16 days), the animals were observed twice daily for mortality and moribundity.

4.3. F_0 AND F_1 ANIMAL HOUSING

Following the initial acclimation period and until pairing, all F_0 parental test animals were individually housed in clean, wire-mesh cages suspended above cage-board. The cage board was changed three times per week. During cohabitation, the animals were paired (1 male:1 female) for mating in the home cage of the male. Following positive evidence of mating, the males were housed in suspended wire-mesh cages until the scheduled necropsy of the parental generation, and the females were transferred to plastic maternity cages with nesting material (Bed-O'Cobs®; The Andersons, Industrial Products Division, Maumee, Ohio) and remained in these cages until the scheduled euthanasia. Analyses of the nesting material were provided by the manufacturer and are presented in Appendix E. Following weaning, each F_1 offspring selected for exposure to the test article was group-housed with its littermate in a plastic cage with nesting material until termination. Clean cages were provided for the selected F_1 offspring once per week; clean nesting material was provided twice per week. Maternal females for which there was no evidence of mating were placed in plastic maternity cages with nesting material upon completion of a 14-day mating period and remained in these cages until euthanasia. Animals were housed in accordance with the "Guide for the Care and Use of Laboratory Animals."[1] The animal facilities at WIL Research Laboratories, Inc., are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

4.4. DIET, DRINKING WATER AND MAINTENANCE OF F_0 AND F_1 ANIMALS

The basal ration used in this study was PMI Nutrition International, LLC, Certified Rodent LabDiet® 5002. The diet used at WIL Research Laboratories, Inc., was a certified

feed with appropriate analyses performed and provided by the manufacturer; results of these analyses are presented in Appendix F. Municipal water supplying the facility is regularly sampled for contaminants according to standard operating procedures; results of these analyses are presented in Appendix G. Contaminants were not present in animal feed or water at concentrations expected to interfere with the objectives of this study. The basal diet and reverse-osmosis-treated (on-site) drinking water, delivered by an automatic watering system, were provided *ad libitum* throughout the acclimation period and during the study (except during exposure). Food jars were equipped with retainers to minimize spillage. Feeders were sanitized weekly.

4.5. ENVIRONMENTAL CONDITIONS

Animals were housed throughout the acclimation period and during the study in an environmentally controlled room. The room temperature and humidity controls were set to maintain daily averages of 71 ± 5°F (22 ± 3°C) and 50 ± 20% relative humidity. Room temperature and relative humidity were monitored using the Metasys DDC Electronic Environmental control system and were recorded approximately hourly. These data are summarized in Appendix H. Actual mean daily temperature ranged from 70.6°F to 70.9°F (21.5°C to 21.6°C) and mean daily relative humidity ranged from 37.3% to 52.7% during the study. Light timers were calibrated to provide a 12-hour light (6 a.m. to 6 p.m.)/12-hour dark photoperiod. Air handling units were set to provide approximately 10 fresh air changes per hour.

During the inhalation exposure periods, controls were set to maintain chamber temperatures of 18-26°C and a relative humidity of 30-70%. Chamber environmental conditions were measured at least eight times daily and are summarized in Appendix C. Actual mean daily temperatures and relative humidities were as follows:

F_0 Generation (9/6/02 - 11/24/02)

	0 ppm/0 mg/kg	100 ppm/90 mg/kg	500 ppm/342 mg/kg	1000 ppm/621 mg/kg
Mean Temperature (°C)	22	22	22	24
Mean % Humidity	45	49	52	46

F_1 Generation (11/5/02 - 11/29/02)

	0 ppm/0 mg/kg	100 ppm/90 mg/kg	500 ppm/342 mg/kg	1000 ppm/621 mg/kg
Mean Temperature (°C)	22	23	23	24
Mean % Humidity	44	44	49	45

4.6. ASSIGNMENT OF F_0 ANIMALS TO TREATMENT GROUPS

At the conclusion of the acclimation period, all available F_0 animals were weighed and examined in detail for physical abnormalities. At the discretion of the study director, animals judged to be in good health and meeting acceptable body weight requirements (350 to 550 g for males and 220 to 300 g for females) were selected for use in the computerized randomization procedure. At that time, the individual body weights and corresponding animal identification numbers were entered into the WIL Toxicology Data Management System (WTDMS™). A printout containing the animal numbers, corresponding body weights and individual group assignment was generated based on body weight stratification randomized in a block design. The animals were then arranged into groups according to the printout. The animals were approximately 11 weeks old at the initiation of test article exposure. Male body weights ranged from 341 g to 406 g and female body weights ranged from 225 g to 273 g on the day of randomization (prior to study initiation). The individual randomization weights are not presented in this report but are contained in the study records.

The experimental design for WIL-186028 consisted of three test article-treated groups and one control group composed of 20 males and 20 females each. Ten females in each

group were assigned to the Inhalation Only Phase, and the remaining 10 females were assigned to the Inhalation and Gavage Phase.

5. PARAMETERS EVALUATED

5.1. F_0 AND SELECTED F_1 OFFSPRING OBSERVATIONS

5.1.1. CLINICAL OBSERVATIONS AND MORTALITY

All F_0 animals and F_1 offspring were observed twice daily (at least seven hours apart) for moribundity and mortality, appearance, behavior and pharmacotoxic signs (prior to exposure and/or gavage dosing and approximately one hour after completion of administration of test article). During inhalation exposures, all animals that were visible through the chamber windows were also observed for appearance and behavior at the midpoint of exposure. Detailed physical examinations were recorded weekly for all animals throughout the study period. These observations included, but were not limited to, evaluation for changes in appearance of skin and fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system function, somatomotor activity and behavior patterns. Special attention was paid to the degree of salivation and lacrimation, presence or absence of urination and defecation (including polyuria and diarrhea), pupil size, degree of palpebral closure, presence of convulsions, tremors or abnormal movements, presence of posture and gait abnormalities, the presence of any unusual or abnormal behaviors and any repetitive actions (stereotypies). F_0 females expected to deliver were also observed twice daily during the period of expected parturition and at parturition for dystocia (prolonged labor, delayed labor) or other difficulties.

5.1.2. BODY WEIGHTS

Individual F_0 male body weights were recorded prior to treatment on the first day of exposure, then weekly throughout the study and prior to the scheduled necropsy. Individual F_0 female body weights were recorded prior to treatment on the first day of exposure and weekly until evidence of copulation was observed. Mean weekly body weights and body weight changes are presented for each interval. Once evidence of mating was observed, female body weights were recorded on gestation days 0, 3, 6, 9, 12, 15, 18 and 20 and on lactation days 1, 4, 5 (pre-exposure), 7, 14, 21 and 28. Body weight

changes are presented for each of these intervals and for the entire gestation and lactation intervals (days 0-20 and 1-28, respectively). F_1 weanlings selected for exposure to the test article were weighed daily during the exposure periods (PND 22-33 and PND 29-33). Body weights for these offspring were recorded on the day of euthanasia (PND 34).

5.1.3. FOOD CONSUMPTION

Individual F_0 male and female food consumption was measured weekly until pairing. Food intake was not recorded during the mating period. Female food consumption was recorded on gestation days 0, 3, 6, 9, 12, 15, 18 and 20 and lactation days 1, 4, 5 (pre-exposure), 7, 14, 21 and 28. Food consumption was calculated and reported as g/animal/day and g/kg/day for the corresponding body weight change intervals. Food efficiency (body weight gained as a percentage of food consumed) was also calculated and reported for these intervals. When food consumption could not be determined for an animal during a given interval (due to a weighing error, food spillage, obvious erroneous value, etc.), the appropriate interval was footnoted as "NA" (Not Applicable) on the individual tables. Food consumption was not recorded for the F_1 weanlings that were exposed to the test article on PND 22-33 or PND 29-33.

5.2. F_0 REPRODUCTIVE PERFORMANCE

5.2.1. BREEDING PROCEDURES

The animals were paired on a 1:1 basis within each treatment group after a minimum of two weeks of exposure. A breeding record containing the male and female identification numbers and the start date of cohabitation was prepared. Each female was housed in the home cage of the male. Positive evidence of mating was confirmed by the presence of a copulatory plug or the presence of sperm following a vaginal lavage. Each mating pair was examined daily. The day when evidence of mating was identified was termed day 0 of gestation. Then the animals were separated and the female was housed in an individual plastic cage with nesting material. When evidence of mating was not apparent after 14 days, the animals were separated without further opportunity for mating and the female was placed in a plastic maternity cage with nesting material.

The F_0 generation was mated once to produce the F_1 litters. Prior to the F_0 pairing (week 2), male body weights ranged from 339 g to 443 g and female body weights ranged from 222 g to 301 g. The animals were approximately 13 weeks old. All animals were randomly selected for pairing.

Pre-coital intervals were calculated according to the following method: rats paired over a 12-hour dark cycle were considered to have been paired for "one" day.

Mating and fertility indices were calculated as follows:

$$\text{Male (Female) Mating Index (\%)} = \frac{\text{No. of Males (Females) with Evidence of Mating (or Confirmed Pregnancy)}}{\text{Total No. of Males (Females) Used for Mating}} \times 100$$

$$\text{Female Fertility Index (\%)} = \frac{\text{No. of Females with Confirmed Pregnancy}}{\text{Total No. of Females Used for Mating}} \times 100$$

$$\text{Male Fertility Index (\%)} = \frac{\text{No. of Males Siring a Litter}}{\text{Total No. of Males Used for Mating}} \times 100$$

5.3. F_0 PARTURITION

All females were allowed to deliver naturally and rear their young to weaning (PND 28), except for one pup/sex/litter that was weaned on PND 21. During the period of expected parturition, the females were observed twice daily for initiation and completion of parturition and for signs of dystocia. Any difficulties at the time of parturition were recorded. On the day parturition was judged complete (PND 0), pups were sexed and examined for gross malformations, and the numbers of stillborn and live pups were recorded. Any changes or abnormalities in nesting and nursing behavior were recorded. Individual gestation lengths were calculated using the date delivery started.

5.4. F_1 LITTER DATA

5.4.1. LITTER VIABILITY AND DEATHS

Each litter was examined twice daily for survival, and all deaths were recorded. All pups were individually identified by application of tattoo markings on the digits on PND 0. A

daily record of litter size was maintained. Intact offspring dying from PND 0 to 4 were necropsied using a fresh dissection technique described by Stuckhardt and Poppe[2] and the carcasses discarded. Findings were recorded as either developmental variations (alterations in anatomic structure that are considered to have no significant biological effect on animals health or body conformity, representing slight deviations from normal) or malformations (those anomalies that alter general body conformity, disrupt or interfere with body function, or may be incompatible with life). A detailed gross necropsy was performed on any pup dying after PND 4 and prior to weaning, and the carcasses discarded. Moribund pups were euthanized by intraperitoneal injection of sodium pentobarbital (PND 0-10) or by carbon dioxide inhalation (PND 11-34) and were necropsied as described above.

5.4.2. LITTER REDUCTION

To reduce variability among the litters, 10 pups per litter of equal sex distribution (4:6; 5:5; 6:4; male:female, as necessary) were randomly selected on PND 4. All selections were performed by computerized randomization. The remaining offspring were weighed, euthanized by intraperitoneal injection of sodium pentobarbital and discarded on PND 4.

5.4.3. CLINICAL OBSERVATIONS

Litters were examined daily for survival and any adverse changes in appearance or behavior. Each pup received a detailed physical examination on PND 1, 4, 7, 14, 21 and 28. Any abnormalities in nesting and nursing behavior were recorded.

5.4.4. BODY WEIGHTS

Pups were individually weighed on PND 1, 4, 7, 14, 21 and 28. Mean pup weights were presented by sex for each litter and by exposure group.

5.4.5. SEX DETERMINATION

Pups were individually sexed on PND 0, 4, 7, 14, 21 and 28.

5.4.6. CALCULATION OF LITTER PARAMETERS

Litter parameters were defined as follows:

$$\text{Live Litter Size} = \frac{\text{Total Viable Pups Day 0}}{\text{No. Litters With Viable Pups Day 0}}$$

$$\text{Postnatal Survival Between Birth and PND 0 or PND 4 (Pre-Selection) (\% Per Litter)} = \frac{\Sigma\,(\text{Viable Pups Per Litter on PND 0 or PND 4/No. Pups Born Per Litter})}{\text{No. Litters Per Group}} \times 100$$

$$\text{Postnatal Survival for All Other Intervals (\% Per Litter)} = \frac{\Sigma\,(\text{Viable Pups Per Litter at End of Interval N/Viable Pups Per Litter at Start of Interval N})}{\text{No. Litters Per Group}} \times 100$$

$$\text{Where N} = \text{PND 0-1, 1-4 (Pre-Selection), 4 (Post-Selection)-7, 7-14, 14-21, 21-28 or 4 (Post-Selection)-28}$$

5.4.7. WEANING AND SELECTION

Each dam and litter remained housed together until weaning on lactation day 28, except for one pup/sex/litter that was weaned on PND 21. The day following weaning (PND 21 or PND 28), one male and one female per litter that were randomly selected were directly exposed to the same concentration of the test article as their dam through PND 33. Direct inhalation exposure periods for the selected pups were PND 22-33 or PND 29-33.

Pups were selected for the F_1 generation as follows. A computerized randomization procedure was used to select one male and one female per litter, when available. Pups selected for the F_1 generation also retained the dam number, followed by a hyphen and the digit tattoo marking (*e.g.*, 99999-01).

5.5. ANATOMIC PATHOLOGY

5.5.1. MACROSCOPIC EXAMINATIONS

5.5.1.1. F_0 GENERATION

All surviving F_0 adults were euthanized by carbon dioxide inhalation. F_0 males were necropsied following the breeding period. F_0 females that delivered were euthanized on lactation day 28; F_0 females which failed to deliver were euthanized on post-mating day 25 (females with evidence of mating) or post-cohabitation day 25 (females without evidence of mating); and F_0 females with total litter losses were euthanized within 24 hours of litter loss. A complete necropsy was conducted on animals at the scheduled termination. The necropsy included examination of the external surface, all orifices, the cranial cavity, the external surface of the brain and spinal cord, the thoracic, abdominal and pelvic cavities including viscera and lymph nodes, thyroid glands and mammary glands. For females that delivered, the number of former implantation sites were recorded. For females which failed to deliver, nongravid uteri were opened and placed in 10% ammonium sulfide solution for detection of implantation sites as described by Salewski[3]. If evidence of macroscopic implantations were present, the number of implantation sites and corpora lutea were recorded. The carcass of each F_0 animal was discarded; no organs or tissues were preserved.

5.5.1.2. F_1 PUPS

All surviving F_1 pups were euthanized by carbon dioxide inhalation on PND 28 (following weaning) or on PND 34 (following exposure). All surviving pups received a gross external examination; the carcass of each animal was discarded. A complete necropsy (as described in Section 5.5.1.1.) was performed on all F_1 pups selected for inhalation exposure during the post-weaning period that were found dead or that were euthanized *in extremis*.

5.5.2. ORGAN WEIGHTS

The kidneys and liver from all F_0 animals euthanized at scheduled termination were weighed. Paired organs were weighed together. Absolute weights and organ to final body weight ratios were reported.

5.6. STATISTICAL METHODS

All statistical tests were performed using appropriate computing devices or programs. Analyses were conducted using two-tailed tests (except as noted otherwise) for a minimum significance level of 5%, comparing each test article-treated group to the control group by sex. Each mean was presented with the standard deviation (S.D.) and the number of animals (N) used to calculate the mean. Due to the different rounding conventions inherent in the types of software used, the means and standard deviations on the summary and individual tables may differ by ±1 in the last significant figure. Statistical analyses were not conducted if the number of animals was two or less. Data obtained from nongravid animals were excluded from statistical analyses following the mating period. Statistical analyses were not performed when weekly food or body weight data for one or more animals were not available because the animals had entered gestation or remained in the lactation phase. The litter was used as the experimental unit.

Parental mating and fertility indices were analyzed using the Chi-square test with Yates' correction factor.[4] Mean F_0 parental (weekly, gestation and lactation) and F_1 offspring body weight data, food consumption and food efficiency data, parental organ weight data, pre-coital intervals, gestation lengths, implantation sites, unaccounted sites, mean number of pups born and live litter size data were analyzed for heterogeneity of variance[5] and normality.[6] If the data were homogeneous and normal, a parametric one-way analysis of variance (ANOVA)[7] was used to determine intergroup differences. If the ANOVA revealed statistically significant ($p<0.05$) intergroup variance, Dunnett's[8] test was applied to the data to compare the control group versus all treatment groups. If the data were not homogeneous and normal, the data were analyzed by the Kruskal-Wallis nonparametric ANOVA[9] test to determine intergroup differences. If this ANOVA revealed statistically

significant ($p<0.05$) intergroup variance, the Mann-Whitney U-Test[9] was applied to the data to compare all treatment groups to the control group. Data generated during gestation were analyzed combined (N = 20/group) Mean litter proportions (percent per litter) of postnatal pup survival and sex ratio at birth (percentage of males per litter) were subjected to the Kruskal-Wallis nonparametric ANOVA test to determine intergroup differences. If the ANOVA revealed statistically significant ($p<0.05$) intergroup variance, the Mann-Whitney U-test[9] was used to compare the test article-treated groups to the control group. Pup weights were analyzed separately by sex by a nested analysis of covariance.[10]

5.7. DATA RETENTION

The sponsor has title to all documentation records, raw data, specimens or other work product generated during the performance of the study. All work product generated by WIL Research Laboratories, Inc., including raw paper data and specimens, are retained in the Archives at WIL Research Laboratories, Inc., as specified in the study protocol. Data generated by Dow Chemical Company will be archived by the sponsor or the sponsor's designee.

Reserve samples of the test and control articles (if appropriate), pertinent electronic storage media and the original final report are retained in the Archives at WIL Research Laboratories, Inc., in compliance with regulatory requirements.

6. RESULTS

6.1. ANALYTICAL CHEMISTRY

Summary Data: Appendix B

The test article samples that were analyzed and used for inhalation exposures were 99.91% pure. Comparison of the purity of samples taken at the beginning and end of use of each drum demonstrated that the test article was stable for the duration of use on this study and are presented in the following table:

Drum No.	Type of Sample	Collected Date	Analyzed Date	Mean Area % Ethylbenzene
5478A#1 Beginning of Use	Purity	8/6/02	9/6/02	99.91%
5478A#1 End of Use	Purity	12/5/02	12/6/02	99.91%

The overall mean analyzed chamber concentrations of ethylbenzene are presented in the following table:

F_0 Generation (9/6/02 - 11/23/02)

	Control	100 ppm	500 ppm	1000 ppm
Mean	0	99	500	1008
S.D.	0.0	2.4	8.5	18.6
C.V. (%)	0.00	2.40	1.71	1.84
N	75	71	79	71

F_1 Generation (11/5/02 - 11/29/02)

	Control	100 ppm	500 ppm	1000 ppm
Mean	0	101	498	1002
S.D.	0.0	1.3	5.8	16.0
C.V. (%)	0.00	1.30	1.17	1.60
N	20	19	24	19

For analysis of the dosing formulations, a precise and accurate method for the quantitation of ethylbenzene in corn oil dosing formulations was validated. The test article was mixed with corn oil to produce homogeneous formulations. Assessment of the resuspension homogeneity of dosing formulation aliquots (at approximate volumes

necessary for one day of dosing) after 1 and 10 days of room temperature storage indicated successful confirmation of homogeneity. Results of these analyses are presented in the following tables:

Ethylbenzene Homogeneity in Representative Dosing Formulations

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	29.5	111	196
Middle	30.0	113	199
Bottom	29.9	112	187
Group Mean (ppm)	29.8	112	194
SD	0.27	0.83	6.1
RSD(%)	0.91	0.74	3.1
Mean % of Target	99.4	98.3	93.6

1-Day Ethylbenzene Resuspension Homogeneity in Dosing Formulation Aliquots

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	34.9	132	215
Bottom	31.6	126	226
Group Mean (ppm)	33.3	129	220
SD	2.3	4.8	8.2
RSD(%)	7.0	3.8	3.7
Mean % of Target	111	113	106

10-Day Ethylbenzene Resuspension Homogeneity in Dosing Formulation Aliquots

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	29.0	106	221
Bottom	27.6	112	230
Group Mean (ppm)	28.3	109	226
SD	0.95	4.1	6.0
RSD(%)	3.3	3.8	2.6
Mean % of Target	94.3	95.4	109

There was insignificant loss of ethylbenzene in these corn oil formulations after 1 and 10 days of room temperature storage. The analyzed dosing formulations had concentrations within the required 15% of the target dose concentrations. Results of these analyses are presented in the following table:

1- and 10-Day Room Temperature Stability of Ethylbenzene in Corn Oil Formulations

		Group 2	Group 3	Group 4
	Target Concentration (mg/mL)	30.0	114	207
Time Zero	Mean Concentration (mg/mL)	29.8	112	194
	% of Target Concentration	99.4	98.3	93.6
1-Day Storage	Mean Concentration (mg/mL)	33.3	129	220
	% of Target Concentration	111	113	106
	% of Time Zero Concentration	112	115	113
10-Day Storage	Mean Concentration (mg/mL)	28.3	109	226
	% of Target Concentration	94.3	95.4	109
	% of Time Zero Concentration	95.0	97.3	116

6.2. F_0 GENERATION

6.2.1. CLINICAL OBSERVATIONS AND SURVIVAL

Summary Data: Tables 1 through 22

Individual Data: Tables 105 through 121

All F_0 parental rats survived to the scheduled euthanasia. No exposure-related clinical findings were noted in this study. Clinical observations for all parental rats were few and unremarkable at the detailed physical examinations and at all observation periods prior to, during and following inhalation exposure or gavage dosing. Findings that included hair loss, salivation, soft stool, diarrhea, malaligned incisors, scabbing and red and/or clear material on various body surfaces occurred similarly in the control group, in single animals or in a manner that was not exposure-related.

6.2.2. BODY WEIGHTS AND FOOD CONSUMPTION

Summary Data: Tables 23 through 49; Figures 1 through 5

Individual Data: Tables 122 through 146

6.2.2.1. MALES

Exposure-related reductions in mean body weight gain, food consumption and food efficiency were noted in the 500 and 1000 ppm group males during the first week of exposure. The differences from the control group were statistically significant ($p<0.01$). Mean body weight gain and food efficiency in the 1000 ppm group continued to be

slightly reduced (not statistically significant) during the second week of exposure (study week 1-2). When the entire exposure period (study weeks 0-4; two weeks prior to mating and throughout the two-week mating period) was evaluated, mean cumulative body weight gains in the 500 and 1000 ppm groups were decreased ($p<0.05$ or $p<0.01$, respectively) compared to the control group. As a result of the reduced body weight gain during the first two weeks of inhalation exposure, mean body weights in the 1000 ppm group F_0 males were reduced (4.2 - 4.7%) during study weeks 2-4; the differences were often statistically significant ($p<0.05$). No other exposure-related effects on body weight or food consumption were noted for the male groups. Other statistically significant decreases from the control group were slight and/or did not occur in an exposure-related manner. Mean body weights and food consumption for the 100 ppm group males were unaffected by inhalation exposure to the test article.

6.2.2.2. FEMALES

Exposure-related reductions in mean body weight gain, food consumption and food efficiency were observed for the 500 and 1000 ppm group females during the first week of exposure. The differences from the control group were statistically significant at $p<0.05$ for mean body weight gain and $p<0.01$ for food consumption. Mean cumulative body weight gains in these groups were decreased (not statistically significant) when the entire pre-mating exposure period (study weeks 0-2) was evaluated. These reductions in body weight gain in the 500 and 1000 ppm F_0 females were not of sufficient magnitude to produce a reduction in mean body weight relative to the control group. No other exposure-related effects on body weight or food consumption were noted during the pre-mating period. Mean body weights and food consumption for the 100 ppm group females were unaffected by inhalation exposure to the test article.

No test article-related effects were noted on mean body weight, body weight gain, food consumption or food efficiency during the gestation or lactation periods (both the inhalation and inhalation/gavage phases) at any exposure level. Statistically significant increases in food consumption (primarily g/kg/day) were noted for the females during the

gestation period in the 1000 ppm group F_1 females; these slight increases were attributed to the slightly reduced mean body weights in this group. Other statistically significant changes noted during the gestation and lactation periods were transient, occurred sporadically and/or were noted in a manner that was not exposure-related.

6.2.3. REPRODUCTIVE PERFORMANCE

Summary Data: Tables 50 through 52

Individual Data: Tables 147 through 149

Historical Control Data: Appendix I

Reproductive performance parameters (mating and fertility indices, precoital intervals, gestation lengths, implantation sites and unaccounted sites) were unaffected in all test article exposure groups. The value for the male and female fertility indices (75.0%) in the control group was within the WIL historical control data range (56.7% - 100.0%); however, these values were below the mean fertility index values for males and females (89.3% and 90.4%, respectively) in the WIL historical control data. None of the differences from the control group were statistically significant. Nineteen males and females, each, in the control, 100, 500 and 1000 ppm groups had evidence of mating. Females with confirmed pregnancies and males siring litters numbered 15, 17, 20 and 19 in the control, 100, 500 and 1000 ppm groups, respectively.

6.3. F_1 LITTER DATA

Summary Data: Tables 53 through 62; Figures 6 through 9

Individual Data: Tables 150 through 159

Historical Control Data: Appendix I

The number of F_1 litters (combined phase) available for evaluation on PND 0 numbered 15, 17, 20 and 19 in the control, 100, 500 and 1000 ppm groups, respectively. The mean number of pups born, live litter size, percentage of males per litter at birth and postnatal survival on PND 0 were unaffected by the test article in all exposure groups. Differences

from the control group were slight, not statistically significant and/or did not occur in an exposure-related manner.

The number of F_1 litters available for evaluation beginning on PND 1 numbered 7, 9, 9 and 9 (inhalation phase) in the control, 100, 500 and 1000 ppm groups, respectively, and 8, 8, 10 and 10 (inhalation/gavage phase) in the control, 100 ppm/90 mg/kg, 500 ppm/342 mg/kg and 1000 ppm/621 mg/kg groups, respectively. Postnatal survival from birth to PND 4 was reduced in the 500 and 1000 ppm groups (inhalation phase) and in the 1000 ppm/621 mg/kg group (inhalation/gavage phase) compared to the control group values and the WIL historical control data. These decreases were a result of a total litter loss in the 500 ppm group on PND 0 (dam no. 10520), one litter (no. 10529) in the 1000 ppm group that had 3/13 pups survive through PND 4 and one litter (no. 10502) in the 1000 ppm/621 mg/kg group that had 4/14 pups survive through PND 4. None of the differences from the control group were statistically significant. Although total litter losses were observed only in six dams in 32 studies in the WIL historical control data, in the absence of other effects on postnatal survival in the 500 ppm group (combined phase) on PND 0, this total litter loss was unlikely due to test article exposure. In contrast, the reductions noted in postnatal survival through PND 4 in the 1000 ppm groups occurred in both the inhalation and inhalation/gavage phases in the presence of other adverse effects (reduced pup weights) and were likely due to maternal ethylbenzene exposure. Following culling on PND 4, postnatal survival in both the inhalation and inhalation/gavage phases were similar to the control group with the following exception. A single total litter loss occurred in one litter (no. 10543) in the 100 ppm group (inhalation phase) on lactation day 15.

Pups that were found dead or euthanized *in extremi*s in the inhalation only phase numbered 1/98, 20/130, 14/149 and 8/120 in the control, 100 ppm, 500 ppm and 1000 ppm groups, respectively, and 0/98, 1/130, 1/149, and 13/120 pups in the same respective groups were missing and presumed to have been cannibalized. Pups that were found dead or euthanized *in extremis* in the inhalation/gavage phase numbered 9/117,

5/120, 7/142 and 11/154 in the control, 100 ppm/90 mg/kg, 500 ppm/342 mg/kg and 1000 ppm/621 mg/kg groups, respectively, and 0/117, 1/120, 3/142 and 6/154 pups in the same respective groups were missing and presumed to have been cannibalized. The general physical condition of all F_1 pups in both phases of this study were unaffected by maternal test article exposure.

Mean male and female pup body weights in the 1000 ppm group were significantly lower ($p<0.05$ or $p<0.01$; 11.1 and 9.0%, respectively) than the control group values on PND 1. These slight reductions continued through PND 28 for the 1000 ppm/621 mg/kg group (inhalation/gavage phase). On PND 28, the reductions in male and female body weight in this group were 14.8 and 10.9%, respectively. Statistically significant ($p<0.05$ or $p<0.01$) differences in male pup body weight were noted in the 1000 ppm/621 mg/kg group on PND 1, 14 and 21. The same trend was observed for mean body weight gains in the 1000 ppm/621 mg/kg group with lower body weight gains noted during PND 7-14, 14-21 and 21-28; the differences were statistically significant ($p<0.01$) on PND 7-14. Statistically significant ($p<0.05$) decreases in mean body weight gain compared to the control group were also observed for males in the 100 ppm/90 mg/kg and 500 ppm/342 mg/kg groups from PND 7-14. As a result of the decreased male body weight gains during PND 7-14, mean body weights were reduced 11.6 and 12.0%, respectively, in the 100 ppm/90 mg/kg and 500 ppm/342 mg/kg groups on PND 14 relative to the concurrent control group. The weights were also reduced 12.7 and 13.1% in these same respective groups relative to the mean value in the WIL historical control data for inhalation studies. However, unlike the 1000 ppm/621 mg/kg group, the reductions in body weight gain for the 100 ppm/90 mg/kg and 500 ppm/342 mg/kg groups did not persist during PND 14-21 and 21-28.

WIL Mean Historical Control Pup Body Weight Data For Inhalation Studies

	Day 1	Day 4 (Pre-Selection)	Day 7	Day 14	Day 21
Males	7.03	9.83	13.86	25.43	41.15
Females	6.63	9.28	13.08	24.61	39.50

In the inhalation phase, mean male pup body weights in the 500 ppm and 1000 ppm groups were slightly lower than the control group on PND 14 and 21 (9.2-10.9% and 8.4-12.6%, respectively) and similar to the control group on PND 28. Mean female pup weights prior to weaning in the inhalation phase were similar to the control group. No other differences from the control group in pup body weights were noted prior to weaning in either phase.

6.4. MACROSCOPIC EXAMINATIONS AND ORGAN WEIGHT DATA

Summary Data: Tables 63 through 73

Individual Data: Tables 160 through 176

6.4.1. F_0 GENERATION

Macroscopic findings for all F_0 parental males and females in the inhalation and inhalation/gavage phases were few and unremarkable at the scheduled necropsy.

Mean absolute and relative (to final body weight) liver and kidney weights in the 500 and 1000 ppm group males were increased compared to the control group values; the differences were generally statistically significant ($p<0.01$). Relative liver weights were increased 13.1 and 26.6% in the 500 and 1000 ppm group males, respectively. Relative kidney weights were increased 10.5 and 19.0% in the same respective groups. Mean absolute and relative liver weights were increased (generally statistically significant at $p<0.05$ or $p<0.01$) in the females exposed to 500 and 1000 ppm in both phases, while kidney weights were similar to the control group. Relative liver weights were increased 21.9 and 37.6% in the 500 and 1000 ppm group females (inhalation phase), respectively, and 14.0 and 25.8% in the 500 ppm/342 mg/kg and 1000 ppm/621 mg/kg group females (inhalation/gavage phase), respectively. Mean liver and kidney weights in the 100 ppm group males and females and 100 ppm/90 mg/kg group females were unaffected by exposure to the test article.

6.4.2. F_1 PUPS FOUND DEAD

No macroscopic findings that could be attributed to parental exposure to the test article were noted in any of the pups found dead in the inhalation only and inhalation/gavage phases. Aside from the presence or absence of milk in the stomach, macroscopic findings were noted for single animals or only in the control group.

6.5. F_1 GENERATION - PND 22-33

6.5.1. CLINICAL OBSERVATIONS AND SURVIVAL

Summary Data: Tables 74 through 83

Individual Data: Tables 177 through 185

One and three weanlings in the 500 and 1000 ppm groups, respectively, in the inhalation only phase and four weanlings in the 1000 ppm/621 mg/kg group in the inhalation/gavage phase were found dead or euthanized *in extremis* between PND 22 and 26. With the exception of one female in the 1000 ppm inhalation only group that was euthanized *in extremis* on PND 23 due to a broken right forelimb, these mortalities were considered to be exposure-related. Two weanlings (nos. 10492-02 and 10492-12) in the 100 ppm/90 mg/kg inhalation/gavage group were found dead on PND 23. As these weanlings were littermates and were very small at weaning on PND 21 (20.2 g and 21.8 g, respectively), these deaths were likely due to their small size and not to test article administration. In addition, two weanlings in the 1000 ppm/621 mg/kg inhalation/gavage group were inadvertently removed from the animal room on PND 24 and were therefore euthanized. All other animals survived to the scheduled euthanasia. Exposure-related clinical signs noted in both phases one hour following exposure for animals found dead, euthanized *in extremis* and at the scheduled termination in the 500 ppm group males and in the 1000 ppm and 1000 ppm/621 mg/kg group males and females included labored respiration, eyelids half-closed, prostrate, animal unable to right itself, and rocking, lurching or swaying while ambulating. These findings were generally noted in the first several days of exposure only. No other exposure-related clinical signs were noted at the other observation periods.

6.5.2. BODY WEIGHTS

Summary Data: Tables 84 through 87; Figures 10 through 13

Individual Data: Tables 186 through 189

Male and female mean body weight gains in the 1000 ppm inhalation only and inhalation/gavage groups were reduced during the entire exposure period (PND 22-34). The differences from the control group were statistically significant ($p<0.01$) with the exception of the 1000 ppm/621 mg/kg group males. These reductions ($p<0.05$ or $p<0.01$) were more pronounced following the first day of exposure. Mean male and female body weights in the 1000 ppm inhalation only group were reduced by 10-19% and 9-16%, respectively, throughout exposure. Mean body weights in the males and females in the 1000 ppm/621 mg/kg inhalation/gavage groups were reduced by 16-26% and 18-27%, respectively, throughout exposure. The differences in mean body weight were statistically significant ($p<0.05$ or $p<0.01$) generally throughout exposure for the inhalation/gavage females; however, these differences were more sporadic for the other groups.

Mean body weights were also slightly decreased in the 500 ppm F_1 animals in both the inhalation only (5-14%) and inhalation/gavage (3-7%) phases compared to the control group values following the start of exposure (PND 23-34) primarily as a result of a decreased body weight gain following the first day of exposure on PND 22. Mean body weight gains continued to be slightly reduced throughout exposure. The reductions in mean body weight and mean body weight gains noted in this group were less pronounced and had fewer occurrences of statistical significance than was noted in the 1000 ppm inhalation and inhalation/gavage groups.

Slightly reduced mean body weights were noted for the 100 ppm group males and females in the inhalation only (4-14%) and inhalation/gavage (6-16%) phases throughout exposure when compared to the control group. The only statistically significant ($p<0.05$) difference from the control group was noted on PND 31 for females in the inhalation phase. These consistent reductions in mean body weights for males and females in these

groups were potentially due to test article exposure. Mean body weight gains during PND 22-34 for these same males and females were similar to the control group throughout exposure. Statistically significant differences in body weight gain were sporadic and no trends were apparent.

6.5.3. MACROSCOPIC EXAMINATION - UNSCHEDULED NECROPSIES

Summary Data: Tables 88 through 90

Individual Data: Tables 190 through 192

One male in the 500 ppm group and two males and one female in the 1000 ppm groups (inhalation phase) and two males and two females in the 1000 ppm/621 mg/kg group (inhalation/gavage phase) were found dead or euthanized *in extremis* between PND 22-26. The female in the 1000 ppm group was euthanized *in extremis* due to a broken right forelimb. One male and one female in the 100 ppm/90 mg/kg inhalation/gavage group were found dead on PND 24. One male and one female in the 1000 ppm/621 mg/kg inhalation/gavage group were euthanized after removal from the animal room. No findings that could be attributed to test article exposure were noted at the macroscopic examinations of the aforementioned animals.

6.6. F_1 GENERATION - PND 29-33

6.6.1. CLINICAL OBSERVATIONS AND SURVIVAL

Summary Data: Tables 91 through 100

Individual Data: Tables 193 through 196

All F_1 animals selected for exposure from PND 29-33 in the inhalation and inhalation/gavage phases survived to the scheduled necropsy. Clinical observations were few and unremarkable at all observation periods prior to, during and following exposure in either phase.

6.6.2. BODY WEIGHTS

Summary Data: Tables 101 through 104; Figures 14 through 17

Individual Data: Tables 197 through 200

Male and female body weight gains in the 1000 ppm inhalation only and inhalation/gavage groups were decreased during the entire exposure period (PND 29-34). The differences from the control group were statistically significant ($p<0.05$ or $p<0.01$) for the inhalation only animals. These reductions ($p<0.05$ or $p<0.01$) were most pronounced following the first day of exposure. Mean F_1 body weights in the 1000 ppm inhalation only and inhalation/gavage groups were slightly reduced (not statistically significant) throughout exposure. By PND 34, mean male and female body weights were reduced by 10% and 6%, respectively, for the inhalation only phase and by 13% and 9%, respectively, for the inhalation/gavage phase.

A similar, though less pronounced, decrease in mean body weight gain was noted for the 500 ppm F_1 animals in both phases during the entire exposure period (PND 29-34). The differences in the inhalation only phase F_1 males and females were statistically significant ($p<0.05$ or $p<0.01$). These reductions were the result of decreased mean body weight gain in these animals following the first day of exposure; these differences were statistically significant ($p<0.05$ or $p<0.01$) with the exception of the 500 ppm inhalation/gavage group females. Mean F_1 body weights in the 500 ppm inhalation/gavage group were slightly (not statistically significant) reduced compared to the control group. By PND 34, male and female mean body weight were reduced by 9% and 5%, respectively, in the inhalation only groups and by 9% for the inhalation/gavage male group. No mean body weight effects were noted for the females in the 500 ppm inhalation/gavage group.

Mean body weights and mean body weight gains in the 100 ppm group F_1 males and females in the inhalation only and inhalation/gavage phases were similar to and not statistically significant compared to the control group throughout exposure.

7. DISCUSSION

This study was conducted to determine the exposure levels of Ethylbenzene to be evaluated in a reproductive toxicity study in rats, to determine the feasibility of gavage dosing of dams during lactation days 1-4 and to determine whether to begin inhalation exposures of weanlings on PND 22 or PND 29 in a subsequent two-generation reproductive toxicity study.

Based on the results of this study, gavage dosing of the F_0 females on lactation days 1-4 had no impact on maternal clinical signs or body weight parameters. In addition, postnatal survival of the litters of dams gavage dosed on lactation days 1-4 was similar to that of dams that received no test article exposure on lactation days 1-4. However, pup weight reductions in the 1000 ppm inhalation exposure groups were more pronounced in the inhalation/gavage phase (14.8 and 10.9% in male and female pups, respectively, on PND 28) than in the inhalation phase (3.4 and 4.3% in the male and female pups, respectively, on PND 28) during the pre-weaning period. These results suggest that the gavage dosing of the dams on lactation days 1-4 affected the growth of the F_1 offspring.

Test article-related clinical findings and/or deaths were observed during the first several days of inhalation exposure of F_1 weanlings on PND 22 to 500 or 1000 ppm of ethylbenzene. In contrast, no deaths or exposure-related clinical signs were observed when inhalation exposures were initiated on PND 29. Body weight gain reductions were observed in the 500 and 1000 ppm groups for both the inhalation and inhalation/gavage phases when weanling inhalation exposures initiated on both PND 22 and PND 29, and reduced mean body weights were noted for the inhalation and inhalation/gavage weanlings exposed to 100 ppm of the test article beginning on PND 22. These results indicate that the PND 22 weanlings are more sensitive to inhalation exposure to ethylbenzene than PND 29 weanlings but growth retardation is observed when inhalation exposures initiate at both ages.

The data from this study suggest that males may be more sensitive to ethylbenzene inhalation exposure than females. Supporting this conclusion is that body weight

parameters and kidney weights in adult animals were affected to a greater magnitude in the males than the females. In addition, male pup weights prior to weaning and following weaning were generally decreased to a greater extent in the 500 and 1000 ppm group males than females in both the inhalation and inhalation/gavage phases. Finally, there were five exposure-related male deaths for males that began exposure on PND 22 compared to only two females.

7.1. CONCLUSIONS

Based on the results of this study, gavage dosing of dams on lactation days 1-4 will be performed and weanling inhalation exposure will initiate on PND 22 in a definitive two-generation reproductive toxicity study of ethylbenzene via whole-body inhalation. Exposure levels for this study will be 25, 100 and 500 ppm, and gavage dose levels on lactation days 1-4 will be 26, 90 and 342 mg/kg/day.

8. KEY STUDY PERSONNEL AND REPORT SUBMISSION

Study Supervisors:

Sally A. Keets, A.S.	Acting Senior Operations Manager, Vivarium
Carol A. Kopp, B.S.	Manager, Gross Pathology and Developmental Toxicology Laboratory
Daniel W. Sved, Ph.D.	Director, Metabolism and Analytical Chemistry

Report Prepared By:

for: Amy D. Headings, B.S.H.E., B.A., R.D.
Associate Study Analyst

8/1/03
Date

Report Reviewed By:

Lewis E. Kaufman, M.S., RAC, RQAP-GLP
Director, Regulatory Affairs and Services

8/1/03
Date

Daniel T. Kirkpatrick, Ph.D., D.A.B.T.
Director, Inhalation Toxicology

8/1/03
Date

Mark D. Nemec, B.S., D.A.B.T.
Director, Developmental and
Reproductive Toxicology

8/1/2003
Date

KEY STUDY PERSONNEL AND REPORT SUBMISSION (CONTINUED)

Report Reviewed By (continued):

Evelyn Tanchevski — 8/1/03

Evelyn Tanchevski, B.S.
Group Supervisor, Study Analysis and Reports

Date

8/1/03

Bennett J. Varsho, B.S., L.A.T.G.
Operations Manager, Developmental,
Reproductive and Neurotoxicology

Date

Report Approved and Submitted By:

Donald G. Stump — 8/1/03

Donald G. Stump, Ph.D., D.A.B.T.
Associate Director, Developmental and
Reproductive Toxicology
Study Director

Date

9. QUALITY ASSURANCE UNIT STATEMENT

9.1. PHASES INSPECTED

Date(s) of Inspection(s)	Phase Inspected	Date(s) Findings Reported to Study Director	Date(s) Findings Reported to Management
9/6/02	Test Article Exposure	9/6/02	10/31/02
9/23/02	Gestational Body and Food Weights	9/23/02	10/31/02
9/27/02	Gestational Observations	9/27/02	10/31/02
10/1/02	Animal Care & Equipment	10/1/02	11/27/02
11/11/02	Necropsy	11/11/02	12/31/02
12/18/02	Study Records (Rx-1)	12/18/02	1/31/03
12/20, 23, 30-31/02, 1/8, 17/03	Study Records (I-1)	1/23/03	2/28/03
12/30/02, 1/2, 17-18/03	Study Records (I-2)	1/20/03	2/28/03
12/30/02, 1/17-18/03	Study Records (I-3)	1/20/03	2/28/03
12/30-31/02, 1/2, 8, 17-18/03	Study Records (I-5)	1/20/03	2/28/03
12/31/02, 1/2, 17-18/03	Study Records (I-8)	1/20/03	2/28/03
1/3, 6-8, 22/03	Study Records (I-4)	1/23/03	2/28/03
1/9, 17-18/03	Study Records (I-6)	1/20/03	2/28/03
1/9-10, 17-18/03	Study Records (I-9)	1/20/03	2/28/03
1/10, 13, 17-18/03	Study Records (N-1)	1/20/03	2/28/03
1/13, 17, 21/03	Study Records (Ex-4)	1/21/03	2/28/03
1/13-14, 20/03	Study Records (Ex-5)	1/20/03	2/28/03
1/14, 20/03	Study Records (Ex-6)	1/20/03	2/28/03
1/14-15, 20/03	Study Records (Ex-7)	1/20/03	2/28/03
1/15, 17-18/03	Study Records (I-7)	1/20/03	2/28/03
1/15, 20/03	Study Records (Ex-8)	1/20/03	2/28/03
1/16-17, 20/03	Study Records (Ex-3)	1/21/03	2/28/03
1/20-24, 27-31/03, 2/6-7, 9/03	Draft Report- Tables Only	2/10/03	3/31/03
1/16/03, 2/19, 26/03	Study Records (Ex-1 & Ex-1A)	2/26/03	3/31/03
1/16-17/03, 2/19, 26/03	Study Records (Ex-2)	2/26/03	3/31/03
2/24-25, 27/03, 3/3-5, 7/03	Draft Report (without Analytical Chemistry)	3/7/03	4/30/03
12/18-20/02, 3/10-11/03	Study Records (A-1 & A-2)	3/11/03	4/30/03
3/11-12/03	Draft Report (Analytical Chemistry Only)	3/12/03	4/30/03
3/12-13, 17/03	Draft Report (Inhalation Only)	3/17/03	4/30/03

This study was inspected in accordance with the U.S. EPA Good Laboratory Practice Regulations (40 CFR Part 792), the OECD Principles of Good Laboratory Practice, the Japanese Ministry of International Trade and Industry (MITI) Directive 31, the standard operating procedures of WIL Research Laboratories, Inc., and the sponsor's protocol and protocol amendments with the following exceptions. The data located in Appendices A (Certificate of Analysis) and D (Estimation of Oral Doses Report) were the responsibility of the sponsor's designee. Quality Assurance findings, derived from the inspections during the conduct of the study and from the inspections of the raw data and draft report, are documented and have been reported to the study director. A status report is submitted to management monthly.

This report accurately reflects the data generated during the study. The methods and procedures used in the study were those specified in the protocol, its amendments and the standard operating procedures of WIL Research Laboratories, Inc.

The raw data, the retention sample(s), if applicable, and the final report will be stored in the Archives at WIL Research Laboratories, Inc., or another location specified by the sponsor.

9.2. APPROVAL

This study was inspected according to the criteria discussed in Section 9.1.

Report Audited By:

Heather L Skelton 8/1/03
for: R. Kelvin Mentzer, B.S. Date
Auditor I, Quality Assurance

Report Released By:

Margaret A. Franklin Unit Supervisor, Quality Assurance

Heather L Skelton 8/1/03
Heather L. Skelton, B.S. Date
Manager, Quality Assurance

10. REFERENCES

1. National Research Council *Guide for the Care and Use of Laboratory Animals,* Institute of Laboratory Animal Resources, Commission on Life Sciences; National Academy Press: Washington, DC, **1996**.

2. Stuckhardt, J.L.; Poppe, S.M. Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. *Teratogenesis, Carcinogenesis and Mutagenesis* **1984,** *4,* 181-188.

3. Salewski, E. Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. *Naunyn - Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologi* **1964**, 247-367.

4. Hollander, M.; Wolfe, D.A. *Nonparametric Statistical Methods*, 2nd ed. John Wiley and Sons, Inc.: New York, NY, **1999**; p 468.

5. Levene, H. Robust Tests for Equality of Variances. In: *Contributions to Probability and Statistics*; Stanford University Press: Palo Alto, CA, **1960**; pp. 278-292.

6. Royston, J.P. An extension of Shapiro and Wilk's *w* test for normality to large samples. *Appl. Statist.* **1982** *31(2),* 115-124.

7. Snedecor, G.W.; Cochran, W.G. One Way Classifications; Analysis of Variance. In *Statistical Methods*, 7th ed.; The Iowa State University Press: Ames, IA, **1980**; pp 215-237.

8. Dunnett, C.W. New tables for multiple comparisons with a control. *Biometrics* **1964,** *20,* 482-491.

9. Kruskal, W.H.; Wallis, W.A. Use of ranks in one-criterion variance analysis. *Journal of the American Statistical Association* **1952,** *47,* 583-621.

10. SAS Institute, Inc. *SAS Proprietary Software Release,* Version 8.2; SAS Institute, Inc.: Cary, NC, **1999-2001**.

11. DEVIATIONS FROM THE PROTOCOL

This study was conducted in accordance with the protocol and protocol amendments, except for the following.

- **Section 4.1.3.** On November 3, 2002, chamber samples were taken manually. On the same date, only five environmental measurements were taken.
- **Section 4.1.3.** On November 20, 2002, nine exposure samples were collected instead of the protocol-specified ten.
- **Section 4.1.3.** For the following samples, chamber concentrations were outside the protocol-specified range of ± 15%:

Date	Chamber	Time	Target Concentration	Actual Concentration
9/9/02	4	00:30	1000 ppm	1212 ppm
9/12/02	2	00:23	100 ppm	134 ppm
9/13/02	2	00:23	100 ppm	74 ppm
9/16/02	2	02:08	100 ppm	83 ppm
9/16/02	4	01:40	1000 ppm	760 ppm
9/26/02	3	00:27	500 ppm	352 ppm
10/16/02	2	00:22	100 ppm	0 ppm
10/16/02	2	00:36	100 ppm	182 ppm
10/18/02	2	00:22	100 ppm	79 ppm
11/2/02	2	00:57	100ppm	83 ppm
11/2/02	2	01:32	100 ppm	77 ppm
11/2/02	2	02:07	100 ppm	71 ppm
11/2/02	2	02:42	100 ppm	71 ppm
11/2/02	2	03:17	100 ppm	79 ppm
11/2/02	2	03:52	100ppm	122 ppm

- **Section 4.1.4.** On September 11, 2002, battery A of the 0 ppm group was not rotated from the previous day's position.
- **Section 4.5.** On November 18, 2001, the light period was 42 minutes longer than the protocol-specified 12 hours.
- **Section 4.6.** At the beginning of the in-life phase (9/6/02), the F_0 animals were 10 weeks and 4 days old, younger than the protocol-specified 11 weeks.
- **Section 4.6.** The minimum body weight at the start of the in-life phase for males and females selected for the F_0 generation were 340 g and 215 g, respectively, below the protocol-specified minimum weights of 350 g and 220 g, respectively.

DEVIATIONS FROM THE PROTOCOL (CONTINUED)

- **Section 5.1.1.** On November 3, 12, 13, 14 and 18, the one-hour post-dosing observations exceeded the SOP optimal time frame by 5 to 37 minutes.
- **Section 5.1.1.** On October 28 and 31, 2002, the one-hour post-dosing observation for female no. 10489 in the 500 ppm/342 mg/kg group exceeded the SOP optimal time frame by 11 and 6 minutes, respectively.
- **Section 5.1.2.** On October 31, 2002, the final body weight for female no. 10511 in the 1000 ppm group was inadvertently not recorded.
- **Section 5.2.2.** On October 17, 2002, organ weights were inadvertently not collected for female no. 10520 in the 500 ppm group.
- **Appendix B.** On August 6, 2002, two samples of the test article were collected and analyzed for purity instead of the protocol-specified one sample.

These deviations did not negatively impact the quality or integrity of the data nor the outcome of the study.

FIGURES 1 - 17

PROJECT NO.:WIL-186028M
SPONSOR:ACC

FIGURE 1 (F0 MALES)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028F
SPONSOR:ACC

FIGURE 2 (F0 FEMALES - PRE-MATING)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028F
SPONSOR:ACC

FIGURE 3 (F0 FEMALES)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS DURING GESTATION [G]



PROJECT NO.:WIL-186028I
SPONSOR:ACC

FIGURE 4 (F0 FEMALES - INHALATION PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS DURING LACTATION [G]



PROJECT NO.:WIL-186028G
SPONSOR:ACC

FIGURE 5 (F0 FEMALES - INHALATION/GAVAGE PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS DURING LACTATION [G]



PROJECT NO.:WIL-186028I
SPONSOR:ACC

FIGURE 6 (F1 MALES - INHALATION PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF OFFSPRING WEIGHTS [G]



PROJECT NO.:WIL-186028I
SPONSOR:ACC

FIGURE 7 (F1 FEMALES - INHALATION PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF OFFSPRING WEIGHTS [G]



PROJECT NO.:WIL-186028G
SPONSOR:ACC

FIGURE 8 (F1 MALES - INHALATION/GAVAGE PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF OFFSPRING WEIGHTS [G]



* = Significantly different from the control group at p<0.05
** = Significantly different from the control group at p<0.01

0 PPM/0 MG/KG — 100 PPM/90 MG/KG — 500 PPM/342MG/KG — 1000PPM/621MG/KG

PROJECT NO.:WIL-186028G
SPONSOR:ACC

FIGURE 9 (F1 FEMALES - INHALATION/GAVAGE PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF OFFSPRING WEIGHTS [G]



PROJECT NO.:WIL-186028A
SPONSOR:ACC

FIGURE 10 (F1 MALES - INHALATION PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028A
SPONSOR:ACC

FIGURE 11 (F1 FEMALES - INHALATION PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028D
SPONSOR:ACC

FIGURE 12 (F1 MALES - INHALATION/GAVAGE PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



* = Significantly different from the control group at p<0.05

0 PPM/0 MG/KG — 100 PPM/90 MG/KG — 500 PPM/342 MG/KG — 1000 PPM/621 MG/KG

PROJECT NO.:WIL-186028D
SPONSOR:ACC

FIGURE 13 (F1 FEMALES - INHALATION/GAVAGE PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



* = Significantly different from the control group at p<0.05
** = Significantly different from the control group at p<0.01

0 PPM/0 MG/KG — 100 PPM/90 MG/KG — 500 PPM/342 MG/KG — 1000 PPM/621 MG/KG

PROJECT NO.:WIL-186028B
SPONSOR:ACC

FIGURE 14 (F1 MALES - INHALATION PHASE - PND 29-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028B
SPONSOR:ACC

FIGURE 15 (F1 FEMALES - INHALATION PHASE - PND 29-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028E
SPONSOR:ACC

FIGURE 16 (F1 MALES - INHALATION/GAVAGE PHASE - PND 29-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



PROJECT NO.:WIL-186028E
SPONSOR:ACC

FIGURE 17 (F1 FEMALES - INHALATION/GAVAGE PHASE - PND 29-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF BODY WEIGHTS [G]



TABLES 1 - 104

TABLE 1 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1				2				3				4			
WEEK	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
1	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
2	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
3	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
4	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0	20

WEEK = WEEK OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PSURVv4.02
01/14/2003

TABLE 2 (F0 FEMALES - PRE-MATING/GESTATION)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1				2				3				4			
WEEK	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
0	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
1	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
2	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
3	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
4	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
5	20	0	0	0	20	0	0	0	20	0	0	0	20	0	0	0
6	16	0	0	4	17	0	0	3	20	0	0	0	20	0	0	0
7	15	0	0	1	17	0	0	0	20	0	0	0	19	0	0	1

WEEK = WEEK OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 3 (F0 FEMALES - LACTATION - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1				2				3				4			
WEEK	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
5	7	0	0	0	9	0	0	0	9	0	0	1	9	0	0	0
6	7	0	0	0	9	0	0	0	9	0	0	0	9	0	0	0
7	7	0	0	0	8	0	0	1	9	0	0	0	9	0	0	0
8	7	0	0	0	8	0	0	0	9	0	0	0	9	0	0	0
9	1	0	0	6	3	0	0	5	2	0	0	7	1	0	0	8
10	0	0	0	1	0	0	0	3	0	0	0	2	0	0	0	1

WEEK = WEEK OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 4 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1				2				3				4			
WEEK	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE	LIVE	FD	EE	SE
5	8	0	0	0	8	0	0	0	10	0	0	0	10	0	0	0
6	8	0	0	0	8	0	0	0	10	0	0	0	10	0	0	0
7	8	0	0	0	8	0	0	0	10	0	0	0	10	0	0	0
8	8	0	0	0	8	0	0	0	10	0	0	0	10	0	0	0
9	2	0	0	6	3	0	0	5	3	0	0	7	1	0	0	9
10	0	0	0	2	0	0	0	3	1	0	0	2	0	0	0	1
11	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0

WEEK = WEEK OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 5 (F0 MALES - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	09-06-02 TO 10-08-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	108/20	113/20	114/20	116/20
DISPOSITION				
-SCHEDULED EUTHANASIA	20/20	20/20	20/20	20/20
BODY/INTEGUMENT				
-HAIR LOSS RIGHT FORELIMB	11/ 4	0/ 0	6/ 3	3/ 1
-HAIR LOSS LEFT FORELIMB	7/ 2	2/ 1	4/ 1	3/ 1
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	2/ 2	1/ 1	0/ 0	0/ 0
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	1/ 1	0/ 0	0/ 0
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	3/ 3	0/ 0	1/ 1
-SALIVATION	0/ 0	1/ 1	0/ 0	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/22/2003

TABLE 6 (F0 MALES - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	09-06-02 TO 10-07-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	1/ 1	1/ 1	0/ 0	0/ 0
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	3/ 3	0/ 0	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 7 (F0 MALES - MIDPOINT OF EXPOSURE)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	09-06-02 TO 10-07-02			
GROUP:	1	2	3	4

THERE WERE NO SIGNIFICANT OBSERVATIONS AT THE MIDPOINT OF EXPOSURE

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 8 (F0 MALES - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	09-06-02 TO 10-07-02			
GROUP:	1	2	3	4
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	0/ 0	1/ 1	1/ 1
-SALIVATION	0/ 0	0/ 0	2/ 1	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 9 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE: 09-06-02 TO 10-31-02

GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	107/18	110/20	112/20	96/20
DISPOSITION				
-SENT TO NECROPSY; POST-MATING DAY 25	5/ 5	3/ 3	0/ 0	0/ 0
-SENT TO NECROPSY; POST-COHABITATION DAY 25	0/ 0	0/ 0	0/ 0	1/ 1
BODY/INTEGUMENT				
-HAIR LOSS RIGHT FORELIMB	22/ 6	17/ 5	9/ 3	24/ 7
-HAIR LOSS LEFT FORELIMB	22/ 6	13/ 4	8/ 3	27/ 9
-HAIR LOSS LEFT ABDOMINAL AREA	2/ 1	0/ 0	0/ 0	0/ 0
-HAIR LOSS LEFT HINDLIMB	2/ 1	0/ 0	0/ 0	0/ 0
-HAIR LOSS RIGHT HINDLIMB	2/ 1	0/ 0	0/ 0	1/ 1
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	0/ 0	1/ 1
SPECIAL II				
-BREEDING PERIOD COMPLETE SEPARATED FROM MALE	1/ 1	1/ 1	1/ 1	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:07/31/2003

TABLE 10 (F0 FEMALES - PRE-MATING/GESTATION - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	09-06-02 TO 10-30-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	0/ 0	3/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/12/2003

TABLE 11 (F0 FEMALES - PRE-MATING/GESTATION - MIDPOINT OF EXPOSURE)

PROJECT NO.:WIL-186028F — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 1

SPONSOR:ACC — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	09-06-02 TO 10-30-02			
GROUP:	1	2	3	4
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/13/2003

TABLE 12 (F0 FEMALES - PRE-MATING/GESTATION - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028F — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 1

SPONSOR:ACC — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE: 09-06-02 TO 10-30-02

GROUP:	1	2	3	4
BODY/INTEGUMENT				
-WET CLEAR MATERIAL VENTRAL NECK	0/ 0	0/ 0	0/ 0	2/ 1
-WET CLEAR MATERIAL LEFT FORELIMB	0/ 0	0/ 0	0/ 0	2/ 1
-WET CLEAR MATERIAL RIGHT FORELIMB	0/ 0	0/ 0	0/ 0	2/ 1
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND LEFT EYE	1/ 1	0/ 0	0/ 0	3/ 1
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	0/ 0	1/ 1	7/ 5

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/13/2003

TABLE 13 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 11-18-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	15/ 4	32/ 8	34/ 8	32/ 7
DISPOSITION				
-SENT TO NECROPSY; TOTAL LITTER LOSS	0/ 0	1/ 1	1/ 1	0/ 0
-SENT TO NECROPSY; LACTATION DAY 28	7/ 7	8/ 8	9/ 9	9/ 9
BEHAVIOR/CNS				
-DYSTOCIA	0/ 0	0/ 0	0/ 0	1/ 1
BODY/INTEGUMENT				
-HAIR LOSS RIGHT FORELIMB	13/ 4	7/ 3	8/ 3	13/ 3
-HAIR LOSS LEFT FORELIMB	18/ 4	8/ 2	9/ 3	13/ 3
-HAIR LOSS LEFT ABDOMINAL AREA	3/ 1	0/ 0	0/ 0	0/ 0
-HAIR LOSS RIGHT LATERAL ABDOMINAL AREA	3/ 1	0/ 0	0/ 0	0/ 0
-HAIR LOSS LEFT HINDLIMB	3/ 1	0/ 0	0/ 0	0/ 0
-SCABBING LEFT FORELIMB	1/ 1	0/ 0	0/ 0	0/ 0
-HAIR LOSS RIGHT HINDLIMB	2/ 1	0/ 0	0/ 0	2/ 1
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND RIGHT EYE	0/ 0	0/ 0	1/ 1	0/ 0
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 13 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- F E M A L E -----			
TABLE RANGE:	10-15-02 TO 11-18-02			
GROUP:	1	2	3	4
EXCRETA				
-SOFT STOOL	1/ 1	2/ 1	1/ 1	0/ 0
ORAL/DENTAL				
-UPPER INCISORS MALALIGNED	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/14/2003
R:02/14/2003

TABLE 14 (F0 FEMALES - LACTATION - INHALATION PHASE - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 11-18-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND RIGHT EYE	0/ 0	0/ 0	1/ 1	0/ 0
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	1/ 1	0/ 0
-DRIED RED MATERIAL AROUND NOSE	0/ 0	0/ 0	1/ 1	0/ 0
EXCRETA				
-SOFT STOOL	1/ 1	1/ 1	1/ 1	0/ 0
ORAL/DENTAL				
-UPPER INCISORS MALALIGNED	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 15 (F0 FEMALES - LACTATION - INHALATION PHASE - MIDPOINT OF EXPOSURE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 11-18-02			
GROUP:	1	2	3	4

THERE WERE NO SIGNIFICANT OBSERVATIONS AT THE MIDPOINT OF EXPOSURE

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 16 (F0 FEMALES - LACTATION - INHALATION PHASE - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 11-18-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 17 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 11-24-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	26/ 6	14/ 3	35/ 8	31/ 7
DISPOSITION				
-SENT TO NECROPSY; LACTATION DAY 28	8/ 8	8/ 8	10/10	10/10
BODY/INTEGUMENT				
-HAIR LOSS RIGHT HINDLIMB	0/ 0	1/ 1	0/ 0	0/ 0
-HAIR LOSS LEFT FORELIMB	13/ 3	20/ 6	7/ 3	15/ 3
-HAIR LOSS RIGHT FORELIMB	14/ 3	21/ 6	13/ 3	15/ 3
EXCRETA				
-SOFT STOOL	0/ 0	0/ 0	1/ 1	4/ 4

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/14/2003
R:02/14/2003

TABLE 18 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - PRIOR TO GAVAGE DOSING)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 10-31-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	1/ 1	0/ 0	0/ 0	0/ 0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 19 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - 1-HOUR POST-GAVAGE DOSING)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-15-02 TO 10-31-02			
GROUP:	1	2	3	4
ORAL/DENTAL				
-WET CLEAR MATERIAL AROUND MOUTH	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
01/14/2003
R:01/23/2003

TABLE 20 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-19-02 TO 11-23-02			
GROUP:	1	2	3	4
EXCRETA				
-DIARRHEA	0/ 0	0/ 0	2/ 2	0/ 0
-SOFT STOOL	0/ 0	0/ 0	2/ 2	4/ 4

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
01/22/2003
R:01/22/2003

TABLE 21 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-19-02 TO 11-23-02			
GROUP:	1	2	3	4

THERE WERE NO SIGNIFICANT OBSERVATIONS AT THE MIDPOINT OF EXPOSURE

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
01/22/2003
R:01/22/2003

TABLE 22 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	10-19-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
01/22/2003
R:01/22/2003

TABLE 23 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

		----- M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0					
	MEAN	372.	371.	371.	372.
	S.D.	18.3	17.8	17.9	14.9
	N	20	20	20	20
1					
	MEAN	388.	382.	377.	374.
	S.D.	19.5	22.6	19.7	17.6
	N	20	20	20	20
2					
	MEAN	407.	397.	393.	388.*
	S.D.	22.0	23.4	19.1	18.7
	N	20	20	20	20
3					
	MEAN	428.	417.	411.	408.*
	S.D.	22.2	25.0	23.0	21.2
	N	20	20	20	20
4					
	MEAN	452.	443.	439.	433.
	S.D.	21.3	27.6	21.2	21.0
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 24 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

		----- M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK	0 TO 1				
	MEAN	16.	11.	6.**	2.**
	S.D.	7.3	12.2	6.5	7.7
	N	20	20	20	20
	1 TO 2				
	MEAN	20.	15.	17.	14.
	S.D.	6.5	7.1	5.8	8.8
	N	20	20	20	20
	2 TO 3				
	MEAN	21.	20.	18.	20.
	S.D.	9.1	5.3	7.8	8.0
	N	20	20	20	20
	3 TO 4				
	MEAN	24.	26.	27.	25.
	S.D.	9.7	6.7	5.9	6.2
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 25 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

		----- M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK	0 TO 4				
	MEAN	80.	72.	68.*	61.**
	S.D.	14.7	18.8	12.9	17.1
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

* = Significantly different from the control group at 0.05

** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:02/14/2003

TABLE 26 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF WEEKLY FOOD CONSUMPTION [G/ANIMAL/DAY]

		----- M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK	0 TO 1				
	MEAN	26.	25.	23.**	22.**
	S.D.	2.1	2.4	2.0	1.8
	N	20	20	20	20
	1 TO 2				
	MEAN	26.	24.+	24.++	24.+
	S.D.	4.1	2.3	1.4	1.9
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05
**, ++ = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 27 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF WEEKLY FOOD CONSUMPTION [G/KG/DAY]

		----- M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK	0 TO 1				
	MEAN	68.	66.	63.**	60.**
	S.D.	5.5	5.4	4.1	3.8
	N	20	20	20	20
	1 TO 2				
	MEAN	65.	61.	61.	62.
	S.D.	10.9	3.8	2.7	4.0
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 28 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	----- M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0 TO 1				
MEAN	8.8	5.6	3.4**	1.3**
S.D.	4.15	7.36	3.98	4.79
N	20	20	20	20
1 TO 2				
MEAN	10.9	9.2	10.1	8.3
S.D.	3.56	4.11	3.53	5.11
N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 29 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

		----- F E M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0					
	MEAN	244.	240.	244.	243.
	S.D.	13.0	15.6	16.9	12.4
	N	20	20	20	20
1					
	MEAN	255.	251.	249.	248.
	S.D.	14.7	14.3	15.6	12.0
	N	20	20	20	20
2					
	MEAN	263.	260.	258.	258.
	S.D.	17.0	18.9	19.1	14.7
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 30 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

	----- F E M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0 TO 1				
MEAN	11.	11.	5.*	5.*
S.D.	6.5	7.9	5.9	7.6
N	20	20	20	20
1 TO 2				
MEAN	9.	9.	9.	10.
S.D.	8.2	7.7	6.5	7.6
N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 31 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

	----- F E M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0 TO 2				
MEAN	20.	19.	14.	15.
S.D.	9.8	11.8	7.6	11.3
N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

* = Significantly different from the control group at 0.05

PBFSTv5.12
01/14/2003
R:02/14/2003

TABLE 32 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF WEEKLY FOOD CONSUMPTION [G/ANIMAL/DAY]

		----- F E M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0 TO 1					
	MEAN	18.	18.	16.**	15.**
	S.D.	1.8	1.6	1.6	1.3
	N	20	20	20	20
1 TO 2					
	MEAN	19.	18.	18.	18.
	S.D.	2.2	1.7	1.9	1.8
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 33 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF WEEKLY FOOD CONSUMPTION [G/KG/DAY]

		----- F E M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK 0 TO 1					
	MEAN	73.	72.	67.**	61.**
	S.D.	5.0	5.2	4.8	4.5
	N	20	20	20	20
1 TO 2					
	MEAN	71.	71.	71.	71.
	S.D.	6.1	3.4	4.5	6.0
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 34 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

		----- F E M A L E -----			
	GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
WEEK	0 TO 1				
	MEAN	8.3	8.6	4.5	4.7
	S.D.	4.80	6.09	5.03	7.50
	N	20	20	20	20
	1 TO 2				
	MEAN	6.5	6.5	6.8	7.9
	S.D.	6.01	5.39	4.56	5.65
	N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PBFSTv5.12
01/14/2003
R:01/22/2003

TABLE 35 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS DURING GESTATION [G]

GROUP :		1	2	3	4
DAY 0	MEAN	269.	266.	265.	262.
	S.D./N	17.5/14	18.0/16	21.7/19	13.2/19
DAY 3	MEAN	287.	285.	282.	279.
	S.D./N	16.6/14	19.1/16	22.3/19	16.4/19
DAY 6	MEAN	297.	296.	293.	291.
	S.D./N	18.0/14	21.1/16	23.5/19	18.2/19
DAY 9	MEAN	308.	308.	304.	301.
	S.D./N	20.1/14	22.3/16	24.3/19	19.0/19
DAY 12	MEAN	321.	322.	319.	318.
	S.D./N	20.7/14	23.3/16	25.0/19	21.1/19
DAY 15	MEAN	335.	338.	335.	332.
	S.D./N	21.4/14	23.2/16	24.6/19	22.8/19
DAY 18	MEAN	374.	376.	375.	369.
	S.D./N	26.4/14	26.5/16	28.6/19	26.8/19
DAY 20	MEAN	402.	408.	405.	398.
	S.D./N	30.0/14	26.9/16	31.7/19	28.0/19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group
NONGRAVID WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PGBWSUv5.02
02/11/2003

TABLE 36 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES DURING GESTATION [G]

GROUP :	1	2	3	4
DAY 0- 3 MEAN	18.	19.	17.	17.
S.D./N	4.8/14	7.1/16	4.9/19	6.3/19
DAY 3- 6 MEAN	10.	11.	11.	11.
S.D./N	4.1/14	3.4/16	4.4/19	4.5/19
DAY 6- 9 MEAN	10.	12.	11.	10.
S.D./N	3.7/14	5.1/16	4.9/19	3.3/19
DAY 9- 12 MEAN	13.	15.	14.	17.**
S.D./N	3.3/14	3.9/16	3.2/19	3.8/19
DAY 12- 15 MEAN	15.	16.	16.	14.
S.D./N	4.0/14	3.2/16	4.7/19	5.4/19
DAY 15- 18 MEAN	39.	38.	39.	37.
S.D./N	10.4/14	6.1/16	8.7/19	6.5/19
DAY 18- 20 MEAN	28.	32.	31.	29.
S.D./N	7.3/14	5.2/16	5.5/19	4.5/19
DAY 0- 20 MEAN	132.	142.	140.	136.
S.D./N	18.8/14	13.8/16	17.7/19	18.8/19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES
NONGRAVID WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PGBWSUv5.02
02/11/2003

TABLE 37 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING GESTATION [G/ANIMAL/DAY]

GROUP :	1	2	3	4
DAY 0- 3 MEAN	20.	20.	19.	19.
S.D./N	1.9/14	2.0/16	2.2/19	2.0/19
DAY 3- 6 MEAN	22.	21.	21.	21.
S.D./N	2.3/14	2.7/16	2.3/19	2.3/19
DAY 6- 9 MEAN	22.	22.	22.	22.
S.D./N	2.3/14	2.4/16	2.4/19	2.6/19
DAY 9- 12 MEAN	22.	23.	22.	24.
S.D./N	2.1/14	2.5/16	2.4/19	2.9/19
DAY 12- 15 MEAN	21.	23.+	22.	24.+
S.D./N	2.4/14	2.2/16	2.0/19	3.1/19
DAY 15- 18 MEAN	25.	25.	25.	26.
S.D./N	3.2/14	3.2/16	3.2/19	3.7/19
DAY 18- 20 MEAN	24.	26.	25.	26.
S.D./N	2.5/14	1.7/16	2.9/19	1.2/19
DAY 0- 20 MEAN	22.	23.	22.	23.
S.D./N	2.1/14	1.9/16	2.1/19	2.3/19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05
NONGRAVID WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PGFWSUv5.02
02/11/2003

TABLE 38 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING GESTATION [G/KG/DAY]

GROUP :	1	2	3	4
DAY 0- 3 MEAN	73.	73.	70.	70.
S.D./N	5.6/14	4.8/16	5.5/19	6.9/19
DAY 3- 6 MEAN	74.	74.	72.	72.
S.D./N	5.0/14	5.1/16	4.7/19	6.9/19
DAY 6- 9 MEAN	73.	73.	72.	73.
S.D./N	5.2/14	5.1/16	4.6/19	6.3/19
DAY 9- 12 MEAN	71.	73.	72.	77.++
S.D./N	3.5/14	4.7/16	5.9/19	7.1/19
DAY 12- 15 MEAN	65.	70.*	68.	73.**
S.D./N	4.9/14	5.8/16	5.0/19	6.5/19
DAY 15- 18 MEAN	69.	69.	71.	75.++
S.D./N	5.4/14	6.8/16	7.5/19	7.7/19
DAY 18- 20 MEAN	62.	66.	65.	68.**
S.D./N	4.3/14	5.0/16	6.4/19	3.7/19
DAY 0- 20 MEAN	69.	70.	69.	71.
S.D./N	3.8/14	3.0/16	4.0/19	4.6/19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
**, ++ = Significantly different from the control group at 0.01
NONGRAVID WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PGFWSUv5.02
02/11/2003

TABLE 39 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF FOOD EFFICIENCY DURING GESTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

GROUP :	1	2	3	4
DAY 0- 3 MEAN	29.2	31.0	30.3	30.3
S.D./N	7.05/14	11.06/16	8.88/19	10.46/19
DAY 3- 6 MEAN	15.6	17.7	17.8	18.4
S.D./N	5.82/14	4.67/16	6.65/19	6.23/19
DAY 6- 9 MEAN	15.3	17.5	16.6	15.7
S.D./N	4.47/14	7.42/16	6.33/19	4.79/19
DAY 9- 12 MEAN	19.8	21.2	21.5	24.4
S.D./N	5.02/14	5.89/16	4.50/19	4.73/19
DAY 12- 15 MEAN	22.9	23.3	24.4	19.0
S.D./N	5.21/14	5.65/16	7.12/19	7.02/19
DAY 15- 18 MEAN	52.3	51.0	52.6	47.1
S.D./N	11.88/14	5.06/16	9.88/19	5.86/19
DAY 18- 20 MEAN	57.7	62.4	60.9	56.9
S.D./N	14.90/14	10.03/16	8.58/19	8.34/19
DAY 0- 20 MEAN	29.8	31.3	31.5	29.9
S.D./N	3.41/14	2.01/16	2.88/19	2.60/19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group
NONGRAVID WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PGFWSUv5.02
02/11/2003

TABLE 40 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS DURING LACTATION [G]

GROUP :		1	2	3	4
DAY 1	MEAN	297.	289.	298.	302.
	S.D./N	25.2/ 7	14.9/ 9	28.6/ 9	30.4/ 9
DAY 4	MEAN	317.	297.	308.	316.
	S.D./N	19.7/ 7	18.0/ 9	35.9/ 9	22.0/ 9
DAY 5	MEAN	319.	303.	314.	318.
	S.D./N	22.2/ 7	14.2/ 9	32.1/ 9	23.4/ 9
DAY 7	MEAN	324.	305.	316.	321.
	S.D./N	29.6/ 7	9.9/ 9	33.7/ 9	21.6/ 9
DAY 14	MEAN	348.	325.	348.	342.
	S.D./N	23.6/ 7	28.4/ 9	39.5/ 8	34.2/ 9
DAY 21	MEAN	341.	344.	351.	350.
	S.D./N	20.6/ 7	17.6/ 8	35.5/ 9	31.0/ 9
DAY 28	MEAN	300.	301.	311.	319.
	S.D./N	27.8/ 7	22.8/ 8	29.4/ 9	34.6/ 9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLBWSUv5.01
02/11/2003

TABLE 41 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES DURING LACTATION [G]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	20.	8.	10.	14.
S.D./N	15.5/ 7	9.0/ 9	10.3/ 9	13.0/ 9
DAY 4- 5 MEAN	2.	6.	6.	2.
S.D./N	9.0/ 7	8.3/ 9	7.9/ 9	10.0/ 9
DAY 5- 7 MEAN	5.	2.	1.	3.
S.D./N	9.8/ 7	7.9/ 9	6.1/ 9	6.7/ 9
DAY 7- 14 MEAN	24.	20.	29.	21.
S.D./N	12.7/ 7	26.3/ 9	10.2/ 8	18.3/ 9
DAY 14- 21 MEAN	-6.	14.	6.	8.
S.D./N	13.5/ 7	27.9/ 8	15.1/ 8	21.8/ 9
DAY 21- 28 MEAN	-41.	-44.	-39.	-31.
S.D./N	19.1/ 7	13.6/ 8	13.6/ 9	18.9/ 9
DAY 1- 28 MEAN	3.	11.	13.	17.
S.D./N	15.5/ 7	17.2/ 8	18.5/ 9	13.7/ 9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

PLBWSUv5.01
02/11/2003

TABLE 42 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	31.	29.	32.	33.
S.D./N	5.3/ 5	6.0/ 9	5.0/ 9	7.5/ 9
DAY 4- 5 MEAN	42.	37.	41.	39.
S.D./N	7.0/ 7	7.9/ 8	4.9/ 9	9.6/ 9
DAY 5- 7 MEAN	41.	34.	36.	34.
S.D./N	6.4/ 6	6.0/ 8	4.3/ 9	7.5/ 8
DAY 7- 14 MEAN	41.	47.	49.	46.
S.D./N	19.6/ 7	7.8/ 9	9.1/ 9	6.9/ 9
DAY 14- 21 MEAN	63.	63.	65.	61.
S.D./N	8.1/ 7	9.3/ 8	9.2/ 9	11.0/ 9
DAY 21- 28 MEAN	81.	78.	83.	74.
S.D./N	13.0/ 6	9.3/ 7	16.3/ 9	15.6/ 8
DAY 1- 28 MEAN	53.	56.	59.	54.
S.D./N	11.7/ 4	6.4/ 7	9.0/ 9	9.0/ 8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLFWSUv5.01
02/11/2003

TABLE 43 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	101.	99.	106.	108.
S.D./N	17.9/ 5	17.1/ 9	8.4/ 9	24.0/ 9
DAY 4- 5 MEAN	133.	123.	133.	123.
S.D./N	22.4/ 7	24.2/ 8	8.4/ 9	32.0/ 9
DAY 5- 7 MEAN	128.	112.	113.	106.
S.D./N	13.7/ 6	18.9/ 8	11.4/ 9	26.4/ 8
DAY 7- 14 MEAN	123.	150.	150.	139.
S.D./N	58.8/ 7	20.3/ 9	16.3/ 9	18.4/ 9
DAY 14- 21 MEAN	184.	187.	189.	176.
S.D./N	24.2/ 7	28.6/ 8	25.8/ 9	30.1/ 9
DAY 21- 28 MEAN	256.	242.	251.	221.
S.D./N	48.9/ 6	30.8/ 7	47.9/ 9	49.2/ 8
DAY 1- 28 MEAN	167.	181.	184.	167.
S.D./N	39.0/ 4	20.7/ 7	23.1/ 9	29.2/ 8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLFWSUv5.01
01/14/2003

TABLE 44 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

GROUP :	1	2	3	4
DAY 1- 4 MEAN	21.2	8.3	9.2	15.2
S.D./N	16.09/ 5	10.11/ 9	8.48/ 9	13.90/ 9
DAY 4- 5 MEAN	2.2	12.8	16.2	1.8
S.D./N	20.39/ 7	21.52/ 8	19.27/ 9	27.96/ 9
DAY 5- 7 MEAN	2.4	2.0	1.4	4.6
S.D./N	11.64/ 6	11.00/ 8	8.26/ 9	10.54/ 8
DAY 7- 14 MEAN	11.6	5.9	5.4	6.3
S.D./N	11.62/ 7	7.29/ 9	8.68/ 9	6.17/ 9
DAY 14- 21 MEAN	-1.6	2.8	3.5	2.0
S.D./N	2.95/ 7	5.91/ 8	6.87/ 9	5.18/ 9
DAY 21- 28 MEAN	-7.5	-8.0	-6.9	-6.2
S.D./N	3.70/ 6	2.49/ 7	2.30/ 9	3.36/ 8
DAY 1- 28 MEAN	0.5	0.9	0.9	1.4
S.D./N	1.60/ 4	1.11/ 7	1.42/ 9	1.13/ 8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLFWSUv5.01
01/14/2003

TABLE 45 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS DURING LACTATION [G]

GROUP :		1	2	3	4
DAY 1	MEAN	304.	311.	306.	293.
	S.D./N	19.0/ 8	18.9/ 8	17.2/10	18.8/10
DAY 4	MEAN	315.	320.	321.	307.
	S.D./N	23.2/ 8	24.0/ 8	20.8/10	15.3/10
DAY 5	MEAN	317.	322.	317.	311.
	S.D./N	23.8/ 8	22.5/ 8	19.6/10	13.8/10
DAY 7	MEAN	333.	331.	317.	317.
	S.D./N	27.3/ 8	27.0/ 8	24.0/10	17.2/10
DAY 14	MEAN	358.	367.	348.	337.
	S.D./N	20.9/ 8	22.4/ 8	16.5/10	21.0/10
DAY 21	MEAN	357.	369.	346.	353.
	S.D./N	18.7/ 8	25.6/ 8	15.0/10	19.4/10
DAY 28	MEAN	316.	324.	315.	314.
	S.D./N	21.2/ 8	25.4/ 8	23.2/10	18.4/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLBWSUv5.01
01/14/2003

TABLE 46 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES DURING LACTATION [G]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	11.	9.	15.	14.
S.D./N	12.4/ 8	9.3/ 8	12.2/10	11.0/10
DAY 4- 5 MEAN	2.	2.	-4.	4.
S.D./N	9.6/ 8	8.3/ 8	9.5/10	5.3/10
DAY 5- 7 MEAN	16.	9.	0.	6.
S.D./N	10.3/ 8	9.8/ 8	15.6/10	7.8/10
DAY 7- 14 MEAN	25.	36.	32.	20.
S.D./N	14.9/ 8	11.9/ 8	23.1/10	16.5/10
DAY 14- 21 MEAN	-1.	2.	-2.	16.+
S.D./N	12.6/ 8	7.9/ 8	11.7/10	21.5/10
DAY 21- 28 MEAN	-41.	-46.	-31.	-40.
S.D./N	14.2/ 8	16.2/ 8	14.5/10	14.3/10
DAY 1- 28 MEAN	12.	13.	9.	21.
S.D./N	7.6/ 8	18.0/ 8	14.9/10	18.0/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

PLBWSUv5.01
01/14/2003

TABLE 47 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	30.	34.	30.	30.
S.D./N	3.9/ 8	9.7/ 7	5.0/10	7.2/10
DAY 4- 5 MEAN	41.	40.	37.	38.
S.D./N	19.8/ 7	2.2/ 5	7.6/10	7.4/10
DAY 5- 7 MEAN	42.	43.	35.	38.
S.D./N	7.6/ 6	7.5/ 8	10.8/10	6.0/10
DAY 7- 14 MEAN	54.	57.	50.	46.**
S.D./N	5.0/ 8	3.5/ 8	5.3/10	6.8/10
DAY 14- 21 MEAN	65.	67.	64.	63.
S.D./N	6.2/ 8	7.7/ 7	7.2/10	11.3/10
DAY 21- 28 MEAN	83.	86.	83.	80.
S.D./N	13.7/ 7	15.9/ 8	7.4/ 8	17.8/10
DAY 1- 28 MEAN	61.	63.	58.	57.
S.D./N	6.8/ 7	6.7/ 7	5.8/ 8	10.4/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

PLFWSUv5.01
02/11/2003

TABLE 48 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

GROUP :	1	2	3	4
DAY 1- 4 MEAN	96.	110.	97.	100.
S.D./N	10.8/ 8	28.4/ 7	16.9/10	24.5/10
DAY 4- 5 MEAN	128.	128.	117.	124.
S.D./N	57.0/ 7	11.0/ 5	22.3/10	24.3/10
DAY 5- 7 MEAN	130.	131.	109.	121.
S.D./N	17.0/ 6	17.0/ 8	34.8/10	17.2/10
DAY 7- 14 MEAN	157.	163.	149.	140.
S.D./N	8.8/ 8	11.2/ 8	17.5/10	20.1/10
DAY 14- 21 MEAN	181.	182.	185.	184.
S.D./N	12.1/ 8	26.5/ 7	26.0/10	33.3/10
DAY 21- 28 MEAN	248.	251.	255.	240.
S.D./N	36.2/ 7	54.1/ 8	32.7/ 8	57.1/10
DAY 1- 28 MEAN	187.	192.	182.	178.
S.D./N	14.7/ 7	25.5/ 7	23.0/ 8	33.1/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PLFWSUv5.01
02/11/2003

TABLE 49 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

GROUP :	1	2	3	4
DAY 1- 4 MEAN	11.7	10.0	14.9	16.0
S.D./N	12.00/ 8	9.41/ 7	11.70/10	10.49/10
DAY 4- 5 MEAN	3.3	-4.7	-15.3	7.9
S.D./N	18.23/ 7	16.03/ 5	43.98/10	16.66/10
DAY 5- 7 MEAN	17.8	9.9	-21.8	8.7
S.D./N	13.93/ 6	10.19/ 8	84.36/10	10.72/10
DAY 7- 14 MEAN	6.7	9.2	9.8	6.3
S.D./N	4.08/ 8	3.30/ 8	9.13/10	5.64/10
DAY 14- 21 MEAN	-0.3	0.7	-0.6	3.6+
S.D./N	2.95/ 8	1.69/ 7	2.58/10	4.38/10
DAY 21- 28 MEAN	-7.9	-7.9	-5.8	-7.2
S.D./N	3.26/ 7	3.06/ 8	2.53/ 8	2.40/10
DAY 1- 28 MEAN	0.7	0.9	0.4	1.5
S.D./N	0.46/ 7	1.15/ 7	0.95/ 8	1.44/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05

PLFWSUv5.01
02/11/2003

TABLE 50 (F0)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETYHLBENZENE IN RATS

SPONSOR: ACC SUMMARY OF REPRODUCTIVE PERFORMANCE

DOSE GROUP :	1		2		3		4	
	NO.	%	NO.	%	NO.	%	NO.	%
FEMALES ON STUDY	20		20		20		20	
FEMALES THAT DIED DURING STUDY	0		0		0		0	
FEMALES ALLOWED TO DELIVER	20		20		20		20	
NONGRAVID	5	25.0	3	15.0	0	0.0	1	5.0
GRAVID	15	75.0	17	85.0	20	100.0	19	95.0
DELIVERED	15	75.0	17	85.0	20	100.0	19	95.0
FEMALES WITH TOTAL LITTER LOSS	0	0.0	1	5.9	1	5.0	0	0.0
FEMALES WITH VIABLE PUPS	15	100.0	16	94.1	19	95.0	19	100.0
FEMALES WITH EVIDENCE OF MATING	19	95.0	19	95.0	19	95.0	19	95.0
NUMBER THAT DELIVERED	14	73.7	16	84.2	19	100.0	19	100.0
NUMBER THAT DID NOT DELIVER	5	26.3	3	15.8	0	0.0	0	0.0
FEMALES WITH NO EVIDENCE OF MATING	1	5.0	1	5.0	1	5.0	1	5.0
NUMBER THAT DELIVERED	1	100.0	1	100.0	1	100.0	0	0.0
NUMBER THAT DID NOT DELIVER	0	0.0	0	0.0	0	0.0	1	100.0
TOTAL FEMALES GRAVID	15	75.0	17	85.0	20	100.0	19	95.0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

NOTE: POSITIVE EVIDENCE OF MATING DURING THE BREEDING PERIOD WAS CONFIRMED BY THE PRESENCE OF SPERM IN A VAGINAL SMEAR OR A COPULATORY PLUG.

TABLE 50 (F0)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETYHLBENZENE IN RATS

SPONSOR: ACC SUMMARY OF REPRODUCTIVE PERFORMANCE

DOSE GROUP :	1		2		3		4	
	NO.	%	NO.	%	NO.	%	NO.	%
MALES ON STUDY	20		20		20		20	
MALES THAT DIED DURING STUDY	0		0		0		0	
MALES WITH EVIDENCE OF MATING	19	95.0	19	95.0	19	95.0	19	95.0
NO. THAT SIRED A LITTER	14	73.7	16	84.2	19	100.0	19	100.0
NO. THAT DID NOT SIRE A LITTER	5	26.3	3	15.8	0	0.0	0	0.0
MALES WITH NO EVIDENCE OF MATING	1	5.0	1	5.0	1	5.0	1	5.0
NO. THAT SIRED A LITTER	1	100.0	1	100.0	1	100.0	0	0.0
NO. THAT DID NOT SIRE A LITTER	0	0.0	0	0.0	0	0.0	1	100.0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

NOTE: MALES WERE CONSIDERED TO HAVE SIRED A LITTER IF THE PAIRED FEMALE WAS GRAVID, REGARDLESS OF DELIVERY STATUS

NOTE: POSITIVE EVIDENCE OF MATING DURING THE BREEDING PERIOD WAS CONFIRMED BY THE PRESENCE OF SPERM IN A VAGINAL SMEAR OR A COPULATORY PLUG.

TABLE 50 (F0)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETYHLBENZENE IN RATS PAGE 3

SPONSOR: ACC SUMMARY OF REPRODUCTIVE PERFORMANCE

DOSE GROUP :	1		2		3		4	
	NO.	%	NO.	%	NO.	%	NO.	%
MALE MATING INDEX	20/20	100.0	20/20	100.0	20/20	100.0	19/20	95.0
FEMALE MATING INDEX	20/20	100.0	20/20	100.0	20/20	100.0	19/20	95.0
MALE FERTILITY INDEX	15/20	75.0	17/20	85.0	20/20	100.0	19/20	95.0
FEMALE FERTILITY INDEX	15/20	75.0	17/20	85.0	20/20	100.0	19/20	95.0
MEAN PRE-COITAL INTERVALS (DAYS)	3.4	NA	2.7	NA	3.2	NA	2.4	NA
S.D.	2.99	NA	1.33	NA	2.61	NA	1.34	NA
N	19		19		19		19	

$$\text{MALE (FEMALE) MATING INDEX (\%)} = \frac{\text{NO. OF MALES (FEMALES) WITH EVIDENCE OF MATING (OR CONFIRMED PREGNANCY)}}{\text{TOTAL NO. OF MALES (FEMALES) USED FOR MATING}} \times 100$$

$$\text{MALE FERTILITY INDEX (\%)} = \frac{\text{NO. OF MALES SIRING A LITTER}}{\text{TOTAL NO. OF MALES USED FOR MATING}} \times 100$$

$$\text{FEMALE FERTILITY INDEX (\%)} = \frac{\text{NO. OF FEMALES WITH CONFIRMED PREGNANCY}}{\text{TOTAL NO. OF FEMALES USED FOR MATING}} \times 100$$

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

NOTE: MALES WERE CONSIDERED TO HAVE SIRED A LITTER IF THE PAIRED FEMALE WAS GRAVID, REGARDLESS OF DELIVERY STATUS

PRE-COITAL INTERVALS NOT SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP USING DUNNETT'S TEST

MATING AND FERTILITY INDICES NOT SIGNIFICANTLY DIFFERENT FROM CONTROL GROUP USING CHI-SQUARE TEST

NA = NOT APPLICABLE

TABLE 51 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF GESTATION LENGTHS [DAYS]

DOSE GROUP :		1	2	3	4
NO. OF ANIMALS		14	16	19	19
GESTATION LENGTH (DAYS)	MEAN	22.1	21.8	21.9	21.8
	S.D.	0.27	0.45	0.32	0.37

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PGLv5.01
01/14/2003

TABLE 52 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF IMPLANTATION SITES

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
IMPLANTATION SITES				
MEAN	15.9	15.5	15.7	15.5
S.D.	2.43	1.59	2.91	2.32
N	15	17	20	19
NUMBER BORN				
MEAN	14.3	14.7	14.6	14.4
S.D.	3.85	1.86	3.79	2.14
N	15	17	20	19
UNACCOUNTED SITES				
MEAN	1.6	0.8	1.1	1.1
S.D.	1.96	0.90	2.20	1.47
N	15	17	20	19

None significantly different from the control group

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

NOTE: ONLY DAMS THAT HAVE DELIVERED ONE OR MORE PUPS ARE INCLUDED IN CALCULATION OF MEAN.

PISSUv5.02
01/21/2003
R:01/21/2003

TABLE 53 (F1 - COMBINED PHASES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF PND 0 LITTER DATA

GROUP :	1	2	3	4
NUMBER BORN				
MEAN	14.3	14.7	14.6	14.4
S.D.	3.85	1.86	3.79	2.14
N	15	17	20	19
SEX AT BIRTH (% MALES PER LITTER)				
MEAN	48.5	48.1	46.0	49.0
S.D.	14.62	9.60	18.12	15.65
N	15	17	19	19
LIVE LITTER SIZE (PND 0)				
MEAN	14.2	14.5	13.8	13.7
S.D.	3.80	1.74	4.24	2.69
N	15	17	20	19
POSTNATAL SURVIVAL % (PND 0 RELATIVE TO NUMBER BORN)				
MEAN	99.2	99.3	91.8	94.7
S.D.	2.18	2.69	22.09	10.72
N	15	17	20	19

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

None significantly different from the control group

MANUALv1.0
01/21/2003
R:03/12/2003

TABLE 54 (F1 - COMBINED PHASES)

PROJECT NO.:WIL-186028 PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHTS [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
PND 1					
MALES	MEAN	7.2	7.3	7.0	6.4**
	S.D.	0.65	0.88	0.71	0.55
	N	15	17	19	19
FEMALES	MEAN	6.7	6.8	6.5	6.1*
	S.D.	0.52	0.80	0.69	0.59
	N	15	17	19	18

PND = POSTNATAL DAY

* = Significantly different from the control group at 0.05 using a nested analysis of covariance

** = Significantly different from the control group at 0.01 using a nested analysis of covariance

MANUALv1.0
11/11/2002
R:02/13/2003

TABLE 55 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF POSTNATAL SURVIVAL [% PER LITTER]

GROUP :	1	2	3	4
PND 0 (RELATIVE TO NUMBER BORN)				
MEAN	99.1	98.8	87.1	93.8
S.D.	2.36	3.70	31.09	12.67
N	7	9	10	9
PND 0 TO PND 1				
MEAN	100.0	97.6	100.0	88.4
S.D.	0.00	7.14	0.00	20.55
N	7	9	9	9
PND 1 TO PND 4 (PRE-SELECTION)				
MEAN	100.0	94.2	99.3	98.6
S.D.	0.00	15.04	2.22	4.17
N	7	9	9	9
PND 4 (POST-SELECTION) TO PND 7				
MEAN	100.0	100.0	100.0	96.7
S.D.	0.00	0.00	0.00	5.00
N	7	9	9	9
PND 7 TO PND 14				
MEAN	100.0	90.0	97.8	100.0
S.D.	0.00	30.00	6.67	0.00
N	7	9	9	9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

TABLE 55 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF POSTNATAL SURVIVAL [% PER LITTER]

GROUP :	1	2	3	4
PND 14 TO PND 21				
MEAN	100.0	88.9	98.9	100.0
S.D.	0.00	33.33	3.33	0.00
N	7	9	9	9
PND 21 TO PND 28				
MEAN	100.0	100.0	100.0	100.0
S.D.	0.00	0.00	0.00	0.00
N	7	8	9	9
BIRTH TO PND 4 (PRE-SELECTION)				
MEAN	99.1	91.7	86.5	84.1
S.D.	2.36	18.74	30.85	25.75
N	7	9	10	9
PND 4 (POST-SELECTION) TO PND 28				
MEAN	100.0	88.9	95.8	95.8
S.D.	0.00	33.33	8.84	6.25
N	7	9	9	9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

STATISTICS PERFORMED USING KRUSKAL-WALLIS

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

PPVIASv5.01
01/14/2003

TABLE 56 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

TOTAL NUMBER OF FINDINGS/NUMBER OF PUPS WITH FINDING

FINDING GROUP :	1	2	3	4
NORMAL				
NO REMARKABLE OBSERVATIONS	435/ 96	520/125	568/139	474/101
DISPOSITION				
FOUND DEAD	1/ 1	19/ 19	13/ 13	6/ 6
EUTHANIZED IN EXTREMIS	0/ 0	1/ 1	0/ 0	2/ 2
SCHEDULED EUTHANASIA (PND 28)	39/ 39	45/ 45	51/ 51	43/ 43
CULLED ON SCHEDULED DAY (PND 4)	31/ 31	33/ 33	48/ 48	22/ 22
MISSING	0/ 0	1/ 1	1/ 1	13/ 13
SELECTED FOR EXPOSURE; PND 22-33	14/ 14	15/ 15	18/ 18	17/ 17
SELECTED FOR EXPOSURE; PND 29-33	13/ 13	16/ 16	18/ 18	17/ 17
BODY/INTEGUMENT				
DISTAL END OF TAIL MISSING	0/ 0	0/ 0	5/ 2	8/ 2
SUBCUTANEOUS HEMORRHAGE(S)	9/ 5	2/ 2	0/ 0	6/ 2
PALE IN COLOR	1/ 1	0/ 0	0/ 0	2/ 2
SMALL IN SIZE	1/ 1	1/ 1	12/ 7	5/ 4
WET RED MATERIAL	0/ 0	0/ 0	0/ 0	2/ 2
BODY COOL TO TOUCH	0/ 0	1/ 1	0/ 0	0/ 0
TAIL SKIN FLAKY IN APPEARANCE	0/ 0	0/ 0	11/ 10	0/ 0
SCABBING	2/ 2	3/ 3	12/ 8	6/ 6
BLACKENED AREA DISTAL END OF TAIL	0/ 0	0/ 0	13/ 7	0/ 0
DRIED RED MATERIAL	1/ 1	4/ 2	0/ 0	2/ 2
UNEVEN HAIR GROWTH	0/ 0	17/ 10	3/ 3	0/ 0
RING-LIKE INDENTATIONS ON TAIL	0/ 0	0/ 0	11/ 6	0/ 0
DARK RED IN COLOR DISTAL END OF TAIL	0/ 0	0/ 0	2/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 56 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

TOTAL NUMBER OF FINDINGS/NUMBER OF PUPS WITH FINDING

FINDING	GROUP : 1	2	3	4
BODY/INTEGUMENT				
MIDDLE THREE TOES NOT SEPARATED	0/ 0	0/ 0	1/ 1	0/ 0
DRIED YELLOW MATERIAL	1/ 1	0/ 0	0/ 0	0/ 0
FILAMENTOUS TAIL	0/ 0	0/ 0	0/ 0	1/ 1
EYES/EARS/NOSE				
EXOPHTHALMUS	0/ 0	0/ 0	2/ 1	0/ 0
SCABBING OVER RIGHT EYE	0/ 0	0/ 0	2/ 1	0/ 0
SCABBING OVER LEFT EYE	0/ 0	0/ 0	2/ 1	0/ 0
DRIED RED MATERIAL AROUND NOSE	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PPOBSIv4.03
07/31/2003
R:07/31/2003

TABLE 57 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHTS [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM	100 PPM	500 PPM	1000 PPM
PND 1					
MALES	MEAN	7.1	7.0	6.9	6.4
	S.D.	0.71	0.82	0.60	0.49
	N	7	9	9	9
FEMALES	MEAN	6.7	6.5	6.5	6.3
	S.D.	0.50	0.76	0.41	0.57
	N	7	9	9	8
PND 4 (BEFORE SELECTION)					
MALES	MEAN	9.9	9.5	9.3	9.5
	S.D.	1.40	1.03	1.00	0.99
	N	7	9	9	9
FEMALES	MEAN	9.2	9.0	8.8	9.2
	S.D.	0.90	0.86	0.79	0.93
	N	7	9	9	8
PND 7					
MALES	MEAN	13.5	12.8	12.5	12.6
	S.D.	1.50	1.92	1.56	1.42
	N	7	9	9	9
FEMALES	MEAN	12.6	12.1	12.0	12.5
	S.D.	1.05	1.65	1.37	1.18
	N	7	9	9	8

PND = POSTNATAL DAY

None significantly different from the control group using a nested analysis of covariance

TABLE 57 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHTS [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM	100 PPM	500 PPM	1000 PPM
PND 14					
MALES	MEAN	23.9	22.8	21.3	20.9
	S.D.	3.48	2.66	3.59	3.97
	N	7	8	9	9
FEMALES	MEAN	22.6	20.2	20.8	21.6
	S.D.	2.04	3.85	4.53	4.15
	N	7	9	9	8
PND 21					
MALES	MEAN	39.3	37.5	35.7	36.0
	S.D.	6.48	4.49	5.38	7.57
	N	7	8	9	9
FEMALES	MEAN	37.3	35.2	35.2	36.5
	S.D.	3.57	3.71	7.07	7.80
	N	7	8	9	8
PND 28					
MALES	MEAN	71.2	72.1	69.9	68.8
	S.D.	4.68	7.30	8.99	11.72
	N	6	8	9	9
FEMALES	MEAN	67.4	66.6	66.0	64.5
	S.D.	4.36	5.08	14.52	9.37
	N	7	8	9	8

PND = POSTNATAL DAY

None significantly different from the control group using a nested analysis of covariance

PPWSUSNv5.02
02/12/2003
R:02/12/2003

TABLE 58 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHT CHANGES [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM	100 PPM	500 PPM	1000 PPM
PND 1 TO 4 (BEFORE SELECTION)					
MALES	MEAN	2.8	2.4	2.4	3.0
	S.D.	0.74	0.70	0.72	0.75
	N	7	9	9	9
FEMALES	MEAN	2.4	2.5	2.3	3.0
	S.D.	0.48	0.58	0.55	0.70
	N	7	9	9	8
PND 4 TO 7					
MALES	MEAN	3.8	3.4	3.3	3.2
	S.D.	0.52	1.07	0.92	0.68
	N	7	9	9	9
FEMALES	MEAN	3.4	3.1	3.2	3.2
	S.D.	0.66	1.02	0.99	0.80
	N	7	9	9	8
PND 7 TO 14					
MALES	MEAN	10.4	9.7	8.8	8.3
	S.D.	2.70	1.78	2.94	3.46
	N	7	8	9	9
FEMALES	MEAN	10.0	8.0	8.8	9.1
	S.D.	2.21	3.27	3.74	3.79
	N	7	9	9	8

PND = POSTNATAL DAY

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

TABLE 58 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHT CHANGES [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM	100 PPM	500 PPM	1000 PPM
PND 14 TO 21					
MALES	MEAN	15.3	14.7	14.4	15.1
	S.D.	3.37	2.14	2.71	4.01
	N	7	8	9	9
FEMALES	MEAN	14.7	13.9	14.4	14.9
	S.D.	2.09	1.88	2.97	3.97
	N	7	8	9	8
PND 21 TO 28					
MALES	MEAN	34.2	34.6	34.8	33.4
	S.D.	5.38	4.96	4.59	4.33
	N	6	8	9	9
FEMALES	MEAN	30.7	31.1	30.8	28.4
	S.D.	5.03	4.03	6.63	4.75
	N	7	8	9	8

PND = POSTNATAL DAY

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

PPWSUSNv5.02
02/12/2003

TABLE 59 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF POSTNATAL SURVIVAL [% PER LITTER]

GROUP :	1	2	3	4
PND 0 (RELATIVE TO NUMBER BORN)				
MEAN	99.2	100.0	96.4	95.4
S.D.	2.21	0.00	4.09	9.23
N	8	8	10	10
PND 0 TO PND 1				
MEAN	98.0	100.0	98.1	96.8
S.D.	3.95	0.00	5.93	7.08
N	8	8	10	10
PND 1 TO PND 4 (PRE-SELECTION)				
MEAN	97.8	97.2	100.0	93.7
S.D.	6.24	5.17	0.00	15.59
N	8	8	10	10
PND 4 (POST-SELECTION) TO PND 7				
MEAN	98.8	100.0	100.0	100.0
S.D.	3.54	0.00	0.00	0.00
N	8	8	10	10
PND 7 TO PND 14				
MEAN	100.0	100.0	100.0	100.0
S.D.	0.00	0.00	0.00	0.00
N	8	8	10	10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

TABLE 59 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF POSTNATAL SURVIVAL [% PER LITTER]

GROUP :	1	2	3	4
PND 14 TO PND 21				
MEAN	98.8	97.5	99.0	100.0
S.D.	3.54	7.07	3.16	0.00
N	8	8	10	10
PND 21 TO PND 28				
MEAN	100.0	100.0	100.0	100.0
S.D.	0.00	0.00	0.00	0.00
N	8	8	10	10
BIRTH TO PND 4 (PRE-SELECTION)				
MEAN	95.1	97.2	94.6	88.7
S.D.	8.05	5.17	7.53	22.35
N	8	8	10	10
PND 4 (POST-SELECTION) TO PND 28				
MEAN	96.9	96.9	98.8	100.0
S.D.	5.79	8.84	3.95	0.00
N	8	8	10	10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

STATISTICS PERFORMED USING KRUSKAL-WALLIS

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

PPVIASv5.01
01/14/2003

TABLE 60 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

TOTAL NUMBER OF FINDINGS/NUMBER OF PUPS WITH FINDING

FINDING	GROUP : 1	2	3	4
NORMAL				
NO REMARKABLE OBSERVATIONS	489/113	531/120	607/133	602/142
DISPOSITION				
FOUND DEAD	8/ 8	5/ 5	7/ 7	8/ 8
EUTHANIZED IN EXTREMIS	1/ 1	0/ 0	0/ 0	3/ 3
SCHEDULED EUTHANASIA (PND 28)	43/ 43	46/ 46	55/ 55	55/ 55
CULLED ON SCHEDULED DAY (PND 4)	33/ 33	36/ 36	37/ 37	43/ 43
MISSING	0/ 0	1/ 1	3/ 3	6/ 6
SELECTED FOR EXPOSURE; PND 22-33	16/ 16	16/ 16	20/ 20	20/ 20
SELECTED FOR EXPOSURE; PND 29-33	16/ 16	16/ 16	20/ 20	19/ 19
BEHAVIOR/CNS				
TREMORS	0/ 0	0/ 0	0/ 0	1/ 1
IMPAIRED EQUILIBRIUM	0/ 0	0/ 0	0/ 0	1/ 1
BODY/INTEGUMENT				
SUBCUTANEOUS HEMORRHAGE(S)	2/ 1	1/ 1	2/ 1	4/ 3
PALE IN COLOR	0/ 0	0/ 0	0/ 0	1/ 1
BODY COOL TO TOUCH	0/ 0	0/ 0	0/ 0	2/ 2
SMALL IN SIZE	11/ 4	1/ 1	1/ 1	8/ 3
LACERATION(S)	0/ 0	0/ 0	1/ 1	0/ 0
SWELLING	4/ 2	0/ 0	0/ 0	0/ 0
SCABBING	6/ 5	1/ 1	6/ 6	1/ 1
UNEVEN HAIR GROWTH	0/ 0	0/ 0	0/ 0	8/ 5
DARK RED IN COLOR DISTAL END OF TAIL	0/ 0	0/ 0	2/ 1	1/ 1

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 60 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

TOTAL NUMBER OF FINDINGS/NUMBER OF PUPS WITH FINDING

FINDING	GROUP : 1	2	3	4
BODY/INTEGUMENT				
DRIED RED MATERIAL	1/ 1	1/ 1	7/ 7	8/ 8
RING-LIKE INDENTATIONS ON TAIL	0/ 0	0/ 0	2/ 1	0/ 0
WET RED MATERIAL	0/ 0	0/ 0	1/ 1	0/ 0
MISSING DISTAL END OF TAIL	0/ 0	0/ 0	1/ 1	0/ 0
BLACKENED IN COLOR RIGHT FORELIMB	1/ 1	0/ 0	0/ 0	0/ 0
EYES/EARS/NOSE				
SUBCUTANEOUS HEMORRHAGE NOSE	0/ 0	0/ 0	0/ 0	2/ 1
WET RED MATERIAL	0/ 0	1/ 1	0/ 0	0/ 0
EXCRETA				
BRIGHT YELLOW FECES	0/ 0	1/ 1	0/ 0	5/ 5
LOOSE FECES	0/ 0	0/ 0	0/ 0	5/ 5

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 61 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHTS [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
PND 1					
MALES	MEAN	7.3	7.6	7.0	6.3**
	S.D.	0.64	0.88	0.82	0.63
	N	8	8	10	10
FEMALES	MEAN	6.7	7.2	6.5	6.0
	S.D.	0.58	0.75	0.90	0.61
	N	8	8	10	10
PND 4 (BEFORE SELECTION)					
MALES	MEAN	9.8	10.2	10.2	8.5
	S.D.	1.68	1.07	1.18	1.20
	N	8	8	10	10
FEMALES	MEAN	9.0	9.7	9.6	8.3
	S.D.	1.67	0.97	1.45	1.01
	N	8	8	10	10
PND 7					
MALES	MEAN	13.4	13.5	13.5	12.3
	S.D.	2.41	1.66	1.15	1.86
	N	8	8	10	10
FEMALES	MEAN	12.1	12.6	12.8	11.8
	S.D.	2.30	1.90	1.53	1.62
	N	8	8	10	10

PND = POSTNATAL DAY

** = Significantly different from the control group at 0.01

TABLE 61 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHTS [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
PND 14					
MALES	MEAN	25.1	22.2	22.1	19.8*
	S.D.	3.79	5.25	2.84	3.19
	N	8	8	10	10
FEMALES	MEAN	23.4	20.9	22.1	19.2
	S.D.	4.12	4.73	2.75	3.70
	N	8	8	10	10
PND 21					
MALES	MEAN	40.9	37.7	38.4	33.0*
	S.D.	5.86	7.19	4.49	6.42
	N	8	8	10	10
FEMALES	MEAN	38.2	36.0	38.1	32.3
	S.D.	6.45	7.05	4.62	6.56
	N	8	8	10	10
PND 28					
MALES	MEAN	77.6	72.1	73.6	66.1
	S.D.	10.91	13.62	5.42	11.05
	N	8	8	10	9
FEMALES	MEAN	69.9	66.5	71.0	62.3
	S.D.	12.86	11.76	7.05	9.99
	N	8	8	10	10

PND = POSTNATAL DAY

* = Significantly different from the control group at 0.05

PPWSUSNv5.02
01/14/2003
R:01/23/2003

TABLE 62 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHT CHANGES [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
PND 1 TO 4 (BEFORE SELECTION)					
MALES	MEAN	2.5	2.6	3.2	2.2
	S.D.	1.13	0.44	0.52	0.85
	N	8	8	10	10
FEMALES	MEAN	2.3	2.5	3.1	2.3
	S.D.	1.18	0.49	0.75	0.51
	N	8	8	10	10
PND 4 TO 7					
MALES	MEAN	3.4	3.3	3.4	3.7
	S.D.	1.23	0.92	0.73	0.76
	N	8	8	10	10
FEMALES	MEAN	3.2	2.9	3.2	3.5
	S.D.	1.04	1.03	0.81	0.66
	N	8	8	10	10
PND 7 TO 14					
MALES	MEAN	11.8	8.7*	8.6*	7.6**
	S.D.	1.75	3.70	2.25	2.25
	N	8	8	10	10
FEMALES	MEAN	11.2	8.3	9.3	7.4**
	S.D.	2.10	3.02	1.90	2.98
	N	8	8	10	10

PND = POSTNATAL DAY

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

* = Significantly different from the control group at 0.05

** = Significantly different from the control group at 0.01

TABLE 62 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF OFFSPRING WEIGHT CHANGES [G]

(LITTER AS EXPERIMENTAL UNIT)

DOSE GROUP:		0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
PND 14 TO 21					
MALES	MEAN	15.6	15.5	16.2	13.2
	S.D.	2.52	2.06	1.99	3.35
	N	8	8	10	10
FEMALES	MEAN	14.9	15.0	16.0	13.1
	S.D.	2.59	2.71	2.24	3.19
	N	8	8	10	10
PND 21 TO 28					
MALES	MEAN	36.9	34.1	35.9	32.8
	S.D.	5.75	7.50	2.58	5.85
	N	8	8	10	9
FEMALES	MEAN	31.9	30.4	32.7	29.8
	S.D.	5.85	6.25	2.56	4.41
	N	8	8	10	10

PND = POSTNATAL DAY

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.

None significantly different from control group

PPWSUSNv5.02
01/14/2003

TABLE 63 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	------- M A L E -------			
GROUP	1	2	3	4
NUMBER OF ANIMALS IN DOSE GROUP	20	20	20	20
NUMBER OF ANIMALS EXAMINED	20	20	20	20
EPIDIDYMIDES				
-SMALL	1	1	0	0
KIDNEYS				
-AREA(S), DEPRESSED	0	1	0	0
-DILATED PELVIS	0	1	0	0
TESTES				
-SMALL	1	1	0	0
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	19	17	20	20

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PGRSIv4.02
01/14/2003
R:01/17/2003

TABLE 64 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF ORGAN WEIGHTS [G]

	----- M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
LIVER (G)				
MEAN	18.34	18.92	20.04**	22.11**
S.D.	1.655	1.993	1.763	1.548
N	20	20	20	20
KIDNEYS (G)				
MEAN	3.49	3.49	3.74++	3.96++
S.D.	0.214	0.276	0.370	0.380
N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
**, ++ = Significantly different from the control group at 0.01

POFBSTv5.02
01/14/2003
R:01/22/2003

TABLE 65 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

	----- M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
FINAL BODY WT (G)				
MEAN	465.	455.	449.	443.*
S.D.	21.0	29.3	23.8	23.0
N	20	20	20	20
LIVER				
MEAN	3.944	4.159	4.462**	4.994**
S.D.	0.3339	0.2850	0.2912	0.2910
N	20	20	20	20
KIDNEYS				
MEAN	0.752	0.770	0.831**	0.895**
S.D.	0.0549	0.0668	0.0607	0.0723
N	20	20	20	20

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01

POFBSTv5.02
01/14/2003
R:01/22/2003

TABLE 66 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	----- F E M A L E -----			
GROUP	1	2	3	4
NUMBER OF ANIMALS EXAMINED	8	8	9	9
SKIN				
-HAIR LOSS	1	0	1	0
UTERUS				
-CONTENTS, CLEAR FLUID	0	0	0	1
TEETH				
-MALALIGNED	0	0	1	0
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	7	8	8	8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PGRSIv4.02
02/11/2003
R:02/13/2003

TABLE 67 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF ORGAN WEIGHTS [G]

	----- F E M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
LIVER (G)				
MEAN	12.21	12.90	15.31*	17.72**
S.D.	2.050	1.862	2.096	2.697
N	8	8	9	9
KIDNEYS (G)				
MEAN	2.29	2.38	2.25	2.50
S.D.	0.158	0.154	0.425	0.237
N	8	8	9	9

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01

POFBSTv5.02
02/11/2003
R:02/12/2003

TABLE 68 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

	----- F E M A L E -----			
GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
FINAL BODY WT (G)				
MEAN	302.	301.	311.	319.
S.D.	26.1	22.8	29.4	34.6
N	8	8	9	9
LIVER				
MEAN	4.030	4.283	4.913**	5.544**
S.D.	0.4170	0.4039	0.4628	0.3986
N	8	8	9	9
KIDNEYS				
MEAN	0.760	0.793	0.726	0.788
S.D.	0.0492	0.0271	0.1399	0.0656
N	8	8	9	9

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

POFBSTv5.02
02/11/2003
R:02/12/2003

TABLE 69 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	----- F E M A L E -----			
GROUP	1	2	3	4
NUMBER OF ANIMALS EXAMINED	8	8	10	10
KIDNEYS				
-DILATED PELVIS	0	0	0	1
URINARY BLADDER				
-CALCULUS(I)	0	0	0	1
-THICKENED	0	0	0	1
-DISTENDED	0	0	0	1
URETER(S)				
-DISTENDED	0	0	0	1
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	8	8	10	9

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PGRSIv4.02
01/14/2003
R:02/13/2003

TABLE 70 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF ORGAN WEIGHTS [G]

	----- F E M A L E -----			
GROUP:	0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
LIVER (G)				
MEAN	13.83	14.13	15.74	17.26**
S.D.	1.769	1.699	1.826	1.709
N	8	8	10	10
KIDNEYS (G)				
MEAN	2.53	2.50	2.56	2.63
S.D.	0.233	0.113	0.326	0.252
N	8	8	10	10

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01

POFBSTv5.02
01/14/2003
R:01/22/2003

TABLE 71 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 1

SPONSOR:ACC — SUMMARY OF ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

	----- F E M A L E -----			
GROUP:	0 PPM/0 MG/KG	100 PPM/90 MG/KG	500 PPM/342MG/KG	1000PPM/621MG/KG
FINAL BODY WT (G)				
MEAN	316.	324.	315.	314.
S.D.	21.2	25.4	23.2	18.4
N	8	8	10	10
LIVER				
MEAN	4.377	4.366	4.989*	5.507**
S.D.	0.3763	0.4234	0.4144	0.4543
N	8	8	10	10
KIDNEYS				
MEAN	0.804	0.775	0.811	0.838
S.D.	0.0637	0.0495	0.0658	0.0508
N	8	8	10	10

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01

POFBSTv5.02
01/14/2003
R:01/22/2003

TABLE 72 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF PUP NECROPSY FINDINGS

FOUND DEAD PUPS

DOSE GROUP:	PUPS 1	PUPS 2	PUPS 3	PUPS 4	LITTERS 1	LITTERS 2	LITTERS 3	LITTERS 4
NUMBER EXAMINED VISCERALLY	1	20	13	8	1	4	5	4
LUNGS								
DISCOLORATION, DARK RED	0	2	0	0	0	1	0	0
STOMACH								
MILK NOT PRESENT	1	2	5	1	1	1	3	1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PPNSIv4.0
01/14/2003
R:01/17/2003

TABLE 73 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

SUMMARY OF PUP NECROPSY FINDINGS

FOUND DEAD PUPS

	PUPS				LITTERS			
DOSE GROUP:	1	2	3	4	1	2	3	4
NUMBER EXAMINED VISCERALLY	9	5	7	11	4	2	5	4
STOMACH								
MILK NOT PRESENT	2	0	4	2	2	0	3	2
MILK PRESENT	1	0	1	3	1	0	1	2
ADRENAL								
DISCOLORATION, DARK RED	1	0	0	0	1	0	0	0
ENLARGED	1	0	0	0	1	0	0	0
MALFORMATION								
DIAPHRAGMATIC HERNIA	1	0	0	0	1	0	0	0
VARIATION								
RENAL PAPILLA(E) NOT FULLY DEVELOPED (WOO AND HOAR GRADE 1)	0	1	0	0	0	1	0	0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PPNSIv4.0
01/14/2003
R:01/17/2003

TABLE 74 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
22	7	0	0	0	0	7	0	0	0	0	9	0	0	0	0	9	0	0	0	0
23	7	0	0	0	0	7	0	0	0	0	9	0	0	0	0	9	0	0	0	0
24	7	0	0	0	0	7	0	0	0	0	8	1	0	0	0	8	1	0	0	0
25	7	0	0	0	0	7	0	0	0	0	9	0	0	0	0	8	0	0	0	0
26	7	0	0	0	0	7	0	0	0	0	9	0	0	0	0	7	1	0	0	0
27	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
28	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
29	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
30	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
31	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
32	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
33	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7	0	0	0	0
34	0	0	0	0	7	0	0	0	0	7	0	0	0	0	8	0	0	0	0	7

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 74 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
22	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
23	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	1	0	0
24	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
25	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
26	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
27	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
28	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
29	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
30	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
31	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
32	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
33	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7	0	0	0	0
34	0	0	0	0	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	7

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 75 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
22	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	1	0	0	0
23	8	0	0	0	0	7	1	0	0	0	10	0	0	0	0	9	0	0	0	0
24	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	1	0	1	0
25	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
26	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
27	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
28	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
29	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
30	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
31	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
32	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
33	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
34	0	0	0	0	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 75 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
22	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	1	0	0	0
23	8	0	0	0	0	7	1	0	0	0	10	0	0	0	0	9	0	0	0	0
24	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	1	1	0
25	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
26	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
27	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
28	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
29	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
30	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
31	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
32	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
33	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7	0	0	0	0
34	0	0	0	0	8	0	0	0	0	7	0	0	0	0	10	0	0	0	0	7

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 76 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-24-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	14/ 7	13/ 7	12/ 6	14/ 7
DISPOSITION				
-FOUND DEAD	0/ 0	0/ 0	1/ 1	2/ 2
-SCHEDULED EUTHANASIA;POSTNATAL DAY 34	7/ 7	7/ 7	8/ 8	7/ 7
BODY/INTEGUMENT				
-DISTAL END OF TAIL MISSING	0/ 0	0/ 0	3/ 2	0/ 0
-BLACK AREA END OF TAIL	0/ 0	0/ 0	1/ 1	0/ 0
-RING-LIKE INDENTATIONS ON TAIL	0/ 0	0/ 0	2/ 1	0/ 0
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	0/ 0	1/ 1	0/ 0	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 76 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-24-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	14/ 7	16/ 8	16/ 8	14/ 7
DISPOSITION				
-EUTHANIZED IN EXTREMIS	0/ 0	0/ 0	0/ 0	1/ 1
-SCHEDULED EUTHANASIA;POSTNATAL DAY 34	7/ 7	8/ 8	9/ 9	7/ 7
BODY/INTEGUMENT				
-DISTAL END OF TAIL MISSING	0/ 0	0/ 0	1/ 1	0/ 0
-BLACK AREA END OF TAIL	0/ 0	0/ 0	1/ 1	0/ 0
-RING-LIKE INDENTATIONS ON TAIL	0/ 0	0/ 0	2/ 1	0/ 0
-BROKEN RIGHT FORELIMB	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/14/2003
R:01/22/2003

TABLE 77 (F1 - INHALATION PHASE - PRIOR TO EXPOSURE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PROJECT NO.:WIL-186028A
SPONSOR:ACC

----- M A L E -----

TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	1/ 1	0/ 0
-DRIED RED MATERIAL AROUND NOSE	0/ 0	0/ 0	1/ 1	0/ 0
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 77 (F1 - INHALATION PHASE - PRIOR TO EXPOSURE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	0/ 0	0/ 0	3/ 3	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/22/2003
R:01/22/2003

TABLE 78 (F1 - INHALATION PHASE - MIDPOINT OF EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT OBSERVATIONS AT THE MIDPOINT OF EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 78 (F1 - INHALATION PHASE - MIDPOINT OF EXPOSURE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4

THERE WERE NO SIGNIFICANT OBSERVATIONS AT THE MIDPOINT OF EXPOSURE

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 79 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4
BEHAVIOR/CNS				
-PROSTRATE	0/ 0	0/ 0	0/ 0	6/ 2
-ROCKS, LURCHES, OR SWAYS AS IT WALKS	0/ 0	0/ 0	0/ 0	1/ 1
BODY/INTEGUMENT				
-BODY COOL TO TOUCH	0/ 0	0/ 0	0/ 0	1/ 1
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	1/ 1	7/ 3
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	7/ 3
-REDDENED AREA AROUND NOSE	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 79 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-23-02			
GROUP:	1	2	3	4
BEHAVIOR/CNS				
-PROSTRATE	0/ 0	0/ 0	0/ 0	1/ 1
-UNABLE TO RIGHT SELF	0/ 0	0/ 0	0/ 0	2/ 1
-ROCKS, LURCHES, OR SWAYS AS IT WALKS	0/ 0	0/ 0	0/ 0	1/ 1
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	0/ 0	4/ 2
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	4/ 2
-REDDENED AREA AROUND NOSE	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
01/22/2003
R:01/22/2003

TABLE 80 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-30-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	16/ 8	14/ 7	20/10	14/ 7
DISPOSITION				
-FOUND DEAD	0/ 0	1/ 1	0/ 0	2/ 2
-SENT TO NECROPSY; ANIMAL INADVERTENTLY REMOVED FROM ANIMAL ROOM	0/ 0	0/ 0	0/ 0	1/ 1
-SCHEDULED EUTHANASIA; PND 34	8/ 8	7/ 7	10/10	7/ 7
BEHAVIOR/CNS				
-HYPOACTIVE	0/ 0	0/ 0	0/ 0	1/ 1
-SPLAYED HINDLIMBS	0/ 0	0/ 0	0/ 0	1/ 1
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 80 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-30-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	15/ 8	14/ 7	20/10	14/ 7
DISPOSITION				
-EUTHANIZED IN EXTREMIS	0/ 0	0/ 0	0/ 0	1/ 1
-FOUND DEAD	0/ 0	1/ 1	0/ 0	1/ 1
-SENT TO NECROPSY; ANIMAL INADVERTENTLY REMOVED FROM ANIMAL ROOM	0/ 0	0/ 0	0/ 0	1/ 1
-SCHEDULED EUTHANASIA; PND 34	8/ 8	7/ 7	10/10	7/ 7
BEHAVIOR/CNS				
-PROSTRATE	0/ 0	0/ 0	0/ 0	1/ 1
-HYPOACTIVE	0/ 0	0/ 0	0/ 0	1/ 1
-SPLAYED HINDLIMBS	0/ 0	0/ 0	0/ 0	1/ 1
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	0/ 0	1/ 1
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	1/ 1
-DRIED RED MATERIAL AROUND NOSE	1/ 1	0/ 0	0/ 0	0/ 0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 81 (F1 - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	0/ 0	1/ 1	1/ 1	3/ 3
-DRIED RED MATERIAL AROUND LEFT EYE	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 81 (F1 - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	1/ 1	0/ 0	2/ 2	3/ 2

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 82 (F1 - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	0/ 0	1/ 1

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 82 (F1 - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 2

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS AT THE MIDPOINT OF EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 83 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
BEHAVIOR/CNS				
-PROSTRATE	0/ 0	0/ 0	0/ 0	4/ 2
-ROCKS, LURCHES, OR SWAYS AS IT WALKS	0/ 0	0/ 0	0/ 0	2/ 2
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	0/ 0	4/ 2
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	4/ 2
-REDDENED AREA AROUND NOSE	0/ 0	0/ 0	2/ 2	0/ 0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 83 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-05-02 TO 11-29-02			
GROUP:	1	2	3	4
BEHAVIOR/CNS				
-PROSTRATE	0/ 0	0/ 0	0/ 0	3/ 2
-UNABLE TO RIGHT SELF	0/ 0	0/ 0	0/ 0	1/ 1
-ANIMAL CIRCLES TO THE RIGHT	0/ 0	0/ 0	0/ 0	1/ 1
-ROCKS, LURCHES, OR SWAYS AS IT WALKS	0/ 0	0/ 0	0/ 0	2/ 2
CARDIO-PULMONARY				
-LABORED RESPIRATION	0/ 0	0/ 0	0/ 0	5/ 3
EYES/EARS/NOSE				
-EYELIDS HALF CLOSED	0/ 0	0/ 0	0/ 0	5/ 3
-REDDENED AREA AROUND NOSE	0/ 0	0/ 0	1/ 1	0/ 0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 84 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 22	MEAN	43.5	39.6	39.4	38.7
	S.D.	7.95	2.66	9.56	11.28
	N	7	7	9	9
DAY 23	MEAN	48.2	44.6	41.6	39.0
	S.D.	8.04	4.65	10.60	12.36
	N	7	7	9	9
DAY 24	MEAN	53.8	50.5	49.5	45.2
	S.D.	7.83	4.45	6.56	12.15
	N	7	7	8	8
DAY 25	MEAN	59.4	55.6	54.6	49.0
	S.D.	7.78	4.52	7.40	13.97
	N	7	7	8	8
DAY 26	MEAN	63.9	60.7	59.9	57.0
	S.D.	8.02	4.00	7.61	10.19
	N	7	7	8	7
DAY 27	MEAN	70.0	66.0	64.5	61.5
	S.D.	8.47	4.23	9.86	11.70
	N	7	7	8	7
DAY 28	MEAN	76.3	72.4	71.5	66.6
	S.D.	9.80	3.85	8.95	12.02
	N	7	7	8	7
DAY 29	MEAN	81.9	77.9	77.2	72.0
	S.D.	9.06	3.60	9.30	13.35
	N	7	7	8	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

TABLE 84 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 30	MEAN	88.1	83.9	83.3	78.2
	S.D.	9.74	3.91	10.09	13.23
	N	7	7	8	7
DAY 31	MEAN	94.9	90.9	90.1	84.5
	S.D.	10.63	4.12	9.83	14.23
	N	7	7	8	7
DAY 32	MEAN	102.8	98.1	96.3	91.2
	S.D.	10.87	4.85	10.80	14.35
	N	7	7	8	7
DAY 33	MEAN	111.1	105.6	104.1	98.3
	S.D.	12.02	4.63	11.66	14.84
	N	7	7	8	7
DAY 34	MEAN	118.0	112.8	111.1	105.7
	S.D.	11.87	5.88	10.73	15.43
	N	7	7	8	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

TABLE 84 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

FEMALES

GROUP :		1	2	3	4
DAY 22	MEAN	42.9	35.7	37.8	39.0
	S.D.	4.72	6.83	5.60	9.76
	N	7	8	9	8
DAY 23	MEAN	46.6	40.3	40.2	39.8
	S.D.	4.68	7.13	6.13	9.57
	N	7	8	9	8
DAY 24	MEAN	52.1	44.9	45.1	45.2
	S.D.	5.28	7.87	5.60	10.28
	N	7	8	9	7
DAY 25	MEAN	56.7	49.9	49.0	48.6
	S.D.	4.64	7.68	6.68	10.98
	N	7	8	9	7
DAY 26	MEAN	61.4	54.8	53.5	52.9
	S.D.	4.64	7.63	6.93	11.66
	N	7	8	9	7
DAY 27	MEAN	66.5	59.6	57.4	56.6
	S.D.	4.93	8.12	7.20	12.43
	N	7	8	9	7
DAY 28	MEAN	71.9	64.5	63.2	60.8
	S.D.	5.01	8.54	7.39	13.26
	N	7	8	9	7
DAY 29	MEAN	77.2	69.8	68.2	64.9
	S.D.	5.47	8.66	7.67	13.55
	N	7	8	9	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

TABLE 84 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

FEMALES

GROUP :		1	2	3	4
DAY 30	MEAN	82.0	75.0	73.2	70.0
	S.D.	4.08	9.44	7.85	14.14
	N	7	8	9	7
DAY 31	MEAN	90.0	80.6+	78.0+	75.4+
	S.D.	4.74	9.38	8.26	14.59
	N	7	8	9	7
DAY 32	MEAN	95.2	86.5	84.0	81.4
	S.D.	5.76	10.25	8.92	14.80
	N	7	8	9	7
DAY 33	MEAN	101.6	93.8	90.7	86.5
	S.D.	5.85	11.49	9.15	14.98
	N	7	8	9	7
DAY 34	MEAN	107.9	100.0	96.0	91.8
	S.D.	6.40	11.73	9.08	15.33
	N	7	8	9	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05

PJTBWSUv5.00
01/14/2003
R:01/22/2003

TABLE 85 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 22- 23	MEAN	4.7	4.9	2.2	0.3**
	S.D.	0.64	2.72	2.18	2.02
	N	7	7	9	9
DAY 23- 24	MEAN	5.6	5.9	4.8	3.7
	S.D.	1.65	1.00	1.35	1.89
	N	7	7	8	8
DAY 24- 25	MEAN	5.6	5.1	5.1	3.7
	S.D.	1.38	0.30	1.27	2.25
	N	7	7	8	8
DAY 25- 26	MEAN	4.5	5.2	5.3	4.3
	S.D.	0.99	0.70	1.73	1.30
	N	7	7	8	7
DAY 26- 27	MEAN	6.1	5.3	4.6	4.5
	S.D.	1.39	1.53	4.84	1.88
	N	7	7	8	7
DAY 27- 28	MEAN	6.3	6.4	7.0	5.1
	S.D.	2.35	0.91	2.75	0.97
	N	7	7	8	7
DAY 28- 29	MEAN	5.7	5.5	5.7	5.5
	S.D.	2.60	0.65	0.90	1.49
	N	7	7	8	7
DAY 29- 30	MEAN	6.2	5.9	6.1	6.1
	S.D.	1.40	0.51	1.09	0.68
	N	7	7	8	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 85 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 30- 31	MEAN	6.7	7.1	6.8	6.3
	S.D.	1.92	1.90	1.41	1.39
	N	7	7	8	7
DAY 31- 32	MEAN	7.9	7.1	6.3	6.7
	S.D.	1.22	1.33	1.50	1.53
	N	7	7	8	7
DAY 32- 33	MEAN	8.3	7.5	7.7	7.1
	S.D.	1.59	1.19	1.19	1.40
	N	7	7	8	7
DAY 33- 34	MEAN	7.0	7.2	7.0	7.3
	S.D.	2.12	2.28	1.99	1.50
	N	7	7	8	7
DAY 22- 34	MEAN	74.5	73.2	69.2	62.7**
	S.D.	6.03	5.69	5.89	7.86
	N	7	7	8	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 85 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 22- 23	MEAN	3.8	4.6	2.4	0.8**
	S.D.	0.82	2.20	0.97	1.69
	N	7	8	9	8
DAY 23- 24	MEAN	5.5	4.6	4.9	4.2
	S.D.	1.10	1.47	1.17	1.21
	N	7	8	9	7
DAY 24- 25	MEAN	4.6	5.0	3.9	3.4
	S.D.	1.18	1.47	1.68	0.93
	N	7	8	9	7
DAY 25- 26	MEAN	4.7	4.9	4.4	4.3
	S.D.	0.68	1.00	1.09	1.20
	N	7	8	9	7
DAY 26- 27	MEAN	5.1	4.8	3.9	3.7
	S.D.	0.58	1.14	2.82	1.03
	N	7	8	9	7
DAY 27- 28	MEAN	5.4	5.0	5.8	4.2
	S.D.	1.22	1.38	2.72	1.03
	N	7	8	9	7
DAY 28- 29	MEAN	5.3	5.2	5.0	4.1
	S.D.	2.18	1.13	1.11	1.18
	N	7	8	9	7
DAY 29- 30	MEAN	4.8	5.3	5.1	5.1
	S.D.	1.56	0.97	0.87	1.21
	N	7	8	9	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 85 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 30- 31	MEAN	8.0	5.6**	4.8**	5.4**
	S.D.	1.23	1.43	1.06	0.95
	N	7	8	9	7
DAY 31- 32	MEAN	5.1	5.9	6.0	5.9
	S.D.	1.93	1.39	1.21	1.37
	N	7	8	9	7
DAY 32- 33	MEAN	6.4	7.3	6.7	5.2
	S.D.	1.08	1.86	1.49	1.00
	N	7	8	9	7
DAY 33- 34	MEAN	6.4	6.2	5.3	5.3
	S.D.	1.11	1.77	1.68	1.83
	N	7	8	9	7
DAY 22- 34	MEAN	65.1	64.3	58.2	51.6**
	S.D.	5.17	7.17	4.31	7.07
	N	7	8	9	7

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

PJTBWSUv5.00
01/14/2003
R:01/22/2003

TABLE 86 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 22	MEAN	45.0	38.2	44.9	34.7
	S.D.	9.53	9.79	7.60	10.16
	N	8	8	10	10
DAY 23	MEAN	50.2	45.5	48.2	37.4*
	S.D.	9.87	5.98	7.06	10.76
	N	8	7	10	9
DAY 24	MEAN	56.0	51.5	53.0	46.2
	S.D.	10.02	6.44	7.31	10.23
	N	8	7	10	7
DAY 25	MEAN	61.6	56.4	58.8	50.5
	S.D.	10.84	7.10	8.36	9.51
	N	8	7	10	7
DAY 26	MEAN	67.6	63.2	64.2	54.7
	S.D.	11.09	6.61	8.84	9.94
	N	8	7	10	7
DAY 27	MEAN	72.6	66.7	70.4	58.6
	S.D.	12.50	8.57	9.20	10.48
	N	8	7	10	7
DAY 28	MEAN	79.0	73.2	75.1	63.7
	S.D.	13.52	8.94	9.69	11.09
	N	8	7	10	7
DAY 29	MEAN	85.0	79.5	81.5	68.3
	S.D.	14.46	9.83	10.92	11.11
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05

TABLE 86 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 30	MEAN	91.8	85.5	87.8	74.7
	S.D.	15.45	9.96	10.88	11.83
	N	8	7	10	7
DAY 31	MEAN	99.2	91.8	95.6	80.7
	S.D.	16.04	10.57	11.44	12.55
	N	8	7	10	7
DAY 32	MEAN	107.4	99.3	103.4	88.0
	S.D.	16.88	11.88	11.75	14.42
	N	8	7	10	7
DAY 33	MEAN	114.8	107.0	111.1	95.7
	S.D.	17.45	12.73	12.46	14.42
	N	8	7	10	7
DAY 34	MEAN	122.4	115.4	118.4	102.3
	S.D.	18.07	14.11	13.30	16.14
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

TABLE 86 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

FEMALES

GROUP :		1	2	3	4
DAY 22	MEAN	41.4	35.5	40.0	31.3*
	S.D.	8.58	9.43	5.32	7.83
	N	8	8	10	10
DAY 23	MEAN	46.3	39.0	43.2	33.6*
	S.D.	9.24	11.92	5.34	8.78
	N	8	8	10	9
DAY 24	MEAN	51.7	47.1	47.9	38.7*
	S.D.	9.62	8.63	6.46	10.31
	N	8	7	10	8
DAY 25	MEAN	56.6	52.4	52.4	45.3
	S.D.	9.72	8.97	5.89	7.60
	N	8	7	10	7
DAY 26	MEAN	61.2	56.3	57.5	48.4*
	S.D.	9.75	8.53	6.34	7.76
	N	8	7	10	7
DAY 27	MEAN	66.2	61.2	61.6	52.8*
	S.D.	10.48	8.70	6.65	8.42
	N	8	7	10	7
DAY 28	MEAN	71.6	66.8	66.6	56.6**
	S.D.	11.18	9.65	6.87	8.65
	N	8	7	10	7
DAY 29	MEAN	76.7	72.0	71.2	60.7**
	S.D.	11.51	9.47	7.41	9.07
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01

TABLE 86 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

FEMALES

GROUP :		1	2	3	4
DAY 30	MEAN	82.8	77.0	77.3	66.0**
	S.D.	11.56	10.38	7.94	9.14
	N	8	7	10	7
DAY 31	MEAN	89.0	82.9	83.0	70.9**
	S.D.	13.01	10.60	8.15	9.73
	N	8	7	10	7
DAY 32	MEAN	94.9	87.7	89.0	76.6*
	S.D.	13.64	11.81	8.57	11.26
	N	8	7	10	7
DAY 33	MEAN	101.5	94.3	94.9	82.3**
	S.D.	12.50	11.51	8.95	11.23
	N	8	7	10	7
DAY 34	MEAN	107.4	100.4	100.9	88.2*
	S.D.	13.54	12.01	9.95	12.54
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01

PJTBWSUv5.00
02/12/2003

TABLE 87 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 22- 23	MEAN	5.2	4.3	3.3++	1.5+
	S.D.	0.77	2.46	1.23	3.48
	N	8	7	10	9
DAY 23- 24	MEAN	5.8	6.0	4.9	5.3
	S.D.	1.17	0.77	0.86	2.76
	N	8	7	10	7
DAY 24- 25	MEAN	5.5	4.9	5.8	4.3
	S.D.	1.15	1.19	1.66	1.33
	N	8	7	10	7
DAY 25- 26	MEAN	6.0	6.8	5.4	4.2
	S.D.	0.82	3.12	1.29	1.42
	N	8	7	10	7
DAY 26- 27	MEAN	5.0	3.5	6.1	3.9
	S.D.	1.49	3.77	1.83	0.85
	N	8	7	10	7
DAY 27- 28	MEAN	6.4	6.5	4.8	5.2+
	S.D.	1.35	0.73	2.21	0.74
	N	8	7	10	7
DAY 28- 29	MEAN	6.1	6.3	6.3	4.6
	S.D.	1.78	1.20	1.54	1.46
	N	8	7	10	7
DAY 29- 30	MEAN	6.7	6.0	6.3	6.4
	S.D.	1.83	0.89	1.64	1.23
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
+ = Significantly different from the control group at 0.05
++ = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 87 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 30- 31	MEAN	7.5	6.4	7.8	6.0
	S.D.	1.63	1.14	1.24	1.27
	N	8	7	10	7
DAY 31- 32	MEAN	8.2	7.4	7.8	7.3
	S.D.	1.75	2.98	1.13	2.20
	N	8	7	10	7
DAY 32- 33	MEAN	7.4	7.7	7.8	7.6
	S.D.	1.64	2.45	1.18	1.08
	N	8	7	10	7
DAY 33- 34	MEAN	7.6	8.4	7.3	6.6
	S.D.	1.77	1.45	1.77	2.07
	N	8	7	10	7
DAY 22- 34	MEAN	77.4	74.3	73.6	64.0
	S.D.	9.59	9.89	7.14	11.11
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 87 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 22- 23	MEAN	4.9	3.5	3.2++	1.4++
	S.D.	0.99	3.01	1.00	2.72
	N	8	8	10	9
DAY 23- 24	MEAN	5.4	4.9	4.7	3.9
	S.D.	0.86	0.88	1.28	2.90
	N	8	7	10	8
DAY 24- 25	MEAN	4.9	5.2	4.6	3.8
	S.D.	1.41	0.53	1.19	1.12
	N	8	7	10	7
DAY 25- 26	MEAN	4.6	4.0	5.1	3.1
	S.D.	0.90	0.98	1.43	1.44
	N	8	7	10	7
DAY 26- 27	MEAN	5.1	4.8	4.1	4.4
	S.D.	1.07	1.25	1.19	1.25
	N	8	7	10	7
DAY 27- 28	MEAN	5.3	5.6	4.9	3.8*
	S.D.	1.24	1.13	1.14	0.88
	N	8	7	10	7
DAY 28- 29	MEAN	5.1	5.2	4.6	4.0
	S.D.	0.83	0.71	0.80	1.20
	N	8	7	10	7
DAY 29- 30	MEAN	6.1	5.0	6.1	5.3
	S.D.	1.03	1.34	1.18	1.36
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
++ = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 87 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 30- 31	MEAN	6.2	5.9	5.7	4.9
	S.D.	1.87	1.56	1.39	0.99
	N	8	7	10	7
DAY 31- 32	MEAN	5.9	4.8	6.0	5.8
	S.D.	1.80	2.06	1.23	1.93
	N	8	7	10	7
DAY 32- 33	MEAN	6.7	6.7	5.9	5.7
	S.D.	2.15	1.39	1.97	1.44
	N	8	7	10	7
DAY 33- 34	MEAN	5.8	6.1	6.0	5.9
	S.D.	1.94	1.12	2.48	1.99
	N	8	7	10	7
DAY 22- 34	MEAN	65.9	62.6	60.9	54.0**
	S.D.	6.61	5.48	5.24	8.45
	N	8	7	10	7

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

PJTBWSUv5.00
02/12/2003

TABLE 88 (F1 - INHALATION PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

FOUND DEAD OR EUTHANIZED MORIBUND OR IN EXTREMIS

	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
NUMBER OF ANIMALS EXAMINED	0	0	1	2	0	0	0	1
KIDNEYS								
-DILATED PELVIS	0	0	0	0	0	0	0	1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PGRSIv4.02
02/11/2003
R:02/13/2003

TABLE 89 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

FOUND DEAD OR EUTHANIZED MORIBUND OR IN EXTREMIS

	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
NUMBER OF ANIMALS EXAMINED	0	1	0	2	0	1	0	2
EYES								
-EYE(S)- OPACITY	0	0	0	0	0	1	0	0
KIDNEYS								
-DILATED PELVIS	0	0	0	1	0	1	0	1
SKIN								
-MATTING, RED	0	0	0	1	0	0	0	0
-MATTING, YELLOW	0	0	0	0	0	0	0	1
STOMACH								
-CONTENTS, DARK RED	0	0	0	0	0	0	0	1
URINARY BLADDER								
-DISTENDED	0	0	0	1	0	0	0	0
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	0	1	0	0	0	0	0	0

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PGRSIv4.02
02/12/2003
R:02/13/2003

TABLE 90 (F1 - INHALATION/GAVAGE PHASE - PUPS REMOVED FROM ANIMAL ROOM - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
NUMBER OF ANIMALS EXAMINED	0	0	0	1	0	0	0	1
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	0	0	0	1	0	0	0	1

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PGRSIv4.02
02/11/2003
R:02/13/2003

TABLE 91 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
29	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9	0	0	0	0
30	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9	0	0	0	0
31	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9	0	0	0	0
32	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9	0	0	0	0
33	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9	0	0	0	0
34	0	0	0	0	6	0	0	0	0	8	0	0	0	0	9	0	0	0	0	9

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 91 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
29	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
30	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
31	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
32	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
33	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8	0	0	0	0
34	0	0	0	0	7	0	0	0	0	8	0	0	0	0	9	0	0	0	0	8

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 92 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

MALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
29	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	0	0	0	0
30	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	0	0	0	0
31	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	0	0	0	0
32	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	0	0	0	0
33	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9	0	0	0	0
34	0	0	0	0	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	9

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 92 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF SURVIVAL AND DISPOSITION

FEMALES

GROUP :	1					2					3					4				
PND	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE	LIVE	FD	EE	EO	SE
29	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10	0	0	0	0
30	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10	0	0	0	0
31	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10	0	0	0	0
32	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10	0	0	0	0
33	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10	0	0	0	0
34	0	0	0	0	8	0	0	0	0	8	0	0	0	0	10	0	0	0	0	10

PND = POSTNATAL DAY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS EO = EUTHANIZED OTHER SE = SCHEDULED EUTHANASIA

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PSURVv4.02
02/14/2003
R:02/14/2003

TABLE 93 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-12-02 TO 11-24-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/ 5	7/ 7	8/ 8	8/ 8
DISPOSITION				
-SCHEDULED EUTHANASIA; PND 34	6/ 6	8/ 8	9/ 9	9/ 9
BODY/INTEGUMENT				
-DISTAL END OF TAIL MISSING	0/ 0	0/ 0	1/ 1	1/ 1
-UNEVEN HAIR GROWTH	0/ 0	1/ 1	0/ 0	0/ 0
EYES/EARS/NOSE				
-DRIED RED MATERIAL AROUND NOSE	1/ 1	0/ 0	0/ 0	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 93 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-24-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	7/ 7	7/ 7	7/ 7	8/ 8
DISPOSITION				
-SCHEDULED EUTHANASIA; PND 34	7/ 7	8/ 8	9/ 9	8/ 8
BODY/INTEGUMENT				
-DISTAL END OF TAIL MISSING	0/ 0	0/ 0	1/ 1	0/ 0
-UNEVEN HAIR GROWTH	0/ 0	1/ 1	1/ 1	0/ 0

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/12/2003

TABLE 94 (F1 - INHALATION PHASE - PRIOR TO EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS PRIOR TO EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 94 (F1 - INHALATION PHASE - PRIOR TO EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS PRIOR TO EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/12/2003

TABLE 95 (F1 - INHALATION PHASE - MIDPOINT OF EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028B — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 1

SPONSOR:ACC — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS AT THE MIDPOINT OF EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 95 (F1 - INHALATION PHASE - MIDPOINT OF EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028B — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 2

SPONSOR:ACC — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS AT THE MIDPOINT OF EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/12/2003

TABLE 96 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028B — PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS — PAGE 1

SPONSOR:ACC — SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

TABLE 96 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 29-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-23-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

PCSUv4.04
02/11/2003
R:02/12/2003

TABLE 97 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

	----- M A L E -----			
TABLE RANGE:	11-12-02 TO 11-30-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	8/ 8	8/ 8	10/10	9/ 9
DISPOSITION				
-SCHEDULED EUTHANASIA; PND 34	8/ 8	8/ 8	10/10	9/ 9

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 97 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-30-02			
GROUP:	1	2	3	4
NORMAL				
-NO SIGNIFICANT CLINICAL OBSERVATIONS	8/ 8	8/ 8	10/10	10/10
DISPOSITION				
-SCHEDULED EUTHANASIA; PND 34	8/ 8	8/ 8	10/10	10/10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 98 (F1 - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS PRIOR TO EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 98 (F1 - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS PRIOR TO EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 99 (F1 - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4

THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS AT THE MIDPOINT OF EXPOSURE

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 99 (F1 - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS AT THE MIDPOINT OF EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 100 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

TABLE 100 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- F E M A L E -----

TABLE RANGE:	11-12-02 TO 11-29-02			
GROUP:	1	2	3	4
THERE WERE NO SIGNIFICANT CLINICAL OBSERVATIONS ONE HOUR FOLLOWING EXPOSURE				

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

PCSUv4.04
02/12/2003
R:02/12/2003

TABLE 101 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 29	MEAN	79.0	80.8	74.5	76.1
	S.D.	9.73	9.39	10.39	13.68
	N	6	8	9	9
DAY 30	MEAN	86.5	87.0	79.5	80.1
	S.D.	10.35	9.92	11.09	14.12
	N	6	8	9	9
DAY 31	MEAN	93.3	93.7	85.0	85.4
	S.D.	11.85	9.97	9.85	15.08
	N	6	8	9	9
DAY 32	MEAN	100.7	100.2	91.6	91.9
	S.D.	12.65	10.31	9.85	15.20
	N	6	8	9	9
DAY 33	MEAN	107.1	107.3	98.4	97.4
	S.D.	13.30	11.40	10.16	15.76
	N	6	8	9	9
DAY 34	MEAN	115.4	115.7	104.6	103.4
	S.D.	14.22	10.60	9.74	17.51
	N	6	8	9	9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

FEMALES

GROUP :		1	2	3	4
DAY 29	MEAN	73.8	72.2	73.6	74.0
	S.D.	10.02	9.25	12.31	11.97
	N	7	8	9	8
DAY 30	MEAN	80.6	78.7	77.0	77.1
	S.D.	9.83	9.07	12.71	11.79
	N	7	8	9	8
DAY 31	MEAN	86.0	84.8	82.3	82.2
	S.D.	10.24	8.37	14.09	12.91
	N	7	8	9	8
DAY 32	MEAN	92.1	90.5	88.4	87.9
	S.D.	11.58	8.71	14.02	13.94
	N	7	8	9	8
DAY 33	MEAN	97.9	97.1	94.2	93.1
	S.D.	11.42	9.20	14.06	13.84
	N	7	8	9	8
DAY 34	MEAN	104.4	103.1	99.3	98.0
	S.D.	12.01	8.77	14.75	14.69
	N	7	8	9	8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

PJTBWSUv5.00
01/15/2003
R:01/22/2003

TABLE 102 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 29- 30	MEAN	7.5	6.2	5.0*	4.0**
	S.D.	2.29	1.26	1.33	1.31
	N	6	8	9	9
DAY 30- 31	MEAN	6.8	6.7	5.6	5.3
	S.D.	1.76	0.92	1.61	1.71
	N	6	8	9	9
DAY 31- 32	MEAN	7.4	6.5	6.6	6.5
	S.D.	1.01	1.01	1.04	1.26
	N	6	8	9	9
DAY 32- 33	MEAN	6.4	7.1	6.8	5.5
	S.D.	1.38	1.61	2.12	1.86
	N	6	8	9	9
DAY 33- 34	MEAN	8.4	8.4	6.2	6.0
	S.D.	2.55	2.01	1.45	2.42
	N	6	8	9	9
DAY 29- 34	MEAN	36.4	34.9	30.1**	27.3**
	S.D.	4.94	2.11	2.65	4.44
	N	6	8	9	9

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 102 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 29- 30	MEAN	6.8	6.6	3.4**	3.1**
	S.D.	1.75	0.98	1.56	1.08
	N	7	8	9	8
DAY 30- 31	MEAN	5.4	6.1	5.3	5.1
	S.D.	0.79	1.00	2.19	1.68
	N	7	8	9	8
DAY 31- 32	MEAN	6.1	5.7	6.1	5.7
	S.D.	2.41	1.29	1.63	1.78
	N	7	8	9	8
DAY 32- 33	MEAN	5.8	6.6	5.8	5.2
	S.D.	2.21	1.22	1.70	1.39
	N	7	8	9	8
DAY 33- 34	MEAN	6.6	6.0	5.0	4.9
	S.D.	1.42	1.45	1.45	1.98
	N	7	8	9	8
DAY 29- 34	MEAN	30.6	31.0	25.6*	24.0**
	S.D.	4.51	2.87	4.20	3.20
	N	7	8	9	8

1- 0 PPM 2- 100 PPM 3- 500 PPM 4- 1000 PPM

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

PJTBWSUv5.00
02/11/2003

TABLE 103 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHTS [G]

MALES

GROUP :		1	2	3	4
DAY 29	MEAN	85.6	78.5	78.9	75.8
	S.D.	12.70	14.75	7.43	11.53
	N	8	8	10	9
DAY 30	MEAN	92.4	84.0	83.7	79.2
	S.D.	13.47	15.49	8.74	11.96
	N	8	8	10	9
DAY 31	MEAN	98.8	90.1	91.0	85.1
	S.D.	14.17	16.12	8.85	12.70
	N	8	8	10	9
DAY 32	MEAN	105.6	97.8	97.7	91.8
	S.D.	14.57	16.20	8.95	13.45
	N	8	8	10	9
DAY 33	MEAN	113.4	105.4	104.2	98.4
	S.D.	15.95	17.48	9.54	14.58
	N	8	8	10	9
DAY 34	MEAN	121.6	112.5	110.9	105.6
	S.D.	17.33	18.43	10.53	15.77
	N	8	8	10	9

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

FEMALES

GROUP :		1	2	3	4
DAY 29	MEAN	75.1	74.7	77.4	70.6
	S.D.	18.92	12.42	9.54	9.42
	N	8	8	10	10
DAY 30	MEAN	80.0	80.0	81.3	73.3
	S.D.	19.72	13.41	9.26	10.14
	N	8	8	10	10
DAY 31	MEAN	86.1	85.1	86.4	78.6
	S.D.	21.59	13.80	9.22	10.03
	N	8	8	10	10
DAY 32	MEAN	91.4	91.5	92.3	84.4
	S.D.	22.67	14.61	10.21	10.74
	N	8	8	10	10
DAY 33	MEAN	97.2	97.9	98.0	90.2
	S.D.	23.26	14.80	11.08	11.41
	N	8	8	10	10
DAY 34	MEAN	103.3	103.7	103.6	94.1
	S.D.	24.50	15.19	11.12	12.97
	N	8	8	10	10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
None significantly different from control group

TABLE 104 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

MALES

GROUP :		1	2	3	4
DAY 29- 30	MEAN	6.8	5.5	4.8*	3.4**
	S.D.	1.62	1.12	1.92	1.45
	N	8	8	10	9
DAY 30- 31	MEAN	6.5	6.2	7.3	5.9
	S.D.	0.99	1.91	0.77	1.53
	N	8	8	10	9
DAY 31- 32	MEAN	6.8	7.7	6.7	6.7
	S.D.	1.11	2.22	1.29	1.21
	N	8	8	10	9
DAY 32- 33	MEAN	7.8	7.5	6.5	6.6
	S.D.	1.64	1.69	1.43	1.39
	N	8	8	10	9
DAY 33- 34	MEAN	8.2	7.1	6.7	7.2
	S.D.	1.84	1.49	2.19	1.72
	N	8	8	10	9
DAY 29- 34	MEAN	36.0	34.0	32.0	29.8
	S.D.	5.53	4.03	4.78	4.86
	N	8	8	10	9

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
** = Significantly different from the control group at 0.01
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

TABLE 104 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC SUMMARY OF BODY WEIGHT CHANGES [G]

FEMALES

GROUP :		1	2	3	4
DAY 29- 30	MEAN	4.9	5.3	3.9	2.7*
	S.D.	1.81	1.26	1.88	1.43
	N	8	8	10	10
DAY 30- 31	MEAN	6.2	5.1	5.2	5.3
	S.D.	2.24	1.30	1.14	1.43
	N	8	8	10	10
DAY 31- 32	MEAN	5.3	6.4	5.9	5.8
	S.D.	1.58	1.62	1.77	1.31
	N	8	8	10	10
DAY 32- 33	MEAN	5.9	6.4	5.7	5.8
	S.D.	2.06	1.43	2.04	0.86
	N	8	8	10	10
DAY 33- 34	MEAN	6.1	5.9	5.6	3.9
	S.D.	1.56	1.37	1.33	2.44
	N	8	8	10	10
DAY 29- 34	MEAN	28.2	29.0	26.2	23.5
	S.D.	6.03	4.12	4.34	4.48
	N	8	8	10	10

1- 0 PPM/0 MG/KG 2-100 PPM/90 MG/KG 3-500 PPM/342MG/KG 4-1000PPM/621MG/KG

MODIFIED STATISTICS USED. * INDICATES PARAMETRIC ANALYSIS AND + INDICATES NON-PARAMETRIC ANALYSIS.
* = Significantly different from the control group at 0.05
MEAN DIFFERENCES CALCULATED FROM INDIVIDUAL DIFFERENCES

FINAL REPORT

Volume 2 of 4
(Individual Tables 105-159)

STUDY TITLE

A PILOT INHALATION STUDY FOR A
REPRODUCTIVE TOXICITY STUDY OF
ETHYLBENZENE IN RATS

STUDY NUMBER

WIL-186028

STUDY DIRECTOR

Donald G. Stump, Ph.D., D.A.B.T.

STUDY INITIATION DATE

August 27, 2002

STUDY COMPLETION DATE

August 1, 2003

PERFORMING LABORATORY

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

AMERICAN CHEMISTRY COUNCIL CONTRACT NUMBER

EB-13.0-VCCEP-Research-WIL

SPONSOR

American Chemistry Council
Ethylbenzene Panel
1300 Wilson Boulevard
Arlington, VA 22209

TABLES 105 - 159

TABLE 105 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH	DAYS ON STUDY
10367	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10368	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10375	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10384	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10386	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10387	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10390	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10394	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10395	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10399	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10402	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10415	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10417	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10425	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10427	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10435	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10439	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10442	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10451	M	0 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10458	M	0 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10372	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10378	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10379	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10383	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10389	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10404	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10405	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10406	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10411	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH	DAYS ON STUDY
10414	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10419	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10422	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10431	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10432	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10438	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10440	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10443	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10455	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10460	M	100 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10461	M	100 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10369	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10370	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10377	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10380	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10381	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10382	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10385	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10391	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10392	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10396	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10400	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10407	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10410	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10421	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10423	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10429	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10437	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10445	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31

INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH	DAYS ON STUDY
10453	M	500 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10454	M	500 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10373	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10374	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10376	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10397	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10398	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10403	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10409	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10412	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10416	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10418	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10420	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10428	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10430	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31
10434	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10444	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10447	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10448	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10449	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10452	M	1000 PPM	SCHEDULED EUTHANASIA	08-OCT-02	32
10459	M	1000 PPM	SCHEDULED EUTHANASIA	07-OCT-02	31

TABLE 106 (F0 FEMALES - PRE-MATING/GESTATION)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH
10494	F	0 PPM	SCHEDULED EUTHANASIA	30-OCT-02
10500	F	0 PPM	SCHEDULED EUTHANASIA	18-OCT-02
10503	F	0 PPM	SCHEDULED EUTHANASIA	18-OCT-02
10513	F	0 PPM	SCHEDULED EUTHANASIA	21-OCT-02
10536	F	0 PPM	SCHEDULED EUTHANASIA	18-OCT-02
10470	F	100 PPM	SCHEDULED EUTHANASIA	19-OCT-02
10472	F	100 PPM	SCHEDULED EUTHANASIA	19-OCT-02
10543	F	100 PPM	SCHEDULED EUTHANASIA	31-OCT-02
10553	F	100 PPM	SCHEDULED EUTHANASIA	22-OCT-02
10511	F	1000 PPM	SCHEDULED EUTHANASIA	31-OCT-02

PDEADv4.02
01/15/2003
R:02/14/2003

TABLE 107 (F0 FEMALES - LACTATION - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH
10463	F	0 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10464	F	0 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10494	F	0 PPM	SCHEDULED EUTHANASIA	30-OCT-02
10503	F	0 PPM	SCHEDULED EUTHANASIA	18-OCT-02
10506	F	0 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10513	F	0 PPM	SCHEDULED EUTHANASIA	21-OCT-02
10524	F	0 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10540	F	0 PPM	SCHEDULED EUTHANASIA	16-NOV-02
10554	F	0 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10555	F	0 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10470	F	100 PPM	SCHEDULED EUTHANASIA	19-OCT-02
10488	F	100 PPM	SCHEDULED EUTHANASIA	11-NOV-02
10493	F	100 PPM	SCHEDULED EUTHANASIA	18-NOV-02
10504	F	100 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10510	F	100 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10519	F	100 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10522	F	100 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10525	F	100 PPM	SCHEDULED EUTHANASIA	15-NOV-02
10528	F	100 PPM	SCHEDULED EUTHANASIA	15-NOV-02
10543	F	100 PPM	SCHEDULED EUTHANASIA	31-OCT-02
10468	F	500 PPM	SCHEDULED EUTHANASIA	16-NOV-02
10478	F	500 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10483	F	500 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10484	F	500 PPM	SCHEDULED EUTHANASIA	15-NOV-02
10520	F	500 PPM	SCHEDULED EUTHANASIA	17-OCT-02
10530	F	500 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10534	F	500 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10546	F	500 PPM	SCHEDULED EUTHANASIA	12-NOV-02

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH
10548	F	500 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10550	F	500 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10465	F	1000 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10473	F	1000 PPM	SCHEDULED EUTHANASIA	17-NOV-02
10480	F	1000 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10481	F	1000 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10486	F	1000 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10507	F	1000 PPM	SCHEDULED EUTHANASIA	12-NOV-02
10511	F	1000 PPM	SCHEDULED EUTHANASIA	31-OCT-02
10529	F	1000 PPM	SCHEDULED EUTHANASIA	13-NOV-02
10532	F	1000 PPM	SCHEDULED EUTHANASIA	14-NOV-02
10547	F	1000 PPM	SCHEDULED EUTHANASIA	13-NOV-02

TABLE 108 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH
10485	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10491	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10496	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	20-NOV-02
10498	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10500	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	18-OCT-02
10512	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10514	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	15-NOV-02
10521	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10536	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	18-OCT-02
10537	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10472	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	19-OCT-02
10487	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10492	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10495	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	16-NOV-02
10499	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10515	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10516	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	15-NOV-02
10552	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	15-NOV-02
10553	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	22-OCT-02
10556	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10475	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10489	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	24-NOV-02
10490	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10497	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10501	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	15-NOV-02
10505	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10517	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10531	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	13-NOV-02

ANIMAL	SEX	GROUP	TYPE OF DEATH	DATE OF DEATH
10533	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10538	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	15-NOV-02
10466	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	16-NOV-02
10469	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10477	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10502	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10526	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	11-NOV-02
10527	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	12-NOV-02
10541	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10542	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	13-NOV-02
10544	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	14-NOV-02
10545	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	12-NOV-02

TABLE 109 (F0 MALES - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 09-06-02 TO 10-08-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10367	M	0 PPM	DISPOSITION	10-08-02	7:02	P	SCHEDULED EUTHANASIA
10368	M	0 PPM	DISPOSITION	10-07-02	6:47	P	SCHEDULED EUTHANASIA
10375	M	0 PPM	DISPOSITION	10-08-02	7:02	P	SCHEDULED EUTHANASIA
10384	M	0 PPM	DISPOSITION	10-08-02	7:02	P	SCHEDULED EUTHANASIA
10386	M	0 PPM	DISPOSITION	10-07-02	6:47	P	SCHEDULED EUTHANASIA
10386	M	0 PPM	BODY/INTEGUMENT	10-04-02	6:15	1	HAIR LOSS RIGHT FORELIMB
				10-07-02	6:11	1	HAIR LOSS RIGHT FORELIMB
10387	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10387	M	0 PPM	EYES/EARS/NOSE	09-20-02	6:21	1	DRIED RED MATERIAL AROUND NOSE
10390	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10394	M	0 PPM	DISPOSITION	10-08-02	7:02	P	SCHEDULED EUTHANASIA
10395	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10395	M	0 PPM	BODY/INTEGUMENT	09-20-02	6:22	2	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:23	3	HAIR LOSS LEFT FORELIMB
				09-27-02	6:37	3	HAIR LOSS RIGHT FORELIMB
				09-27-02	6:37	3	HAIR LOSS LEFT FORELIMB
				10-04-02	6:17	3	HAIR LOSS LEFT FORELIMB
				10-04-02	6:17	2	HAIR LOSS RIGHT FORELIMB
				10-07-02	6:12	2	HAIR LOSS RIGHT FORELIMB
				10-07-02	6:12	2	HAIR LOSS LEFT FORELIMB
10395	M	0 PPM	EYES/EARS/NOSE	09-27-02	6:37	1	DRIED RED MATERIAL AROUND NOSE
10399	M	0 PPM	DISPOSITION	10-08-02	7:02	P	SCHEDULED EUTHANASIA
10402	M	0 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10402	M	0 PPM	BODY/INTEGUMENT	10-04-02	6:17	1	HAIR LOSS RIGHT FORELIMB
				10-08-02	6:19	1	HAIR LOSS RIGHT FORELIMB
10415	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10417	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10425	M	0 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10427	M	0 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 09-06-02 TO 10-08-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10435	M	0 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10439	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10442	M	0 PPM	DISPOSITION	10-07-02	6:48	P	SCHEDULED EUTHANASIA
10451	M	0 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10458	M	0 PPM	DISPOSITION	10-07-02	6:49	P	SCHEDULED EUTHANASIA
10458	M	0 PPM	BODY/INTEGUMENT	09-20-02	6:27	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:27	2	HAIR LOSS RIGHT FORELIMB
				10-04-02	6:23	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	6:23	1	HAIR LOSS LEFT FORELIMB
				10-07-02	6:15	1	HAIR LOSS RIGHT FORELIMB
				10-07-02	6:15	2	HAIR LOSS LEFT FORELIMB
10372	M	100 PPM	DISPOSITION	10-07-02	6:49	P	SCHEDULED EUTHANASIA
10378	M	100 PPM	DISPOSITION	10-07-02	6:49	P	SCHEDULED EUTHANASIA
10378	M	100 PPM	EYES/EARS/NOSE	09-27-02	6:45	1	DRIED RED MATERIAL AROUND LEFT EYE
10379	M	100 PPM	DISPOSITION	10-07-02	6:49	P	SCHEDULED EUTHANASIA
10383	M	100 PPM	DISPOSITION	10-07-02	6:49	P	SCHEDULED EUTHANASIA
10389	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10389	M	100 PPM	ORAL/DENTAL	09-20-02	6:30	1	WET CLEAR MATERIAL AROUND MOUTH
10404	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10405	M	100 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10405	M	100 PPM	ORAL/DENTAL	09-20-02	6:31	1	WET CLEAR MATERIAL AROUND MOUTH
10406	M	100 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10406	M	100 PPM	BODY/INTEGUMENT	09-20-02	6:32	1	HAIR LOSS LEFT FORELIMB
				09-27-02	6:49	1	HAIR LOSS LEFT FORELIMB
10406	M	100 PPM	EYES/EARS/NOSE	09-20-02	6:32	1	DRIED RED MATERIAL AROUND NOSE
10411	M	100 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10414	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10419	M	100 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA
10422	M	100 PPM	DISPOSITION	10-08-02	7:03	P	SCHEDULED EUTHANASIA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 09-06-02 TO 10-08-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10431	M	100 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10432	M	100 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10432	M	100 PPM	ORAL/DENTAL	09-20-02	6:34	1	WET CLEAR MATERIAL AROUND MOUTH
				09-27-02	6:52	1	SALIVATION
10438	M	100 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10440	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10443	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10455	M	100 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10460	M	100 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10461	M	100 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10369	M	500 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10370	M	500 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10377	M	500 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10380	M	500 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10380	M	500 PPM	BODY/INTEGUMENT	09-20-02	6:39	3	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:39	3	HAIR LOSS LEFT FORELIMB
				09-27-02	6:58	3	HAIR LOSS RIGHT FORELIMB
				09-27-02	6:58	3	HAIR LOSS LEFT FORELIMB
				10-04-02	6:31	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	6:31	1	HAIR LOSS LEFT FORELIMB
				10-08-02	6:25	1	HAIR LOSS RIGHT FORELIMB
				10-08-02	6:25	1	HAIR LOSS LEFT FORELIMB
10381	M	500 PPM	DISPOSITION	10-07-02	6:50	P	SCHEDULED EUTHANASIA
10381	M	500 PPM	BODY/INTEGUMENT	09-13-02	6:36	1	HAIR LOSS RIGHT FORELIMB
10382	M	500 PPM	DISPOSITION	10-08-02	7:04	P	SCHEDULED EUTHANASIA
10385	M	500 PPM	DISPOSITION	10-07-02	6:51	P	SCHEDULED EUTHANASIA
10391	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10392	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10396	M	500 PPM	DISPOSITION	10-07-02	6:51	P	SCHEDULED EUTHANASIA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 109 (F0 MALES - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 09-06-02 TO 10-08-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10400	M	500 PPM	DISPOSITION	10-07-02	6:51	P	SCHEDULED EUTHANASIA
10407	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10410	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10410	M	500 PPM	BODY/INTEGUMENT	09-20-02	6:44	1	HAIR LOSS RIGHT FORELIMB
10421	M	500 PPM	DISPOSITION	10-07-02	6:51	P	SCHEDULED EUTHANASIA
10423	M	500 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10429	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10437	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10445	M	500 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10453	M	500 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10454	M	500 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10373	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10374	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10376	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10397	M	1000 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10398	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10403	M	1000 PPM	DISPOSITION	10-08-02	7:05	P	SCHEDULED EUTHANASIA
10409	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10412	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10416	M	1000 PPM	DISPOSITION	10-07-02	6:52	P	SCHEDULED EUTHANASIA
10416	M	1000 PPM	BODY/INTEGUMENT	09-20-02	6:50	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:50	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:12	2	HAIR LOSS RIGHT FORELIMB
				09-27-02	7:12	2	HAIR LOSS LEFT FORELIMB
				10-07-02	6:25	1	HAIR LOSS RIGHT FORELIMB
				10-07-02	6:25	1	HAIR LOSS LEFT FORELIMB
10418	M	1000 PPM	DISPOSITION	10-07-02	6:53	P	SCHEDULED EUTHANASIA
10420	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10428	M	1000 PPM	DISPOSITION	10-07-02	6:53	P	SCHEDULED EUTHANASIA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 09-06-02 TO 10-08-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10430	M	1000 PPM	DISPOSITION	10-07-02	6:53	P	SCHEDULED EUTHANASIA
10434	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10444	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10447	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10447	M	1000 PPM	ORAL/DENTAL	09-20-02	6:53	1	WET CLEAR MATERIAL AROUND MOUTH
10448	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10449	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10452	M	1000 PPM	DISPOSITION	10-08-02	7:06	P	SCHEDULED EUTHANASIA
10459	M	1000 PPM	DISPOSITION	10-07-02	6:53	P	SCHEDULED EUTHANASIA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 110 (F0 MALES - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 09-06-02 TO 10-07-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10387	M	0 PPM	EYES/EARS/NOSE	09-20-02	7:39	1	DRIED RED MATERIAL AROUND NOSE
10389	M	100 PPM	ORAL/DENTAL	09-20-02	7:39	1	WET CLEAR MATERIAL AROUND MOUTH
10405	M	100 PPM	ORAL/DENTAL	09-20-02	7:39	1	WET CLEAR MATERIAL AROUND MOUTH
10406	M	100 PPM	EYES/EARS/NOSE	09-20-02	7:40	1	DRIED RED MATERIAL AROUND NOSE
10432	M	100 PPM	ORAL/DENTAL	09-20-02	7:40	1	WET CLEAR MATERIAL AROUND MOUTH
10447	M	1000 PPM	ORAL/DENTAL	09-20-02	7:40	1	WET CLEAR MATERIAL AROUND MOUTH

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
01/15/2003

TABLE 111 (F0 MALES - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 09-06-02 TO 10-07-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10370	M	500 PPM	ORAL/DENTAL	09-15-02	13:33	2	WET CLEAR MATERIAL AROUND MOUTH
				09-15-02	13:34	P	SALIVATION
				09-23-02	15:24	2	SALIVATION
10420	M	1000 PPM	ORAL/DENTAL	09-06-02	15:32	1	WET CLEAR MATERIAL AROUND MOUTH
10430	M	1000 PPM	ORAL/DENTAL	09-23-02	15:42	1	SALIVATION

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/11/2003

TABLE 112 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10463	F	0 PPM	BODY/INTEGUMENT	10-11-02	6:15	1	HAIR LOSS LEFT FORELIMB
10494	F	0 PPM	DISPOSITION	10-30-02	8:04	P	SENT TO NECROPSY; POST-MATING DAY 25
10500	F	0 PPM	DISPOSITION	10-18-02	7:52	P	SENT TO NECROPSY; POST-MATING DAY 25
10503	F	0 PPM	DISPOSITION	10-18-02	7:52	P	SENT TO NECROPSY; POST-MATING DAY 25
10513	F	0 PPM	DISPOSITION	10-21-02	6:43	P	SENT TO NECROPSY; POST-MATING DAY 25
10513	F	0 PPM	BODY/INTEGUMENT	09-06-02	6:22	2	HAIR LOSS RIGHT FORELIMB
				09-06-02	6:22	2	HAIR LOSS LEFT FORELIMB
				09-13-02	6:18	2	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:18	2	HAIR LOSS LEFT FORELIMB
				09-20-02	6:24	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:24	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:07	1	HAIR LOSS LEFT FORELIMB
				09-27-02	9:01	2	HAIR LOSS RIGHT FORELIMB
				10-04-02	6:57	2	HAIR LOSS RIGHT FORELIMB
				10-04-02	6:57	2	HAIR LOSS LEFT FORELIMB
				10-11-02	6:19	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:19	3	HAIR LOSS LEFT FORELIMB
				10-18-02	6:22	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:22	2	HAIR LOSS LEFT FORELIMB
				10-21-02	6:41	1	HAIR LOSS RIGHT FORELIMB
				10-21-02	6:41	2	HAIR LOSS LEFT FORELIMB
10514	F	0 PPM	BODY/INTEGUMENT	10-11-02	6:19	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:19	3	HAIR LOSS LEFT FORELIMB
10521	F	0 PPM	BODY/INTEGUMENT	10-11-02	6:20	1	HAIR LOSS RIGHT FORELIMB
10521	F	0 PPM	SPECIAL II	10-06-02	15:00	P	BREEDING PERIOD COMPLETE
							SEPARATED FROM MALE
10536	F	0 PPM	DISPOSITION	10-18-02	7:52	P	SENT TO NECROPSY; POST-MATING DAY 25
10537	F	0 PPM	BODY/INTEGUMENT	09-06-02	6:24	1	HAIR LOSS RIGHT FORELIMB
				09-06-02	6:24	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 112 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10537	F	0 PPM	BODY/INTEGUMENT	09-13-02	6:20	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:20	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:27	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:27	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:10	2	HAIR LOSS RIGHT FORELIMB
				09-27-02	9:01	2	HAIR LOSS LEFT FORELIMB
				10-04-02	6:58	1	HAIR LOSS LEFT FORELIMB
				10-04-02	6:58	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:21	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:21	3	HAIR LOSS LEFT FORELIMB
10554	F	0 PPM	BODY/INTEGUMENT	10-04-02	7:00	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:00	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:01	1	HAIR LOSS LEFT ABDOMINAL AREA
				10-04-02	7:01	1	HAIR LOSS LEFT HINDLIMB
				10-04-02	7:01	1	HAIR LOSS RIGHT HINDLIMB
				10-11-02	6:22	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:22	2	HAIR LOSS LEFT FORELIMB
				10-11-02	6:22	2	HAIR LOSS LEFT ABDOMINAL AREA
				10-11-02	6:22	2	HAIR LOSS LEFT HINDLIMB
				10-11-02	6:22	2	HAIR LOSS RIGHT HINDLIMB
10555	F	0 PPM	BODY/INTEGUMENT	09-20-02	6:29	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:29	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:13	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	9:02	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:02	2	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:02	2	HAIR LOSS LEFT FORELIMB
				10-11-02	6:22	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:23	3	HAIR LOSS LEFT FORELIMB
10470	F	100 PPM	DISPOSITION	10-19-02	7:18	P	SENT TO NECROPSY; POST-MATING DAY 25

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 112 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10472	F	100 PPM	DISPOSITION	10-19-02	7:18	P	SENT TO NECROPSY; POST-MATING DAY 25
10487	F	100 PPM	BODY/INTEGUMENT	09-06-02	6:27	1	HAIR LOSS RIGHT FORELIMB
				09-06-02	6:27	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:31	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:31	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:20	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	9:03	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:03	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:03	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:24	2	HAIR LOSS LEFT FORELIMB
				10-11-02	6:24	1	HAIR LOSS RIGHT FORELIMB
10492	F	100 PPM	BODY/INTEGUMENT	10-04-02	7:04	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:04	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:24	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:24	2	HAIR LOSS LEFT FORELIMB
10493	F	100 PPM	SPECIAL II	10-06-02	15:00	P	BREEDING PERIOD COMPLETE
							SEPARATED FROM MALE
10499	F	100 PPM	BODY/INTEGUMENT	10-11-02	6:25	3	HAIR LOSS RIGHT FORELIMB
10510	F	100 PPM	BODY/INTEGUMENT	09-13-02	6:23	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:23	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:35	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:35	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:32	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	9:03	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:05	3	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:05	3	HAIR LOSS LEFT FORELIMB
				10-11-02	6:26	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:26	3	HAIR LOSS LEFT FORELIMB
10516	F	100 PPM	BODY/INTEGUMENT	09-13-02	6:24	1	HAIR LOSS RIGHT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 112 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10516	F	100 PPM	BODY/INTEGUMENT	09-13-02	6:24	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:36	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	7:34	1	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:27	1	HAIR LOSS RIGHT FORELIMB
10553	F	100 PPM	DISPOSITION	10-22-02	9:01	P	SENT TO NECROPSY; POST-MATING DAY 25
10489	F	500 PPM	BODY/INTEGUMENT	10-18-02	6:40	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:33	1	HAIR LOSS LEFT FORELIMB
10497	F	500 PPM	BODY/INTEGUMENT	09-13-02	6:29	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:29	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:43	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:43	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:47	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	7:47	1	HAIR LOSS LEFT FORELIMB
10497	F	500 PPM	SPECIAL II	10-06-02	15:00	P	BREEDING PERIOD COMPLETE
							SEPARATED FROM MALE
10520	F	500 PPM	BODY/INTEGUMENT	09-20-02	6:45	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:45	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:10	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:10	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:33	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:33	2	HAIR LOSS LEFT FORELIMB
10548	F	500 PPM	BODY/INTEGUMENT	09-27-02	8:04	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:12	1	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:35	1	HAIR LOSS RIGHT FORELIMB
10473	F	1000 PPM	BODY/INTEGUMENT	09-06-02	6:38	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:34	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:34	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:49	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:49	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 112 (F0 FEMALES - PRE-MATING/GESTATION - DETAILED PHYSICAL EXAMINATIONS)

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10473	F	1000 PPM	BODY/INTEGUMENT	09-27-02	7:48	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	7:48	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:14	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:14	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:36	1	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:36	1	HAIR LOSS LEFT FORELIMB
10481	F	1000 PPM	BODY/INTEGUMENT	09-13-02	6:34	1	HAIR LOSS LEFT FORELIMB
10486	F	1000 PPM	BODY/INTEGUMENT	10-11-02	6:37	1	HAIR LOSS LEFT FORELIMB
10502	F	1000 PPM	BODY/INTEGUMENT	09-06-02	6:39	1	HAIR LOSS RIGHT FORELIMB
				09-06-02	6:39	1	HAIR LOSS LEFT FORELIMB
				09-13-02	6:35	1	HAIR LOSS LEFT FORELIMB
				09-13-02	6:35	2	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:51	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:51	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:15	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:15	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:38	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:38	2	HAIR LOSS LEFT FORELIMB
10511	F	1000 PPM	DISPOSITION	10-31-02	7:58	P	SENT TO NECROPSY; POST-COHABITATION DAY 25
10511	F	1000 PPM	BODY/INTEGUMENT	09-20-02	6:52	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:52	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:49	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	7:49	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:38	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:40	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:40	1	HAIR LOSS LEFT FORELIMB
				10-31-02	7:57	1	HAIR LOSS RIGHT FORELIMB
				10-31-02	7:57	1	HAIR LOSS LEFT FORELIMB
10511	F	1000 PPM	SPECIAL II	10-06-02	14:58	P	BREEDING PERIOD COMPLETE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 09-06-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
							SEPARATED FROM MALE
10526	F	1000 PPM	BODY/INTEGUMENT	09-20-02	6:52	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:16	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:16	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:39	2	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:39	2	HAIR LOSS LEFT FORELIMB
10529	F	1000 PPM	BODY/INTEGUMENT	10-11-02	6:39	1	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:39	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:39	1	HAIR LOSS RIGHT HINDLIMB
10529	F	1000 PPM	EYES/EARS/NOSE	09-06-02	6:41	1	DRIED RED MATERIAL AROUND LEFT EYE
10532	F	1000 PPM	BODY/INTEGUMENT	09-13-02	6:38	1	HAIR LOSS RIGHT FORELIMB
				09-13-02	6:38	1	HAIR LOSS LEFT FORELIMB
				09-20-02	6:54	1	HAIR LOSS RIGHT FORELIMB
				09-20-02	6:54	1	HAIR LOSS LEFT FORELIMB
				09-27-02	7:16	1	HAIR LOSS RIGHT FORELIMB
				09-27-02	9:07	1	HAIR LOSS LEFT FORELIMB
				10-04-02	7:18	1	HAIR LOSS RIGHT FORELIMB
				10-04-02	7:18	1	HAIR LOSS LEFT FORELIMB
				10-11-02	6:40	3	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:40	3	HAIR LOSS LEFT FORELIMB
10544	F	1000 PPM	BODY/INTEGUMENT	10-11-02	6:41	1	HAIR LOSS RIGHT FORELIMB
				10-11-02	6:41	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 113 (F0 FEMALES - PRE-MATING/GESTATION - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 09-06-02 TO 10-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10529	F	1000 PPM	EYES/EARS/NOSE	09-06-02	7:33	1	DRIED RED MATERIAL AROUND LEFT EYE
				09-07-02	6:33	2	DRIED RED MATERIAL AROUND LEFT EYE
				09-08-02	6:48	1	DRIED RED MATERIAL AROUND LEFT EYE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/13/2003
R:02/13/2003

TABLE 114 (F0 FEMALES - PRE-MATING/GESTATION - MIDPOINT OF EXPOSURE)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 09-06-02 TO 10-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10486	F	1000 PPM	ORAL/DENTAL	10-14-02	10:52	1	WET CLEAR MATERIAL AROUND MOUTH

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/13/2003
R:02/13/2003

TABLE 115 (F0 FEMALES - PRE-MATING/GESTATION - 1-HOUR POST-EXPOSURE)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 09-06-02 TO 10-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10536	F	0 PPM	EYES/EARS/NOSE	09-08-02	13:45	1	DRIED RED MATERIAL AROUND LEFT EYE
10531	F	500 PPM	ORAL/DENTAL	09-06-02	15:16	1	WET CLEAR MATERIAL AROUND MOUTH
10465	F	1000 PPM	BODY/INTEGUMENT	09-14-02	13:58	2	WET CLEAR MATERIAL VENTRAL NECK
				09-14-02	13:58	2	WET CLEAR MATERIAL LEFT FORELIMB
				09-14-02	13:58	2	WET CLEAR MATERIAL RIGHT FORELIMB
				09-15-02	13:39	1	WET CLEAR MATERIAL VENTRAL NECK
				09-15-02	13:39	1	WET CLEAR MATERIAL LEFT FORELIMB
				09-15-02	13:39	1	WET CLEAR MATERIAL RIGHT FORELIMB
10465	F	1000 PPM	ORAL/DENTAL	09-14-02	13:58	2	WET CLEAR MATERIAL AROUND MOUTH
				09-15-02	13:39	2	WET CLEAR MATERIAL AROUND MOUTH
10502	F	1000 PPM	ORAL/DENTAL	09-24-02	15:34	1	WET CLEAR MATERIAL AROUND MOUTH
				10-08-02	14:54	1	WET CLEAR MATERIAL AROUND MOUTH
10511	F	1000 PPM	ORAL/DENTAL	09-24-02	15:35	1	WET CLEAR MATERIAL AROUND MOUTH
10529	F	1000 PPM	EYES/EARS/NOSE	09-06-02	15:23	1	DRIED RED MATERIAL AROUND LEFT EYE
				09-07-02	13:52	1	DRIED RED MATERIAL AROUND LEFT EYE
				09-08-02	13:46	1	DRIED RED MATERIAL AROUND LEFT EYE
10529	F	1000 PPM	ORAL/DENTAL	10-13-02	13:49	1	WET CLEAR MATERIAL AROUND MOUTH
10545	F	1000 PPM	ORAL/DENTAL	10-13-02	13:49	2	WET CLEAR MATERIAL AROUND MOUTH

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 116 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10463	F	0 PPM	DISPOSITION	11-13-02	11:02	P	SENT TO NECROPSY; LACTATION DAY 28
10463	F	0 PPM	BODY/INTEGUMENT	10-18-02	6:19	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:17	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:17	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:25	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:25	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:02	1	HAIR LOSS LEFT FORELIMB
10464	F	0 PPM	DISPOSITION	11-14-02	10:49	P	SENT TO NECROPSY; LACTATION DAY 28
10506	F	0 PPM	DISPOSITION	11-14-02	10:49	P	SENT TO NECROPSY; LACTATION DAY 28
10506	F	0 PPM	BODY/INTEGUMENT	10-25-02	6:19	1	HAIR LOSS RIGHT FORELIMB
10524	F	0 PPM	DISPOSITION	11-12-02	10:06	P	SENT TO NECROPSY; LACTATION DAY 28
10540	F	0 PPM	DISPOSITION	11-16-02	10:20	P	SENT TO NECROPSY; LACTATION DAY 28
10540	F	0 PPM	BODY/INTEGUMENT	10-25-02	6:21	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:26	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:23	1	HAIR LOSS LEFT FORELIMB
				11-15-02	6:18	1	HAIR LOSS LEFT FORELIMB
10554	F	0 PPM	DISPOSITION	11-14-02	10:50	P	SENT TO NECROPSY; LACTATION DAY 28
10554	F	0 PPM	BODY/INTEGUMENT	10-18-02	6:30	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:30	2	HAIR LOSS LEFT FORELIMB
				10-18-02	6:31	2	HAIR LOSS LEFT ABDOMINAL AREA
				10-18-02	6:31	1	HAIR LOSS RIGHT LATERAL ABDOMINAL AREA
				10-25-02	6:22	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:22	2	HAIR LOSS LEFT FORELIMB
				10-25-02	6:22	2	HAIR LOSS LEFT HINDLIMB
				10-25-02	6:23	2	HAIR LOSS RIGHT LATERAL ABDOMINAL AREA
				10-25-02	6:24	2	HAIR LOSS LEFT ABDOMINAL AREA
				10-25-02	6:25	P	SCABBING LEFT FORELIMB
				11-01-02	6:27	2	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:27	2	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 116 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10554	F	0 PPM	BODY/INTEGUMENT	11-01-02	6:27	1	HAIR LOSS LEFT ABDOMINAL AREA
				11-01-02	6:27	1	HAIR LOSS LEFT HINDLIMB
				11-01-02	6:27	1	HAIR LOSS RIGHT HINDLIMB
				11-08-02	6:24	2	HAIR LOSS LEFT FORELIMB
				11-08-02	6:24	1	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:49	2	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:49	2	HAIR LOSS LEFT FORELIMB
				11-14-02	10:49	2	HAIR LOSS LEFT HINDLIMB
				11-14-02	10:50	2	HAIR LOSS RIGHT HINDLIMB
				11-14-02	10:50	2	HAIR LOSS RIGHT LATERAL ABDOMINAL AREA
10554	F	0 PPM	EXCRETA	10-25-02	6:21	P	SOFT STOOL
10555	F	0 PPM	DISPOSITION	11-14-02	10:51	P	SENT TO NECROPSY; LACTATION DAY 28
10555	F	0 PPM	BODY/INTEGUMENT	10-18-02	6:32	3	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:32	3	HAIR LOSS LEFT FORELIMB
				10-25-02	6:25	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:25	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:28	3	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:28	3	HAIR LOSS LEFT FORELIMB
				11-08-02	6:25	3	HAIR LOSS LEFT FORELIMB
				11-08-02	6:25	3	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:51	3	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:51	3	HAIR LOSS LEFT FORELIMB
10488	F	100 PPM	DISPOSITION	11-11-02	8:49	P	SENT TO NECROPSY; LACTATION DAY 28
10493	F	100 PPM	DISPOSITION	11-18-02	9:34	P	SENT TO NECROPSY; LACTATION DAY 28
10504	F	100 PPM	DISPOSITION	11-13-02	11:03	P	SENT TO NECROPSY; LACTATION DAY 28
10504	F	100 PPM	BODY/INTEGUMENT	10-25-02	6:28	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:29	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:02	1	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:02	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 116 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10510	F	100 PPM	DISPOSITION	11-14-02	10:51	P	SENT TO NECROPSY; LACTATION DAY 28
10510	F	100 PPM	BODY/INTEGUMENT	10-18-02	6:35	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:35	3	HAIR LOSS LEFT FORELIMB
				10-25-02	6:28	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:28	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:29	2	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:29	2	HAIR LOSS LEFT FORELIMB
				11-08-02	6:28	2	HAIR LOSS LEFT FORELIMB
				11-08-02	6:28	2	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:51	2	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:51	2	HAIR LOSS LEFT FORELIMB
10519	F	100 PPM	DISPOSITION	11-14-02	10:53	P	SENT TO NECROPSY; LACTATION DAY 28
10519	F	100 PPM	BODY/INTEGUMENT	10-25-02	6:29	1	HAIR LOSS RIGHT FORELIMB
10522	F	100 PPM	DISPOSITION	11-12-02	10:06	P	SENT TO NECROPSY; LACTATION DAY 28
10525	F	100 PPM	DISPOSITION	11-15-02	9:55	P	SENT TO NECROPSY; LACTATION DAY 28
10528	F	100 PPM	DISPOSITION	11-15-02	9:55	P	SENT TO NECROPSY; LACTATION DAY 28
10543	F	100 PPM	DISPOSITION	10-31-02	7:52	P	SENT TO NECROPSY; TOTAL LITTER LOSS
10543	F	100 PPM	EXCRETA	10-25-02	6:30	P	SOFT STOOL
				10-31-02	7:52	P	SOFT STOOL
10468	F	500 PPM	DISPOSITION	11-16-02	10:20	P	SENT TO NECROPSY; LACTATION DAY 28
10478	F	500 PPM	DISPOSITION	11-14-02	10:53	P	SENT TO NECROPSY; LACTATION DAY 28
10483	F	500 PPM	DISPOSITION	11-13-02	11:03	P	SENT TO NECROPSY; LACTATION DAY 28
10484	F	500 PPM	DISPOSITION	11-15-02	9:55	P	SENT TO NECROPSY; LACTATION DAY 28
10520	F	500 PPM	DISPOSITION	10-17-02	13:45	P	SENT TO NECROPSY; TOTAL LITTER LOSS
10520	F	500 PPM	BODY/INTEGUMENT	10-17-02	13:43	1	HAIR LOSS RIGHT FORELIMB
				10-17-02	13:43	1	HAIR LOSS LEFT FORELIMB
10530	F	500 PPM	DISPOSITION	11-12-02	10:06	P	SENT TO NECROPSY; LACTATION DAY 28
10534	F	500 PPM	DISPOSITION	11-13-02	11:03	P	SENT TO NECROPSY; LACTATION DAY 28
10546	F	500 PPM	DISPOSITION	11-12-02	10:07	P	SENT TO NECROPSY; LACTATION DAY 28

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 116 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10546	F	500 PPM	BODY/INTEGUMENT	10-25-02	6:37	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:37	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:33	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:37	1	HAIR LOSS LEFT FORELIMB
				11-12-02	10:06	1	HAIR LOSS RIGHT FORELIMB
10548	F	500 PPM	DISPOSITION	11-12-02	10:09	P	SENT TO NECROPSY; LACTATION DAY 28
10548	F	500 PPM	BODY/INTEGUMENT	10-18-02	6:44	1	HAIR LOSS LEFT FORELIMB
				10-18-02	6:44	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:37	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:37	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:33	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:33	2	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:38	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:38	1	HAIR LOSS RIGHT FORELIMB
				11-12-02	10:08	1	HAIR LOSS LEFT FORELIMB
				11-12-02	10:08	2	HAIR LOSS RIGHT FORELIMB
10548	F	500 PPM	EYES/EARS/NOSE	11-12-02	10:09	2	DRIED RED MATERIAL AROUND RIGHT EYE
				11-12-02	10:09	2	DRIED RED MATERIAL AROUND LEFT EYE
10548	F	500 PPM	ORAL/DENTAL	11-12-02	10:08	P	UPPER INCISORS MALALIGNED
10550	F	500 PPM	DISPOSITION	11-13-02	11:04	P	SENT TO NECROPSY; LACTATION DAY 28
10550	F	500 PPM	EXCRETA	10-25-02	6:37	P	SOFT STOOL
10465	F	1000 PPM	DISPOSITION	11-14-02	10:53	P	SENT TO NECROPSY; LACTATION DAY 28
10473	F	1000 PPM	DISPOSITION	11-17-02	8:47	P	SENT TO NECROPSY; LACTATION DAY 28
10473	F	1000 PPM	BODY/INTEGUMENT	11-01-02	6:34	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:34	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:40	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:40	1	HAIR LOSS LEFT FORELIMB
				11-15-02	6:20	1	HAIR LOSS RIGHT FORELIMB
				11-15-02	6:20	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 116 (F0 FEMALES - LACTATION - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10480	F	1000 PPM	DISPOSITION	11-13-02	11:04	P	SENT TO NECROPSY; LACTATION DAY 28
10481	F	1000 PPM	DISPOSITION	11-12-02	10:10	P	SENT TO NECROPSY; LACTATION DAY 28
10486	F	1000 PPM	DISPOSITION	11-14-02	10:53	P	SENT TO NECROPSY; LACTATION DAY 28
10507	F	1000 PPM	DISPOSITION	11-12-02	10:10	P	SENT TO NECROPSY; LACTATION DAY 28
10507	F	1000 PPM	BEHAVIOR/CNS	10-15-02	14:27	P	DYSTOCIA
10529	F	1000 PPM	DISPOSITION	11-13-02	11:05	P	SENT TO NECROPSY; LACTATION DAY 28
10529	F	1000 PPM	BODY/INTEGUMENT	10-18-02	6:49	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:49	2	HAIR LOSS LEFT FORELIMB
				10-25-02	6:42	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:42	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:36	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:36	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:44	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:44	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:44	1	HAIR LOSS RIGHT HINDLIMB
				11-13-02	11:05	1	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:05	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:05	1	HAIR LOSS RIGHT HINDLIMB
10532	F	1000 PPM	DISPOSITION	11-14-02	10:54	P	SENT TO NECROPSY; LACTATION DAY 28
10532	F	1000 PPM	BODY/INTEGUMENT	10-18-02	6:49	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:49	2	HAIR LOSS LEFT FORELIMB
				10-25-02	6:42	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:42	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:36	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:36	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:45	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:45	1	HAIR LOSS LEFT FORELIMB
				11-14-02	10:54	1	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:54	1	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10547	F	1000 PPM	DISPOSITION	11-13-02	11:06	P	SENT TO NECROPSY; LACTATION DAY 28

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 117 (F0 FEMALES - LACTATION - INHALATION PHASE - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 10-15-02 TO 11-18-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10554	F	0 PPM	EXCRETA	10-25-02	7:00	P	SOFT STOOL
10543	F	100 PPM	EXCRETA	10-25-02	7:00	P	SOFT STOOL
10548	F	500 PPM	EYES/EARS/NOSE	11-09-02	7:30	1	DRIED RED MATERIAL AROUND RIGHT EYE
				11-09-02	7:30	1	DRIED RED MATERIAL AROUND LEFT EYE
				11-09-02	7:30	2	DRIED RED MATERIAL AROUND NOSE
10548	F	500 PPM	ORAL/DENTAL	11-09-02	7:30	P	UPPER INCISORS MALALIGNED
10550	F	500 PPM	EXCRETA	10-25-02	7:02	P	SOFT STOOL

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
01/15/2003
R:01/22/2003

TABLE 118 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10485	F	0 PPM/0 MG/KG	DISPOSITION	11-14-02	10:55	P	SENT TO NECROPSY; LACTATION DAY 28
10491	F	0 PPM/0 MG/KG	DISPOSITION	11-14-02	10:56	P	SENT TO NECROPSY; LACTATION DAY 28
10496	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	8:03	P	SENT TO NECROPSY; LACTATION DAY 28
10498	F	0 PPM/0 MG/KG	DISPOSITION	11-13-02	11:08	P	SENT TO NECROPSY; LACTATION DAY 28
10512	F	0 PPM/0 MG/KG	DISPOSITION	11-13-02	11:08	P	SENT TO NECROPSY; LACTATION DAY 28
10514	F	0 PPM/0 MG/KG	DISPOSITION	11-15-02	9:56	P	SENT TO NECROPSY; LACTATION DAY 28
10514	F	0 PPM/0 MG/KG	BODY/INTEGUMENT	10-18-02	6:23	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:23	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:19	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:19	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:38	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:38	2	HAIR LOSS RIGHT FORELIMB
				11-08-02	6:53	3	HAIR LOSS LEFT FORELIMB
				11-08-02	6:53	3	HAIR LOSS RIGHT FORELIMB
				11-15-02	6:21	2	HAIR LOSS LEFT FORELIMB
				11-15-02	6:21	1	HAIR LOSS RIGHT FORELIMB
10521	F	0 PPM/0 MG/KG	DISPOSITION	11-14-02	10:56	P	SENT TO NECROPSY; LACTATION DAY 28
10521	F	0 PPM/0 MG/KG	BODY/INTEGUMENT	10-18-02	6:28	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:20	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:20	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:38	2	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:39	2	HAIR LOSS LEFT FORELIMB
				11-08-02	6:57	3	HAIR LOSS LEFT FORELIMB
				11-08-02	6:57	3	HAIR LOSS RIGHT FORELIMB
				11-14-02	10:56	2	HAIR LOSS LEFT FORELIMB
				11-14-02	10:56	2	HAIR LOSS RIGHT FORELIMB
10537	F	0 PPM/0 MG/KG	DISPOSITION	11-13-02	11:08	P	SENT TO NECROPSY; LACTATION DAY 28
10537	F	0 PPM/0 MG/KG	BODY/INTEGUMENT	10-18-02	6:29	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:29	2	HAIR LOSS LEFT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 118 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10537	F	0 PPM/0 MG/KG	BODY/INTEGUMENT	11-01-02	6:39	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:39	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:57	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:57	3	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:08	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:08	1	HAIR LOSS RIGHT FORELIMB
10487	F	100 PPM/90 MG/KG	DISPOSITION	11-13-02	11:09	P	SENT TO NECROPSY; LACTATION DAY 28
10487	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-18-02	6:33	1	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:33	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:26	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:26	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:39	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:39	1	HAIR LOSS LEFT FORELIMB
				11-08-02	6:59	2	HAIR LOSS LEFT FORELIMB
				11-08-02	6:59	1	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:09	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:09	1	HAIR LOSS RIGHT FORELIMB
10492	F	100 PPM/90 MG/KG	DISPOSITION	11-12-02	10:12	P	SENT TO NECROPSY; LACTATION DAY 28
10492	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-18-02	6:33	2	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:33	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:27	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:40	2	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:40	2	HAIR LOSS LEFT FORELIMB
				11-08-02	7:00	3	HAIR LOSS LEFT FORELIMB
				11-08-02	7:00	3	HAIR LOSS RIGHT FORELIMB
				11-12-02	10:11	1	HAIR LOSS LEFT FORELIMB
				11-12-02	10:11	1	HAIR LOSS RIGHT HINDLIMB
10495	F	100 PPM/90 MG/KG	DISPOSITION	11-16-02	10:20	P	SENT TO NECROPSY; LACTATION DAY 28
10495	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-25-02	6:27	1	HAIR LOSS RIGHT FORELIMB

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 118 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10495	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-25-02	6:27	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:40	1	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:40	1	HAIR LOSS LEFT FORELIMB
				11-08-02	7:00	2	HAIR LOSS LEFT FORELIMB
				11-15-02	6:22	1	HAIR LOSS LEFT FORELIMB
10499	F	100 PPM/90 MG/KG	DISPOSITION	11-12-02	10:13	P	SENT TO NECROPSY; LACTATION DAY 28
10499	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-18-02	6:34	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:28	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:28	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:41	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:01	3	HAIR LOSS RIGHT FORELIMB
				11-12-02	10:12	1	HAIR LOSS RIGHT FORELIMB
10515	F	100 PPM/90 MG/KG	DISPOSITION	11-13-02	11:09	P	SENT TO NECROPSY; LACTATION DAY 28
10516	F	100 PPM/90 MG/KG	DISPOSITION	11-15-02	9:56	P	SENT TO NECROPSY; LACTATION DAY 28
10516	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-18-02	6:36	1	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:36	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:29	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:29	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:42	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:02	1	HAIR LOSS LEFT FORELIMB
				11-08-02	7:02	2	HAIR LOSS RIGHT FORELIMB
				11-15-02	6:22	1	HAIR LOSS LEFT FORELIMB
				11-15-02	6:22	1	HAIR LOSS RIGHT FORELIMB
10552	F	100 PPM/90 MG/KG	DISPOSITION	11-15-02	9:56	P	SENT TO NECROPSY; LACTATION DAY 28
10552	F	100 PPM/90 MG/KG	BODY/INTEGUMENT	10-25-02	6:30	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:30	1	HAIR LOSS LEFT FORELIMB
10556	F	100 PPM/90 MG/KG	DISPOSITION	11-12-02	10:13	P	SENT TO NECROPSY; LACTATION DAY 28
10475	F	500 PPM/342MG/KG	DISPOSITION	11-12-02	10:14	P	SENT TO NECROPSY; LACTATION DAY 28
10489	F	500 PPM/342MG/KG	DISPOSITION	11-24-02	8:29	P	SENT TO NECROPSY; LACTATION DAY 28

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10490	F	500 PPM/342MG/KG	DISPOSITION	11-14-02	10:57	P	SENT TO NECROPSY; LACTATION DAY 28
10490	F	500 PPM/342MG/KG	EXCRETA	10-25-02	6:33	P	SOFT STOOL
10497	F	500 PPM/342MG/KG	DISPOSITION	11-13-02	11:10	P	SENT TO NECROPSY; LACTATION DAY 28
10497	F	500 PPM/342MG/KG	BODY/INTEGUMENT	10-18-02	6:40	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:33	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:33	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:43	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:07	1	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:10	1	HAIR LOSS RIGHT FORELIMB
10501	F	500 PPM/342MG/KG	DISPOSITION	11-15-02	9:56	P	SENT TO NECROPSY; LACTATION DAY 28
10505	F	500 PPM/342MG/KG	DISPOSITION	11-13-02	11:10	P	SENT TO NECROPSY; LACTATION DAY 28
10505	F	500 PPM/342MG/KG	BODY/INTEGUMENT	10-18-02	6:41	1	HAIR LOSS RIGHT FORELIMB
				10-18-02	6:41	1	HAIR LOSS LEFT FORELIMB
				10-25-02	6:34	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:34	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:44	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:44	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:08	3	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:08	1	HAIR LOSS LEFT FORELIMB
				11-13-02	11:10	2	HAIR LOSS LEFT FORELIMB
				11-13-02	11:10	1	HAIR LOSS RIGHT FORELIMB
10517	F	500 PPM/342MG/KG	DISPOSITION	11-13-02	11:11	P	SENT TO NECROPSY; LACTATION DAY 28
10517	F	500 PPM/342MG/KG	BODY/INTEGUMENT	10-25-02	6:35	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:44	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:09	2	HAIR LOSS RIGHT FORELIMB
				11-13-02	11:11	1	HAIR LOSS RIGHT FORELIMB
10531	F	500 PPM/342MG/KG	DISPOSITION	11-13-02	11:11	P	SENT TO NECROPSY; LACTATION DAY 28
10533	F	500 PPM/342MG/KG	DISPOSITION	11-14-02	10:57	P	SENT TO NECROPSY; LACTATION DAY 28
10538	F	500 PPM/342MG/KG	DISPOSITION	11-15-02	9:56	P	SENT TO NECROPSY; LACTATION DAY 28

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 118 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10466	F	1000PPM/621MG/KG	DISPOSITION	11-16-02	10:20	P	SENT TO NECROPSY; LACTATION DAY 28
10469	F	1000PPM/621MG/KG	DISPOSITION	11-13-02	11:12	P	SENT TO NECROPSY; LACTATION DAY 28
10477	F	1000PPM/621MG/KG	DISPOSITION	11-13-02	11:12	P	SENT TO NECROPSY; LACTATION DAY 28
10477	F	1000PPM/621MG/KG	EXCRETA	10-25-02	6:39	P	SOFT STOOL
10502	F	1000PPM/621MG/KG	DISPOSITION	11-12-02	10:15	P	SENT TO NECROPSY; LACTATION DAY 28
10502	F	1000PPM/621MG/KG	BODY/INTEGUMENT	10-18-02	6:47	2	HAIR LOSS LEFT FORELIMB
				10-18-02	6:47	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:40	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:40	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:46	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:46	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:14	2	HAIR LOSS LEFT FORELIMB
				11-08-02	7:14	2	HAIR LOSS RIGHT FORELIMB
				11-12-02	10:15	1	HAIR LOSS LEFT FORELIMB
				11-12-02	10:15	1	HAIR LOSS RIGHT FORELIMB
10526	F	1000PPM/621MG/KG	DISPOSITION	11-11-02	8:48	P	SENT TO NECROPSY; LACTATION DAY 28
10526	F	1000PPM/621MG/KG	BODY/INTEGUMENT	10-18-02	6:48	2	HAIR LOSS LEFT FORELIMB
				10-18-02	6:48	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:40	2	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:40	2	HAIR LOSS LEFT FORELIMB
				11-01-02	6:46	2	HAIR LOSS RIGHT FORELIMB
				11-01-02	6:46	1	HAIR LOSS LEFT FORELIMB
				11-08-02	7:15	3	HAIR LOSS LEFT FORELIMB
				11-08-02	7:15	3	HAIR LOSS RIGHT FORELIMB
				11-11-02	8:47	1	HAIR LOSS LEFT FORELIMB
				11-11-02	8:47	2	HAIR LOSS RIGHT FORELIMB
10526	F	1000PPM/621MG/KG	EXCRETA	10-25-02	6:40	P	SOFT STOOL
10527	F	1000PPM/621MG/KG	DISPOSITION	11-12-02	10:15	P	SENT TO NECROPSY; LACTATION DAY 28
10541	F	1000PPM/621MG/KG	DISPOSITION	11-13-02	11:12	P	SENT TO NECROPSY; LACTATION DAY 28

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 10-15-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10542	F	1000PPM/621MG/KG	DISPOSITION	11-13-02	11:13	P	SENT TO NECROPSY; LACTATION DAY 28
10542	F	1000PPM/621MG/KG	EXCRETA	10-25-02	6:42	P	SOFT STOOL
10544	F	1000PPM/621MG/KG	DISPOSITION	11-14-02	10:57	P	SENT TO NECROPSY; LACTATION DAY 28
10544	F	1000PPM/621MG/KG	BODY/INTEGUMENT	10-18-02	6:50	1	HAIR LOSS LEFT FORELIMB
				10-18-02	6:50	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:43	1	HAIR LOSS RIGHT FORELIMB
				10-25-02	6:43	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:48	1	HAIR LOSS LEFT FORELIMB
				11-01-02	6:48	1	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:17	2	HAIR LOSS RIGHT FORELIMB
				11-08-02	7:17	2	HAIR LOSS LEFT FORELIMB
				11-14-02	10:57	1	HAIR LOSS LEFT FORELIMB
				11-14-02	10:57	1	HAIR LOSS RIGHT FORELIMB
10545	F	1000PPM/621MG/KG	DISPOSITION	11-12-02	10:16	P	SENT TO NECROPSY; LACTATION DAY 28
10545	F	1000PPM/621MG/KG	EXCRETA	10-25-02	6:43	P	SOFT STOOL

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 119 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - PRIOR TO GAVAGE DOSING)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 10-15-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10485	F	0 PPM/0 MG/KG	EYES/EARS/NOSE	10-20-02	8:00	1	DRIED RED MATERIAL AROUND NOSE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/11/2003
R:02/13/2003

TABLE 120 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - 1-HOUR POST-GAVAGE DOSING)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 10-15-02 TO 10-31-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10544	F	1000PPM/621MG/KG	ORAL/DENTAL	10-19-02	13:05	1	WET CLEAR MATERIAL AROUND MOUTH

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
01/22/2003
R:01/22/2003

TABLE 121 (F0 FEMALES - LACTATION - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 10-19-02 TO 11-23-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10490	F	500 PPM/342MG/KG	EXCRETA	10-24-02	7:06	P	DIARRHEA
				10-25-02	7:03	P	SOFT STOOL
10501	F	500 PPM/342MG/KG	EXCRETA	11-11-02	7:28	P	DIARRHEA
10505	F	500 PPM/342MG/KG	EXCRETA	10-25-02	7:04	P	SOFT STOOL
10477	F	1000PPM/621MG/KG	EXCRETA	10-25-02	7:04	P	SOFT STOOL
10526	F	1000PPM/621MG/KG	EXCRETA	10-25-02	7:05	P	SOFT STOOL
10542	F	1000PPM/621MG/KG	EXCRETA	10-25-02	7:05	P	SOFT STOOL
10545	F	1000PPM/621MG/KG	EXCRETA	10-25-02	7:05	P	SOFT STOOL

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/13/2003
R:02/13/2003

TABLE 122 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 0 PPM

WEEK	0	1	2	3	4	5
ANIMAL						
10367	354.	368.	387.	414.	437.	SCHEDULED EUTH
10368	348.	375.	397.	416.	443.	SCHEDULED EUTH
10375	367.	383.	400.	442.	453.	SCHEDULED EUTH
10384	388.	404.	413.	439.	449.	SCHEDULED EUTH
10386	373.	380.	407.	411.	420.	SCHEDULED EUTH
10387	389.	414.	443.	465.	475.	SCHEDULED EUTH
10390	378.	389.	411.	423.	446.	SCHEDULED EUTH
10394	365.	385.	409.	429.	457.	SCHEDULED EUTH
10395	395.	418.	439.	468.	488.	SCHEDULED EUTH
10399	362.	373.	385.	411.	440.	SCHEDULED EUTH
10402	359.	376.	395.	417.	456.	SCHEDULED EUTH
10415	411.	421.	438.	455.	494.	SCHEDULED EUTH
10417	380.	394.	408.	434.	467.	SCHEDULED EUTH
10425	401.	413.	440.	451.	473.	SCHEDULED EUTH
10427	341.	355.	367.	394.	426.	SCHEDULED EUTH
10435	356.	353.	363.	381.	407.	SCHEDULED EUTH
10439	365.	390.	413.	440.	460.	SCHEDULED EUTH
10442	371.	397.	414.	419.	456.	SCHEDULED EUTH
10451	356.	375.	408.	418.	451.	SCHEDULED EUTH
10458	378.	394.	410.	430.	446.	SCHEDULED EUTH
MEAN	372.	388.	407.	428.	452.	
S.D.	18.3	19.5	22.0	22.2	21.3	
N	20	20	20	20	20	

TABLE 122 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 100 PPM

WEEK	0	1	2	3	4	5
ANIMAL						
10372	340.	348.	362.	380.	409.	SCHEDULED EUTH
10378	367.	375.	400.	410.	427.	SCHEDULED EUTH
10379	385.	376.	400.	417.	452.	SCHEDULED EUTH
10383	375.	407.	413.	441.	461.	SCHEDULED EUTH
10389	374.	392.	406.	423.	446.	SCHEDULED EUTH
10404	364.	379.	396.	419.	443.	SCHEDULED EUTH
10405	375.	380.	385.	413.	432.	SCHEDULED EUTH
10406	384.	413.	437.	468.	500.	SCHEDULED EUTH
10411	365.	383.	401.	424.	450.	SCHEDULED EUTH
10414	347.	364.	394.	415.	448.	SCHEDULED EUTH
10419	397.	402.	415.	439.	468.	SCHEDULED EUTH
10422	364.	380.	397.	409.	438.	SCHEDULED EUTH
10431	356.	368.	372.	388.	411.	SCHEDULED EUTH
10432	414.	421.	431.	451.	476.	SCHEDULED EUTH
10438	381.	404.	416.	435.	454.	SCHEDULED EUTH
10440	348.	351.	367.	387.	406.	SCHEDULED EUTH
10443	375.	382.	404.	422.	447.	SCHEDULED EUTH
10455	354.	331.	339.	361.	376.	SCHEDULED EUTH
10460	375.	386.	398.	413.	454.	SCHEDULED EUTH
10461	386.	397.	413.	431.	462.	SCHEDULED EUTH
MEAN	371.	382.	397.	417.	443.	
S.D.	17.8	22.6	23.4	25.0	27.6	
N	20	20	20	20	20	

TABLE 122 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 500 PPM

WEEK	0	1	2	3	4	5
ANIMAL						
10369	348.	358.	376.	391.	417.	SCHEDULED EUTH
10370	408.	406.	416.	426.	458.	SCHEDULED EUTH
10377	362.	369.	385.	405.	428.	SCHEDULED EUTH
10380	363.	369.	392.	412.	439.	SCHEDULED EUTH
10381	382.	383.	399.	408.	438.	SCHEDULED EUTH
10382	371.	387.	403.	415.	442.	SCHEDULED EUTH
10385	353.	348.	370.	386.	407.	SCHEDULED EUTH
10391	384.	396.	419.	448.	470.	SCHEDULED EUTH
10392	345.	351.	367.	384.	409.	SCHEDULED EUTH
10396	360.	358.	380.	402.	439.	SCHEDULED EUTH
10400	347.	348.	365.	384.	414.	SCHEDULED EUTH
10407	360.	374.	399.	426.	455.	SCHEDULED EUTH
10410	367.	360.	376.	388.	422.	SCHEDULED EUTH
10421	391.	397.	412.	441.	465.	SCHEDULED EUTH
10423	378.	389.	413.	437.	464.	SCHEDULED EUTH
10429	380.	388.	402.	431.	444.	SCHEDULED EUTH
10437	394.	408.	414.	422.	455.	SCHEDULED EUTH
10445	355.	364.	375.	379.	416.	SCHEDULED EUTH
10453	373.	375.	379.	389.	418.	SCHEDULED EUTH
10454	396.	404.	424.	449.	470.	SCHEDULED EUTH
MEAN	371.	377.	393.	411.	439.	
S.D.	17.9	19.7	19.1	23.0	21.2	
N	20	20	20	20	20	

TABLE 122 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALE GROUP: 1000 PPM

WEEK	0	1	2	3	4	5
ANIMAL						
10373	380.	387.	386.	395.	407.	SCHEDULED EUTH
10374	364.	360.	380.	402.	426.	SCHEDULED EUTH
10376	403.	406.	423.	452.	474.	SCHEDULED EUTH
10397	372.	396.	406.	427.	448.	SCHEDULED EUTH
10398	364.	362.	377.	396.	421.	SCHEDULED EUTH
10403	361.	368.	388.	411.	433.	SCHEDULED EUTH
10409	345.	341.	353.	363.	386.	SCHEDULED EUTH
10412	373.	378.	387.	417.	446.	SCHEDULED EUTH
10416	351.	350.	367.	385.	409.	SCHEDULED EUTH
10418	365.	380.	397.	424.	449.	SCHEDULED EUTH
10420	386.	385.	399.	410.	424.	SCHEDULED EUTH
10428	399.	396.	410.	426.	449.	SCHEDULED EUTH
10430	362.	367.	399.	432.	454.	SCHEDULED EUTH
10434	386.	386.	401.	412.	446.	SCHEDULED EUTH
10444	377.	380.	369.	384.	418.	SCHEDULED EUTH
10447	382.	386.	410.	424.	444.	SCHEDULED EUTH
10448	354.	342.	354.	378.	410.	SCHEDULED EUTH
10449	366.	370.	388.	422.	452.	SCHEDULED EUTH
10452	371.	376.	391.	401.	436.	SCHEDULED EUTH
10459	370.	364.	373.	398.	418.	SCHEDULED EUTH
MEAN	372.	374.	388.	408.	433.	
S.D.	14.9	17.6	18.7	21.2	21.0	
N	20	20	20	20	20	

TABLE 123 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL					
10367	14.	19.	27.	23.	SCHEDULED EUTH
10368	27.	22.	19.	27.	SCHEDULED EUTH
10375	16.	17.	42.	11.	SCHEDULED EUTH
10384	16.	9.	26.	10.	SCHEDULED EUTH
10386	7.	27.	4.	9.	SCHEDULED EUTH
10387	25.	29.	22.	10.	SCHEDULED EUTH
10390	11.	22.	12.	23.	SCHEDULED EUTH
10394	20.	24.	20.	28.	SCHEDULED EUTH
10395	23.	21.	29.	20.	SCHEDULED EUTH
10399	11.	12.	26.	29.	SCHEDULED EUTH
10402	17.	19.	22.	39.	SCHEDULED EUTH
10415	10.	17.	17.	39.	SCHEDULED EUTH
10417	14.	14.	26.	33.	SCHEDULED EUTH
10425	12.	27.	11.	22.	SCHEDULED EUTH
10427	14.	12.	27.	32.	SCHEDULED EUTH
10435	-3.	10.	18.	26.	SCHEDULED EUTH
10439	25.	23.	27.	20.	SCHEDULED EUTH
10442	26.	17.	5.	37.	SCHEDULED EUTH
10451	19.	33.	10.	33.	SCHEDULED EUTH
10458	16.	16.	20.	16.	SCHEDULED EUTH
MEAN	16.	20.	21.	24.	
S.D.	7.3	6.5	9.1	9.7	
N	20	20	20	20	

TABLE 123 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL					
10372	8.	14.	18.	29.	SCHEDULED EUTH
10378	8.	25.	10.	17.	SCHEDULED EUTH
10379	-9.	24.	17.	35.	SCHEDULED EUTH
10383	32.	6.	28.	20.	SCHEDULED EUTH
10389	18.	14.	17.	23.	SCHEDULED EUTH
10404	15.	17.	23.	24.	SCHEDULED EUTH
10405	5.	5.	28.	19.	SCHEDULED EUTH
10406	29.	24.	31.	32.	SCHEDULED EUTH
10411	18.	18.	23.	26.	SCHEDULED EUTH
10414	17.	30.	21.	33.	SCHEDULED EUTH
10419	5.	13.	24.	29.	SCHEDULED EUTH
10422	16.	17.	12.	29.	SCHEDULED EUTH
10431	12.	4.	16.	23.	SCHEDULED EUTH
10432	7.	10.	20.	25.	SCHEDULED EUTH
10438	23.	12.	19.	19.	SCHEDULED EUTH
10440	3.	16.	20.	19.	SCHEDULED EUTH
10443	7.	22.	18.	25.	SCHEDULED EUTH
10455	-23.	8.	22.	15.	SCHEDULED EUTH
10460	11.	12.	15.	41.	SCHEDULED EUTH
10461	11.	16.	18.	31.	SCHEDULED EUTH
MEAN	11.	15.	20.	26.	
S.D.	12.2	7.1	5.3	6.7	
N	20	20	20	20	

TABLE 123 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL					
10369	10.	18.	15.	26.	SCHEDULED EUTH
10370	-2.	10.	10.	32.	SCHEDULED EUTH
10377	7.	16.	20.	23.	SCHEDULED EUTH
10380	6.	23.	20.	27.	SCHEDULED EUTH
10381	1.	16.	9.	30.	SCHEDULED EUTH
10382	16.	16.	12.	27.	SCHEDULED EUTH
10385	-5.	22.	16.	21.	SCHEDULED EUTH
10391	12.	23.	29.	22.	SCHEDULED EUTH
10392	6.	16.	17.	25.	SCHEDULED EUTH
10396	-2.	22.	22.	37.	SCHEDULED EUTH
10400	1.	17.	19.	30.	SCHEDULED EUTH
10407	14.	25.	27.	29.	SCHEDULED EUTH
10410	-7.	16.	12.	34.	SCHEDULED EUTH
10421	6.	15.	29.	24.	SCHEDULED EUTH
10423	11.	24.	24.	27.	SCHEDULED EUTH
10429	8.	14.	29.	13.	SCHEDULED EUTH
10437	14.	6.	8.	33.	SCHEDULED EUTH
10445	9.	11.	4.	37.	SCHEDULED EUTH
10453	2.	4.	10.	29.	SCHEDULED EUTH
10454	8.	20.	25.	21.	SCHEDULED EUTH
MEAN	6.	17.	18.	27.	
S.D.	6.5	5.8	7.8	5.9	
N	20	20	20	20	

TABLE 123 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
ANIMAL					
10373	7.	-1.	9.	12.	SCHEDULED EUTH
10374	-4.	20.	22.	24.	SCHEDULED EUTH
10376	3.	17.	29.	22.	SCHEDULED EUTH
10397	24.	10.	21.	21.	SCHEDULED EUTH
10398	-2.	15.	19.	25.	SCHEDULED EUTH
10403	7.	20.	23.	22.	SCHEDULED EUTH
10409	-4.	12.	10.	23.	SCHEDULED EUTH
10412	5.	9.	30.	29.	SCHEDULED EUTH
10416	-1.	17.	18.	24.	SCHEDULED EUTH
10418	15.	17.	27.	25.	SCHEDULED EUTH
10420	-1.	14.	11.	14.	SCHEDULED EUTH
10428	-3.	14.	16.	23.	SCHEDULED EUTH
10430	5.	32.	33.	22.	SCHEDULED EUTH
10434	0.	15.	11.	34.	SCHEDULED EUTH
10444	3.	-11.	15.	34.	SCHEDULED EUTH
10447	4.	24.	14.	20.	SCHEDULED EUTH
10448	-12.	12.	24.	32.	SCHEDULED EUTH
10449	4.	18.	34.	30.	SCHEDULED EUTH
10452	5.	15.	10.	35.	SCHEDULED EUTH
10459	-6.	9.	25.	20.	SCHEDULED EUTH
MEAN	2.	14.	20.	25.	
S.D.	7.7	8.8	8.0	6.2	
N	20	20	20	20	

TABLE 123A (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 0 PPM

WEEK 0 TO 4		
ANIMAL		
10367	83.	SCHEDULED EUTH
10368	95.	SCHEDULED EUTH
10375	86.	SCHEDULED EUTH
10384	61.	SCHEDULED EUTH
10386	47.	SCHEDULED EUTH
10387	86.	SCHEDULED EUTH
10390	68.	SCHEDULED EUTH
10394	92.	SCHEDULED EUTH
10395	93.	SCHEDULED EUTH
10399	78.	SCHEDULED EUTH
10402	97.	SCHEDULED EUTH
10415	83.	SCHEDULED EUTH
10417	87.	SCHEDULED EUTH
10425	72.	SCHEDULED EUTH
10427	85.	SCHEDULED EUTH
10435	51.	SCHEDULED EUTH
10439	95.	SCHEDULED EUTH
10442	85.	SCHEDULED EUTH
10451	95.	SCHEDULED EUTH
10458	68.	SCHEDULED EUTH
MEAN	80.	
S.D.	14.7	
N	20	

TABLE 123A (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

MALE GROUP: 100 PPM

WEEK 0 TO 4		
ANIMAL		
10372	69.	SCHEDULED EUTH
10378	60.	SCHEDULED EUTH
10379	67.	SCHEDULED EUTH
10383	86.	SCHEDULED EUTH
10389	72.	SCHEDULED EUTH
10404	79.	SCHEDULED EUTH
10405	57.	SCHEDULED EUTH
10406	116.	SCHEDULED EUTH
10411	85.	SCHEDULED EUTH
10414	101.	SCHEDULED EUTH
10419	71.	SCHEDULED EUTH
10422	74.	SCHEDULED EUTH
10431	55.	SCHEDULED EUTH
10432	62.	SCHEDULED EUTH
10438	73.	SCHEDULED EUTH
10440	58.	SCHEDULED EUTH
10443	72.	SCHEDULED EUTH
10455	22.	SCHEDULED EUTH
10460	79.	SCHEDULED EUTH
10461	76.	SCHEDULED EUTH
MEAN	72.	
S.D.	18.8	
N	20	

MALE GROUP: 500 PPM

WEEK 0 TO 4

ANIMAL		
10369	69.	SCHEDULED EUTH
10370	50.	SCHEDULED EUTH
10377	66.	SCHEDULED EUTH
10380	76.	SCHEDULED EUTH
10381	56.	SCHEDULED EUTH
10382	71.	SCHEDULED EUTH
10385	54.	SCHEDULED EUTH
10391	86.	SCHEDULED EUTH
10392	64.	SCHEDULED EUTH
10396	79.	SCHEDULED EUTH
10400	67.	SCHEDULED EUTH
10407	95.	SCHEDULED EUTH
10410	55.	SCHEDULED EUTH
10421	74.	SCHEDULED EUTH
10423	86.	SCHEDULED EUTH
10429	64.	SCHEDULED EUTH
10437	61.	SCHEDULED EUTH
10445	61.	SCHEDULED EUTH
10453	45.	SCHEDULED EUTH
10454	74.	SCHEDULED EUTH
MEAN	68.	
S.D.	12.9	
N	20	

MALE GROUP: 1000 PPM

WEEK 0 TO 4

ANIMAL		
10373	27.	SCHEDULED EUTH
10374	62.	SCHEDULED EUTH
10376	71.	SCHEDULED EUTH
10397	76.	SCHEDULED EUTH
10398	57.	SCHEDULED EUTH
10403	72.	SCHEDULED EUTH
10409	41.	SCHEDULED EUTH
10412	73.	SCHEDULED EUTH
10416	58.	SCHEDULED EUTH
10418	84.	SCHEDULED EUTH
10420	38.	SCHEDULED EUTH
10428	50.	SCHEDULED EUTH
10430	92.	SCHEDULED EUTH
10434	60.	SCHEDULED EUTH
10444	41.	SCHEDULED EUTH
10447	62.	SCHEDULED EUTH
10448	56.	SCHEDULED EUTH
10449	86.	SCHEDULED EUTH
10452	65.	SCHEDULED EUTH
10459	48.	SCHEDULED EUTH
MEAN	61.	
S.D.	17.1	
N	20	

TABLE 124 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10367	24.	23.	SCHEDULED EUTH
10368	24.	25.	SCHEDULED EUTH
10375	25.	26.	SCHEDULED EUTH
10384	28.	26.	SCHEDULED EUTH
10386	24.	24.	SCHEDULED EUTH
10387	29.	27.	SCHEDULED EUTH
10390	28.	25.	SCHEDULED EUTH
10394	26.	24.	SCHEDULED EUTH
10395	25.	26.	SCHEDULED EUTH
10399	25.	23.	SCHEDULED EUTH
10402	31.	42.	SCHEDULED EUTH
10415	28.	25.	SCHEDULED EUTH
10417	23.	23.	SCHEDULED EUTH
10425	26.	27.	SCHEDULED EUTH
10427	26.	25.	SCHEDULED EUTH
10435	23.	21.	SCHEDULED EUTH
10439	24.	25.	SCHEDULED EUTH
10442	27.	25.	SCHEDULED EUTH
10451	26.	27.	SCHEDULED EUTH
10458	25.	27.	SCHEDULED EUTH
MEAN	26.	26.	
S.D.	2.1	4.1	
N	20	20	

TABLE 124 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10372	23.	22.	SCHEDULED EUTH
10378	24.	25.	SCHEDULED EUTH
10379	21.	21.	SCHEDULED EUTH
10383	27.	26.	SCHEDULED EUTH
10389	26.	24.	SCHEDULED EUTH
10404	26.	22.	SCHEDULED EUTH
10405	24.	23.	SCHEDULED EUTH
10406	28.	26.	SCHEDULED EUTH
10411	25.	23.	SCHEDULED EUTH
10414	27.	26.	SCHEDULED EUTH
10419	24.	24.	SCHEDULED EUTH
10422	25.	24.	SCHEDULED EUTH
10431	22.	20.	SCHEDULED EUTH
10432	27.	28.	SCHEDULED EUTH
10438	27.	26.	SCHEDULED EUTH
10440	24.	22.	SCHEDULED EUTH
10443	25.	25.	SCHEDULED EUTH
10455	19.	19.	SCHEDULED EUTH
10460	28.	24.	SCHEDULED EUTH
10461	24.	23.	SCHEDULED EUTH
MEAN	25.	24.	
S.D.	2.4	2.3	
N	20	20	

TABLE 124 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

MALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10369	22.	23.	SCHEDULED EUTH
10370	24.	24.	SCHEDULED EUTH
10377	24.	23.	SCHEDULED EUTH
10380	24.	25.	SCHEDULED EUTH
10381	27.	23.	SCHEDULED EUTH
10382	26.	24.	SCHEDULED EUTH
10385	20.	21.	SCHEDULED EUTH
10391	26.	26.	SCHEDULED EUTH
10392	22.	23.	SCHEDULED EUTH
10396	20.	22.	SCHEDULED EUTH
10400	21.	23.	SCHEDULED EUTH
10407	21.	23.	SCHEDULED EUTH
10410	22.	23.	SCHEDULED EUTH
10421	25.	26.	SCHEDULED EUTH
10423	23.	25.	SCHEDULED EUTH
10429	24.	24.	SCHEDULED EUTH
10437	26.	25.	SCHEDULED EUTH
10445	24.	22.	SCHEDULED EUTH
10453	23.	21.	SCHEDULED EUTH
10454	24.	24.	SCHEDULED EUTH
MEAN	23.	24.	
S.D.	2.0	1.4	
N	20	20	

MALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10373	24.	22.	SCHEDULED EUTH
10374	22.	23.	SCHEDULED EUTH
10376	25.	25.	SCHEDULED EUTH
10397	25.	26.	SCHEDULED EUTH
10398	20.	21.	SCHEDULED EUTH
10403	23.	25.	SCHEDULED EUTH
10409	20.	21.	SCHEDULED EUTH
10412	20.	23.	SCHEDULED EUTH
10416	22.	23.	SCHEDULED EUTH
10418	24.	23.	SCHEDULED EUTH
10420	22.	24.	SCHEDULED EUTH
10428	23.	26.	SCHEDULED EUTH
10430	23.	27.	SCHEDULED EUTH
10434	23.	23.	SCHEDULED EUTH
10444	22.	21.	SCHEDULED EUTH
10447	25.	26.	SCHEDULED EUTH
10448	19.	23.	SCHEDULED EUTH
10449	20.	24.	SCHEDULED EUTH
10452	24.	24.	SCHEDULED EUTH
10459	22.	20.	SCHEDULED EUTH
MEAN	22.	24.	
S.D.	1.8	1.9	
N	20	20	

TABLE 125 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

MALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10367	66.	61.	SCHEDULED EUTH
10368	66.	65.	SCHEDULED EUTH
10375	67.	66.	SCHEDULED EUTH
10384	71.	64.	SCHEDULED EUTH
10386	64.	61.	SCHEDULED EUTH
10387	72.	63.	SCHEDULED EUTH
10390	73.	63.	SCHEDULED EUTH
10394	69.	60.	SCHEDULED EUTH
10395	61.	61.	SCHEDULED EUTH
10399	68.	61.	SCHEDULED EUTH
10402	84.	109.	SCHEDULED EUTH
10415	67.	58.	SCHEDULED EUTH
10417	59.	57.	SCHEDULED EUTH
10425	64.	63.	SCHEDULED EUTH
10427	75.	69.	SCHEDULED EUTH
10435	65.	59.	SCHEDULED EUTH
10439	63.	62.	SCHEDULED EUTH
10442	70.	62.	SCHEDULED EUTH
10451	71.	69.	SCHEDULED EUTH
10458	65.	67.	SCHEDULED EUTH
MEAN	68.	65.	
S.D.	5.5	10.9	
N	20	20	

TABLE 125 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

MALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10372	67.	62.	SCHEDULED EUTH
10378	65.	64.	SCHEDULED EUTH
10379	55.	54.	SCHEDULED EUTH
10383	69.	63.	SCHEDULED EUTH
10389	68.	60.	SCHEDULED EUTH
10404	70.	57.	SCHEDULED EUTH
10405	63.	60.	SCHEDULED EUTH
10406	70.	61.	SCHEDULED EUTH
10411	67.	59.	SCHEDULED EUTH
10414	76.	69.	SCHEDULED EUTH
10419	60.	59.	SCHEDULED EUTH
10422	67.	62.	SCHEDULED EUTH
10431	61.	54.	SCHEDULED EUTH
10432	65.	66.	SCHEDULED EUTH
10438	69.	63.	SCHEDULED EUTH
10440	69.	61.	SCHEDULED EUTH
10443	66.	64.	SCHEDULED EUTH
10455	55.	57.	SCHEDULED EUTH
10460	73.	61.	SCHEDULED EUTH
10461	61.	57.	SCHEDULED EUTH
MEAN	66.	61.	
S.D.	5.4	3.8	
N	20	20	

MALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10369	62.	63.	SCHEDULED EUTH
10370	59.	58.	SCHEDULED EUTH
10377	66.	61.	SCHEDULED EUTH
10380	66.	66.	SCHEDULED EUTH
10381	70.	59.	SCHEDULED EUTH
10382	69.	61.	SCHEDULED EUTH
10385	57.	58.	SCHEDULED EUTH
10391	67.	64.	SCHEDULED EUTH
10392	63.	64.	SCHEDULED EUTH
10396	56.	60.	SCHEDULED EUTH
10400	60.	64.	SCHEDULED EUTH
10407	57.	59.	SCHEDULED EUTH
10410	60.	63.	SCHEDULED EUTH
10421	63.	64.	SCHEDULED EUTH
10423	60.	62.	SCHEDULED EUTH
10429	63.	61.	SCHEDULED EUTH
10437	65.	61.	SCHEDULED EUTH
10445	67.	59.	SCHEDULED EUTH
10453	61.	56.	SCHEDULED EUTH
10454	60.	58.	SCHEDULED EUTH
MEAN	63.	61.	
S.D.	4.1	2.7	
N	20	20	

MALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10373	63.	57.	SCHEDULED EUTH
10374	61.	62.	SCHEDULED EUTH
10376	62.	60.	SCHEDULED EUTH
10397	65.	65.	SCHEDULED EUTH
10398	55.	57.	SCHEDULED EUTH
10403	63.	66.	SCHEDULED EUTH
10409	58.	61.	SCHEDULED EUTH
10412	53.	60.	SCHEDULED EUTH
10416	63.	64.	SCHEDULED EUTH
10418	64.	59.	SCHEDULED EUTH
10420	57.	61.	SCHEDULED EUTH
10428	58.	65.	SCHEDULED EUTH
10430	63.	70.	SCHEDULED EUTH
10434	60.	58.	SCHEDULED EUTH
10444	58.	56.	SCHEDULED EUTH
10447	65.	65.	SCHEDULED EUTH
10448	55.	66.	SCHEDULED EUTH
10449	54.	63.	SCHEDULED EUTH
10452	64.	63.	SCHEDULED EUTH
10459	60.	54.	SCHEDULED EUTH
MEAN	60.	62.	
S.D.	3.8	4.0	
N	20	20	

TABLE 126 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

MALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10367	8.3	11.8	SCHEDULED EUTH
10368	16.1	12.6	SCHEDULED EUTH
10375	9.1	9.3	SCHEDULED EUTH
10384	8.2	4.9	SCHEDULED EUTH
10386	4.2	16.1	SCHEDULED EUTH
10387	12.3	15.3	SCHEDULED EUTH
10390	5.6	12.6	SCHEDULED EUTH
10394	11.0	14.3	SCHEDULED EUTH
10395	13.1	11.5	SCHEDULED EUTH
10399	6.3	7.5	SCHEDULED EUTH
10402	7.8	6.5	SCHEDULED EUTH
10415	5.1	9.7	SCHEDULED EUTH
10417	8.7	8.7	SCHEDULED EUTH
10425	6.6	14.3	SCHEDULED EUTH
10427	7.7	6.9	SCHEDULED EUTH
10435	-1.9	6.8	SCHEDULED EUTH
10439	14.9	13.1	SCHEDULED EUTH
10442	13.8	9.7	SCHEDULED EUTH
10451	10.4	17.5	SCHEDULED EUTH
10458	9.1	8.5	SCHEDULED EUTH
MEAN	8.8	10.9	
S.D.	4.15	3.56	
N	20	20	

TABLE 126 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

MALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10372	5.0	9.1	SCHEDULED EUTH
10378	4.8	14.3	SCHEDULED EUTH
10379	-6.1	16.3	SCHEDULED EUTH
10383	16.9	3.3	SCHEDULED EUTH
10389	9.9	8.3	SCHEDULED EUTH
10404	8.2	11.0	SCHEDULED EUTH
10405	3.0	3.1	SCHEDULED EUTH
10406	14.8	13.2	SCHEDULED EUTH
10411	10.3	11.2	SCHEDULED EUTH
10414	9.0	16.5	SCHEDULED EUTH
10419	3.0	7.7	SCHEDULED EUTH
10422	9.1	10.1	SCHEDULED EUTH
10431	7.8	2.9	SCHEDULED EUTH
10432	3.7	5.1	SCHEDULED EUTH
10438	12.2	6.6	SCHEDULED EUTH
10440	1.8	10.4	SCHEDULED EUTH
10443	4.0	12.6	SCHEDULED EUTH
10455	-17.3	6.0	SCHEDULED EUTH
10460	5.6	7.1	SCHEDULED EUTH
10461	6.5	9.9	SCHEDULED EUTH
MEAN	5.6	9.2	
S.D.	7.36	4.11	
N	20	20	

TABLE 126 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

MALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10369	6.5	11.2	SCHEDULED EUTH
10370	-1.2	6.0	SCHEDULED EUTH
10377	4.2	9.9	SCHEDULED EUTH
10380	3.6	13.1	SCHEDULED EUTH
10381	0.5	9.9	SCHEDULED EUTH
10382	8.8	9.5	SCHEDULED EUTH
10385	-3.6	15.0	SCHEDULED EUTH
10391	6.6	12.6	SCHEDULED EUTH
10392	3.9	9.9	SCHEDULED EUTH
10396	-1.4	14.3	SCHEDULED EUTH
10400	0.7	10.6	SCHEDULED EUTH
10407	9.5	15.5	SCHEDULED EUTH
10410	-4.5	9.9	SCHEDULED EUTH
10421	3.4	8.2	SCHEDULED EUTH
10423	6.8	13.7	SCHEDULED EUTH
10429	4.8	8.3	SCHEDULED EUTH
10437	7.7	3.4	SCHEDULED EUTH
10445	5.4	7.1	SCHEDULED EUTH
10453	1.2	2.7	SCHEDULED EUTH
10454	4.8	11.9	SCHEDULED EUTH
MEAN	3.4	10.1	
S.D.	3.98	3.53	
N	20	20	

TABLE 126 (F0 MALES)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

MALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	
ANIMAL			
10373	4.2	-0.6	SCHEDULED EUTH
10374	-2.6	12.4	SCHEDULED EUTH
10376	1.7	9.7	SCHEDULED EUTH
10397	13.7	5.5	SCHEDULED EUTH
10398	-1.4	10.2	SCHEDULED EUTH
10403	4.3	11.4	SCHEDULED EUTH
10409	-2.9	8.2	SCHEDULED EUTH
10412	3.6	5.6	SCHEDULED EUTH
10416	-0.6	10.6	SCHEDULED EUTH
10418	8.9	10.6	SCHEDULED EUTH
10420	-0.6	8.3	SCHEDULED EUTH
10428	-1.9	7.7	SCHEDULED EUTH
10430	3.1	16.9	SCHEDULED EUTH
10434	0.0	9.3	SCHEDULED EUTH
10444	1.9	-7.5	SCHEDULED EUTH
10447	2.3	13.2	SCHEDULED EUTH
10448	-9.0	7.5	SCHEDULED EUTH
10449	2.9	10.7	SCHEDULED EUTH
10452	3.0	8.9	SCHEDULED EUTH
10459	-3.9	6.4	SCHEDULED EUTH
MEAN	1.3	8.3	
S.D.	4.79	5.11	
N	20	20	

TABLE 127 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 0 PPM

WEEK	0	1	2	3	4	5	6	7
ANIMAL								
10463	246.	263.	276.	NA	NA	NA	NA	NA
10464	245.	254.	263.	NA	NA	NA	NA	NA
10485	220.	228.	238.	NA	NA	NA	NA	NA
10491	262.	266.	283.	NA	NA	NA	NA	NA
10494	267.	287.	290.	303.	319.	NA	NA	NA
10496	259.	278.	294.	299.	NA	NA	NA	NA
10498	258.	259.	265.	NA	NA	NA	NA	NA
10500	236.	256.	251.	NA	NA	NA	NA	
10503	234.	247.	258.	NA	NA	NA	NA	
10506	232.	250.	263.	NA	NA	NA	NA	NA
10512	237.	247.	250.	NA	NA	NA	NA	NA
10513	247.	253.	275.	NA	NA	NA	NA	
10514	236.	252.	260.	NA	NA	NA	NA	NA
10521	244.	256.	264.	285.	319.	355.	NA	NA
10524	252.	254.	255.	NA	NA	NA	NA	NA
10536	233.	232.	233.	NA	NA	NA	NA	
10537	259.	274.	277.	NA	NA	NA	NA	NA
10540	227.	234.	255.	NA	NA	NA	NA	NA
10554	251.	258.	280.	NA	NA	NA	NA	NA
10555	231.	243.	238.	NA	NA	NA	NA	NA
MEAN	244.	255.	263.	296.	319.	355.		
S.D.	13.0	14.7	17.0	9.5	0.0	0.0		
N	20	20	20	3	2	1		

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 100 PPM

WEEK	0	1	2	3	4	5	6	7
ANIMAL								
10470	216.	235.	237.	NA	NA	NA	NA	
10472	219.	246.	253.	NA	NA	NA	NA	
10487	240.	251.	252.	NA	NA	NA	NA	NA
10488	246.	247.	255.	NA	NA	NA	NA	NA
10492	275.	282.	284.	NA	NA	NA	NA	NA
10493	231.	242.	248.	256.	288.	303.	352.	NA
10495	253.	260.	279.	NA	NA	NA	NA	NA
10499	260.	269.	291.	NA	NA	NA	NA	NA
10504	238.	247.	248.	NA	NA	NA	NA	NA
10510	238.	238.	253.	NA	NA	NA	NA	NA
10515	255.	265.	269.	NA	NA	NA	NA	NA
10516	234.	248.	254.	NA	NA	NA	NA	NA
10519	242.	256.	268.	NA	NA	NA	NA	NA
10522	222.	229.	231.	NA	NA	NA	NA	NA
10525	222.	233.	239.	NA	NA	NA	NA	NA
10528	223.	247.	264.	NA	NA	NA	NA	NA
10543	242.	241.	238.	NA	NA	NA	NA	NA
10552	255.	255.	274.	NA	NA	NA	NA	NA
10553	256.	279.	301.	NA	NA	NA	NA	
10556	236.	246.	252.	NA	NA	NA	NA	NA
MEAN	240.	251.	260.	256.	288.	303.	352.	
S.D.	15.6	14.3	18.9	0.0	0.0	0.0	0.0	
N	20	20	20	1	1	1	1	

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 500 PPM

WEEK	0	1	2	3	4	5	6	7
ANIMAL								
10468	242.	247.	258.	NA	NA	NA	NA	NA
10475	215.	233.	245.	NA	NA	NA	NA	NA
10478	231.	230.	246.	NA	NA	NA	NA	NA
10483	247.	261.	266.	NA	NA	NA	NA	NA
10484	218.	229.	235.	NA	NA	NA	NA	NA
10489	232.	232.	242.	256.	273.	NA	NA	NA
10490	265.	269.	284.	NA	NA	NA	NA	NA
10497	242.	251.	263.	285.	316.	369.	NA	NA
10501	243.	256.	266.	NA	NA	NA	NA	NA
10505	257.	258.	264.	NA	NA	NA	NA	NA
10517	257.	260.	265.	NA	NA	NA	NA	NA
10520	260.	259.	279.	NA	NA	NA	NA	NA
10530	224.	228.	227.	NA	NA	NA	NA	NA
10531	236.	243.	244.	NA	NA	NA	NA	NA
10533	276.	272.	296.	NA	NA	NA	NA	NA
10534	225.	222.	222.	NA	NA	NA	NA	NA
10538	236.	243.	248.	NA	NA	NA	NA	NA
10546	244.	250.	260.	NA	NA	NA	NA	NA
10548	253.	261.	265.	NA	NA	NA	NA	NA
10550	268.	271.	278.	NA	NA	NA	NA	NA
MEAN	244.	249.	258.	271.	295.	369.		
S.D.	16.9	15.6	19.1	20.5	30.4	0.0		
N	20	20	20	2	2	1		

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 1000 PPM

WEEK	0	1	2	3	4	5	6	7
ANIMAL								
10465	243.	251.	264.	NA	NA	NA	NA	NA
10466	261.	262.	276.	NA	NA	NA	NA	NA
10469	227.	232.	245.	NA	NA	NA	NA	NA
10473	260.	270.	277.	298.	NA	NA	NA	NA
10477	246.	256.	255.	NA	NA	NA	NA	NA
10480	234.	238.	240.	NA	NA	NA	NA	NA
10481	239.	245.	246.	NA	NA	NA	NA	NA
10486	254.	252.	264.	NA	NA	NA	NA	NA
10502	245.	250.	253.	NA	NA	NA	NA	NA
10507	223.	235.	240.	NA	NA	NA	NA	NA
10511	251.	254.	271.	276.	277.	292.	297.	313.
10526	243.	258.	284.	NA	NA	NA	NA	NA
10527	228.	234.	247.	NA	NA	NA	NA	NA
10529	221.	240.	251.	NA	NA	NA	NA	NA
10532	231.	229.	243.	NA	NA	NA	NA	NA
10541	247.	247.	246.	NA	NA	NA	NA	NA
10542	252.	257.	263.	NA	NA	NA	NA	NA
10544	244.	229.	243.	NA	NA	NA	NA	NA
10545	263.	260.	269.	NA	NA	NA	NA	NA
10547	243.	257.	282.	NA	NA	NA	NA	NA
MEAN	243.	248.	258.	287.	277.	292.	297.	313.
S.D.	12.4	12.0	14.7	15.6	0.0	0.0	0.0	0.0
N	20	20	20	2	1	1	1	1

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 0 PPM

WEEK	8
ANIMAL	
10463	NA
10464	NA
10485	NA
10491	NA
10494	
10496	NA
10498	NA
10506	NA
10512	NA
10514	NA
10521	NA
10524	NA
10537	NA
10540	NA
10554	NA
10555	NA

NO ANIMALS WITH WEIGHTS FOR THESE INTERVALS

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 100 PPM

WEEK	8
ANIMAL	
10487	NA
10488	NA
10492	NA
10493	NA
10495	NA
10499	NA
10504	NA
10510	NA
10515	NA
10516	NA
10519	NA
10522	NA
10525	NA
10528	NA
10543	
10552	NA
10556	NA

NO ANIMALS WITH WEIGHTS FOR THESE INTERVALS

NA = NOT APPLICABLE

TABLE 127 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 500 PPM

WEEK	8
ANIMAL	
10468	NA
10475	NA
10478	NA
10483	NA
10484	NA
10489	NA
10490	NA
10497	NA
10501	NA
10505	NA
10517	NA
10520	NA
10530	NA
10531	NA
10533	NA
10534	NA
10538	NA
10546	NA
10548	NA
10550	NA

NO ANIMALS WITH WEIGHTS FOR THESE INTERVALS

NA = NOT APPLICABLE

FEMALE GROUP: 1000 PPM

WEEK	8
ANIMAL	
10465	NA
10466	NA
10469	NA
10473	NA
10477	NA
10480	NA
10481	NA
10486	NA
10502	NA
10507	NA
10511	307.
10526	NA
10527	NA
10529	NA
10532	NA
10541	NA
10542	NA
10544	NA
10545	NA
10547	NA
MEAN	307.
S.D.	0.0
N	1

NA = NOT APPLICABLE

TABLE 128 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL								
10463	17.	13.	NA	NA	NA	NA	NA	NA
10464	9.	9.	NA	NA	NA	NA	NA	NA
10485	8.	10.	NA	NA	NA	NA	NA	NA
10491	4.	17.	NA	NA	NA	NA	NA	NA
10494	20.	3.	13.	16.	NA	NA	NA	
10496	19.	16.	5.	NA	NA	NA	NA	NA
10498	1.	6.	NA	NA	NA	NA	NA	NA
10500	20.	-5.	NA	NA	NA	NA		
10503	13.	11.	NA	NA	NA	NA		
10506	18.	13.	NA	NA	NA	NA	NA	NA
10512	10.	3.	NA	NA	NA	NA	NA	NA
10513	6.	22.	NA	NA	NA	NA		
10514	16.	8.	NA	NA	NA	NA	NA	NA
10521	12.	8.	21.	34.	36.	NA	NA	NA
10524	2.	1.	NA	NA	NA	NA	NA	NA
10536	-1.	1.	NA	NA	NA	NA		
10537	15.	3.	NA	NA	NA	NA	NA	NA
10540	7.	21.	NA	NA	NA	NA	NA	NA
10554	7.	22.	NA	NA	NA	NA	NA	NA
10555	12.	-5.	NA	NA	NA	NA	NA	NA
MEAN	11.	9.	13.	25.	36.			
S.D.	6.5	8.2	8.0	12.7	0.0			
N	20	20	3	2	1			

NA = NOT APPLICABLE

TABLE 128 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL								
10470	19.	2.	NA	NA	NA	NA		
10472	27.	7.	NA	NA	NA	NA		
10487	11.	1.	NA	NA	NA	NA	NA	NA
10488	1.	8.	NA	NA	NA	NA	NA	NA
10492	7.	2.	NA	NA	NA	NA	NA	NA
10493	11.	6.	8.	32.	15.	49.	NA	NA
10495	7.	19.	NA	NA	NA	NA	NA	NA
10499	9.	22.	NA	NA	NA	NA	NA	NA
10504	9.	1.	NA	NA	NA	NA	NA	NA
10510	0.	15.	NA	NA	NA	NA	NA	NA
10515	10.	4.	NA	NA	NA	NA	NA	NA
10516	14.	6.	NA	NA	NA	NA	NA	NA
10519	14.	12.	NA	NA	NA	NA	NA	NA
10522	7.	2.	NA	NA	NA	NA	NA	NA
10525	11.	6.	NA	NA	NA	NA	NA	NA
10528	24.	17.	NA	NA	NA	NA	NA	NA
10543	-1.	-3.	NA	NA	NA	NA	NA	
10552	0.	19.	NA	NA	NA	NA	NA	NA
10553	23.	22.	NA	NA	NA	NA		
10556	10.	6.	NA	NA	NA	NA	NA	NA
MEAN	11.	9.	8.	32.	15.	49.		
S.D.	7.9	7.7	0.0	0.0	0.0	0.0		
N	20	20	1	1	1	1		

NA = NOT APPLICABLE

TABLE 128 (F0 FEMALES - PRE-MATING)
INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL								
10468	5.	11.	NA	NA	NA	NA	NA	NA
10475	18.	12.	NA	NA	NA	NA	NA	NA
10478	-1.	16.	NA	NA	NA	NA	NA	NA
10483	14.	5.	NA	NA	NA	NA	NA	NA
10484	11.	6.	NA	NA	NA	NA	NA	NA
10489	0.	10.	14.	17.	NA	NA	NA	NA
10490	4.	15.	NA	NA	NA	NA	NA	NA
10497	9.	12.	22.	31.	53.	NA	NA	NA
10501	13.	10.	NA	NA	NA	NA	NA	NA
10505	1.	6.	NA	NA	NA	NA	NA	NA
10517	3.	5.	NA	NA	NA	NA	NA	NA
10520	-1.	20.	NA	NA	NA	NA	NA	NA
10530	4.	-1.	NA	NA	NA	NA	NA	NA
10531	7.	1.	NA	NA	NA	NA	NA	NA
10533	-4.	24.	NA	NA	NA	NA	NA	NA
10534	-3.	0.	NA	NA	NA	NA	NA	NA
10538	7.	5.	NA	NA	NA	NA	NA	NA
10546	6.	10.	NA	NA	NA	NA	NA	NA
10548	8.	4.	NA	NA	NA	NA	NA	NA
10550	3.	7.	NA	NA	NA	NA	NA	NA
MEAN	5.	9.	18.	24.	53.			
S.D.	5.9	6.5	5.7	9.9	0.0			
N	20	20	2	2	1			

NA = NOT APPLICABLE

TABLE 128 (F0 FEMALES - PRE-MATING)
INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL								
10465	8.	13.	NA	NA	NA	NA	NA	NA
10466	1.	14.	NA	NA	NA	NA	NA	NA
10469	5.	13.	NA	NA	NA	NA	NA	NA
10473	10.	7.	21.	NA	NA	NA	NA	NA
10477	10.	-1.	NA	NA	NA	NA	NA	NA
10480	4.	2.	NA	NA	NA	NA	NA	NA
10481	6.	1.	NA	NA	NA	NA	NA	NA
10486	-2.	12.	NA	NA	NA	NA	NA	NA
10502	5.	3.	NA	NA	NA	NA	NA	NA
10507	12.	5.	NA	NA	NA	NA	NA	NA
10511	3.	17.	5.	1.	15.	5.	16.	-6.
10526	15.	26.	NA	NA	NA	NA	NA	NA
10527	6.	13.	NA	NA	NA	NA	NA	NA
10529	19.	11.	NA	NA	NA	NA	NA	NA
10532	-2.	14.	NA	NA	NA	NA	NA	NA
10541	0.	-1.	NA	NA	NA	NA	NA	NA
10542	5.	6.	NA	NA	NA	NA	NA	NA
10544	-15.	14.	NA	NA	NA	NA	NA	NA
10545	-3.	9.	NA	NA	NA	NA	NA	NA
10547	14.	25.	NA	NA	NA	NA	NA	NA
MEAN	5.	10.	13.	1.	15.	5.	16.	-6.
S.D.	7.6	7.6	11.3	0.0	0.0	0.0	0.0	0.0
N	20	20	2	1	1	1	1	1

NA = NOT APPLICABLE

TABLE 128A (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 PPM

WEEK 0 TO 2	
ANIMAL	
10463	30.
10464	18.
10485	18.
10491	21.
10494	23.
10496	35.
10498	7.
10500	15.
10503	24.
10506	31.
10512	13.
10513	28.
10514	24.
10521	20.
10524	3.
10536	0.
10537	18.
10540	28.
10554	29.
10555	7.
MEAN	20.
S.D.	9.8
N	20

TABLE 128A (F0 FEMALES - PRE-MATING)

SPONSOR:ACC INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 100 PPM

WEEK 0 TO 2	
ANIMAL	
10470	21.
10472	34.
10487	12.
10488	9.
10492	9.
10493	17.
10495	26.
10499	31.
10504	10.
10510	15.
10515	14.
10516	20.
10519	26.
10522	9.
10525	17.
10528	41.
10543	-4.
10552	19.
10553	45.
10556	16.
MEAN	19.
S.D.	11.8
N	20

TABLE 128A (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

FEMALE GROUP: 500 PPM

WEEK 0 TO 2	
ANIMAL	
10468	16.
10475	30.
10478	15.
10483	19.
10484	17.
10489	10.
10490	19.
10497	21.
10501	23.
10505	7.
10517	8.
10520	19.
10530	3.
10531	8.
10533	20.
10534	-3.
10538	12.
10546	16.
10548	12.
10550	10.
MEAN	14.
S.D.	7.6
N	20

FEMALE GROUP: 1000 PPM

WEEK 0 TO 2	
ANIMAL	
10465	21.
10466	15.
10469	18.
10473	17.
10477	9.
10480	6.
10481	7.
10486	10.
10502	8.
10507	17.
10511	20.
10526	41.
10527	19.
10529	30.
10532	12.
10541	-1.
10542	11.
10544	-1.
10545	6.
10547	39.
MEAN	15.
S.D.	11.3
N	20

TABLE 129 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10463	20.	18.	NA	NA	NA	NA
10464	18.	17.	NA	NA	NA	NA
10485	16.	17.	NA	NA	NA	NA
10491	20.	24.	NA	NA	NA	NA
10494	20.	19.	NA	NA	NA	
10496	22.	21.	NA	NA	NA	NA
10498	18.	19.	NA	NA	NA	NA
10500	18.	17.	NA	NA		
10503	19.	19.	NA	NA		
10506	17.	18.	NA	NA	NA	NA
10512	18.	18.	NA	NA	NA	NA
10513	18.	21.	NA	NA		
10514	18.	17.	NA	NA	NA	NA
10521	19.	20.	NA	NA	NA	NA
10524	15.	15.	NA	NA	NA	NA
10536	16.	16.	NA	NA		
10537	20.	21.	NA	NA	NA	NA
10540	15.	18.	NA	NA	NA	NA
10554	18.	20.	NA	NA	NA	NA
10555	17.	16.	NA	NA	NA	NA
MEAN	18.	19.				
S.D.	1.8	2.2				
N	20	20				

NA = NOT APPLICABLE

TABLE 129 (F0 FEMALES - PRE-MATING)

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10470	17.	17.	NA	NA		
10472	18.	18.	NA	NA		
10487	18.	19.	NA	NA	NA	NA
10488	16.	17.	NA	NA	NA	NA
10492	20.	21.	NA	NA	NA	NA
10493	17.	17.	NA	22.	NA	NA
10495	18.	19.	NA	NA	NA	NA
10499	19.	21.	NA	NA	NA	NA
10504	15.	16.	NA	NA	NA	NA
10510	18.	19.	NA	NA	NA	NA
10515	17.	18.	NA	NA	NA	NA
10516	17.	17.	NA	NA	NA	NA
10519	17.	18.	NA	NA	NA	NA
10522	15.	16.	NA	NA	NA	NA
10525	16.	16.	NA	NA	NA	NA
10528	19.	19.	NA	NA	NA	NA
10543	16.	17.	NA	NA	NA	
10552	20.	20.	NA	NA	NA	NA
10553	21.	22.	NA	NA		
10556	18.	18.	NA	NA	NA	NA
MEAN	18.	18.		22.		
S.D.	1.6	1.7		0.0		
N	20	20		1		

NA = NOT APPLICABLE

TABLE 129 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10468	17.	18.	NA	NA	NA	NA
10475	17.	18.	NA	NA	NA	NA
10478	15.	18.	NA	NA	NA	NA
10483	17.	19.	NA	NA	NA	NA
10484	14.	15.	NA	NA	NA	NA
10489	14.	16.	NA	NA	NA	NA
10490	15.	18.	NA	NA	NA	NA
10497	18.	20.	NA	NA	NA	NA
10501	17.	17.	NA	NA	NA	NA
10505	16.	18.	NA	NA	NA	NA
10517	19.	19.	NA	NA	NA	NA
10520	18.	21.	NA	NA	NA	NA
10530	14.	15.	NA	NA	NA	NA
10531	16.	17.	NA	NA	NA	NA
10533	19.	22.	NA	NA	NA	NA
10534	15.	15.	NA	NA	NA	NA
10538	16.	16.	NA	NA	NA	NA
10546	17.	19.	NA	NA	NA	NA
10548	18.	19.	NA	NA	NA	NA
10550	17.	19.	NA	NA	NA	NA
MEAN	16.	18.				
S.D.	1.6	1.9				
N	20	20				

NA = NOT APPLICABLE

INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

FEMALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10465	16.	21.	NA	NA	NA	NA
10466	16.	19.	NA	NA	NA	NA
10469	15.	16.	NA	NA	NA	NA
10473	15.	19.	NA	NA	NA	NA
10477	17.	19.	NA	NA	NA	NA
10480	15.	16.	NA	NA	NA	NA
10481	13.	15.	NA	NA	NA	NA
10486	16.	19.	NA	NA	NA	NA
10502	14.	17.	NA	NA	NA	NA
10507	16.	20.	NA	NA	NA	NA
10511	15.	19.	NA	22.	20.	21.
10526	16.	19.	NA	NA	NA	NA
10527	14.	19.	NA	NA	NA	NA
10529	14.	17.	NA	NA	NA	NA
10532	13.	17.	NA	NA	NA	NA
10541	15.	16.	NA	NA	NA	NA
10542	14.	17.	NA	NA	NA	NA
10544	13.	16.	NA	NA	NA	NA
10545	17.	17.	NA	NA	NA	NA
10547	16.	21.	NA	NA	NA	NA
MEAN	15.	18.		22.	20.	21.
S.D.	1.3	1.8		0.0	0.0	0.0
N	20	20		1	1	1

NA = NOT APPLICABLE

TABLE 130 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

FEMALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10463	78.	67.	NA	NA	NA	NA
10464	72.	66.	NA	NA	NA	NA
10485	71.	73.	NA	NA	NA	NA
10491	76.	87.	NA	NA	NA	NA
10494	72.	66.	NA	NA	NA	
10496	82.	73.	NA	NA	NA	NA
10498	69.	73.	NA	NA	NA	NA
10500	73.	67.	NA	NA		
10503	79.	75.	NA	NA		
10506	71.	70.	NA	NA	NA	NA
10512	74.	72.	NA	NA	NA	NA
10513	72.	80.	NA	NA		
10514	74.	66.	NA	NA	NA	NA
10521	76.	77.	NA	NA	NA	NA
10524	59.	59.	NA	NA	NA	NA
10536	69.	69.	NA	NA		
10537	75.	76.	NA	NA	NA	NA
10540	65.	73.	NA	NA	NA	NA
10554	71.	74.	NA	NA	NA	NA
10555	72.	66.	NA	NA	NA	NA
MEAN	73.	71.				
S.D.	5.0	6.1				
N	20	20				

NA = NOT APPLICABLE

TABLE 130 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

FEMALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10470	75.	72.	NA	NA		
10472	77.	72.	NA	NA		
10487	73.	75.	NA	NA	NA	NA
10488	65.	68.	NA	NA	NA	NA
10492	72.	74.	NA	NA	NA	NA
10493	72.	69.	NA	67.	NA	NA
10495	70.	70.	NA	NA	NA	NA
10499	72.	75.	NA	NA	NA	NA
10504	62.	65.	NA	NA	NA	NA
10510	76.	77.	NA	NA	NA	NA
10515	65.	67.	NA	NA	NA	NA
10516	71.	68.	NA	NA	NA	NA
10519	68.	69.	NA	NA	NA	NA
10522	66.	70.	NA	NA	NA	NA
10525	70.	68.	NA	NA	NA	NA
10528	81.	74.	NA	NA	NA	NA
10543	66.	71.	NA	NA	NA	
10552	78.	75.	NA	NA	NA	NA
10553	78.	76.	NA	NA		
10556	75.	72.	NA	NA	NA	NA
MEAN	72.	71.		67.		
S.D.	5.2	3.4		0.0		
N	20	20		1		

NA = NOT APPLICABLE

TABLE 130 (F0 FEMALES - PRE-MATING)

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

FEMALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10468	69.	71.	NA	NA	NA	NA
10475	76.	75.	NA	NA	NA	NA
10478	65.	76.	NA	NA	NA	NA
10483	67.	72.	NA	NA	NA	NA
10484	63.	65.	NA	NA	NA	NA
10489	60.	68.	NA	NA	NA	NA
10490	56.	65.	NA	NA	NA	NA
10497	73.	78.	NA	NA	NA	NA
10501	68.	65.	NA	NA	NA	NA
10505	62.	69.	NA	NA	NA	NA
10517	73.	72.	NA	NA	NA	NA
10520	69.	78.	NA	NA	NA	NA
10530	62.	66.	NA	NA	NA	NA
10531	67.	70.	NA	NA	NA	NA
10533	69.	77.	NA	NA	NA	NA
10534	67.	68.	NA	NA	NA	NA
10538	67.	65.	NA	NA	NA	NA
10546	69.	75.	NA	NA	NA	NA
10548	70.	72.	NA	NA	NA	NA
10550	63.	69.	NA	NA	NA	NA
MEAN	67.	71.				
S.D.	4.8	4.5				
N	20	20				

NA = NOT APPLICABLE

TABLE 130 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION [G/KG/DAY]

FEMALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10465	65.	81.	NA	NA	NA	NA
10466	61.	71.	NA	NA	NA	NA
10469	65.	67.	NA	NA	NA	NA
10473	57.	69.	NA	NA	NA	NA
10477	68.	74.	NA	NA	NA	NA
10480	64.	67.	NA	NA	NA	NA
10481	54.	61.	NA	NA	NA	NA
10486	63.	74.	NA	NA	NA	NA
10502	56.	67.	NA	NA	NA	NA
10507	70.	84.	NA	NA	NA	NA
10511	59.	72.	NA	75.	66.	68.
10526	64.	70.	NA	NA	NA	NA
10527	61.	79.	NA	NA	NA	NA
10529	61.	69.	NA	NA	NA	NA
10532	57.	72.	NA	NA	NA	NA
10541	61.	65.	NA	NA	NA	NA
10542	55.	65.	NA	NA	NA	NA
10544	55.	68.	NA	NA	NA	NA
10545	65.	64.	NA	NA	NA	NA
10547	64.	78.	NA	NA	NA	NA
MEAN	61.	71.		75.	66.	68.
S.D.	4.5	6.0		0.0	0.0	0.0
N	20	20		1	1	1

NA = NOT APPLICABLE

TABLE 131 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

FEMALE GROUP: 0 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10463	12.1	10.3	NA	NA	NA	NA
10464	7.1	7.6	NA	NA	NA	NA
10485	7.1	8.4	NA	NA	NA	NA
10491	2.9	10.1	NA	NA	NA	NA
10494	14.3	2.3	NA	NA	NA	
10496	12.3	10.9	NA	NA	NA	NA
10498	0.8	4.5	NA	NA	NA	NA
10500	15.9	-4.2	NA	NA		
10503	9.8	8.3	NA	NA		
10506	15.1	10.3	NA	NA	NA	NA
10512	7.9	2.4	NA	NA	NA	NA
10513	4.8	15.0	NA	NA		
10514	12.7	6.7	NA	NA	NA	NA
10521	9.0	5.7	NA	NA	NA	NA
10524	1.9	1.0	NA	NA	NA	NA
10536	-0.9	0.9	NA	NA		
10537	10.7	2.0	NA	NA	NA	NA
10540	6.7	16.7	NA	NA	NA	NA
10554	5.6	15.7	NA	NA	NA	NA
10555	10.1	-4.5	NA	NA	NA	NA
MEAN	8.3	6.5				
S.D.	4.80	6.01				
N	20	20				

NA = NOT APPLICABLE

TABLE 131 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

FEMALE GROUP: 100 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10470	16.0	1.7	NA	NA		
10472	21.4	5.6	NA	NA		
10487	8.7	0.8	NA	NA	NA	NA
10488	0.9	6.7	NA	NA	NA	NA
10492	5.0	1.4	NA	NA	NA	NA
10493	9.2	5.0	NA	31.8	NA	NA
10495	5.6	14.3	NA	NA	NA	NA
10499	6.8	15.0	NA	NA	NA	NA
10504	8.6	0.9	NA	NA	NA	NA
10510	0.0	11.3	NA	NA	NA	NA
10515	8.4	3.2	NA	NA	NA	NA
10516	11.8	5.0	NA	NA	NA	NA
10519	11.8	9.5	NA	NA	NA	NA
10522	6.7	1.8	NA	NA	NA	NA
10525	9.8	5.4	NA	NA	NA	NA
10528	18.0	12.8	NA	NA	NA	NA
10543	-0.9	-2.5	NA	NA	NA	
10552	0.0	13.6	NA	NA	NA	NA
10553	15.6	14.3	NA	NA		
10556	7.9	4.8	NA	NA	NA	NA
MEAN	8.6	6.5		31.8		
S.D.	6.09	5.39		0.00		
N	20	20		1		

NA = NOT APPLICABLE

TABLE 131 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

FEMALE GROUP: 500 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10468	4.2	8.7	NA	NA	NA	NA
10475	15.1	9.5	NA	NA	NA	NA
10478	-1.0	12.7	NA	NA	NA	NA
10483	11.8	3.8	NA	NA	NA	NA
10484	11.2	5.7	NA	NA	NA	NA
10489	0.0	8.9	NA	NA	NA	NA
10490	3.8	11.9	NA	NA	NA	NA
10497	7.1	8.6	NA	NA	NA	NA
10501	10.9	8.4	NA	NA	NA	NA
10505	0.9	4.8	NA	NA	NA	NA
10517	2.3	3.8	NA	NA	NA	NA
10520	-0.8	13.6	NA	NA	NA	NA
10530	4.1	-1.0	NA	NA	NA	NA
10531	6.3	0.8	NA	NA	NA	NA
10533	-3.0	15.6	NA	NA	NA	NA
10534	-2.9	0.0	NA	NA	NA	NA
10538	6.3	4.5	NA	NA	NA	NA
10546	5.0	7.5	NA	NA	NA	NA
10548	6.3	3.0	NA	NA	NA	NA
10550	2.5	5.3	NA	NA	NA	NA
MEAN	4.5	6.8				
S.D.	5.03	4.56				
N	20	20				

NA = NOT APPLICABLE

TABLE 131 (F0 FEMALES - PRE-MATING)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

FEMALE GROUP: 1000 PPM

WEEK	0 TO 1	1 TO 2	2 TO 5	5 TO 6	6 TO 7	7 TO 8
ANIMAL						
10465	7.1	8.8	NA	NA	NA	NA
10466	0.9	10.5	NA	NA	NA	NA
10469	4.8	11.6	NA	NA	NA	NA
10473	9.5	5.3	NA	NA	NA	NA
10477	8.4	-0.8	NA	NA	NA	NA
10480	3.8	1.8	NA	NA	NA	NA
10481	6.6	1.0	NA	NA	NA	NA
10486	-1.8	9.0	NA	NA	NA	NA
10502	5.1	2.5	NA	NA	NA	NA
10507	10.7	3.6	NA	NA	NA	NA
10511	2.9	12.8	NA	3.2	11.4	-4.1
10526	13.4	19.5	NA	NA	NA	NA
10527	6.1	9.8	NA	NA	NA	NA
10529	19.4	9.2	NA	NA	NA	NA
10532	-2.2	11.8	NA	NA	NA	NA
10541	0.0	-0.9	NA	NA	NA	NA
10542	5.1	5.0	NA	NA	NA	NA
10544	-16.5	12.5	NA	NA	NA	NA
10545	-2.5	7.6	NA	NA	NA	NA
10547	12.5	17.0	NA	NA	NA	NA
MEAN	4.7	7.9		3.2	11.4	-4.1
S.D.	7.50	5.65		0.00	0.00	0.00
N	20	20		1	1	1

NA = NOT APPLICABLE

TABLE 132 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0	3	6	9	12	15	18	20
DAMS FROM GROUP 1: 0 PPM									
10463	G	280.	297.	307.	320.	329.	344.	395.	433.
10464	G	271.	283.	294.	306.	323.	340.	379.	404.
10485	G	242.	262.	270.	278.	290.	298.	335.	360.
10491	G	278.	297.	313.	324.	335.	344.	358.	373.
10494	NG	314.	314.	314.	325.	318.	312.	306.	322.
10496	G	300.	319.	326.	335.	355.	371.	419.	451.
10498	G	285.	299.	309.	319.	333.	345.	385.	412.
10500	NG	257.	284.	292.	291.	279.	264.	279.	282.
10503	NG	272.	261.	255.	268.	275.	281.	275.	290.
10506	G	259.	276.	290.	298.	311.	323.	353.	366.
10512	G	259.	274.	289.	298.	308.	321.	360.	384.
10513	NG	282.	294.	300.	296.	294.	301.	302.	302.
10514	G	273.	283.	294.	297.	315.	332.	380.	415.
10524	G	254.	272.	274.	280.	293.	307.	335.	369.
10536	NG	236.	252.	262.	273.	280.	261.	263.	263.
10537	G	290.	305.	317.	333.	345.	360.	414.	442.
10540	G	256.	285.	290.	304.	313.	337.	376.	412.
10554	G	279.	302.	317.	333.	345.	362.	394.	423.
10555	G	243.	265.	272.	281.	294.	312.	352.	377.
MEAN		269.	287.	297.	308.	321.	335.	374.	402.
S.D.		17.5	16.6	18.0	20.1	20.7	21.4	26.4	30.0
N		14	14	14	14	14	14	14	14

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 132 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0	3	6	9	12	15	18	20
DAMS FROM GROUP 2: 100 PPM									
10470	NG	243.	242.	236.	246.	252.	247.	242.	256.
10472	NG	256.	252.	255.	260.	265.	262.	263.	273.
10487	G	268.	275.	282.	300.	308.	325.	360.	398.
10488	G	260.	279.	284.	287.	302.	322.	359.	392.
10492	G	303.	325.	339.	355.	371.	388.	430.	461.
10495	G	286.	317.	330.	345.	362.	375.	429.	458.
10499	G	280.	304.	319.	335.	348.	365.	404.	433.
10504	G	267.	271.	286.	302.	313.	326.	358.	393.
10510	G	261.	279.	288.	300.	312.	324.	363.	390.
10515	G	266.	292.	308.	317.	338.	353.	395.	423.
10516	G	262.	280.	292.	305.	318.	335.	370.	403.
10519	G	278.	296.	311.	314.	333.	350.	387.	433.
10522	G	234.	262.	269.	285.	296.	316.	358.	385.
10525	G	240.	261.	273.	282.	298.	317.	351.	379.
10528	G	270.	288.	300.	315.	332.	344.	378.	409.
10543	G	242.	262.	270.	285.	297.	309.	353.	378.
10552	G	282.	293.	306.	316.	326.	348.	382.	415.
10553	NG	311.	305.	317.	318.	314.	321.	319.	322.
10556	G	255.	271.	281.	284.	305.	318.	345.	380.
MEAN		266.	285.	296.	308.	322.	338.	376.	408.
S.D.		18.0	19.1	21.1	22.3	23.3	23.2	26.5	26.9
N		16	16	16	16	16	16	16	16

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 132 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0	3	6	9	12	15	18	20
DAMS FROM GROUP 3: 500 PPM									
10468	G	259.	282.	295.	306.	322.	337.	387.	417.
10475	G	245.	261.	274.	283.	298.	311.	343.	373.
10478	G	256.	279.	287.	294.	317.	332.	376.	413.
10483	G	274.	297.	305.	321.	335.	350.	394.	429.
10484	G	230.	258.	259.	271.	284.	300.	330.	351.
10489	G	270.	279.	293.	301.	314.	329.	363.	389.
10490	G	293.	311.	323.	329.	345.	364.	403.	435.
10501	G	274.	291.	297.	305.	317.	333.	369.	399.
10505	G	272.	288.	300.	315.	329.	349.	398.	437.
10517	G	270.	286.	293.	311.	323.	337.	374.	409.
10520	G	285.	303.	314.	321.	341.	358.	400.	431.
10530	G	223.	236.	244.	252.	266.	285.	319.	349.
10531	G	250.	267.	282.	291.	306.	324.	358.	388.
10533	G	303.	321.	339.	344.	355.	368.	393.	414.
10534	G	234.	243.	257.	265.	273.	292.	333.	356.
10538	G	260.	277.	289.	296.	310.	329.	360.	387.
10546	G	269.	280.	300.	319.	335.	357.	393.	434.
10548	G	278.	299.	307.	329.	344.	345.	403.	434.
10550	G	291.	306.	318.	331.	345.	368.	422.	455.
MEAN		265.	282.	293.	304.	319.	335.	375.	405.
S.D.		21.7	22.3	23.5	24.3	25.0	24.6	28.6	31.7
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

PREGNANCY STATUS	DAY 0	3	6	9	12	15	18	20
DAMS FROM GROUP 4: 1000 PPM								
10465 G	275.	283.	287.	301.	313.	325.	353.	376.
10466 G	281.	297.	307.	313.	326.	347.	393.	432.
10469 G	248.	262.	274.	278.	297.	312.	339.	372.
10473 G	291.	318.	333.	343.	365.	381.	422.	448.
10477 G	267.	281.	302.	315.	335.	345.	393.	425.
10480 G	242.	257.	265.	273.	287.	300.	335.	359.
10481 G	252.	267.	281.	291.	303.	319.	350.	374.
10486 G	272.	283.	289.	308.	324.	343.	379.	414.
10502 G	258.	279.	288.	301.	322.	331.	366.	387.
10507 G	250.	266.	283.	294.	309.	328.	369.	399.
10526 G	275.	295.	311.	321.	340.	360.	392.	424.
10527 G	247.	260.	270.	281.	297.	305.	341.	369.
10529 G	258.	276.	286.	297.	312.	330.	363.	395.
10532 G	250.	269.	280.	285.	300.	315.	346.	380.
10541 G	257.	265.	271.	281.	302.	306.	342.	372.
10542 G	263.	290.	301.	310.	332.	334.	368.	395.
10544 G	254.	264.	273.	282.	298.	308.	346.	376.
10545 G	264.	291.	301.	311.	328.	347.	394.	425.
10547 G	273.	300.	319.	330.	356.	371.	418.	446.
MEAN	262.	279.	291.	301.	318.	332.	369.	398.
S.D.	13.2	16.4	18.2	19.0	21.1	22.8	26.8	28.0
N	19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 133 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 1:		0 PPM							
10463	G	17.	10.	13.	9.	15.	51.	38.	153.
10464	G	12.	11.	12.	17.	17.	39.	25.	133.
10485	G	20.	8.	8.	12.	8.	37.	25.	118.
10491	G	19.	16.	11.	11.	9.	14.	15.	95.
10494	NG	0.	0.	11.	-7.	-6.	-6.	16.	8.
10496	G	19.	7.	9.	20.	16.	48.	32.	151.
10498	G	14.	10.	10.	14.	12.	40.	27.	127.
10500	NG	27.	8.	-1.	-12.	-15.	15.	3.	25.
10503	NG	-11.	-6.	13.	7.	6.	-6.	15.	18.
10506	G	17.	14.	8.	13.	12.	30.	13.	107.
10512	G	15.	15.	9.	10.	13.	39.	24.	125.
10513	NG	12.	6.	-4.	-2.	7.	1.	0.	20.
10514	G	10.	11.	3.	18.	17.	48.	35.	142.
10524	G	18.	2.	6.	13.	14.	28.	34.	115.
10536	NG	16.	10.	11.	7.	-19.	2.	0.	27.
10537	G	15.	12.	16.	12.	15.	54.	28.	152.
10540	G	29.	5.	14.	9.	24.	39.	36.	156.
10554	G	23.	15.	16.	12.	17.	32.	29.	144.
10555	G	22.	7.	9.	13.	18.	40.	25.	134.
MEAN		18.	10.	10.	13.	15.	39.	28.	132.
S.D.		4.8	4.1	3.7	3.3	4.0	10.4	7.3	18.8
N		14	14	14	14	14	14	14	14

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

INDIVIDUAL BODY WEIGHT CHANGES DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 2: 100 PPM									
10470	NG	-1.	-6.	10.	6.	-5.	-5.	14.	13.
10472	NG	-4.	3.	5.	5.	-3.	1.	10.	17.
10487	G	7.	7.	18.	8.	17.	35.	38.	130.
10488	G	19.	5.	3.	15.	20.	37.	33.	132.
10492	G	22.	14.	16.	16.	17.	42.	31.	158.
10495	G	31.	13.	15.	17.	13.	54.	29.	172.
10499	G	24.	15.	16.	13.	17.	39.	29.	153.
10504	G	4.	15.	16.	11.	13.	32.	35.	126.
10510	G	18.	9.	12.	12.	12.	39.	27.	129.
10515	G	26.	16.	9.	21.	15.	42.	28.	157.
10516	G	18.	12.	13.	13.	17.	35.	33.	141.
10519	G	18.	15.	3.	19.	17.	37.	46.	155.
10522	G	28.	7.	16.	11.	20.	42.	27.	151.
10525	G	21.	12.	9.	16.	19.	34.	28.	139.
10528	G	18.	12.	15.	17.	12.	34.	31.	139.
10543	G	20.	8.	15.	12.	12.	44.	25.	136.
10552	G	11.	13.	10.	10.	22.	34.	33.	133.
10553	NG	-6.	12.	1.	-4.	7.	-2.	3.	11.
10556	G	16.	10.	3.	21.	13.	27.	35.	125.
MEAN		19.	11.	12.	15.	16.	38.	32.	142.
S.D.		7.1	3.4	5.1	3.9	3.2	6.1	5.2	13.8
N		16	16	16	16	16	16	16	16

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

INDIVIDUAL BODY WEIGHT CHANGES DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 3: 500 PPM									
10468	G	23.	13.	11.	16.	15.	50.	30.	158.
10475	G	16.	13.	9.	15.	13.	32.	30.	128.
10478	G	23.	8.	7.	23.	15.	44.	37.	157.
10483	G	23.	8.	16.	14.	15.	44.	35.	155.
10484	G	28.	1.	12.	13.	16.	30.	21.	121.
10489	G	9.	14.	8.	13.	15.	34.	26.	119.
10490	G	18.	12.	6.	16.	19.	39.	32.	142.
10501	G	17.	6.	8.	12.	16.	36.	30.	125.
10505	G	16.	12.	15.	14.	20.	49.	39.	165.
10517	G	16.	7.	18.	12.	14.	37.	35.	139.
10520	G	18.	11.	7.	20.	17.	42.	31.	146.
10530	G	13.	8.	8.	14.	19.	34.	30.	126.
10531	G	17.	15.	9.	15.	18.	34.	30.	138.
10533	G	18.	18.	5.	11.	13.	25.	21.	111.
10534	G	9.	14.	8.	8.	19.	41.	23.	122.
10538	G	17.	12.	7.	14.	19.	31.	27.	127.
10546	G	11.	20.	19.	16.	22.	36.	41.	165.
10548	G	21.	8.	22.	15.	1.	58.	31.	156.
10550	G	15.	12.	13.	14.	23.	54.	33.	164.
MEAN		17.	11.	11.	14.	16.	39.	31.	140.
S.D.		4.9	4.4	4.9	3.2	4.7	8.7	5.5	17.7
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

INDIVIDUAL BODY WEIGHT CHANGES DURING GESTATION [G]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 4: 1000 PPM									
10465	G	8.	4.	14.	12.	12.	28.	23.	101.
10466	G	16.	10.	6.	13.	21.	46.	39.	151.
10469	G	14.	12.	4.	19.	15.	27.	33.	124.
10473	G	27.	15.	10.	22.	16.	41.	26.	157.
10477	G	14.	21.	13.	20.	10.	48.	32.	158.
10480	G	15.	8.	8.	14.	13.	35.	24.	117.
10481	G	15.	14.	10.	12.	16.	31.	24.	122.
10486	G	11.	6.	19.	16.	19.	36.	35.	142.
10502	G	21.	9.	13.	21.	9.	35.	21.	129.
10507	G	16.	17.	11.	15.	19.	41.	30.	149.
10526	G	20.	16.	10.	19.	20.	32.	32.	149.
10527	G	13.	10.	11.	16.	8.	36.	28.	122.
10529	G	18.	10.	11.	15.	18.	33.	32.	137.
10532	G	19.	11.	5.	15.	15.	31.	34.	130.
10541	G	8.	6.	10.	21.	4.	36.	30.	115.
10542	G	27.	11.	9.	22.	2.	34.	27.	132.
10544	G	10.	9.	9.	16.	10.	38.	30.	122.
10545	G	27.	10.	10.	17.	19.	47.	31.	161.
10547	G	27.	19.	11.	26.	15.	47.	28.	173.
MEAN		17.	11.	10.	17.	14.	37.	29.	136.
S.D.		6.3	4.5	3.3	3.8	5.4	6.5	4.5	18.8
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 134 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/ANIMAL/DAY]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 1:		0 PPM							
10463	G	22.	23.	23.	23.	20.	28.	27.	24.
10464	G	18.	20.	22.	21.	23.	23.	23.	21.
10485	G	19.	19.	21.	20.	18.	20.	21.	20.
10491	G	21.	25.	23.	23.	21.	24.	24.	23.
10494	NG	17.	17.	21.	17.	15.	16.	19.	17.
10496	G	22.	24.	23.	25.	25.	27.	25.	24.
10498	G	22.	23.	25.	23.	22.	25.	26.	24.
10500	NG	21.	22.	21.	14.	14.	22.	15.	19.
10503	NG	16.	16.	19.	18.	19.	19.	21.	18.
10506	G	18.	21.	22.	23.	19.	23.	23.	21.
10512	G	19.	21.	21.	22.	19.	22.	20.	21.
10513	NG	19.	21.	18.	21.	19.	19.	20.	20.
10514	G	19.	20.	20.	21.	21.	24.	25.	21.
10524	G	17.	17.	17.	18.	18.	19.	20.	18.
10536	NG	20.	20.	20.	21.	16.	15.	14.	18.
10537	G	22.	23.	24.	26.	22.	31.	27.	25.
10540	G	23.	23.	24.	21.	24.	26.	27.	24.
10554	G	22.	24.	25.	24.	25.	27.	26.	25.
10555	G	20.	19.	19.	21.	21.	24.	24.	21.
MEAN		20.	22.	22.	22.	21.	25.	24.	22.
S.D.		1.9	2.3	2.3	2.1	2.4	3.2	2.5	2.1
N		14	14	14	14	14	14	14	14

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 134 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/ANIMAL/DAY]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 2: 100 PPM									
10470	NG	15.	16.	17.	17.	15.	16.	18.	16.
10472	NG	18.	20.	20.	21.	17.	20.	21.	19.
10487	G	19.	20.	21.	23.	22.	24.	25.	22.
10488	G	20.	19.	20.	20.	21.	24.	24.	21.
10492	G	22.	27.	24.	28.	22.	27.	25.	25.
10495	G	25.	26.	28.	25.	26.	30.	26.	26.
10499	G	22.	24.	25.	27.	29.	29.	28.	26.
10504	G	18.	20.	21.	22.	22.	22.	23.	21.
10510	G	21.	23.	23.	23.	26.	26.	28.	24.
10515	G	20.	22.	22.	24.	24.	27.	25.	23.
10516	G	18.	19.	22.	20.	22.	25.	26.	22.
10519	G	21.	23.	22.	23.	22.	23.	29.	23.
10522	G	18.	20.	23.	23.	22.	25.	26.	22.
10525	G	18.	20.	19.	19.	22.	23.	27.	21.
10528	G	21.	23.	24.	26.	24.	25.	26.	24.
10543	G	19.	18.	20.	21.	22.	24.	24.	21.
10552	G	18.	20.	21.	22.	22.	25.	26.	22.
10553	NG	18.	22.	22.	19.	22.	17.	20.	20.
10556	G	20.	19.	19.	22.	22.	16.	24.	20.
MEAN		20.	21.	22.	23.	23.	25.	26.	23.
S.D.		2.0	2.7	2.4	2.5	2.2	3.2	1.7	1.9
N		16	16	16	16	16	16	16	16

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 134 (F0 FEMALES)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/ANIMAL/DAY]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 3: 500 PPM									
10468	G	19.	20.	21.	21.	22.	25.	24.	22.
10475	G	18.	19.	20.	22.	22.	22.	23.	21.
10478	G	19.	22.	21.	23.	23.	28.	27.	23.
10483	G	21.	21.	23.	26.	25.	30.	29.	25.
10484	G	17.	17.	18.	19.	19.	20.	21.	19.
10489	G	17.	20.	22.	21.	21.	18.	20.	20.
10490	G	19.	22.	21.	21.	22.	25.	26.	22.
10501	G	18.	20.	21.	21.	21.	24.	24.	21.
10505	G	18.	21.	23.	23.	24.	28.	28.	23.
10517	G	19.	22.	24.	25.	22.	26.	26.	23.
10520	G	21.	24.	24.	25.	27.	30.	29.	26.
10530	G	16.	16.	17.	19.	21.	23.	24.	19.
10531	G	17.	20.	21.	22.	21.	24.	23.	21.
10533	G	22.	24.	23.	21.	22.	24.	26.	23.
10534	G	17.	18.	18.	20.	19.	25.	26.	20.
10538	G	18.	20.	20.	22.	22.	23.	25.	21.
10546	G	24.	24.	26.	27.	25.	28.	32.	26.
10548	G	22.	24.	24.	26.	20.	28.	26.	24.
10550	G	21.	21.	24.	23.	23.	25.	23.	23.
MEAN		19.	21.	22.	22.	22.	25.	25.	22.
S.D.		2.2	2.3	2.4	2.4	2.0	3.2	2.9	2.1
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 4: 1000 PPM									
10465	G	19.	22.	23.	24.	24.	25.	26.	23.
10466	G	19.	22.	25.	22.	25.	27.	26.	24.
10469	G	16.	19.	20.	21.	22.	22.	25.	21.
10473	G	22.	23.	26.	27.	28.	31.	26.	26.
10477	G	22.	24.	25.	28.	24.	29.	27.	25.
10480	G	17.	18.	19.	22.	19.	23.	24.	20.
10481	G	16.	19.	19.	20.	22.	24.	25.	20.
10486	G	17.	20.	23.	23.	25.	26.	26.	23.
10502	G	18.	21.	22.	24.	24.	26.	26.	23.
10507	G	22.	25.	25.	29.	27.	30.	28.	26.
10526	G	18.	21.	22.	25.	26.	28.	27.	24.
10527	G	20.	20.	20.	22.	23.	25.	26.	22.
10529	G	18.	18.	20.	25.	23.	26.	26.	22.
10532	G	18.	17.	18.	20.	20.	17.	27.	19.
10541	G	17.	17.	18.	21.	19.	25.	24.	20.
10542	G	18.	20.	20.	23.	20.	24.	25.	21.
10544	G	20.	21.	20.	23.	22.	26.	26.	22.
10545	G	20.	23.	24.	25.	28.	31.	28.	25.
10547	G	22.	22.	24.	30.	30.	33.	28.	27.
MEAN		19.	21.	22.	24.	24.	26.	26.	23.
S.D.		2.0	2.3	2.6	2.9	3.1	3.7	1.2	2.3
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 135 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/KG/DAY]

PREGNANCY STATUS DAY	0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 1: 0 PPM								
10463 G	76.	76.	73.	71.	59.	76.	65.	71.
10464 G	65.	69.	73.	67.	69.	64.	59.	65.
10485 G	75.	71.	77.	70.	61.	63.	60.	68.
10491 G	73.	82.	72.	70.	62.	68.	66.	70.
10494 NG	54.	54.	66.	53.	48.	52.	61.	54.
10496 G	71.	74.	69.	72.	69.	68.	57.	67.
10498 G	75.	76.	80.	71.	65.	68.	65.	71.
10500 NG	77.	76.	72.	49.	51.	81.	53.	68.
10503 NG	60.	62.	73.	66.	68.	68.	74.	66.
10506 G	67.	74.	75.	75.	60.	68.	64.	68.
10512 G	71.	74.	71.	73.	60.	65.	54.	67.
10513 NG	66.	71.	60.	71.	64.	63.	66.	68.
10514 G	68.	69.	68.	69.	65.	67.	63.	65.
10524 G	65.	62.	61.	63.	60.	59.	57.	60.
10536 NG	82.	78.	75.	76.	59.	57.	53.	69.
10537 G	74.	74.	74.	77.	62.	80.	63.	71.
10540 G	85.	80.	81.	68.	74.	73.	69.	75.
10554 G	76.	77.	77.	71.	71.	71.	64.	73.
10555 G	79.	71.	69.	73.	69.	72.	66.	70.
MEAN	73.	74.	73.	71.	65.	69.	62.	69.
S.D.	5.6	5.0	5.2	3.5	4.9	5.4	4.3	3.8
N	14	14	14	14	14	14	14	14

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 135 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/KG/DAY]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 2: 100 PPM									
10470	NG	62.	67.	71.	68.	60.	65.	72.	65.
10472	NG	71.	79.	78.	80.	64.	76.	78.	73.
10487	G	70.	72.	72.	76.	69.	70.	66.	70.
10488	G	74.	67.	70.	68.	67.	70.	64.	68.
10492	G	70.	81.	69.	77.	58.	66.	56.	67.
10495	G	83.	80.	83.	71.	70.	75.	59.	72.
10499	G	75.	77.	76.	79.	81.	75.	67.	74.
10504	G	67.	72.	71.	71.	69.	64.	61.	67.
10510	G	78.	81.	78.	75.	82.	76.	74.	76.
10515	G	72.	73.	70.	73.	69.	72.	61.	68.
10516	G	66.	66.	74.	64.	67.	71.	67.	69.
10519	G	73.	76.	70.	71.	64.	62.	71.	68.
10522	G	73.	75.	83.	79.	72.	74.	70.	73.
10525	G	72.	75.	68.	66.	71.	69.	74.	70.
10528	G	75.	78.	78.	80.	71.	69.	66.	73.
10543	G	75.	68.	72.	72.	73.	73.	66.	70.
10552	G	63.	67.	68.	69.	65.	68.	65.	66.
10553	NG	58.	71.	69.	60.	69.	53.	62.	63.
10556	G	76.	69.	67.	75.	71.	48.	66.	66.
MEAN		73.	74.	73.	73.	70.	69.	66.	70.
S.D.		4.8	5.1	5.1	4.7	5.8	6.8	5.0	3.0
N		16	16	16	16	16	16	16	16

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 135 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING GESTATION [G/KG/DAY]

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 3: 500 PPM									
10468	G	70.	69.	70.	67.	67.	69.	60.	67.
10475	G	71.	71.	72.	76.	72.	67.	64.	70.
10478	G	71.	78.	72.	75.	71.	79.	68.	72.
10483	G	73.	70.	73.	79.	73.	81.	70.	74.
10484	G	70.	66.	68.	68.	65.	63.	62.	67.
10489	G	62.	70.	74.	68.	65.	52.	53.	63.
10490	G	63.	69.	64.	62.	62.	65.	62.	63.
10501	G	64.	68.	70.	68.	65.	68.	63.	65.
10505	G	64.	71.	75.	71.	71.	75.	67.	68.
10517	G	68.	76.	79.	79.	67.	73.	66.	71.
10520	G	71.	78.	75.	76.	77.	79.	70.	76.
10530	G	70.	67.	69.	73.	76.	76.	72.	70.
10531	G	66.	73.	73.	74.	67.	70.	62.	68.
10533	G	71.	73.	67.	60.	61.	63.	64.	65.
10534	G	71.	72.	69.	74.	67.	80.	75.	71.
10538	G	67.	71.	68.	73.	69.	67.	67.	67.
10546	G	87.	83.	84.	83.	72.	75.	77.	77.
10548	G	76.	79.	75.	77.	58.	75.	62.	70.
10550	G	70.	67.	74.	68.	64.	63.	52.	65.
MEAN		70.	72.	72.	72.	68.	71.	65.	69.
S.D.		5.5	4.7	4.6	5.9	5.0	7.5	6.4	4.0
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 4: 1000 PPM									
10465	G	68.	77.	78.	78.	75.	74.	71.	73.
10466	G	66.	73.	81.	69.	74.	73.	63.	71.
10469	G	63.	71.	72.	73.	72.	67.	70.	70.
10473	G	72.	71.	77.	76.	75.	77.	60.	72.
10477	G	80.	82.	81.	86.	71.	79.	66.	75.
10480	G	68.	69.	71.	79.	65.	72.	69.	69.
10481	G	62.	69.	66.	67.	71.	72.	69.	66.
10486	G	61.	70.	77.	73.	75.	72.	65.	70.
10502	G	67.	74.	75.	77.	73.	74.	69.	73.
10507	G	85.	91.	87.	96.	85.	86.	73.	83.
10526	G	63.	69.	70.	76.	74.	74.	66.	71.
10527	G	79.	75.	72.	76.	76.	77.	73.	74.
10529	G	67.	64.	68.	82.	72.	75.	69.	70.
10532	G	69.	62.	64.	68.	65.	51.	74.	63.
10541	G	65.	63.	65.	72.	63.	77.	67.	67.
10542	G	65.	68.	65.	72.	60.	68.	65.	65.
10544	G	77.	78.	72.	79.	73.	80.	72.	73.
10545	G	72.	78.	78.	78.	83.	84.	68.	75.
10547	G	77.	71.	74.	87.	82.	84.	65.	77.
MEAN		70.	72.	73.	77.	73.	75.	68.	71.
S.D.		6.9	6.9	6.3	7.1	6.5	7.7	3.7	4.6
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 136 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING GESTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 1:		0 PPM							
10463	G	25.4	14.7	18.6	13.2	24.6	60.7	71.7	32.4
10464	G	21.9	18.3	18.4	27.0	24.3	56.5	54.3	31.1
10485	G	35.7	14.0	12.9	20.3	14.6	61.7	59.5	30.1
10491	G	30.2	21.1	15.7	15.9	14.1	19.7	31.9	20.7
10494	NG	0.0	0.0	17.7	-13.7	-13.3	-12.7	42.1	2.3
10496	G	28.4	9.7	13.0	27.0	21.3	59.3	65.3	30.9
10498	G	21.2	14.7	13.5	20.0	17.9	52.7	52.9	26.9
10500	NG	42.9	12.1	-1.6	-29.2	-35.7	22.4	10.3	6.7
10503	NG	-23.4	-12.7	23.2	13.0	10.5	-10.7	35.7	5.0
10506	G	31.0	22.5	12.3	19.1	20.7	42.9	28.3	25.2
10512	G	26.3	23.5	14.1	15.2	23.2	58.3	60.0	30.2
10513	NG	21.1	9.4	-7.5	-3.2	12.1	1.8	0.0	5.1
10514	G	17.3	18.3	5.1	28.2	26.6	66.7	70.0	33.2
10524	G	34.7	4.0	11.8	23.7	25.9	49.9	85.0	32.1
10536	NG	27.1	16.4	18.3	11.3	-38.9	4.4	0.0	7.4
10537	G	22.7	17.2	22.2	15.6	22.7	58.6	52.8	30.6
10540	G	41.5	7.2	19.4	14.3	33.8	49.4	67.9	32.6
10554	G	35.3	20.8	21.1	16.7	22.9	40.0	55.8	29.3
10555	G	36.7	12.1	15.8	20.3	28.2	55.6	52.1	31.6
MEAN		29.2	15.6	15.3	19.8	22.9	52.3	57.7	29.8
S.D.		7.05	5.82	4.47	5.02	5.21	11.88	14.90	3.41
N		14	14	14	14	14	14	14	14

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 136 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING GESTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 2: 100 PPM									
10470	NG	-2.2	-12.5	19.6	12.0	-10.9	-10.4	40.0	4.0
10472	NG	-7.5	5.1	8.5	8.1	-5.9	1.7	23.8	4.4
10487	G	12.1	11.7	28.6	11.6	26.1	48.0	77.6	29.7
10488	G	31.2	8.9	4.9	25.4	31.3	50.8	68.8	31.3
10492	G	33.8	17.5	21.9	19.3	25.8	52.4	62.0	31.7
10495	G	41.8	16.9	17.9	22.7	16.9	59.4	56.9	32.5
10499	G	36.4	20.6	21.3	16.2	19.7	44.4	52.7	29.2
10504	G	7.4	25.0	25.4	16.7	19.4	47.8	76.1	29.7
10510	G	28.6	13.2	17.2	17.4	15.4	49.4	49.1	26.8
10515	G	42.7	23.9	13.5	29.5	20.8	52.4	57.1	33.5
10516	G	32.8	20.7	19.7	21.3	25.8	46.1	64.7	32.5
10519	G	28.6	22.0	4.6	27.9	25.4	54.3	79.3	33.8
10522	G	51.0	11.7	23.5	15.9	30.3	56.7	52.9	34.0
10525	G	38.3	20.3	15.5	27.6	28.4	48.6	51.9	32.9
10528	G	29.0	17.2	20.8	21.8	16.7	45.9	59.6	29.0
10543	G	35.7	14.6	25.0	18.8	17.9	60.4	52.1	32.1
10552	G	20.0	21.3	15.6	15.4	32.9	44.8	64.7	30.2
10553	NG	-10.9	18.2	1.5	-7.1	10.6	-3.9	7.5	2.8
10556	G	27.1	17.3	5.3	32.3	19.7	55.2	72.9	31.1
MEAN		31.0	17.7	17.5	21.2	23.3	51.0	62.4	31.3
S.D.		11.06	4.67	7.42	5.89	5.65	5.06	10.03	2.01
N		16	16	16	16	16	16	16	16

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 136 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING GESTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 3: 500 PPM									
10468	G	39.7	21.7	17.5	25.4	22.4	67.5	63.8	36.6
10475	G	29.1	22.5	14.8	23.0	19.4	47.8	66.7	30.6
10478	G	40.4	12.3	11.0	33.3	21.5	52.9	69.8	34.0
10483	G	36.0	12.9	23.2	17.9	20.0	48.9	60.3	31.3
10484	G	53.9	2.0	21.9	22.8	27.6	49.3	50.0	32.2
10489	G	18.0	23.0	12.3	20.6	24.2	64.0	65.0	30.2
10490	G	32.1	18.4	9.4	25.4	28.8	52.6	62.7	32.3
10501	G	31.5	10.0	12.7	19.0	25.0	50.6	62.5	29.5
10505	G	30.1	19.0	21.5	20.3	27.8	58.3	69.6	35.3
10517	G	27.6	10.8	25.3	16.2	20.9	46.9	67.3	29.8
10520	G	28.2	15.5	9.6	27.0	20.8	46.2	53.4	28.4
10530	G	27.1	16.4	15.4	25.0	30.2	49.3	62.5	32.6
10531	G	33.3	25.0	14.3	22.7	28.6	47.2	65.2	32.7
10533	G	27.3	25.3	7.3	17.2	19.4	34.3	40.4	24.0
10534	G	17.3	25.5	14.6	13.3	32.8	54.0	45.1	29.9
10538	G	32.0	20.3	11.7	21.5	29.2	44.3	55.1	30.1
10546	G	15.3	27.4	24.4	19.5	29.3	42.9	64.1	31.3
10548	G	32.3	11.3	30.6	19.0	1.7	69.8	59.6	32.4
10550	G	23.8	18.8	18.1	20.0	33.3	72.9	73.3	35.8
MEAN		30.3	17.8	16.6	21.5	24.4	52.6	60.9	31.5
S.D.		8.88	6.65	6.33	4.50	7.12	9.88	8.58	2.88
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 136 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING GESTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	PREGNANCY STATUS	DAY 0- 3	3- 6	6- 9	9-12	12-15	15-18	18-20	0-20
DAMS FROM GROUP 4: 1000 PPM									
10465	G	14.0	6.0	20.6	16.7	16.5	36.9	45.1	21.8
10466	G	27.6	15.2	8.1	20.0	28.3	56.2	75.0	32.0
10469	G	28.6	20.7	6.8	30.6	22.4	40.4	67.3	30.1
10473	G	40.4	21.5	12.8	27.2	19.0	44.5	51.0	30.0
10477	G	21.5	29.2	17.5	24.1	13.7	55.2	59.3	31.1
10480	G	29.9	14.8	14.0	21.5	23.2	50.1	51.1	29.3
10481	G	30.7	25.0	17.3	20.3	24.6	43.6	49.0	29.9
10486	G	21.2	10.2	27.9	23.2	25.3	45.6	67.3	31.3
10502	G	38.3	14.5	20.0	29.2	12.3	44.9	41.2	28.3
10507	G	24.2	22.9	14.7	17.4	23.7	45.6	54.5	28.3
10526	G	37.7	25.4	15.2	25.3	25.3	38.5	60.4	31.6
10527	G	22.0	16.4	18.1	24.2	11.4	48.0	53.8	27.5
10529	G	33.9	18.2	18.3	19.8	25.8	41.8	61.5	30.7
10532	G	35.8	21.6	9.4	24.6	24.6	59.7	64.2	33.9
10541	G	15.4	11.6	18.8	33.3	7.0	48.0	62.5	28.8
10542	G	50.8	18.6	14.8	31.5	3.3	47.2	55.1	31.1
10544	G	16.9	14.1	15.2	23.5	15.4	49.3	57.7	27.5
10545	G	45.0	14.5	13.9	22.7	22.9	51.0	55.4	31.7
10547	G	41.5	28.4	15.3	29.2	16.8	47.9	50.0	32.3
MEAN		30.3	18.4	15.7	24.4	19.0	47.1	56.9	29.9
S.D.		10.46	6.23	4.79	4.73	7.02	5.86	8.34	2.60
N		19	19	19	19	19	19	19	19

G = GRAVID NG = NONGRAVID - WEIGHT(S) NOT INCLUDED IN CALCULATION OF MEAN

TABLE 137 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING LACTATION [G]

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10463	313.	321.	338.	354.	375.	360.	323.
10464	298.	328.	320.	334.	343.	341.	276.
10506	298.	300.	302.	303.	342.	337.	321.
10524	258.	300.	296.	283.	313.	300.	268.
10540	308.	313.	323.	331.	340.	357.	322.
10554	333.	355.	356.	362.	382.	356.	324.
10555	272.	305.	299.	299.	338.	337.	268.
MEAN	297.	317.	319.	324.	348.	341.	300.
S.D.	25.2	19.7	22.2	29.6	23.6	20.6	27.8
N	7	7	7	7	7	7	7

TABLE 137 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING LACTATION [G]

DAY	1	4	5	7	14	21	28	
DAMS FROM GROUP 2: 100 PPM								
10488	292.	316.	325.	313.	348.	344.	274.	
10493	281.	279.	301.	306.	329.	320.	292.	
10504	296.	300.	309.	306.	343.	342.	304.	
10510	301.	312.	311.	315.	332.	340.	295.	
10519	309.	321.	314.	308.	368.	379.	348.	
10522	266.	280.	284.	297.	337.	330.	287.	
10525	270.	281.	292.	300.	293.	344.	288.	
10528	302.	306.	307.	316.	292.	356.	316.	
10543	281.	275.	283.	285.	287.	NA	NA	TOTAL LITTER LOSS DAY 15
MEAN	289.	297.	303.	305.	325.	344.	301.	
S.D.	14.9	18.0	14.2	9.9	28.4	17.6	22.8	
N	9	9	9	9	9	8	8	

NA = NOT APPLICABLE

TABLE 137 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING LACTATION [G]

DAY	1	4	5	7	14	21	28	
DAMS FROM GROUP 3: 500 PPM								
10468	319.	336.	337.	336.	367.	347.	315.	
10478	280.	289.	305.	304.	333.	363.	329.	
10483	321.	354.	344.	350.	377.	372.	322.	
10484	270.	277.	282.	290.	NA	328.	287.	
10520	NA	NA	NA	NA	NA	NA	NA	TOTAL LITTER LOSS DAY 0
10530	252.	250.	257.	255.	280.	296.	267.	
10534	274.	274.	289.	283.	298.	300.	274.	
10546	327.	336.	347.	342.	370.	375.	343.	
10548	322.	329.	333.	345.	369.	385.	315.	
10550	317.	326.	333.	335.	386.	391.	350.	
MEAN	298.	308.	314.	316.	348.	351.	311.	
S.D.	28.6	35.9	32.1	33.7	39.5	35.5	29.4	
N	9	9	9	9	8	9	9	

NA = NOT APPLICABLE

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10465	296.	325.	309.	309.	350.	357.	290.
10473	351.	351.	365.	360.	380.	390.	363.
10480	255.	274.	286.	286.	262.	306.	280.
10481	288.	300.	306.	311.	330.	348.	313.
10486	313.	326.	322.	337.	359.	333.	319.
10507	291.	307.	312.	314.	344.	336.	310.
10529	302.	316.	315.	317.	345.	337.	332.
10532	277.	310.	301.	314.	332.	336.	283.
10547	343.	334.	342.	340.	372.	407.	380.
MEAN	302.	316.	318.	321.	342.	350.	319.
S.D.	30.4	22.0	23.4	21.6	34.2	31.0	34.6
N	9	9	9	9	9	9	9

TABLE 138 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM							
10463	8.	17.	16.	21.	-15.	-37.	10.
10464	30.	-8.	14.	9.	-2.	-65.	-22.
10506	2.	2.	1.	39.	-5.	-16.	23.
10524	42.	-4.	-13.	30.	-13.	-32.	10.
10540	5.	10.	8.	9.	17.	-35.	14.
10554	22.	1.	6.	20.	-26.	-32.	-9.
10555	33.	-6.	0.	39.	-1.	-69.	-4.
MEAN	20.	2.	5.	24.	-6.	-41.	3.
S.D.	15.5	9.0	9.8	12.7	13.5	19.1	15.5
N	7	7	7	7	7	7	7

TABLE 138 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 2: 100 PPM								
10488	24.	9.	-12.	35.	-4.	-70.	-18.	
10493	-2.	22.	5.	23.	-9.	-28.	11.	
10504	4.	9.	-3.	37.	-1.	-38.	8.	
10510	11.	-1.	4.	17.	8.	-45.	-6.	
10519	12.	-7.	-6.	60.	11.	-31.	39.	
10522	14.	4.	13.	40.	-7.	-43.	21.	
10525	11.	11.	8.	-7.	51.	-56.	18.	
10528	4.	1.	9.	-24.	64.	-40.	14.	
10543	-6.	8.	2.	2.	NA	NA	NA	TOTAL LITTER LOSS DAY 15
MEAN	8.	6.	2.	20.	14.	-44.	11.	
S.D.	9.0	8.3	7.9	26.3	27.9	13.6	17.2	
N	9	9	9	9	8	8	8	

NA = NOT APPLICABLE

TABLE 138 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 3: 500 PPM								
10468	17.	1.	-1.	31.	-20.	-32.	-4.	
10478	9.	16.	-1.	29.	30.	-34.	49.	
10483	33.	-10.	6.	27.	-5.	-50.	1.	
10484	7.	5.	8.	NA	NA	-41.	17.	
10520	NA	NA	NA	NA	NA	NA	NA	TOTAL LITTER LOSS DAY 0
10530	-2.	7.	-2.	25.	16.	-29.	15.	
10534	0.	15.	-6.	15.	2.	-26.	0.	
10546	9.	11.	-5.	28.	5.	-32.	16.	
10548	7.	4.	12.	24.	16.	-70.	-7.	
10550	9.	7.	2.	51.	5.	-41.	33.	
MEAN	10.	6.	1.	29.	6.	-39.	13.	
S.D.	10.3	7.9	6.1	10.2	15.1	13.6	18.5	
N	9	9	9	8	8	9	9	

NA = NOT APPLICABLE

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000 PPM							
10465	29.	-16.	0.	41.	7.	-67.	-6.
10473	0.	14.	-5.	20.	10.	-27.	12.
10480	19.	12.	0.	-24.	44.	-26.	25.
10481	12.	6.	5.	19.	18.	-35.	25.
10486	13.	-4.	15.	22.	-26.	-14.	6.
10507	16.	5.	2.	30.	-8.	-26.	19.
10529	14.	-1.	2.	28.	-8.	-5.	30.
10532	33.	-9.	13.	18.	4.	-53.	6.
10547	-9.	8.	-2.	32.	35.	-27.	37.
MEAN	14.	2.	3.	21.	8.	-31.	17.
S.D.	13.0	10.0	6.7	18.3	21.8	18.9	13.7
N	9	9	9	9	9	9	9

TABLE 139 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM							
10463	35.	49.	NA	51.	63.	89.	63.
10464	32.	32.	44.	11.	70.	85.	51.
10506	22.	34.	31.	15.	49.	57.	37.
10524	34.	42.	36.	49.	59.	92.	60.
10540	NA	50.	44.	57.	74.	87.	NA
10554	33.	42.	49.	54.	62.	NA	NA
10555	NA	46.	41.	53.	67.	75.	NA
MEAN	31.	42.	41.	41.	63.	81.	53.
S.D.	5.3	7.0	6.4	19.6	8.1	13.0	11.7
N	5	7	6	7	7	6	4

NA = NOT APPLICABLE

TABLE 139 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 2: 100 PPM								
10488	33.	43.	39.	53.	59.	78.	57.	
10493	18.	NA	30.	39.	45.	59.	43.	
10504	30.	43.	28.	49.	59.	81.	56.	
10510	40.	45.	29.	54.	70.	NA	NA	
10519	31.	30.	34.	54.	67.	76.	58.	
10522	27.	36.	38.	49.	69.	88.	61.	
10525	26.	22.	NA	43.	61.	80.	56.	
10528	31.	42.	45.	53.	75.	84.	63.	
10543	26.	36.	30.	32.	NA	NA	NA	TOTAL LITTER LOSS DAY 15
MEAN	29.	37.	34.	47.	63.	78.	56.	
S.D.	6.0	7.9	6.0	7.8	9.3	9.3	6.4	
N	9	8	8	9	8	7	7	

NA = NOT APPLICABLE

TABLE 139 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 3: 500 PPM								
10468	35.	48.	32.	49.	62.	76.	57.	
10478	31.	42.	34.	38.	49.	50.	43.	
10483	42.	46.	42.	57.	76.	104.	71.	
10484	29.	40.	39.	42.	66.	86.	58.	
10520	NA	NA	NA	NA	NA	NA	NA	TOTAL LITTER LOSS DAY 0
10530	25.	34.	29.	40.	60.	79.	53.	
10534	29.	35.	31.	42.	56.	79.	53.	
10546	34.	46.	36.	51.	64.	79.	58.	
10548	36.	43.	39.	59.	71.	85.	64.	
10550	30.	39.	38.	63.	77.	105.	71.	
MEAN	32.	41.	36.	49.	65.	83.	59.	
S.D.	5.0	4.9	4.3	9.1	9.2	16.3	9.0	
N	9	9	9	9	9	9	9	

NA = NOT APPLICABLE

TABLE 139 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000 PPM							
10465	32.	33.	32.	49.	68.	76.	57.
10473	28.	38.	28.	46.	57.	74.	52.
10480	23.	41.	29.	40.	54.	81.	52.
10481	36.	39.	33.	43.	57.	76.	54.
10486	41.	44.	35.	54.	73.	NA	NA
10507	45.	58.	50.	48.	62.	73.	59.
10529	24.	25.	NA	32.	38.	38.	34.
10532	33.	29.	37.	48.	65.	79.	57.
10547	38.	43.	26.	54.	73.	92.	65.
MEAN	33.	39.	34.	46.	61.	74.	54.
S.D.	7.5	9.6	7.5	6.9	11.0	15.6	9.0
N	9	9	8	9	9	8	8

NA = NOT APPLICABLE

TABLE 140 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM							
10463	110.	148.	NA	140.	171.	260.	185.
10464	102.	99.	135.	32.	205.	275.	159.
10506	74.	113.	102.	46.	144.	173.	117.
10524	122.	141.	124.	164.	192.	324.	208.
10540	NA	157.	135.	170.	212.	256.	NA
10554	96.	118.	136.	145.	168.	NA	NA
10555	NA	152.	137.	166.	198.	248.	NA
MEAN	101.	133.	128.	123.	184.	256.	167.
S.D.	17.9	22.4	13.7	58.8	24.2	48.9	39.0
N	5	7	6	7	7	6	4

NA = NOT APPLICABLE

TABLE 140 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 2: 100 PPM								
10488	109.	134.	122.	160.	171.	252.	180.	
10493	64.	NA	99.	123.	138.	193.	143.	
10504	101.	141.	91.	151.	172.	251.	178.	
10510	130.	144.	93.	167.	208.	NA	NA	
10519	98.	94.	109.	160.	179.	209.	173.	
10522	99.	128.	131.	155.	207.	285.	205.	
10525	94.	77.	NA	145.	191.	253.	190.	
10528	102.	137.	144.	174.	231.	250.	201.	
10543	94.	129.	106.	112.	NA	NA	NA	TOTAL LITTER LOSS DAY 15
MEAN	99.	123.	112.	150.	187.	242.	181.	
S.D.	17.1	24.2	18.9	20.3	28.6	30.8	20.7	
N	9	8	8	9	8	7	7	

NA = NOT APPLICABLE

TABLE 140 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 3: 500 PPM								
10468	107.	142.	95.	139.	174.	230.	169.	
10478	109.	141.	111.	119.	141.	145.	137.	
10483	124.	132.	121.	157.	203.	300.	203.	
10484	106.	143.	136.	158.	232.	279.	206.	
10520	NA	NA	NA	NA	NA	NA	NA	TOTAL LITTER LOSS DAY 0
10530	100.	134.	113.	149.	208.	280.	200.	
10534	106.	124.	108.	144.	187.	275.	186.	
10546	102.	135.	104.	143.	172.	220.	166.	
10548	110.	130.	115.	165.	188.	243.	187.	
10550	93.	118.	114.	175.	198.	283.	204.	
MEAN	106.	133.	113.	150.	189.	251.	184.	
S.D.	8.4	8.4	11.4	16.3	25.8	47.9	23.1	
N	9	9	9	9	9	9	9	

NA = NOT APPLICABLE

TABLE 140 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

DAY	1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000 PPM							
10465	103.	104.	104.	148.	192.	235.	179.
10473	80.	106.	77.	124.	148.	196.	142.
10480	87.	146.	101.	146.	190.	276.	187.
10481	122.	129.	107.	134.	168.	230.	172.
10486	128.	136.	106.	155.	211.	NA	NA
10507	151.	187.	160.	146.	182.	226.	187.
10529	78.	79.	NA	97.	111.	113.	105.
10532	112.	95.	120.	149.	195.	255.	185.
10547	112.	127.	76.	152.	187.	234.	181.
MEAN	108.	123.	106.	139.	176.	221.	167.
S.D.	24.0	32.0	26.4	18.4	30.1	49.2	29.2
N	9	9	8	9	9	8	8

NA = NOT APPLICABLE

TABLE 141 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM							
10463	7.6	34.7	NA	5.9	-3.4	-5.9	0.6
10464	31.5	-25.0	15.9	11.8	-0.4	-10.9	-1.6
10506	3.0	5.9	1.6	36.9	-1.5	-4.0	2.3
10524	41.5	-9.5	-18.3	8.7	-3.1	-5.0	0.6
10540	NA	20.0	9.2	2.2	3.3	-5.7	NA
10554	22.4	2.4	6.2	5.3	-6.0	NA	NA
10555	NA	-13.0	0.0	10.5	-0.2	-13.2	NA
MEAN	21.2	2.2	2.4	11.6	-1.6	-7.5	0.5
S.D.	16.09	20.39	11.64	11.62	2.95	3.70	1.60
N	5	7	6	7	7	6	4

NA = NOT APPLICABLE

TABLE 141 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 2: 100 PPM								
10488	24.0	20.9	-15.6	9.5	-1.0	-12.8	-1.2	
10493	-3.8	NA	8.3	8.5	-2.9	-6.7	1.0	
10504	4.4	20.9	-5.4	10.7	-0.2	-6.7	0.5	
10510	9.1	-2.2	7.0	4.5	1.6	NA	NA	
10519	12.8	-23.3	-8.8	16.0	2.4	-5.9	2.5	
10522	17.5	11.1	17.3	11.6	-1.4	-7.0	1.3	
10525	13.9	50.0	NA	-2.3	11.9	-10.0	1.2	
10528	4.3	2.4	10.1	-6.5	12.1	-6.8	0.8	
10543	-7.7	22.2	3.4	0.9	NA	NA	NA	TOTAL LITTER LOSS DAY 15
MEAN	8.3	12.8	2.0	5.9	2.8	-8.0	0.9	
S.D.	10.11	21.52	11.00	7.29	5.91	2.49	1.11	
N	9	8	8	9	8	7	7	

NA = NOT APPLICABLE

TABLE 141 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28	
DAMS FROM GROUP 3: 500 PPM								
10468	16.2	2.1	-1.6	9.0	-4.6	-6.0	-0.3	
10478	9.8	38.1	-1.5	10.9	8.7	-9.7	4.2	
10483	26.2	-21.7	7.1	6.8	-0.9	-6.8	0.1	
10484	8.0	12.5	10.4	-17.0	19.1	-6.8	1.1	
10520	NA	NA	NA	NA	NA	NA	NA	TOTAL LITTER LOSS DAY 0
10530	-2.7	20.6	-3.5	8.9	3.8	-5.2	1.1	
10534	0.0	42.9	-9.7	5.1	0.5	-4.7	0.0	
10546	8.9	23.9	-7.0	7.9	1.1	-5.8	1.0	
10548	6.4	9.3	15.4	5.9	3.2	-11.7	-0.4	
10550	10.0	17.9	2.7	11.5	0.9	-5.6	1.7	
MEAN	9.2	16.2	1.4	5.4	3.5	-6.9	0.9	
S.D.	8.48	19.27	8.26	8.68	6.87	2.30	1.42	
N	9	9	9	9	9	9	9	

NA = NOT APPLICABLE

TABLE 141 (F0 FEMALES - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000 PPM							
10465	30.5	-48.5	0.0	11.9	1.5	-12.6	-0.4
10473	0.0	36.8	-8.9	6.3	2.5	-5.2	0.8
10480	27.2	29.3	0.0	-8.6	11.7	-4.6	1.8
10481	11.1	15.4	7.7	6.3	4.5	-6.5	1.7
10486	10.5	-9.1	21.7	5.9	-5.1	NA	NA
10507	11.9	8.6	2.0	8.9	-1.8	-5.1	1.2
10529	19.7	-4.0	NA	12.5	-3.0	-1.9	3.3
10532	33.6	-31.0	17.8	5.4	0.9	-9.5	0.4
10547	-7.8	18.6	-3.8	8.5	6.8	-4.2	2.1
MEAN	15.2	1.8	4.6	6.3	2.0	-6.2	1.4
S.D.	13.90	27.96	10.54	6.17	5.18	3.36	1.13
N	9	9	8	9	9	8	8

NA = NOT APPLICABLE

TABLE 142 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING LACTATION [G]

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485	274.	276.	273.	297.	320.	335.	281.
10491	320.	326.	326.	353.	371.	351.	327.
10496	325.	327.	348.	361.	370.	386.	335.
10498	308.	331.	326.	340.	347.	348.	328.
10512	279.	283.	291.	288.	342.	344.	290.
10514	308.	311.	319.	325.	356.	342.	307.
10521	298.	334.	326.	345.	375.	372.	317.
10537	319.	333.	329.	354.	383.	377.	339.
MEAN	304.	315.	317.	333.	358.	357.	316.
S.D.	19.0	23.2	23.8	27.3	20.9	18.7	21.2
N	8	8	8	8	8	8	8

TABLE 142 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS DURING LACTATION [G]

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487	285.	297.	296.	306.	346.	340.	310.
10492	323.	336.	346.	343.	386.	394.	358.
10495	334.	338.	339.	363.	383.	381.	334.
10499	329.	358.	345.	363.	388.	398.	321.
10515	318.	328.	330.	340.	390.	387.	334.
10516	305.	307.	311.	326.	349.	364.	325.
10552	306.	307.	322.	322.	364.	364.	336.
10556	284.	287.	286.	285.	333.	327.	271.
MEAN	311.	320.	322.	331.	367.	369.	324.
S.D.	18.9	24.0	22.5	27.0	22.4	25.6	25.4
N	8	8	8	8	8	8	8

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475	282.	309.	311.	311.	334.	311.	285.
10489	298.	303.	307.	308.	329.	340.	291.
10490	325.	357.	352.	357.	371.	355.	347.
10497	317.	335.	336.	336.	357.	347.	323.
10501	299.	296.	291.	313.	336.	344.	286.
10505	317.	333.	333.	326.	375.	368.	349.
10517	312.	323.	322.	322.	346.	355.	321.
10531	294.	325.	321.	329.	346.	348.	312.
10533	332.	335.	306.	267.	358.	353.	329.
10538	283.	290.	292.	298.	331.	339.	309.
MEAN	306.	321.	317.	317.	348.	346.	315.
S.D.	17.2	20.8	19.6	24.0	16.5	15.0	23.2
N	10	10	10	10	10	10	10

DAY	1	4	5	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466	305.	311.	316.	321.	343.	335.	306.
10469	268.	281.	292.	309.	324.	339.	311.
10477	322.	317.	324.	328.	369.	381.	334.
10502	296.	309.	303.	310.	338.	344.	327.
10526	313.	324.	326.	326.	305.	378.	315.
10527	274.	311.	308.	314.	338.	341.	299.
10541	282.	295.	296.	290.	319.	335.	300.
10542	289.	314.	321.	339.	365.	374.	345.
10544	271.	284.	293.	292.	317.	336.	282.
10545	307.	324.	326.	339.	351.	367.	316.
MEAN	293.	307.	311.	317.	337.	353.	314.
S.D.	18.8	15.3	13.8	17.2	21.0	19.4	18.4
N	10	10	10	10	10	10	10

TABLE 143 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485	2.	-3.	24.	23.	15.	-54.	7.
10491	6.	0.	27.	18.	-20.	-24.	7.
10496	2.	21.	13.	9.	16.	-51.	10.
10498	23.	-5.	14.	7.	1.	-20.	20.
10512	4.	8.	-3.	54.	2.	-54.	11.
10514	3.	8.	6.	31.	-14.	-35.	-1.
10521	36.	-8.	19.	30.	-3.	-55.	19.
10537	14.	-4.	25.	29.	-6.	-38.	20.
MEAN	11.	2.	16.	25.	-1.	-41.	12.
S.D.	12.4	9.6	10.3	14.9	12.6	14.2	7.6
N	8	8	8	8	8	8	8

TABLE 143 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487	12.	-1.	10.	40.	-6.	-30.	25.
10492	13.	10.	-3.	43.	8.	-36.	35.
10495	4.	1.	24.	20.	-2.	-47.	0.
10499	29.	-13.	18.	25.	10.	-77.	-8.
10515	10.	2.	10.	50.	-3.	-53.	16.
10516	2.	4.	15.	23.	15.	-39.	20.
10552	1.	15.	0.	42.	0.	-28.	30.
10556	3.	-1.	-1.	48.	-6.	-56.	-13.
MEAN	9.	2.	9.	36.	2.	-46.	13.
S.D.	9.3	8.3	9.8	11.9	7.9	16.2	18.0
N	8	8	8	8	8	8	8

TABLE 143 (F0 FEMALES - INHALATION/GAVAGE PHASE)
INDIVIDUAL BODY WEIGHT CHANGES DURING LACTATION [G]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475	27.	2.	0.	23.	-23.	-26.	3.
10489	5.	4.	1.	21.	11.	-49.	-7.
10490	32.	-5.	5.	14.	-16.	-8.	22.
10497	18.	1.	0.	21.	-10.	-24.	6.
10501	-3.	-5.	22.	23.	8.	-58.	-13.
10505	16.	0.	-7.	49.	-7.	-19.	32.
10517	11.	-1.	0.	24.	9.	-34.	9.
10531	31.	-4.	8.	17.	2.	-36.	18.
10533	3.	-29.	-39.	91.	-5.	-24.	-3.
10538	7.	2.	6.	33.	8.	-30.	26.
MEAN	15.	-4.	0.	32.	-2.	-31.	9.
S.D.	12.2	9.5	15.6	23.1	11.7	14.5	14.9
N	10	10	10	10	10	10	10

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466	6.	5.	5.	22.	-8.	-29.	1.
10469	13.	11.	17.	15.	15.	-28.	43.
10477	-5.	7.	4.	41.	12.	-47.	12.
10502	13.	-6.	7.	28.	6.	-17.	31.
10526	11.	2.	0.	-21.	73.	-63.	2.
10527	37.	-3.	6.	24.	3.	-42.	25.
10541	13.	1.	-6.	29.	16.	-35.	18.
10542	25.	7.	18.	26.	9.	-29.	56.
10544	13.	9.	-1.	25.	19.	-54.	11.
10545	17.	2.	13.	12.	16.	-51.	9.
MEAN	14.	4.	6.	20.	16.	-40.	21.
S.D.	11.0	5.3	7.8	16.5	21.5	14.3	18.0
N	10	10	10	10	10	10	10

TABLE 144 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485	23.	24.	37.	45.	56.	60.	48.
10491	30.	18.	52.	55.	59.	NA	NA
10496	29.	80.	NA	54.	67.	75.	62.
10498	33.	NA	36.	52.	62.	89.	61.
10512	31.	42.	33.	52.	68.	90.	62.
10514	25.	40.	43.	56.	62.	82.	59.
10521	34.	43.	NA	60.	71.	83.	66.
10537	32.	37.	49.	61.	74.	104.	70.
MEAN	30.	41.	42.	54.	65.	83.	61.
S.D.	3.9	19.8	7.6	5.0	6.2	13.7	6.8
N	8	7	6	8	8	7	7

NA = NOT APPLICABLE

TABLE 144 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487	30.	40.	42.	59.	NA	105.	68.
10492	25.	NA	45.	58.	52.	59.	52.
10495	NA	43.	52.	55.	70.	82.	NA
10499	37.	41.	51.	60.	69.	90.	66.
10515	54.	NA	37.	56.	66.	73.	61.
10516	28.	37.	42.	58.	71.	104.	68.
10552	36.	NA	46.	59.	77.	97.	71.
10556	30.	41.	29.	49.	67.	81.	58.
MEAN	34.	40.	43.	57.	67.	86.	63.
S.D.	9.7	2.2	7.5	3.5	7.7	15.9	6.7
N	7	5	8	8	7	8	7

NA = NOT APPLICABLE

TABLE 144 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/ANIMAL/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475	35.	43.	43.	55.	72.	92.	65.
10489	35.	37.	41.	48.	66.	80.	59.
10490	33.	39.	40.	46.	56.	NA	NA
10497	30.	38.	33.	47.	59.	84.	56.
10501	25.	33.	39.	52.	63.	80.	57.
10505	33.	46.	26.	50.	67.	81.	59.
10517	30.	44.	41.	53.	67.	78.	59.
10531	36.	42.	33.	56.	67.	NA	NA
10533	21.	21.	8.	38.	50.	74.	46.
10538	26.	30.	42.	52.	73.	96.	64.
MEAN	30.	37.	35.	50.	64.	83.	58.
S.D.	5.0	7.6	10.8	5.3	7.2	7.4	5.8
N	10	10	10	10	10	8	8

NA = NOT APPLICABLE

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466	27.	39.	42.	52.	69.	94.	63.
10469	22.	37.	33.	39.	55.	72.	49.
10477	33.	42.	39.	48.	65.	82.	59.
10502	18.	21.	25.	32.	35.	35.	31.
10526	31.	32.	39.	41.	70.	73.	55.
10527	44.	48.	41.	55.	71.	91.	66.
10541	35.	43.	40.	47.	66.	93.	62.
10542	27.	40.	39.	47.	62.	81.	57.
10544	30.	38.	34.	46.	67.	80.	57.
10545	33.	43.	47.	51.	74.	95.	66.
MEAN	30.	38.	38.	46.	63.	80.	57.
S.D.	7.2	7.4	6.0	6.8	11.3	17.8	10.4
N	10	10	10	10	10	10	10

TABLE 145 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485	84.	87.	130.	146.	171.	195.	163.
10491	93.	55.	153.	152.	163.	NA	NA
10496	89.	237.	NA	148.	177.	208.	177.
10498	103.	NA	108.	151.	178.	263.	183.
10512	110.	146.	114.	165.	198.	284.	205.
10514	81.	127.	134.	164.	178.	252.	182.
10521	108.	130.	NA	167.	190.	241.	195.
10537	98.	112.	143.	165.	195.	291.	201.
MEAN	96.	128.	130.	157.	181.	248.	187.
S.D.	10.8	57.0	17.0	8.8	12.1	36.2	14.7
N	8	7	6	8	8	7	7

NA = NOT APPLICABLE

TABLE 145 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

DAY	1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487	103.	135.	140.	181.	NA	323.	219.
10492	76.	NA	130.	159.	133.	157.	146.
10495	NA	127.	148.	147.	183.	229.	NA
10499	108.	116.	144.	160.	176.	250.	185.
10515	167.	NA	110.	153.	170.	202.	176.
10516	92.	120.	132.	172.	199.	301.	208.
10552	117.	NA	143.	172.	212.	277.	214.
10556	105.	143.	101.	159.	203.	271.	196.
MEAN	110.	128.	131.	163.	182.	251.	192.
S.D.	28.4	11.0	17.0	11.2	26.5	54.1	25.5
N	7	5	8	8	7	8	7

NA = NOT APPLICABLE

TABLE 145 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475	118.	139.	138.	170.	223.	309.	212.
10489	116.	121.	133.	150.	197.	253.	190.
10490	97.	110.	113.	126.	154.	NA	NA
10497	92.	113.	98.	135.	168.	251.	167.
10501	84.	112.	129.	160.	185.	254.	184.
10505	102.	138.	79.	142.	180.	226.	172.
10517	94.	136.	127.	159.	191.	231.	179.
10531	116.	130.	102.	166.	193.	NA	NA
10533	63.	65.	28.	121.	140.	217.	141.
10538	91.	103.	142.	165.	218.	296.	209.
MEAN	97.	117.	109.	149.	185.	255.	182.
S.D.	16.9	22.3	34.8	17.5	26.0	32.7	23.0
N	10	10	10	10	10	8	8

NA = NOT APPLICABLE

TABLE 145 (F0 FEMALES - INHALATION/GAVAGE PHASE)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL FOOD CONSUMPTION DURING LACTATION [G/KG/DAY]

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466	88.	124.	132.	157.	204.	293.	197.
10469	80.	129.	110.	123.	166.	222.	162.
10477	103.	131.	120.	138.	173.	229.	174.
10502	59.	69.	81.	99.	103.	104.	97.
10526	97.	98.	120.	130.	205.	210.	168.
10527	150.	155.	132.	169.	209.	284.	212.
10541	121.	145.	137.	154.	202.	292.	205.
10542	89.	126.	118.	134.	168.	225.	170.
10544	108.	131.	116.	151.	205.	259.	193.
10545	104.	132.	141.	148.	206.	278.	198.
MEAN	100.	124.	121.	140.	184.	240.	178.
S.D.	24.5	24.3	17.2	20.1	33.3	57.1	33.1
N	10	10	10	10	10	10	10

TABLE 146 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485	2.9	-12.5	32.9	7.2	3.8	-12.9	0.5
10491	6.7	0.0	26.0	4.7	-4.8	NA	NA
10496	2.3	26.3	NA	2.4	3.4	-9.7	0.6
10498	23.4	NA	19.7	1.9	0.2	-3.2	1.2
10512	4.3	19.0	-4.5	15.0	0.4	-8.6	0.7
10514	4.0	20.0	7.1	8.0	-3.2	-6.1	-0.1
10521	35.3	-18.6	NA	7.2	-0.6	-9.5	1.1
10537	14.7	-10.8	25.5	6.8	-1.2	-5.2	1.1
MEAN	11.7	3.3	17.8	6.7	-0.3	-7.9	0.7
S.D.	12.00	18.23	13.93	4.08	2.95	3.26	0.46
N	8	7	6	8	8	7	7

NA = NOT APPLICABLE

TABLE 146 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487	13.2	-2.5	11.9	9.6	NA	-4.1	1.4
10492	17.5	NA	-3.3	10.6	2.2	-8.7	2.5
10495	NA	2.3	23.1	5.2	-0.4	-8.2	NA
10499	26.3	-31.7	17.8	6.0	2.1	-12.3	-0.4
10515	6.2	NA	13.5	12.8	-0.7	-10.4	1.0
10516	2.4	10.8	17.9	5.7	3.0	-5.4	1.1
10552	0.9	NA	0.0	10.1	0.0	-4.1	1.6
10556	3.4	-2.4	-1.8	13.9	-1.3	-9.9	-0.8
MEAN	10.0	-4.7	9.9	9.2	0.7	-7.9	0.9
S.D.	9.41	16.03	10.19	3.30	1.69	3.06	1.15
N	7	5	8	8	7	8	7

NA = NOT APPLICABLE

TABLE 146 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475	25.9	4.7	0.0	5.9	-4.6	-4.1	0.2
10489	4.7	10.8	1.2	6.3	2.4	-8.8	-0.4
10490	32.0	-12.8	6.3	4.4	-4.1	NA	NA
10497	20.0	2.6	0.0	6.4	-2.4	-4.1	0.4
10501	-4.0	-15.2	28.2	6.3	1.8	-10.4	-0.8
10505	16.0	0.0	-13.5	14.0	-1.5	-3.4	2.0
10517	12.1	-2.3	0.0	6.5	1.9	-6.2	0.6
10531	28.5	-9.5	12.3	4.3	0.4	NA	NA
10533	4.8	-138.1	-260.0	34.5	-1.4	-4.6	-0.2
10538	8.9	6.7	7.1	9.1	1.6	-4.5	1.5
MEAN	14.9	-15.3	-21.8	9.8	-0.6	-5.8	0.4
S.D.	11.70	43.98	84.36	9.13	2.58	2.53	0.95
N	10	10	10	10	10	8	8

NA = NOT APPLICABLE

TABLE 146 (F0 FEMALES - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL FOOD EFFICIENCY DURING LACTATION

(BODY WEIGHT GAINED AS PER CENT OF FEED CONSUMED)

	DAY 1- 4	4- 5	5- 7	7-14	14-21	21-28	1-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466	7.4	12.8	6.0	6.1	-1.7	-4.4	0.1
10469	20.0	29.7	26.2	5.5	3.9	-5.5	3.2
10477	-5.1	16.7	5.2	12.3	2.6	-8.2	0.8
10502	23.7	-28.6	14.3	12.7	2.4	-6.9	3.7
10526	11.7	6.3	0.0	-7.4	15.0	-12.3	0.1
10527	28.2	-6.3	7.4	6.3	0.6	-6.6	1.4
10541	12.3	2.3	-7.5	8.9	3.5	-5.4	1.1
10542	30.5	17.5	23.1	7.9	2.1	-5.1	3.7
10544	14.3	23.7	-1.5	7.8	4.1	-9.6	0.7
10545	17.2	4.7	13.8	3.3	3.1	-7.6	0.5
MEAN	16.0	7.9	8.7	6.3	3.6	-7.2	1.5
S.D.	10.49	16.66	10.72	5.64	4.38	2.40	1.44
N	10	10	10	10	10	10	10

TABLE 147 (F0)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL REPRODUCTIVE PERFORMANCE

GROUP 1: 0 PPM

FEMALE NUMBER	FIRST MALE	DATE	SECOND MALE	DATE	DAYS PRE-COITUS	PREGNANCY STATUS
10463	10367	09/22/02			2	G
10464	10368	09/22/02			3	G
10485	10375	09/22/02			3	G
10491	10384	09/22/02			3	G
10494	10386	09/22/02			13	NG
10496	10387	09/22/02			9	G
10498	10390	09/22/02			2	G
10500	10394	09/22/02			1	NG
10503	10395	09/22/02			1	NG
10506	10399	09/22/02			2	G
10512	10402	09/22/02			2	G
10513	10415	09/22/02			4	NG
10514	10417	09/22/02			4	G
10521	10425	09/22/02			B	G
10524	10427	09/22/02			1	G
10536	10435	09/22/02			1	NG
10537	10439	09/22/02			2	G
10540	10442	09/22/02			5	G
10554	10451	09/22/02			3	G
10555	10458	09/22/02			3	G

G = GRAVID, NG = NONGRAVID, B = NO EVIDENCE OF MATING

GROUP 2: 100 PPM

FEMALE NUMBER	FIRST MALE	DATE	SECOND MALE	DATE	DAYS PRE-COITUS	PREGNANCY STATUS
10470	10372	09/22/02			2	NG
10472	10378	09/22/02			2	NG
10487	10379	09/22/02			2	G
10488	10383	09/22/02			1	G
10492	10389	09/22/02			2	G
10493	10404	09/22/02			B	G
10495	10405	09/22/02			5	G
10499	10406	09/22/02			1	G
10504	10411	09/22/02			2	G
10510	10414	09/22/02			3	G
10515	10419	09/22/02			2	G
10516	10422	09/22/02			4	G
10519	10431	09/22/02			4	G
10522	10432	09/22/02			2	G
10525	10438	09/22/02			4	G
10528	10440	09/22/02			4	G
10543	10443	09/22/02			2	G
10552	10455	09/22/02			4	G
10553	10460	09/22/02			5	NG
10556	10461	09/22/02			1	G

G = GRAVID, NG = NONGRAVID, NA = NOT APPLICABLE, B = NO EVIDENCE OF MATING

TABLE 147 (F0)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL REPRODUCTIVE PERFORMANCE

GROUP 3: 500 PPM

FEMALE NUMBER	FIRST MALE	DATE	SECOND MALE	DATE	DAYS PRE-COITUS	PREGNANCY STATUS
10468	10369	09/22/02			5	G
10475	10370	09/22/02			1	G
10478	10377	09/22/02			3	G
10483	10380	09/22/02			2	G
10484	10381	09/22/02			4	G
10489	10382	09/22/02			13	G
10490	10385	09/22/02			3	G
10497	10391	09/22/02			B	G
10501	10392	09/22/02			4	G
10505	10396	09/22/02			2	G
10517	10400	09/22/02			2	G
10520	10407	09/22/02			3	G
10530	10410	09/22/02			1	G
10531	10421	09/22/02			2	G
10533	10423	09/22/02			3	G
10534	10429	09/22/02			2	G
10538	10437	09/22/02			4	G
10546	10445	09/22/02			2	G
10548	10453	09/22/02			2	G
10550	10454	09/22/02			2	G

G = GRAVID, B = NO EVIDENCE OF MATING

GROUP 4: 1000 PPM

FEMALE NUMBER	FIRST MALE	DATE	SECOND MALE	DATE	DAYS PRE-COITUS	PREGNANCY STATUS
10465	10373	09/22/02			3	G
10466	10374	09/22/02			5	G
10469	10376	09/22/02			3	G
10473	10397	09/22/02			6	G
10477	10398	09/22/02			2	G
10480	10403	09/22/02			2	G
10481	10409	09/22/02			1	G
10486	10412	09/22/02			3	G
10502	10416	09/22/02			1	G
10507	10418	09/22/02			2	G
10511	10420	09/22/02			B	NG
10526	10428	09/22/02			1	G
10527	10430	09/22/02			1	G
10529	10434	09/22/02			2	G
10532	10444	09/22/02			3	G
10541	10447	09/22/02			2	G
10542	10448	09/22/02			2	G
10544	10449	09/22/02			3	G
10545	10452	09/22/02			1	G
10547	10459	09/22/02			2	G

G = GRAVID, NG = NONGRAVID, B = NO EVIDENCE OF MATING

TABLE 148 (F0 FEMALES)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL GESTATION LENGTHS [DAYS]

0 PPM		100 PPM		500 PPM		1000 PPM	
ANIMAL	GESTATION LENGTH	ANIMAL	GESTATION LENGTH	ANIMAL	GESTATION LENGTH	ANIMAL	GESTATION LENGTH
10463	22.	10487	22.	10468	22.	10465	22.
10464	22.	10488	21.	10475	22.	10466	22.
10485	22.	10492	21.	10478	22.	10469	21.
10491	22.	10495	22.	10483	22.	10473	22.
10496	22.	10499	22.	10484	22.	10477	22.
10498	22.	10504	22.	10489	22.	10480	22.
10506	23.	10510	22.	10490	22.	10481	22.
10512	22.	10515	22.	10501	22.	10486	22.
10514	22.	10516	22.	10505	22.	10502	22.
10524	22.	10519	21.	10517	22.	10507	21.
10537	22.	10522	21.	10520	22.	10526	21.
10540	22.	10525	22.	10530	22.	10527	22.
10554	22.	10528	22.	10531	22.	10529	22.
10555	22.	10543	22.	10533	22.	10532	22.
		10552	22.	10534	22.	10541	22.
		10556	22.	10538	22.	10542	22.
				10546	21.	10544	22.
				10548	21.	10545	22.
				10550	22.	10547	22.
MEAN	22.1		21.8		21.9		21.8
S.D.	0.27		0.45		0.32		0.37
N	14		16		19		19

TABLE 149 (F0 FEMALES)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL IMPLANTATION SITES

0 PPM

DAM NO.	IMPLANTATION SITES	PUPS BORN	UNACCOUNTED SITES
10463	19	19	0
10464	16	14	2
10485	15	12	3
10491	12	7	5
10496	20	19	1
10498	16	15	1
10506	11	6	5
10512	15	14	1
10514	16	16	0
10521	19	18	1
10524	14	14	0
10537	16	16	0
10540	17	17	0
10554	17	12	5
10555	16	16	0
MEAN	15.9	14.3	1.6
S.D.	2.43	3.85	1.96
N	15	15	15

NOTE: ONLY DAMS THAT HAVE DELIVERED ONE OR MORE PUPS ARE INCLUDED IN CALCULATION OF MEAN.

TABLE 149 (F0 FEMALES)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL IMPLANTATION SITES

100 PPM

DAM NO.	IMPLANTATION SITES	PUPS BORN	UNACCOUNTED SITES
10487	15	12	3
10488	13	13	0
10492	17	17	0
10493	14	14	0
10495	19	19	0
10499	14	14	0
10504	15	13	2
10510	16	15	1
10515	15	15	0
10516	14	13	1
10519	18	18	0
10522	16	15	1
10525	15	14	1
10528	17	15	2
10543	14	13	1
10552	16	15	1
10556	15	15	0
MEAN	15.5	14.7	0.8
S.D.	1.59	1.86	0.90
N	17	17	17

NOTE: ONLY DAMS THAT HAVE DELIVERED ONE OR MORE PUPS ARE INCLUDED IN CALCULATION OF MEAN.

INDIVIDUAL IMPLANTATION SITES

500 PPM

DAM NO.	IMPLANTATION SITES	PUPS BORN	UNACCOUNTED SITES
10468	18	18	0
10475	14	13	1
10478	18	18	0
10483	16	15	1
10484	15	14	1
10489	17	17	0
10490	16	15	1
10497	17	17	0
10501	15	14	1
10505	18	18	0
10517	15	14	1
10520	15	5	10
10530	14	14	0
10531	16	15	1
10533	6	6	0
10534	13	12	1
10538	15	13	2
10546	17	15	2
10548	17	17	0
10550	21	21	0
MEAN	15.7	14.6	1.1
S.D.	2.91	3.79	2.20
N	20	20	20

NOTE: ONLY DAMS THAT HAVE DELIVERED ONE OR MORE PUPS ARE INCLUDED IN CALCULATION OF MEAN.

INDIVIDUAL IMPLANTATION SITES

1000 PPM

DAM NO.	IMPLANTATION SITES	PUPS BORN	UNACCOUNTED SITES
10465	10	10	0
10466	18	16	2
10469	17	16	1
10473	17	11	6
10477	19	18	1
10480	13	12	1
10481	13	13	0
10486	17	16	1
10502	16	14	2
10507	15	15	0
10526	16	16	0
10527	18	15	3
10529	14	13	1
10532	14	13	1
10541	14	14	0
10542	13	13	0
10544	15	15	0
10545	18	17	1
10547	17	17	0
MEAN	15.5	14.4	1.1
S.D.	2.32	2.14	1.47
N	19	19	19

NOTE: ONLY DAMS THAT HAVE DELIVERED ONE OR MORE PUPS ARE INCLUDED IN CALCULATION OF MEAN.

TABLE 150 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL LITTER VIABILITY

LITTERS FROM GROUP 1: 0 PPM

DAM #	NO. DEAD DAY 0 M	F	U	NO. VIABLE DAY 0 M	%	F	%	TOTAL	NUMBER OF VIABLE PUPS DAY 1 M	F	BEFORE SELECTION DAY 4 M	F	AFTER SELECTION DAY 4 M	F	DAY 7 M	F	DAY 14 M	F	DAY 21 M	F
10463	0	0	0	9/ 9	100	10/10	100	19	9	10	9	10	5	5	5	5	5	5	5	5
10464	0	0	0	9/ 9	100	5/ 5	100	14	9	5	9	5	5	5	5	5	5	5	5	5
10506	0	0	0	1/ 1	100	5/ 5	100	6	1	5	1	5	1	5	1	5	1	5	1	5
10524	0	0	0	8/ 8	100	6/ 6	100	14	8	6	8	6	5	5	5	5	5	5	5	5
10540	0	0	0	12/12	100	5/ 5	100	17	12	5	12	5	5	5	5	5	5	5	5	5
10554	0	0	0	5/ 5	100	7/ 7	100	12	5	7	5	7	5	5	5	5	5	5	5	5
10555	1	0	0	10/11	91	5/ 5	100	15	10	5	10	5	5	5	5	5	5	5	5	5
TOTAL	1	0	0	54/ 55		43/ 43		97	54	43	54	43	31	35	31	35	31	35	31	35

M = MALE, F = FEMALE, U = UNDETERMINED

LITTERS FROM GROUP 2: 100 PPM

DAM #	NO. DEAD DAY 0 M	F	U	NO. VIABLE DAY 0 M	%	F	%	TOTAL	NUMBER OF VIABLE PUPS DAY 1 M	F	BEFORE SELECTION DAY 4 M	F	AFTER SELECTION DAY 4 M	F	DAY 7 M	F	DAY 14 M	F	DAY 21 M	F
10488	0	0	0	7/ 7	100	6/ 6	100	13	7	6	7	6	5	5	5	5	5	5	5	5
10493	0	0	0	5/ 5	100	9/ 9	100	14	3	8	1	5	1	5	1	5	1	5	1	5
10504	0	0	0	4/ 4	100	9/ 9	100	13	4	9	4	9	4	6	4	6	4	6	4	6
10510	0	0	0	9/ 9	100	6/ 6	100	15	9	6	8	6	5	5	5	5	5	5	5	5
10519	0	1	1	9/ 9	100	7/ 8	88	16	9	7	9	7	5	5	5	5	5	5	5	5
10522	0	0	0	8/ 8	100	7/ 7	100	15	8	7	8	7	5	5	5	5	5	5	5	5
10525	0	0	0	5/ 5	100	9/ 9	100	14	5	9	5	9	5	5	5	5	5	5	5	5
10528	0	0	0	8/ 8	100	7/ 7	100	15	8	7	8	7	5	5	5	5	5	5	5	5
10543	0	0	0	7/ 7	100	6/ 6	100	13	7	6	7	6	5	5	5	5	0	1	0	0
TOTAL	0	1	1	62/ 62		66/ 67		128	60	65	57	62	40	46	40	46	35	42	35	41

M = MALE, F = FEMALE, U = UNDETERMINED

LITTERS FROM GROUP 3: 500 PPM

DAM #	NO. DEAD DAY 0 M	F	U	NO. VIABLE DAY 0 M	%	F	%	TOTAL	NUMBER OF VIABLE PUPS DAY 1 M	F	BEFORE SELECTION DAY 4 M	F	AFTER SELECTION DAY 4 M	F	DAY 7 M	F	DAY 14 M	F	DAY 21 M	F
10468	0	0	0	8/ 8	100	10/10	100	18	8	10	8	10	5	5	5	5	5	5	5	5
10478	1	2	0	5/ 6	83	10/12	83	15	5	10	5	10	5	5	5	5	3	5	3	5
10483	0	0	0	3/ 3	100	12/12	100	15	3	12	3	12	3	7	3	7	3	7	3	7
10484	0	0	0	11/11	100	3/ 3	100	14	11	3	11	3	7	3	7	3	7	3	7	3
10520	1	0	4	0/ 1	0	0/ 0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10530	0	1	0	3/ 3	100	10/11	91	13	3	10	3	10	3	7	3	7	3	7	3	7
10534	0	0	0	5/ 5	100	7/ 7	100	12	5	7	5	7	5	5	5	5	5	5	5	5
10546	0	0	0	9/ 9	100	6/ 6	100	15	9	6	8	6	5	5	5	5	5	5	5	4
10548	0	0	0	11/11	100	6/ 6	100	17	11	6	11	6	5	5	5	5	5	5	5	5
10550	0	1	0	14/14	100	6/ 7	86	20	14	6	14	6	5	5	5	5	5	5	5	5
TOTAL	2	4	4	69/ 71		70/ 74		139	69	70	68	70	43	47	43	47	41	47	41	46

M = MALE, F = FEMALE, U = UNDETERMINED

LITTERS FROM GROUP 4: 1000 PPM

	NO. DEAD DAY 0			NO. VIABLE DAY 0					NUMBER OF VIABLE PUPS											
									DAY 1		BEFORE SELECTION DAY 4		AFTER SELECTION DAY 4		DAY 7		DAY 14		DAY 21	
DAM #	M	F	U	M	%	F	%	TOTAL	M	F	M	F	M	F	M	F	M	F	M	F
10465	0	0	0	5/ 5	100	5/ 5	100	10	5	5	5	5	5	5	5	5	5	5	5	5
10473	1	0	0	4/ 5	80	6/ 6	100	10	3	5	3	4	3	4	3	4	3	4	3	4
10480	1	0	0	8/ 9	89	3/ 3	100	11	8	3	8	3	7	3	7	3	7	3	7	3
10481	0	0	0	9/ 9	100	4/ 4	100	13	9	4	9	4	6	4	6	4	6	4	6	4
10486	0	0	0	9/ 9	100	7/ 7	100	16	8	7	8	7	5	5	5	4	5	4	5	4
10507	0	0	0	7/ 7	100	8/ 8	100	15	7	8	7	8	5	5	5	5	5	5	5	5
10529	3	2	0	6/ 9	67	2/ 4	50	8	3	0	3	0	3	0	3	0	3	0	3	0
10532	0	0	0	5/ 5	100	8/ 8	100	13	5	6	5	6	5	5	5	4	5	4	5	4
10547	0	0	0	12/12	100	5/ 5	100	17	12	5	12	5	5	5	5	4	5	4	5	4
TOTAL	5	2	0	65/ 70		48/ 50		113	60	43	60	42	44	36	44	33	44	33	44	33

M = MALE, F = FEMALE, U = UNDETERMINED

PPLVv4.0
02/12/2003

TABLE 151 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 1: 0 PPM

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
10463	16-OCT-02	a28	e28	C	a28	C	C	b21	a28	C	C	C	e28	b21	C	a28	C	a28	C	a28		
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F		
10464	17-OCT-02	C	a28	C	C	C	e28	a28	b21	a28	b21	a28	a28	a28	e28							
		M	M	M	M	M	M	M	M	M	F	F	F	F	F							
10506	17-OCT-02	b21	a28	a28	a28	b21	e28															
		M	F	F	F	F	F															
10524	15-OCT-02	e28	a28	C	C	a28	C	b21	a28	b21	a28	a28	a28	C	e28							
		M	M	M	M	M	M	M	M	F	F	F	F	F	F							
10540	19-OCT-02	C	C	C	b21	b21	C	C	C	a28	C	e28	a28	a28	a28	a28	a28	e28				
		M	M	M	M	F	M	M	M	M	M	M	M	M	F	F	F	F				
10554	17-OCT-02	e28	a28	b21	a28	a28	a28	e28	b21	a28	C	a28	C									
		M	M	M	M	M	F	F	F	F	F	F	F									
10555	17-OCT-02	0	C	C	e28	a28	a28	a28	C	C	b21	C	a28	a28	a28	b21	e28					
		M	M	M	M	M	M	M	M	M	M	M	F	F	F	F	F					

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; PND 22-33
e=SELECTED FOR EXPOSURE; PND 29-33

TABLE 151 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 2: 100 PPM

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
10488	14-OCT-02	a28	a28	e28	C	a28	b21	C	C	b21	e28	a28	a28	a28								
		M	M	M	M	M	M	M	F	F	F	F	F	F								
10493	21-OCT-02	1	2	2	e28	a28	2	b21	2	e28	a28	1	2	a28	1							
		M	M	M	M	F	F	F	F	F	F	F	F	F	M							
10504	16-OCT-02	a28	b21	a28	e28	a28	a28	a28	C	C	e28	b21	a28	C								
		M	M	M	M	F	F	F	F	F	F	F	F	F								
10510	17-OCT-02	e28	b21	a28	a28	4	C	C	C	a28	a28	e28	a28	a28	b21	C						
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F						
10519	17-OCT-02	0	0	a28	b21	C	C	C	e28	a28	C	a28	a28	e28	a28	b21	a28	C	C			
		F	U	M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F			
10522	15-OCT-02	e28	b21	a28	a28	C	C	C	a28	a28	C	C	e28	a28	b21	a28						
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F						
10525	18-OCT-02	e28	a28	C	b21	a28	a28	b21	C	a28	a28	a28	C	C	e28							
		M	M	F	M	M	M	F	F	F	F	F	F	F	F							
10528	18-OCT-02	a28	e28	a28	C	C	b21	C	a28	e28	a28	b21	C	a28	C	a28						
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F						
10543	16-OCT-02	11	11	11	11	C	11	C	13	11	12	12	C	15								
		M	M	M	M	M	M	M	F	F	F	F	F	F								

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; PND 22-33
e=SELECTED FOR EXPOSURE; PND 29-33

TABLE 151 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 3: 500 PPM

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
10468	19-OCT-02	C	b21	C	e28	a28	C	a28	a28	C	C	b21	a28	C	C	a28	e28	a28	C			
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F			
10478	17-OCT-02	0	0	0	a28	11	11	b21	e28	e28	b21	C	C	C	a28	C	a28	a28	C			
		M	F	F	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F			
10483	16-OCT-02	a28	b21	e28	C	b21	a28	a28	a28	a28	C	C	C	e28	C	a28						
		M	M	M	F	F	F	F	F	F	F	F	F	F	F	F						
10484	18-OCT-02	b21	C	a28	C	a28	a28	a28	a28	e28	C	C	a28	e28	b21							
		M	M	M	M	M	M	M	M	M	M	M	F	F	F							
10520	17-OCT-02	0	0	0	0	0																
		M	U	U	U	U																
10530	15-OCT-02	0	a28	b21	e28	a28	C	b21	e28	a28	a28	C	a28	C	a28							
		F	M	M	M	F	F	F	F	F	F	F	F	F	F							
10534	16-OCT-02	a28	e28	b21	a28	a28	b21	C	e28	C	a28	a28	a28									
		M	M	M	M	F	F	F	F	F	M	F	F									
10546	15-OCT-02	b21	C	a28	a28	e28	C	C	2	a28	a28	b21	e28	C	21	a28						
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F						
10548	15-OCT-02	C	e28	a28	a28	C	C	b21	a28	C	C	C	a28	a28	C	a28	e28	b21				
		M	M	M	M	M	M	M	M	M	M	M	F	F	F	F	F	F				

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; PND 22-33
e=SELECTED FOR EXPOSURE; PND 29-33

TABLE 151 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 3: 500 PPM

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
10550	16-OCT-02	0	a28	C	a28	C	C	C	C	C	a28	C	b21	C	e28	C	C	e28	a28	a28	b21	a28
		F	M	M	M	M	M	M	M	M	M	M	M	M	M	M	F	F	F	F	F	F

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; PND 22-33
e=SELECTED FOR EXPOSURE; PND 29-33

LITTERS FROM GROUP 4: 1000 PPM

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
10465	17-OCT-02	b21	e28	a28	a28	a28	a28	e28	a28	b21	a28											
		M	M	M	M	M	F	F	F	F	F											
10473	20-OCT-02	0	1	e28	a28	b21	b21	a28	1	a28	e28	3										
		M	M	M	M	M	F	F	F	F	F	F										
10480	16-OCT-02	0	a28	a28	e28	a28	C	a28	e28	b21	a28	a28	b21									
		M	M	M	M	M	M	M	F	M	F	M	F									
10481	15-OCT-02	a28	a28	a28	C	a28	e28	b21	C	C	e28	b21	a28	a28								
		M	M	M	M	M	M	M	M	M	F	F	F	F								
10486	17-OCT-02	b21	a28	a28	C	C	1	a28	C	e28	C	e28	a28	a28	C	b21	5					
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F					
10507	15-OCT-02	b21	a28	e28	a28	a28	C	C	a28	C	a28	C	e28	a28	C	b21						
		M	M	M	M	M	M	M	F	F	F	F	F	F	F	F						
10529	16-OCT-02	e28	0	1	b21	1	a28	1	0	0	1	0	1	0								
		M	M	M	M	M	M	M	M	M	F	F	F	F								
10532	17-OCT-02	b21	a28	a28	e28	a28	1	e28	b21	1	a28	C	5	a28								
		M	M	M	M	M	F	F	F	F	F	F	F	F								
10547	16-OCT-02	a28	e28	C	C	b21	C	C	a28	a28	6	a28	e28	b21	a28	C	C	C				
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	M	M	M				

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; PND 22-33
e=SELECTED FOR EXPOSURE; PND 29-33

TABLE 152 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10463	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SELECTED FOR EXPOSURE; PND 22-33	21
	8	M	SCHEDULED EUTHANASIA	28
	9	M	CULLED ON SCHEDULED DAY	4
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SELECTED FOR EXPOSURE; PND 22-33	21
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
	16	F	CULLED ON SCHEDULED DAY	4
	17	F	SCHEDULED EUTHANASIA	28
	18	F	CULLED ON SCHEDULED DAY	4
	19	F	SCHEDULED EUTHANASIA	28
10464	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SELECTED FOR EXPOSURE; PND 29-33	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10464	9	M	SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SELECTED FOR EXPOSURE; PND 29-33	28
10506	1	M	PALE IN COLOR	0
			SELECTED FOR EXPOSURE; PND 22-33	21
	2	F	SCHEDULED EUTHANASIA	28
	3	F	SCHEDULED EUTHANASIA	28
	4	F	SCHEDULED EUTHANASIA	28
	5	F	SELECTED FOR EXPOSURE; PND 22-33	21
	6	F	SMALL IN SIZE	21
			DRIED YELLOW MATERIAL	28
			UROGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 29-33	28
10524	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SCHEDULED EUTHANASIA	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SELECTED FOR EXPOSURE; PND 22-33	21
	8	M	SCHEDULED EUTHANASIA	28
	9	F	SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10524	11	F	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SELECTED FOR EXPOSURE; PND 29-33	28
10540	1	M	SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	0
			SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	1
			SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	4
			CULLED ON SCHEDULED DAY	4
	2	M	SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	0
			SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	1
			CULLED ON SCHEDULED DAY	4
	3	M	SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	0
			CULLED ON SCHEDULED DAY	4
	4	M	SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	0
			SELECTED FOR EXPOSURE; PND 22-33	21
	5	F	SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	0
			SUBCUTANEOUS HEMORRHAGE(S) DORSAL THORACIC AREA	1
			SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10540	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	SCHEDULED EUTHANASIA	28
	10	M	CULLED ON SCHEDULED DAY	4
	11	M	SELECTED FOR EXPOSURE; PND 29-33	28
	12	M	SCHEDULED EUTHANASIA	28
	13	M	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SCHEDULED EUTHANASIA	28
	16	F	SCHEDULED EUTHANASIA	28
	17	F	SELECTED FOR EXPOSURE; PND 29-33	28
10554	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	6	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	7	F	SELECTED FOR EXPOSURE; PND 29-33	28
	8	F	SELECTED FOR EXPOSURE; PND 22-33	21
	9	F	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10554	12	F	CULLED ON SCHEDULED DAY	4
10555	1	M	FOUND DEAD	0
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SCHEDULED EUTHANASIA	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	CULLED ON SCHEDULED DAY	4
	10	M	SELECTED FOR EXPOSURE; PND 22-33	21
	11	M	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
	16	F	DRIED RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10488	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	M	CULLED ON SCHEDULED DAY	4
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
10493	1	M	FOUND DEAD	1
	2	M	FOUND DEAD PARTIALLY CANNIBALIZED	2
	3	M	FOUND DEAD PARTIALLY CANNIBALIZED	2
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	F	SCHEDULED EUTHANASIA	28
	6	F	MISSING	2
	7	F	SELECTED FOR EXPOSURE; PND 22-33	21
	8	F	FOUND DEAD PARTIALLY CANNIBALIZED	2
	9	F	SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	FOUND DEAD	1

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10493	12	F	FOUND DEAD	2
	13	F	SCHEDULED EUTHANASIA	28
	14	M	FOUND DEAD	1
10504	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	F	SCHEDULED EUTHANASIA	28
	6	F	SCHEDULED EUTHANASIA	28
	7	F	SCHEDULED EUTHANASIA	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
10510	1	M	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH DORSAL HEAD	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH	21
			UNEVEN HAIR GROWTH	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10510	3	M	SCHEDULED EUTHANASIA	28
	4	M	UNEVEN HAIR GROWTH	14
			SCHEDULED EUTHANASIA	28
	5	M	FOUND DEAD	4
	6	M	SUBCUTANEOUS HEMORRHAGE(S)	1
			LEFT LATERAL SIDE	
			CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	UNEVEN HAIR GROWTH	14
			DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			UNEVEN HAIR GROWTH	21
			DRIED RED MATERIAL	21
			ANOGENITAL AREA	
			UNEVEN HAIR GROWTH	28
			DRIED RED MATERIAL	28
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	10	F	UNEVEN HAIR GROWTH	14
			DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	11	F	UNEVEN HAIR GROWTH	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	12	F	UNEVEN HAIR GROWTH	14
			SCHEDULED EUTHANASIA	28
	13	F	UNEVEN HAIR GROWTH	14

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10510	13	F	SCHEDULED EUTHANASIA	28
			UNEVEN HAIR GROWTH	28
			DORSAL HEAD	
	14	F	UNEVEN HAIR GROWTH	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	15	F	CULLED ON SCHEDULED DAY	4
10519	1	F	EUTHANIZED IN EXTREMIS	0
			PARTIALLY CANNIBALIZED	
	2	U	FOUND DEAD	0
			PARTIALLY CANNIBALIZED	
	3	M	SUBCUTANEOUS HEMORRHAGE(S)	1
			MANDIBULAR AREA	
			SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SELECTED FOR EXPOSURE; PND 29-33	28
	9	M	SCHEDULED EUTHANASIA	28
	10	M	CULLED ON SCHEDULED DAY	4
	11	M	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SMALL IN SIZE	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SCABBING	14
			ANOGENITAL AREA	

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10519	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
	16	F	SCHEDULED EUTHANASIA	28
	17	F	CULLED ON SCHEDULED DAY	4
	18	F	CULLED ON SCHEDULED DAY	4
10522	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SCHEDULED EUTHANASIA	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SELECTED FOR EXPOSURE; PND 22-33	21
	15	F	SCHEDULED EUTHANASIA	28
10525	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SCHEDULED EUTHANASIA	28
	3	F	CULLED ON SCHEDULED DAY	4
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SCHEDULED EUTHANASIA	28
	7	F	SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10525	8	F	CULLED ON SCHEDULED DAY	4
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SELECTED FOR EXPOSURE; PND 29-33	28
10528	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SCHEDULED EUTHANASIA	28
	9	F	SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SCABBING	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10543	1	M	FOUND DEAD	11
	2	M	FOUND DEAD	11
	3	M	FOUND DEAD	11
	4	M	FOUND DEAD	11
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	FOUND DEAD	11
	7	M	CULLED ON SCHEDULED DAY	4
	8	F	FOUND DEAD	13
	9	F	FOUND DEAD	11
	10	F	FOUND DEAD	12
	11	F	FOUND DEAD	12
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	BODY COOL TO TOUCH	14
			FOUND DEAD	15

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10468	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SCHEDULED EUTHANASIA	28
	8	M	SCHEDULED EUTHANASIA	28
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
	16	F	SELECTED FOR EXPOSURE; PND 29-33	28
	17	F	SCHEDULED EUTHANASIA	28
	18	F	CULLED ON SCHEDULED DAY	4
10478	1	M	FOUND DEAD	0
	2	F	FOUND DEAD	0
	3	F	FOUND DEAD	0
	4	M	SMALL IN SIZE	14
			SCHEDULED EUTHANASIA	28
	5	M	MISSING	11
	6	M	FOUND DEAD	11
	7	M	SMALL IN SIZE	14
			SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10478	8	M	SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	SMALL IN SIZE	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SMALL IN SIZE	14
			SMALL IN SIZE	21
			SCABBING OVER RIGHT EYE	21
			SCABBING OVER LEFT EYE	21
			EXOPHTHALMUS	21
			LEFT EYE	
			UNEVEN HAIR GROWTH	28
			EXOPHTHALMUS	28
			LEFT EYE	
			SCABBING OVER RIGHT EYE	28
			SCABBING OVER LEFT EYE	28
			SCHEDULED EUTHANASIA	28
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SMALL IN SIZE	14
			SMALL IN SIZE	21
			SMALL IN SIZE	28
			UNEVEN HAIR GROWTH	28
			SCHEDULED EUTHANASIA	28
	17	F	SMALL IN SIZE	14
			UNEVEN HAIR GROWTH	28
			DORSAL HEAD	

TABLE 152 (F1 - INHALATION PHASE)

INDIVIDUAL PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10478	17	F	SCHEDULED EUTHANASIA	28
	18	F	CULLED ON SCHEDULED DAY	4
10483	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	F	CULLED ON SCHEDULED DAY	4
	5	F	SELECTED FOR EXPOSURE; PND 22-33	21
	6	F	SCHEDULED EUTHANASIA	28
	7	F	SCHEDULED EUTHANASIA	28
	8	F	SCHEDULED EUTHANASIA	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SELECTED FOR EXPOSURE; PND 29-33	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
10484	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	SCHEDULED EUTHANASIA	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SCHEDULED EUTHANASIA	28
	7	M	DRIED RED MATERIAL AROUND NOSE	21
			SCHEDULED EUTHANASIA	28
	8	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10484	9	M	SELECTED FOR EXPOSURE; PND 29-33	28
	10	M	CULLED ON SCHEDULED DAY	4
	11	M	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SELECTED FOR EXPOSURE; PND 29-33	28
	14	F	SELECTED FOR EXPOSURE; PND 22-33	21
10520	1	M	FOUND DEAD PARTIALLY CANNIBALIZED	0
	2	U	FOUND DEAD PARTIALLY CANNIBALIZED	0
	3	U	FOUND DEAD PARTIALLY CANNIBALIZED	0
	4	U	FOUND DEAD PARTIALLY CANNIBALIZED	0
	5	U	FOUND DEAD PARTIALLY CANNIBALIZED	0
10530	1	F	FOUND DEAD	0
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	F	SCHEDULED EUTHANASIA	28
	6	F	CULLED ON SCHEDULED DAY	4
	7	F	SELECTED FOR EXPOSURE; PND 22-33	21
	8	F	SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10530	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SCHEDULED EUTHANASIA	28
10534	1	M	SCABBING	14
			DISTAL END OF TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			SCABBING	21
			DISTAL END OF TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	21
			SCHEDULED EUTHANASIA	28
	2	M	SMALL IN SIZE	14
			TAIL SKIN FLAKY IN APPEARANCE	14
			RING-LIKE INDENTATIONS ON TAIL	21
			SMALL IN SIZE	21
			BLACKENED AREA DISTAL END OF TAIL	21
			RING-LIKE INDENTATIONS ON TAIL	28
			SMALL IN SIZE	28
			BLACKENED AREA DISTAL END OF TAIL	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCABBING	14
			VENTRAL TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			BLACKENED AREA DISTAL END OF TAIL	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SCABBING	14
			VENTRAL TAIL	

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10534	4	M	TAIL SKIN FLAKY IN APPEARANCE	14
			SCABBING	21
			VENTRAL TAIL	
			RING-LIKE INDENTATIONS ON TAIL	21
			SCABBING	28
			VENTRAL TAIL	
			RING-LIKE INDENTATIONS ON TAIL	28
			SCHEDULED EUTHANASIA	28
	5	F	TAIL SKIN FLAKY IN APPEARANCE	14
			BLACKENED AREA DISTAL END OF TAIL	14
			BLACKENED AREA DISTAL END OF TAIL	21
			SCHEDULED EUTHANASIA	28
	6	F	SCABBING	14
			VENTRAL TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			BLACKENED AREA DISTAL END OF TAIL	14
			RING-LIKE INDENTATIONS ON TAIL	21
			SCABBING	21
			TAIL	
			BLACKENED AREA DISTAL END OF TAIL	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	7	F	CULLED ON SCHEDULED DAY	4
	8	F	TAIL SKIN FLAKY IN APPEARANCE	14
			RING-LIKE INDENTATIONS ON TAIL	21
			BLACKENED AREA DISTAL END OF TAIL	21
			RING-LIKE INDENTATIONS ON TAIL	28
			DISTAL END OF TAIL MISSING	28
			SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10534	8	F	SCABBING	14
			VENTRAL TAIL	
	9	F	CULLED ON SCHEDULED DAY	4
	10	M	SCABBING	14
			VENTRAL TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			DARK RED IN COLOR DISTAL END OF TAIL	21
			DARK RED IN COLOR DISTAL END OF TAIL	28
			SCHEDULED EUTHANASIA	28
	11	F	SCABBING	14
			VENTRAL TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			BLACKENED AREA DISTAL END OF TAIL	14
			RING-LIKE INDENTATIONS ON TAIL	21
			BLACKENED AREA DISTAL END OF TAIL	21
			RING-LIKE INDENTATIONS ON TAIL	28
			BLACKENED AREA DISTAL END OF TAIL	28
			SCHEDULED EUTHANASIA	28
	12	F	SCABBING	14
			VENTRAL TAIL	
			TAIL SKIN FLAKY IN APPEARANCE	14
			RING-LIKE INDENTATIONS ON TAIL	21
			BLACKENED AREA DISTAL END OF TAIL	21
			RING-LIKE INDENTATIONS ON TAIL	28
			BLACKENED AREA DISTAL END OF TAIL	28
			SCHEDULED EUTHANASIA	28
10546	1	M	DISTAL END OF TAIL MISSING	1

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10546	1	M	DISTAL END OF TAIL MISSING	4
			DISTAL END OF TAIL MISSING	7
			DISTAL END OF TAIL MISSING	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	MIDDLE THREE TOES NOT SEPARATED LEFT HINDLIMB	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	FOUND DEAD	2
	9	M	SCHEDULED EUTHANASIA	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	FOUND DEAD	21
	15	F	SCHEDULED EUTHANASIA	28
10548	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10548	8	M	SCHEDULED EUTHANASIA	28
	9	M	CULLED ON SCHEDULED DAY	4
	10	M	CULLED ON SCHEDULED DAY	4
	11	M	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
	16	F	SELECTED FOR EXPOSURE; PND 29-33	28
	17	F	SELECTED FOR EXPOSURE; PND 22-33	21
10550	1	F	FOUND DEAD	0
	2	M	SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	CULLED ON SCHEDULED DAY	4
	10	M	SCHEDULED EUTHANASIA	28
	11	M	CULLED ON SCHEDULED DAY	4
	12	M	SELECTED FOR EXPOSURE; PND 22-33	21
	13	M	CULLED ON SCHEDULED DAY	4
	14	M	SELECTED FOR EXPOSURE; PND 29-33	28
	15	M	CULLED ON SCHEDULED DAY	4
	16	F	CULLED ON SCHEDULED DAY	4
	17	F	SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10550	18	F	SCHEDULED EUTHANASIA	28
	19	F	SCHEDULED EUTHANASIA	28
	20	F	SELECTED FOR EXPOSURE; PND 22-33	21
	21	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10465	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SCABBING	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	4	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	5	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	6	F	SCHEDULED EUTHANASIA	28
	7	F	WET RED MATERIAL	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 29-33	28
	8	F	SCHEDULED EUTHANASIA	28
	9	F	SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SCHEDULED EUTHANASIA	28
10473	1	M	FOUND DEAD	0
	2	M	DISTAL END OF TAIL MISSING	0
			PALE IN COLOR	0
			MISSING	1
	3	M	DISTAL END OF TAIL MISSING	0
			DISTAL END OF TAIL MISSING	1
			DISTAL END OF TAIL MISSING	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10473	3	M	SMALL IN SIZE	4
			DISTAL END OF TAIL MISSING	7
			DISTAL END OF TAIL MISSING	14
			DISTAL END OF TAIL MISSING	21
			DISTAL END OF TAIL MISSING	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCABBING	14
			DISTAL END OF TAIL	
			SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	F	SELECTED FOR EXPOSURE; PND 22-33	21
	7	F	SCHEDULED EUTHANASIA	28
	8	F	MISSING	1
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SUBCUTANEOUS HEMORRHAGE(S)	1
			VENTRAL NECK	
			SUBCUTANEOUS HEMORRHAGE(S)	1
			VENTRAL THORACIC	
			SUBCUTANEOUS HEMORRHAGE(S)	1
			VENTRAL ABDOMINAL	
			SUBCUTANEOUS HEMORRHAGE(S)	1
			DORSAL THORACIC AREA	
			MISSING	3
10480	1	M	FOUND DEAD	0
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10480	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SCHEDULED EUTHANASIA	28
	8	F	SELECTED FOR EXPOSURE; PND 29-33	28
	9	M	SMALL IN SIZE	14
			SMALL IN SIZE	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SCHEDULED EUTHANASIA	28
	11	M	SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 22-33	21
10481	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SELECTED FOR EXPOSURE; PND 29-33	28
	7	M	SELECTED FOR EXPOSURE; PND 22-33	21
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	CULLED ON SCHEDULED DAY	4
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
10486	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10486	3	M	SCHEDULED EUTHANASIA	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	MISSING	1
	7	M	SCHEDULED EUTHANASIA	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SELECTED FOR EXPOSURE; PND 29-33	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
	16	F	MISSING	5
10507	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SCHEDULED EUTHANASIA	28
	3	M	WET RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	F	SCHEDULED EUTHANASIA	28
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10507	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
10529	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	EUTHANIZED IN EXTREMIS PARTIALLY CANNIBALIZED	0
	3	M	MISSING	1
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	MISSING	1
	6	M	SCHEDULED EUTHANASIA	28
	7	M	FOUND DEAD	1
	8	M	EUTHANIZED IN EXTREMIS PARTIALLY CANNIBALIZED	0
	9	M	MISSING	0
	10	F	MISSING	1
	11	F	FOUND DEAD PARTIALLY CANNIBALIZED	0
	12	F	MISSING	1
	13	F	FOUND DEAD PARTIALLY CANNIBALIZED FILAMENTOUS TAIL	0
10532	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10532	5	M	SCHEDULED EUTHANASIA	28
	6	F	MISSING	1
	7	F	SELECTED FOR EXPOSURE; PND 29-33	28
	8	F	SELECTED FOR EXPOSURE; PND 22-33	21
	9	F	MISSING	1
	10	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SMALL IN SIZE	4
			PALE IN COLOR	4
			MISSING	5
	13	F	SCHEDULED EUTHANASIA	28
10547	1	M	SUBCUTANEOUS HEMORRHAGE(S)	0
			MANDIBULAR AREA	
			SUBCUTANEOUS HEMORRHAGE(S)	1
			MANDIBULAR AREA	
			DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	2	M	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000 PPM	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10547	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SCHEDULED EUTHANASIA	28
	9	M	SCHEDULED EUTHANASIA	28
	10	F	FOUND DEAD	6
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SELECTED FOR EXPOSURE; PND 22-33	21
	14	F	SMALL IN SIZE	28
			SCHEDULED EUTHANASIA	28
	15	M	CULLED ON SCHEDULED DAY	4
	16	M	CULLED ON SCHEDULED DAY	4
	17	M	CULLED ON SCHEDULED DAY	4

PPOBSv4.03
07/31/2003
R:07/31/2003

TABLE 153 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHTS [G]

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10463-01	M	6.5	8.9	14.1	24.4	41.5	80.7
10463-02	M	6.9	9.6	14.2	23.7	37.0	83.1
10463-03	M	6.5	9.0				
10463-04	M	6.5	7.8	12.3	16.9	28.6	62.0
10463-05	M	6.5	9.6				
10463-06	M	6.5	9.3				
10463-07	M	6.1	8.3	12.4	19.2	32.8	
10463-08	M	6.5	9.2	13.6	18.3	31.1	67.7
10463-09	M	6.8	9.2				
10463-10	F	6.4	8.8				
10463-11	F	6.2	8.3				
10463-12	F	6.3	8.1	12.5	19.5	34.6	68.5
10463-13	F	6.3	8.2	12.2	18.5	32.4	
10463-14	F	6.5	8.1				
10463-15	F	6.0	8.5	12.7	19.9	34.9	62.0
10463-16	F	6.4	8.5				
10463-17	F	5.7	8.4	12.5	17.8	29.9	64.2
10463-18	F	6.7	8.9				
10463-19	F	6.5	8.7	12.4	19.7	33.5	70.8
MALES MEAN		6.5	9.0	13.3	20.5	34.2	73.4
FEMALES MEAN		6.3	8.5	12.5	19.1	33.1	66.4
10464-01	M	7.6	10.4				
10464-02	M	7.7	10.5	14.6	26.7	47.6	78.1
10464-03	M	7.9	10.5				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10464-04	M	8.0	10.4				
10464-05	M	8.3	10.8				
10464-06	M	7.2	9.9	14.3	26.1	46.9	75.6
10464-07	M	7.8	9.5	13.8	24.5	44.6	75.4
10464-08	M	7.4	9.9	13.9	24.7	43.6	
10464-09	M	7.5	10.1	14.1	25.0	44.2	75.8
10464-10	F	7.5	10.1	13.5	24.1	43.3	
10464-11	F	7.0	9.2	13.5	25.4	45.1	69.9
10464-12	F	5.9	8.2	11.7	22.7	39.1	63.3
10464-13	F	6.5	8.6	12.4	23.5	41.1	64.6
10464-14	F	7.6	10.7	14.7	26.7	46.6	73.1
MALES MEAN		7.7	10.2	14.1	25.4	45.4	76.2
FEMALES MEAN		6.9	9.4	13.2	24.5	43.0	67.7
10506-01	M	8.3	12.5	15.9	31.1	51.0	
10506-02	F	5.7	7.4	8.5	19.3	30.3	59.0
10506-03	F	7.5	10.9	14.1	29.3	49.0	86.2
10506-04	F	7.8	11.5	14.6	28.3	45.0	85.3
10506-05	F	7.7	11.3	14.3	28.3	44.5	
10506-06	F	8.6	9.8	11.7	20.0	26.8	52.4
MALES MEAN		8.3	12.5	15.9	31.1	51.0	
FEMALES MEAN		7.5	10.2	12.6	25.0	39.1	70.7
10524-01	M	6.4	9.1	12.7	21.9	32.6	64.9

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10524-02	M	7.1	9.6	13.3	22.6	33.9	71.0
10524-03	M	7.2	9.8				
10524-04	M	6.9	9.1				
10524-05	M	7.4	10.4	14.7	23.4	36.9	70.0
10524-06	M	7.2	10.0				
10524-07	M	6.7	9.2	13.0	20.6	30.2	
10524-08	M	7.2	9.9	14.1	23.6	37.4	75.1
10524-09	F	7.4	9.8	14.0	22.6	34.4	
10524-10	F	6.8	9.6	13.4	22.1	33.5	64.3
10524-11	F	6.6	8.8	13.0	22.4	35.4	65.9
10524-12	F	7.6	10.2	14.4	24.0	39.7	77.3
10524-13	F	7.2	9.8				
10524-14	F	6.9	9.5	13.5	22.4	36.4	68.2
MALES MEAN		7.0	9.6	13.6	22.4	34.2	70.3
FEMALES MEAN		7.1	9.6	13.7	22.7	35.9	68.9
10540-01	M	5.7	6.9				
10540-02	M	6.0	7.9				
10540-03	M	6.4	8.6				
10540-04	M	6.2	8.3	12.6	27.6	46.6	
10540-05	F	5.7	7.5	10.5	24.1	43.6	
10540-06	M	6.4	8.1				
10540-07	M	7.2	9.2				
10540-08	M	5.6	7.4				
10540-09	M	6.2	7.8	11.8	25.6	42.4	82.6

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10540-10	M	6.5	8.4				
10540-11	M	6.8	8.5	10.3	19.1	28.1	62.8
10540-12	M	6.0	7.7	10.8	24.3	39.1	80.4
10540-13	M	5.1	6.4	8.6	18.7	30.8	64.4
10540-14	F	5.7	7.2	9.4	18.7	32.0	64.8
10540-15	F	6.5	8.4	12.3	27.6	42.7	79.4
10540-16	F	5.8	7.0	9.0	18.7	33.3	70.5
10540-17	F	6.1	7.2	10.8	24.8	41.8	78.3
MALES MEAN		6.2	7.9	10.8	23.1	37.4	72.6
FEMALES MEAN		6.0	7.5	10.4	22.8	38.7	73.3
10554-01	M	7.0	9.8	13.8	20.2	31.0	65.7
10554-02	M	6.6	9.2	12.3	22.3	35.0	73.1
10554-03	M	7.6	11.0	13.8	23.7	37.0	
10554-04	M	6.8	9.8	13.3	22.1	34.0	71.8
10554-05	M	7.3	10.6	14.2	24.6	37.6	78.8
10554-06	F	6.6	9.5	11.8	20.0	30.1	61.1
10554-07	F	6.7	10.1	13.2	21.9	34.5	69.3
10554-08	F	7.5	10.5	13.2	21.1	34.8	
10554-09	F	7.6	11.2	16.0	15.4	41.1	79.0
10554-10	F	7.3	10.7				
10554-11	F	5.7	7.6	9.2	25.7	24.5	52.2

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM							
10554-12	F	6.0	8.6				
MALES MEAN		7.1	10.1	13.5	22.6	34.9	72.4
FEMALES MEAN		6.8	9.7	12.7	20.8	33.0	65.4
10555-02	M	7.2	10.8				
10555-03	M	7.5	10.4				
10555-04	M	7.7	10.9	14.0	20.7	37.7	67.2
10555-05	M	7.1	10.1	14.1	22.8	40.7	67.3
10555-06	M	7.5	10.4	14.6	25.6	42.9	65.2
10555-07	M	5.2	7.7	10.6	18.3	28.4	50.4
10555-08	M	7.0	9.4				
10555-09	M	7.0	10.5				
10555-10	M	6.9	9.9	14.0	23.9	38.8	
10555-11	M	7.3	10.4				
10555-12	F	6.2	9.1	13.2	21.5	34.4	56.9
10555-13	F	6.8	9.8	13.6	23.6	39.3	62.2
10555-14	F	6.8	9.1	12.9	24.3	42.9	63.4
10555-15	F	6.6	9.2	13.0	25.7	40.4	
10555-16	F	6.6	8.9	12.4	19.9	32.9	56.0
MALES MEAN		7.0	10.1	13.5	22.3	37.7	62.5
FEMALES MEAN		6.6	9.2	13.0	23.0	38.0	59.6
MALES MEAN		7.1	9.9	13.5	23.9	39.3	71.2
	SD	0.71	1.40	1.50	3.48	6.48	4.68
	N	7	7	7	7	7	6
FEMALES MEAN		6.7	9.2	12.6	22.6	37.3	67.4
	SD	0.50	0.90	1.05	2.04	3.57	4.36
	N	7	7	7	7	7	7

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10488-01	M	7.8	10.8	16.2	25.6	39.7	63.5
10488-02	M	7.6	10.8	15.4	28.3	47.0	71.3
10488-03	M	7.2	10.0	14.5	27.2	43.3	67.2
10488-04	M	6.5	9.5				
10488-05	M	7.6	11.2	16.0	25.8	39.3	65.3
10488-06	M	7.1	10.5	15.3	25.4	42.9	
10488-07	M	7.4	10.7				
10488-08	F	6.6	9.4				
10488-09	F	6.9	9.8	14.4	21.2	35.4	
10488-10	F	7.2	10.2	14.7	25.0	44.4	66.4
10488-11	F	7.3	10.7	15.3	22.3	33.8	53.9
10488-12	F	6.5	9.4	13.8	22.0	32.9	53.3
10488-13	F	7.0	10.5	15.0	26.1	39.4	64.4
MALES MEAN		7.3	10.5	15.5	26.5	42.4	66.8
FEMALES MEAN		6.9	10.0	14.6	23.3	37.2	59.5
10493-02	M	5.6					
10493-03	M	5.1					
10493-04	M	5.6	7.9	10.7	21.5	35.2	70.2
10493-05	F	5.2	7.3	9.9	20.6	31.7	62.5
10493-06	F	5.7					
10493-07	F	5.7	9.1	11.9	23.1	38.6	
10493-08	F	5.0					
10493-09	F	6.0	8.7	11.6	22.8	37.6	70.3
10493-10	F	5.3	7.0	8.8	18.7	30.1	60.4

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10493-12	F	4.4					
10493-13	F	5.9	8.3	11.0	22.0	36.7	71.9
MALES MEAN		5.4	7.9	10.7	21.5	35.2	70.2
FEMALES MEAN		5.4	8.1	10.6	21.4	34.9	66.3
10504-01	M	6.7	8.5	10.9	18.9	29.6	62.3
10504-02	M	7.6	10.0	11.6	20.4	33.5	
10504-03	M	7.9	9.6	12.4	22.8	36.2	73.7
10504-04	M	6.7	8.5	11.0	17.2	27.0	59.4
10504-05	F	6.7	9.0	11.4	22.0	35.2	70.7
10504-06	F	7.3	9.5	12.0	23.0	37.7	71.5
10504-07	F	6.9	8.8	10.8	21.4	35.3	66.3
10504-08	F	7.9	10.3				
10504-09	F	6.7	8.9				
10504-10	F	8.0	10.2	12.6	21.3	32.6	63.3
10504-11	F	7.3	9.1	11.5	22.7	36.9	
10504-12	F	7.1	9.6	12.1	22.4	36.2	69.7
10504-13	F	7.7	10.2				
MALES MEAN		7.2	9.2	11.5	19.8	31.6	65.1
FEMALES MEAN		7.3	9.5	11.7	22.1	35.7	68.3
10510-01	M	7.2	10.6	14.3	22.9	41.7	79.9
10510-02	M	7.3	10.7	14.8	21.4	34.9	
10510-03	M	7.6	11.2	15.7	24.7	44.9	85.1

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10510-04	M	7.1	10.4	14.5	25.0	40.4	84.7
10510-05	M	6.1					
10510-06	M	7.4	11.2				
10510-07	M	6.9	10.5				
10510-08	M	7.5	11.5				
10510-09	M	7.0	10.1	14.3	22.5	39.1	78.0
10510-10	F	6.7	10.4	14.1	21.5	35.9	69.7
10510-11	F	6.6	10.3	13.4	24.7	35.7	66.9
10510-12	F	6.9	10.1	14.2	22.7	39.6	76.3
10510-13	F	7.1	10.6	14.7	21.2	36.4	69.7
10510-14	F	6.8	9.8	14.0	19.9	33.1	
10510-15	F	5.7	8.7				
MALES MEAN		7.1	10.8	14.7	23.3	40.2	81.9
FEMALES MEAN		6.6	10.0	14.1	22.0	36.1	70.7
10519-03	M	5.8	7.0	10.3	21.5	33.0	66.8
10519-04	M	6.3	8.7	12.7	23.1	37.0	
10519-05	M	6.3	8.2				
10519-06	M	6.4	8.3				
10519-07	M	5.4	7.8				
10519-08	M	6.2	8.3	12.8	26.4	40.4	73.9
10519-09	M	5.9	7.8	11.3	24.4	36.7	64.6
10519-10	M	6.3	9.3				
10519-11	M	5.9	8.1	11.5	21.5	33.6	68.3
10519-12	F	6.0	7.3	11.2	21.3	32.6	65.7

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10519-13	F	5.1	6.8	10.1	14.1	25.6	51.1
10519-14	F	4.7	6.2	8.8	18.1	30.7	61.9
10519-15	F	6.0	8.5	12.2	17.1	26.9	
10519-16	F	5.2	7.6	10.6	23.5	34.1	61.9
10519-17	F	5.8	8.5				
10519-18	F	5.8	8.2				
MALES MEAN		6.1	8.2	11.7	23.4	36.1	68.4
FEMALES MEAN		5.5	7.6	10.6	18.8	30.0	60.2
10522-01	M	6.4	9.4	13.1	22.9	37.0	71.4
10522-02	M	6.2	9.2	13.6	23.0	38.8	
10522-03	M	6.6	9.8	13.6	23.5	40.6	75.6
10522-04	M	6.6	9.3	13.2	23.8	39.9	75.5
10522-05	M	5.7	7.6				
10522-06	M	6.8	9.8				
10522-07	M	7.1	10.5				
10522-08	M	6.3	8.9	13.0	23.9	39.0	75.3
10522-09	F	6.2	9.1	12.7	22.8	41.0	73.0
10522-10	F	5.6	8.1				
10522-11	F	5.6	8.3				
10522-12	F	5.4	8.0	12.0	21.9	35.7	64.6
10522-13	F	6.1	9.5	13.4	23.3	42.3	75.7
10522-14	F	6.1	8.7	13.0	22.9	40.2	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10522-15	F	5.7	8.0	11.9	21.9	37.0	68.3
MALES MEAN		6.5	9.3	13.3	23.4	39.1	74.5
FEMALES MEAN		5.8	8.5	12.6	22.6	39.2	70.4
10525-01	M	7.7	9.9	12.9	18.2	29.5	66.6
10525-02	M	7.8	9.6	11.8	16.0	26.8	59.5
10525-03	F	6.7	9.3				
10525-04	M	7.9	9.5	12.7	20.1	35.0	
10525-05	M	7.3	9.3	12.0	19.6	34.3	67.0
10525-06	M	7.5	9.8	13.1	20.8	34.8	71.0
10525-07	F	7.0	8.9	11.2	15.1	24.3	
10525-08	F	3.0	9.2				
10525-09	F	7.0	8.9	11.6	17.4	30.2	64.4
10525-10	F	7.6	10.0	12.6	20.1	33.3	65.5
10525-11	F	7.3	9.1	11.8	17.7	29.6	62.6
10525-12	F	7.1	9.2				
10525-13	F	7.8	9.4				
10525-14	F	7.8	9.4	12.7	18.0	29.7	63.1
MALES MEAN		7.6	9.6	12.5	18.9	32.1	66.0
FEMALES MEAN		6.8	9.3	12.0	17.7	29.4	63.9
10528-01	M	8.0	11.0	14.3	22.8	39.5	76.4
10528-02	M	8.2	11.3	15.7	29.5	49.5	90.8
10528-03	M	8.1	10.4	15.2	24.4	39.9	80.7

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10528-04	M	7.9	10.8				
10528-05	M	7.2	10.0				
10528-06	M	7.3	9.9	14.3	26.7	42.7	
10528-07	M	7.5	10.2				
10528-08	M	8.0	11.2	15.6	25.7	45.8	87.5
10528-09	F	7.3	10.5	14.2	25.4	45.0	80.9
10528-10	F	6.9	9.7	13.6	21.2	38.6	72.1
10528-11	F	7.5	10.0	14.3	23.5	38.1	
10528-12	F	7.3	10.0				
10528-13	F	6.0	8.0	10.9	17.8	29.4	60.2
10528-14	F	7.3	9.7				
10528-15	F	6.9	9.8	13.3	26.7	44.1	80.7
MALES MEAN		7.8	10.6	15.0	25.8	43.5	83.9
FEMALES MEAN		7.0	9.7	13.3	22.9	39.0	73.5
10543-01	M	7.1	8.0	8.9			
10543-02	M	8.2	9.5	11.0			
10543-03	M	7.8	9.3	10.8			
10543-04	M	7.5	8.4	10.4			
10543-05	M	8.6	10.1				
10543-06	M	7.6	8.9	10.4			
10543-07	M	7.9	9.5				
10543-08	F	7.2	8.3	9.4			
10543-09	F	7.7	8.8	9.8			
10543-10	F	7.2	8.5	9.4			

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM							
10543-11	F	6.7	7.9	9.3			
10543-12	F	7.6	9.2				
10543-13	F	7.7	9.7	11.0	11.3		
MALES MEAN		7.8	9.1	10.3			
FEMALES MEAN		7.4	8.7	9.8	11.3		
MALES MEAN		7.0	9.5	12.8	22.8	37.5	72.1
SD		0.82	1.03	1.92	2.66	4.49	7.30
N		9	9	9	8	8	8
FEMALES MEAN		6.5	9.0	12.1	20.2	35.2	66.6
SD		0.76	0.86	1.65	3.85	3.71	5.08
N		9	9	9	9	8	8

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10468-01	M	7.3	10.1				
10468-02	M	7.5	9.4	14.2	25.1	41.1	
10468-03	M	6.9	9.2				
10468-04	M	7.1	9.0	9.2	20.1	33.6	68.7
10468-05	M	7.1	9.4	11.9	24.3	34.5	73.0
10468-06	M	6.1	8.9				
10468-07	M	7.4	9.8	10.8	21.7	36.1	72.1
10468-08	M	6.0	7.8	10.7	21.5	39.1	70.6
10468-09	F	6.3	8.1				
10468-10	F	6.4	9.0				
10468-11	F	6.3	8.4	9.0	16.3	29.8	
10468-12	F	7.0	8.9	9.6	20.3	34.8	66.4
10468-13	F	6.3	8.9				
10468-14	F	7.0	9.4				
10468-15	F	6.6	9.3	13.1	24.4	40.2	69.9
10468-16	F	6.3	7.6	9.9	19.9	33.5	62.2
10468-17	F	6.3	8.8	12.8	24.1	39.6	70.0
10468-18	F	5.6	7.9				
MALES MEAN		6.9	9.2	11.4	22.5	36.9	71.1
FEMALES MEAN		6.4	8.6	10.9	21.0	35.6	67.1
10478-04	M	6.2	7.6	9.2	12.5	24.5	50.7
10478-05	M	6.9	8.4	10.5			
10478-06	M	7.3	8.5	10.9			
10478-07	M	7.0	8.5	9.9	10.5	22.1	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10478-08	M	7.0	8.3	10.4	16.0	30.4	61.4
10478-09	F	7.0	8.5	10.2	10.3	21.8	43.9
10478-10	F	6.6	7.7	10.0	16.6	32.1	
10478-11	F	6.4	7.5				
10478-12	F	6.1	6.8				
10478-13	F	6.1	7.5				
10478-14	F	6.7	7.7	10.0	8.5	16.6	32.1
10478-15	F	6.2	7.5				
10478-16	F	6.7	8.0	10.0	7.3	8.5	13.6
10478-17	F	7.2	8.4	9.8	9.7	20.9	42.7
10478-18	F	6.3	7.2				
MALES MEAN		6.9	8.3	10.2	13.0	25.7	56.1
FEMALES MEAN		6.5	7.7	10.0	10.5	20.0	33.1
10483-01	M	8.1	11.2	15.9	22.6	41.7	80.9
10483-02	M	7.7	11.2	16.6	25.3	45.8	
10483-03	M	7.6	11.2	15.3	23.9	41.8	82.1
10483-04	F	7.1	10.2				
10483-05	F	6.8	9.9	14.2	22.1	39.6	
10483-06	F	7.0	9.4	14.4	23.6	41.5	74.8
10483-07	F	7.3	9.9	15.4	25.0	42.0	84.6
10483-08	F	7.3	10.7	15.6	26.3	46.0	84.9
10483-09	F	7.8	10.9	15.6	26.1	44.4	83.1
10483-10	F	7.1	10.4				
10483-11	F	7.4	10.6				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10483-12	F	7.0	10.6				
10483-13	F	7.2	10.0	14.9	24.8	43.9	79.9
10483-14	F	6.4	9.6				
10483-15	F	6.7	9.2	14.1	22.3	41.6	74.9
MALES MEAN		7.8	11.2	15.9	23.9	43.1	81.5
FEMALES MEAN		7.1	10.1	14.9	24.3	42.7	80.4
10484-01	M	7.1	9.9	13.3	22.2	38.1	
10484-02	M	7.5	10.4				
10484-03	M	7.1	9.6	13.4	20.5	36.6	75.0
10484-04	M	7.0	9.5				
10484-05	M	7.4	10.1	13.7	22.3	38.4	79.7
10484-06	M	7.5	10.2	13.7	23.1	40.6	79.9
10484-07	M	7.2	10.0	13.7	23.2	39.3	77.5
10484-08	M	7.6	10.2	13.8	23.4	40.8	80.8
10484-09	M	7.0	9.4	12.0	19.5	36.3	72.5
10484-10	M	8.2	10.8				
10484-11	M	6.9	9.6				
10484-12	F	6.0	8.5	11.8	20.5	36.5	69.2
10484-13	F	7.0	9.1	12.7	22.0	38.0	70.3

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10484-14	F	6.2	8.9	12.5	20.6	37.2	
MALES MEAN		7.3	10.0	13.4	22.0	38.6	77.6
FEMALES MEAN		6.4	8.8	12.3	21.0	37.2	69.8
10530-02	M	7.6	8.8	11.7	18.4	33.9	61.1
10530-03	M		10.5	13.4	21.7	39.1	
10530-04	M	8.0	9.8	12.3	19.2	31.3	59.7
10530-05	F	6.7	9.4	12.3	19.1	34.0	61.4
10530-06	F	7.5	10.8				
10530-07	F	7.3	9.1	11.9	19.4	36.5	
10530-08	F	7.0	9.3	12.3	17.8	32.6	58.7
10530-09	F	7.1	9.5	12.4	18.0	30.4	58.3
10530-10	F	7.2	9.9	13.1	20.4	35.8	58.9
10530-11	F	7.1	8.8				
10530-12	F	6.8	9.3	12.3	19.3	33.7	59.5
10530-13	F	7.0	9.3				
10530-14	F	7.4	9.7	12.7	18.4	32.1	57.0
MALES MEAN		7.8	9.7	12.5	19.8	34.8	60.4
FEMALES MEAN		7.1	9.5	12.4	18.9	33.6	59.0
10534-01	M	6.7	10.2	13.1	21.8	35.4	66.6
10534-02	M	6.5	9.7	12.4	13.1	22.6	48.7
10534-03	M	6.8	10.0	12.4	18.7	30.1	
10534-04	M	6.7	10.3	13.2	21.8	33.9	69.3

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10534-05	F	6.5	9.4	11.6	20.5	35.7	67.3
10534-06	F	6.0	8.7	10.5	17.2	30.8	
10534-07	F	6.4	9.4				
10534-08	F	6.6	9.9	12.4	20.9	32.1	62.9
10534-09	F	6.6	9.4				
10534-10	M	6.7	10.0	12.5	20.3	26.8	58.3
10534-11	F	6.4	9.2	11.1	19.8	32.8	62.7
10534-12	F	6.4	9.6	12.3	20.6	33.6	65.3
MALES MEAN		6.7	10.0	12.7	19.1	29.8	60.7
FEMALES MEAN		6.4	9.4	11.6	19.8	33.0	64.6
10546-01	M	6.5	9.0	12.6	23.4	34.0	
10546-02	M	7.1	9.7				
10546-03	M	6.0	7.9	11.1	22.4	32.8	63.0
10546-04	M	6.7	9.0	12.5	23.7	36.8	74.3
10546-05	M	6.2	9.0	11.7	21.1	33.4	67.7
10546-06	M	6.5	9.0				
10546-07	M	6.8	9.3				
10546-08	M	6.4					
10546-09	M	6.7	9.4	13.0	23.9	36.4	73.7
10546-10	F	6.1	8.6	12.0	22.7	33.2	66.7
10546-11	F	6.0	8.0	11.4	21.3	33.1	
10546-12	F	6.2	8.8	12.1	22.4	35.4	65.0
10546-13	F	6.7	8.9				
10546-14	F	6.2	8.5	12.1	22.6		

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10546-15	F	6.2	8.5	11.2	20.6	33.2	64.8
MALES MEAN		6.5	9.0	12.2	22.9	34.7	69.7
FEMALES MEAN		6.2	8.6	11.8	21.9	33.7	65.5
10548-01	M	6.0	8.3				
10548-02	M	5.8	7.8	12.1	23.7	36.0	75.1
10548-03	M	6.3	8.7	13.0	25.1	38.2	77.6
10548-04	M	5.9	7.4	11.4	22.9	34.5	71.3
10548-05	M	5.8	7.5				
10548-06	M	6.1	7.7				
10548-07	M	5.9	7.6	11.4	22.3	37.4	
10548-08	M	5.9	7.9	11.8	23.0	35.6	72.8
10548-09	M	5.6	7.3				
10548-10	M	6.5	9.2				
10548-11	M	6.1	8.0				
10548-12	F	5.8	7.7	11.5	23.8	38.0	76.5
10548-13	F	5.3	6.8	10.2	21.9	34.2	67.8
10548-14	F	6.1	7.9				
10548-15	F	5.7	7.7	11.3	22.4	35.1	67.3
10548-16	F	6.2	7.9	12.2	24.0	36.0	71.6

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10548-17	F	5.8	8.5	12.4	25.2	38.1	
MALES MEAN		6.0	7.9	11.9	23.4	36.3	74.2
FEMALES MEAN		5.8	7.8	11.5	23.5	36.3	70.8
10550-02	M	6.0	7.8	12.0	19.5	35.5	74.4
10550-03	M	6.6	8.6				
10550-04	M	6.6	8.5	12.6	20.7	34.3	74.1
10550-05	M	6.3	8.3				
10550-06	M	6.2	8.6				
10550-07	M	7.3	9.5				
10550-08	M	6.5	9.2				
10550-09	M	6.4	9.0				
10550-10	M	6.9	9.3	14.1	30.9	51.7	92.1
10550-11	M	7.1	9.0				
10550-12	M	7.2	9.1	13.1	28.9	48.0	
10550-13	M	7.4	9.8				
10550-14	M	5.4	7.0	10.4	23.7	36.3	71.6
10550-15	M	6.9	9.4				
10550-16	F	5.6	7.4				
10550-17	F	6.5	8.6	12.6	26.7	47.8	85.4
10550-18	F	6.1	8.3	12.3	27.3	45.8	82.5
10550-19	F	6.5	8.6	13.0	29.1	47.8	87.9
10550-20	F	6.5	8.6	12.9	25.3	42.8	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM							
10550-21	F	6.6	8.9	13.0	23.9	41.1	78.3
MALES MEAN		6.6	8.8	12.4	24.7	41.2	78.1
FEMALES MEAN		6.3	8.4	12.8	26.5	45.1	83.5
MALES MEAN		6.9	9.3	12.5	21.3	35.7	69.9
SD		0.60	1.00	1.56	3.59	5.38	8.99
N		9	9	9	9	9	9
FEMALES MEAN		6.5	8.8	12.0	20.8	35.2	66.0
SD		0.41	0.79	1.37	4.53	7.07	14.52
N		9	9	9	9	9	9

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10465-01	M	6.4	10.0	13.0	18.8	34.7	
10465-02	M	7.3	11.3	14.4	20.3	35.7	65.4
10465-03	M	7.0	11.1	14.3	21.2	38.3	68.9
10465-04	M	7.5	11.7	14.4	21.5	38.2	70.6
10465-05	M	7.4	11.5	14.8	20.9	35.0	64.2
10465-06	F	7.2	11.2	14.2	20.2	37.4	65.5
10465-07	F	7.0	10.7	13.6	18.8	33.3	62.2
10465-08	F	6.6	10.9	14.0	21.9	36.4	63.9
10465-09	F	6.6	10.4	13.2	21.0	36.5	
10465-10	F	7.3	11.4	14.4	21.0	37.2	63.8
MALES MEAN		7.1	11.1	14.2	20.5	36.4	67.3
FEMALES MEAN		6.9	10.9	13.9	20.6	36.2	63.9
10473-03	M	4.7	6.9	8.9	19.7	32.0	62.4
10473-04	M	5.8	9.6	13.0	26.2	40.7	78.7
10473-05	M	5.6	9.8	13.6	29.0	47.9	
10473-06	F	5.7	9.6	12.9	26.7	44.1	
10473-07	F	5.7	9.5	13.3	26.6	43.3	78.4
10473-09	F	5.4	8.6	11.6	25.5	41.6	75.1
10473-10	F	5.2	8.4	10.9	22.6	38.3	70.0

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10473-11	F	5.3					
MALES MEAN		5.4	8.8	11.8	25.0	40.2	70.6
FEMALES MEAN		5.5	9.0	12.2	25.4	41.8	74.5
10480-02	M	5.4	7.5	9.3	17.6	25.4	57.3
10480-03	M	6.3	9.3	12.0	16.6	25.0	54.6
10480-04	M	7.0	10.0	12.9	19.8	29.0	65.2
10480-05	M	7.0	9.4	12.2	20.5	28.4	63.3
10480-06	M	7.4	10.3				
10480-07	M	7.0	9.5	12.0	20.9	29.6	63.5
10480-08	F	7.5	9.9	12.6	21.8	31.2	67.4
10480-09	M	5.8	8.3	10.7	13.9	22.3	
10480-10	F	6.7	9.4	11.6	16.4	24.0	52.3
10480-11	M	6.7	9.3	12.3	20.3	29.2	64.1
10480-12	F	7.3	9.9	12.2	20.4	29.1	
MALES MEAN		6.6	9.2	11.6	18.5	27.0	61.3
FEMALES MEAN		7.2	9.7	12.1	19.5	28.1	59.9
10481-01	M	6.7	10.5	14.0	17.9	29.6	63.8
10481-02	M	6.6	10.5	14.0	17.0	27.3	59.9
10481-03	M	6.5	10.1	14.0	18.2	29.6	67.2
10481-04	M	6.8	10.3				
10481-05	M	6.4	9.5	13.0	16.9	27.1	58.6
10481-06	M	6.1	9.5	13.1	16.3	26.7	58.5

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10481-07	M	6.5	10.1	14.3	17.4	30.2	
10481-08	M	7.1	10.7				
10481-09	M	5.9	9.3				
10481-10	F	5.0	8.3	11.4	15.8	25.7	53.8
10481-11	F	6.4	10.2	13.7	16.4	28.9	
10481-12	F	5.8	9.1	12.4	16.9	27.6	55.1
10481-13	F	6.7	10.4	13.7	16.5	28.2	58.2
MALES MEAN		6.5	10.1	13.7	17.3	28.4	61.6
FEMALES MEAN		6.0	9.5	12.8	16.4	27.6	55.7
10486-01	M	5.8	8.1	9.9	18.5	32.5	
10486-02	M	6.3	9.8	15.0	28.4	51.6	92.1
10486-03	M	6.6	10.3	15.2	28.4	51.0	89.9
10486-04	M	6.3	9.0				
10486-05	M	5.9	9.0				
10486-07	M	6.4	9.8	15.0	28.8	51.5	92.1
10486-08	M	5.7	10.1				
10486-09	M	6.6	10.3	15.2	28.9	51.0	94.5
10486-10	F	6.4	9.5				
10486-11	F	6.1	9.1	13.6	25.8	46.9	82.4
10486-12	F	5.9	8.5	13.1	25.9	43.9	75.8
10486-13	F	5.9	9.4	14.3	27.4	48.2	80.7
10486-14	F	5.2	8.1				
10486-15	F	6.4	9.4	14.3	27.0	45.2	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10486-16	F	6.3	9.9				
MALES MEAN		6.2	9.6	14.1	26.6	47.5	92.2
FEMALES MEAN		6.0	9.1	13.8	26.5	46.1	79.6
10507-01	M	6.6	8.6	11.4	15.9	28.2	
10507-02	M	5.9	8.4	9.6	13.7	24.8	50.8
10507-03	M	6.2	8.3	10.9	14.9	26.5	54.0
10507-04	M	6.3	8.8	10.9	13.8	24.9	49.9
10507-05	M	5.9	7.4	9.2	12.1	22.0	42.6
10507-06	M	6.6	9.0				
10507-07	M	6.3	8.3				
10507-08	F	5.5	7.5	8.9	13.3	23.4	46.2
10507-09	F	6.1	8.6				
10507-10	F	6.1	8.5	11.3	16.2	29.5	55.5
10507-11	F	6.0	8.1				
10507-12	F	5.6	8.0	10.5	16.0	27.9	51.9
10507-13	F	6.1	7.6	9.0	17.5	28.9	51.9
10507-14	F	5.2	6.9				
10507-15	F	6.3	8.7	11.6	16.2	28.0	
MALES MEAN		6.3	8.4	10.4	14.1	25.3	49.3
FEMALES MEAN		5.9	8.0	10.3	15.8	27.5	51.4
10529-01	M	5.8	7.9	10.6	19.7	37.1	74.2
10529-04	M	6.9	9.6	12.2	22.2	39.6	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10529-06	M	6.4	8.1	11.0	20.2	36.9	72.7
MALES MEAN		6.4	8.5	11.3	20.7	37.9	73.5
FEMALES MEAN							
10532-01	M	7.3	11.7	14.8	25.4	45.4	
10532-02	M	7.0	10.7	14.2	25.0	44.2	79.1
10532-03	M	6.2	10.3	13.3	23.2	39.3	70.5
10532-04	M	7.2	10.3	13.2	23.8	43.8	75.1
10532-05	M	7.1	10.7	13.9	24.2	41.4	74.1
10532-07	F	6.6	10.1	12.9	22.5	39.4	65.9
10532-08	F	6.7	9.8	12.8	23.2	42.6	
10532-10	F	7.2	11.5	14.5	23.4	40.3	72.5
10532-11	F	6.8	11.1				
10532-12	F	5.8	4.9				
10532-13	F	6.4	9.5	12.9	22.6	39.7	66.3
MALES MEAN		7.0	10.7	13.9	24.3	42.8	74.7
FEMALES MEAN		6.6	9.5	13.3	22.9	40.5	68.2
10547-01	M	5.9	7.3	10.7	18.9	33.2	68.0
10547-02	M	6.4	8.2	11.2	17.7	31.6	65.7
10547-03	M	6.2	9.0				
10547-04	M	6.4	8.3				
10547-05	M	6.7	9.9	14.5	29.3	51.9	
10547-06	M	6.8	9.4				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000 PPM							
10547-07	M	6.7	9.4				
10547-08	M	6.1	7.7	10.8	22.0	40.3	74.6
10547-09	M	7.1	9.7	13.4	18.1	34.7	66.9
10547-10	F	6.3	8.3				
10547-11	F	5.8	7.5	10.6	23.3	40.7	70.9
10547-12	F	6.4	8.7	13.1	24.8	40.5	74.9
10547-13	F	6.1	7.9	11.9	26.9	47.2	
10547-14	F	6.0	8.0	11.9	26.5	48.4	43.3
10547-15	M	6.5	8.5				
10547-16	M	6.2	7.9				
10547-17	M	6.9	8.9				
MALES MEAN		6.5	8.7	12.1	21.2	38.3	68.8
FEMALES MEAN		6.1	8.1	11.9	25.4	44.2	63.0
MALES MEAN		6.4	9.5	12.6	20.9	36.0	68.8
SD		0.49	0.99	1.42	3.97	7.57	11.72
N		9	9	9	9	9	9
FEMALES MEAN		6.3	9.2	12.5	21.6	36.5	64.5
SD		0.57	0.93	1.18	4.15	7.80	9.37
N		8	8	8	8	8	8

TABLE 154 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM						
10463-01	M	2.4	5.2	10.3	17.1	39.2
10463-02	M	2.7	4.6	9.5	13.3	46.1
10463-03	M	2.5				
10463-04	M	1.3	4.5	4.6	11.7	33.4
10463-05	M	3.1				
10463-06	M	2.8				
10463-07	M	2.2	4.1	6.8	13.6	
10463-08	M	2.7	4.4	4.7	12.8	36.6
10463-09	M	2.4				
10463-10	F	2.4				
10463-11	F	2.1				
10463-12	F	1.8	4.4	7.0	15.1	33.9
10463-13	F	1.9	4.0	6.3	13.9	
10463-14	F	1.6				
10463-15	F	2.5	4.2	7.2	15.0	27.1
10463-16	F	2.1				
10463-17	F	2.7	4.1	5.3	12.1	34.3
10463-18	F	2.2				
10463-19	F	2.2	3.7	7.3	13.8	37.3
MALES MEAN		2.5	4.6	7.2	13.7	38.8
FEMALES MEAN		2.2	4.1	6.6	14.0	33.2
10464-01	M	2.8				
10464-02	M	2.8	4.1	12.1	20.9	30.5
10464-03	M	2.6				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM						
10464-04	M	2.4				
10464-05	M	2.5				
10464-06	M	2.7	4.4	11.8	20.8	28.7
10464-07	M	1.7	4.3	10.7	20.1	30.8
10464-08	M	2.5	4.0	10.8	18.9	
10464-09	M	2.6	4.0	10.9	19.2	31.6
10464-10	F	2.6	3.4	10.6	19.2	
10464-11	F	2.2	4.3	11.9	19.7	24.8
10464-12	F	2.3	3.5	11.0	16.4	24.2
10464-13	F	2.1	3.8	11.1	17.6	23.5
10464-14	F	3.1	4.0	12.0	19.9	26.5
MALES MEAN		2.5	4.2	11.3	20.0	30.4
FEMALES MEAN		2.5	3.8	11.3	18.6	24.8
10506-01	M	4.2	3.4	15.2	19.9	
10506-02	F	1.7	1.1	10.8	11.0	28.7
10506-03	F	3.4	3.2	15.2	19.7	37.2
10506-04	F	3.7	3.1	13.7	16.7	40.3
10506-05	F	3.6	3.0	14.0	16.2	
10506-06	F	1.2	1.9	8.3	6.8	25.6
MALES MEAN		4.2	3.4	15.2	19.9	
FEMALES MEAN		2.7	2.5	12.4	14.1	33.0
10524-01	M	2.7	3.6	9.2	10.7	32.3

TABLE 154 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM						
10524-02	M	2.5	3.7	9.3	11.3	37.1
10524-03	M	2.6				
10524-04	M	2.2				
10524-05	M	3.0	4.3	8.7	13.5	33.1
10524-06	M	2.8				
10524-07	M	2.5	3.8	7.6	9.6	
10524-08	M	2.7	4.2	9.5	13.8	37.7
10524-09	F	2.4	4.2	8.6	11.8	
10524-10	F	2.8	3.8	8.7	11.4	30.8
10524-11	F	2.2	4.2	9.4	13.0	30.5
10524-12	F	2.6	4.2	9.6	15.7	37.6
10524-13	F	2.6				
10524-14	F	2.6	4.0	8.9	14.0	31.8
MALES MEAN		2.6	3.9	8.9	11.8	35.1
FEMALES MEAN		2.5	4.1	9.0	13.2	32.7
10540-01	M	1.2				
10540-02	M	1.9				
10540-03	M	2.2				
10540-04	M	2.1	4.3	15.0	19.0	
10540-05	F	1.8	3.0	13.6	19.5	
10540-06	M	1.7				
10540-07	M	2.0				
10540-08	M	1.8				
10540-09	M	1.6	4.0	13.8	16.8	40.2

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM						
10540-10	M	1.9				
10540-11	M	1.7	1.8	8.8	9.0	34.7
10540-12	M	1.7	3.1	13.5	14.8	41.3
10540-13	M	1.3	2.2	10.1	12.1	33.6
10540-14	F	1.5	2.2	9.3	13.3	32.8
10540-15	F	1.9	3.9	15.3	15.1	36.7
10540-16	F	1.2	2.0	9.7	14.6	37.2
10540-17	F	1.1	3.6	14.0	17.0	36.5
MALES MEAN		1.8	3.1	12.2	14.3	37.5
FEMALES MEAN		1.5	2.9	12.4	15.9	35.8
10554-01	M	2.8	4.0	6.4	10.8	34.7
10554-02	M	2.6	3.1	10.0	12.7	38.1
10554-03	M	3.4	2.8	9.9	13.3	
10554-04	M	3.0	3.5	8.8	11.9	37.8
10554-05	M	3.3	3.6	10.4	13.0	41.2
10554-06	F	2.9	2.3	8.2	10.1	31.0
10554-07	F	3.4	3.1	8.7	12.6	34.8
10554-08	F	3.0	2.7	7.9	13.7	
10554-09	F	3.6	4.8	-0.6	25.7	37.9
10554-10	F	3.4				
10554-11	F	1.9	1.6	16.5	-1.2	27.7

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM						
10554-12	F	2.6				
MALES MEAN		3.0	3.4	9.1	12.3	38.0
FEMALES MEAN		3.0	2.9	8.1	12.2	32.9
10555-02	M	3.6				
10555-03	M	2.9				
10555-04	M	3.2	3.1	6.7	17.0	29.5
10555-05	M	3.0	4.0	8.7	17.9	26.6
10555-06	M	2.9	4.2	11.0	17.3	22.3
10555-07	M	2.5	2.9	7.7	10.1	22.0
10555-08	M	2.4				
10555-09	M	3.5				
10555-10	M	3.0	4.1	9.9	14.9	
10555-11	M	3.1				
10555-12	F	2.9	4.1	8.3	12.9	22.5
10555-13	F	3.0	3.8	10.0	15.7	22.9
10555-14	F	2.3	3.8	11.4	18.6	20.5
10555-15	F	2.6	3.8	12.7	14.7	
10555-16	F	2.3	3.5	7.5	13.0	23.1
MALES MEAN		3.0	3.7	8.8	15.4	25.1
FEMALES MEAN		2.6	3.8	10.0	15.0	22.3
MALES MEAN		2.8	3.8	10.4	15.3	34.2
SD		0.74	0.52	2.70	3.37	5.38
N		7	7	7	7	6
FEMALES MEAN		2.4	3.4	10.0	14.7	30.7
SD		0.48	0.66	2.21	2.09	5.03
N		7	7	7	7	7

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10488-01	M	3.0	5.4	9.4	14.1	23.8
10488-02	M	3.2	4.6	12.9	18.7	24.3
10488-03	M	2.8	4.5	12.7	16.1	23.9
10488-04	M	3.0				
10488-05	M	3.6	4.8	9.8	13.5	26.0
10488-06	M	3.4	4.8	10.1	17.5	
10488-07	M	3.3				
10488-08	F	2.8				
10488-09	F	2.9	4.6	6.8	14.2	
10488-10	F	3.0	4.5	10.3	19.4	22.0
10488-11	F	3.4	4.6	7.0	11.5	20.1
10488-12	F	2.9	4.4	8.2	10.9	20.4
10488-13	F	3.5	4.5	11.1	13.3	25.0
MALES MEAN		3.2	4.8	11.0	16.0	24.5
FEMALES MEAN		3.1	4.5	8.7	13.9	21.9
10493-04	M	2.3	2.8	10.8	13.7	35.0
10493-05	F	2.1	2.6	10.7	11.1	30.8
10493-07	F	3.4	2.8	11.2	15.5	
10493-09	F	2.7	2.9	11.2	14.8	32.7
10493-10	F	1.7	1.8	9.9	11.4	30.3
10493-13	F	2.4	2.7	11.0	14.7	35.2
MALES MEAN		2.3	2.8	10.8	13.7	35.0
FEMALES MEAN		2.5	2.6	10.8	13.5	32.3

TABLE 154 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10504-01	M	1.8	2.4	8.0	10.7	32.7
10504-02	M	2.4	1.6	8.8	13.1	
10504-03	M	1.7	2.8	10.4	13.4	37.5
10504-04	M	1.8	2.5	6.2	9.8	32.4
10504-05	F	2.3	2.4	10.6	13.2	35.5
10504-06	F	2.2	2.5	11.0	14.7	33.8
10504-07	F	1.9	2.0	10.6	13.9	31.0
10504-08	F	2.4				
10504-09	F	2.2				
10504-10	F	2.2	2.4	8.7	11.3	30.7
10504-11	F	1.8	2.4	11.2	14.2	
10504-12	F	2.5	2.5	10.3	13.8	33.5
10504-13	F	2.5				
MALES MEAN		1.9	2.3	8.4	11.8	34.2
FEMALES MEAN		2.2	2.4	10.4	13.5	32.9
10510-01	M	3.4	3.7	8.6	18.8	38.2
10510-02	M	3.4	4.1	6.6	13.5	
10510-03	M	3.6	4.5	9.0	20.2	40.2
10510-04	M	3.3	4.1	10.5	15.4	44.3
10510-06	M	3.8				
10510-07	M	3.6				
10510-08	M	4.0				
10510-09	M	3.1	4.2	8.2	16.6	38.9
10510-10	F	3.7	3.7	7.4	14.4	33.8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10510-11	F	3.7	3.1	11.3	11.0	31.2
10510-12	F	3.2	4.1	8.5	16.9	36.7
10510-13	F	3.5	4.1	6.5	15.2	33.3
10510-14	F	3.0	4.2	5.9	13.2	
10510-15	F	3.0				
MALES MEAN		3.5	4.1	8.6	16.9	40.4
FEMALES MEAN		3.4	3.8	7.9	14.1	33.8
10519-03	M	1.2	3.3	11.2	11.5	33.8
10519-04	M	2.4	4.0	10.4	13.9	
10519-05	M	1.9				
10519-06	M	1.9				
10519-07	M	2.4				
10519-08	M	2.1	4.5	13.6	14.0	33.5
10519-09	M	1.9	3.5	13.1	12.3	27.9
10519-10	M	3.0				
10519-11	M	2.2	3.4	10.0	12.1	34.7
10519-12	F	1.3	3.9	10.1	11.3	33.1
10519-13	F	1.7	3.3	4.0	11.5	25.5
10519-14	F	1.5	2.6	9.3	12.6	31.2
10519-15	F	2.5	3.7	4.9	9.8	
10519-16	F	2.4	3.0	12.9	10.6	27.8
10519-17	F	2.7				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10519-18	F	2.4				
MALES MEAN		2.1	3.7	11.7	12.8	32.5
FEMALES MEAN		2.1	3.3	8.2	11.2	29.4
10522-01	M	3.0	3.7	9.8	14.1	34.4
10522-02	M	3.0	4.4	9.4	15.8	
10522-03	M	3.2	3.8	9.9	17.1	35.0
10522-04	M	2.7	3.9	10.6	16.1	35.6
10522-05	M	1.9				
10522-06	M	3.0				
10522-07	M	3.4				
10522-08	M	2.6	4.1	10.9	15.1	36.3
10522-09	F	2.9	3.6	10.1	18.2	32.0
10522-10	F	2.5				
10522-11	F	2.7				
10522-12	F	2.6	4.0	9.9	13.8	28.9
10522-13	F	3.4	3.9	9.9	19.0	33.4
10522-14	F	2.6	4.3	9.9	17.3	
10522-15	F	2.3	3.9	10.0	15.1	31.3
MALES MEAN		2.9	4.0	10.1	15.6	35.3
FEMALES MEAN		2.7	3.9	10.0	16.7	31.4
10525-01	M	2.2	3.0	5.3	11.3	37.1
10525-02	M	1.8	2.2	4.2	10.8	32.7

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10525-03	F	2.6				
10525-04	M	1.6	3.2	7.4	14.9	
10525-05	M	2.0	2.7	7.6	14.7	32.7
10525-06	M	2.3	3.3	7.7	14.0	36.2
10525-07	F	1.9	2.3	3.9	9.2	
10525-08	F	6.2				
10525-09	F	1.9	2.7	5.8	12.8	34.2
10525-10	F	2.4	2.6	7.5	13.2	32.2
10525-11	F	1.8	2.7	5.9	11.9	33.0
10525-12	F	2.1				
10525-13	F	1.6				
10525-14	F	1.6	3.3	5.3	11.7	33.4
MALES MEAN		2.0	2.9	6.4	13.1	34.7
FEMALES MEAN		2.5	2.7	5.7	11.8	33.2
10528-01	M	3.0	3.3	8.5	16.7	36.9
10528-02	M	3.1	4.4	13.8	20.0	41.3
10528-03	M	2.3	4.8	9.2	15.5	40.8
10528-04	M	2.9				
10528-05	M	2.8				
10528-06	M	2.6	4.4	12.4	16.0	
10528-07	M	2.7				
10528-08	M	3.2	4.4	10.1	20.1	41.7
10528-09	F	3.2	3.7	11.2	19.6	35.9
10528-10	F	2.8	3.9	7.6	17.4	33.5

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10528-11	F	2.5	4.3	9.2	14.6	
10528-12	F	2.7				
10528-13	F	2.0	2.9	6.9	11.6	30.8
10528-14	F	2.4				
10528-15	F	2.9	3.5	13.4	17.4	36.6
MALES MEAN		2.8	4.3	10.8	17.7	40.2
FEMALES MEAN		2.6	3.7	9.7	16.1	34.2
10543-01	M	0.9	0.9			
10543-02	M	1.3	1.5			
10543-03	M	1.5	1.5			
10543-04	M	0.9	2.0			
10543-05	M	1.5				
10543-06	M	1.3	1.5			
10543-07	M	1.6				
10543-08	F	1.1	1.1			
10543-09	F	1.1	1.0			
10543-10	F	1.3	0.9			
10543-11	F	1.2	1.4			
10543-12	F	1.6				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM						
10543-13	F	2.0	1.3	0.3		
MALES MEAN		1.3	1.5			
FEMALES MEAN		1.4	1.1	0.3		
MALES MEAN		2.4	3.4	9.7	14.7	34.6
	SD	0.70	1.07	1.78	2.14	4.96
	N	9	9	8	8	8
FEMALES MEAN		2.5	3.1	8.0	13.9	31.1
	SD	0.58	1.02	3.27	1.88	4.03
	N	9	9	9	8	8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10468-01	M	2.8				
10468-02	M	1.9	4.8	10.9	16.0	
10468-03	M	2.3				
10468-04	M	1.9	0.2	10.9	13.5	35.1
10468-05	M	2.3	2.5	12.4	10.2	38.5
10468-06	M	2.8				
10468-07	M	2.4	1.0	10.9	14.4	36.0
10468-08	M	1.8	2.9	10.8	17.6	31.5
10468-09	F	1.8				
10468-10	F	2.6				
10468-11	F	2.1	0.6	7.3	13.5	
10468-12	F	1.9	0.7	10.7	14.5	31.6
10468-13	F	2.6				
10468-14	F	2.4				
10468-15	F	2.7	3.8	11.3	15.8	29.7
10468-16	F	1.3	2.3	10.0	13.6	28.7
10468-17	F	2.5	4.0	11.3	15.5	30.4
10468-18	F	2.3				
MALES MEAN		2.3	2.3	11.2	14.3	35.3
FEMALES MEAN		2.2	2.3	10.1	14.6	30.1
10478-04	M	1.4	1.6	3.3	12.0	26.2
10478-05	M	1.5	2.1			
10478-06	M	1.2	2.4			
10478-07	M	1.5	1.4	0.6	11.6	

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10478-08	M	1.3	2.1	5.6	14.4	31.0
10478-09	F	1.5	1.7	0.1	11.5	22.1
10478-10	F	1.1	2.3	6.6	15.5	
10478-11	F	1.1				
10478-12	F	0.7				
10478-13	F	1.4				
10478-14	F	1.0	2.3	-1.5	8.1	15.5
10478-15	F	1.3				
10478-16	F	1.3	2.0	-2.7	1.2	5.1
10478-17	F	1.2	1.4	-0.1	11.2	21.8
10478-18	F	0.9				
MALES MEAN		1.4	1.9	3.2	12.7	28.6
FEMALES MEAN		1.2	1.9	0.5	9.5	16.1
10483-01	M	3.1	4.7	6.7	19.1	39.2
10483-02	M	3.5	5.4	8.7	20.5	
10483-03	M	3.6	4.1	8.6	17.9	40.3
10483-04	F	3.1				
10483-05	F	3.1	4.3	7.9	17.5	
10483-06	F	2.4	5.0	9.2	17.9	33.3
10483-07	F	2.6	5.5	9.6	17.0	42.6
10483-08	F	3.4	4.9	10.7	19.7	38.9
10483-09	F	3.1	4.7	10.5	18.3	38.7
10483-10	F	3.3				
10483-11	F	3.2				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10483-12	F	3.6				
10483-13	F	2.8	4.9	9.9	19.1	36.0
10483-14	F	3.2				
10483-15	F	2.5	4.9	8.2	19.3	33.3
MALES MEAN		3.4	4.7	8.0	19.2	39.8
FEMALES MEAN		3.0	4.9	9.4	18.4	37.1
10484-01	M	2.8	3.4	8.9	15.9	
10484-02	M	2.9				
10484-03	M	2.5	3.8	7.1	16.1	38.4
10484-04	M	2.5				
10484-05	M	2.7	3.6	8.6	16.1	41.3
10484-06	M	2.7	3.5	9.4	17.5	39.3
10484-07	M	2.8	3.7	9.5	16.1	38.2
10484-08	M	2.6	3.6	9.6	17.4	40.0
10484-09	M	2.4	2.6	7.5	16.8	36.2
10484-10	M	2.6				
10484-11	M	2.7				
10484-12	F	2.5	3.3	8.7	16.0	32.7
10484-13	F	2.1	3.6	9.3	16.0	32.3

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10484-14	F	2.7	3.6	8.1	16.6	
MALES MEAN		2.7	3.5	8.7	16.6	38.9
FEMALES MEAN		2.4	3.5	8.7	16.2	32.5
10530-02	M	1.2	2.9	6.7	15.5	27.2
10530-03	M		2.9	8.3	17.4	
10530-04	M	1.8	2.5	6.9	12.1	28.4
10530-05	F	2.7	2.9	6.8	14.9	27.4
10530-06	F	3.3				
10530-07	F	1.8	2.8	7.5	17.1	
10530-08	F	2.3	3.0	5.5	14.8	26.1
10530-09	F	2.4	2.9	5.6	12.4	27.9
10530-10	F	2.7	3.2	7.3	15.4	23.1
10530-11	F	1.7				
10530-12	F	2.5	3.0	7.0	14.4	25.8
10530-13	F	2.3				
10530-14	F	2.3	3.0	5.7	13.7	24.9
MALES MEAN		1.5	2.8	7.3	15.0	27.8
FEMALES MEAN		2.4	3.0	6.5	14.7	25.9
10534-01	M	3.5	2.9	8.7	13.6	31.2
10534-02	M	3.2	2.7	0.7	9.5	26.1
10534-03	M	3.2	2.4	6.3	11.4	
10534-04	M	3.6	2.9	8.6	12.1	35.4

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10534-05	F	2.9	2.2	8.9	15.2	31.6
10534-06	F	2.7	1.8	6.7	13.6	
10534-07	F	3.0				
10534-08	F	3.3	2.5	8.5	11.2	30.8
10534-09	F	2.8				
10534-10	M	3.3	2.5	7.8	6.5	31.5
10534-11	F	2.8	1.9	8.7	13.0	29.9
10534-12	F	3.2	2.7	8.3	13.0	31.7
MALES MEAN		3.4	2.7	6.4	10.6	31.1
FEMALES MEAN		3.0	2.2	8.2	13.2	31.0
10546-01	M	2.5	3.6	10.8	10.6	
10546-02	M	2.6				
10546-03	M	1.9	3.2	11.3	10.4	30.2
10546-04	M	2.3	3.5	11.2	13.1	37.5
10546-05	M	2.8	2.7	9.4	12.3	34.3
10546-06	M	2.5				
10546-07	M	2.5				
10546-09	M	2.7	3.6	10.9	12.5	37.3
10546-10	F	2.5	3.4	10.7	10.5	33.5
10546-11	F	2.0	3.4	9.9	11.8	
10546-12	F	2.6	3.3	10.3	13.0	29.6
10546-13	F	2.2				
10546-14	F	2.3	3.6	10.5		

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10546-15	F	2.3	2.7	9.4	12.6	31.6
MALES MEAN		2.5	3.3	10.7	11.8	34.8
FEMALES MEAN		2.3	3.3	10.2	12.0	31.6
10548-01	M	2.3				
10548-02	M	2.0	4.3	11.6	12.3	39.1
10548-03	M	2.4	4.3	12.1	13.1	39.4
10548-04	M	1.5	4.0	11.5	11.6	36.8
10548-05	M	1.7				
10548-06	M	1.6				
10548-07	M	1.7	3.8	10.9	15.1	
10548-08	M	2.0	3.9	11.2	12.6	37.2
10548-09	M	1.7				
10548-10	M	2.7				
10548-11	M	1.9				
10548-12	F	1.9	3.8	12.3	14.2	38.5
10548-13	F	1.5	3.4	11.7	12.3	33.6
10548-14	F	1.8				
10548-15	F	2.0	3.6	11.1	12.7	32.2
10548-16	F	1.7	4.3	11.8	12.0	35.6

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10548-17	F	2.7	3.9	12.8	12.9	
MALES MEAN		2.0	4.1	11.5	12.9	38.1
FEMALES MEAN		1.9	3.8	11.9	12.8	35.0
10550-02	M	1.8	4.2	7.5	16.0	38.9
10550-03	M	2.0				
10550-04	M	1.9	4.1	8.1	13.6	39.8
10550-05	M	2.0				
10550-06	M	2.4				
10550-07	M	2.2				
10550-08	M	2.7				
10550-09	M	2.6				
10550-10	M	2.4	4.8	16.8	20.8	40.4
10550-11	M	1.9				
10550-12	M	1.9	4.0	15.8	19.1	
10550-13	M	2.4				
10550-14	M	1.6	3.4	13.3	12.6	35.3
10550-15	M	2.5				
10550-16	F	1.8				
10550-17	F	2.1	4.0	14.1	21.1	37.6
10550-18	F	2.2	4.0	15.0	18.5	36.7
10550-19	F	2.1	4.4	16.1	18.7	40.1
10550-20	F	2.1	4.3	12.4	17.5	

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM						
10550-21	F	2.3	4.1	10.9	17.2	37.2
MALES MEAN		2.2	4.1	12.3	16.4	38.6
FEMALES MEAN		2.1	4.2	13.7	18.6	37.9
MALES MEAN		2.4	3.3	8.8	14.4	34.8
	SD	0.72	0.92	2.94	2.71	4.59
	N	9	9	9	9	9
FEMALES MEAN		2.3	3.2	8.8	14.4	30.8
	SD	0.55	0.99	3.74	2.97	6.63
	N	9	9	9	9	9

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10465-01	M	3.6	3.0	5.8	15.9	
10465-02	M	4.0	3.1	5.9	15.4	29.7
10465-03	M	4.1	3.2	6.9	17.1	30.6
10465-04	M	4.2	2.7	7.1	16.7	32.4
10465-05	M	4.1	3.3	6.1	14.1	29.2
10465-06	F	4.0	3.0	6.0	17.2	28.1
10465-07	F	3.7	2.9	5.2	14.5	28.9
10465-08	F	4.3	3.1	7.9	14.5	27.5
10465-09	F	3.8	2.8	7.8	15.5	
10465-10	F	4.1	3.0	6.6	16.2	26.6
MALES MEAN		4.0	3.1	6.4	15.8	30.5
FEMALES MEAN		4.0	3.0	6.7	15.6	27.8
10473-03	M	2.2	2.0	10.8	12.3	30.4
10473-04	M	3.8	3.4	13.2	14.5	38.0
10473-05	M	4.2	3.8	15.4	18.9	
10473-06	F	3.9	3.3	13.8	17.4	
10473-07	F	3.8	3.8	13.3	16.7	35.1
10473-09	F	3.2	3.0	13.9	16.1	33.5
10473-10	F	3.2	2.5	11.7	15.7	31.7
MALES MEAN		3.4	3.1	13.1	15.2	34.2
FEMALES MEAN		3.5	3.2	13.2	16.5	33.4
10480-02	M	2.1	1.8	8.3	7.8	31.9

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10480-03	M	3.0	2.7	4.6	8.4	29.6
10480-04	M	3.0	2.9	6.9	9.2	36.2
10480-05	M	2.4	2.8	8.3	7.9	34.9
10480-06	M	2.9				
10480-07	M	2.5	2.5	8.9	8.7	33.9
10480-08	F	2.4	2.7	9.2	9.4	36.2
10480-09	M	2.5	2.4	3.2	8.4	
10480-10	F	2.7	2.2	4.8	7.6	28.3
10480-11	M	2.6	3.0	8.0	8.9	34.9
10480-12	F	2.6	2.3	8.2	8.7	
MALES MEAN		2.6	2.6	6.9	8.5	33.6
FEMALES MEAN		2.6	2.4	7.4	8.6	32.3
10481-01	M	3.8	3.5	3.9	11.7	34.2
10481-02	M	3.9	3.5	3.0	10.3	32.6
10481-03	M	3.6	3.9	4.2	11.4	37.6
10481-04	M	3.5				
10481-05	M	3.1	3.5	3.9	10.2	31.5
10481-06	M	3.4	3.6	3.2	10.4	31.8
10481-07	M	3.6	4.2	3.1	12.8	
10481-08	M	3.6				
10481-09	M	3.4				
10481-10	F	3.3	3.1	4.4	9.9	28.1
10481-11	F	3.8	3.5	2.7	12.5	
10481-12	F	3.3	3.3	4.5	10.7	27.5

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10481-13	F	3.7	3.3	2.8	11.7	30.0
MALES MEAN		3.5	3.7	3.6	11.1	33.5
FEMALES MEAN		3.5	3.3	3.6	11.2	28.5
10486-01	M	2.3	1.8	8.6	14.0	
10486-02	M	3.5	5.2	13.4	23.2	40.5
10486-03	M	3.7	4.9	13.2	22.6	38.9
10486-04	M	2.7				
10486-05	M	3.1				
10486-07	M	3.4	5.2	13.8	22.7	40.6
10486-08	M	4.4				
10486-09	M	3.7	4.9	13.7	22.1	43.5
10486-10	F	3.1				
10486-11	F	3.0	4.5	12.2	21.1	35.5
10486-12	F	2.6	4.6	12.8	18.0	31.9
10486-13	F	3.5	4.9	13.1	20.8	32.5
10486-14	F	2.9				
10486-15	F	3.0	4.9	12.7	18.2	
10486-16	F	3.6				
MALES MEAN		3.4	4.4	12.5	20.9	40.9
FEMALES MEAN		3.1	4.7	12.7	19.5	33.3
10507-01	M	2.0	2.8	4.5	12.3	
10507-02	M	2.5	1.2	4.1	11.1	26.0

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10507-03	M	2.1	2.6	4.0	11.6	27.5
10507-04	M	2.5	2.1	2.9	11.1	25.0
10507-05	M	1.5	1.8	2.9	9.9	20.6
10507-06	M	2.4				
10507-07	M	2.0				
10507-08	F	2.0	1.4	4.4	10.1	22.8
10507-09	F	2.5				
10507-10	F	2.4	2.8	4.9	13.3	26.0
10507-11	F	2.1				
10507-12	F	2.4	2.5	5.5	11.9	24.0
10507-13	F	1.5	1.4	8.5	11.4	23.0
10507-14	F	1.7				
10507-15	F	2.4	2.9	4.6	11.8	
MALES MEAN		2.1	2.1	3.7	11.2	24.8
FEMALES MEAN		2.1	2.2	5.6	11.7	24.0
10529-01	M	2.1	2.7	9.1	17.4	37.1
10529-04	M	2.7	2.6	10.0	17.4	
10529-06	M	1.7	2.9	9.2	16.7	35.8
MALES MEAN		2.2	2.7	9.4	17.2	36.5
FEMALES MEAN						
10532-01	M	4.4	3.1	10.6	20.0	
10532-02	M	3.7	3.5	10.8	19.2	34.9

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10532-03	M	4.1	3.0	9.9	16.1	31.2
10532-04	M	3.1	2.9	10.6	20.0	31.3
10532-05	M	3.6	3.2	10.3	17.2	32.7
10532-07	F	3.5	2.8	9.6	16.9	26.5
10532-08	F	3.1	3.0	10.4	19.4	
10532-10	F	4.3	3.0	8.9	16.9	32.2
10532-11	F	4.3				
10532-12	F	-0.9				
10532-13	F	3.1	3.4	9.7	17.1	26.6
MALES MEAN		3.8	3.1	10.4	18.5	32.5
FEMALES MEAN		2.9	3.1	9.7	17.6	28.4
10547-01	M	1.4	3.4	8.2	14.3	34.8
10547-02	M	1.8	3.0	6.5	13.9	34.1
10547-03	M	2.8				
10547-04	M	1.9				
10547-05	M	3.2	4.6	14.8	22.6	
10547-06	M	2.6				
10547-07	M	2.7				
10547-08	M	1.6	3.1	11.2	18.3	34.3
10547-09	M	2.6	3.7	4.7	16.6	32.2
10547-10	F	2.0				
10547-11	F	1.7	3.1	12.7	17.4	30.2
10547-12	F	2.3	4.4	11.7	15.7	34.4
10547-13	F	1.8	4.0	15.0	20.3	

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000 PPM						
10547-14	F	2.0	3.9	14.6	21.9	-5.1
10547-15	M	2.0				
10547-16	M	1.7				
10547-17	M	2.0				
MALES MEAN		2.2	3.6	9.1	17.1	33.9
FEMALES MEAN		2.0	3.9	13.5	18.8	19.8
MALES MEAN		3.0	3.2	8.3	15.1	33.4
	SD	0.75	0.68	3.46	4.01	4.33
	N	9	9	9	9	9
FEMALES MEAN		3.0	3.2	9.1	14.9	28.4
	SD	0.70	0.80	3.79	3.97	4.75
	N	8	8	8	8	8

TABLE 155 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL LITTER VIABILITY

LITTERS FROM GROUP 1: 0 PPM/0 MG/KG

DAM #	NO. DEAD DAY 0 M	F	U	NO. VIABLE DAY 0 M	%	F	%	TOTAL	NUMBER OF VIABLE PUPS DAY 1 M	F	BEFORE SELECTION DAY 4 M	F	AFTER SELECTION DAY 4 M	F	DAY 7 M	F	DAY 14 M	F	DAY 21 M	F
10485	0	0	0	5/ 5	100	7/ 7	100	12	5	7	5	7	5	5	5	5	5	5	4	5
10491	0	0	0	2/ 2	100	5/ 5	100	7	2	5	2	5	2	5	2	5	2	5	2	5
10496	0	0	0	9/ 9	100	10/10	100	19	8	9	8	9	5	5	5	5	5	5	5	5
10498	0	0	0	9/ 9	100	6/ 6	100	15	9	6	9	6	5	5	5	5	5	5	5	5
10512	0	0	0	8/ 8	100	6/ 6	100	14	8	6	8	6	5	5	5	5	5	5	5	5
10514	1	0	0	7/ 8	88	8/ 8	100	15	7	8	7	8	5	5	5	4	5	4	5	4
10521	0	0	0	8/ 8	100	10/10	100	18	8	9	6	8	5	5	5	5	5	5	5	5
10537	0	0	0	6/ 6	100	10/10	100	16	6	10	6	10	5	5	5	5	5	5	5	5
TOTAL	1	0	0	54/ 55		62/ 62		116	53	60	51	59	37	40	37	39	37	39	36	39

M = MALE, F = FEMALE, U = UNDETERMINED

TABLE 155 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL LITTER VIABILITY

LITTERS FROM GROUP 2: 100 PPM/90 MG/KG

	NO. DEAD DAY 0			NO. VIABLE DAY 0					NUMBER OF VIABLE PUPS											
									DAY 1		BEFORE SELECTION DAY 4		AFTER SELECTION DAY 4		DAY 7		DAY 14		DAY 21	
DAM #	M	F	U	M	%	F	%	TOTAL	M	F	M	F	M	F	M	F	M	F	M	F
10487	0	0	0	4/ 4	100	8/ 8	100	12	4	8	4	8	4	6	4	6	4	6	4	6
10492	0	0	0	8/ 8	100	9/ 9	100	17	8	9	7	8	5	5	5	5	5	5	4	4
10495	0	0	0	9/ 9	100	10/10	100	19	9	10	8	9	5	5	5	5	5	5	5	5
10499	0	0	0	8/ 8	100	6/ 6	100	14	8	6	8	6	5	5	5	5	5	5	5	5
10515	0	0	0	8/ 8	100	7/ 7	100	15	8	7	8	7	5	5	5	5	5	5	5	5
10516	0	0	0	6/ 6	100	7/ 7	100	13	6	7	6	7	5	5	5	5	5	5	5	5
10552	0	0	0	9/ 9	100	6/ 6	100	15	9	6	9	6	5	5	5	5	5	5	5	5
10556	0	0	0	6/ 6	100	9/ 9	100	15	6	9	6	9	5	5	5	5	5	5	5	5
TOTAL	0	0	0	58/ 58		62/ 62		120	58	62	56	60	39	41	39	41	39	41	38	40

M = MALE, F = FEMALE, U = UNDETERMINED

LITTERS FROM GROUP 3: 500 PPM/342MG/KG

	NO. DEAD DAY 0			NO. VIABLE DAY 0					NUMBER OF VIABLE PUPS											
									DAY 1		BEFORE SELECTION DAY 4		AFTER SELECTION DAY 4		DAY 7		DAY 14		DAY 21	
DAM #	M	F	U	M	%	F	%	TOTAL	M	F	M	F	M	F	M	F	M	F	M	F
10475	0	0	0	10/10	100	3/ 3	100	13	10	3	10	3	7	3	7	3	7	3	7	3
10489	0	1	0	4/ 4	100	12/13	92	16	4	12	4	12	4	6	4	6	4	6	4	6
10490	1	0	0	6/ 7	86	8/ 8	100	14	6	8	6	8	5	5	5	5	5	5	5	5
10497	0	1	0	7/ 7	100	9/10	90	16	7	6	7	6	5	5	5	5	5	5	5	5
10501	0	0	0	4/ 4	100	10/10	100	14	4	10	4	10	4	6	4	6	4	6	4	6
10505	0	2	0	9/ 9	100	7/ 9	78	16	9	7	9	7	5	5	5	5	5	5	5	5
10517	0	0	0	8/ 8	100	6/ 6	100	14	8	6	8	6	5	5	5	5	5	5	4	5
10531	0	1	0	6/ 6	100	8/ 9	89	14	6	8	6	8	5	5	5	5	5	5	5	5
10533	0	0	0	2/ 2	100	4/ 4	100	6	2	4	2	4	2	4	2	4	2	4	2	4
10538	0	0	0	4/ 4	100	9/ 9	100	13	4	9	4	9	4	6	4	6	4	6	4	6
TOTAL	1	5	0	60/ 61		76/ 81		136	60	73	60	73	46	50	46	50	46	50	45	50

M = MALE, F = FEMALE, U = UNDETERMINED

LITTERS FROM GROUP 4: 1000PPM/621MG/KG

	NO. DEAD DAY 0			NO. VIABLE DAY 0					NUMBER OF VIABLE PUPS											
									DAY 1		BEFORE SELECTION DAY 4		AFTER SELECTION DAY 4		DAY 7		DAY 14		DAY 21	
DAM #	M	F	U	M	%	F	%	TOTAL	M	F	M	F	M	F	M	F	M	F	M	F
10466	0	0	0	4/ 4	100	12/12	100	16	4	12	4	12	4	6	4	6	4	6	4	6
10469	0	0	0	10/10	100	6/ 6	100	16	10	4	9	4	6	4	6	4	6	4	6	4
10477	0	2	0	7/ 7	100	9/11	82	16	7	9	7	8	5	5	5	5	5	5	5	5
10502	3	1	0	3/ 6	50	7/ 8	88	10	3	5	1	3	1	3	1	3	1	3	1	3
10526	0	0	0	5/ 5	100	11/11	100	16	5	11	5	11	5	5	5	5	5	5	5	5
10527	0	0	0	7/ 7	100	8/ 8	100	15	7	8	7	8	5	5	5	5	5	5	5	5
10541	0	0	0	6/ 6	100	8/ 8	100	14	6	8	6	8	5	5	5	5	5	5	5	5
10542	0	0	0	5/ 5	100	8/ 8	100	13	5	8	5	8	5	5	5	5	5	5	5	5
10544	0	0	0	9/ 9	100	6/ 6	100	15	9	6	9	6	5	5	5	5	5	5	5	5
10545	0	1	0	5/ 5	100	11/12	92	16	5	11	5	11	5	5	5	5	5	5	5	5
TOTAL	3	4	0	61/ 64		86/ 90		147	61	82	58	79	46	48	46	48	46	48	46	48

M = MALE, F = FEMALE, U = UNDETERMINED

TABLE 156 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 1: 0 PPM/0 MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10485	17-OCT-02	20	a28	b21	d28	a28	C	a28	a28	b21	d28	a28	C							
		M	M	M	M	M	F	F	F	F	F	F	F							
10491	17-OCT-02	d28	b21	a28	d28	a28	a28	b21												
		M	M	F	F	F	F	F												
10496	23-OCT-02	1	b21	C	a28	d28	C	C	a28	a28	a28	C	C	a28	d28	C	b21	C	a28	1
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F
10498	16-OCT-02	C	a28	a28	a28	C	b21	C	d28	C	b21	C	a28	a28	a28	d28				
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F				
10512	16-OCT-02	C	a28	C	d28	b21	a28	a28	C	a28	a28	a28	d28	b21	C					
		M	M	M	M	M	M	M	M	F	F	F	F	F	F					
10514	18-OCT-02	0	a28	a28	a28	C	b21	C	d28	C	a28	b21	C	a28	7	C	d28			
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F			
10521	17-OCT-02	C	b21	a28	3	d28	a28	a28	3	C	a28	1	C	C	d28	a28	a28	b21	4	
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F	
10537	16-OCT-02	b21	d28	a28	a28	C	a28	d28	C	C	a28	a28	b21	a28	C	C	C			
		M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F			

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

TABLE 156 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 2: 100 PPM/90 MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10487	16-OCT-02	d28	a28	a28	b21	C	d28	a28	a28	b21	a28	a28	C							
		M	M	M	M	F	F	F	F	F	F	F	F							
10492	15-OCT-02	C	b21	a28	a28	d28	3	15	C	d28	a28	15	b21	C	C	C	a28	2		
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F		
10495	19-OCT-02	a28	b21	C	a28	2	C	d28	C	a28	C	C	C	a28	C	b21	3	a28	a28	d28
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F
10499	15-OCT-02	a28	d28	a28	b21	a28	C	C	C	a28	b21	C	d28	a28	a28					
		M	M	M	M	M	M	M	M	F	F	F	F	F	F					
10515	16-OCT-02	a28	d28	a28	C	C	a28	C	b21	C	b21	a28	a28	a28	C	d28				
		M	M	M	M	M	M	M	M	F	F	F	F	F	F	F				
10516	18-OCT-02	a28	a28	a28	d28	b21	C	b21	a28	a28	d28	a28	C	C						
		M	M	M	M	M	M	F	F	F	F	F	F	F						
10552	18-OCT-02	C	a28	C	C	C	a28	a28	b21	d28	a28	b21	a28	d28	C	a28				
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F				
10556	15-OCT-02	a28	a28	a28	d28	b21	C	d28	C	C	a28	b21	a28	a28	C	C				
		M	M	M	M	M	M	F	F	F	F	F	F	F	F	F				

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

LITTERS FROM GROUP 3: 500 PPM/342MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10475	15-OCT-02	C	d28	a28	a28	b21	a28	a28	C	C	a28	a28	d28	b21						
		M	M	M	M	M	M	M	M	M	M	F	F	F						
10489	27-OCT-02	0	b21	a28	a28	d28	a28	a28	C	a28	C	d28	C	a28	C	C	b21	C		
		F	M	M	M	M	F	F	F	F	F	F	F	F	F	F	F	F		
10490	17-OCT-02	0	a28	a28	a28	d28	C	b21	b21	a28	d28	C	a28	C	C	a28				
		M	M	M	M	M	M	M	F	F	F	F	F	F	F	F				
10497	16-OCT-02	0	a28	C	b21	C	d28	a28	a28	1	1	a28	d28	C	a28	a28	b21	1		
		F	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F		
10501	18-OCT-02	b21	a28	d28	a28	b21	a28	C	C	C	d28	C	a28	a28	a28					
		M	M	M	M	F	F	F	F	F	F	F	F	F	F					
10505	16-OCT-02	0	0	d28	a28	b21	a28	C	a28	C	C	C	a28	a28	C	b21	a28	d28	C	
		F	F	M	M	M	M	M	M	M	M	M	F	F	F	F	F	F	F	
10517	16-OCT-02	a28	b21	a28	20	C	C	C	d28	a28	b21	a28	d28	a28	C					
		M	M	M	M	M	M	M	M	F	F	F	F	F	F					
10531	16-OCT-02	0	d28	a28	b21	C	a28	a28	d28	C	C	b21	a28	a28	C	a28				
		F	M	M	M	M	M	M	F	F	F	F	F	F	F	F				
10533	17-OCT-02	b21	d28	d28	a28	a28	b21													
		M	M	F	F	F	F													

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

TABLE 156 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 3: 500 PPM/342MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10538	18-OCT-02	a28	a28	d28	b21	d28	C	a28	C	b21	a28	C	a28	a28						
		M	M	M	M	F	F	F	F	F	F	F	F	F						

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

TABLE 156 (F1 - INHALATION/GAVAGE PHASE)

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 4: 1000PPM/621MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10466	19-OCT-02	a28	b21	d28	a28	C	a28	C	a28	a28	C	C	C	C	b21	d28	a28			
		M	M	M	M	F	F	F	F	F	F	F	F	F	F	F	F			
10469	16-OCT-02	1	1	b21	C	a28	d28	2	a28	a28	C	a28	C	d28	b21	a28	a28			
		F	F	M	M	M	M	M	M	M	M	M	M	F	F	F	F			
10477	16-OCT-02	0	0	b21	a28	d28	a28	C	C	a28	C	a28	b21	C	a28	a28	4	d28	C	
		F	F	M	M	M	M	M	M	M	F	F	F	F	F	F	F	F	F	
10502	15-OCT-02	0	3	0	0	2	0	2	b21	1	1	d28	2	b21	a28					
		M	M	M	M	M	F	F	F	F	F	F	F	M	F					
10526	14-OCT-02	d28	a28	a28	b21	a28	C	C	d28	C	C	a28	a28	a28	C	C	b21			
		M	M	M	M	M	F	F	F	F	F	F	F	F	F	F	F			
10527	15-OCT-02	b21	C	a28	a28	d28	C	a28	C	C	d28	a28	C	a28	a28	b21				
		M	M	M	M	M	M	M	F	F	F	F	F	F	F	F				
10541	16-OCT-02	a28	C	b21	a28	a28	d28	a28	d28	C	a28	a28	C	b21	C					
		M	M	M	M	M	M	F	F	F	F	F	F	F	F					
10542	16-OCT-02	a28	a28	d28	a28	a28	b21	a28	C	a28	d28	b21	C	C						
		M	M	M	M	F	M	F	F	F	F	F	F	F						
10544	17-OCT-02	C	C	d28	a28	b21	C	a28	C	a28	a28	a28	b21	a28	C	d28				
		M	M	M	M	M	M	M	M	M	F	F	F	F	F	F				

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

TABLE 156 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP VIABILITY

LITTERS FROM GROUP 4: 1000PPM/621MG/KG

DAM #	DAY OF BIRTH	PUP # 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
10545	15-OCT-02	0	d28	a28	a28	a28	b21	C	C	d28	C	C	a28	C	b21	C	a28	a28		
		F	M	M	M	M	M	F	F	F	F	F	F	F	F	F	F	F		

A = ALIVE, NUMBER INDICATES POSTNATAL DAY WHEN DEATH OCCURRED, C = CULLED DAY 4
M = MALE, F = FEMALE, U = UNDETERMINED
a=SCHEDULED EUTHANASIA
b=SELECTED FOR EXPOSURE; POST NATAL DAY 22-33
d=SELECTED FOR EXPOSURE; POST NATAL DAY 29-33

PLITRv4.0
01/15/2003

TABLE 157 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10485	1	M	SUBCUTANEOUS HEMORRHAGE(S)	0
			AROUND NOSE	
			SUBCUTANEOUS HEMORRHAGE(S)	1
			AROUND NOSE	
			FOUND DEAD	20
			PARTIALLY CANNIBALIZED	
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	6	F	CULLED ON SCHEDULED DAY	4
	7	F	SCHEDULED EUTHANASIA	28
	8	F	SCHEDULED EUTHANASIA	28
	9	F	SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SMALL IN SIZE	14
			SMALL IN SIZE	21
			SMALL IN SIZE	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SMALL IN SIZE	14
			SMALL IN SIZE	21
			SMALL IN SIZE	28
			SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
10491	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10491	3	F	SCHEDULED EUTHANASIA	28
	4	F	SELECTED FOR EXPOSURE; PND 29-33	28
	5	F	SCHEDULED EUTHANASIA	28
	6	F	SCHEDULED EUTHANASIA	28
	7	F	SELECTED FOR EXPOSURE; PND 22-33	21
10496	1	M	FOUND DEAD	1
	2	M	SCABBING	4
			VENTRAL THORACIC AREA	
			SCABBING	7
			VENTRAL THORACIC AREA	
			SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SMALL IN SIZE	7
			SMALL IN SIZE	14
			SMALL IN SIZE	21
			SCHEDULED EUTHANASIA	28
	9	M	SCHEDULED EUTHANASIA	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SELECTED FOR EXPOSURE; PND 29-33	28
	15	F	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10496	16	F	SELECTED FOR EXPOSURE; PND 22-33	21
	17	F	CULLED ON SCHEDULED DAY	4
	18	F	SCHEDULED EUTHANASIA	28
	19	F	FOUND DEAD	1
10498	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SELECTED FOR EXPOSURE; PND 29-33	28
	9	M	CULLED ON SCHEDULED DAY	4
	10	F	SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SELECTED FOR EXPOSURE; PND 29-33	28
10512	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10512	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	SCHEDULED EUTHANASIA	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SELECTED FOR EXPOSURE; PND 22-33	21
	14	F	CULLED ON SCHEDULED DAY	4
10514	1	M	FOUND DEAD	0
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SELECTED FOR EXPOSURE; PND 29-33	28
			BLACKENED IN COLOR RIGHT FORELIMB	5
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SWELLING	7
			LEFT FORELIMB; BLACK AREA SURROUNDED BY WHITE AREA	

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10514	14	F	EUTHANIZED IN EXTREMIS	7
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SWELLING	7
			RIGHT FORELIMB	
			SCABBING	7
			RIGHT FORELIMB	
			SWELLING	14
			RIGHT FORELIMB	
			SWELLING	21
			RIGHT FORELIMB	
			SELECTED FOR EXPOSURE; PND 29-33	28
10521	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	FOUND DEAD	3
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	SCHEDULED EUTHANASIA	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	FOUND DEAD	3
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	FOUND DEAD	1
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SMALL IN SIZE	7
			SMALL IN SIZE	14
			SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 1: 0 PPM/0 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10521	15	F	SCHEDULED EUTHANASIA	28
	16	F	SCHEDULED EUTHANASIA	28
	17	F	SELECTED FOR EXPOSURE; PND 22-33	21
	18	F	FOUND DEAD	4
10537	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SCHEDULED EUTHANASIA	28
	7	F	SELECTED FOR EXPOSURE; PND 29-33	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	DRIED RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM/90 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10487	1	M	SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	F	SUBCUTANEOUS HEMORRHAGE(S)	1
			MANDIBULAR AREA	
			CULLED ON SCHEDULED DAY	4
	6	F	SELECTED FOR EXPOSURE; PND 29-33	28
	7	F	SCHEDULED EUTHANASIA	28
	8	F	SCHEDULED EUTHANASIA	28
	9	F	WET RED MATERIAL	14
			NOSE	
			SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
10492	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	FOUND DEAD	3
	7	M	FOUND DEAD	15
	8	M	CULLED ON SCHEDULED DAY	4
	9	F	SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM/90 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10492	10	F	SCHEDULED EUTHANASIA	28
	11	F	FOUND DEAD	15
	12	F	SELECTED FOR EXPOSURE; PND 22-33	21
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SCHEDULED EUTHANASIA	28
	17	F	FOUND DEAD	2
10495	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SCHEDULED EUTHANASIA	28
	5	M	MISSING	2
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SELECTED FOR EXPOSURE; PND 29-33	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SMALL IN SIZE	14
			BRIGHT YELLOW FECES	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	16	F	FOUND DEAD	3
	17	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM/90 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10495	18	F	SCHEDULED EUTHANASIA	28
	19	F	SELECTED FOR EXPOSURE; PND 29-33	28
10499	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	SCHEDULED EUTHANASIA	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	CULLED ON SCHEDULED DAY	4
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28
10515	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SCHEDULED EUTHANASIA	28
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	DRIED RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM/90 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10515	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SELECTED FOR EXPOSURE; PND 29-33	28
10516	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	CULLED ON SCHEDULED DAY	4
	7	F	SELECTED FOR EXPOSURE; PND 22-33	21
	8	F	SCHEDULED EUTHANASIA	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
10552	1	M	CULLED ON SCHEDULED DAY	4
	2	M	SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 2: 100 PPM/90 MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10552	7	M	SCHEDULED EUTHANASIA	28
	8	M	SELECTED FOR EXPOSURE; PND 22-33	21
	9	M	SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SELECTED FOR EXPOSURE; PND 29-33	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
10556	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 29-33	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	CULLED ON SCHEDULED DAY	4
	7	F	SELECTED FOR EXPOSURE; PND 29-33	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	CULLED ON SCHEDULED DAY	4

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10475	1	M	SUBCUTANEOUS HEMORRHAGE(S) RIGHT MANDIBULAR AREA	0
			SUBCUTANEOUS HEMORRHAGE(S) RIGHT MANDIBULAR AREA	1
			CULLED ON SCHEDULED DAY	4
	2	M	DARK RED IN COLOR DISTAL END OF TAIL	14
			DARK RED IN COLOR DISTAL END OF TAIL	21
			MISSING DISTAL END OF TAIL	28
			SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	SCHEDULED EUTHANASIA	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	CULLED ON SCHEDULED DAY	4
	10	M	SCHEDULED EUTHANASIA	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	SELECTED FOR EXPOSURE; PND 22-33	21
10489	1	F	FOUND DEAD	0
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	F	SCHEDULED EUTHANASIA	28
	7	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10489	8	F	CULLED ON SCHEDULED DAY	4
	9	F	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SELECTED FOR EXPOSURE; PND 29-33	28
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SELECTED FOR EXPOSURE; PND 22-33	21
	17	F	CULLED ON SCHEDULED DAY	4
10490	1	M	FOUND DEAD	0
	2	M	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SELECTED FOR EXPOSURE; PND 22-33	21
	8	F	SELECTED FOR EXPOSURE; PND 22-33	21
	9	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCABBING	14
			ANOGENITAL AREA	

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10490	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
10497	1	F	FOUND DEAD	0
	2	M	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	3	M	CULLED ON SCHEDULED DAY	4
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SELECTED FOR EXPOSURE; PND 29-33	28
	7	M	SCHEDULED EUTHANASIA	28
	8	M	SCHEDULED EUTHANASIA	28
	9	F	FOUND DEAD	1
	10	F	MISSING	1
	11	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			RING-LIKE INDENTATIONS ON TAIL	14
			RING-LIKE INDENTATIONS ON TAIL	21
			SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10497	16	F	SELECTED FOR EXPOSURE; PND 22-33	21
	17	F	MISSING	1
10501	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCHEDULED EUTHANASIA	28
	5	F	SELECTED FOR EXPOSURE; PND 22-33	21
	6	F	SCHEDULED EUTHANASIA	28
	7	F	CULLED ON SCHEDULED DAY	4
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	WET RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28
10505	1	F	FOUND DEAD	0
	2	F	FOUND DEAD	0
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	DRIED RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10505	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SCHEDULED EUTHANASIA	28
	9	M	CULLED ON SCHEDULED DAY	4
	10	M	CULLED ON SCHEDULED DAY	4
	11	M	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
	16	F	SCHEDULED EUTHANASIA	28
	17	F	SELECTED FOR EXPOSURE; PND 29-33	28
	18	F	CULLED ON SCHEDULED DAY	4
10517	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SMALL IN SIZE	14
			MISSING	20
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 22-33	21
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10517	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
10531	1	F	FOUND DEAD	0
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	CULLED ON SCHEDULED DAY	4
	6	M	SCHEDULED EUTHANASIA	28
	7	M	SCHEDULED EUTHANASIA	28
	8	F	SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SCABBING ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SCHEDULED EUTHANASIA	28
10533	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	SELECTED FOR EXPOSURE; PND 29-33	28
	3	F	SELECTED FOR EXPOSURE; PND 29-33	28
	4	F	SCHEDULED EUTHANASIA	28
	5	F	SCHEDULED EUTHANASIA	28
	6	F	SELECTED FOR EXPOSURE; PND 22-33	21

ALL OBSERVATION PERIODS

DAMS FROM GROUP 3: 500 PPM/342MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10538	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	F	SELECTED FOR EXPOSURE; PND 29-33	28
	6	F	CULLED ON SCHEDULED DAY	4
	7	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	LACERATION(S)	1
			NOSE	
			SCABBING	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 22-33	21
	10	F	SCHEDULED EUTHANASIA	28
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10466	1	M	SCHEDULED EUTHANASIA	28
	2	M	SELECTED FOR EXPOSURE; PND 22-33	21
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCHEDULED EUTHANASIA	28
	5	F	CULLED ON SCHEDULED DAY	4
	6	F	SCHEDULED EUTHANASIA	28
	7	F	CULLED ON SCHEDULED DAY	4
	8	F	SCHEDULED EUTHANASIA	28
	9	F	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SELECTED FOR EXPOSURE; PND 22-33	21
	15	F	SELECTED FOR EXPOSURE; PND 29-33	28
	16	F	SCHEDULED EUTHANASIA	28
10469	1	F	MISSING	1
	2	F	FOUND DEAD	1
	3	M	BRIGHT YELLOW FECES	14
			LOOSE FECES	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	CULLED ON SCHEDULED DAY	4
	5	M	SMALL IN SIZE	4
			SMALL IN SIZE	7
			SMALL IN SIZE	14
			BRIGHT YELLOW FECES	14
			LOOSE FECES	14

TABLE 157 (F1 - INHALATION/GAVAGE PHASE)

INDIVIDUAL PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10469	5	M	SMALL IN SIZE	21
			SMALL IN SIZE	28
			SCHEDULED EUTHANASIA	28
	6	M	BRIGHT YELLOW FECES	14
			LOOSE FECES	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	7	M	FOUND DEAD	2
	8	M	BRIGHT YELLOW FECES	14
			LOOSE FECES	14
			SCHEDULED EUTHANASIA	28
	9	M	SCHEDULED EUTHANASIA	28
	10	M	SMALL IN SIZE	1
			SMALL IN SIZE	4
			CULLED ON SCHEDULED DAY	4
	11	M	SCHEDULED EUTHANASIA	28
	12	M	CULLED ON SCHEDULED DAY	4
	13	F	SELECTED FOR EXPOSURE; PND 29-33	28
	14	F	BRIGHT YELLOW FECES	14
			LOOSE FECES	14
			SELECTED FOR EXPOSURE; PND 22-33	21
	15	F	SUBCUTANEOUS HEMORRHAGE(S) ANOGENITAL AREA	14
			SCHEDULED EUTHANASIA	28
	16	F	SCHEDULED EUTHANASIA	28
10477	1	F	FOUND DEAD	0
	2	M	FOUND DEAD	0
	3	M	DRIED RED MATERIAL ANOGENITAL AREA	14

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10477	3	M	SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	7	M	CULLED ON SCHEDULED DAY	4
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	SCHEDULED EUTHANASIA	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	12	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 22-33	21
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SCHEDULED EUTHANASIA	28
	15	F	SMALL IN SIZE	14
			UNEVEN HAIR GROWTH	28
			SCHEDULED EUTHANASIA	28
	16	F	MISSING	4
	17	F	SELECTED FOR EXPOSURE; PND 29-33	28
	18	F	CULLED ON SCHEDULED DAY	4
10502	1	M	FOUND DEAD	0
	2	M	FOUND DEAD	3
	3	M	EUTHANIZED IN EXTREMIS	0
			PARTIALLY CANNIBALIZED	

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10502	4	M	EUTHANIZED IN EXTREMIS	0
			PARTIALLY CANNIBALIZED	
	5	M	MISSING	2
	6	F	EUTHANIZED IN EXTREMIS	0
			PARTIALLY CANNIBALIZED	
	7	F	FOUND DEAD	2
	8	F	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	9	F	MISSING	1
	10	F	MISSING	1
	11	F	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH	21
			SELECTED FOR EXPOSURE; PND 29-33	28
	12	F	MISSING	2
	13	M	UNEVEN HAIR GROWTH	14
			UNEVEN HAIR GROWTH	21
			SELECTED FOR EXPOSURE; PND 22-33	21
	14	F	UNEVEN HAIR GROWTH	14
			SCHEDULED EUTHANASIA	28
10526	1	M	SUBCUTANEOUS HEMORRHAGE NOSE	0
			SUBCUTANEOUS HEMORRHAGE NOSE	1
			SELECTED FOR EXPOSURE; PND 29-33	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SELECTED FOR EXPOSURE; PND 22-33	21
	5	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10526	6	F	CULLED ON SCHEDULED DAY	4
	7	F	CULLED ON SCHEDULED DAY	4
	8	F	SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	SCHEDULED EUTHANASIA	28
	12	F	SCHEDULED EUTHANASIA	28
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SUBCUTANEOUS HEMORRHAGE(S) MOUTH	1
			CULLED ON SCHEDULED DAY	4
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SELECTED FOR EXPOSURE; PND 22-33	21
10527	1	M	SELECTED FOR EXPOSURE; PND 22-33	21
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 29-33	28
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	SCHEDULED EUTHANASIA	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SCHEDULED EUTHANASIA	28
	14	F	SCHEDULED EUTHANASIA	28

TABLE 157 (F1 - INHALATION/GAVAGE PHASE)

INDIVIDUAL PUP CLINICAL OBSERVATIONS

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10527	15	F	SELECTED FOR EXPOSURE; PND 22-33	21
10541	1	M	SCHEDULED EUTHANASIA	28
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	SELECTED FOR EXPOSURE; PND 22-33	21
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	BODY COOL TO TOUCH	14
			DARK RED IN COLOR DISTAL END OF TAIL	14
			SELECTED FOR EXPOSURE; PND 29-33	28
			TREMORS	14
			IMPAIRED EQUILIBRIUM	14
	7	F	SCHEDULED EUTHANASIA	28
	8	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SELECTED FOR EXPOSURE; PND 29-33	28
	9	F	CULLED ON SCHEDULED DAY	4
	10	F	SCHEDULED EUTHANASIA	28
	11	F	DRIED RED MATERIAL	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	SELECTED FOR EXPOSURE; PND 22-33	21
	14	F	CULLED ON SCHEDULED DAY	4
10542	1	M	SCHEDULED EUTHANASIA	28
	2	M	SCHEDULED EUTHANASIA	28
	3	M	SELECTED FOR EXPOSURE; PND 29-33	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10542	4	M	SCHEDULED EUTHANASIA	28
	5	F	SCHEDULED EUTHANASIA	28
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	F	SCHEDULED EUTHANASIA	28
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	SCHEDULED EUTHANASIA	28
	10	F	SELECTED FOR EXPOSURE; PND 29-33	28
	11	F	SELECTED FOR EXPOSURE; PND 22-33	21
	12	F	CULLED ON SCHEDULED DAY	4
	13	F	CULLED ON SCHEDULED DAY	4
10544	1	M	SUBCUTANEOUS HEMORRHAGE(S) MANDIBULAR AREA	0
			SUBCUTANEOUS HEMORRHAGE(S) MANDIBULAR AREA	1
			CULLED ON SCHEDULED DAY	4
	2	M	CULLED ON SCHEDULED DAY	4
	3	M	DRIED RED MATERIAL ANOGENITAL AREA	14
			SELECTED FOR EXPOSURE; PND 29-33	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SELECTED FOR EXPOSURE; PND 22-33	21
	6	M	CULLED ON SCHEDULED DAY	4
	7	M	DRIED RED MATERIAL ANOGENITAL AREA	14
			SCHEDULED EUTHANASIA	28
	8	M	CULLED ON SCHEDULED DAY	4
	9	M	SCHEDULED EUTHANASIA	28

ALL OBSERVATION PERIODS

DAMS FROM GROUP 4: 1000PPM/621MG/KG	PUP #	SEX	PUP GROSS OBSERVATION	POSTNATAL DAY
10544	10	F	SCHEDULED EUTHANASIA	28
	11	F	SCABBING	14
			ANOGENITAL AREA	
			SCHEDULED EUTHANASIA	28
	12	F	SELECTED FOR EXPOSURE; PND 22-33	21
	13	F	SCHEDULED EUTHANASIA	28
	14	F	CULLED ON SCHEDULED DAY	4
	15	F	SELECTED FOR EXPOSURE; PND 29-33	28
10545	1	F	FOUND DEAD	0
	2	M	PALE IN COLOR	0
			BODY COOL TO TOUCH	0
			SELECTED FOR EXPOSURE; PND 29-33	28
	3	M	SCHEDULED EUTHANASIA	28
	4	M	SCHEDULED EUTHANASIA	28
	5	M	SCHEDULED EUTHANASIA	28
	6	M	SELECTED FOR EXPOSURE; PND 22-33	21
	7	F	CULLED ON SCHEDULED DAY	4
	8	F	CULLED ON SCHEDULED DAY	4
	9	F	SELECTED FOR EXPOSURE; PND 29-33	28
	10	F	CULLED ON SCHEDULED DAY	4
	11	F	CULLED ON SCHEDULED DAY	4
	12	F	SCHEDULED EUTHANASIA	28
	13	F	CULLED ON SCHEDULED DAY	4
	14	F	SELECTED FOR EXPOSURE; PND 22-33	21
	15	F	CULLED ON SCHEDULED DAY	4
	16	F	SCHEDULED EUTHANASIA	28
	17	F	SCHEDULED EUTHANASIA	28

TABLE 158 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHTS [G]

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10485-01	M	7.0	8.1	9.4	14.6		
10485-02	M	6.9	7.4	8.4	19.6	31.5	61.8
10485-03	M	6.1	7.2	8.3	18.5	29.3	
10485-04	M	6.4	7.8	9.5	23.3	36.3	66.1
10485-05	M	6.6	8.2	9.3	20.2	32.7	63.8
10485-06	F	6.2	7.7				
10485-07	F	5.8	6.7	8.3	18.2	29.6	53.3
10485-08	F	6.1	7.5	8.9	15.3	25.6	50.3
10485-09	F	6.1	7.7	9.3	19.9	31.0	
10485-10	F	5.7	5.9	6.7	11.8	20.7	37.6
10485-11	F	5.8	6.3	7.5	10.8	20.3	38.9
10485-12	F	5.8	7.0				
MALES MEAN		6.6	7.7	9.0	19.2	32.5	63.9
FEMALES MEAN		5.9	7.0	8.1	15.2	25.4	45.0
10491-01	M	8.5	12.9	16.7	30.0	49.7	93.5
10491-02	M	8.6	13.3	17.1	30.5	49.4	
10491-03	F	7.1	11.2	14.7	26.7	40.6	79.2
10491-04	F	8.2	13.1	16.2	28.4	48.1	86.3
10491-05	F	7.5	12.0	15.9	30.3	49.3	83.0
10491-06	F	7.1	11.3	15.3	27.9	43.9	76.9

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10491-07	F	8.0	12.6	16.7	30.2	49.6	
MALES MEAN		8.6	13.1	16.9	30.3	49.6	93.5
FEMALES MEAN		7.6	12.0	15.8	28.7	46.3	81.4
10496-02	M	7.0	9.3	15.0	28.6	46.6	
10496-03	M	7.1	8.4				
10496-04	M	6.6	8.0	13.0	26.6	41.3	79.0
10496-05	M	7.3	8.8	14.8	28.4	43.9	86.0
10496-06	M	6.2	7.3				
10496-07	M	6.1	7.7				
10496-08	M	6.7	8.1	8.8	18.8	28.2	61.1
10496-09	M	7.7	8.9	15.6	29.7	44.4	85.4
10496-10	F	6.6	7.3	12.3	24.7	39.8	74.5
10496-11	F	7.1	9.0				
10496-12	F	6.3	7.1				
10496-13	F	6.1	6.1	9.9	21.3	31.1	61.3
10496-14	F	6.9	8.3	13.5	26.1	41.1	79.0
10496-15	F	5.6	5.4				
10496-16	F	5.9	7.2	12.3	25.2	42.4	
10496-17	F	6.7	7.4				
10496-18	F	5.2	5.5	9.2	20.0	32.9	61.0
MALES MEAN		6.8	8.3	13.4	26.4	40.9	77.9
FEMALES MEAN		6.3	7.0	11.4	23.5	37.5	69.0

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10498-01	M	6.9	8.9				
10498-02	M	7.7	10.1	12.9	20.7	35.5	71.1
10498-03	M	7.2	9.5	13.1	26.7	42.1	81.2
10498-04	M	7.3	9.0	10.2	16.8	28.1	55.3
10498-05	M	7.3	8.9				
10498-06	M	7.5	9.1	10.9	19.1	31.9	
10498-07	M	7.8	9.6				
10498-08	M	7.3	8.8	11.8	19.4	33.2	67.2
10498-09	M	6.8	8.8				
10498-10	F	6.4	8.2	11.0	23.1	40.4	
10498-11	F	7.4	8.5				
10498-12	F	6.9	9.2	10.9	22.9	39.0	74.0
10498-13	F	6.7	9.0	12.4	25.1	41.6	74.7
10498-14	F	7.1	10.0	12.8	25.7	44.2	79.1
10498-15	F	6.7	8.9	12.0	24.1	41.3	74.6
MALES MEAN		7.3	9.2	11.8	20.5	34.2	68.7
FEMALES MEAN		6.9	9.0	11.8	24.2	41.3	75.6
10512-01	M	7.2	10.8				
10512-02	M	7.5	10.7	15.0	26.1	42.7	78.0
10512-03	M	7.2	10.4				
10512-04	M	7.3	11.1	14.2	25.4	37.6	76.5
10512-05	M	8.0	12.0	16.0	27.6	42.5	
10512-06	M	7.2	10.6	14.1	25.3	41.0	79.3
10512-07	M	7.5	10.8	14.6	25.6	40.7	80.0

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10512-08	M	7.4	11.1				
10512-09	F	7.4	10.8	14.9	25.4	40.7	75.5
10512-10	F	6.4	9.4	13.2	24.1	39.6	73.5
10512-11	F	7.4	10.5	13.9	24.2	37.3	72.3
10512-12	F	6.6	9.2	12.6	22.8	33.6	68.4
10512-13	F	7.3	10.6	14.5	25.8	41.3	
10512-14	F	6.7	9.8				
MALES MEAN		7.4	10.9	14.8	26.0	40.9	78.5
FEMALES MEAN		7.0	10.1	13.8	24.5	38.5	72.4
10514-02	M	6.8	7.8	10.8	22.5	35.2	64.6
10514-03	M	7.6	10.0	13.6	28.4	45.0	82.1
10514-04	M	7.1	9.6	13.9	27.9	47.9	87.7
10514-05	M	7.6	9.8				
10514-06	M	7.1	9.2	12.8	27.5	42.6	
10514-07	M	7.6	9.6				
10514-08	M	7.4	10.3	14.5	28.6	44.2	89.1
10514-09	F	6.8	9.0				
10514-10	F	7.2	9.5	13.3	27.5	42.6	79.3
10514-11	F	6.6	8.8	12.3	26.9	43.7	
10514-12	F	6.8	8.6				
10514-13	F	6.8	8.6	12.0	25.1	38.4	72.1
10514-14	F	6.6	7.4	10.5			
10514-15	F	6.7	8.3				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10514-16	F	6.9	9.4	12.8	25.3	39.4	70.2
MALES MEAN		7.3	9.5	13.1	27.0	43.0	80.9
FEMALES MEAN		6.8	8.7	12.2	26.2	41.0	73.9
10521-01	M	6.7	9.0				
10521-02	M	7.6	10.5	13.4	24.9	40.8	
10521-03	M	6.3	8.6	11.0	21.1	33.3	61.2
10521-04	M	6.2					
10521-05	M	6.4	8.7	11.6	21.4	33.6	60.3
10521-06	M	7.0	9.7	12.2	22.9	37.7	64.7
10521-07	M	7.5	10.6	14.1	27.8	48.0	79.3
10521-08	M	6.5					
10521-09	F	6.4	8.7				
10521-10	F	6.6	9.3	12.3	23.8	39.3	64.7
10521-12	F	6.6	9.0				
10521-13	F	6.0	7.6				
10521-14	F	5.4	6.1	7.4	14.2	24.3	45.5
10521-15	F	5.7	7.4	9.5	17.7	29.0	63.7
10521-16	F	6.5	9.6	12.8	23.5	37.7	56.4
10521-17	F	5.9	8.1	10.6	21.0	36.4	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG							
10521-18	F	5.7					
MALES MEAN		6.8	9.5	12.5	23.6	38.7	66.4
FEMALES MEAN		6.1	8.2	10.5	20.0	33.3	57.6
10537-01	M	7.9	11.1	16.6	29.1	49.6	
10537-02	M	7.7	10.7	14.7	25.7	43.4	86.0
10537-03	M	7.7	10.2	14.9	28.0	46.8	88.9
10537-04	M	7.9	10.5	16.1	30.3	51.1	95.8
10537-05	M	7.7	10.0				
10537-06	M	7.5	9.8	14.4	27.4	45.2	92.7
10537-07	F	7.0	9.9	12.2	22.8	42.3	82.6
10537-08	F	7.5	10.0				
10537-09	F	7.7	10.6				
10537-10	F	7.5	10.2	15.5	27.5	45.0	84.5
10537-11	F	7.5	9.8	14.6	28.8	47.5	85.2
10537-12	F	5.7	7.4	10.0	17.3	30.4	
10537-13	F	6.8	9.2	14.0	27.7	47.9	83.7
10537-14	F	8.3	10.0				
10537-15	F	6.9	9.5				
10537-16	F	7.4	10.4				
MALES MEAN		7.7	10.4	15.3	28.1	47.2	90.9
FEMALES MEAN		7.2	9.7	13.3	24.8	42.6	84.0
MALES MEAN		7.3	9.8	13.4	25.1	40.9	77.6
SD		0.64	1.68	2.41	3.79	5.86	10.91
N		8	8	8	8	8	8
FEMALES MEAN		6.7	9.0	12.1	23.4	38.2	69.9
SD		0.58	1.67	2.30	4.12	6.45	12.86
N		8	8	8	8	8	8

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10487-01	M	9.0	11.5	14.9	26.8	44.3	82.3
10487-02	M	8.7	11.8	15.2	27.2	48.0	89.0
10487-03	M	9.1	12.2	15.7	28.0	44.0	85.5
10487-04	M	9.0	12.4	15.3	27.2	43.5	
10487-05	F	8.4	10.5				
10487-06	F	7.5	10.6	13.3	24.4	43.7	80.9
10487-07	F	8.6	12.0	15.6	26.8	48.9	85.4
10487-08	F	8.7	12.1	16.1	28.3	49.1	88.2
10487-09	F	9.0	12.4	15.5	27.1	47.2	
10487-10	F	7.8	10.7	14.4	22.9	37.7	77.0
10487-11	F	8.8	12.2	15.6	26.8	47.4	85.5
10487-12	F	8.7	10.8				
MALES MEAN		9.0	12.0	15.3	27.3	45.0	85.6
FEMALES MEAN		8.4	11.4	15.1	26.1	45.7	83.4
10492-01	M	7.4	8.8				
10492-02	M	6.2	8.4	9.7	10.9	20.2	
10492-03	M	6.6	8.6	10.2	11.3	23.0	48.0
10492-04	M	6.2	8.2	10.3	11.8	24.0	49.2
10492-05	M	6.6	8.3	10.5	12.4	24.8	48.8
10492-06	M	6.6					
10492-07	M	6.8	8.8	9.7	10.3		
10492-08	M	6.6	8.7				
10492-09	F	6.2	8.1	9.8	11.6	21.9	45.6
10492-10	F	6.2	8.5	10.1	12.6	26.0	53.0

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10492-11	F	5.6	6.9	8.0	9.2		
10492-12	F	6.6	8.7	10.4	12.4	21.8	
10492-13	F	6.6	8.2				
10492-14	F	6.2	8.2				
10492-15	F	6.3	8.7				
10492-16	F	5.9	7.9	9.4	11.5	21.7	44.0
10492-17	F	6.7					
MALES MEAN		6.6	8.5	10.1	11.3	23.0	48.7
FEMALES MEAN		6.3	8.2	9.5	11.5	22.9	47.5
10495-01	M	6.9	9.7	13.1	24.2	41.5	84.7
10495-02	M	6.1	9.6	11.9	21.5	37.2	
10495-03	M	7.1	9.6				
10495-04	M	7.6	10.4	14.6	29.2	48.1	90.0
10495-05	M	7.1					
10495-06	M	6.5	9.3				
10495-07	M	6.9	9.6	13.0	21.5	37.4	76.0
10495-08	M	7.4	10.2				
10495-09	M	7.0	9.8	13.2	22.9	36.9	73.8
10495-10	F	6.5	9.3				
10495-11	F	6.3	8.6				
10495-12	F	7.2	9.5				
10495-13	F	6.9	9.7	12.2	23.6	39.2	76.4
10495-14	F	6.8	8.8				
10495-15	F	5.9	7.7	8.8	13.8	25.1	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10495-16	F	6.4					
10495-17	F	6.5	9.3	11.4	18.9	33.2	62.1
10495-18	F	6.6	9.3	10.7	20.8	34.5	66.8
10495-19	F	7.3	10.0	13.0	19.5	33.7	68.2
MALES MEAN		7.0	9.8	13.2	23.9	40.2	81.1
FEMALES MEAN		6.6	9.1	11.2	19.3	33.1	68.4
10499-01	M	7.5	9.4	13.3	22.5	38.1	72.0
10499-02	M	8.3	11.5	15.9	19.8	31.8	69.7
10499-03	M	7.9	10.7	14.8	28.0	45.0	80.4
10499-04	M	7.8	10.2	13.4	21.6	38.1	
10499-05	M	7.5	10.3	14.6	19.3	30.7	63.0
10499-06	M	7.8	10.5				
10499-07	M	7.5	10.7				
10499-08	M	7.3	9.7				
10499-09	F	7.7	10.3	13.8	26.9	43.2	76.7
10499-10	F	7.2	10.9	14.0	17.9	31.5	
10499-11	F	7.3	9.8				
10499-12	F	7.8	10.8	15.4	24.5	40.7	74.3
10499-13	F	7.4	9.7	13.3	25.6	36.9	69.8

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10499-14	F	8.2	11.2	15.4	20.9	36.4	70.3
MALES MEAN		7.7	10.4	14.4	22.2	36.7	71.3
FEMALES MEAN		7.6	10.5	14.4	23.2	37.7	72.8
10515-01	M	7.7	9.8	13.0	17.1	31.1	62.5
10515-02	M	7.7	9.8	11.8	16.3	30.2	58.4
10515-03	M	8.7	10.9	12.8	19.2	32.9	61.6
10515-04	M	8.4	10.7				
10515-05	M	8.0	9.7				
10515-06	M	7.6	9.3	11.8	16.3	30.1	58.8
10515-07	M	8.1	10.3				
10515-08	M	8.5	10.4	13.0	19.5	34.4	
10515-09	F	7.7	9.1				
10515-10	F	7.7	9.6	12.1	18.9	34.7	
10515-11	F	7.9	9.2	11.0	14.1	25.2	46.6
10515-12	F	7.6	9.2	11.2	15.9	29.4	55.0
10515-13	F	7.4	9.3	10.6	14.8	28.1	56.1
10515-14	F	8.1	9.9				
10515-15	F	7.9	9.0	9.9	21.6	35.3	63.0
MALES MEAN		8.1	10.1	12.5	17.7	31.7	60.3
FEMALES MEAN		7.8	9.3	11.0	17.1	30.5	55.2
10516-01	M	8.7	11.3	14.9	26.5	43.9	85.3
10516-02	M	8.7	11.5	15.1	26.5	43.0	83.2

TABLE 158 (F1 - INHALATION/GAVAGE PHASE)
INDIVIDUAL OFFSPRING WEIGHTS [G]

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10516-03	M	9.0	11.8	14.9	26.0	41.6	83.2
10516-04	M	9.1	12.3	15.9	28.5	49.2	94.2
10516-05	M	7.4	9.9	12.3	22.0	34.2	
10516-06	M	7.9	10.7				
10516-07	F	8.0	10.9	13.8	24.6	38.6	
10516-08	F	6.9	9.4	11.5	21.0	33.4	66.4
10516-09	F	7.4	9.9	12.6	22.4	35.1	68.9
10516-10	F	7.7	10.8	14.1	25.8	42.4	77.9
10516-11	F	7.4	9.9	12.4	22.5	37.9	73.5
10516-12	F	6.8	9.3				
10516-13	F	7.3	9.5				
MALES MEAN		8.5	11.3	14.6	25.9	42.4	86.5
FEMALES MEAN		7.4	10.0	12.9	23.3	37.5	71.7
10552-01	M	7.3	9.9				
10552-02	M	7.5	10.6	15.1	25.8	44.0	83.5
10552-03	M	7.3	10.6				
10552-04	M	7.4	10.9				
10552-05	M	6.9	9.8				
10552-06	M	6.7	10.0	14.5	21.3	35.6	74.1
10552-07	M	8.0	10.3	15.0	28.0	46.1	83.3
10552-08	M	7.1	10.0	14.6	26.9	46.0	
10552-09	M	7.2	10.1	14.4	24.0	40.4	78.5
10552-10	F	6.6	9.1	13.6	25.0	41.4	78.6
10552-11	F	6.7	9.7	14.3	25.9	45.9	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10552-12	F	7.4	11.0	15.1	27.3	46.9	82.6
10552-13	F	6.9	9.6	13.7	21.6	38.5	71.1
10552-14	F	6.7	9.7				
10552-15	F	6.5	8.5	12.4	20.0	35.7	65.4
MALES MEAN		7.3	10.2	14.7	25.2	42.4	79.9
FEMALES MEAN		6.8	9.6	13.8	24.0	41.7	74.4
10556-01	M	6.5	9.7	13.3	24.0	39.8	62.9
10556-02	M	6.9	10.2	13.7	24.4	41.6	64.1
10556-03	M	6.8	9.9	14.3	24.0	41.3	65.5
10556-04	M	6.2	9.0	13.2	23.2	38.3	60.2
10556-05	M	6.3	8.8	12.5	23.3	38.5	
10556-06	M	6.9	9.4				
10556-07	F	6.8	8.9	12.9	22.3	38.6	58.4
10556-08	F	6.4	9.4				
10556-09	F	6.5	9.0				
10556-10	F	6.7	9.3	12.8	22.7	38.1	58.9
10556-11	F	6.1	9.0	12.2	22.5	37.3	
10556-12	F	6.2	8.5	11.5	22.5	37.7	56.5
10556-13	F	6.2	9.5	13.9	23.4	40.8	61.0
10556-14	F	6.1	9.0				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG							
10556-15	F	6.7	9.9				
MALES MEAN		6.6	9.5	13.4	23.8	39.9	63.2
FEMALES MEAN		6.4	9.2	12.7	22.7	38.5	58.7
MALES MEAN		7.6	10.2	13.5	22.2	37.7	72.1
SD		0.88	1.07	1.66	5.25	7.19	13.62
N		8	8	8	8	8	8
FEMALES MEAN		7.2	9.7	12.6	20.9	36.0	66.5
SD		0.75	0.97	1.90	4.73	7.05	11.76
N		8	8	8	8	8	8

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10475-01	M	5.4	7.8				
10475-02	M	6.4	10.1	13.5	16.1	31.1	61.4
10475-03	M	6.4	9.1	13.2	25.4	42.4	74.2
10475-04	M	7.4	10.4	13.6	21.1	37.5	71.6
10475-05	M	6.8	11.3	15.7	29.8	51.7	
10475-06	M	6.8	10.5	14.8	24.9	44.2	78.7
10475-07	M	6.9	10.5	14.8	25.6	45.9	81.8
10475-08	M	7.1	9.8				
10475-09	M	6.4	9.9				
10475-10	M	7.2	10.0	14.0	19.5	33.7	66.8
10475-11	F	6.1	9.8	13.2	26.8	45.5	76.5
10475-12	F	6.5	10.1	14.2	26.9	46.1	81.8
10475-13	F	6.5	9.6	13.8	20.9	38.1	
MALES MEAN		6.7	9.9	14.2	23.2	40.9	72.4
FEMALES MEAN		6.4	9.8	13.7	24.9	43.2	79.2
10489-02	M	6.9	9.7	14.4	24.5	42.4	
10489-03	M	6.2	8.7	12.3	21.6	35.5	68.9
10489-04	M	6.1	7.9	11.7	20.6	33.8	68.0
10489-05	M	6.3	10.0	14.4	24.4	40.7	75.9
10489-06	F	5.7	8.4	11.4	22.1	37.2	72.8
10489-07	F	6.5	9.5	14.0	24.2	41.7	76.5
10489-08	F	6.3	9.3				
10489-09	F	5.6	8.9	12.7	21.1	36.0	70.4
10489-10	F	5.6	8.1				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10489-11	F	5.9	9.0	13.0	22.3	38.0	71.8
10489-12	F	6.1	8.9				
10489-13	F	5.8	8.8	13.5	23.0	39.4	72.8
10489-14	F	5.5	8.3				
10489-15	F	6.2	9.7				
10489-16	F	5.4	7.7	11.4	20.9	36.9	
10489-17	F	5.3	6.7				
MALES MEAN		6.4	9.1	13.2	22.8	38.1	70.9
FEMALES MEAN		5.8	8.6	12.7	22.3	38.2	72.9
10490-02	M	7.9	10.7	15.1	21.2	33.7	72.3
10490-03	M	6.2	9.2	12.7	18.1	33.0	65.5
10490-04	M	7.4	10.5	14.6	17.3	31.4	64.6
10490-05	M	7.0	10.3	13.6	19.7	32.2	67.4
10490-06	M	6.8	9.7				
10490-07	M	6.8	9.8	13.1	18.4	30.4	
10490-08	F	7.8	11.0	14.7	20.9	36.1	
10490-09	F	5.9	8.7	12.4	17.5	30.8	60.3
10490-10	F	6.8	9.5	13.3	19.1	31.8	61.3
10490-11	F	7.0	10.0				
10490-12	F	6.6	9.6	13.1	17.3	29.8	61.8
10490-13	F	7.2	9.8				
10490-14	F	6.9	9.8				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10490-15	F	6.5	9.5	12.9	16.4	30.4	60.8
MALES MEAN		7.0	10.0	13.8	18.9	32.1	67.5
FEMALES MEAN		6.8	9.7	13.3	18.2	31.8	61.1
10497-02	M	5.0	8.1	10.2	17.1	30.3	62.2
10497-03	M	5.3	8.3				
10497-04	M	5.8	8.2	10.7	19.4	33.9	
10497-05	M	5.8	9.1				
10497-06	M	5.3	8.3	10.3	16.1	29.5	64.5
10497-07	M	5.7	8.5	11.2	20.3	34.8	75.1
10497-08	M	5.3	8.5	10.6	16.1	28.4	61.3
10497-11	F	4.8	7.5	9.0	15.9	29.8	59.3
10497-12	F	4.7	7.2	9.3	20.0	33.3	63.4
10497-13	F	5.3	8.0				
10497-14	F	4.5	6.6	8.7	16.4	30.2	61.3
10497-15	F	5.3	8.1	10.0	16.2	28.0	58.7
10497-16	F	4.9	7.3	9.7	19.2	29.8	
MALES MEAN		5.5	8.4	10.6	17.8	31.4	65.8
FEMALES MEAN		4.9	7.5	9.3	17.5	30.2	60.7
10501-01	M	7.3	10.1	13.2	22.8	35.1	
10501-02	M	7.1	9.7	12.7	24.6	41.3	74.6
10501-03	M	7.7	10.9	13.9	24.7	37.0	71.0
10501-04	M	7.8	10.7	13.4	25.4	43.1	72.3

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10501-05	F	5.4	7.8	10.2	19.3	29.2	
10501-06	F	6.7	10.0	13.9	24.6	40.2	66.4
10501-07	F	6.0	8.7				
10501-08	F	6.8	9.4				
10501-09	F	6.9	9.5				
10501-10	F	6.6	9.1	12.1	17.2	27.0	53.5
10501-11	F	5.8	7.9				
10501-12	F	7.0	9.1	11.7	23.3	35.7	63.7
10501-13	F	7.0	9.6	12.3	23.0	39.2	68.1
10501-14	F	6.6	8.9	11.7	22.7	35.6	61.8
MALES MEAN		7.5	10.4	13.3	24.4	39.1	72.6
FEMALES MEAN		6.5	9.0	12.0	21.7	34.5	62.7
10505-03	M	6.6	9.5	12.8	19.3	33.3	75.2
10505-04	M	7.0	10.0	13.3	18.6	35.3	73.3
10505-05	M	7.6	10.5	13.7	18.2	34.5	
10505-06	M	6.8	9.6	13.1	19.4	35.2	71.0
10505-07	M	7.1	10.4				
10505-08	M	7.1	9.9	13.8	18.8	34.4	76.4
10505-09	M	6.7	10.4				
10505-10	M	7.7	10.3				
10505-11	M	6.7	9.8				
10505-12	F	6.9	10.0	13.5	18.0	35.3	70.5
10505-13	F	6.5	9.4	12.6	18.2	34.3	68.2
10505-14	F	6.4	9.0				

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10505-15	F	6.4	9.5	13.1	23.1	41.6	
10505-16	F	6.8	10.6	13.7	19.3	34.5	68.6
10505-17	F	6.2	9.0	12.9	24.5	43.4	79.6
10505-18	F	6.8	10.2				
MALES MEAN		7.0	10.0	13.3	18.9	34.5	74.0
FEMALES MEAN		6.6	9.7	13.2	20.6	37.8	71.7
10517-01	M	6.7	10.4	14.4	20.8	34.8	68.7
10517-02	M	6.7	9.5	14.1	25.6	44.7	
10517-03	M	6.4	9.5	13.5	24.6	44.9	84.6
10517-04	M	6.1	9.3	12.4	13.1		
10517-05	M	6.8	9.7				
10517-06	M	7.0	10.0				
10517-07	M	6.1	9.0				
10517-08	M	6.9	10.2	13.3	18.3	30.4	63.5
10517-09	F	5.9	8.8	11.7	22.0	38.4	70.3
10517-10	F	6.1	9.0	13.0	22.0	42.5	
10517-11	F	5.3	8.2	11.3	20.6	36.9	71.5
10517-12	F	5.9	8.5	11.2	21.6	38.7	70.7
10517-13	F	5.9	8.6	12.2	23.4	43.1	83.1

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10517-14	F	5.9	8.8				
MALES MEAN		6.6	9.7	13.5	20.5	38.7	72.3
FEMALES MEAN		5.8	8.7	11.9	21.9	39.9	73.9
10531-02	M	7.8	10.6	14.6	22.9	37.6	73.3
10531-03	M	6.9	9.6	13.0	22.7	38.8	73.7
10531-04	M	7.1	10.7	14.6	27.2	45.3	
10531-05	M	7.3	10.9				
10531-06	M	7.9	11.0	14.5	27.3	46.3	85.4
10531-07	M	7.3	11.1	15.0	26.5	45.8	86.7
10531-08	F	7.2	10.3	14.2	26.6	44.6	77.9
10531-09	F	7.3	10.7				
10531-10	F	7.7	11.0				
10531-11	F	6.9	10.3	13.8	23.3	38.7	
10531-12	F	7.4	10.3	14.8	27.7	46.5	79.1
10531-13	F	7.3	11.0	14.6	24.7	39.1	71.9
10531-14	F	6.8	10.4				
10531-15	F	7.2	10.2	14.5	23.0	38.5	71.8
MALES MEAN		7.4	10.7	14.3	25.3	42.8	79.8
FEMALES MEAN		7.2	10.5	14.4	25.1	41.5	75.2
10533-01	M	8.5	13.1	14.8	25.5	45.3	
10533-02	M	8.3	12.6	14.7	25.1	43.7	84.0
10533-03	F	8.2	12.8	14.4	25.3	43.6	72.3

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 3: 500 PPM/342MG/KG							
10533-04	F	7.8	12.7	15.0	25.2	45.2	84.5
10533-05	F	7.8	13.0	14.8	25.2	44.1	81.4
10533-06	F	8.6	13.5	14.6	25.2	41.1	
MALES MEAN		8.4	12.9	14.8	25.3	44.5	84.0
FEMALES MEAN		8.1	13.0	14.7	25.2	43.5	79.4
10538-01	M	7.2	9.3	12.8	22.3	39.5	74.5
10538-02	M	8.1	10.9	14.7	23.7	40.5	79.4
10538-03	M	8.0	10.5	13.4	22.8	39.7	75.3
10538-04	M	8.1	11.3	15.5	27.1	48.9	
10538-05	F	7.9	10.5	14.3	25.8	44.1	79.5
10538-06	F	7.3	10.3				
10538-07	F	7.6	10.1	13.9	25.6	44.8	77.8
10538-08	F	7.5	9.2				
10538-09	F	7.0	8.6	11.7	21.1	43.3	
10538-10	F	6.6	8.9	12.7	22.1	35.9	68.4
10538-11	F	7.2	9.4				
10538-12	F	7.0	9.0	12.0	24.8	36.2	68.5
10538-13	F	7.3	9.7	12.7	22.5	40.4	73.7
MALES MEAN		7.9	10.5	14.1	24.0	42.2	76.4
FEMALES MEAN		7.3	9.5	12.9	23.7	40.8	73.6
MALES MEAN		7.0	10.2	13.5	22.1	38.4	73.6
SD		0.82	1.18	1.15	2.84	4.49	5.42
N		10	10	10	10	10	10
FEMALES MEAN		6.5	9.6	12.8	22.1	38.1	71.0
SD		0.90	1.45	1.53	2.75	4.62	7.05
N		10	10	10	10	10	10

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10466-01	M	6.8	8.9	13.5	25.9	43.8	84.4
10466-02	M	7.5	9.9	14.7	27.7	49.5	
10466-03	M	7.4	10.0	14.9	27.7	46.6	87.9
10466-04	M	7.4	10.0	14.4	26.4	48.4	90.8
10466-05	F	6.6	9.5				
10466-06	F	7.2	10.2	15.2	27.4	48.4	85.4
10466-07	F	7.2	10.0				
10466-08	F	7.2	9.4	13.7	26.3	46.2	83.0
10466-09	F	7.5	9.7	14.6	26.0	46.1	81.9
10466-10	F	6.7	9.6				
10466-11	F	7.4	9.8				
10466-12	F	6.7	8.8				
10466-13	F	7.4	10.4				
10466-14	F	6.9	9.3	14.0	27.2	43.1	
10466-15	F	6.8	9.8	14.1	26.3	44.2	80.6
10466-16	F	7.2	10.0	14.7	28.3	52.0	89.8
MALES MEAN		7.3	9.7	14.4	26.9	47.1	87.7
FEMALES MEAN		7.1	9.7	14.4	26.9	46.7	84.1
10469-03	M	5.3	7.9	10.6	15.7	25.9	
10469-04	M	7.0	9.8				
10469-05	M	5.0	5.2	6.9	11.9	17.3	37.5
10469-06	M	5.7	7.8	10.9	16.8	25.9	51.1
10469-07	M	4.9					
10469-08	M	5.6	7.4	10.6	17.6	27.8	57.5

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10469-09	M	5.6	8.0	11.5	19.3	29.7	64.9
10469-10	M	4.4	4.6				
10469-11	M	5.1	6.2	8.7	15.3	20.9	45.0
10469-12	M	5.4	6.8				
10469-13	F	5.7	7.7	10.9	18.8	27.4	58.2
10469-14	F	5.4	6.9	9.5	16.0	25.4	
10469-15	F	4.6	5.6	7.4	13.7	23.0	49.3
10469-16	F	5.5	7.7	11.0	17.4	27.4	55.7
MALES MEAN		5.4	7.1	9.9	16.1	24.6	51.2
FEMALES MEAN		5.3	7.0	9.7	16.5	25.8	54.4
10477-03	M	6.0	8.8	13.1	18.5	32.0	
10477-04	M	5.5	8.4	12.7	17.7	30.7	65.0
10477-05	M	6.1	8.6	13.4	15.6	29.4	63.4
10477-06	M	5.7	8.3	13.1	14.5	25.6	58.4
10477-07	M	5.6	7.8				
10477-08	M	5.2	7.8				
10477-09	M	5.9	8.5	12.9	18.4	30.8	63.6
10477-10	F	5.8	9.1				
10477-11	F	5.7	8.0	12.0	13.2	25.2	53.7
10477-12	F	5.6	7.7	11.7	14.5	26.8	
10477-13	F	5.9	9.9				
10477-14	F	5.6	8.2	12.4	14.6	26.2	55.1
10477-15	F	5.4	8.1	11.8	11.7	22.2	49.1
10477-16	F	5.4					

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10477-17	F	5.7	8.1	12.2	13.7	27.0	56.3
10477-18	F	4.8	6.8				
MALES MEAN		5.7	8.3	13.0	16.9	29.7	62.6
FEMALES MEAN		5.5	8.2	12.0	13.5	25.5	53.6
10502-02	M	5.6					
10502-05	M	5.5					
10502-07	F	5.2					
10502-08	F	5.8	7.1	10.1	15.6	24.3	
10502-11	F	5.4	6.9	10.0	20.3	29.2	61.2
10502-12	F	5.2					
10502-13	M	6.1	6.1	8.7	16.6	25.8	
10502-14	F	5.1	6.1	8.5	16.8	25.9	54.9
MALES MEAN		5.7	6.1	8.7	16.6	25.8	
FEMALES MEAN		5.3	6.7	9.5	17.6	26.5	58.1
10526-01	M	6.2	8.7	11.7	19.3	30.9	56.2
10526-02	M	6.0	8.4	12.3	21.2	34.1	56.4
10526-03	M	6.0	8.1	11.6	18.7	29.2	50.6
10526-04	M	5.8	7.9	11.5	21.7	34.7	
10526-05	M	5.6	7.0	10.4	19.3	31.9	55.1
10526-06	F	5.6	8.0				
10526-07	F	5.5	7.1				
10526-08	F	5.7	8.4	12.2	17.2	27.8	49.8

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10526-09	F	5.7	8.4				
10526-10	F	5.8	7.8				
10526-11	F	5.0	6.5	9.8	18.0	30.3	51.6
10526-12	F	5.3	7.3	10.1	17.1	29.0	49.6
10526-13	F	5.2	7.2	10.3	18.3	30.6	50.4
10526-14	F	5.2	7.0				
10526-15	F	5.1	6.7				
10526-16	F	5.4	7.7	10.9	19.1	30.6	
MALES MEAN		5.9	8.0	11.5	20.0	32.2	54.6
FEMALES MEAN		5.4	7.5	10.7	17.9	29.7	50.4
10527-01	M	6.8	10.1	13.9	20.9	35.6	
10527-02	M	6.4	8.4				
10527-03	M	5.9	8.2	10.7	20.3	32.4	70.1
10527-04	M	6.2	8.3	11.9	20.1	31.4	70.0
10527-05	M	6.4	8.9	11.5	22.6	37.6	73.8
10527-06	M	6.2	8.4				
10527-07	M	6.4	9.6	13.6	19.9	34.0	70.1
10527-08	F	5.3	6.6				
10527-09	F	6.0	8.2				
10527-10	F	6.0	8.4	11.7	23.9	37.5	73.7
10527-11	F	6.0	8.8	11.6	24.4	38.3	75.8
10527-12	F	6.4	9.4				
10527-13	F	5.8	7.8	10.4	17.1	30.0	58.8
10527-14	F	6.4	9.0	12.9	24.2	36.4	71.2

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10527-15	F	5.5	7.4	10.7	21.5	36.2	
MALES MEAN		6.3	8.8	12.3	20.8	34.2	71.0
FEMALES MEAN		5.9	8.2	11.5	22.2	35.7	69.9
10541-01	M	6.6	10.0	13.9	18.7	34.4	72.7
10541-02	M	6.8	10.2				
10541-03	M	6.7	9.8	14.3	23.5	38.9	
10541-04	M	7.0	10.3	15.1	22.7	38.5	76.7
10541-05	M	7.5	10.5	14.7	19.8	35.3	73.8
10541-06	M	7.3	10.4	15.2	22.7	36.0	76.8
10541-07	F	6.7	9.8	14.1	17.3	32.8	64.9
10541-08	F	6.9	10.2	14.6	21.6	37.5	73.5
10541-09	F	6.2	8.5				
10541-10	F	6.1	8.9	12.8	19.9	31.6	62.3
10541-11	F	6.1	8.6	12.4	17.1	30.7	61.0
10541-12	F	6.8	10.1				
10541-13	F	6.3	9.8	14.1	21.5	33.6	
10541-14	F	6.3	9.1				
MALES MEAN		7.0	10.2	14.6	21.5	36.6	75.0
FEMALES MEAN		6.4	9.4	13.6	19.5	33.2	65.4
10542-01	M	6.4	8.7	11.3	17.9	29.7	58.2
10542-02	M	7.0	9.4	13.1	19.9	31.2	62.0
10542-03	M	6.9	8.9	12.7	19.8	25.6	65.4

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10542-04	M	6.8	9.1	12.4	15.5	31.7	57.5
10542-05	F	6.6	8.7	12.1	17.4	30.1	61.1
10542-06	M	5.8	8.6	11.9	17.9	28.6	
10542-07	F	6.4	9.3	12.1	17.8	30.5	61.4
10542-08	F	6.2	8.0				
10542-09	F	6.0	8.4	11.8	15.7	25.7	53.7
10542-10	F	5.7	7.4	10.5	16.1	26.8	54.2
10542-11	F	5.8	8.4	11.8	18.2	29.6	
10542-12	F	6.1	8.3				
10542-13	F	6.4	8.6				
MALES MEAN		6.6	8.9	12.3	18.2	29.4	60.8
FEMALES MEAN		6.2	8.4	11.7	17.0	28.5	57.6
10544-01	M	6.2	8.7				
10544-02	M	5.9	7.8				
10544-03	M	5.9	8.3	11.7	17.6	31.4	57.6
10544-04	M	5.8	8.6	11.9	16.4	29.7	58.2
10544-05	M	7.1	9.6	13.7	24.4	40.5	
10544-06	M	6.1	8.6				
10544-07	M	6.6	8.6	12.3	19.9	33.7	64.4
10544-08	M	6.6	9.6				
10544-09	M	6.7	8.7	12.2	21.9	40.7	73.9
10544-10	F	6.0	8.5	11.4	21.6	36.5	57.8
10544-11	F	6.1	7.9	11.4	17.9	33.0	63.6
10544-12	F	5.8	8.3	11.9	15.7	29.5	

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10544-13	F	6.0	8.4	11.4	21.7	37.7	61.1
10544-14	F	5.9	8.1				
10544-15	F	6.2	8.9	12.6	19.0	34.8	63.0
MALES MEAN		6.3	8.7	12.4	20.0	35.2	63.5
FEMALES MEAN		6.0	8.4	11.7	19.2	34.3	61.4
10545-02	M	6.1	8.7	13.5	20.9	35.3	68.9
10545-03	M	6.5	8.2	12.3	19.5	32.1	61.8
10545-04	M	6.9	9.1	14.1	24.4	38.0	72.8
10545-05	M	6.9	9.6	13.7	21.7	35.1	69.5
10545-06	M	7.5	10.0	14.3	20.0	36.7	
10545-07	F	6.8	9.8				
10545-08	F	6.5	8.9				
10545-09	F	6.5	8.1	12.1	19.3	31.1	61.8
10545-10	F	7.1	9.7				
10545-11	F	6.4	9.4				
10545-12	F	6.8	9.6	13.9	25.0	41.6	73.8
10545-13	F	6.2	8.9				
10545-14	F	6.5	8.8	12.7	19.0	33.8	
10545-15	F	6.7	9.4				
10545-16	F	6.6	9.6	13.6	21.9	36.5	66.6

PUP NUMBER	SEX	POSTNATAL DAY 1	4	7	14	21	28
DAMS FROM GROUP 4: 1000PPM/621MG/KG							
10545-17	F	6.6	9.7	14.6	23.2	40.8	70.7
MALES MEAN		6.8	9.1	13.6	21.3	35.4	68.3
FEMALES MEAN		6.6	9.3	13.4	21.7	36.8	68.2
MALES MEAN		6.3	8.5	12.3	19.8	33.0	66.1
	SD	0.63	1.20	1.86	3.19	6.42	11.05
	N	10	10	10	10	10	9
FEMALES MEAN		6.0	8.3	11.8	19.2	32.3	62.3
	SD	0.61	1.01	1.62	3.70	6.56	9.99
	N	10	10	10	10	10	10

TABLE 159 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10485-01	M	1.1	1.3	5.2		
10485-02	M	0.5	1.0	11.2	11.9	30.3
10485-03	M	1.1	1.1	10.2	10.8	
10485-04	M	1.4	1.7	13.8	13.0	29.8
10485-05	M	1.6	1.1	10.9	12.5	31.1
10485-06	F	1.5				
10485-07	F	0.9	1.6	9.9	11.4	23.7
10485-08	F	1.4	1.4	6.4	10.3	24.7
10485-09	F	1.6	1.6	10.6	11.1	
10485-10	F	0.2	0.8	5.1	8.9	16.9
10485-11	F	0.5	1.2	3.3	9.5	18.6
10485-12	F	1.2				
MALES MEAN		1.1	1.2	10.3	12.1	30.4
FEMALES MEAN		1.0	1.3	7.1	10.2	21.0
10491-01	M	4.4	3.8	13.3	19.7	43.8
10491-02	M	4.7	3.8	13.4	18.9	
10491-03	F	4.1	3.5	12.0	13.9	38.6
10491-04	F	4.9	3.1	12.2	19.7	38.2
10491-05	F	4.5	3.9	14.4	19.0	33.7
10491-06	F	4.2	4.0	12.6	16.0	33.0

TABLE 159 (F1 - INHALATION/GAVAGE PHASE)
INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10491-07	F	4.6	4.1	13.5	19.4	
MALES MEAN		4.6	3.8	13.4	19.3	43.8
FEMALES MEAN		4.5	3.7	12.9	17.6	35.9
10496-02	M	2.3	5.7	13.6	18.0	
10496-03	M	1.3				
10496-04	M	1.4	5.0	13.6	14.7	37.7
10496-05	M	1.5	6.0	13.6	15.5	42.1
10496-06	M	1.1				
10496-07	M	1.6				
10496-08	M	1.4	0.7	10.0	9.4	32.9
10496-09	M	1.2	6.7	14.1	14.7	41.0
10496-10	F	0.7	5.0	12.4	15.1	34.7
10496-11	F	1.9				
10496-12	F	0.8				
10496-13	F	0.0	3.8	11.4	9.8	30.2
10496-14	F	1.4	5.2	12.6	15.0	37.9
10496-15	F	-0.2				
10496-16	F	1.3	5.1	12.9	17.2	
10496-17	F	0.7				
10496-18	F	0.3	3.7	10.8	12.9	28.1
MALES MEAN		1.5	4.8	13.0	14.5	38.4
FEMALES MEAN		0.8	4.6	12.0	14.0	32.7

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10498-01	M	2.0				
10498-02	M	2.4	2.8	7.8	14.8	35.6
10498-03	M	2.3	3.6	13.6	15.4	39.1
10498-04	M	1.7	1.2	6.6	11.3	27.2
10498-05	M	1.6				
10498-06	M	1.6	1.8	8.2	12.8	
10498-07	M	1.8				
10498-08	M	1.5	3.0	7.6	13.8	34.0
10498-09	M	2.0				
10498-10	F	1.8	2.8	12.1	17.3	
10498-11	F	1.1				
10498-12	F	2.3	1.7	12.0	16.1	35.0
10498-13	F	2.3	3.4	12.7	16.5	33.1
10498-14	F	2.9	2.8	12.9	18.5	34.9
10498-15	F	2.2	3.1	12.1	17.2	33.3
MALES MEAN		1.9	2.5	8.8	13.6	34.0
FEMALES MEAN		2.1	2.8	12.4	17.1	34.1
10512-01	M	3.6				
10512-02	M	3.2	4.3	11.1	16.6	35.3
10512-03	M	3.2				
10512-04	M	3.8	3.1	11.2	12.2	38.9
10512-05	M	4.0	4.0	11.6	14.9	
10512-06	M	3.4	3.5	11.2	15.7	38.3
10512-07	M	3.3	3.8	11.0	15.1	39.3

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10512-08	M	3.7				
10512-09	F	3.4	4.1	10.5	15.3	34.8
10512-10	F	3.0	3.8	10.9	15.5	33.9
10512-11	F	3.1	3.4	10.3	13.1	35.0
10512-12	F	2.6	3.4	10.2	10.8	34.8
10512-13	F	3.3	3.9	11.3	15.5	
10512-14	F	3.1				
MALES MEAN		3.5	3.7	11.2	14.9	38.0
FEMALES MEAN		3.1	3.7	10.6	14.0	34.6
10514-02	M	1.0	3.0	11.7	12.7	29.4
10514-03	M	2.4	3.6	14.8	16.6	37.1
10514-04	M	2.5	4.3	14.0	20.0	39.8
10514-05	M	2.2				
10514-06	M	2.1	3.6	14.7	15.1	
10514-07	M	2.0				
10514-08	M	2.9	4.2	14.1	15.6	44.9
10514-09	F	2.2				
10514-10	F	2.3	3.8	14.2	15.1	36.7
10514-11	F	2.2	3.5	14.6	16.8	
10514-12	F	1.8				
10514-13	F	1.8	3.4	13.1	13.3	33.7
10514-14	F	0.8	3.1			
10514-15	F	1.6				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10514-16	F	2.5	3.4	12.5	14.1	30.8
MALES MEAN		2.2	3.7	13.9	16.0	37.8
FEMALES MEAN		1.9	3.4	13.6	14.8	33.7
10521-01	M	2.3				
10521-02	M	2.9	2.9	11.5	15.9	
10521-03	M	2.3	2.4	10.1	12.2	27.9
10521-05	M	2.3	2.9	9.8	12.2	26.7
10521-06	M	2.7	2.5	10.7	14.8	27.0
10521-07	M	3.1	3.5	13.7	20.2	31.3
10521-09	F	2.3				
10521-10	F	2.7	3.0	11.5	15.5	25.4
10521-12	F	2.4				
10521-13	F	1.6				
10521-14	F	0.7	1.3	6.8	10.1	21.2
10521-15	F	1.7	2.1	8.2	11.3	34.7
10521-16	F	3.1	3.2	10.7	14.2	18.7
10521-17	F	2.2	2.5	10.4	15.4	
MALES MEAN		2.6	2.8	11.2	15.1	28.2
FEMALES MEAN		2.1	2.4	9.5	13.3	25.0
10537-01	M	3.2	5.5	12.5	20.5	
10537-02	M	3.0	4.0	11.0	17.7	42.6
10537-03	M	2.5	4.7	13.1	18.8	42.1

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 1: 0 PPM/0 MG/KG						
10537-04	M	2.6	5.6	14.2	20.8	44.7
10537-05	M	2.3				
10537-06	M	2.3	4.6	13.0	17.8	47.5
10537-07	F	2.9	2.3	10.6	19.5	40.3
10537-08	F	2.5				
10537-09	F	2.9				
10537-10	F	2.7	5.3	12.0	17.5	39.5
10537-11	F	2.3	4.8	14.2	18.7	37.7
10537-12	F	1.7	2.6	7.3	13.1	
10537-13	F	2.4	4.8	13.7	20.2	35.8
10537-14	F	1.7				
10537-15	F	2.6				
10537-16	F	3.0				
MALES MEAN		2.7	4.9	12.8	19.1	44.2
FEMALES MEAN		2.5	4.0	11.6	17.8	38.3
MALES MEAN		2.5	3.4	11.8	15.6	36.9
SD		1.13	1.23	1.75	2.52	5.75
N		8	8	8	8	8
FEMALES MEAN		2.3	3.2	11.2	14.9	31.9
SD		1.18	1.04	2.10	2.59	5.85
N		8	8	8	8	8

TABLE 159 (F1 - INHALATION/GAVAGE PHASE)
INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10487-01	M	2.5	3.4	11.9	17.5	38.0
10487-02	M	3.1	3.4	12.0	20.8	41.0
10487-03	M	3.1	3.5	12.3	16.0	41.5
10487-04	M	3.4	2.9	11.9	16.3	
10487-05	F	2.1				
10487-06	F	3.1	2.7	11.1	19.3	37.2
10487-07	F	3.4	3.6	11.2	22.1	36.5
10487-08	F	3.4	4.0	12.2	20.8	39.1
10487-09	F	3.4	3.1	11.6	20.1	
10487-10	F	2.9	3.7	8.5	14.8	39.3
10487-11	F	3.4	3.4	11.2	20.6	38.1
10487-12	F	2.1				
MALES MEAN		3.0	3.3	12.0	17.7	40.2
FEMALES MEAN		3.0	3.4	11.0	19.6	38.0
10492-01	M	1.4				
10492-02	M	2.2	1.3	1.2	9.3	
10492-03	M	2.0	1.6	1.1	11.7	25.0
10492-04	M	2.0	2.1	1.5	12.2	25.2
10492-05	M	1.7	2.2	1.9	12.4	24.0
10492-07	M	2.0	0.9	0.6		
10492-08	M	2.1				
10492-09	F	1.9	1.7	1.8	10.3	23.7
10492-10	F	2.3	1.6	2.5	13.4	27.0
10492-11	F	1.3	1.1	1.2		

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10492-12	F	2.1	1.7	2.0	9.4	
10492-13	F	1.6				
10492-14	F	2.0				
10492-15	F	2.4				
10492-16	F	2.0	1.5	2.1	10.2	22.3
MALES MEAN		1.9	1.6	1.3	11.4	24.7
FEMALES MEAN		2.0	1.5	1.9	10.8	24.3
10495-01	M	2.8	3.4	11.1	17.3	43.2
10495-02	M	3.5	2.3	9.6	15.7	
10495-03	M	2.5				
10495-04	M	2.8	4.2	14.6	18.9	41.9
10495-06	M	2.8				
10495-07	M	2.7	3.4	8.5	15.9	38.6
10495-08	M	2.8				
10495-09	M	2.8	3.4	9.7	14.0	36.9
10495-10	F	2.8				
10495-11	F	2.3				
10495-12	F	2.3				
10495-13	F	2.8	2.5	11.4	15.6	37.2
10495-14	F	2.0				
10495-15	F	1.8	1.1	5.0	11.3	
10495-17	F	2.8	2.1	7.5	14.3	28.9
10495-18	F	2.7	1.4	10.1	13.7	32.3

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10495-19	F	2.7	3.0	6.5	14.2	34.5
MALES MEAN		2.8	3.3	10.7	16.4	40.2
FEMALES MEAN		2.5	2.0	8.1	13.8	33.2
10499-01	M	1.9	3.9	9.2	15.6	33.9
10499-02	M	3.2	4.4	3.9	12.0	37.9
10499-03	M	2.8	4.1	13.2	17.0	35.4
10499-04	M	2.4	3.2	8.2	16.5	
10499-05	M	2.8	4.3	4.7	11.4	32.3
10499-06	M	2.7				
10499-07	M	3.2				
10499-08	M	2.4				
10499-09	F	2.6	3.5	13.1	16.3	33.5
10499-10	F	3.7	3.1	3.9	13.6	
10499-11	F	2.5				
10499-12	F	3.0	4.6	9.1	16.2	33.6
10499-13	F	2.3	3.6	12.3	11.3	32.9
10499-14	F	3.0	4.2	5.5	15.5	33.9
MALES MEAN		2.7	4.0	7.8	14.5	34.9
FEMALES MEAN		2.9	3.8	8.8	14.6	33.5
10515-01	M	2.1	3.2	4.1	14.0	31.4
10515-02	M	2.1	2.0	4.5	13.9	28.2
10515-03	M	2.2	1.9	6.4	13.7	28.7

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10515-04	M	2.3				
10515-05	M	1.7				
10515-06	M	1.7	2.5	4.5	13.8	28.7
10515-07	M	2.2				
10515-08	M	1.9	2.6	6.5	14.9	
10515-09	F	1.4				
10515-10	F	1.9	2.5	6.8	15.8	
10515-11	F	1.3	1.8	3.1	11.1	21.4
10515-12	F	1.6	2.0	4.7	13.5	25.6
10515-13	F	1.9	1.3	4.2	13.3	28.0
10515-14	F	1.8				
10515-15	F	1.1	0.9	11.7	13.7	27.7
MALES MEAN		2.0	2.4	5.2	14.1	29.3
FEMALES MEAN		1.6	1.7	6.1	13.5	25.7
10516-01	M	2.6	3.6	11.6	17.4	41.4
10516-02	M	2.8	3.6	11.4	16.5	40.2
10516-03	M	2.8	3.1	11.1	15.6	41.6
10516-04	M	3.2	3.6	12.6	20.7	45.0
10516-05	M	2.5	2.4	9.7	12.2	
10516-06	M	2.8				
10516-07	F	2.9	2.9	10.8	14.0	
10516-08	F	2.5	2.1	9.5	12.4	33.0
10516-09	F	2.5	2.7	9.8	12.7	33.8
10516-10	F	3.1	3.3	11.7	16.6	35.5

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10516-11	F	2.5	2.5	10.1	15.4	35.6
10516-12	F	2.5				
10516-13	F	2.2				
MALES MEAN		2.8	3.3	11.3	16.5	42.1
FEMALES MEAN		2.6	2.7	10.4	14.2	34.5
10552-01	M	2.6				
10552-02	M	3.1	4.5	10.7	18.2	39.5
10552-03	M	3.3				
10552-04	M	3.5				
10552-05	M	2.9				
10552-06	M	3.3	4.5	6.8	14.3	38.5
10552-07	M	2.3	4.7	13.0	18.1	37.2
10552-08	M	2.9	4.6	12.3	19.1	
10552-09	M	2.9	4.3	9.6	16.4	38.1
10552-10	F	2.5	4.5	11.4	16.4	37.2
10552-11	F	3.0	4.6	11.6	20.0	
10552-12	F	3.6	4.1	12.2	19.6	35.7
10552-13	F	2.7	4.1	7.9	16.9	32.6
10552-14	F	3.0				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 2: 100 PPM/90 MG/KG						
10552-15	F	2.0	3.9	7.6	15.7	29.7
MALES MEAN		3.0	4.5	10.5	17.2	38.3
FEMALES MEAN		2.8	4.2	10.1	17.7	33.8
10556-01	M	3.2	3.6	10.7	15.8	23.1
10556-02	M	3.3	3.5	10.7	17.2	22.5
10556-03	M	3.1	4.4	9.7	17.3	24.2
10556-04	M	2.8	4.2	10.0	15.1	21.9
10556-05	M	2.5	3.7	10.8	15.2	
10556-06	M	2.5				
10556-07	F	2.1	4.0	9.4	16.3	19.8
10556-08	F	3.0				
10556-09	F	2.5				
10556-10	F	2.6	3.5	9.9	15.4	20.8
10556-11	F	2.9	3.2	10.3	14.8	
10556-12	F	2.3	3.0	11.0	15.2	18.8
10556-13	F	3.3	4.4	9.5	17.4	20.2
10556-14	F	2.9				
10556-15	F	3.2				
MALES MEAN		2.9	3.9	10.4	16.1	22.9
FEMALES MEAN		2.8	3.6	10.0	15.8	19.9
MALES MEAN		2.6	3.3	8.7	15.5	34.1
SD		0.44	0.92	3.70	2.06	7.50
N		8	8	8	8	8
FEMALES MEAN		2.5	2.9	8.3	15.0	30.4
SD		0.49	1.03	3.02	2.71	6.25
N		8	8	8	8	8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10475-01	M	2.4				
10475-02	M	3.7	3.4	2.6	15.0	30.3
10475-03	M	2.7	4.1	12.2	17.0	31.8
10475-04	M	3.0	3.2	7.5	16.4	34.1
10475-05	M	4.5	4.4	14.1	21.9	
10475-06	M	3.7	4.3	10.1	19.3	34.5
10475-07	M	3.6	4.3	10.8	20.3	35.9
10475-08	M	2.7				
10475-09	M	3.5				
10475-10	M	2.8	4.0	5.5	14.2	33.1
10475-11	F	3.7	3.4	13.6	18.7	31.0
10475-12	F	3.6	4.1	12.7	19.2	35.7
10475-13	F	3.1	4.2	7.1	17.2	
MALES MEAN		3.3	4.0	9.0	17.7	33.3
FEMALES MEAN		3.5	3.9	11.1	18.4	33.4
10489-02	M	2.8	4.7	10.1	17.9	
10489-03	M	2.5	3.6	9.3	13.9	33.4
10489-04	M	1.8	3.8	8.9	13.2	34.2
10489-05	M	3.7	4.4	10.0	16.3	35.2
10489-06	F	2.7	3.0	10.7	15.1	35.6
10489-07	F	3.0	4.5	10.2	17.5	34.8
10489-08	F	3.0				
10489-09	F	3.3	3.8	8.4	14.9	34.4
10489-10	F	2.5				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10489-11	F	3.1	4.0	9.3	15.7	33.8
10489-12	F	2.8				
10489-13	F	3.0	4.7	9.5	16.4	33.4
10489-14	F	2.8				
10489-15	F	3.5				
10489-16	F	2.3	3.7	9.5	16.0	
10489-17	F	1.4				
MALES MEAN		2.7	4.1	9.6	15.3	34.3
FEMALES MEAN		2.8	4.0	9.6	15.9	34.4
10490-02	M	2.8	4.4	6.1	12.5	38.6
10490-03	M	3.0	3.5	5.4	14.9	32.5
10490-04	M	3.1	4.1	2.7	14.1	33.2
10490-05	M	3.3	3.3	6.1	12.5	35.2
10490-06	M	2.9				
10490-07	M	3.0	3.3	5.3	12.0	
10490-08	F	3.2	3.7	6.2	15.2	
10490-09	F	2.8	3.7	5.1	13.3	29.5
10490-10	F	2.7	3.8	5.8	12.7	29.5
10490-11	F	3.0				
10490-12	F	3.0	3.5	4.2	12.5	32.0
10490-13	F	2.6				
10490-14	F	2.9				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10490-15	F	3.0	3.4	3.5	14.0	30.4
MALES MEAN		3.0	3.7	5.1	13.2	34.9
FEMALES MEAN		2.9	3.6	5.0	13.5	30.4
10497-02	M	3.1	2.1	6.9	13.2	31.9
10497-03	M	3.0				
10497-04	M	2.4	2.5	8.7	14.5	
10497-05	M	3.3				
10497-06	M	3.0	2.0	5.8	13.4	35.0
10497-07	M	2.8	2.7	9.1	14.5	40.3
10497-08	M	3.2	2.1	5.5	12.3	32.9
10497-11	F	2.7	1.5	6.9	13.9	29.5
10497-12	F	2.5	2.1	10.7	13.3	30.1
10497-13	F	2.7				
10497-14	F	2.1	2.1	7.7	13.8	31.1
10497-15	F	2.8	1.9	6.2	11.8	30.7
10497-16	F	2.4	2.4	9.5	10.6	
MALES MEAN		3.0	2.3	7.2	13.6	35.0
FEMALES MEAN		2.5	2.0	8.2	12.7	30.4
10501-01	M	2.8	3.1	9.6	12.3	
10501-02	M	2.6	3.0	11.9	16.7	33.3
10501-03	M	3.2	3.0	10.8	12.3	34.0
10501-04	M	2.9	2.7	12.0	17.7	29.2

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10501-05	F	2.4	2.4	9.1	9.9	
10501-06	F	3.3	3.9	10.7	15.6	26.2
10501-07	F	2.7				
10501-08	F	2.6				
10501-09	F	2.6				
10501-10	F	2.5	3.0	5.1	9.8	26.5
10501-11	F	2.1				
10501-12	F	2.1	2.6	11.6	12.4	28.0
10501-13	F	2.6	2.7	10.7	16.2	28.9
10501-14	F	2.3	2.8	11.0	12.9	26.2
MALES MEAN		2.9	3.0	11.1	14.8	32.2
FEMALES MEAN		2.5	2.9	9.7	12.8	27.2
10505-03	M	2.9	3.3	6.5	14.0	41.9
10505-04	M	3.0	3.3	5.3	16.7	38.0
10505-05	M	2.9	3.2	4.5	16.3	
10505-06	M	2.8	3.5	6.3	15.8	35.8
10505-07	M	3.3				
10505-08	M	2.8	3.9	5.0	15.6	42.0
10505-09	M	3.7				
10505-10	M	2.6				
10505-11	M	3.1				
10505-12	F	3.1	3.5	4.5	17.3	35.2
10505-13	F	2.9	3.2	5.6	16.1	33.9
10505-14	F	2.6				

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10505-15	F	3.1	3.6	10.0	18.5	
10505-16	F	3.8	3.1	5.6	15.2	34.1
10505-17	F	2.8	3.9	11.6	18.9	36.2
10505-18	F	3.4				
MALES MEAN		3.0	3.4	5.5	15.7	39.4
FEMALES MEAN		3.1	3.5	7.5	17.2	34.9
10517-01	M	3.7	4.0	6.4	14.0	33.9
10517-02	M	2.8	4.6	11.5	19.1	
10517-03	M	3.1	4.0	11.1	20.3	39.7
10517-04	M	3.2	3.1	0.7		
10517-05	M	2.9				
10517-06	M	3.0				
10517-07	M	2.9				
10517-08	M	3.3	3.1	5.0	12.1	33.1
10517-09	F	2.9	2.9	10.3	16.4	31.9
10517-10	F	2.9	4.0	9.0	20.5	
10517-11	F	2.9	3.1	9.3	16.3	34.6
10517-12	F	2.6	2.7	10.4	17.1	32.0
10517-13	F	2.7	3.6	11.2	19.7	40.0

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10517-14	F	2.9				
MALES MEAN		3.1	3.8	6.9	16.4	35.6
FEMALES MEAN		2.8	3.3	10.0	18.0	34.6
10531-02	M	2.8	4.0	8.3	14.7	35.7
10531-03	M	2.7	3.4	9.7	16.1	34.9
10531-04	M	3.6	3.9	12.6	18.1	
10531-05	M	3.6				
10531-06	M	3.1	3.5	12.8	19.0	39.1
10531-07	M	3.8	3.9	11.5	19.3	40.9
10531-08	F	3.1	3.9	12.4	18.0	33.3
10531-09	F	3.4				
10531-10	F	3.3				
10531-11	F	3.4	3.5	9.5	15.4	
10531-12	F	2.9	4.5	12.9	18.8	32.6
10531-13	F	3.7	3.6	10.1	14.4	32.8
10531-14	F	3.6				
10531-15	F	3.0	4.3	8.5	15.5	33.3
MALES MEAN		3.3	3.7	11.0	17.4	37.7
FEMALES MEAN		3.3	4.0	10.7	16.4	33.0
10533-01	M	4.6	1.7	10.7	19.8	
10533-02	M	4.3	2.1	10.4	18.6	40.3
10533-03	F	4.6	1.6	10.9	18.3	28.7

TABLE 159 (F1 - INHALATION/GAVAGE PHASE)
INDIVIDUAL OFFSPRING WEIGHT CHANGES [G]

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 3: 500 PPM/342MG/KG						
10533-04	F	4.9	2.3	10.2	20.0	39.3
10533-05	F	5.2	1.8	10.4	18.9	37.3
10533-06	F	4.9	1.1	10.6	15.9	
MALES MEAN		4.5	1.9	10.6	19.2	40.3
FEMALES MEAN		4.9	1.7	10.5	18.3	35.1
10538-01	M	2.1	3.5	9.5	17.2	35.0
10538-02	M	2.8	3.8	9.0	16.8	38.9
10538-03	M	2.5	2.9	9.4	16.9	35.6
10538-04	M	3.2	4.2	11.6	21.8	
10538-05	F	2.6	3.8	11.5	18.3	35.4
10538-06	F	3.0				
10538-07	F	2.5	3.8	11.7	19.2	33.0
10538-08	F	1.7				
10538-09	F	1.6	3.1	9.4	22.2	
10538-10	F	2.3	3.8	9.4	13.8	32.5
10538-11	F	2.2				
10538-12	F	2.0	3.0	12.8	11.4	32.3
10538-13	F	2.4	3.0	9.8	17.9	33.3
MALES MEAN		2.7	3.6	9.9	18.2	36.5
FEMALES MEAN		2.3	3.4	10.8	17.1	33.3
MALES MEAN		3.2	3.4	8.6	16.2	35.9
	SD	0.52	0.73	2.25	1.99	2.58
	N	10	10	10	10	10
FEMALES MEAN		3.1	3.2	9.3	16.0	32.7
	SD	0.75	0.81	1.90	2.24	2.56
	N	10	10	10	10	10

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10466-01	M	2.1	4.6	12.4	17.9	40.6
10466-02	M	2.4	4.8	13.0	21.8	
10466-03	M	2.6	4.9	12.8	18.9	41.3
10466-04	M	2.6	4.4	12.0	22.0	42.4
10466-05	F	2.9				
10466-06	F	3.0	5.0	12.2	21.0	37.0
10466-07	F	2.8				
10466-08	F	2.2	4.3	12.6	19.9	36.8
10466-09	F	2.2	4.9	11.4	20.1	35.8
10466-10	F	2.9				
10466-11	F	2.4				
10466-12	F	2.1				
10466-13	F	3.0				
10466-14	F	2.4	4.7	13.2	15.9	
10466-15	F	3.0	4.3	12.2	17.9	36.4
10466-16	F	2.8	4.7	13.6	23.7	37.8
MALES MEAN		2.4	4.7	12.6	20.2	41.4
FEMALES MEAN		2.6	4.7	12.5	19.8	36.8
10469-03	M	2.6	2.7	5.1	10.2	
10469-04	M	2.8				
10469-05	M	0.2	1.7	5.0	5.4	20.2
10469-06	M	2.1	3.1	5.9	9.1	25.2
10469-08	M	1.8	3.2	7.0	10.2	29.7
10469-09	M	2.4	3.5	7.8	10.4	35.2

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10469-10	M	0.2				
10469-11	M	1.1	2.5	6.6	5.6	24.1
10469-12	M	1.4				
10469-13	F	2.0	3.2	7.9	8.6	30.8
10469-14	F	1.5	2.6	6.5	9.4	
10469-15	F	1.0	1.8	6.3	9.3	26.3
10469-16	F	2.2	3.3	6.4	10.0	28.3
MALES MEAN		1.6	2.8	6.2	8.5	26.9
FEMALES MEAN		1.7	2.7	6.8	9.3	28.5
10477-03	M	2.8	4.3	5.4	13.5	
10477-04	M	2.9	4.3	5.0	13.0	34.3
10477-05	M	2.5	4.8	2.2	13.8	34.0
10477-06	M	2.6	4.8	1.4	11.1	32.8
10477-07	M	2.2				
10477-08	M	2.6				
10477-09	M	2.6	4.4	5.5	12.4	32.8
10477-10	F	3.3				
10477-11	F	2.3	4.0	1.2	12.0	28.5
10477-12	F	2.1	4.0	2.8	12.3	
10477-13	F	4.0				
10477-14	F	2.6	4.2	2.2	11.6	28.9
10477-15	F	2.7	3.7	-0.1	10.5	26.9
10477-17	F	2.4	4.1	1.5	13.3	29.3

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10477-18	F	2.0				
MALES MEAN		2.6	4.5	3.9	12.8	33.5
FEMALES MEAN		2.7	4.0	1.5	11.9	28.4
10502-08	F	1.3	3.0	5.5	8.7	
10502-11	F	1.5	3.1	10.3	8.9	32.0
10502-13	M	0.0	2.6	7.9	9.2	
10502-14	F	1.0	2.4	8.3	9.1	29.0
MALES MEAN		0.0	2.6	7.9	9.2	
FEMALES MEAN		1.3	2.8	8.0	8.9	30.5
10526-01	M	2.5	3.0	7.6	11.6	25.3
10526-02	M	2.4	3.9	8.9	12.9	22.3
10526-03	M	2.1	3.5	7.1	10.5	21.4
10526-04	M	2.1	3.6	10.2	13.0	
10526-05	M	1.4	3.4	8.9	12.6	23.2
10526-06	F	2.4				
10526-07	F	1.6				
10526-08	F	2.7	3.8	5.0	10.6	22.0
10526-09	F	2.7				
10526-10	F	2.0				
10526-11	F	1.5	3.3	8.2	12.3	21.3
10526-12	F	2.0	2.8	7.0	11.9	20.6
10526-13	F	2.0	3.1	8.0	12.3	19.8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10526-14	F	1.8				
10526-15	F	1.6				
10526-16	F	2.3	3.2	8.2	11.5	
MALES MEAN		2.1	3.5	8.5	12.1	23.1
FEMALES MEAN		2.1	3.2	7.3	11.7	20.9
10527-01	M	3.3	3.8	7.0	14.7	
10527-02	M	2.0				
10527-03	M	2.3	2.5	9.6	12.1	37.7
10527-04	M	2.1	3.6	8.2	11.3	38.6
10527-05	M	2.5	2.6	11.1	15.0	36.2
10527-06	M	2.2				
10527-07	M	3.2	4.0	6.3	14.1	36.1
10527-08	F	1.3				
10527-09	F	2.2				
10527-10	F	2.4	3.3	12.2	13.6	36.2
10527-11	F	2.8	2.8	12.8	13.9	37.5
10527-12	F	3.0				
10527-13	F	2.0	2.6	6.7	12.9	28.8
10527-14	F	2.6	3.9	11.3	12.2	34.8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10527-15	F	1.9	3.3	10.8	14.7	
MALES MEAN		2.5	3.3	8.4	13.4	37.2
FEMALES MEAN		2.3	3.2	10.8	13.5	34.3
10541-01	M	3.4	3.9	4.8	15.7	38.3
10541-02	M	3.4				
10541-03	M	3.1	4.5	9.2	15.4	
10541-04	M	3.3	4.8	7.6	15.8	38.2
10541-05	M	3.0	4.2	5.1	15.5	38.5
10541-06	M	3.1	4.8	7.5	13.3	40.8
10541-07	F	3.1	4.3	3.2	15.5	32.1
10541-08	F	3.3	4.4	7.0	15.9	36.0
10541-09	F	2.3				
10541-10	F	2.8	3.9	7.1	11.7	30.7
10541-11	F	2.5	3.8	4.7	13.6	30.3
10541-12	F	3.3				
10541-13	F	3.5	4.3	7.4	12.1	
10541-14	F	2.8				
MALES MEAN		3.2	4.4	6.8	15.1	39.0
FEMALES MEAN		3.0	4.1	5.9	13.8	32.3
10542-01	M	2.3	2.6	6.6	11.8	28.5
10542-02	M	2.4	3.7	6.8	11.3	30.8
10542-03	M	2.0	3.8	7.1	5.8	39.8

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10542-04	M	2.3	3.3	3.1	16.2	25.8
10542-05	F	2.1	3.4	5.3	12.7	31.0
10542-06	M	2.8	3.3	6.0	10.7	
10542-07	F	2.9	2.8	5.7	12.7	30.9
10542-08	F	1.8				
10542-09	F	2.4	3.4	3.9	10.0	28.0
10542-10	F	1.7	3.1	5.6	10.7	27.4
10542-11	F	2.6	3.4	6.4	11.4	
10542-12	F	2.2				
10542-13	F	2.2				
MALES MEAN		2.4	3.3	5.9	11.2	31.2
FEMALES MEAN		2.2	3.2	5.4	11.5	29.3
10544-01	M	2.5				
10544-02	M	1.9				
10544-03	M	2.4	3.4	5.9	13.8	26.2
10544-04	M	2.8	3.3	4.5	13.3	28.5
10544-05	M	2.5	4.1	10.7	16.1	
10544-06	M	2.5				
10544-07	M	2.0	3.7	7.6	13.8	30.7
10544-08	M	3.0				
10544-09	M	2.0	3.5	9.7	18.8	33.2
10544-10	F	2.5	2.9	10.2	14.9	21.3
10544-11	F	1.8	3.5	6.5	15.1	30.6
10544-12	F	2.5	3.6	3.8	13.8	

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10544-13	F	2.4	3.0	10.3	16.0	23.4
10544-14	F	2.2				
10544-15	F	2.7	3.7	6.4	15.8	28.2
MALES MEAN		2.4	3.6	7.7	15.2	29.7
FEMALES MEAN		2.4	3.3	7.4	15.1	25.9
10545-02	M	2.6	4.8	7.4	14.4	33.6
10545-03	M	1.7	4.1	7.2	12.6	29.7
10545-04	M	2.2	5.0	10.3	13.6	34.8
10545-05	M	2.7	4.1	8.0	13.4	34.4
10545-06	M	2.5	4.3	5.7	16.7	
10545-07	F	3.0				
10545-08	F	2.4				
10545-09	F	1.6	4.0	7.2	11.8	30.7
10545-10	F	2.6				
10545-11	F	3.0				
10545-12	F	2.8	4.3	11.1	16.6	32.2
10545-13	F	2.7				
10545-14	F	2.3	3.9	6.3	14.8	
10545-15	F	2.7				
10545-16	F	3.0	4.0	8.3	14.6	30.1

PUP NUMBER	SEX	POSTNATAL DAY 1- 4	4- 7	7-14	14-21	21-28
DAMS FROM GROUP 4: 1000PPM/621MG/KG						
10545-17	F	3.1	4.9	8.6	17.6	29.9
MALES MEAN		2.3	4.5	7.7	14.1	33.1
FEMALES MEAN		2.7	4.2	8.3	15.1	30.7
MALES MEAN		2.2	3.7	7.6	13.2	32.8
	SD	0.85	0.76	2.25	3.35	5.85
	N	10	10	10	10	9
FEMALES MEAN		2.3	3.5	7.4	13.1	29.8
	SD	0.51	0.66	2.98	3.19	4.41
	N	10	10	10	10	10

FINAL REPORT

Volume 3 of 4
(Individual Tables 160-200)

STUDY TITLE

A PILOT INHALATION STUDY FOR A
REPRODUCTIVE TOXICITY STUDY OF
ETHYLBENZENE IN RATS

STUDY NUMBER

WIL-186028

STUDY DIRECTOR

Donald G. Stump, Ph.D., D.A.B.T.

STUDY INITIATION DATE

August 27, 2002

STUDY COMPLETION DATE

August 1, 2003

PERFORMING LABORATORY

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

AMERICAN CHEMISTRY COUNCIL CONTRACT NUMBER

EB-13.0-VCCEP-Research-WIL

SPONSOR

American Chemistry Council
Ethylbenzene Panel
1300 Wilson Boulevard
Arlington, VA 22209

TABLES 160 - 200

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10367 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.30	3.737	
KIDNEYS	3.27	0.706	
FINAL BODY WT(G)	463.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10368 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.51	4.006	
KIDNEYS	3.53	0.764	
FINAL BODY WT(G)	462.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10375 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.34	4.300	
KIDNEYS	3.53	0.746	
FINAL BODY WT(G)	473.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10384 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.38	3.961	
KIDNEYS	3.44	0.741	
FINAL BODY WT(G)	464.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10386 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.			GRADE
LIVER	17.22	3.950	EPIDIDYMIDES	GROSS: SMALL BILATERAL	P
KIDNEYS	3.42	0.784	TESTES	GROSS: SMALL BILATERAL	P
FINAL BODY WT(G)	436.				

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	PANCREAS
PITUITARY	PROSTATE	SPINAL CORD	SAL. GLAND MAND
SKIN	SPLEEN	STOMACH	SEMINAL VESICLES
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10387 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.99	3.883	
KIDNEYS	3.43	0.701	
FINAL BODY WT(G)	489.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10390 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	16.64	3.673	
KIDNEYS	3.42	0.755	
FINAL BODY WT(G)	453.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10394 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.02	4.047	
KIDNEYS	3.32	0.706	
FINAL BODY WT(G)	470.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10395 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.16	3.632	
KIDNEYS	3.29	0.658	
FINAL BODY WT(G)	500.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10399 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.11	3.980	
KIDNEYS	3.81	0.837	
FINAL BODY WT(G)	455.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10402 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.37	4.130	
KIDNEYS	3.64	0.776	
FINAL BODY WT(G)	469.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10415 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	21.00	4.126	
KIDNEYS	3.64	0.715	
FINAL BODY WT(G)	509.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10417 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	17.15	3.580	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.74	0.781			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	479.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10425 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	15.97	3.457	
KIDNEYS	3.76	0.814	
FINAL BODY WT(G)	462.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10427 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.73	4.039	
KIDNEYS	3.41	0.777	
FINAL BODY WT(G)	439.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10435 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	16.98	4.082	
KIDNEYS	3.32	0.798	
FINAL BODY WT(G)	416.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10439 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	16.29	3.437	
KIDNEYS	3.07	0.648	
FINAL BODY WT(G)	474.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10442 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.77	4.215	
KIDNEYS	3.26	0.695	
FINAL BODY WT(G)	469.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10451 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.44	3.742	
KIDNEYS	3.75	0.805	
FINAL BODY WT(G)	466.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10458 GROUP 1: 0 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GRADE GROSS:			
LIVER	22.51	4.904		ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.83	0.834		EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	459.			LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
				PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
				TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10372 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	16.05	3.840	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.20	0.766			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	418.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10378 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.28	4.392	
KIDNEYS	3.32	0.756	
FINAL BODY WT(G)	439.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10379 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.44	3.949	
KIDNEYS	3.24	0.694	
FINAL BODY WT(G)	467.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10383 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.26	4.055	
KIDNEYS	3.60	0.758	
FINAL BODY WT(G)	475.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10389 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.			GRADE
LIVER	17.94	4.004	EPIDIDYMIDES	GROSS: SMALL LEFT	P
KIDNEYS	3.43	0.766	TESTES	GROSS: SMALL LEFT	P
FINAL BODY WT(G)	448.				

NO SIGNIFICANT CHANGES OBSERVED

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, PANCREAS, PITUITARY, PROSTATE, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, SEMINAL VESICLES, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10404 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	16.25	3.603	
KIDNEYS	3.12	0.692	
FINAL BODY WT(G)	451.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10405 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.59	4.110	
KIDNEYS	4.17	0.974	
FINAL BODY WT(G)	428.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10406 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	KIDNEYS	GROSS: DILATED PELVIS RIGHT	GRADE
LIVER	22.00	4.255			1
KIDNEYS	3.48	0.673	NO SIGNIFICANT		
FINAL BODY WT(G)	517.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, EPIDIDYMIDES, ESOPHAGUS, EYES, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, PANCREAS, PITUITARY, PROSTATE, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, SEMINAL VESICLES, TESTES, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10411 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.42	3.795	
KIDNEYS	3.49	0.760	
FINAL BODY WT(G)	459.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10414 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	21.81	4.772	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.73	0.816			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	457.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10419 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.14	4.153	
KIDNEYS	3.44	0.709	
FINAL BODY WT(G)	485.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10422 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.46	4.139	
KIDNEYS	3.68	0.825	
FINAL BODY WT(G)	446.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10431 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.20	4.262	
KIDNEYS	3.01	0.705	
FINAL BODY WT(G)	427.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10432 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	21.09	4.278	
KIDNEYS	3.82	0.775	
FINAL BODY WT(G)	493.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10438 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.83	4.210	
KIDNEYS	3.60	0.764	
FINAL BODY WT(G)	471.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10440 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.46	4.197	
KIDNEYS	3.34	0.803	
FINAL BODY WT(G)	416.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10443 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.05	3.958	
KIDNEYS	3.41	0.748	
FINAL BODY WT(G)	456.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10455 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	15.99	4.058	NO SIGNIFICANT CHANGES OBSERVED
KIDNEYS	3.33	0.845	
FINAL BODY WT(G)	394.		

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10460 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	KIDNEYS	GRADE
LIVER	20.28	4.409	GROSS: AREA(S), DEPRESSED FEW, 1 MM IN DIAMETER, IN CORTEX, BILATERAL	P
KIDNEYS	3.49	0.759	NO SIGNIFICANT	
FINAL BODY WT(G)	460.		CHANGES OBSERVED	

GROSS: ADRENAL GLANDS, BRAIN, EPIDIDYMIDES, ESOPHAGUS, EYES, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, PANCREAS, PITUITARY, PROSTATE, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, SEMINAL VESICLES, TESTES, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10461 GROUP 2: 100 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.89	4.739	
KIDNEYS	3.88	0.803	
FINAL BODY WT(G)	483.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10369 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.46	4.837	
KIDNEYS	3.15	0.745	
FINAL BODY WT(G)	423.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 42

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10370 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	23.64	5.084	
KIDNEYS	3.62	0.778	
FINAL BODY WT(G)	465.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10377 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.13	4.149	
KIDNEYS	3.84	0.879	
FINAL BODY WT(G)	437.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10380 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.47	4.356	
KIDNEYS	3.77	0.843	
FINAL BODY WT(G)	447.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10381 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.99	4.502	
KIDNEYS	3.49	0.786	
FINAL BODY WT(G)	444.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10382 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.77	4.605	
KIDNEYS	3.54	0.785	
FINAL BODY WT(G)	451.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10385 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.34	4.694	
KIDNEYS	3.13	0.760	
FINAL BODY WT(G)	412.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10391 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.33	4.642	
KIDNEYS	3.92	0.815	
FINAL BODY WT(G)	481.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10392 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.54	4.176	
KIDNEYS	3.41	0.812	
FINAL BODY WT(G)	420.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10396 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.84	4.570	
KIDNEYS	3.86	0.846	
FINAL BODY WT(G)	456.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10400 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.66	4.155	
KIDNEYS	3.77	0.887	
FINAL BODY WT(G)	425.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10407 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	19.17	4.131	
KIDNEYS	3.53	0.761	
FINAL BODY WT(G)	464.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10410 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GRADE
LIVER	19.73	4.621		
KIDNEYS	3.52	0.824		
FINAL BODY WT(G)	427.			

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10421 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.51	4.300	
KIDNEYS	3.93	0.824	
FINAL BODY WT(G)	477.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10423 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.01	4.529	
KIDNEYS	4.89	1.006	
FINAL BODY WT(G)	486.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10429 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.98	3.943	
KIDNEYS	3.88	0.851	
FINAL BODY WT(G)	456.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10437 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.90	4.841	
KIDNEYS	4.00	0.846	
FINAL BODY WT(G)	473.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10445 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	17.82	4.213	
KIDNEYS	3.87	0.915	
FINAL BODY WT(G)	423.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10453 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GRADE
LIVER	19.69	4.579		
KIDNEYS	3.66	0.851		
FINAL BODY WT(G)	430.			

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10454 GROUP 3: 500 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.88	4.305	
KIDNEYS	3.92	0.808	
FINAL BODY WT(G)	485.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10373 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.85	4.941	
KIDNEYS	4.01	0.950	
FINAL BODY WT(G)	422.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10374 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	21.09	4.750	
KIDNEYS	3.76	0.847	
FINAL BODY WT(G)	444.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10376 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.25	4.569	
KIDNEYS	4.44	0.912	
FINAL BODY WT(G)	487.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10397 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	21.79	4.676	
KIDNEYS	3.70	0.794	
FINAL BODY WT(G)	466.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10398 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	18.80	4.424	
KIDNEYS	3.31	0.779	
FINAL BODY WT(G)	425.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10403 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GRADE				
LIVER	22.86	5.160		GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.85	0.869			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	443.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10409 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.75	5.280	
KIDNEYS	3.72	0.947	
FINAL BODY WT(G)	393.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10412 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	23.53	5.138	
KIDNEYS	3.65	0.797	
FINAL BODY WT(G)	458.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10416 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.27	4.873	
KIDNEYS	3.63	0.873	
FINAL BODY WT(G)	416.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10418 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	25.96	5.631	
KIDNEYS	4.85	1.052	
FINAL BODY WT(G)	461.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10420 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	21.32	4.834	
KIDNEYS	3.98	0.902	
FINAL BODY WT(G)	441.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10428 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	22.23	5.146	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.74	0.866			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	432.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10430 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GRADE				
LIVER	23.50	5.098		GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	3.86	0.837			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	461.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10434 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	23.17	5.104	
KIDNEYS	4.42	0.974	
FINAL BODY WT(G)	454.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10444 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.08	5.171	
KIDNEYS	3.71	0.869	
FINAL BODY WT(G)	427.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10447 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.31	4.882	
KIDNEYS	4.00	0.875	
FINAL BODY WT(G)	457.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10448 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	20.67	4.864	
KIDNEYS	3.61	0.849	
FINAL BODY WT(G)	425.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 160 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10449 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

ORGAN WEIGHT	ABS.(G)	REL.	GRADE
LIVER	22.49	4.745	
KIDNEYS	4.45	0.939	
FINAL BODY WT(G)	474.		

NO SIGNIFICANT CHANGES OBSERVED

GROSS:

ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
EYES	HEART	INTESTINE	KIDNEYS
LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10452 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/08/02 DATE OF DEATH: 10/08/02 STUDY DAY: 32

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	23.88	5.237	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	4.33	0.950			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	456.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10459 GROUP 4: 1000 PPM MALE SCHEDULED EUTH 10/07/02 DATE OF DEATH: 10/07/02 STUDY DAY: 31

	ABS.(G)	REL.						GRADE
ORGAN WEIGHT			NO SIGNIFICANT					
LIVER	22.47	5.363	CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	EPIDIDYMIDES	ESOPHAGUS
KIDNEYS	4.23	1.010			EYES	HEART	INTESTINE	KIDNEYS
FINAL BODY WT(G)	419.				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
					PANCREAS	PITUITARY	PROSTATE	SPINAL CORD
					SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
					SEMINAL VESICLES	TESTES	THYMUS	THYROID GLANDS
					TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
01/15/2003

TABLE 161 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

MALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10367	463.	17.30	3.27
10368	462.	18.51	3.53
10375	473.	20.34	3.53
10384	464.	18.38	3.44
10386	436.	17.22	3.42
10387	489.	18.99	3.43
10390	453.	16.64	3.42
10394	470.	19.02	3.32
10395	500.	18.16	3.29
10399	455.	18.11	3.81
10402	469.	19.37	3.64
10415	509.	21.00	3.64
10417	479.	17.15	3.74
10425	462.	15.97	3.76
10427	439.	17.73	3.41
10435	416.	16.98	3.32
10439	474.	16.29	3.07
10442	469.	19.77	3.26
10451	466.	17.44	3.75
10458	459.	22.51	3.83
MEAN	465.	18.34	3.49
S.D.	21.0	1.655	0.214
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 161 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

MALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10372	418.	16.05	3.20
10378	439.	19.28	3.32
10379	467.	18.44	3.24
10383	475.	19.26	3.60
10389	448.	17.94	3.43
10404	451.	16.25	3.12
10405	428.	17.59	4.17
10406	517.	22.00	3.48
10411	459.	17.42	3.49
10414	457.	21.81	3.73
10419	485.	20.14	3.44
10422	446.	18.46	3.68
10431	427.	18.20	3.01
10432	493.	21.09	3.82
10438	471.	19.83	3.60
10440	416.	17.46	3.34
10443	456.	18.05	3.41
10455	394.	15.99	3.33
10460	460.	20.28	3.49
10461	483.	22.89	3.88
MEAN	455.	18.92	3.49
S.D.	29.3	1.993	0.276
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 161 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

MALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10369	423.	20.46	3.15
10370	465.	23.64	3.62
10377	437.	18.13	3.84
10380	447.	19.47	3.77
10381	444.	19.99	3.49
10382	451.	20.77	3.54
10385	412.	19.34	3.13
10391	481.	22.33	3.92
10392	420.	17.54	3.41
10396	456.	20.84	3.86
10400	425.	17.66	3.77
10407	464.	19.17	3.53
10410	427.	19.73	3.52
10421	477.	20.51	3.93
10423	486.	22.01	4.89
10429	456.	17.98	3.88
10437	473.	22.90	4.00
10445	423.	17.82	3.87
10453	430.	19.69	3.66
10454	485.	20.88	3.92
MEAN	449.	20.04	3.74
S.D.	23.8	1.763	0.370
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 161 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

MALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10373	422.	20.85	4.01
10374	444.	21.09	3.76
10376	487.	22.25	4.44
10397	466.	21.79	3.70
10398	425.	18.80	3.31
10403	443.	22.86	3.85
10409	393.	20.75	3.72
10412	458.	23.53	3.65
10416	416.	20.27	3.63
10418	461.	25.96	4.85
10420	441.	21.32	3.98
10428	432.	22.23	3.74
10430	461.	23.50	3.86
10434	454.	23.17	4.42
10444	427.	22.08	3.71
10447	457.	22.31	4.00
10448	425.	20.67	3.61
10449	474.	22.49	4.45
10452	456.	23.88	4.33
10459	419.	22.47	4.23
MEAN	443.	22.11	3.96
S.D.	23.0	1.548	0.380
N	20	20	20

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003
R:01/22/2003

TABLE 162 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G] WEEK 5

MALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10367	463.	3.737	0.706
10368	462.	4.006	0.764
10375	473.	4.300	0.746
10384	464.	3.961	0.741
10386	436.	3.950	0.784
10387	489.	3.883	0.701
10390	453.	3.673	0.755
10394	470.	4.047	0.706
10395	500.	3.632	0.658
10399	455.	3.980	0.837
10402	469.	4.130	0.776
10415	509.	4.126	0.715
10417	479.	3.580	0.781
10425	462.	3.457	0.814
10427	439.	4.039	0.777
10435	416.	4.082	0.798
10439	474.	3.437	0.648
10442	469.	4.215	0.695
10451	466.	3.742	0.805
10458	459.	4.904	0.834
MEAN	465.	3.944	0.752
S.D.	21.0	0.3339	0.0549
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 162 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 2

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G] WEEK 5

MALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10372	418.	3.840	0.766
10378	439.	4.392	0.756
10379	467.	3.949	0.694
10383	475.	4.055	0.758
10389	448.	4.004	0.766
10404	451.	3.603	0.692
10405	428.	4.110	0.974
10406	517.	4.255	0.673
10411	459.	3.795	0.760
10414	457.	4.772	0.816
10419	485.	4.153	0.709
10422	446.	4.139	0.825
10431	427.	4.262	0.705
10432	493.	4.278	0.775
10438	471.	4.210	0.764
10440	416.	4.197	0.803
10443	456.	3.958	0.748
10455	394.	4.058	0.845
10460	460.	4.409	0.759
10461	483.	4.739	0.803
MEAN	455.	4.159	0.770
S.D.	29.3	0.2850	0.0668
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 162 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G] WEEK 5

MALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10369	423.	4.837	0.745
10370	465.	5.084	0.778
10377	437.	4.149	0.879
10380	447.	4.356	0.843
10381	444.	4.502	0.786
10382	451.	4.605	0.785
10385	412.	4.694	0.760
10391	481.	4.642	0.815
10392	420.	4.176	0.812
10396	456.	4.570	0.846
10400	425.	4.155	0.887
10407	464.	4.131	0.761
10410	427.	4.621	0.824
10421	477.	4.300	0.824
10423	486.	4.529	1.006
10429	456.	3.943	0.851
10437	473.	4.841	0.846
10445	423.	4.213	0.915
10453	430.	4.579	0.851
10454	485.	4.305	0.808
MEAN	449.	4.462	0.831
S.D.	23.8	0.2912	0.0607
N	20	20	20

FBW = FINAL BODY WEIGHT

TABLE 162 (F0 MALES - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028M PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G] WEEK 5

MALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10373	422.	4.941	0.950
10374	444.	4.750	0.847
10376	487.	4.569	0.912
10397	466.	4.676	0.794
10398	425.	4.424	0.779
10403	443.	5.160	0.869
10409	393.	5.280	0.947
10412	458.	5.138	0.797
10416	416.	4.873	0.873
10418	461.	5.631	1.052
10420	441.	4.834	0.902
10428	432.	5.146	0.866
10430	461.	5.098	0.837
10434	454.	5.104	0.974
10444	427.	5.171	0.869
10447	457.	4.882	0.875
10448	425.	4.864	0.849
10449	474.	4.745	0.939
10452	456.	5.237	0.950
10459	419.	5.363	1.010
MEAN	443.	4.994	0.895
S.D.	23.0	0.2910	0.0723
N	20	20	20

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10463 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	14.52	4.495		11,8	P
KIDNEYS	2.39	0.740	NO SIGNIFICANT		
FINAL BODY WT(G)	323.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10464 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	10.09	3.656		10,6	P
KIDNEYS	1.97	0.714	NO SIGNIFICANT		
FINAL BODY WT(G)	276.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10494 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/30/02 DATE OF DEATH: 10/30/02 STUDY DAY: 54

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE			GRADE
LIVER	10.45	3.360	NO SIGNIFICANT				P
KIDNEYS	2.23	0.717	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
FINAL BODY WT(G)	311.			HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10506 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	13.24	4.125		5,6	P
KIDNEYS	2.40	0.748	NO SIGNIFICANT		
FINAL BODY WT(G)	321.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10524 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	10.28	3.836		10,4	P
KIDNEYS	2.17	0.810	NO SIGNIFICANT		
FINAL BODY WT(G)	268.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10540 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/16/02 DATE OF DEATH: 11/16/02 STUDY DAY: 71

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	14.77	4.587		12,5	P
KIDNEYS	2.41	0.748	NO SIGNIFICANT		
FINAL BODY WT(G)	322.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10554 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GRADE
LIVER	13.75	4.244	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT) 9,8	P
KIDNEYS	2.42	0.747	SKIN GROSS: HAIR LOSS LEFT LATERAL ABDOMINAL; HINDLIMB, RIGHT	P
FINAL BODY WT(G)	324.			

NO SIGNIFICANT CHANGES OBSERVED

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10555 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	10.54	3.933		8,8	P
KIDNEYS	2.30	0.858	NO SIGNIFICANT		
FINAL BODY WT(G)	268.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10488 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/11/02 DATE OF DEATH: 11/11/02 STUDY DAY: 66

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				5,8			
LIVER	11.23	4.099					P
KIDNEYS	2.29	0.836	NO SIGNIFICANT				
FINAL BODY WT(G)	274.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10493 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/18/02 DATE OF DEATH: 11/18/02 STUDY DAY: 73

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	13.03	4.462		3,11	P
KIDNEYS	2.26	0.774	NO SIGNIFICANT		
FINAL BODY WT(G)	292.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10504 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	12.27	4.036		5,10	P
KIDNEYS	2.48	0.816	NO SIGNIFICANT		
FINAL BODY WT(G)	304.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10510 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	11.35	3.847		9,7	P
KIDNEYS	2.31	0.783	NO SIGNIFICANT		
FINAL BODY WT(G)	295.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10519 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	15.31	4.399		13,5	P
KIDNEYS	2.62	0.753	NO SIGNIFICANT		
FINAL BODY WT(G)	348.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10522 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	11.17	3.892		3,13			P
KIDNEYS	2.26	0.787	NO SIGNIFICANT				
FINAL BODY WT(G)	287.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10525 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	12.83	4.455		8,7			P
KIDNEYS	2.25	0.781	NO SIGNIFICANT				
FINAL BODY WT(G)	288.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10528 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				8,9			
LIVER	16.04	5.076					P
KIDNEYS	2.58	0.816	NO SIGNIFICANT				
FINAL BODY WT(G)	316.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10468 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/16/02 DATE OF DEATH: 11/16/02 STUDY DAY: 71

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	15.90	5.048		5,13	P
KIDNEYS	2.44	0.775	NO SIGNIFICANT		
FINAL BODY WT(G)	315.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10478 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	15.23	4.629		11,7	P
KIDNEYS	2.37	0.720	NO SIGNIFICANT		
FINAL BODY WT(G)	329.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10483 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	17.30	5.373		8,8			P
KIDNEYS	2.78	0.863	NO SIGNIFICANT				
FINAL BODY WT(G)	322.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 163 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10484 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	16.59	5.780		6,9	P
KIDNEYS	2.34	0.815	NO SIGNIFICANT		
FINAL BODY WT(G)	287.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10530 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				7,7			
LIVER	11.98	4.487					P
KIDNEYS	2.11	0.790	NO SIGNIFICANT				
FINAL BODY WT(G)	267.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10534 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	12.64	4.613		9,4	P
KIDNEYS	2.04	0.745	NO SIGNIFICANT		
FINAL BODY WT(G)	274.		CHANGES OBSERVED		

GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10546 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				5,12			
LIVER	16.41	4.784					P
KIDNEYS	1.29	0.376	NO SIGNIFICANT				
FINAL BODY WT(G)	343.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10548 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.			GRADE
LIVER	13.72	4.356	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT) 12,5	P
KIDNEYS	2.24	0.711	SKIN	GROSS: HAIR LOSS FORELIMB, BILATERAL; CEO HAIR LOSS	P
FINAL BODY WT(G)	315.		TEETH	GROSS: MALALIGNED UPPER INCISOR, LEFT; CEO MALALIGNED	P

NO SIGNIFICANT CHANGES OBSERVED GROSS:

ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SPLEEN	STOMACH	THYMUS
THYROID GLANDS	TRACHEA	URINARY BLADDER	UTERUS
CERVIX			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10550 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	18.00	5.143		9,12			P
KIDNEYS	2.60	0.743	NO SIGNIFICANT				
FINAL BODY WT(G)	350.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10465 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	16.45	5.672		5,5			P
KIDNEYS	2.70	0.931	NO SIGNIFICANT				
FINAL BODY WT(G)	290.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10473 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/17/02 DATE OF DEATH: 11/17/02 STUDY DAY: 72

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	21.11	5.815		10,7			P
KIDNEYS	2.57	0.708	NO SIGNIFICANT				
FINAL BODY WT(G)	363.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10480 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	14.82	5.293		6,7			P
KIDNEYS	2.26	0.807	NO SIGNIFICANT				
FINAL BODY WT(G)	280.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10481 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.			GRADE
LIVER	16.34	5.220	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT) 5,8	P
KIDNEYS	2.60	0.831	UTERUS	GROSS: CONTENTS, CLEAR FLUID BOTH HORNS	P
FINAL BODY WT(G)	313.				

NO SIGNIFICANT CHANGES OBSERVED

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10486 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				7,10			
LIVER	18.93	5.934					P
KIDNEYS	2.43	0.762	NO SIGNIFICANT				
FINAL BODY WT(G)	319.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10507 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	17.00	5.484		5,10			P
KIDNEYS	2.42	0.781	NO SIGNIFICANT				
FINAL BODY WT(G)	310.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10529 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.82	4.765		8,6			P
KIDNEYS	2.40	0.723	NO SIGNIFICANT				
FINAL BODY WT(G)	332.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10532 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				7,7			
LIVER	16.12	5.696					P
KIDNEYS	2.18	0.770	NO SIGNIFICANT				
FINAL BODY WT(G)	283.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10547 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	22.88	6.021		8,9			P
KIDNEYS	2.96	0.779	NO SIGNIFICANT				
FINAL BODY WT(G)	380.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
01/15/2003

TABLE 164 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G] WEEK 10

FEMALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10463	323.	14.52	2.39
10464	276.	10.09	1.97
10494	311.	10.45	2.23
10506	321.	13.24	2.40
10524	268.	10.28	2.17
10540	322.	14.77	2.41
10554	324.	13.75	2.42
10555	268.	10.54	2.30
MEAN	302.	12.21	2.29
S.D.	26.1	2.050	0.158
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 164 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G] WEEK 10

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10488	274.	11.23	2.29
10493	292.	13.03	2.26
10504	304.	12.27	2.48
10510	295.	11.35	2.31
10519	348.	15.31	2.62
10522	287.	11.17	2.26
10525	288.	12.83	2.25
10528	316.	16.04	2.58
MEAN	301.	12.90	2.38
S.D.	22.8	1.862	0.154
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 164 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G] WEEK 10

FEMALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10468	315.	15.90	2.44
10478	329.	15.23	2.37
10483	322.	17.30	2.78
10484	287.	16.59	2.34
10530	267.	11.98	2.11
10534	274.	12.64	2.04
10546	343.	16.41	1.29
10548	315.	13.72	2.24
10550	350.	18.00	2.60
MEAN	311.	15.31	2.25
S.D.	29.4	2.096	0.425
N	9	9	9

FBW = FINAL BODY WEIGHT

TABLE 164 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G] WEEK 10

FEMALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10465	290.	16.45	2.70
10473	363.	21.11	2.57
10480	280.	14.82	2.26
10481	313.	16.34	2.60
10486	319.	18.93	2.43
10507	310.	17.00	2.42
10529	332.	15.82	2.40
10532	283.	16.12	2.18
10547	380.	22.88	2.96
MEAN	319.	17.72	2.50
S.D.	34.6	2.697	0.237
N	9	9	9

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003

TABLE 165 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10463	323.	4.495	0.740
10464	276.	3.656	0.714
10494	311.	3.360	0.717
10506	321.	4.125	0.748
10524	268.	3.836	0.810
10540	322.	4.587	0.748
10554	324.	4.244	0.747
10555	268.	3.933	0.858
MEAN	302.	4.030	0.760
S.D.	26.1	0.4170	0.0492
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 165 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10488	274.	4.099	0.836
10493	292.	4.462	0.774
10504	304.	4.036	0.816
10510	295.	3.847	0.783
10519	348.	4.399	0.753
10522	287.	3.892	0.787
10525	288.	4.455	0.781
10528	316.	5.076	0.816
MEAN	301.	4.283	0.793
S.D.	22.8	0.4039	0.0271
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 165 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10468	315.	5.048	0.775
10478	329.	4.629	0.720
10483	322.	5.373	0.863
10484	287.	5.780	0.815
10530	267.	4.487	0.790
10534	274.	4.613	0.745
10546	343.	4.784	0.376
10548	315.	4.356	0.711
10550	350.	5.143	0.743
MEAN	311.	4.913	0.726
S.D.	29.4	0.4628	0.1399
N	9	9	9

FBW = FINAL BODY WEIGHT

TABLE 165 (F0 FEMALES - INHALATION PHASE - SCHEDULED NECROPSY)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10465	290.	5.672	0.931
10473	363.	5.815	0.708
10480	280.	5.293	0.807
10481	313.	5.220	0.831
10486	319.	5.934	0.762
10507	310.	5.484	0.781
10529	332.	4.765	0.723
10532	283.	5.696	0.770
10547	380.	6.021	0.779
MEAN	319.	5.544	0.788
S.D.	34.6	0.3986	0.0656
N	9	9	9

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003
R:01/22/2003

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10485 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	12.45	4.431		8,7			P
KIDNEYS	2.15	0.765	NO SIGNIFICANT				
FINAL BODY WT(G)	281.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10491 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	13.44	4.110		5,7			P
KIDNEYS	2.58	0.789	NO SIGNIFICANT				
FINAL BODY WT(G)	327.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10496 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/20/02 DATE OF DEATH: 11/20/02 STUDY DAY: 75

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.74	4.699		7,13			P
KIDNEYS	2.43	0.725	NO SIGNIFICANT				
FINAL BODY WT(G)	335.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10498 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.54	4.738		10,6			P
KIDNEYS	2.58	0.787	NO SIGNIFICANT				
FINAL BODY WT(G)	328.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10512 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	12.54	4.324		9,6			P
KIDNEYS	2.67	0.921	NO SIGNIFICANT				
FINAL BODY WT(G)	290.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10514 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	12.82	4.176		9,7			P
KIDNEYS	2.47	0.805	NO SIGNIFICANT				
FINAL BODY WT(G)	307.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10521 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	11.77	3.713		9,10			P
KIDNEYS	2.42	0.763	NO SIGNIFICANT				
FINAL BODY WT(G)	317.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10537 GROUP 1: 0 PPM/0 MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	16.35	4.823		11,5			P
KIDNEYS	2.96	0.873	NO SIGNIFICANT				
FINAL BODY WT(G)	339.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10487 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.67	5.055		10,5			P
KIDNEYS	2.48	0.800	NO SIGNIFICANT				
FINAL BODY WT(G)	310.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10492 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.61	4.360		9,8			P
KIDNEYS	2.61	0.729	NO SIGNIFICANT				
FINAL BODY WT(G)	358.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10495 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/16/02 DATE OF DEATH: 11/16/02 STUDY DAY: 71

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	14.21	4.254		11,8			P
KIDNEYS	2.44	0.731	NO SIGNIFICANT				
FINAL BODY WT(G)	334.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10499 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	11.55	3.598		7,7			P
KIDNEYS	2.45	0.763	NO SIGNIFICANT				
FINAL BODY WT(G)	321.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10515 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	13.85	4.147		9,6			P
KIDNEYS	2.57	0.769	NO SIGNIFICANT				
FINAL BODY WT(G)	334.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10516 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.02	4.622		6,8			P
KIDNEYS	2.39	0.735	NO SIGNIFICANT				
FINAL BODY WT(G)	325.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10552 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.48	4.607		11,5			P
KIDNEYS	2.69	0.801	NO SIGNIFICANT				
FINAL BODY WT(G)	336.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10556 GROUP 2:100 PPM/90 MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				9,6			
LIVER	11.62	4.288					P
KIDNEYS	2.37	0.875	NO SIGNIFICANT				
FINAL BODY WT(G)	271.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10475 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	13.12	4.604		10,4			P
KIDNEYS	2.13	0.747	NO SIGNIFICANT				
FINAL BODY WT(G)	285.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10489 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/24/02 DATE OF DEATH: 11/24/02 STUDY DAY: 79

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	14.62	5.024		6,11	P
KIDNEYS	2.01	0.691	NO SIGNIFICANT		
FINAL BODY WT(G)	291.		CHANGES OBSERVED		

GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10490 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	17.25	4.971		5,11	P
KIDNEYS	2.73	0.787	NO SIGNIFICANT		
FINAL BODY WT(G)	347.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10497 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	16.61	5.142		6,11	P
KIDNEYS	2.38	0.737	NO SIGNIFICANT		
FINAL BODY WT(G)	323.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10501 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	13.35	4.668		8,7	P
KIDNEYS	2.37	0.829	NO SIGNIFICANT		
FINAL BODY WT(G)	286.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10505 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	17.35	4.971		11,7	P
KIDNEYS	3.05	0.874	NO SIGNIFICANT		
FINAL BODY WT(G)	349.		CHANGES OBSERVED		

GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10517 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	16.34	5.090		11,4	P
KIDNEYS	2.80	0.872	NO SIGNIFICANT		
FINAL BODY WT(G)	321.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10531 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	14.34	4.596		7,9	P
KIDNEYS	2.68	0.859	NO SIGNIFICANT		
FINAL BODY WT(G)	312.		CHANGES OBSERVED		

GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10533 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	15.80	4.802		6,0	P
KIDNEYS	2.77	0.842	NO SIGNIFICANT		
FINAL BODY WT(G)	329.		CHANGES OBSERVED		

GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10538 GROUP 3:500 PPM/342MG/KG FEMALE SCHEDULED EUTH 11/15/02 DATE OF DEATH: 11/15/02 STUDY DAY: 70

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)				GRADE
LIVER	18.61	6.023		5,10				P
KIDNEYS	2.68	0.867	NO SIGNIFICANT					
FINAL BODY WT(G)	309.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES	
				HEART	INTESTINE	KIDNEYS	LIVER	
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS	
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD	
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH	
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER	
				UTERUS	CERVIX			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10466 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/16/02 DATE OF DEATH: 11/16/02 STUDY DAY: 71

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	17.71	5.788		4,14	P
KIDNEYS	2.40	0.784	NO SIGNIFICANT		
FINAL BODY WT(G)	306.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10469 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	18.95	6.093		8,9			P
KIDNEYS	2.44	0.785	NO SIGNIFICANT				
FINAL BODY WT(G)	311.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10477 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	19.25	5.763		7,12	P
KIDNEYS	2.71	0.811	NO SIGNIFICANT		
FINAL BODY WT(G)	334.		CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 166 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10502 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
				6,10			
LIVER	14.71	4.498					P
KIDNEYS	2.58	0.789	NO SIGNIFICANT				
FINAL BODY WT(G)	327.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10526 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/11/02 DATE OF DEATH: 11/11/02 STUDY DAY: 66

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)	GRADE
LIVER	16.94	5.378		12,4	P
KIDNEYS	2.63	0.835	NO SIGNIFICANT		
FINAL BODY WT(G)	315.		CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
HEART	INTESTINE	KIDNEYS	LIVER
LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
OVARIES	PANCREAS	PITUITARY	SPINAL CORD
SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10527 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)				GRADE
LIVER	16.46	5.505		11,7				P
KIDNEYS	2.65	0.886	NO SIGNIFICANT					
FINAL BODY WT(G)	299.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES	
				HEART	INTESTINE	KIDNEYS	LIVER	
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS	
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD	
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH	
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER	
				UTERUS	CERVIX			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10541 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)				GRADE
LIVER	16.55	5.517		8,6				P
KIDNEYS	2.61	0.870	NO SIGNIFICANT					
FINAL BODY WT(G)	300.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES	
				HEART	INTESTINE	KIDNEYS	LIVER	
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS	
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD	
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH	
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER	
				UTERUS	CERVIX			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10542 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/13/02 DATE OF DEATH: 11/13/02 STUDY DAY: 68

ORGAN WEIGHT	ABS.(G)	REL.			GRADE
LIVER	20.10	5.826	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT) 7,6	P
KIDNEYS	3.25	0.942	KIDNEYS	GROSS: DILATED PELVIS LEFT	1
FINAL BODY WT(G)	345.		URINARY BLADDER	GROSS: CALCULUS(I) MULTIPLE, PINPOINT TO 20 MM IN DIAMETER	P
			URINARY BLADDER	GROSS: THICKENED	P
			URINARY BLADDER	GROSS: DISTENDED	P
			URETER(S)	GROSS: DISTENDED BILATERAL	1

NO SIGNIFICANT CHANGES OBSERVED

GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, UTERUS, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10544 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/14/02 DATE OF DEATH: 11/14/02 STUDY DAY: 69

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.94	5.652		9,6			P
KIDNEYS	2.34	0.830	NO SIGNIFICANT				
FINAL BODY WT(G)	282.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10545 GROUP 4:1000PPM/621MG/KG FEMALE SCHEDULED EUTH 11/12/02 DATE OF DEATH: 11/12/02 STUDY DAY: 67

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	15.95	5.047		10,8			P
KIDNEYS	2.69	0.851	NO SIGNIFICANT				
FINAL BODY WT(G)	316.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
				HEART	INTESTINE	KIDNEYS	LIVER
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
				OVARIES	PANCREAS	PITUITARY	SPINAL CORD
				SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
				THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
				UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
01/15/2003
R:01/23/2003

TABLE 167 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP: 0 PPM/0 MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10485	281.	12.45	2.15
10491	327.	13.44	2.58
10496	335.	15.74	2.43
10498	328.	15.54	2.58
10512	290.	12.54	2.67
10514	307.	12.82	2.47
10521	317.	11.77	2.42
10537	339.	16.35	2.96
MEAN	316.	13.83	2.53
S.D.	21.2	1.769	0.233
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 167 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP:100 PPM/90 MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10487	310.	15.67	2.48
10492	358.	15.61	2.61
10495	334.	14.21	2.44
10499	321.	11.55	2.45
10515	334.	13.85	2.57
10516	325.	15.02	2.39
10552	336.	15.48	2.69
10556	271.	11.62	2.37
MEAN	324.	14.13	2.50
S.D.	25.4	1.699	0.113
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 167 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP:500 PPM/342MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10475	285.	13.12	2.13
10489	291.	14.62	2.01
10490	347.	17.25	2.73
10497	323.	16.61	2.38
10501	286.	13.35	2.37
10505	349.	17.35	3.05
10517	321.	16.34	2.80
10531	312.	14.34	2.68
10533	329.	15.80	2.77
10538	309.	18.61	2.68
MEAN	315.	15.74	2.56
S.D.	23.2	1.826	0.326
N	10	10	10

FBW = FINAL BODY WEIGHT

INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP:1000PPM/621MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10466	306.	17.71	2.40
10469	311.	18.95	2.44
10477	334.	19.25	2.71
10502	327.	14.71	2.58
10526	315.	16.94	2.63
10527	299.	16.46	2.65
10541	300.	16.55	2.61
10542	345.	20.10	3.25
10544	282.	15.94	2.34
10545	316.	15.95	2.69
MEAN	314.	17.26	2.63
S.D.	18.4	1.709	0.252
N	10	10	10

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003
R:01/23/2003

TABLE 168 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 0 PPM/0 MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10485	281.	4.431	0.765
10491	327.	4.110	0.789
10496	335.	4.699	0.725
10498	328.	4.738	0.787
10512	290.	4.324	0.921
10514	307.	4.176	0.805
10521	317.	3.713	0.763
10537	339.	4.823	0.873
MEAN	316.	4.377	0.804
S.D.	21.2	0.3763	0.0637
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 168 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP:100 PPM/90 MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10487	310.	5.055	0.800
10492	358.	4.360	0.729
10495	334.	4.254	0.731
10499	321.	3.598	0.763
10515	334.	4.147	0.769
10516	325.	4.622	0.735
10552	336.	4.607	0.801
10556	271.	4.288	0.875
MEAN	324.	4.366	0.775
S.D.	25.4	0.4234	0.0495
N	8	8	8

FBW = FINAL BODY WEIGHT

TABLE 168 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP:500 PPM/342MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10475	285.	4.604	0.747
10489	291.	5.024	0.691
10490	347.	4.971	0.787
10497	323.	5.142	0.737
10501	286.	4.668	0.829
10505	349.	4.971	0.874
10517	321.	5.090	0.872
10531	312.	4.596	0.859
10533	329.	4.802	0.842
10538	309.	6.023	0.867
MEAN	315.	4.989	0.811
S.D.	23.2	0.4144	0.0658
N	10	10	10

FBW = FINAL BODY WEIGHT

TABLE 168 (F0 FEMALES - INHALATION/GAVAGE PHASE - SCHEDULED NECROPSY)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP:1000PPM/621MG/KG

ANIMAL	FBW(G)	LIVER	KIDNEYS
10466	306.	5.788	0.784
10469	311.	6.093	0.785
10477	334.	5.763	0.811
10502	327.	4.498	0.789
10526	315.	5.378	0.835
10527	299.	5.505	0.886
10541	300.	5.517	0.870
10542	345.	5.826	0.942
10544	282.	5.652	0.830
10545	316.	5.047	0.851
MEAN	314.	5.507	0.838
S.D.	18.4	0.4543	0.0508
N	10	10	10

FBW = FINAL BODY WEIGHT

POFBWv4.12
01/15/2003
R:01/23/2003

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10494 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/30/02 DATE OF DEATH: 10/30/02 STUDY DAY: 54

			GRADE
	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE	P
FINAL BODY WT(G) 311.	NO SIGNIFICANT CHANGES OBSERVED	GROSS:	

ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN
SPLEEN	STOMACH	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER	UTERUS	CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10500 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/18/02 DATE OF DEATH: 10/18/02 STUDY DAY: 42

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE				GRADE
LIVER	8.87	3.145	NO SIGNIFICANT					P
KIDNEYS	1.79	0.635	CHANGES OBSERVED	GROSS: ADRENAL GLANDS	ESOPHAGUS	EYES	HEART	
FINAL BODY WT(G)	282.			INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES	
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES	
				PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN	
				SPLEEN	STOMACH	THYMUS	THYROID GLANDS	
				TRACHEA	URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10503 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/18/02 DATE OF DEATH: 10/18/02 STUDY DAY: 42

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE				GRADE
LIVER	9.27	3.197	NO SIGNIFICANT					P
KIDNEYS	2.14	0.738	CHANGES OBSERVED	GROSS: ADRENAL GLANDS	ESOPHAGUS	EYES	HEART	
FINAL BODY WT(G)	290.			INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES	
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES	
				PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN	
				SPLEEN	STOMACH	THYMUS	THYROID GLANDS	
				TRACHEA	URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10513 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/21/02 DATE OF DEATH: 10/21/02 STUDY DAY: 45

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE				GRADE
LIVER	10.24	3.402	NO SIGNIFICANT					P
KIDNEYS	1.79	0.595	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	ESOPHAGUS	EYES	HEART	
FINAL BODY WT(G)	301.			INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES	
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES	
				PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN	
				SPLEEN	STOMACH	THYMUS	THYROID GLANDS	
				TRACHEA	URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10536 GROUP 1: 0 PPM FEMALE SCHEDULED EUTH 10/18/02 DATE OF DEATH: 10/18/02 STUDY DAY: 42

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE				GRADE
LIVER	9.13	3.407	NO SIGNIFICANT					P
KIDNEYS	1.95	0.728	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	ESOPHAGUS	EYES	HEART	
FINAL BODY WT(G)	268.			INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES	
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES	
				PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN	
				SPLEEN	STOMACH	THYMUS	THYROID GLANDS	
				TRACHEA	URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10470 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 10/19/02 DATE OF DEATH: 10/19/02 STUDY DAY: 43

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE	GRADE
LIVER	10.10	3.961	UTERUS	GROSS: CONTENTS, CLEAR FLUID	P
KIDNEYS	1.97	0.773		BOTH HORNS	P
FINAL BODY WT(G)	255.		NO SIGNIFICANT CHANGES OBSERVED		

GROSS: ADRENAL GLANDS, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10472 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 10/19/02 DATE OF DEATH: 10/19/02 STUDY DAY: 43

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE	GRADE
LIVER	10.08	3.747	UTERUS	GROSS: CONTENTS, CLEAR FLUID	P
KIDNEYS	2.14	0.796		BOTH HORNS	P
FINAL BODY WT(G)	269.		NO SIGNIFICANT CHANGES OBSERVED		

GROSS:			
ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN
SPLEEN	STOMACH	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 169 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10553 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 10/22/02 DATE OF DEATH: 10/22/02 STUDY DAY: 46

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE			GRADE
LIVER	11.31	3.557	NO SIGNIFICANT				P
KIDNEYS	2.26	0.711	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
FINAL BODY WT(G)	318.			INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
				PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN
				SPLEEN	STOMACH	THYMUS	THYROID GLANDS
				TRACHEA	URINARY BLADDER	UTERUS	CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10511 GROUP 4: 1000 PPM FEMALE SCHEDULED EUTH 10/31/02 DATE OF DEATH: 10/31/02 STUDY DAY: 55

		GRADE
GENERAL COMMENT	GROSS: NONGRAVID- AMMONIUM SULFIDE NEGATIVE	P
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	

ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
PANCREAS	SPINAL CORD	SAL. GLAND MAND	SKIN
SPLEEN	STOMACH	THYMUS	THYROID GLANDS
TRACHEA	URINARY BLADDER	UTERUS	CERVIX

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 170 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10494	311.	10.45	2.23
10500	282.	8.87	1.79
10503	290.	9.27	2.14
10513	301.	10.24	1.79
10536	268.	9.13	1.95
MEAN	290.	9.59	1.98
S.D.	16.7	0.706	0.201
N	5	5	5

FBW = FINAL BODY WEIGHT

TABLE 170 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10470	255.	10.10	1.97
10472	269.	10.08	2.14
10553	318.	11.31	2.26
MEAN	281.	10.50	2.12
S.D.	33.1	0.704	0.146
N	3	3	3

FBW = FINAL BODY WEIGHT

TABLE 170 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10511	NA	16.14	2.51
MEAN		16.14	2.51
S.D.		0.000	0.000
N		1	1

FBW = FINAL BODY WEIGHT
NA = NOT APPLICABLE

POFBWv4.12
02/13/2003
R:02/13/2003

TABLE 171 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 0 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10494	311.	3.360	0.717
10500	282.	3.145	0.635
10503	290.	3.197	0.738
10513	301.	3.402	0.595
10536	268.	3.407	0.728
MEAN	290.	3.302	0.683
S.D.	16.7	0.1225	0.0637
N	5	5	5

FBW = FINAL BODY WEIGHT

TABLE 171 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10470	255.	3.961	0.773
10472	269.	3.747	0.796
10553	318.	3.557	0.711
MEAN	281.	3.755	0.760
S.D.	33.1	0.2021	0.0440
N	3	3	3

FBW = FINAL BODY WEIGHT

TABLE 171 (F0 FEMALES - FAILED TO DELIVER)

PROJECT NO.:WIL-186028F PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 1000 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10511	NA	NA	NA
MEAN			
S.D.			
N			

FBW = FINAL BODY WEIGHT
NA = NOT APPLICABLE

POFBWv4.12
02/13/2003
R:02/13/2003

TABLE 172 (F0 FEMALES - INHALATION PHASE - TOTAL LITTER LOSS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO. 10543 GROUP 2: 100 PPM FEMALE SCHEDULED EUTH 10/31/02 DATE OF DEATH: 10/31/02 STUDY DAY: 55

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT)			GRADE
LIVER	11.94	4.342		7,7			P
KIDNEYS	2.31	0.840	NO SIGNIFICANT				
FINAL BODY WT(G)	275.		CHANGES OBSERVED	GROSS:ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
				INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
				LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
				PANCREAS	SAL. GLAND MAND	SKIN	SPLEEN
				STOMACH	THYMUS	THYROID GLANDS	TRACHEA
				URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO. 10520 GROUP 3: 500 PPM FEMALE SCHEDULED EUTH 10/17/02 DATE OF DEATH: 10/17/02 STUDY DAY: 41

		GRADE
FINAL BODY WT(G) 353.	GENERAL COMMENT GROSS: CORPORA LUTEA (LEFT,RIGHT) 7,8	P
	GENERAL COMMENT GROSS: FORMER IMPLANTATION SITES (LEFT,RIGHT) 7,8	P
	NO SIGNIFICANT CHANGES OBSERVED GROSS:	

ADRENAL GLANDS	ESOPHAGUS	EYES	HEART
INTESTINE	KIDNEYS	LIVER	LYMPH NODE, MES
LUNGS	MAMMARY GLAND	OVIDUCTS	OVARIES
PANCREAS	SAL. GLAND MAND	SKIN	SPLEEN
STOMACH	THYMUS	THYROID GLANDS	TRACHEA
URINARY BLADDER	UTERUS	CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 173 (F0 FEMALES - INHALATION PHASE - TOTAL LITTER LOSS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10543	275.	11.94	2.31
MEAN	275.	11.94	2.31
S.D.	0.0	0.000	0.000
N	1	1	1

FBW = FINAL BODY WEIGHT

FEMALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10520	353.	NA	NA
MEAN	353.		
S.D.	0.0		
N	1		

FBW = FINAL BODY WEIGHT
NA = NOT APPLICABLE

POFBWv4.12
02/12/2003
R:07/31/2003

TABLE 174 (F0 FEMALES - INHALATION PHASE - TOTAL LITTER LOSS)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 100 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10543	275.	4.342	0.840
MEAN	275.	4.342	0.840
S.D.	0.0	0.0000	0.0000
N	1	1	1

FBW = FINAL BODY WEIGHT

TABLE 174 (F0 FEMALES - INHALATION PHASE - TOTAL LITTER LOSS)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

FEMALE GROUP: 500 PPM

ANIMAL	FBW(G)	LIVER	KIDNEYS
10520	353.	NA	NA
MEAN	353.		
S.D.	0.0		
N	1		

FBW = FINAL BODY WEIGHT
NA = NOT APPLICABLE

POFBWv4.12
02/12/2003
R:02/13/2003

TABLE 175 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

GROUP 1: 0 PPM

PUP NO.	SEX	LACT DAY	TISSUE	FINDING	GRADE
10555	1	M	0	STOMACH	MILK NOT PRESENT	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 175 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 2

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

GROUP 2: 100 PPM

	PUP NO.	SEX	LACT DAY	TISSUE	FINDING	GRADE
10493	1	M	1	STOMACH	MILK NOT PRESENT	P
	2	M	2	GENERAL COMMENT	CANNIBALIZED	P
	3	M	2	GENERAL COMMENT	CANNIBALIZED	P
	8	F	2	GENERAL COMMENT	CANNIBALIZED	P
	11	F	1	STOMACH	MILK NOT PRESENT	P
	12	F	2	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, ABDOMINAL AND URINARY/REPRODUCTIVE	P
	14	U	1	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
10510	5	M	4	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL	P
10519	1	F	0	GENERAL COMMENT	CANNIBALIZED	P
	2	U	0	GENERAL COMMENT	CANNIBALIZED	P
10543	1	M	11		NO REMARKABLE OBSERVATIONS	
	2	M	11		NO REMARKABLE OBSERVATIONS	
	3	M	11	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
	4	M	11		NO REMARKABLE OBSERVATIONS	
	6	M	11		NO REMARKABLE OBSERVATIONS	
	8	F	13	GENERAL COMMENT	CANNIBALIZED	P
	9	F	11	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
	10	F	12	LUNGS	DISCOLORATION, DARK RED ALL LOBES	P
	11	F	12	LUNGS	DISCOLORATION, DARK RED ALL LOBES	P
	13	F	15		NO REMARKABLE OBSERVATIONS	

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 175 (F1 - INHALATION PHASE)

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

	PUP NO.	SEX	LACT DAY	TISSUE	GROUP 3: 500 PPM FINDING	GRADE
10478	1	M	0	STOMACH	MILK NOT PRESENT	P
	2	F	0	STOMACH	MILK NOT PRESENT	P
	3	F	0	STOMACH	MILK NOT PRESENT	P
	6	M	11	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, THORACIC, ABDOMINAL AND URINARY/REPRODUCTIVE	P
10520	1	M	0	GENERAL COMMENT	CANNIBALIZED	P
	2	U	0	GENERAL COMMENT	CANNIBALIZED	P
	3	U	0	GENERAL COMMENT	CANNIBALIZED	P
	4	U	0	GENERAL COMMENT	CANNIBALIZED	P
	5	U	0	GENERAL COMMENT	CANNIBALIZED	P
10530	1	F	0	STOMACH	MILK NOT PRESENT	P
10546	8	M	2	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE DIAPHRAGM, STOMACH, INTESTINE AND URINARY/REPRODUCTIVE	P
	14	F	21		NO REMARKABLE OBSERVATIONS	
10550	1	F	0	STOMACH	MILK NOT PRESENT	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 175 (F1 - INHALATION PHASE)
INDIVIDUAL PUP NECROPSY FINDINGS
FOUND DEAD PUPS

	PUP NO.	SEX	LACT DAY	TISSUE	GROUP 4: 1000 PPM FINDING	GRADE
10473	1	M	0	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
10480	1	M	0	STOMACH	MILK NOT PRESENT	P
10529	2	M	0	GENERAL COMMENT	CANNIBALIZED	P
	7	M	1	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL, URINARY/REPRODUCTIVE	P
	8	M	0	GENERAL COMMENT	CANNIBALIZED	P
	11	F	0	GENERAL COMMENT	CANNIBALIZED	P
	13	F	0	GENERAL COMMENT	CANNIBALIZED	P
10547	10	F	6	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 176 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

GROUP 1: 0 PPM/0 MG/KG

	PUP NO.	SEX	LACT DAY	TISSUE	FINDING	GRADE
10485	1	M	20	GENERAL COMMENT	CANNIBALIZED	P
10496	1	M	1	STOMACH	MILK PRESENT	P
	19	F	1	STOMACH	MILK NOT PRESENT	P
10514	1	M	0	MALFORMATION	DIAPHRAGMATIC HERNIA MANY LOOPS OF INTESTINE AND 3 MM IN DIAMETER PORTION OF MEDIAN LOBE OF LIVER EXTENDS INTO THORACIC CAVITY THROUGH AN OPENING IN THE DIAPHRAGM	P
				ADRENAL	DISCOLORATION, DARK RED BILATERAL	P
				ADRENAL	ENLARGED BILATERAL	P
				STOMACH	MILK NOT PRESENT	P
	14	F	7		NO REMARKABLE OBSERVATIONS	
10521	4	M	3		NO REMARKABLE OBSERVATIONS	
	8	M	3		NO REMARKABLE OBSERVATIONS	
	11	F	1	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, THORACIC, ABDOMINAL AND URINARY/REPRODUCTIVE	P
	18	F	4	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 176 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

	PUP NO.	SEX	LACT DAY	TISSUE	GROUP 2: 100 PPM/90 MG/KG FINDING	GRADE
10492	6	M	3		NO REMARKABLE OBSERVATIONS	
	7	M	15	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
	11	F	15		NO REMARKABLE OBSERVATIONS	
	17	F	2	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, THORACIC, ABDOMINAL AND URINARY/REPRODUCTIVE	P
10495	16	F	3	VARIATION	RENAL PAPILLA(E) NOT FULLY DEVELOPED (WOO AND HOAR GRADE 1) LEFT	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 176 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

	PUP NO.	SEX	LACT DAY	TISSUE	GROUP 3: 500 PPM/342MG/KG FINDING	GRADE
10489	1	F	0	STOMACH	MILK NOT PRESENT	P
10490	1	M	0	STOMACH	MILK NOT PRESENT	P
10497	1	F	0	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
	9	F	1	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
10505	1	F	0	STOMACH	MILK NOT PRESENT	P
	2	F	0	STOMACH	MILK NOT PRESENT	P
10531	1	F	0	STOMACH	MILK PRESENT	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 176 (F1 - INHALATION/GAVAGE PHASE)

PROJECT NO.:WIL-186028G PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC

INDIVIDUAL PUP NECROPSY FINDINGS

FOUND DEAD PUPS

	PUP NO.	SEX	LACT DAY	TISSUE	GROUP 4: 1000PPM/621MG/KG FINDING	GRADE
10469	2	F	1	STOMACH	MILK PRESENT	P
	7	M	2	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, THORACIC, ABDOMINAL AND URINARY/REPRODUCTIVE	P
10477	1	F	0	STOMACH	MILK PRESENT	P
	2	F	0	STOMACH	MILK PRESENT	P
				GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE INTESTINE	P
10502	1	M	0	STOMACH	MILK NOT PRESENT	P
	2	M	3	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE CRANIAL, THORACIC, ABDOMINAL AND URINARY/REPRODUCTIVE	P
	3	M	0	GENERAL COMMENT	CANNIBALIZED	P
	4	M	0	GENERAL COMMENT	CANNIBALIZED	P
	6	F	0	GENERAL COMMENT	CANNIBALIZED	P
	7	F	2	GENERAL COMMENT	TOO AUTOLYZED TO EXAMINE ABDOMINAL AND URINARY/REPRODUCTIVE	P
10545	1	F	0	STOMACH	MILK NOT PRESENT	P

GRADE CODE: 1 - SLIGHT, 2 - MODERATE, 3 - MARKED, P - PRESENT

TABLE 177 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10463-07	M	0 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10464-08	M	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10506-01	M	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10524-07	M	0 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10540-04	M	0 PPM	SCHEDULED EUTHANASIA	8	22-NOV-02
10554-03	M	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10555-10	M	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10488-06	M	100 PPM	SCHEDULED EUTHANASIA	7	17-NOV-02
10504-02	M	100 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10510-02	M	100 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10519-04	M	100 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10522-02	M	100 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10525-04	M	100 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10528-06	M	100 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10468-02	M	500 PPM	SCHEDULED EUTHANASIA	8	22-NOV-02
10478-07	M	500 PPM	FOUND DEAD	6	10-NOV-02
10483-02	M	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10484-01	M	500 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10530-03	M	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10534-03	M	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10546-01	M	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10548-07	M	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10550-12	M	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10465-01	M	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10473-05	M	1000 PPM	SCHEDULED EUTHANASIA	8	23-NOV-02
10480-09	M	1000 PPM	FOUND DEAD	6	09-NOV-02
10481-07	M	1000 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

TABLE 177 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10486-01	M	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10507-01	M	1000 PPM	FOUND DEAD	6	10-NOV-02
10529-04	M	1000 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10532-01	M	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10547-05	M	1000 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10463-13	F	0 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10464-10	F	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10506-05	F	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10524-09	F	0 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10540-05	F	0 PPM	SCHEDULED EUTHANASIA	8	22-NOV-02
10554-08	F	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10555-15	F	0 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10488-09	F	100 PPM	SCHEDULED EUTHANASIA	7	17-NOV-02
10493-07	F	100 PPM	SCHEDULED EUTHANASIA	8	24-NOV-02
10504-11	F	100 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10510-14	F	100 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10519-15	F	100 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10522-14	F	100 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10525-07	F	100 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10528-11	F	100 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10468-11	F	500 PPM	SCHEDULED EUTHANASIA	8	22-NOV-02
10478-10	F	500 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10483-05	F	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10484-14	F	500 PPM	SCHEDULED EUTHANASIA	8	21-NOV-02
10530-07	F	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10534-06	F	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10546-11	F	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10548-17	F	500 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10550-20	F	500 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02
10465-09	F	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10473-06	F	1000 PPM	SCHEDULED EUTHANASIA	8	23-NOV-02
10480-12	F	1000 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10481-11	F	1000 PPM	EUTHANIZED IN EXTREMIS	6	07-NOV-02
10486-15	F	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10507-15	F	1000 PPM	SCHEDULED EUTHANASIA	8	18-NOV-02
10532-08	F	1000 PPM	SCHEDULED EUTHANASIA	8	20-NOV-02
10547-13	F	1000 PPM	SCHEDULED EUTHANASIA	8	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

PDEADv4.02
01/17/2003
R:02/14/2003

INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10485-03	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10491-02	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10496-02	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	26-NOV-02
10498-06	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10512-05	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10514-06	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10521-02	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10537-01	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10487-04	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10492-02	M	100 PPM/90 MG/KG	FOUND DEAD	6	07-NOV-02
10495-02	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	22-NOV-02
10499-04	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10515-08	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10516-05	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10552-08	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10556-05	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10475-05	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10489-02	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	30-NOV-02
10490-07	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10497-04	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10501-01	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10505-05	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10517-02	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10531-04	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10533-01	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10538-04	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10466-02	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	22-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

TABLE 178 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10469-03	M	1000PPM/621MG/KG	EUTHANIZED IN EXTREMIS	6	07-NOV-02
10477-03	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10502-13	M	1000PPM/621MG/KG	FOUND DEAD	6	08-NOV-02
10526-04	M	1000PPM/621MG/KG	FOUND DEAD	6	07-NOV-02
10527-01	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10541-03	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10542-06	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10544-05	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10545-06	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10485-09	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10491-07	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10496-16	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	26-NOV-02
10498-10	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10512-13	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10514-11	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10521-17	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10537-12	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10487-09	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10492-12	F	100 PPM/90 MG/KG	FOUND DEAD	6	07-NOV-02
10495-15	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	22-NOV-02
10499-10	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10515-10	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10516-07	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10552-11	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10556-11	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10475-13	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10489-16	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	30-NOV-02
10490-08	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10497-16	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10501-05	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10505-15	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10517-10	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10531-11	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10533-06	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10538-09	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	8	21-NOV-02
10466-14	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	22-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10469-14	F	1000PPM/621MG/KG	EUTHANIZED IN EXTREMIS	6	07-NOV-02
10477-12	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10502-08	F	1000PPM/621MG/KG	EUTHANIZED IN EXTREMIS	6	08-NOV-02
10526-16	F	1000PPM/621MG/KG	FOUND DEAD	6	07-NOV-02
10527-15	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02
10541-13	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10542-11	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	19-NOV-02
10544-12	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	20-NOV-02
10545-14	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (3)

PDEADv4.02
02/12/2003
R:02/14/2003

TABLE 179 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-05-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10463-07	M	0 PPM	DISPOSITION	11-19-02	8:40	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10464-08	M	0 PPM	DISPOSITION	11-20-02	8:58	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10506-01	M	0 PPM	DISPOSITION	11-20-02	8:58	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10524-07	M	0 PPM	DISPOSITION	11-18-02	10:01	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10540-04	M	0 PPM	DISPOSITION	11-22-02	7:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10554-03	M	0 PPM	DISPOSITION	11-20-02	8:58	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10555-10	M	0 PPM	DISPOSITION	11-20-02	8:58	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10488-06	M	100 PPM	DISPOSITION	11-17-02	8:50	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10504-02	M	100 PPM	DISPOSITION	11-19-02	8:40	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10510-02	M	100 PPM	DISPOSITION	11-20-02	8:58	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10519-04	M	100 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10522-02	M	100 PPM	DISPOSITION	11-18-02	10:01	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10522-02	M	100 PPM	EYES/EARS/NOSE	11-18-02	6:27	1	DRIED RED MATERIAL AROUND NOSE
10525-04	M	100 PPM	DISPOSITION	11-21-02	7:50	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10528-06	M	100 PPM	DISPOSITION	11-21-02	7:50	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10468-02	M	500 PPM	DISPOSITION	11-22-02	7:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10478-07	M	500 PPM	DISPOSITION	11-10-02	7:29	P	FOUND DEAD
10483-02	M	500 PPM	DISPOSITION	11-19-02	8:40	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10484-01	M	500 PPM	DISPOSITION	11-21-02	7:51	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10530-03	M	500 PPM	DISPOSITION	11-18-02	10:01	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10534-03	M	500 PPM	DISPOSITION	11-19-02	8:40	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10534-03	M	500 PPM	BODY/INTEGUMENT	11-13-02	6:46	P	BLACK AREA END OF TAIL
				11-13-02	6:46	P	RING-LIKE INDENTATIONS ON TAIL
				11-19-02	6:27	P	DISTAL END OF TAIL MISSING
				11-19-02	6:27	P	RING-LIKE INDENTATIONS ON TAIL
10546-01	M	500 PPM	DISPOSITION	11-18-02	10:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10546-01	M	500 PPM	BODY/INTEGUMENT	11-12-02	6:38	P	DISTAL END OF TAIL MISSING
				11-18-02	6:32	P	DISTAL END OF TAIL MISSING
10548-07	M	500 PPM	DISPOSITION	11-18-02	10:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 179 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-05-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10550-12	M	500 PPM	DISPOSITION	11-19-02	8:40	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10465-01	M	1000 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10473-05	M	1000 PPM	DISPOSITION	11-23-02	8:53	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10480-09	M	1000 PPM	DISPOSITION	11-09-02	7:56	P	FOUND DEAD
10481-07	M	1000 PPM	DISPOSITION	11-18-02	10:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10486-01	M	1000 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10507-01	M	1000 PPM	DISPOSITION	11-10-02	7:29	P	FOUND DEAD
10529-04	M	1000 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10532-01	M	1000 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10547-05	M	1000 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10463-13	F	0 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10464-10	F	0 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10506-05	F	0 PPM	DISPOSITION	11-20-02	8:59	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10524-09	F	0 PPM	DISPOSITION	11-18-02	10:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10540-05	F	0 PPM	DISPOSITION	11-22-02	7:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10554-08	F	0 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10555-15	F	0 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10488-09	F	100 PPM	DISPOSITION	11-17-02	8:50	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10493-07	F	100 PPM	DISPOSITION	11-24-02	8:36	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10504-11	F	100 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10510-14	F	100 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10519-15	F	100 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10522-14	F	100 PPM	DISPOSITION	11-18-02	10:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10525-07	F	100 PPM	DISPOSITION	11-21-02	7:51	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10528-11	F	100 PPM	DISPOSITION	11-21-02	7:51	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10468-11	F	500 PPM	DISPOSITION	11-22-02	7:02	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10478-10	F	500 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10483-05	F	500 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10484-14	F	500 PPM	DISPOSITION	11-21-02	7:51	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE RANGE: 11-05-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10530-07	F	500 PPM	DISPOSITION	11-18-02	10:03	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10534-06	F	500 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10534-06	F	500 PPM	BODY/INTEGUMENT	11-13-02	6:59	P	BLACK AREA END OF TAIL
				11-13-02	6:59	P	RING-LIKE INDENTATIONS ON TAIL
				11-19-02	6:36	P	DISTAL END OF TAIL MISSING
				11-19-02	6:36	P	RING-LIKE INDENTATIONS ON TAIL
10546-11	F	500 PPM	DISPOSITION	11-18-02	0:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10548-17	F	500 PPM	DISPOSITION	11-18-02	10:03	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10550-20	F	500 PPM	DISPOSITION	11-19-02	8:41	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10465-09	F	1000 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10473-06	F	1000 PPM	DISPOSITION	11-23-02	8:53	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10480-12	F	1000 PPM	DISPOSITION	11-19-02	8:42	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10481-11	F	1000 PPM	DISPOSITION	11-07-02	0:00	P	EUTHANIZED IN EXTREMIS
10481-11	F	1000 PPM	BODY/INTEGUMENT	11-07-02	15:02	P	BROKEN RIGHT FORELIMB
10486-15	F	1000 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10507-15	F	1000 PPM	DISPOSITION	11-18-02	10:03	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10532-08	F	1000 PPM	DISPOSITION	11-20-02	9:00	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34
10547-13	F	1000 PPM	DISPOSITION	11-19-02	8:42	P	SCHEDULED EUTHANASIA;POSTNATAL DAY 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 180 (F1 - INHALATION PHASE - PRIOR TO EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-23-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10478-07	M	500 PPM	EYES/EARS/NOSE	11-09-02	7:17	1	DRIED RED MATERIAL AROUND NOSE
				11-09-02	7:17	1	DRIED RED MATERIAL AROUND LEFT EYE
				11-09-02	7:18	P	EYELIDS HALF CLOSED
10468-11	F	500 PPM	EYES/EARS/NOSE	11-10-02	6:58	1	DRIED RED MATERIAL AROUND NOSE
10478-10	F	500 PPM	EYES/EARS/NOSE	11-09-02	7:11	1	DRIED RED MATERIAL AROUND NOSE
10534-06	F	500 PPM	EYES/EARS/NOSE	11-08-02	8:28	1	DRIED RED MATERIAL AROUND NOSE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/12/2003
R:02/13/2003

TABLE 181 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-23-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10478-07	M	500 PPM	CARDIO-PULMONARY	11-09-02	14:32	P	LABORED RESPIRATION
10480-09	M	1000 PPM	BEHAVIOR/CNS	11-07-02	15:08	P	PROSTRATE
				11-08-02	16:00	P	PROSTRATE
10480-09	M	1000 PPM	CARDIO-PULMONARY	11-07-02	15:08	P	LABORED RESPIRATION
				11-08-02	16:00	P	LABORED RESPIRATION
10480-09	M	1000 PPM	EYES/EARS/NOSE	11-07-02	15:08	P	EYELIDS HALF CLOSED
				11-08-02	16:01	P	EYELIDS HALF CLOSED
10481-07	M	1000 PPM	BODY/INTEGUMENT	11-06-02	14:34	P	BODY COOL TO TOUCH
10481-07	M	1000 PPM	CARDIO-PULMONARY	11-06-02	14:34	P	LABORED RESPIRATION
10481-07	M	1000 PPM	EYES/EARS/NOSE	11-09-02	14:35	P	EYELIDS HALF CLOSED
10486-01	M	1000 PPM	BEHAVIOR/CNS	11-08-02	16:03	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS
10507-01	M	1000 PPM	BEHAVIOR/CNS	11-06-02	14:40	P	PROSTRATE
				11-07-02	15:11	P	PROSTRATE
				11-08-02	16:04	P	PROSTRATE
				11-09-02	14:36	P	PROSTRATE
10507-01	M	1000 PPM	CARDIO-PULMONARY	11-06-02	14:40	P	LABORED RESPIRATION
				11-07-02	15:11	P	LABORED RESPIRATION
				11-08-02	16:04	P	LABORED RESPIRATION
				11-09-02	14:36	P	LABORED RESPIRATION
10507-01	M	1000 PPM	EYES/EARS/NOSE	11-06-02	14:40	P	EYELIDS HALF CLOSED
				11-07-02	15:12	P	EYELIDS HALF CLOSED
				11-08-02	16:04	P	EYELIDS HALF CLOSED
				11-09-02	14:36	P	EYELIDS HALF CLOSED
10532-01	M	1000 PPM	EYES/EARS/NOSE	11-09-02	14:38	P	REDDENED AREA AROUND NOSE
10480-12	F	1000 PPM	BEHAVIOR/CNS	11-07-02	15:09	P	PROSTRATE
				11-08-02	16:01	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS
10480-12	F	1000 PPM	CARDIO-PULMONARY	11-07-02	15:09	P	LABORED RESPIRATION
10480-12	F	1000 PPM	EYES/EARS/NOSE	11-07-02	15:09	P	EYELIDS HALF CLOSED
10507-15	F	1000 PPM	BEHAVIOR/CNS	11-07-02	15:12	P	UNABLE TO RIGHT SELF

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 181 (F1 - INHALATION PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

SPONSOR:ACC

INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-23-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10507-15	F	1000 PPM	BEHAVIOR/CNS	11-08-02	16:04	P	UNABLE TO RIGHT SELF
10507-15	F	1000 PPM	CARDIO-PULMONARY	11-06-02	14:41	P	LABORED RESPIRATION
				11-07-02	15:12	P	LABORED RESPIRATION
				11-08-02	16:05	P	LABORED RESPIRATION
10507-15	F	1000 PPM	EYES/EARS/NOSE	11-06-02	14:40	P	EYELIDS HALF CLOSED
				11-07-02	15:12	P	EYELIDS HALF CLOSED
				11-08-02	16:05	P	EYELIDS HALF CLOSED
10532-08	F	1000 PPM	EYES/EARS/NOSE	11-09-02	14:38	P	REDDENED AREA AROUND NOSE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/13/2003
R:02/13/2003

TABLE 182 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-05-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10485-03	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:01	P	SCHEDULED EUTHANASIA; PND 34
10491-02	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:01	P	SCHEDULED EUTHANASIA; PND 34
10496-02	M	0 PPM/0 MG/KG	DISPOSITION	11-26-02	7:20	P	SCHEDULED EUTHANASIA; PND 34
10498-06	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:42	P	SCHEDULED EUTHANASIA; PND 34
10512-05	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:42	P	SCHEDULED EUTHANASIA; PND 34
10514-06	M	0 PPM/0 MG/KG	DISPOSITION	11-21-02	7:51	P	SCHEDULED EUTHANASIA; PND 34
10521-02	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:01	P	SCHEDULED EUTHANASIA; PND 34
10537-01	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:42	P	SCHEDULED EUTHANASIA; PND 34
10487-04	M	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10492-02	M	100 PPM/90 MG/KG	DISPOSITION	11-07-02	8:08	P	FOUND DEAD
10495-02	M	100 PPM/90 MG/KG	DISPOSITION	11-22-02	7:03	P	SCHEDULED EUTHANASIA; PND 34
10499-04	M	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:12	P	SCHEDULED EUTHANASIA; PND 34
10515-08	M	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10516-05	M	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:52	P	SCHEDULED EUTHANASIA; PND 34
10552-08	M	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:52	P	SCHEDULED EUTHANASIA; PND 34
10556-05	M	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:13	P	SCHEDULED EUTHANASIA; PND 34
10475-05	M	500 PPM/342MG/KG	DISPOSITION	11-18-02	10:13	P	SCHEDULED EUTHANASIA; PND 34
10489-02	M	500 PPM/342MG/KG	DISPOSITION	11-30-02	8:09	P	SCHEDULED EUTHANASIA; PND 34
10490-07	M	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:01	P	SCHEDULED EUTHANASIA; PND 34
10497-04	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10501-01	M	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:52	P	SCHEDULED EUTHANASIA; PND 34
10505-05	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10517-02	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10531-04	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:43	P	SCHEDULED EUTHANASIA; PND 34
10533-01	M	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:01	P	SCHEDULED EUTHANASIA; PND 34
10538-04	M	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:52	P	SCHEDULED EUTHANASIA; PND 34
10466-02	M	1000PPM/621MG/KG	DISPOSITION	11-22-02	7:03	P	SCHEDULED EUTHANASIA; PND 34
10469-03	M	1000PPM/621MG/KG	DISPOSITION	11-07-02	16:02	P	SENT TO NECROPSY; ANIMAL INADVERTENTLY REMOVED FROM ANIMAL ROOM
10469-03	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	16:00	P	HYPOACTIVE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 182 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-05-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10469-03	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	16:00	P	SPLAYED HINDLIMBS
10469-03	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-07-02	16:00	P	EYELIDS HALF CLOSED
10477-03	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:44	P	SCHEDULED EUTHANASIA; PND 34
10502-13	M	1000PPM/621MG/KG	DISPOSITION	11-08-02	9:16	P	FOUND DEAD
10526-04	M	1000PPM/621MG/KG	DISPOSITION	11-07-02	8:08	P	FOUND DEAD
10527-01	M	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:13	P	SCHEDULED EUTHANASIA; PND 34
10541-03	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:44	P	SCHEDULED EUTHANASIA; PND 34
10542-06	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:44	P	SCHEDULED EUTHANASIA; PND 34
10544-05	M	1000PPM/621MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10545-06	M	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:13	P	SCHEDULED EUTHANASIA; PND 34
10485-09	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10491-07	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10496-16	F	0 PPM/0 MG/KG	DISPOSITION	11-26-02	7:20	P	SCHEDULED EUTHANASIA; PND 34
10498-10	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:44	P	SCHEDULED EUTHANASIA; PND 34
10512-13	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10514-11	F	0 PPM/0 MG/KG	DISPOSITION	11-21-02	7:53	P	SCHEDULED EUTHANASIA; PND 34
10521-17	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10537-12	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10537-12	F	0 PPM/0 MG/KG	EYES/EARS/NOSE	11-13-02	7:05	1	DRIED RED MATERIAL AROUND NOSE
10487-09	F	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10492-12	F	100 PPM/90 MG/KG	DISPOSITION	11-07-02	7:59	P	FOUND DEAD
10495-15	F	100 PPM/90 MG/KG	DISPOSITION	11-22-02	7:03	P	SCHEDULED EUTHANASIA; PND 34
10499-10	F	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:14	P	SCHEDULED EUTHANASIA; PND 34
10515-10	F	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10516-07	F	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:52	P	SCHEDULED EUTHANASIA; PND 34
10552-11	F	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:54	P	SCHEDULED EUTHANASIA; PND 34
10556-11	F	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:14	P	SCHEDULED EUTHANASIA; PND 34
10475-13	F	500 PPM/342MG/KG	DISPOSITION	11-18-02	10:14	P	SCHEDULED EUTHANASIA; PND 34
10489-16	F	500 PPM/342MG/KG	DISPOSITION	11-30-02	8:09	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 182 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 22-33)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-05-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10490-08	F	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10497-16	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10501-05	F	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:54	P	SCHEDULED EUTHANASIA; PND 34
10505-15	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10517-10	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10531-11	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:45	P	SCHEDULED EUTHANASIA; PND 34
10533-06	F	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10538-09	F	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:54	P	SCHEDULED EUTHANASIA; PND 34
10466-14	F	1000PPM/621MG/KG	DISPOSITION	11-22-02	7:04	P	SCHEDULED EUTHANASIA; PND 34
10469-14	F	1000PPM/621MG/KG	DISPOSITION	11-07-02	16:02	P	SENT TO NECROPSY; ANIMAL INADVERTENTLY REMOVED FROM ANIMAL ROOM
10469-14	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	16:01	P	HYPOACTIVE
				11-07-02	16:01	P	SPLAYED HINDLIMBS
10469-14	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-07-02	16:01	P	EYELIDS HALF CLOSED
10477-12	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:46	P	SCHEDULED EUTHANASIA; PND 34
10502-08	F	1000PPM/621MG/KG	DISPOSITION	11-08-02	9:17	P	EUTHANIZED IN EXTREMIS
10502-08	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-08-02	9:16	P	PROSTRATE
10502-08	F	1000PPM/621MG/KG	CARDIO-PULMONARY	11-08-02	9:17	P	LABORED RESPIRATION
10526-16	F	1000PPM/621MG/KG	DISPOSITION	11-07-02	8:09	P	FOUND DEAD
10527-15	F	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:14	P	SCHEDULED EUTHANASIA; PND 34
10541-13	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:46	P	SCHEDULED EUTHANASIA; PND 34
10542-11	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:46	P	SCHEDULED EUTHANASIA; PND 34
10544-12	F	1000PPM/621MG/KG	DISPOSITION	11-20-02	9:02	P	SCHEDULED EUTHANASIA; PND 34
10545-14	F	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:14	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 183 (F1 - INHALATION/GAVAGE PHASE - PRIOR TO EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-29-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10492-02	M	100 PPM/90 MG/KG	EYES/EARS/NOSE	11-06-02	7:17	1	DRIED RED MATERIAL AROUND NOSE
10505-05	M	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	8:23	1	DRIED RED MATERIAL AROUND NOSE
10469-03	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-07-02	7:28	1	DRIED RED MATERIAL AROUND NOSE
10502-13	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	7:04	1	DRIED RED MATERIAL AROUND NOSE
10526-04	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	7:06	1	DRIED RED MATERIAL AROUND NOSE
10541-03	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-09-02	7:25	1	DRIED RED MATERIAL AROUND LEFT EYE
10537-12	F	0 PPM/0 MG/KG	EYES/EARS/NOSE	11-13-02	8:44	1	DRIED RED MATERIAL AROUND NOSE
10505-15	F	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	8:23	1	DRIED RED MATERIAL AROUND NOSE
10533-06	F	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	8:25	1	DRIED RED MATERIAL AROUND NOSE
10502-08	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	7:05	1	DRIED RED MATERIAL AROUND NOSE
				11-07-02	7:32	1	DRIED RED MATERIAL AROUND NOSE
10526-16	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	7:06	1	DRIED RED MATERIAL AROUND NOSE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/12/2003
R:02/13/2003

TABLE 184 (F1 - INHALATION/GAVAGE PHASE - MIDPOINT OF EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-29-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10469-03	M	1000PPM/621MG/KG	CARDIO-PULMONARY	11-07-02	11:25	P	LABORED RESPIRATION

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/12/2003
R:02/13/2003

TABLE 185 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-29-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10517-02	M	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	16:10	P	REDDENED AREA AROUND NOSE
10533-01	M	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	16:09	P	REDDENED AREA AROUND NOSE
10477-03	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	15:15	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS
10502-13	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-06-02	14:43	P	PROSTRATE
				11-07-02	15:15	P	PROSTRATE
10502-13	M	1000PPM/621MG/KG	CARDIO-PULMONARY	11-06-02	14:42	P	LABORED RESPIRATION
				11-07-02	15:15	P	LABORED RESPIRATION
10502-13	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	14:43	P	EYELIDS HALF CLOSED
				11-07-02	15:15	P	EYELIDS HALF CLOSED
10526-04	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-05-02	14:05	P	PROSTRATE
				11-06-02	14:43	P	PROSTRATE
10526-04	M	1000PPM/621MG/KG	CARDIO-PULMONARY	11-05-02	14:17	P	LABORED RESPIRATION
				11-06-02	14:44	P	LABORED RESPIRATION
10526-04	M	1000PPM/621MG/KG	EYES/EARS/NOSE	11-05-02	14:15	P	EYELIDS HALF CLOSED
				11-06-02	14:44	P	EYELIDS HALF CLOSED
10542-06	M	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	15:16	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS
10533-06	F	500 PPM/342MG/KG	EYES/EARS/NOSE	11-08-02	16:10	P	REDDENED AREA AROUND NOSE
10477-12	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	15:14	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS
10477-12	F	1000PPM/621MG/KG	CARDIO-PULMONARY	11-07-02	15:14	P	LABORED RESPIRATION
10477-12	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-07-02	15:13	P	EYELIDS HALF CLOSED
10502-08	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-06-02	14:42	P	PROSTRATE
				11-07-02	15:15	P	PROSTRATE
10502-08	F	1000PPM/621MG/KG	CARDIO-PULMONARY	11-06-02	14:42	P	LABORED RESPIRATION
				11-07-02	15:16	P	LABORED RESPIRATION
10502-08	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-06-02	14:42	P	EYELIDS HALF CLOSED
				11-07-02	15:16	P	EYELIDS HALF CLOSED
10526-16	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-05-02	14:19	P	UNABLE TO RIGHT SELF
				11-05-02	14:19	P	ANIMAL CIRCLES TO THE RIGHT
				11-06-02	14:44	P	PROSTRATE

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 185 (F1 - INHALATION/GAVAGE PHASE - 1-HOUR POST-EXPOSURE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS

TABLE RANGE: 11-05-02 TO 11-29-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10526-16	F	1000PPM/621MG/KG	CARDIO-PULMONARY	11-05-02	14:18	P	LABORED RESPIRATION
				11-06-02	14:44	P	LABORED RESPIRATION
10526-16	F	1000PPM/621MG/KG	EYES/EARS/NOSE	11-05-02	14:20	P	EYELIDS HALF CLOSED
				11-06-02	14:44	P	EYELIDS HALF CLOSED
10542-11	F	1000PPM/621MG/KG	BEHAVIOR/CNS	11-07-02	15:16	P	ROCKS, LURCHES, OR SWAYS AS IT WALKS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.05
02/12/2003
R:02/13/2003

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 1: 0 PPM												
10463-07	36.1	39.9	46.1	51.9	56.5	61.7	67.9	72.6	79.2	87.1	94.1	101.2
10464-08	48.3	52.2	59.6	66.7	71.1	79.7	85.8	92.8	99.0	108.8	117.4	125.4
10506-01	55.9	61.2	66.9	70.3	76.3	81.4	92.5	93.2	102.2	107.9	117.2	128.8
10524-07	35.2	40.1	45.0	48.9	53.8	60.0	65.5	70.2	76.3	79.9	89.2	96.6
10540-04	50.2	54.7	57.0	63.3	66.9	74.0	77.7	84.7	90.5	96.7	102.8	111.8
10554-03	40.0	45.4	51.6	57.6	60.6	66.8	73.3	82.0	86.8	93.8	101.0	108.3
10555-10	38.9	43.9	50.5	57.0	62.1	66.6	71.3	78.1	83.0	89.9	97.8	105.4
MEAN	43.5	48.2	53.8	59.4	63.9	70.0	76.3	81.9	88.1	94.9	102.8	111.1
S.D.	7.95	8.04	7.83	7.78	8.02	8.47	9.80	9.06	9.74	10.63	10.87	12.02
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY 34

ANIMALS FROM GROUP 1:	0 PPM
10463-07	107.6
10464-08	133.7
10506-01	132.8
10524-07	103.6
10540-04	120.0
10554-03	118.4
10555-10	110.2
MEAN	118.0
S.D.	11.87
N	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 2: 100 PPM												
10488-06	44.8	50.8	55.0	60.2	64.2	70.8	76.9	82.8	89.5	95.2	103.8	112.2
10504-02	38.6	42.6	48.5	53.7	58.9	63.5	69.4	74.9	80.4	86.1	93.2	100.4
10510-02	38.6	43.3	49.0	54.5	60.0	64.2	71.7	78.0	83.2	91.9	98.8	104.5
10519-04	36.2	39.3	46.5	51.8	57.3	63.0	70.8	76.4	82.1	92.6	99.5	106.3
10522-02	39.0	42.0	47.5	52.2	58.4	66.3	71.8	77.5	83.6	90.7	99.7	108.0
10525-04	39.3	42.5	48.3	53.0	58.1	61.6	67.9	73.4	79.5	84.8	89.9	99.1
10528-06	40.8	51.4	58.4	63.6	68.2	72.8	78.4	82.6	88.9	95.3	101.6	108.5
MEAN	39.6	44.6	50.5	55.6	60.7	66.0	72.4	77.9	83.9	90.9	98.1	105.6
S.D.	2.66	4.65	4.45	4.52	4.00	4.23	3.85	3.60	3.91	4.12	4.85	4.63
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY 34

ANIMALS FROM GROUP 2:	100 PPM
10488-06	119.3
10504-02	108.0
10510-02	111.5
10519-04	117.3
10522-02	116.4
10525-04	102.6
10528-06	114.5
MEAN	112.8
S.D.	5.88
N	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 3: 500 PPM												
10468-02	44.0	47.1	53.4	57.8	61.8	70.1	74.8	79.4	85.1	92.8	98.0	107.4
10478-07	19.4	17.2	NA									
10483-02	48.6	52.2	57.9	64.9	71.3	77.8	84.6	90.9	98.1	105.5	112.4	121.6
10484-01	40.9	42.8	46.7	53.0	57.5	50.6	64.1	70.3	76.3	83.3	87.6	95.0
10530-03	38.7	40.3	42.3	46.0	50.9	58.2	64.3	68.3	72.8	78.3	84.7	90.8
10534-03	33.5	36.6	41.5	46.4	50.3	54.8	60.7	66.5	71.4	81.0	85.6	91.9
10546-01	36.3	40.8	45.6	49.8	56.2	61.1	66.3	72.1	79.4	85.3	91.5	99.6
10548-07	40.4	44.7	50.2	54.2	62.9	68.0	74.6	81.1	87.2	92.9	101.0	108.6
10550-12	52.7	52.7	58.2	64.6	68.3	75.5	82.4	88.6	95.9	101.6	109.9	117.7
MEAN	39.4	41.6	49.5	54.6	59.9	64.5	71.5	77.2	83.3	90.1	96.3	104.1
S.D.	9.56	10.60	6.56	7.40	7.61	9.86	8.95	9.30	10.09	9.83	10.80	11.66
N	9	9	8	8	8	8	8	8	8	8	8	8

NA = NOT APPLICABLE

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY 34

ANIMALS FROM GROUP 3: 500 PPM	
10468-02	113.4
10483-02	126.6
10484-01	102.7
10530-03	102.1
10534-03	97.6
10546-01	105.6
10548-07	116.4
10550-12	124.1
MEAN	111.1
S.D.	10.73
N	8

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 4: 1000 PPM												
10465-01	36.0	37.8	41.9	45.5	49.7	53.7	59.0	64.3	71.3	79.2	87.3	92.6
10473-05	49.9	52.4	57.7	61.6	66.1	70.5	77.1	83.3	89.1	96.1	103.8	111.0
10480-09	21.5	18.9	NA									
10481-07	31.9	34.4	36.6	40.2	43.0	46.2	50.7	54.8	61.0	65.0	71.5	77.6
10486-01	36.0	36.5	40.1	44.8	48.4	51.1	55.6	59.5	65.3	70.8	75.9	83.1
10507-01	25.9	23.0	23.3	22.5	NA							
10529-04	43.1	44.6	48.4	51.2	57.2	60.1	65.0	69.5	75.9	81.5	88.5	97.4
10532-01	50.5	50.5	57.1	62.1	68.0	74.6	80.5	88.6	95.4	103.1	107.4	116.3
10547-05	53.3	52.8	56.8	63.9	66.8	74.3	78.0	84.2	89.2	95.9	104.2	110.3
MEAN	38.7	39.0	45.2	49.0	57.0	61.5	66.6	72.0	78.2	84.5	91.2	98.3
S.D.	11.28	12.36	12.15	13.97	10.19	11.70	12.02	13.35	13.23	14.23	14.35	14.84
N	9	9	8	8	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 8

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY 34

ANIMALS FROM GROUP 4: 1000 PPM	
10465-01	101.6
10473-05	117.0
10481-07	84.2
10486-01	89.4
10529-04	103.2
10532-01	124.5
10547-05	119.7
MEAN	105.7
S.D.	15.43
N	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES											
DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 1: 0 PPM												
10463-13	35.1	38.3	43.7	49.3	54.2	58.4	65.4	69.1	76.2	84.6	88.3	96.5
10464-10	47.7	50.6	58.0	60.9	66.5	72.3	77.8	82.6	87.0	96.9	101.0	108.4
10506-05	46.6	50.4	56.2	60.3	64.4	69.8	75.3	76.9	82.0	90.3	94.8	100.7
10524-09	41.2	45.2	48.9	53.0	57.9	63.0	67.2	72.6	78.2	84.0	87.0	92.0
10540-05	47.1	51.5	57.1	61.2	65.1	70.1	75.1	81.4	85.2	93.1	98.5	104.6
10554-08	39.0	44.1	49.0	54.0	58.1	63.7	67.6	74.5	80.1	88.2	95.0	101.5
10555-15	43.5	46.4	51.8	58.3	63.7	68.2	75.2	83.4	85.6	93.0	101.5	107.2
MEAN	42.9	46.6	52.1	56.7	61.4	66.5	71.9	77.2	82.0	90.0	95.2	101.6
S.D.	4.72	4.68	5.28	4.64	4.64	4.93	5.01	5.47	4.08	4.74	5.76	5.85
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALES

DAY 34

ANIMALS FROM GROUP 1:	0 PPM
10463-13	103.1
10464-10	116.6
10506-05	107.8
10524-09	97.5
10540-05	109.5
10554-08	107.2
10555-15	113.9
MEAN	107.9
S.D.	6.40
N	7

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 2:		100 PPM										
10488-09	39.2	42.4	45.4	52.5	57.0	61.9	67.4	71.9	78.1	83.7	90.1	95.4
10493-07	35.7	45.2	51.2	54.4	59.0	63.4	69.9	76.2	81.5	87.1	95.0	101.6
10504-11	40.8	45.5	48.7	54.8	58.7	64.5	69.1	72.8	79.1	84.2	88.5	97.1
10510-14	35.5	40.0	44.5	50.7	55.8	60.2	66.8	71.7	77.1	83.3	88.1	96.2
10519-15	25.1	30.1	33.3	38.1	42.3	47.1	52.8	57.4	61.7	69.7	74.4	81.5
10522-14	42.7	45.3	52.2	55.0	61.8	68.7	73.4	80.4	85.8	92.4	100.2	110.9
10525-07	25.6	28.3	32.6	37.5	43.3	46.9	49.6	55.8	59.2	63.7	68.9	73.8
10528-11	40.7	45.5	51.2	56.4	60.4	63.8	67.3	72.0	77.7	80.9	87.0	93.9
MEAN	35.7	40.3	44.9	49.9	54.8	59.6	64.5	69.8	75.0	80.6	86.5	93.8
S.D.	6.83	7.13	7.87	7.68	7.63	8.12	8.54	8.66	9.44	9.38	10.25	11.49
N	8	8	8	8	8	8	8	8	8	8	8	8

FEMALES

DAY 34

ANIMALS FROM GROUP 2:	100 PPM
10488-09	103.0
10493-07	109.4
10504-11	102.0
10510-14	104.8
10519-15	88.5
10522-14	114.9
10525-07	78.0
10528-11	99.4
MEAN	100.0
S.D.	11.73
N	8

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES											
DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 3: 500 PPM												
10468-11	30.8	33.2	39.2	43.2	47.3	52.5	57.6	62.4	67.7	72.5	77.2	83.6
10478-10	30.2	31.2	36.8	40.0	43.1	47.3	51.0	55.9	61.4	67.2	72.1	77.6
10483-05	42.6	46.3	49.6	56.2	61.2	65.6	69.4	74.5	79.4	84.8	90.6	97.3
10484-14	39.5	40.4	47.3	52.2	56.2	53.1	65.7	68.8	73.6	78.3	83.2	90.9
10530-07	40.2	42.9	46.6	47.9	52.1	56.6	61.9	65.8	72.0	75.2	81.3	85.4
10534-06	33.9	36.2	40.6	43.3	48.0	53.7	57.7	64.2	67.6	71.8	78.3	87.9
10546-11	34.5	37.3	42.3	44.6	50.9	54.1	60.5	65.0	69.3	72.9	79.1	86.0
10548-17	42.7	44.8	50.2	55.4	58.4	65.2	70.8	77.1	83.2	87.9	96.6	103.5
10550-20	45.7	49.2	53.2	58.3	63.9	68.2	73.9	79.8	84.9	91.5	97.5	104.2
MEAN	37.8	40.2	45.1	49.0	53.5	57.4	63.2	68.2	73.2	78.0	84.0	90.7
S.D.	5.60	6.13	5.60	6.68	6.93	7.20	7.39	7.67	7.85	8.26	8.92	9.15
N	9	9	9	9	9	9	9	9	9	9	9	9

FEMALES

DAY 34

ANIMALS FROM GROUP 3: 500 PPM	
10468-11	87.3
10478-10	84.4
10483-05	102.4
10484-14	97.8
10530-07	93.3
10534-06	90.7
10546-11	90.2
10548-17	109.3
10550-20	108.6
MEAN	96.0
S.D.	9.08
N	9

TABLE 186 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES											
DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 4: 1000 PPM												
10465-09	38.0	39.3	43.5	47.7	50.7	55.8	60.8	66.4	72.5	79.0	87.8	91.8
10473-06	46.6	46.3	52.0	55.8	60.2	64.3	68.2	73.0	79.3	84.7	90.1	96.1
10480-12	27.9	32.1	34.4	36.0	39.7	42.2	45.3	48.9	52.7	57.8	63.9	68.5
10481-11	30.6	31.6										
10486-15	48.6	48.8	52.0	55.7	61.5	65.2	69.3	71.3	77.8	82.0	87.8	91.9
10507-15	25.7	24.0	28.1	30.9	34.5	36.7	39.5	43.0	47.3	51.7	56.7	62.3
10532-08	45.4	46.5	52.0	56.0	59.3	63.5	68.4	72.7	76.4	83.0	87.6	92.7
10547-13	49.2	49.6	54.3	58.3	64.3	68.5	74.1	78.9	83.8	89.7	95.6	102.3
MEAN	39.0	39.8	45.2	48.6	52.9	56.6	60.8	64.9	70.0	75.4	81.4	86.5
S.D.	9.76	9.57	10.28	10.98	11.66	12.43	13.26	13.55	14.14	14.59	14.80	14.98
N	8	8	7	7	7	7	7	7	7	7	7	7

FEMALES

DAY 34

ANIMALS FROM GROUP 4: 1000 PPM	
10465-09	100.3
10473-06	100.3
10480-12	72.2
10486-15	98.9
10507-15	67.3
10532-08	97.5
10547-13	105.9
MEAN	91.8
S.D.	15.33
N	7

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM												
10463-07	3.8	6.2	5.8	4.6	5.2	6.2	4.7	6.6	7.9	7.0	7.1	6.4
10464-08	3.9	7.4	7.1	4.4	8.6	6.1	7.0	6.2	9.8	8.6	8.0	8.3
10506-01	5.3	5.7	3.4	6.0	5.1	11.1	0.7	9.0	5.7	9.3	11.6	4.0
10524-07	4.9	4.9	3.9	4.9	6.2	5.5	4.7	6.1	3.6	9.3	7.4	7.0
10540-04	4.5	2.3	6.3	3.6	7.1	3.7	7.0	5.8	6.2	6.1	9.0	8.2
10554-03	5.4	6.2	6.0	3.0	6.2	6.5	8.7	4.8	7.0	7.2	7.3	10.1
10555-10	5.0	6.6	6.5	5.1	4.5	4.7	6.8	4.9	6.9	7.9	7.6	4.8
MEAN	4.7	5.6	5.6	4.5	6.1	6.3	5.7	6.2	6.7	7.9	8.3	7.0
S.D.	0.64	1.65	1.38	0.99	1.39	2.35	2.60	1.40	1.92	1.22	1.59	2.12
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM												
10488-06	6.0	4.2	5.2	4.0	6.6	6.1	5.9	6.7	5.7	8.6	8.4	7.1
10504-02	4.0	5.9	5.2	5.2	4.6	5.9	5.5	5.5	5.7	7.1	7.2	7.6
10510-02	4.7	5.7	5.5	5.5	4.2	7.5	6.3	5.2	8.7	6.9	5.7	7.0
10519-04	3.1	7.2	5.3	5.5	5.7	7.8	5.6	5.7	10.5	6.9	6.8	11.0
10522-02	3.0	5.5	4.7	6.2	7.9	5.5	5.7	6.1	7.1	9.0	8.3	8.4
10525-04	3.2	5.8	4.7	5.1	3.5	6.3	5.5	6.1	5.3	5.1	9.2	3.5
10528-06	10.6	7.0	5.2	4.6	4.6	5.6	4.2	6.3	6.4	6.3	6.9	6.0
MEAN	4.9	5.9	5.1	5.2	5.3	6.4	5.5	5.9	7.1	7.1	7.5	7.2
S.D.	2.72	1.00	0.30	0.70	1.53	0.91	0.65	0.51	1.90	1.33	1.19	2.28
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM												
10468-02	3.1	6.3	4.4	4.0	8.3	4.7	4.6	5.7	7.7	5.2	9.4	6.0
10478-07	-2.2	NA										
10483-02	3.6	5.7	7.0	6.4	6.5	6.8	6.3	7.2	7.4	6.9	9.2	5.0
10484-01	1.9	3.9	6.3	4.5	-6.9	13.5	6.2	6.0	7.0	4.3	7.4	7.7
10530-03	1.6	2.0	3.7	4.9	7.3	6.1	4.0	4.5	5.5	6.4	6.1	11.3
10534-03	3.1	4.9	4.9	3.9	4.5	5.9	5.8	4.9	9.6	4.6	6.3	5.7
10546-01	4.5	4.8	4.2	6.4	4.9	5.2	5.8	7.3	5.9	6.2	8.1	6.0
10548-07	4.3	5.5	4.0	8.7	5.1	6.6	6.5	6.1	5.7	8.1	7.6	7.8
10550-12	0.0	5.5	6.4	3.7	7.2	6.9	6.2	7.3	5.7	8.3	7.8	6.4
MEAN	2.2	4.8	5.1	5.3	4.6	7.0	5.7	6.1	6.8	6.3	7.7	7.0
S.D.	2.18	1.35	1.27	1.73	4.84	2.75	0.90	1.09	1.41	1.50	1.19	1.99
N	9	8	8	8	8	8	8	8	8	8	8	8

NA = NOT APPLICABLE

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000 PPM												
10465-01	1.8	4.1	3.6	4.2	4.0	5.3	5.3	7.0	7.9	8.1	5.3	9.0
10473-05	2.5	5.3	3.9	4.5	4.4	6.6	6.2	5.8	7.0	7.7	7.2	6.0
10480-09	-2.6	NA										
10481-07	2.5	2.2	3.6	2.8	3.2	4.5	4.1	6.2	4.0	6.5	6.1	6.6
10486-01	0.5	3.6	4.7	3.6	2.7	4.5	3.9	5.8	5.5	5.1	7.2	6.3
10507-01	-2.9	0.3	-0.8	NA								
10529-04	1.5	3.8	2.8	6.0	2.9	4.9	4.5	6.4	5.6	7.0	8.9	5.8
10532-01	0.0	6.6	5.0	5.9	6.6	5.9	8.1	6.8	7.7	4.3	8.9	8.2
10547-05	-0.5	4.0	7.1	2.9	7.5	3.7	6.2	5.0	6.7	8.3	6.1	9.4
MEAN	0.3	3.7	3.7	4.3	4.5	5.1	5.5	6.1	6.3	6.7	7.1	7.3
S.D.	2.02	1.89	2.25	1.30	1.88	0.97	1.49	0.68	1.39	1.53	1.40	1.50
N	9	8	8	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM												
10463-13	3.2	5.4	5.6	4.9	4.2	7.0	3.7	7.1	8.4	3.7	8.2	6.6
10464-10	2.9	7.4	2.9	5.6	5.8	5.5	4.8	4.4	9.9	4.1	7.4	8.2
10506-05	3.8	5.8	4.1	4.1	5.4	5.5	1.6	5.1	8.3	4.5	5.9	7.1
10524-09	4.0	3.7	4.1	4.9	5.1	4.2	5.4	5.6	5.8	3.0	5.0	5.5
10540-05	4.4	5.6	4.1	3.9	5.0	5.0	6.3	3.8	7.9	5.4	6.1	4.9
10554-08	5.1	4.9	5.0	4.1	5.6	3.9	6.9	5.6	8.1	6.8	6.5	5.7
10555-15	2.9	5.4	6.5	5.4	4.5	7.0	8.2	2.2	7.4	8.5	5.7	6.7
MEAN	3.8	5.5	4.6	4.7	5.1	5.4	5.3	4.8	8.0	5.1	6.4	6.4
S.D.	0.82	1.10	1.18	0.68	0.58	1.22	2.18	1.56	1.23	1.93	1.08	1.11
N	7	7	7	7	7	7	7	7	7	7	7	7

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM												
10488-09	3.2	3.0	7.1	4.5	4.9	5.5	4.5	6.2	5.6	6.4	5.3	7.6
10493-07	9.5	6.0	3.2	4.6	4.4	6.5	6.3	5.3	5.6	7.9	6.6	7.8
10504-11	4.7	3.2	6.1	3.9	5.8	4.6	3.7	6.3	5.1	4.3	8.6	4.9
10510-14	4.5	4.5	6.2	5.1	4.4	6.6	4.9	5.4	6.2	4.8	8.1	8.6
10519-15	5.0	3.2	4.8	4.2	4.8	5.7	4.6	4.3	8.0	4.7	7.1	7.0
10522-14	2.6	6.9	2.8	6.8	6.9	4.7	7.0	5.4	6.6	7.8	10.7	4.0
10525-07	2.7	4.3	4.9	5.8	3.6	2.7	6.2	3.4	4.5	5.2	4.9	4.2
10528-11	4.8	5.7	5.2	4.0	3.4	3.5	4.7	5.7	3.2	6.1	6.9	5.5
MEAN	4.6	4.6	5.0	4.9	4.8	5.0	5.2	5.3	5.6	5.9	7.3	6.2
S.D.	2.20	1.47	1.47	1.00	1.14	1.38	1.13	0.97	1.43	1.39	1.86	1.77
N	8	8	8	8	8	8	8	8	8	8	8	8

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM												
10468-11	2.4	6.0	4.0	4.1	5.2	5.1	4.8	5.3	4.8	4.7	6.4	3.7
10478-10	1.0	5.6	3.2	3.1	4.2	3.7	4.9	5.5	5.8	4.9	5.5	6.8
10483-05	3.7	3.3	6.6	5.0	4.4	3.8	5.1	4.9	5.4	5.8	6.7	5.1
10484-14	0.9	6.9	4.9	4.0	-3.1	12.6	3.1	4.8	4.7	4.9	7.7	6.9
10530-07	2.7	3.7	1.3	4.2	4.5	5.3	3.9	6.2	3.2	6.1	4.1	7.9
10534-06	2.3	4.4	2.7	4.7	5.7	4.0	6.5	3.4	4.2	6.5	9.6	2.8
10546-11	2.8	5.0	2.3	6.3	3.2	6.4	4.5	4.3	3.6	6.2	6.9	4.2
10548-17	2.1	5.4	5.2	3.0	6.8	5.6	6.3	6.1	4.7	8.7	6.9	5.8
10550-20	3.5	4.0	5.1	5.6	4.3	5.7	5.9	5.1	6.6	6.0	6.7	4.4
MEAN	2.4	4.9	3.9	4.4	3.9	5.8	5.0	5.1	4.8	6.0	6.7	5.3
S.D.	0.97	1.17	1.68	1.09	2.82	2.72	1.11	0.87	1.06	1.21	1.49	1.68
N	9	9	9	9	9	9	9	9	9	9	9	9

TABLE 187 (F1 - INHALATION PHASE - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000 PPM												
10465-09	1.3	4.2	4.2	3.0	5.1	5.0	5.6	6.1	6.5	8.8	4.0	8.5
10473-06	-0.3	5.7	3.8	4.4	4.1	3.9	4.8	6.3	5.4	5.4	6.0	4.2
10480-12	4.2	2.3	1.6	3.7	2.5	3.1	3.6	3.8	5.1	6.1	4.6	3.7
10481-11	1.0											
10486-15	0.2	3.2	3.7	5.8	3.7	4.1	2.0	6.5	4.2	5.8	4.1	7.0
10507-15	-1.7	4.1	2.8	3.6	2.2	2.8	3.5	4.3	4.4	5.0	5.6	5.0
10532-08	1.1	5.5	4.0	3.3	4.2	4.9	4.3	3.7	6.6	4.6	5.1	4.8
10547-13	0.4	4.7	4.0	6.0	4.2	5.6	4.8	4.9	5.9	5.9	6.7	3.6
MEAN	0.8	4.2	3.4	4.3	3.7	4.2	4.1	5.1	5.4	5.9	5.2	5.3
S.D.	1.69	1.21	0.93	1.20	1.03	1.03	1.18	1.21	0.95	1.37	1.00	1.83
N	8	7	7	7	7	7	7	7	7	7	7	7

PJTBWv4.08
01/17/2003
R:01/22/2003

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG												
10485-03	27.7	32.6	36.9	41.1	46.4	49.2	53.4	57.7	63.5	68.7	75.9	81.3
10491-02	55.7	60.4	65.6	71.8	76.7	82.5	89.2	94.5	103.0	108.6	117.7	126.1
10496-02	50.3	55.2	59.7	63.8	71.1	77.4	86.3	91.0	97.2	106.7	113.0	120.9
10498-06	34.0	37.9	45.3	50.2	55.5	58.5	63.7	69.5	74.3	81.3	87.9	95.9
10512-05	47.0	53.2	58.4	63.8	70.1	74.9	81.5	89.4	93.4	102.8	113.5	117.8
10514-06	47.5	53.5	60.0	65.9	72.1	77.6	83.9	90.8	100.0	107.2	117.5	125.2
10521-02	44.8	50.3	56.5	62.4	69.2	74.2	80.7	85.1	92.6	101.3	107.9	117.1
10537-01	52.9	58.7	65.8	73.4	79.5	86.5	93.1	102.3	110.2	117.2	126.0	133.9
MEAN	45.0	50.2	56.0	61.6	67.6	72.6	79.0	85.0	91.8	99.2	107.4	114.8
S.D.	9.53	9.87	10.02	10.84	11.09	12.50	13.52	14.46	15.45	16.04	16.88	17.45
N	8	8	8	8	8	8	8	8	8	8	8	8

MALES

DAY 34

ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG	
10485-03	88.6
10491-02	130.7
10496-02	129.7
10498-06	101.6
10512-05	125.9
10514-06	135.4
10521-02	124.9
10537-01	142.4
MEAN	122.4
S.D.	18.07
N	8

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG												
10487-04	46.6	54.9	61.5	66.8	71.9	78.8	86.3	93.8	100.6	107.5	118.8	126.6
10492-02	17.4	NA										
10495-02	38.7	43.1	49.3	55.0	59.2	65.1	70.8	77.1	84.0	89.9	97.3	103.8
10499-04	41.4	47.8	52.8	57.8	64.6	71.6	78.4	83.7	88.4	96.7	107.7	114.0
10515-08	34.9	38.0	43.2	47.5	52.1	55.3	61.1	65.4	71.3	76.2	84.2	88.1
10516-05	35.2	39.3	45.1	47.7	61.1	57.6	64.1	70.1	76.4	83.2	89.4	97.5
10552-08	49.4	50.0	57.2	62.3	69.6	73.8	79.9	87.5	93.8	100.3	104.4	115.3
10556-05	41.7	45.2	51.1	57.4	63.7	64.7	72.1	79.0	83.8	89.1	93.0	103.5
MEAN	38.2	45.5	51.5	56.4	63.2	66.7	73.2	79.5	85.5	91.8	99.3	107.0
S.D.	9.79	5.98	6.44	7.10	6.61	8.57	8.94	9.83	9.96	10.57	11.88	12.73
N	8	7	7	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY 34

ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG	
10487-04	137.8
10495-02	112.2
10499-04	122.9
10515-08	95.0
10516-05	104.7
10552-08	124.2
10556-05	111.1
MEAN	115.4
S.D.	14.11
N	7

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG												
10475-05	57.0	58.3	63.3	71.6	77.0	83.2	89.1	98.6	102.6	110.2	117.2	125.4
10489-02	47.2	50.1	55.7	63.8	69.3	76.8	82.3	88.7	96.1	105.0	113.5	122.7
10490-07	34.6	38.0	43.0	46.4	49.9	54.5	59.4	64.1	69.7	76.8	83.2	89.9
10497-04	36.1	41.0	45.5	49.3	56.3	59.9	66.1	72.0	78.8	84.9	93.5	100.1
10501-01	39.3	43.6	47.6	53.1	58.1	63.6	70.6	75.6	83.6	90.8	96.8	105.7
10505-05	37.2	39.9	44.3	50.4	55.1	65.4	66.0	70.9	77.2	84.0	92.6	100.0
10517-02	48.4	51.2	56.1	62.2	67.9	74.1	80.4	85.5	89.9	100.4	110.1	116.9
10531-04	48.0	53.2	56.6	62.2	66.1	72.0	73.5	80.4	84.6	93.1	100.6	107.5
10533-01	48.4	50.4	56.8	63.6	69.2	74.1	77.5	84.8	93.2	100.9	108.6	115.6
10538-04	52.6	55.8	61.3	65.6	73.4	80.0	86.5	94.2	101.8	109.5	117.7	127.5
MEAN	44.9	48.2	53.0	58.8	64.2	70.4	75.1	81.5	87.8	95.6	103.4	111.1
S.D.	7.60	7.06	7.31	8.36	8.84	9.20	9.69	10.92	10.88	11.44	11.75	12.46
N	10	10	10	10	10	10	10	10	10	10	10	10

MALES

DAY 34

ANIMALS FROM GROUP 3: 500 PPM/342MG/KG

10475-05	135.0
10489-02	129.3
10490-07	96.8
10497-04	106.4
10501-01	113.8
10505-05	106.7
10517-02	123.0
10531-04	111.7
10533-01	125.7
10538-04	136.0
MEAN	118.4
S.D.	13.30
N	10

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG												
10466-02	57.3	57.7	62.4	64.5	68.3	71.8	77.5	79.4	86.7	93.0	101.8	108.3
10469-03	23.2											
10477-03	28.8	35.1	37.5	40.8	44.1	47.5	52.2	57.0	64.0	68.0	75.7	82.9
10502-13	23.8	22.5	NA									
10526-04	31.4	27.8	NA									
10527-01	34.9	33.4	43.0	48.7	51.2	55.1	60.2	65.9	71.9	78.2	84.1	91.4
10541-03	40.0	43.6	49.7	55.1	59.2	63.7	69.7	74.7	82.3	88.5	97.0	103.9
10542-06	30.6	30.5	32.2	37.6	41.1	43.6	47.4	50.8	55.7	60.7	64.2	71.8
10544-05	43.3	46.9	54.4	58.1	63.5	68.4	73.6	79.8	87.1	93.3	103.5	111.6
10545-06	33.3	39.1	44.1	48.6	55.3	60.0	65.6	70.5	75.1	83.2	89.9	99.7
MEAN	34.7	37.4	46.2	50.5	54.7	58.6	63.7	68.3	74.7	80.7	88.0	95.7
S.D.	10.16	10.76	10.23	9.51	9.94	10.48	11.09	11.11	11.83	12.55	14.42	14.42
N	10	9	7	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

MALES

DAY 34

ANIMALS FROM GROUP 4: 1000PPM/621MG/KG

10466-02	115.7
10477-03	87.5
10527-01	99.7
10541-03	110.0
10542-06	75.4
10544-05	121.2
10545-06	106.4
MEAN	102.3
S.D.	16.14
N	7

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG												
10485-09	28.2	32.9	38.3	42.3	46.9	51.0	56.3	59.8	67.0	72.8	78.4	86.5
10491-07	54.2	60.2	66.4	70.7	75.2	81.1	86.7	91.7	98.1	106.9	111.9	116.9
10496-16	45.5	49.6	56.3	60.4	64.2	70.1	77.7	83.1	89.3	96.4	103.4	106.4
10498-10	41.9	47.4	52.6	56.2	62.5	66.2	70.7	77.2	81.2	85.0	88.6	98.0
10512-13	44.4	48.9	53.0	61.1	64.8	70.1	76.0	81.4	88.7	95.4	103.0	107.8
10514-11	47.6	53.9	59.9	64.5	69.9	76.6	82.6	87.5	93.8	102.2	109.9	117.8
10521-17	38.5	42.9	47.5	52.8	56.6	60.6	64.4	69.3	75.0	78.9	82.1	89.6
10537-12	31.2	34.6	39.7	44.5	49.2	54.1	58.1	63.2	69.0	74.4	81.7	89.3
MEAN	41.4	46.3	51.7	56.6	61.2	66.2	71.6	76.7	82.8	89.0	94.9	101.5
S.D.	8.58	9.24	9.62	9.72	9.75	10.48	11.18	11.51	11.56	13.01	13.64	12.50
N	8	8	8	8	8	8	8	8	8	8	8	8

FEMALES

DAY 34

ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG	
10485-09	92.2
10491-07	122.7
10496-16	115.4
10498-10	102.2
10512-13	115.4
10514-11	123.9
10521-17	95.1
10537-12	91.9
MEAN	107.4
S.D.	13.54
N	8

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES											
DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG												
10487-09	44.8	52.2	57.6	62.8	65.6	69.8	76.5	81.1	88.1	93.1	100.0	107.8
10492-12	19.3	16.6										
10495-15	25.2	27.4	32.6	37.2	41.5	46.6	50.5	55.3	60.0	64.2	69.1	76.0
10499-10	34.4	39.5	43.5	48.9	53.9	57.6	63.4	68.4	72.8	77.9	79.6	87.9
10515-10	33.6	38.7	42.4	47.0	52.1	55.3	60.9	67.5	70.7	77.3	80.5	86.3
10516-07	41.1	43.7	50.0	56.1	59.3	65.7	71.5	77.1	83.0	89.3	96.8	103.5
10552-11	46.2	51.1	56.2	61.8	66.2	71.1	78.2	82.8	88.8	93.9	99.5	103.6
10556-11	39.6	42.8	47.5	52.7	55.6	62.0	66.5	71.6	75.5	84.4	88.2	95.3
MEAN	35.5	39.0	47.1	52.4	56.3	61.2	66.8	72.0	77.0	82.9	87.7	94.3
S.D.	9.43	11.92	8.63	8.97	8.53	8.70	9.65	9.47	10.38	10.60	11.81	11.51
N	8	8	7	7	7	7	7	7	7	7	7	7

FEMALES

DAY 34	
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG	
10487-09	114.7
10495-15	81.4
10499-10	93.0
10515-10	92.2
10516-07	111.0
10552-11	108.2
10556-11	102.5
MEAN	100.4
S.D.	12.01
N	7

TABLE 188 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

FEMALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG												
10475-13	40.2	42.8	48.0	53.2	59.6	65.0	68.5	74.1	78.3	84.3	90.1	97.9
10489-16	39.4	41.8	45.6	52.0	55.8	61.4	64.3	68.5	74.2	80.7	86.4	92.7
10490-08	40.0	42.6	47.9	52.5	57.2	62.2	66.5	71.8	76.6	83.3	90.0	90.8
10497-16	30.5	33.5	35.6	40.8	44.9	47.7	52.6	56.3	62.1	65.8	71.4	77.6
10501-05	31.8	35.2	38.5	43.5	49.3	52.7	58.1	61.9	67.7	75.7	79.2	85.5
10505-15	44.6	47.1	51.9	56.5	60.7	66.1	71.0	75.8	83.2	87.7	95.3	101.3
10517-10	44.9	49.0	53.9	58.9	65.2	69.2	75.0	79.6	86.0	93.0	99.3	106.0
10531-11	38.4	43.8	48.8	53.5	57.9	61.1	66.1	69.6	75.4	79.9	86.9	92.2
10533-06	44.7	48.6	54.4	57.0	64.8	67.1	73.0	78.7	86.9	92.7	97.4	105.3
10538-09	45.2	47.4	53.9	56.4	59.7	63.9	70.6	75.6	82.5	86.9	94.0	99.7
MEAN	40.0	43.2	47.9	52.4	57.5	61.6	66.6	71.2	77.3	83.0	89.0	94.9
S.D.	5.32	5.34	6.46	5.89	6.34	6.65	6.87	7.41	7.94	8.15	8.57	8.95
N	10	10	10	10	10	10	10	10	10	10	10	10

FEMALES

DAY 34	
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG	
10475-13	103.0
10489-16	98.2
10490-08	101.9
10497-16	79.9
10501-05	91.4
10505-15	106.8
10517-10	115.0
10531-11	97.2
10533-06	109.3
10538-09	106.3
MEAN	100.9
S.D.	9.95
N	10

FEMALES

DAY	22	23	24	25	26	27	28	29	30	31	32	33
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG												
10466-14	48.0	48.2	53.0	56.0	57.2	62.6	65.8	69.8	72.9	79.2	85.0	89.3
10469-14	23.2											
10477-12	23.8	25.1	30.2	32.5	33.9	37.8	40.6	43.3	48.0	51.6	54.5	60.6
10502-08	23.4	21.8	19.3									
10526-16	27.2	23.8	NA									
10527-15	37.2	38.8	46.0	50.0	54.2	58.0	62.8	66.7	71.7	76.1	82.6	88.7
10541-13	37.3	41.0	44.5	49.8	52.5	59.2	62.5	67.3	74.3	78.9	85.9	93.7
10542-11	30.6	33.6	37.5	41.7	45.3	49.3	52.5	55.8	62.0	67.4	70.9	77.8
10544-12	31.0	32.9	38.8	41.7	45.3	48.2	53.1	59.4	64.1	68.1	74.5	78.4
10545-14	31.7	37.3	40.3	45.3	50.4	54.6	59.1	62.4	69.0	74.8	83.1	87.8
MEAN	31.3	33.6	38.7	45.3	48.4	52.8	56.6	60.7	66.0	70.9	76.6	82.3
S.D.	7.83	8.78	10.31	7.60	7.76	8.42	8.65	9.07	9.14	9.73	11.26	11.23
N	10	9	8	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

FEMALES

DAY 34	
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG	
10466-14	96.3
10477-12	63.3
10527-15	95.2
10541-13	98.1
10542-11	83.0
10544-12	84.8
10545-14	96.7
MEAN	88.2
S.D.	12.54
N	7

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG												
10485-03	4.9	4.3	4.2	5.3	2.8	4.2	4.3	5.8	5.2	7.2	5.4	7.3
10491-02	4.7	5.2	6.2	4.9	5.8	6.7	5.3	8.5	5.6	9.1	8.4	4.6
10496-02	4.9	4.5	4.1	7.3	6.3	8.9	4.7	6.2	9.5	6.3	7.9	8.8
10498-06	3.9	7.4	4.9	5.3	3.0	5.2	5.8	4.8	7.0	6.6	8.0	5.7
10512-05	6.2	5.2	5.4	6.3	4.8	6.6	7.9	4.0	9.4	10.7	4.3	8.1
10514-06	6.0	6.5	5.9	6.2	5.5	6.3	6.9	9.2	7.2	10.3	7.7	10.2
10521-02	5.5	6.2	5.9	6.8	5.0	6.5	4.4	7.5	8.7	6.6	9.2	7.8
10537-01	5.8	7.1	7.6	6.1	7.0	6.6	9.2	7.9	7.0	8.8	7.9	8.5
MEAN	5.2	5.8	5.5	6.0	5.0	6.4	6.1	6.7	7.5	8.2	7.4	7.6
S.D.	0.77	1.17	1.15	0.82	1.49	1.35	1.78	1.83	1.63	1.75	1.64	1.77
N	8	8	8	8	8	8	8	8	8	8	8	8

MALES

DAY 22- 34

ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG

10485-03	60.9
10491-02	75.0
10496-02	79.4
10498-06	67.6
10512-05	78.9
10514-06	87.9
10521-02	80.1
10537-01	89.5
MEAN	77.4
S.D.	9.59
N	8

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG												
10487-04	8.3	6.6	5.3	5.1	6.9	7.5	7.5	6.8	6.9	11.3	7.8	11.2
10492-02	NA											
10495-02	4.4	6.2	5.7	4.2	5.9	5.7	6.3	6.9	5.9	7.4	6.5	8.4
10499-04	6.4	5.0	5.0	6.8	7.0	6.8	5.3	4.7	8.3	11.0	6.3	8.9
10515-08	3.1	5.2	4.3	4.6	3.2	5.8	4.3	5.9	4.9	8.0	3.9	6.9
10516-05	4.1	5.8	2.6	13.4	-3.5	6.5	6.0	6.3	6.8	6.2	8.1	7.2
10552-08	0.6	7.2	5.1	7.3	4.2	6.1	7.6	6.3	6.5	4.1	10.9	8.9
10556-05	3.5	5.9	6.3	6.3	1.0	7.4	6.9	4.8	5.3	3.9	10.5	7.6
MEAN	4.3	6.0	4.9	6.8	3.5	6.5	6.3	6.0	6.4	7.4	7.7	8.4
S.D.	2.46	0.77	1.19	3.12	3.77	0.73	1.20	0.89	1.14	2.98	2.45	1.45
N	7	7	7	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

MALES

DAY 22- 34

ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG	
10487-04	91.2
10495-02	73.5
10499-04	81.5
10515-08	60.1
10516-05	69.5
10552-08	74.8
10556-05	69.4
MEAN	74.3
S.D.	9.89
N	7

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG												
10475-05	1.3	5.0	8.3	5.4	6.2	5.9	9.5	4.0	7.6	7.0	8.2	9.6
10489-02	2.9	5.6	8.1	5.5	7.5	5.5	6.4	7.4	8.9	8.5	9.2	6.6
10490-07	3.4	5.0	3.4	3.5	4.6	4.9	4.7	5.6	7.1	6.4	6.7	6.9
10497-04	4.9	4.5	3.8	7.0	3.6	6.2	5.9	6.8	6.1	8.6	6.6	6.3
10501-01	4.3	4.0	5.5	5.0	5.5	7.0	5.0	8.0	7.2	6.0	8.9	8.1
10505-05	2.7	4.4	6.1	4.7	10.3	0.6	4.9	6.3	6.8	8.6	7.4	6.7
10517-02	2.8	4.9	6.1	5.7	6.2	6.3	5.1	4.4	10.5	9.7	6.8	6.1
10531-04	5.2	3.4	5.6	3.9	5.9	1.5	6.9	4.2	8.5	7.5	6.9	4.2
10533-01	2.0	6.4	6.8	5.6	4.9	3.4	7.3	8.4	7.7	7.7	7.0	10.1
10538-04	3.2	5.5	4.3	7.8	6.6	6.5	7.7	7.6	7.7	8.2	9.8	8.5
MEAN	3.3	4.9	5.8	5.4	6.1	4.8	6.3	6.3	7.8	7.8	7.8	7.3
S.D.	1.23	0.86	1.66	1.29	1.83	2.21	1.54	1.64	1.24	1.13	1.18	1.77
N	10	10	10	10	10	10	10	10	10	10	10	10

MALES

DAY 22- 34

ANIMALS FROM GROUP 3: 500 PPM/342MG/KG

10475-05	78.0
10489-02	82.1
10490-07	62.2
10497-04	70.3
10501-01	74.5
10505-05	69.5
10517-02	74.6
10531-04	63.7
10533-01	77.3
10538-04	83.4
MEAN	73.6
S.D.	7.14
N	10

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG												
10466-02	0.4	4.7	2.1	3.8	3.5	5.7	1.9	7.3	6.3	8.8	6.5	7.4
10477-03	6.3	2.4	3.3	3.3	3.4	4.7	4.8	7.0	4.0	7.7	7.2	4.6
10502-13	-1.3	NA										
10526-04	-3.6	NA										
10527-01	-1.5	9.6	5.7	2.5	3.9	5.1	5.7	6.0	6.3	5.9	7.3	8.3
10541-03	3.6	6.1	5.4	4.1	4.5	6.0	5.0	7.6	6.2	8.5	6.9	6.1
10542-06	-0.1	1.7	5.4	3.5	2.5	3.8	3.4	4.9	5.0	3.5	7.6	3.6
10544-05	3.6	7.5	3.7	5.4	4.9	5.2	6.2	7.3	6.2	10.2	8.1	9.6
10545-06	5.8	5.0	4.5	6.7	4.7	5.6	4.9	4.6	8.1	6.7	9.8	6.7
MEAN	1.5	5.3	4.3	4.2	3.9	5.2	4.6	6.4	6.0	7.3	7.6	6.6
S.D.	3.48	2.76	1.33	1.42	0.85	0.74	1.46	1.23	1.27	2.20	1.08	2.07
N	9	7	7	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

MALES

DAY 22- 34

ANIMALS FROM GROUP 4: 1000PPM/621MG/KG

10466-02	58.4
10477-03	58.7
10527-01	64.8
10541-03	70.0
10542-06	44.8
10544-05	77.9
10545-06	73.1
MEAN	64.0
S.D.	11.11
N	7

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALES

DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG												
10485-09	4.7	5.4	4.0	4.6	4.1	5.3	3.5	7.2	5.8	5.6	8.1	5.7
10491-07	6.0	6.2	4.3	4.5	5.9	5.6	5.0	6.4	8.8	5.0	5.0	5.8
10496-16	4.1	6.7	4.1	3.8	5.9	7.6	5.4	6.2	7.1	7.0	3.0	9.0
10498-10	5.5	5.2	3.6	6.3	3.7	4.5	6.5	4.0	3.8	3.6	9.4	4.2
10512-13	4.5	4.1	8.1	3.7	5.3	5.9	5.4	7.3	6.7	7.6	4.8	7.6
10514-11	6.3	6.0	4.6	5.4	6.7	6.0	4.9	6.3	8.4	7.7	7.9	6.1
10521-17	4.4	4.6	5.3	3.8	4.0	3.8	4.9	5.7	3.9	3.2	7.5	5.5
10537-12	3.4	5.1	4.8	4.7	4.9	4.0	5.1	5.8	5.4	7.3	7.6	2.6
MEAN	4.9	5.4	4.9	4.6	5.1	5.3	5.1	6.1	6.2	5.9	6.7	5.8
S.D.	0.99	0.86	1.41	0.90	1.07	1.24	0.83	1.03	1.87	1.80	2.15	1.94
N	8	8	8	8	8	8	8	8	8	8	8	8

FEMALES

DAY 22- 34

ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG	
10485-09	64.0
10491-07	68.5
10496-16	69.9
10498-10	60.3
10512-13	71.0
10514-11	76.3
10521-17	56.6
10537-12	60.7
MEAN	65.9
S.D.	6.61
N	8

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG												
10487-09	7.4	5.4	5.2	2.8	4.2	6.7	4.6	7.0	5.0	6.9	7.8	6.9
10492-12	-2.7											
10495-15	2.2	5.2	4.6	4.3	5.1	3.9	4.8	4.7	4.2	4.9	6.9	5.4
10499-10	5.1	4.0	5.4	5.0	3.7	5.8	5.0	4.4	5.1	1.7	8.3	5.1
10515-10	5.1	3.7	4.6	5.1	3.2	5.6	6.6	3.2	6.6	3.2	5.8	5.9
10516-07	2.6	6.3	6.1	3.2	6.4	5.8	5.6	5.9	6.3	7.5	6.7	7.5
10552-11	4.9	5.1	5.6	4.4	4.9	7.1	4.6	6.0	5.1	5.6	4.1	4.6
10556-11	3.2	4.7	5.2	2.9	6.4	4.5	5.1	3.9	8.9	3.8	7.1	7.2
MEAN	3.5	4.9	5.2	4.0	4.8	5.6	5.2	5.0	5.9	4.8	6.7	6.1
S.D.	3.01	0.88	0.53	0.98	1.25	1.13	0.71	1.34	1.56	2.06	1.39	1.12
N	8	7	7	7	7	7	7	7	7	7	7	7

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALES

DAY 22- 34

ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG	
10487-09	69.9
10495-15	56.2
10499-10	58.6
10515-10	58.6
10516-07	69.9
10552-11	62.0
10556-11	62.9
MEAN	62.6
S.D.	5.48
N	7

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG												
10475-13	2.6	5.2	5.2	6.4	5.4	3.5	5.6	4.2	6.0	5.8	7.8	5.1
10489-16	2.4	3.8	6.4	3.8	5.6	2.9	4.2	5.7	6.5	5.7	6.3	5.5
10490-08	2.6	5.3	4.6	4.7	5.0	4.3	5.3	4.8	6.7	6.7	0.8	11.1
10497-16	3.0	2.1	5.2	4.1	2.8	4.9	3.7	5.8	3.7	5.6	6.2	2.3
10501-05	3.4	3.3	5.0	5.8	3.4	5.4	3.8	5.8	8.0	3.5	6.3	5.9
10505-15	2.5	4.8	4.6	4.2	5.4	4.9	4.8	7.4	4.5	7.6	6.0	5.5
10517-10	4.1	4.9	5.0	6.3	4.0	5.8	4.6	6.4	7.0	6.3	6.7	9.0
10531-11	5.4	5.0	4.7	4.4	3.2	5.0	3.5	5.8	4.5	7.0	5.3	5.0
10533-06	3.9	5.8	2.6	7.8	2.3	5.9	5.7	8.2	5.8	4.7	7.9	4.0
10538-09	2.2	6.5	2.5	3.3	4.2	6.7	5.0	6.9	4.4	7.1	5.7	6.6
MEAN	3.2	4.7	4.6	5.1	4.1	4.9	4.6	6.1	5.7	6.0	5.9	6.0
S.D.	1.00	1.28	1.19	1.43	1.19	1.14	0.80	1.18	1.39	1.23	1.97	2.48
N	10	10	10	10	10	10	10	10	10	10	10	10

FEMALES

DAY 22- 34

ANIMALS FROM GROUP 3: 500 PPM/342MG/KG	
10475-13	62.8
10489-16	58.8
10490-08	61.9
10497-16	49.4
10501-05	59.6
10505-15	62.2
10517-10	70.1
10531-11	58.8
10533-06	64.6
10538-09	61.1
MEAN	60.9
S.D.	5.24
N	10

TABLE 189 (F1 - INHALATION/GAVAGE PHASE - PND 22-33)
PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS
INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES											
DAY	22- 23	23- 24	24- 25	25- 26	26- 27	27- 28	28- 29	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG												
10466-14	0.2	4.8	3.0	1.2	5.4	3.2	4.0	3.1	6.3	5.8	4.3	7.0
10477-12	1.3	5.1	2.3	1.4	3.9	2.8	2.7	4.7	3.6	2.9	6.1	2.7
10502-08	-1.6	-2.5										
10526-16	-3.4	NA										
10527-15	1.6	7.2	4.0	4.2	3.8	4.8	3.9	5.0	4.4	6.5	6.1	6.5
10541-13	3.7	3.5	5.3	2.7	6.7	3.3	4.8	7.0	4.6	7.0	7.8	4.4
10542-11	3.0	3.9	4.2	3.6	4.0	3.2	3.3	6.2	5.4	3.5	6.9	5.2
10544-12	1.9	5.9	2.9	3.6	2.9	4.9	6.3	4.7	4.0	6.4	3.9	6.4
10545-14	5.6	3.0	5.0	5.1	4.2	4.5	3.3	6.6	5.8	8.3	4.7	8.9
MEAN	1.4	3.9	3.8	3.1	4.4	3.8	4.0	5.3	4.9	5.8	5.7	5.9
S.D.	2.72	2.90	1.12	1.44	1.25	0.88	1.20	1.36	0.99	1.93	1.44	1.99
N	9	8	7	7	7	7	7	7	7	7	7	7

NA = NOT APPLICABLE

FEMALES

DAY 22- 34

ANIMALS FROM GROUP 4: 1000PPM/621MG/KG

10466-14	48.3
10477-12	39.5
10527-15	58.0
10541-13	60.8
10542-11	52.4
10544-12	53.8
10545-14	65.0
MEAN	54.0
S.D.	8.45
N	7

TABLE 190 (F1 - INHALATION PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10478-07 GROUP 3: 500 PPM MALE FOUND DEAD 11/10/02 DATE OF DEATH: 11/10/02 STUDY DAY: 27

		GRADE
GENERAL COMMENT	GROSS: ADVANCED DEGREE OF AUTOLYSIS PRECLUDES COMPLETE EXAMINATION INTESTINE, ENTIRE LENGTH; STOMACH	P
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 190 (F1 - INHALATION PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028A PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10480-09 GROUP 4: 1000 PPM MALE FOUND DEAD 11/09/02 DATE OF DEATH: 11/09/02 STUDY DAY: 26

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
		HEART	INTESTINE	KIDNEYS	LIVER
		LYMPH NODE, MES	LUNGS	MAMMARY GLAND	PANCREAS
		PITUITARY	SPINAL CORD	SAL. GLAND MAND	SKIN
		SPLEEN	STOMACH	THYMUS	THYROID GLANDS
		TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO.10507-01 GROUP 4: 1000 PPM MALE FOUND DEAD 11/10/02 DATE OF DEATH: 11/10/02 STUDY DAY: 27

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
		HEART	INTESTINE	KIDNEYS	LIVER
		LYMPH NODE, MES	LUNGS	MAMMARY GLAND	PANCREAS
		PITUITARY	SPINAL CORD	SAL. GLAND MAND	SKIN
		SPLEEN	STOMACH	THYMUS	THYROID GLANDS
		TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO.10481-11 GROUP 4: 1000 PPM FEMALE EUTH IN EXTREMIS 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

		GRADE
GENERAL COMMENT	GROSS: MECHANICAL TRAUMA FRACTURE, FOREPAW, RIGHT	P
KIDNEYS	GROSS: DILATED PELVIS RIGHT	2
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
02/13/2003
R:02/13/2003

TABLE 191 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10492-02 GROUP 2:100 PPM/90 MG/KG MALE FOUND DEAD 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
		HEART	INTESTINE	KIDNEYS	LIVER
		LYMPH NODE, MES	LUNGS	MAMMARY GLAND	PANCREAS
		PITUITARY	SPINAL CORD	SAL. GLAND MAND	SKIN
		SPLEEN	STOMACH	THYMUS	THYROID GLANDS
		TRACHEA	URINARY BLADDER		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 191 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10502-13 GROUP 4:1000PPM/621MG/KG MALE FOUND DEAD 11/08/02 DATE OF DEATH: 11/08/02 STUDY DAY: 25

		GRADE
URINARY BLADDER	GROSS: DISTENDED	P
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 191 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10526-04 GROUP 4:1000PPM/621MG/KG MALE FOUND DEAD 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

						GRADE
KIDNEYS	GROSS: DILATED PELVIS RIGHT					1
SKIN	GROSS: MATTING, RED NASAL					P
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES	
		HEART	INTESTINE	LIVER	LYMPH NODE, MES	
		LUNGS	MAMMARY GLAND	PANCREAS	PITUITARY	
		SPINAL CORD	SAL. GLAND MAND	SPLEEN	STOMACH	
		THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 191 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 4

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10492-12 GROUP 2:100 PPM/90 MG/KG FEMALE FOUND DEAD 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

		GRADE
GENERAL COMMENT	GROSS: ANIMAL DIED PRIOR TO EUTHANASIA	P
EYES	GROSS: EYE(S)- OPACITY BILATERAL	P
KIDNEYS	GROSS: DILATED PELVIS RIGHT	1
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 191 (F1 - INHALATION/GAVAGE PHASE - UNSCHEDULED DEATHS - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10502-08 GROUP 4:1000PPM/621MG/KG FEMALE EUTH IN EXTREMIS 11/08/02 DATE OF DEATH: 11/08/02 STUDY DAY: 25

		GRADE
SKIN	GROSS: MATTING, YELLOW UROGENITAL	P
STOMACH	GROSS: CONTENTS, DARK RED	P
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, KIDNEYS, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SPLEEN, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

ANIMAL NO.10526-16 GROUP 4:1000PPM/621MG/KG FEMALE FOUND DEAD 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

		GRADE
KIDNEYS	GROSS: DILATED PELVIS LEFT	2
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS, BRAIN, ESOPHAGUS, EYES, HEART, INTESTINE, LIVER, LYMPH NODE, MES, LUNGS, MAMMARY GLAND, OVIDUCTS, OVARIES, PANCREAS, PITUITARY, SPINAL CORD, SAL. GLAND MAND, SKIN, SPLEEN, STOMACH, THYMUS, THYROID GLANDS, TRACHEA, URINARY BLADDER, UTERUS, CERVIX	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
02/13/2003
R:02/13/2003

TABLE 192 (F1 - INHALATION/GAVAGE PHASE - PUPS REMOVED FROM ANIMAL ROOM - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10469-03 GROUP 4:1000PPM/621MG/KG MALE EUTH IN EXTREMIS 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

		GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS: ADRENAL GLANDS	
	BRAIN	
	ESOPHAGUS	
	EYES	
	HEART	
	INTESTINE	
	KIDNEYS	
	LIVER	
	LYMPH NODE, MES	
	LUNGS	
	MAMMARY GLAND	
	PANCREAS	
	PITUITARY	
	SPINAL CORD	
	SAL. GLAND MAND	
	SKIN	
	SPLEEN	
	STOMACH	
	THYMUS	
	THYROID GLANDS	
	TRACHEA	
	URINARY BLADDER	

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

TABLE 192 (F1 - INHALATION/GAVAGE PHASE - PUPS REMOVED FROM ANIMAL ROOM - PND 22-33)

PROJECT NO.:WIL-186028D PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL MACROSCOPIC FINDINGS

ANIMAL NO.10469-14 GROUP 4:1000PPM/621MG/KG FEMALE EUTH IN EXTREMIS 11/07/02 DATE OF DEATH: 11/07/02 STUDY DAY: 24

					GRADE
NO SIGNIFICANT CHANGES OBSERVED	GROSS:	ADRENAL GLANDS	BRAIN	ESOPHAGUS	EYES
		HEART	INTESTINE	KIDNEYS	LIVER
		LYMPH NODE, MES	LUNGS	MAMMARY GLAND	OVIDUCTS
		OVARIES	PANCREAS	PITUITARY	SPINAL CORD
		SAL. GLAND MAND	SKIN	SPLEEN	STOMACH
		THYMUS	THYROID GLANDS	TRACHEA	URINARY BLADDER
		UTERUS	CERVIX		

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

PGRHv4.41
02/13/2003
R:02/13/2003

TABLE 193 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10463-02	M	0 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10464-06	M	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10524-01	M	0 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10540-11	M	0 PPM	SCHEDULED EUTHANASIA	9	22-NOV-02
10554-01	M	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10555-04	M	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10488-03	M	100 PPM	SCHEDULED EUTHANASIA	8	17-NOV-02
10493-04	M	100 PPM	SCHEDULED EUTHANASIA	9	24-NOV-02
10504-04	M	100 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10510-01	M	100 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10519-08	M	100 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10522-01	M	100 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10525-01	M	100 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10528-02	M	100 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10468-04	M	500 PPM	SCHEDULED EUTHANASIA	9	22-NOV-02
10478-08	M	500 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10483-03	M	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10484-09	M	500 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10530-04	M	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10534-02	M	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10546-05	M	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10548-02	M	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10550-14	M	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10465-02	M	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10473-03	M	1000 PPM	SCHEDULED EUTHANASIA	9	23-NOV-02
10480-04	M	1000 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10481-06	M	1000 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

TABLE 193 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10486-09	M	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10507-03	M	1000 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10529-01	M	1000 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10532-04	M	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10547-02	M	1000 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10463-12	F	0 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10464-14	F	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10506-06	F	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10524-14	F	0 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10540-17	F	0 PPM	SCHEDULED EUTHANASIA	9	22-NOV-02
10554-07	F	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10555-16	F	0 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10488-10	F	100 PPM	SCHEDULED EUTHANASIA	8	17-NOV-02
10493-09	F	100 PPM	SCHEDULED EUTHANASIA	9	24-NOV-02
10504-10	F	100 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10510-11	F	100 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10519-13	F	100 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10522-12	F	100 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10525-14	F	100 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10528-09	F	100 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10468-16	F	500 PPM	SCHEDULED EUTHANASIA	9	22-NOV-02
10478-09	F	500 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10483-13	F	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10484-13	F	500 PPM	SCHEDULED EUTHANASIA	9	21-NOV-02
10530-08	F	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10534-08	F	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10546-12	F	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10548-16	F	500 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10550-17	F	500 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02
10465-07	F	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10473-10	F	1000 PPM	SCHEDULED EUTHANASIA	9	23-NOV-02
10480-08	F	1000 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

TABLE 193 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10481-10	F	1000 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10486-11	F	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10507-12	F	1000 PPM	SCHEDULED EUTHANASIA	9	18-NOV-02
10532-07	F	1000 PPM	SCHEDULED EUTHANASIA	9	20-NOV-02
10547-12	F	1000 PPM	SCHEDULED EUTHANASIA	9	19-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

PDEADv4.02
01/22/2003
R:02/14/2003

INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10485-04	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10491-01	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10496-05	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	10	26-NOV-02
10498-08	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10512-04	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10514-08	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10521-05	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10537-02	M	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10487-01	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10492-05	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10495-07	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	22-NOV-02
10499-02	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10515-02	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10516-04	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10552-09	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10556-04	M	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10475-02	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10489-05	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	10	30-NOV-02
10490-05	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10497-06	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10501-03	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10505-03	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10517-08	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10531-02	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10533-02	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10538-03	M	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10466-03	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	22-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

TABLE 194 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL SURVIVAL AND DISPOSITION

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10469-06	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10477-05	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10526-01	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	17-NOV-02
10527-05	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10541-06	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10542-03	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10544-03	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10545-02	M	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10485-10	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10491-04	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10496-14	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	10	26-NOV-02
10498-15	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10512-12	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10514-16	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10521-14	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10537-07	F	0 PPM/0 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10487-06	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10492-09	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10495-19	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	22-NOV-02
10499-12	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10515-15	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10516-10	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10552-13	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10556-07	F	100 PPM/90 MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10475-12	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10489-11	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	10	30-NOV-02
10490-10	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10497-12	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10501-10	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10505-17	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10517-12	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10531-08	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10533-03	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10538-05	F	500 PPM/342MG/KG	SCHEDULED EUTHANASIA	9	21-NOV-02
10466-15	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	22-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH
10469-13	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10477-17	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10502-11	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10526-08	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	8	17-NOV-02
10527-10	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02
10541-08	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10542-10	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	19-NOV-02
10544-15	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	20-NOV-02
10545-09	F	1000PPM/621MG/KG	SCHEDULED EUTHANASIA	9	18-NOV-02

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (4)

PDEADv4.02
02/12/2003
R:02/14/2003

TABLE 195 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-12-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10463-02	M	0 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10464-06	M	0 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10524-01	M	0 PPM	DISPOSITION	11-18-02	10:05	P	SCHEDULED EUTHANASIA; PND 34
10540-11	M	0 PPM	DISPOSITION	11-22-02	7:04	P	SCHEDULED EUTHANASIA; PND 34
10540-11	M	0 PPM	EYES/EARS/NOSE	11-22-02	6:16	1	DRIED RED MATERIAL AROUND NOSE
10554-01	M	0 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10555-04	M	0 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10488-03	M	100 PPM	DISPOSITION	11-17-02	8:56	P	SCHEDULED EUTHANASIA; PND 34
10493-04	M	100 PPM	DISPOSITION	11-24-02	8:37	P	SCHEDULED EUTHANASIA; PND 34
10504-04	M	100 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10510-01	M	100 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10510-01	M	100 PPM	BODY/INTEGUMENT	11-20-02	6:19	P	UNEVEN HAIR GROWTH
10519-08	M	100 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10522-01	M	100 PPM	DISPOSITION	11-18-02	10:05	P	SCHEDULED EUTHANASIA; PND 34
10525-01	M	100 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10528-02	M	100 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10468-04	M	500 PPM	DISPOSITION	11-22-02	7:04	P	SCHEDULED EUTHANASIA; PND 34
10478-08	M	500 PPM	DISPOSITION	11-20-02	9:03	P	SCHEDULED EUTHANASIA; PND 34
10483-03	M	500 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10484-09	M	500 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10530-04	M	500 PPM	DISPOSITION	11-18-02	10:05	P	SCHEDULED EUTHANASIA; PND 34
10534-02	M	500 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10534-02	M	500 PPM	BODY/INTEGUMENT	11-19-02	6:21	P	DISTAL END OF TAIL MISSING
10546-05	M	500 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10548-02	M	500 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10550-14	M	500 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10465-02	M	1000 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10473-03	M	1000 PPM	DISPOSITION	11-23-02	8:58	P	SCHEDULED EUTHANASIA; PND 34
10473-03	M	1000 PPM	BODY/INTEGUMENT	11-23-02	6:08	P	DISTAL END OF TAIL MISSING

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 195 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-12-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10480-04	M	1000 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10481-06	M	1000 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10486-09	M	1000 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10507-03	M	1000 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10529-01	M	1000 PPM	DISPOSITION	11-19-02	8:47	P	SCHEDULED EUTHANASIA; PND 34
10532-04	M	1000 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10547-02	M	1000 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10463-12	F	0 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10464-14	F	0 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10506-06	F	0 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10524-14	F	0 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10540-17	F	0 PPM	DISPOSITION	11-22-02	7:05	P	SCHEDULED EUTHANASIA; PND 34
10554-07	F	0 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10555-16	F	0 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10488-10	F	100 PPM	DISPOSITION	11-17-02	8:56	P	SCHEDULED EUTHANASIA; PND 34
10493-09	F	100 PPM	DISPOSITION	11-24-02	8:37	P	SCHEDULED EUTHANASIA; PND 34
10504-10	F	100 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10510-11	F	100 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10510-11	F	100 PPM	BODY/INTEGUMENT	11-20-02	6:24	P	UNEVEN HAIR GROWTH
10519-13	F	100 PPM	DISPOSITION	11-20-02	9:04	P	SCHEDULED EUTHANASIA; PND 34
10522-12	F	100 PPM	DISPOSITION	11-18-02	10:06	P	SCHEDULED EUTHANASIA; PND 34
10525-14	F	100 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10528-09	F	100 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10468-16	F	500 PPM	DISPOSITION	11-22-02	7:05	P	SCHEDULED EUTHANASIA; PND 34
10478-09	F	500 PPM	DISPOSITION	11-20-02	9:05	P	SCHEDULED EUTHANASIA; PND 34
10478-09	F	500 PPM	BODY/INTEGUMENT	11-20-02	6:26	P	UNEVEN HAIR GROWTH
10483-13	F	500 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10484-13	F	500 PPM	DISPOSITION	11-21-02	7:55	P	SCHEDULED EUTHANASIA; PND 34
10530-08	F	500 PPM	DISPOSITION	11-18-02	10:10	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 195 (F1 - INHALATION PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

TABLE RANGE: 11-12-02 TO 11-24-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10534-08	F	500 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10534-08	F	500 PPM	BODY/INTEGUMENT	11-19-02	6:31	P	DISTAL END OF TAIL MISSING
10546-12	F	500 PPM	DISPOSITION	11-18-02	10:10	P	SCHEDULED EUTHANASIA; PND 34
10548-16	F	500 PPM	DISPOSITION	11-18-02	10:10	P	SCHEDULED EUTHANASIA; PND 34
10550-17	F	500 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10465-07	F	1000 PPM	DISPOSITION	11-20-02	9:05	P	SCHEDULED EUTHANASIA; PND 34
10473-10	F	1000 PPM	DISPOSITION	11-23-02	8:58	P	SCHEDULED EUTHANASIA; PND 34
10480-08	F	1000 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34
10481-10	F	1000 PPM	DISPOSITION	11-18-02	10:11	P	SCHEDULED EUTHANASIA; PND 34
10486-11	F	1000 PPM	DISPOSITION	11-20-02	9:05	P	SCHEDULED EUTHANASIA; PND 34
10507-12	F	1000 PPM	DISPOSITION	11-18-02	10:11	P	SCHEDULED EUTHANASIA; PND 34
10532-07	F	1000 PPM	DISPOSITION	11-20-02	9:05	P	SCHEDULED EUTHANASIA; PND 34
10547-12	F	1000 PPM	DISPOSITION	11-19-02	8:48	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 196 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-12-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10485-04	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10491-01	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10496-05	M	0 PPM/0 MG/KG	DISPOSITION	11-26-02	7:21	P	SCHEDULED EUTHANASIA; PND 34
10498-08	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:49	P	SCHEDULED EUTHANASIA; PND 34
10512-04	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:49	P	SCHEDULED EUTHANASIA; PND 34
10514-08	M	0 PPM/0 MG/KG	DISPOSITION	11-21-02	7:56	P	SCHEDULED EUTHANASIA; PND 34
10521-05	M	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10537-02	M	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:49	P	SCHEDULED EUTHANASIA; PND 34
10487-01	M	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:49	P	SCHEDULED EUTHANASIA; PND 34
10492-05	M	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:15	P	SCHEDULED EUTHANASIA; PND 34
10495-07	M	100 PPM/90 MG/KG	DISPOSITION	11-22-02	7:06	P	SCHEDULED EUTHANASIA; PND 34
10499-02	M	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:15	P	SCHEDULED EUTHANASIA; PND 34
10515-02	M	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:49	P	SCHEDULED EUTHANASIA; PND 34
10516-04	M	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:56	P	SCHEDULED EUTHANASIA; PND 34
10552-09	M	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:56	P	SCHEDULED EUTHANASIA; PND 34
10556-04	M	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:15	P	SCHEDULED EUTHANASIA; PND 34
10475-02	M	500 PPM/342MG/KG	DISPOSITION	11-18-02	10:15	P	SCHEDULED EUTHANASIA; PND 34
10489-05	M	500 PPM/342MG/KG	DISPOSITION	11-30-02	8:10	P	SCHEDULED EUTHANASIA; PND 34
10490-05	M	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10497-06	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10501-03	M	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:56	P	SCHEDULED EUTHANASIA; PND 34
10505-03	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10517-08	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10531-02	M	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10533-02	M	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10538-03	M	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:57	P	SCHEDULED EUTHANASIA; PND 34
10466-03	M	1000PPM/621MG/KG	DISPOSITION	11-22-02	7:07	P	SCHEDULED EUTHANASIA; PND 34
10469-06	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10477-05	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 196 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-12-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10526-01	M	1000PPM/621MG/KG	DISPOSITION	11-17-02	8:57	P	SCHEDULED EUTHANASIA; PND 34
10527-05	M	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10541-06	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:50	P	SCHEDULED EUTHANASIA; PND 34
10542-03	M	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10544-03	M	1000PPM/621MG/KG	DISPOSITION	11-20-02	9:06	P	SCHEDULED EUTHANASIA; PND 34
10545-02	M	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10485-10	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10491-04	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10496-14	F	0 PPM/0 MG/KG	DISPOSITION	11-26-02	7:21	P	SCHEDULED EUTHANASIA; PND 34
10498-15	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10512-12	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10514-16	F	0 PPM/0 MG/KG	DISPOSITION	11-21-02	7:57	P	SCHEDULED EUTHANASIA; PND 34
10521-14	F	0 PPM/0 MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10537-07	F	0 PPM/0 MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10487-06	F	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10492-09	F	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10495-19	F	100 PPM/90 MG/KG	DISPOSITION	11-22-02	7:07	P	SCHEDULED EUTHANASIA; PND 34
10499-12	F	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10515-15	F	100 PPM/90 MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10516-10	F	100 PPM/90 MG/KG	DISPOSITION	11-21-02	0:00	P	SCHEDULED EUTHANASIA; PND 34
10552-13	F	100 PPM/90 MG/KG	DISPOSITION	11-21-02	7:57	P	SCHEDULED EUTHANASIA; PND 34
10556-07	F	100 PPM/90 MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10475-12	F	500 PPM/342MG/KG	DISPOSITION	11-18-02	10:16	P	SCHEDULED EUTHANASIA; PND 34
10489-11	F	500 PPM/342MG/KG	DISPOSITION	11-30-02	8:10	P	SCHEDULED EUTHANASIA; PND 34
10490-10	F	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10497-12	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10501-10	F	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:57	P	SCHEDULED EUTHANASIA; PND 34
10505-17	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10517-12	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 196 (F1 - INHALATION/GAVAGE PHASE - DETAILED PHYSICAL EXAMINATIONS - PND 29-33)

SPONSOR:ACC INDIVIDUAL CLINICAL OBSERVATIONS [POSITIVE FINDINGS ONLY]

TABLE RANGE: 11-12-02 TO 11-30-02

ANIMAL	SEX	GROUP	CATEGORY	DATE	TIME	GRADE	OBSERVATIONS
10531-08	F	500 PPM/342MG/KG	DISPOSITION	11-19-02	8:51	P	SCHEDULED EUTHANASIA; PND 34
10533-03	F	500 PPM/342MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10538-05	F	500 PPM/342MG/KG	DISPOSITION	11-21-02	7:57	P	SCHEDULED EUTHANASIA; PND 34
10466-15	F	1000PPM/621MG/KG	DISPOSITION	11-22-02	7:07	P	SCHEDULED EUTHANASIA; PND 34
10469-13	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:52	P	SCHEDULED EUTHANASIA; PND 34
10477-17	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:52	P	SCHEDULED EUTHANASIA; PND 34
10502-11	F	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:17	P	SCHEDULED EUTHANASIA; PND 34
10526-08	F	1000PPM/621MG/KG	DISPOSITION	11-17-02	8:57	P	SCHEDULED EUTHANASIA; PND 34
10527-10	F	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:17	P	SCHEDULED EUTHANASIA; PND 34
10541-08	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:52	P	SCHEDULED EUTHANASIA; PND 34
10542-10	F	1000PPM/621MG/KG	DISPOSITION	11-19-02	8:52	P	SCHEDULED EUTHANASIA; PND 34
10544-15	F	1000PPM/621MG/KG	DISPOSITION	11-20-02	9:07	P	SCHEDULED EUTHANASIA; PND 34
10545-09	F	1000PPM/621MG/KG	DISPOSITION	11-18-02	10:17	P	SCHEDULED EUTHANASIA; PND 34

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 1: 0 PPM						
10463-02	89.5	98.6	107.0	115.6	121.6	127.8
10464-06	91.5	97.4	105.9	114.5	122.2	134.7
10524-01	73.3	77.4	81.5	87.9	94.5	104.4
10540-11	67.2	74.2	79.6	86.6	91.9	97.6
10554-01	73.1	81.5	89.2	96.3	100.9	109.4
10555-04	79.5	89.9	96.8	103.2	111.4	118.7
MEAN	79.0	86.5	93.3	100.7	107.1	115.4
S.D.	9.73	10.35	11.85	12.65	13.30	14.22
N	6	6	6	6	6	6

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	MALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 2: 100 PPM						
10488-03	82.9	88.2	96.7	102.9	109.8	119.7
10493-04	77.0	82.5	88.7	94.5	102.0	110.6
10504-04	65.0	70.1	77.0	84.5	88.7	98.2
10510-01	86.7	95.1	102.0	108.1	115.4	124.4
10519-08	82.0	87.7	93.6	99.7	108.1	119.3
10522-01	81.7	86.8	94.1	99.8	108.9	115.7
10525-01	74.0	81.6	87.2	93.2	98.6	106.0
10528-02	97.1	103.9	110.2	118.8	126.9	131.7
MEAN	80.8	87.0	93.7	100.2	107.3	115.7
S.D.	9.39	9.92	9.97	10.31	11.40	10.60
N	8	8	8	8	8	8

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

MALES

DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 3: 500 PPM						
10468-04	76.1	79.8	87.3	93.1	101.4	108.5
10478-08	68.1	73.0	79.8	86.3	92.9	100.6
10483-03	88.7	95.1	99.4	106.7	114.0	120.5
10484-09	79.4	83.4	87.5	94.8	100.3	107.7
10530-04	66.6	70.3	76.0	81.7	89.8	97.0
10534-02	54.2	59.0	66.8	74.7	78.6	85.3
10546-05	75.3	80.7	86.1	93.4	101.8	107.1
10548-02	85.1	92.7	95.7	102.6	105.9	109.9
10550-14	77.1	81.2	86.7	91.3	100.7	104.6
MEAN	74.5	79.5	85.0	91.6	98.4	104.6
S.D.	10.39	11.09	9.85	9.85	10.16	9.74
N	9	9	9	9	9	9

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	MALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 4: 1000 PPM						
10465-02	77.0	81.2	84.2	91.9	96.5	104.0
10473-03	68.8	72.3	77.9	83.7	85.4	89.1
10480-04	70.8	75.9	79.2	87.0	92.6	95.4
10481-06	65.9	67.4	73.4	79.4	85.5	90.8
10486-09	106.2	110.1	118.8	126.6	132.4	142.9
10507-03	58.6	62.4	67.0	74.8	79.1	85.2
10529-01	80.7	84.2	90.1	94.5	102.0	110.3
10532-04	84.2	90.6	95.2	101.1	107.1	112.3
10547-02	72.6	76.5	82.6	88.3	96.3	100.8
MEAN	76.1	80.1	85.4	91.9	97.4	103.4
S.D.	13.68	14.12	15.08	15.20	15.76	17.51
N	9	9	9	9	9	9

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 1: 0 PPM						
10463-12	70.0	78.4	83.8	86.5	96.0	100.3
10464-14	86.6	94.9	100.8	111.2	117.3	125.7
10506-06	56.8	63.7	68.7	75.5	81.3	87.3
10524-14	76.4	80.4	86.1	92.3	97.6	103.8
10540-17	83.5	88.9	95.4	102.3	106.7	112.9
10554-07	75.4	81.3	85.3	89.6	91.9	100.2
10555-16	68.2	76.7	81.8	87.3	94.2	100.9
MEAN	73.8	80.6	86.0	92.1	97.9	104.4
S.D.	10.02	9.83	10.24	11.58	11.42	12.01
N	7	7	7	7	7	7

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 2: 100 PPM						
10488-10	78.5	83.2	88.7	94.8	99.3	105.4
10493-09	75.1	81.3	85.8	90.3	98.4	104.0
10504-10	66.7	73.9	80.8	87.2	93.8	97.9
10510-11	72.0	80.1	86.5	93.9	100.5	108.6
10519-13	55.2	61.8	68.8	74.4	79.9	87.1
10522-12	75.2	81.3	87.7	94.3	100.6	107.6
10525-14	68.0	74.7	81.8	85.1	92.2	98.1
10528-09	86.5	93.4	98.3	104.2	112.3	116.3
MEAN	72.2	78.7	84.8	90.5	97.1	103.1
S.D.	9.25	9.07	8.37	8.71	9.20	8.77
N	8	8	8	8	8	8

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 3: 500 PPM						
10468-16	68.8	69.9	74.7	79.1	84.8	88.4
10478-09	50.7	53.6	58.7	65.0	70.7	76.1
10483-13	85.7	88.1	96.8	100.3	107.9	115.0
10484-13	75.5	79.5	83.0	88.4	92.9	97.1
10530-08	66.4	69.9	74.7	81.9	87.9	92.1
10534-08	68.4	71.3	74.7	83.2	90.4	93.1
10546-12	74.5	78.0	80.9	87.1	90.5	96.8
10548-16	79.1	86.0	91.4	96.8	105.2	111.5
10550-17	93.7	97.0	106.0	114.0	117.9	123.5
MEAN	73.6	77.0	82.3	88.4	94.2	99.3
S.D.	12.31	12.71	14.09	14.02	14.06	14.75
N	9	9	9	9	9	9

TABLE 197 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 4: 1000 PPM						
10465-07	74.8	78.9	82.9	87.7	91.3	96.6
10473-10	75.6	79.5	85.5	90.6	96.3	98.7
10480-08	74.0	77.6	81.1	87.2	92.9	96.6
10481-10	60.2	61.6	66.0	69.8	76.5	80.7
10486-11	95.6	97.0	103.6	111.9	117.9	126.4
10507-12	56.8	60.5	63.2	69.5	75.3	80.2
10532-07	73.8	77.0	84.5	88.0	90.5	97.4
10547-12	80.9	84.3	90.4	98.4	103.7	107.1
MEAN	74.0	77.1	82.2	87.9	93.1	98.0
S.D.	11.97	11.79	12.91	13.94	13.84	14.69
N	8	8	8	8	8	8

PJTBWv4.08
01/17/2003
R:01/22/2003

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM					
10463-02	9.1	8.4	8.6	6.0	6.2
10464-06	5.9	8.5	8.6	7.7	12.5
10524-01	4.1	4.1	6.4	6.6	9.9
10540-11	7.0	5.4	7.0	5.3	5.7
10554-01	8.4	7.7	7.1	4.6	8.5
10555-04	10.4	6.9	6.4	8.2	7.3
MEAN	7.5	6.8	7.4	6.4	8.4
S.D.	2.29	1.76	1.01	1.38	2.55
N	6	6	6	6	6

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM					
10488-03	5.3	8.5	6.2	6.9	9.9
10493-04	5.5	6.2	5.8	7.5	8.6
10504-04	5.1	6.9	7.5	4.2	9.5
10510-01	8.4	6.9	6.1	7.3	9.0
10519-08	5.7	5.9	6.1	8.4	11.2
10522-01	5.1	7.3	5.7	9.1	6.8
10525-01	7.6	5.6	6.0	5.4	7.4
10528-02	6.8	6.3	8.6	8.1	4.8
MEAN	6.2	6.7	6.5	7.1	8.4
S.D.	1.26	0.92	1.01	1.61	2.01
N	8	8	8	8	8

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM					
10468-04	3.7	7.5	5.8	8.3	7.1
10478-08	4.9	6.8	6.5	6.6	7.7
10483-03	6.4	4.3	7.3	7.3	6.5
10484-09	4.0	4.1	7.3	5.5	7.4
10530-04	3.7	5.7	5.7	8.1	7.2
10534-02	4.8	7.8	7.9	3.9	6.7
10546-05	5.4	5.4	7.3	8.4	5.3
10548-02	7.6	3.0	6.9	3.3	4.0
10550-14	4.1	5.5	4.6	9.4	3.9
MEAN	5.0	5.6	6.6	6.8	6.2
S.D.	1.33	1.61	1.04	2.12	1.45
N	9	9	9	9	9

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

MALES

DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000 PPM					
10465-02	4.2	3.0	7.7	4.6	7.5
10473-03	3.5	5.6	5.8	1.7	3.7
10480-04	5.1	3.3	7.8	5.6	2.8
10481-06	1.5	6.0	6.0	6.1	5.3
10486-09	3.9	8.7	7.8	5.8	10.5
10507-03	3.8	4.6	7.8	4.3	6.1
10529-01	3.5	5.9	4.4	7.5	8.3
10532-04	6.4	4.6	5.9	6.0	5.2
10547-02	3.9	6.1	5.7	8.0	4.5
MEAN	4.0	5.3	6.5	5.5	6.0
S.D.	1.31	1.71	1.26	1.86	2.42
N	9	9	9	9	9

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES				
DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 1: 0 PPM					
10463-12	8.4	5.4	2.7	9.5	4.3
10464-14	8.3	5.9	10.4	6.1	8.4
10506-06	6.9	5.0	6.8	5.8	6.0
10524-14	4.0	5.7	6.2	5.3	6.2
10540-17	5.4	6.5	6.9	4.4	6.2
10554-07	5.9	4.0	4.3	2.3	8.3
10555-16	8.5	5.1	5.5	6.9	6.7
MEAN	6.8	5.4	6.1	5.8	6.6
S.D.	1.75	0.79	2.41	2.21	1.42
N	7	7	7	7	7

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES				
DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 2: 100 PPM					
10488-10	4.7	5.5	6.1	4.5	6.1
10493-09	6.2	4.5	4.5	8.1	5.6
10504-10	7.2	6.9	6.4	6.6	4.1
10510-11	8.1	6.4	7.4	6.6	8.1
10519-13	6.6	7.0	5.6	5.5	7.2
10522-12	6.1	6.4	6.6	6.3	7.0
10525-14	6.7	7.1	3.3	7.1	5.9
10528-09	6.9	4.9	5.9	8.1	4.0
MEAN	6.6	6.1	5.7	6.6	6.0
S.D.	0.98	1.00	1.29	1.22	1.45
N	8	8	8	8	8

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES				
DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 3: 500 PPM					
10468-16	1.1	4.8	4.4	5.7	3.6
10478-09	2.9	5.1	6.3	5.7	5.4
10483-13	2.4	8.7	3.5	7.6	7.1
10484-13	4.0	3.5	5.4	4.5	4.2
10530-08	3.5	4.8	7.2	6.0	4.2
10534-08	2.9	3.4	8.5	7.2	2.7
10546-12	3.5	2.9	6.2	3.4	6.3
10548-16	6.9	5.4	5.4	8.4	6.3
10550-17	3.3	9.0	8.0	3.9	5.6
MEAN	3.4	5.3	6.1	5.8	5.0
S.D.	1.56	2.19	1.63	1.70	1.45
N	9	9	9	9	9

TABLE 198 (F1 - INHALATION PHASE - PND 29-33)

PROJECT NO.:WIL-186028B PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES				
DAY	29- 30	30- 31	31- 32	32- 33	33- 34
ANIMALS FROM GROUP 4: 1000 PPM					
10465-07	4.1	4.0	4.8	3.6	5.3
10473-10	3.9	6.0	5.1	5.7	2.4
10480-08	3.6	3.5	6.1	5.7	3.7
10481-10	1.4	4.4	3.8	6.7	4.2
10486-11	1.4	6.6	8.3	6.0	8.5
10507-12	3.7	2.7	6.3	5.8	4.9
10532-07	3.2	7.5	3.5	2.5	6.9
10547-12	3.4	6.1	8.0	5.3	3.4
MEAN	3.1	5.1	5.7	5.2	4.9
S.D.	1.08	1.68	1.78	1.39	1.98
N	8	8	8	8	8

PJTBWv4.08
01/17/2003
R:01/22/2003

TABLE 199 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	MALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG						
10485-04	70.7	74.2	79.7	84.3	90.5	95.2
10491-01	100.3	107.1	114.2	120.4	130.3	140.7
10496-05	93.1	100.7	106.8	113.9	120.5	129.3
10498-08	73.9	82.0	87.4	95.8	102.8	110.6
10512-04	84.0	92.6	100.7	108.0	116.7	123.4
10514-08	100.2	107.7	115.1	122.4	131.7	141.8
10521-05	70.2	75.9	81.5	87.8	93.5	102.1
10537-02	92.3	98.6	105.2	112.2	121.5	129.9
MEAN	85.6	92.4	98.8	105.6	113.4	121.6
S.D.	12.70	13.47	14.17	14.57	15.95	17.33
N	8	8	8	8	8	8

TABLE 199 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	MALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG						
10487-01	89.2	96.4	101.5	109.9	116.7	125.0
10492-05	54.8	58.9	65.2	70.4	74.9	80.3
10495-07	82.7	88.0	94.7	102.4	111.2	117.6
10499-02	83.0	87.3	94.8	101.6	111.0	120.2
10515-02	62.4	68.0	73.4	80.9	88.2	95.2
10516-04	100.6	107.6	114.6	121.5	130.8	139.6
10552-09	82.9	87.9	96.7	103.3	111.2	116.5
10556-04	72.1	77.6	80.0	92.7	98.9	105.5
MEAN	78.5	84.0	90.1	97.8	105.4	112.5
S.D.	14.75	15.49	16.12	16.20	17.48	18.43
N	8	8	8	8	8	8

MALES

DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG						
10475-02	71.8	74.4	82.0	89.5	94.5	100.7
10489-05	81.6	87.0	94.6	98.1	101.5	103.8
10490-05	73.1	77.9	86.5	92.6	99.1	106.9
10497-06	70.0	71.3	77.8	85.4	91.5	97.7
10501-03	86.2	90.9	98.4	104.9	112.6	120.8
10505-03	82.6	86.4	94.7	102.1	107.8	117.0
10517-08	70.5	74.9	81.8	88.0	95.3	102.5
10531-02	80.1	86.6	92.8	99.7	107.2	111.0
10533-02	92.5	99.1	106.6	114.6	122.2	131.1
10538-03	80.6	88.3	95.0	102.4	110.1	117.2
MEAN	78.9	83.7	91.0	97.7	104.2	110.9
S.D.	7.43	8.74	8.85	8.95	9.54	10.53
N	10	10	10	10	10	10

TABLE 199 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	MALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG						
10466-03	97.4	100.9	106.8	115.1	124.1	132.9
10469-06	57.6	60.2	64.0	70.8	75.6	80.0
10477-05	69.9	75.5	81.5	87.2	94.8	100.4
10526-01	68.7	71.6	76.9	83.7	90.4	99.2
10527-05	79.6	82.6	87.2	95.0	101.9	109.1
10541-06	85.9	91.2	99.3	107.1	113.9	122.5
10542-03	72.5	76.6	81.2	86.1	91.5	96.5
10544-03	70.1	71.1	78.5	83.7	88.4	96.4
10545-02	80.3	82.7	90.5	97.7	104.9	113.0
MEAN	75.8	79.2	85.1	91.8	98.4	105.6
S.D.	11.53	11.96	12.70	13.45	14.58	15.77
N	9	9	9	9	9	9

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG						
10485-10	41.0	44.1	47.1	51.6	54.6	57.9
10491-04	94.7	97.3	104.5	111.8	115.5	124.0
10496-14	86.1	91.4	100.0	106.8	113.4	119.6
10498-15	81.1	86.8	92.3	97.6	104.0	109.3
10512-12	75.8	80.8	86.8	90.7	98.4	104.1
10514-16	80.1	88.1	93.1	96.8	106.0	113.5
10521-14	51.7	54.9	59.1	62.6	68.3	73.8
10537-07	90.2	96.2	105.9	112.9	117.6	124.2
MEAN	75.1	80.0	86.1	91.4	97.2	103.3
S.D.	18.92	19.72	21.59	22.67	23.26	24.50
N	8	8	8	8	8	8

TABLE 199 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG						
10487-06	86.9	93.8	99.5	106.4	113.3	119.8
10492-09	50.8	54.5	59.8	64.6	71.0	76.8
10495-19	75.6	81.7	86.6	95.7	102.8	108.2
10499-12	87.7	94.7	102.0	107.9	116.1	123.3
10515-15	66.9	71.9	75.2	80.2	86.4	92.2
10516-10	84.5	89.2	92.6	100.9	104.1	110.9
10552-13	76.1	81.2	86.7	91.6	98.1	100.9
10556-07	69.2	73.1	78.7	84.7	91.1	97.7
MEAN	74.7	80.0	85.1	91.5	97.9	103.7
S.D.	12.42	13.41	13.80	14.61	14.80	15.19
N	8	8	8	8	8	8

TABLE 199 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHTS [G]

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG						
10475-12	91.8	95.1	100.7	109.5	117.8	122.7
10489-11	79.1	83.5	90.3	94.7	100.7	108.6
10490-10	65.8	71.5	78.0	80.9	87.0	92.5
10497-12	65.9	68.3	73.7	80.5	84.7	89.8
10501-10	63.7	68.7	73.8	78.9	84.7	91.9
10505-17	86.9	87.3	92.7	98.1	102.6	107.9
10517-12	76.8	78.5	82.7	87.5	93.4	96.4
10531-08	81.1	86.3	89.6	97.8	100.0	105.2
10533-03	78.0	83.3	87.0	93.0	97.5	102.8
10538-05	84.4	90.2	95.9	102.3	111.6	117.7
MEAN	77.4	81.3	86.4	92.3	98.0	103.6
S.D.	9.54	9.26	9.22	10.21	11.08	11.12
N	10	10	10	10	10	10

	FEMALES					
DAY	29	30	31	32	33	34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG						
10466-15	87.2	93.0	96.9	103.4	110.6	117.4
10469-13	63.0	65.5	71.5	76.4	81.4	86.0
10477-17	61.2	65.4	70.4	75.1	81.3	80.3
10502-11	67.5	69.9	74.4	79.8	84.6	86.3
10526-08	62.4	63.1	69.0	73.4	78.9	84.1
10527-10	79.8	81.3	85.2	92.2	97.8	102.3
10541-08	81.1	84.2	89.8	95.9	102.9	106.9
10542-10	60.6	62.7	66.3	71.5	76.3	78.0
10544-15	73.0	75.1	83.3	88.0	93.5	100.0
10545-09	70.2	72.8	79.3	87.9	94.2	99.6
MEAN	70.6	73.3	78.6	84.4	90.2	94.1
S.D.	9.42	10.14	10.03	10.74	11.41	12.97
N	10	10	10	10	10	10

TABLE 200 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	MALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG						
10485-04	3.5	5.5	4.6	6.2	4.7	24.5
10491-01	6.8	7.1	6.2	9.9	10.4	40.4
10496-05	7.6	6.1	7.1	6.6	8.8	36.2
10498-08	8.1	5.4	8.4	7.0	7.8	36.7
10512-04	8.6	8.1	7.3	8.7	6.7	39.4
10514-08	7.5	7.4	7.3	9.3	10.1	41.6
10521-05	5.7	5.6	6.3	5.7	8.6	31.9
10537-02	6.3	6.6	7.0	9.3	8.4	37.6
MEAN	6.8	6.5	6.8	7.8	8.2	36.0
S.D.	1.62	0.99	1.11	1.64	1.84	5.53
N	8	8	8	8	8	8

TABLE 200 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	MALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG						
10487-01	7.2	5.1	8.4	6.8	8.3	35.8
10492-05	4.1	6.3	5.2	4.5	5.4	25.5
10495-07	5.3	6.7	7.7	8.8	6.4	34.9
10499-02	4.3	7.5	6.8	9.4	9.2	37.2
10515-02	5.6	5.4	7.5	7.3	7.0	32.8
10516-04	7.0	7.0	6.9	9.3	8.8	39.0
10552-09	5.0	8.8	6.6	7.9	5.3	33.6
10556-04	5.5	2.4	12.7	6.2	6.6	33.4
MEAN	5.5	6.2	7.7	7.5	7.1	34.0
S.D.	1.12	1.91	2.22	1.69	1.49	4.03
N	8	8	8	8	8	8

MALES

DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG						
10475-02	2.6	7.6	7.5	5.0	6.2	28.9
10489-05	5.4	7.6	3.5	3.4	2.3	22.2
10490-05	4.8	8.6	6.1	6.5	7.8	33.8
10497-06	1.3	6.5	7.6	6.1	6.2	27.7
10501-03	4.7	7.5	6.5	7.7	8.2	34.6
10505-03	3.8	8.3	7.4	5.7	9.2	34.4
10517-08	4.4	6.9	6.2	7.3	7.2	32.0
10531-02	6.5	6.2	6.9	7.5	3.8	30.9
10533-02	6.6	7.5	8.0	7.6	8.9	38.6
10538-03	7.7	6.7	7.4	7.7	7.1	36.6
MEAN	4.8	7.3	6.7	6.5	6.7	32.0
S.D.	1.92	0.77	1.29	1.43	2.19	4.78
N	10	10	10	10	10	10

TABLE 200 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	MALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG						
10466-03	3.5	5.9	8.3	9.0	8.8	35.5
10469-06	2.6	3.8	6.8	4.8	4.4	22.4
10477-05	5.6	6.0	5.7	7.6	5.6	30.5
10526-01	2.9	5.3	6.8	6.7	8.8	30.5
10527-05	3.0	4.6	7.8	6.9	7.2	29.5
10541-06	5.3	8.1	7.8	6.8	8.6	36.6
10542-03	4.1	4.6	4.9	5.4	5.0	24.0
10544-03	1.0	7.4	5.2	4.7	8.0	26.3
10545-02	2.4	7.8	7.2	7.2	8.1	32.7
MEAN	3.4	5.9	6.7	6.6	7.2	29.8
S.D.	1.45	1.53	1.21	1.39	1.72	4.86
N	9	9	9	9	9	9

TABLE 200 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 1: 0 PPM/0 MG/KG						
10485-10	3.1	3.0	4.5	3.0	3.3	16.9
10491-04	2.6	7.2	7.3	3.7	8.5	29.3
10496-14	5.3	8.6	6.8	6.6	6.2	33.5
10498-15	5.7	5.5	5.3	6.4	5.3	28.2
10512-12	5.0	6.0	3.9	7.7	5.7	28.3
10514-16	8.0	5.0	3.7	9.2	7.5	33.4
10521-14	3.2	4.2	3.5	5.7	5.5	22.1
10537-07	6.0	9.7	7.0	4.7	6.6	34.0
MEAN	4.9	6.2	5.3	5.9	6.1	28.2
S.D.	1.81	2.24	1.58	2.06	1.56	6.03
N	8	8	8	8	8	8

TABLE 200 (F1 - INHALATION/GAVAGE PHASE - PND 29-33)

PROJECT NO.:WIL-186028E PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC INDIVIDUAL BODY WEIGHT CHANGES [G]

	FEMALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 2: 100 PPM/90 MG/KG						
10487-06	6.9	5.7	6.9	6.9	6.5	32.9
10492-09	3.7	5.3	4.8	6.4	5.8	26.0
10495-19	6.1	4.9	9.1	7.1	5.4	32.6
10499-12	7.0	7.3	5.9	8.2	7.2	35.6
10515-15	5.0	3.3	5.0	6.2	5.8	25.3
10516-10	4.7	3.4	8.3	3.2	6.8	26.4
10552-13	5.1	5.5	4.9	6.5	2.8	24.8
10556-07	3.9	5.6	6.0	6.4	6.6	28.5
MEAN	5.3	5.1	6.4	6.4	5.9	29.0
S.D.	1.26	1.30	1.62	1.43	1.37	4.12
N	8	8	8	8	8	8

	FEMALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 3: 500 PPM/342MG/KG						
10475-12	3.3	5.6	8.8	8.3	4.9	30.9
10489-11	4.4	6.8	4.4	6.0	7.9	29.5
10490-10	5.7	6.5	2.9	6.1	5.5	26.7
10497-12	2.4	5.4	6.8	4.2	5.1	23.9
10501-10	5.0	5.1	5.1	5.8	7.2	28.2
10505-17	0.4	5.4	5.4	4.5	5.3	21.0
10517-12	1.7	4.2	4.8	5.9	3.0	19.6
10531-08	5.2	3.3	8.2	2.2	5.2	24.1
10533-03	5.3	3.7	6.0	4.5	5.3	24.8
10538-05	5.8	5.7	6.4	9.3	6.1	33.3
MEAN	3.9	5.2	5.9	5.7	5.6	26.2
S.D.	1.88	1.14	1.77	2.04	1.33	4.34
N	10	10	10	10	10	10

	FEMALES					
DAY	29- 30	30- 31	31- 32	32- 33	33- 34	29- 34
ANIMALS FROM GROUP 4: 1000PPM/621MG/KG						
10466-15	5.8	3.9	6.5	7.2	6.8	30.2
10469-13	2.5	6.0	4.9	5.0	4.6	23.0
10477-17	4.2	5.0	4.7	6.2	-1.0	19.1
10502-11	2.4	4.5	5.4	4.8	1.7	18.8
10526-08	0.7	5.9	4.4	5.5	5.2	21.7
10527-10	1.5	3.9	7.0	5.6	4.5	22.5
10541-08	3.1	5.6	6.1	7.0	4.0	25.8
10542-10	2.1	3.6	5.2	4.8	1.7	17.4
10544-15	2.1	8.2	4.7	5.5	6.5	27.0
10545-09	2.6	6.5	8.6	6.3	5.4	29.4
MEAN	2.7	5.3	5.8	5.8	3.9	23.5
S.D.	1.43	1.43	1.31	0.86	2.44	4.48
N	10	10	10	10	10	10

FINAL REPORT

Volume 4 of 4
(Appendices A - J)

STUDY TITLE

A PILOT INHALATION STUDY FOR A
REPRODUCTIVE TOXICITY STUDY OF
ETHYLBENZENE IN RATS

STUDY NUMBER

WIL-186028

STUDY DIRECTOR

Donald G. Stump, Ph.D., D.A.B.T.

STUDY INITIATION DATE

August 27, 2002

STUDY COMPLETION DATE

August 1, 2003

PERFORMING LABORATORY

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

AMERICAN CHEMISTRY COUNCIL CONTRACT NUMBER

EB-13.0-VCCEP-Research-WIL

SPONSOR

American Chemistry Council
Ethylbenzene Panel
1300 Wilson Boulevard
Arlington, VA 22209

APPENDIX A

Certificate Of Analysis (Sponsor-Provided Data)

R&D Report

The Dow Chemical Company

CRI Number

Laboratory Report Code
GL-AL MD-2002-003711-REV1

Department	Geographic Location	Date Issued
Analytical Sciences	Midland, MI	November 6, 2002 (Original issue date of report was 10/30/2002.)

11 pages in full report

Protocol Study Number
GL-AL MD-2002-003711

Title
Purity and Identification of Ethylbenzene, Lot WIL-186028

Author(s): Last Name and initials (Master Number)

VanderKamp, J. A. (821021); Putzig, C. L. (071834); Langer, V. L. (249822)

Author Signature(s)/Date 11/6/02 11/6/02 11/06/02

Reviewer and/or Supervisor Name(s)

Barr, S. W.

Reviewer and/or Supervisor Signature(s)/Date Stephen W. Barr 11-6-02

Descriptive Summary and Conclusions

Analytical Sciences has been requested to provide analytical data on the purity and structure confirmation of ethylbenzene, lot WIL-186028, for the Toxicology Laboratories. Melissa Mielke submitted the sample of ethylbenzene on September 5, 2002.

An average area percent assay of 99.894% ± 0.001% was obtained by gas chromatography with flame ionization detection (GC/FID). No peaks with areas greater than 0.1% were detected. The water content of the sample was determined to be 0.02% using a Karl Fischer coulometric titration. A purity of 99.9% ± 0.1% ethylbenzene was reported for the sample based on area percent gas chromatography, corrected for water content.

Infrared spectroscopy (FTIR) and gas chromatography/mass spectroscopy (GC/MS) were used to confirm the proposed structure of ethylbenzene, lot WIL-186028.

QA Verified by 11/6/02 on October 28, 2002.
G. A. Von Wald

Reason for Report Revision: To add QA Verification signature to report coversheet and C of A page.

OP Contact: Gunther, L.A. (989-638-5914) Form Date: 5/5/99

CERTIFICATE OF ANALYSIS FOR TEST SUBSTANCES

OBJECTIVE: Characterization of the following substance for use as a Test Substance.

SUBSTANCE BEING CHARACTERIZED:
CHEMICAL NAME: Ethylbenzene LOT: WIL-186028
DESCRIPTION: Clear liquid

REFERENCE MATERIAL(S) USED: N/A (not applicable) PURITY: N/A EXPIRATION DATE: N/A

STUDY INITIATION DATE: September 5, 2002

METHODS USED:
PURITY: Gas Chromatography (Area Percent), Water (Karl Fischer titration)
IDENTIFICATION: FTIR, GC/MS

RESULTS AND CONCLUSIONS:
__X__ INITIAL DETERMINATION
Result: A purity of 99.9% ± 0.1% determined by GC/FID, corrected for water, was reported for the sample. Experimental work was completed on September 26, 2002.

or

__N/A__ RECERTIFICATION
Current value of _____ is within experimental variation of previously established purity. The purity is unchanged and remains _____.

__X__ OTHER
The water content was determined to be 0.02% by Karl Fischer coulometric titration. GC/MS and FTIR spectra were consistent with the proposed structure for ethylbenzene.

CALCULATIONS:
Area Normalized: X Internal Standard: N/A External Standard: N/A
Other (explain): N/A

STUDY DIRECTOR SIGNATURE: J A Vander Kamp **COMPLETION DATE:** 11-6-02

PEER REVIEWER SIGNATURE: Stephen W Baum **DATE:** 11-6-02

STUDY DIRECTOR AND TESTING FACILITY ADDRESS:

The Dow Chemical Company, Analytical Sciences Laboratory, 1897 Building, Midland, MI 48667

All raw data associated with this study will be archived in the testing facility archive. Only descriptive statistics were used unless otherwise noted in the results. This study was conducted in accordance with the Good Laboratory Practice Standard, 40 CFR part 160.135(b) unless otherwise noted.

QA Verified by Brent Von Wald 11/6/02 on October 28, 2002.
G. A. Von Wald

Reason for Report Revision: To add QA Verification signature to report coversheet and C of A page. Original issue date of report was 10/30/2002.

Purity and Identification of Ethylbenzene, Lot WIL-186028

INTRODUCTION

Analytical Sciences has been requested to provide analytical data on the purity and structure confirmation of ethylbenzene, lot WIL-186028, for the Toxicology Laboratories. Melissa Mielke submitted the sample of ethylbenzene on September 5, 2002.

Area percent gas chromatography with flame ionization detection (GC/FID) was used to determine the purity of the sample. The water content was determined by Karl Fischer coulometric titration. Infrared spectroscopy (FTIR) and gas chromatography/mass spectroscopy (GC/MS) were used to confirm the proposed structure of ethylbenzene, lot WIL-186028.

RESULTS

A neat sample of ethylbenzene, lot WIL-186028, was analyzed in triplicate by area percent GC/FID. The average assay of the three injections was 99.894% ± 0.001% ethylbenzene. No impurities with areas greater than 0.1% were detected. The individual results for the GC/FID analyses are displayed in Table I. A representative chromatogram of the sample is shown in Figure 1.

FTIR and GC/MS were used to confirm the proposed structure of ethylbenzene, lot WIL-186028. The IR spectrum matches Sadtler Standard IR Spectrum 82K for ethylbenzene and is displayed in Figure 2. A representative total ion chromatogram from the GC/MS/EI analysis is presented in Figure 3. A representative mass spectrum plus tentative assignments for the major peak from the GC/MS/EI analysis is presented in Figure 4. The mass spectra were consistent with the proposed structure. A summary of the mass spectral data is presented in Table II.

The water content of ethylbenzene, lot WIL-186028, was determined to be 0.02% by Karl Fischer coulometric titration.

A purity of 99.9% ± 0.1% ethylbenzene, lot WIL-186028, was reported for the sample based on area percent GC/FID, corrected for water content.

EXPERIMENTAL

GC/FID

The sample was analyzed by gas chromatography based on conditions outlined in ASTM D 5060 (1) and a previous analysis of ethylbenzene (2). The instrumentation and conditions used are listed below:

Instrument:	Agilent 6890N GC with Agilent 7683 autoinjector
Integrator:	PE Nelson Access*Chrom data system, v 1.9
Column:	Chrompack, WCOT Fused Silica, CP-WAX 52CB, 50 m x 0.25-mm ID, 0.2-µm film
Detector Type:	Flame ionization detector (FID)
Injector Temp:	230°C
Detector Temp:	240°C
Oven Temp:	110°C for 14 minutes
Carrier Gas:	Helium @ 27.8 psi, constant pressure mode
Split Ratio:	300:1
Split Vent:	15 mL/min
Detector Range:	5
Air Flow:	275 mL/min
Hydrogen Flow:	30 mL/min
Makeup Flow (He):	23 mL/min
Injection Mode:	Split
Injection Volume:	1.0 µL
Sample Prep:	Neat

FTIR

The sample was prepared as a neat film cast between sodium chloride plates. The IR spectrum was recorded employing the Nicolet 710 FT-IR spectrometer in % Transmittance from 4000 to 400 cm^{-1}.

GC/MS

A five-tenths microliter (nominal volume) aliquot of the sample was analyzed on a Finnigan SSQ 7000 GC/MS system operating in the electron ionization mode. Representative analysis conditions are listed below:

Column:	Chrompack WCOT Fused Silica, CP-WAX 52CB, 50 m x 0.25-mm ID, 0.2-µm film	
Temperatures:	Oven: 110°C, hold 15 minutes	
	Injector: 230°C	Ion source: 150°C
	Transfer Line: 240°C	Manifold: 70°C
Detector:	EMULT: 1200 V	Preamp: 10^{-7} A/V
	Conv. Dyn.: (±)15kV	Mode: + Q1MS, CENT
	ELEN: 70 V	ECURR: 1.0 mA
	Rate: 0.5 sec/scan	Scan: 35 to 450 amu
Injection:	Volume (nominal): 0.5 µL	Split Ratio: 300/1

Karl Fischer Titration

The amount of water in ethylbenzene, lot WIL-186028, was determined by Karl Fischer titration via a Model 737 Brinkmann Metrohm coulometric titrator. Sample aliquots of 433.7 mg, 426.7 mg, and 428.5 mg were titrated separately and 83.1 µg (0.019%), 87.6 µg (0.021%), and 96.0 µg (0.022%) of water were found, respectively, in the sample. The results were averaged to 0.02%.

REFERENCES

1. ASTM D 5060-95, "Standard Test Method for Determining Impurities in High-Purity Ethylbenzene by Gas Chromatography."
2. VanderKamp, J.A., et al., "Purity and Identification of Ethyl Benzene Lot # TEX102899," GL-AL MD-1999-014783, January 4, 2000.
3. Raw data are filed in data envelope GL-AL MD-2002-003711.

TABLE I

Area Percent Results for Ethylbenzene, Lot WIL-186028, by Gas Chromatography

	% Ethylbenzene
1st injection	99.893
2nd injection	99.895
3rd injection	99.895
Mean	99.894
Std Dev	0.001
%RSD	0.001

TABLE II

Summary of Mass Spectral Data Plus Proposed Structure of Main Component from the GC/MS/EI Analysis of Ethylbenzene, Lot WIL-186028

m/z Observed	MW	Proposed Structure
$106(M)^+$,91,77,65,51,39	106	 C_8H_{10} 106.078250 or isomer

FIGURE 1

Representative Chromatogram of Ethylbenzene, Lot WIL-186028, by Gas Chromatography





FIGURE 2

Infrared Spectrum of Ethylbenzene, Lot WIL-186028



FIGURE 3

Representative Total Ion Chromatogram from the GC/MS/EI Analysis of Ethylbenzene, Lot WIL-186028



FIGURE 4

Representative Mass Spectrum Plus Tentative Assignments for the Main Component from the GC/MS/EI Analysis of Ethylbenzene, Lot WIL-186028



APPENDIX B

Analytical Chemistry Report (WIL Research Laboratories, Inc.)

A PILOT INHALATION STUDY FOR REPRODUCTIVE TOXICITY AND DEVELOPMENTAL NEUROTOXICITY OF ETHYLBENZENE IN RATS

Analyses Of Dosing Formulations

Analytical Chemistry Department

WIL Research Laboratories, Inc.

TABLE OF CONTENTS

Page

Table Of Contents **2**
Index Of Figures **3**
Index Of Tables **3**
Index Of Attachments **4**
1. Introduction **5**
2. Summary **5**
3. Experimental - Dosing Formulations **6**
3.1. Gas Chromatography 6
3.2. Preparation Of Calibration Stock Solution And Standards 6
3.3. Preparation Of Quality Control (QC) Stock Solution 7
3.4. Processing Of Formulation Samples 7
3.5. Calibration And Quantitation 7
4. Results and Discussion **7**
4.1. Specificity/Selectivity 10
4.2. Calibration Reproducibility 10
4.3. Precision And Accuracy 11
4.4. Assay Ruggedness 12
4.5. Processed Sample Stability 12
4.6. Homogeneity And Resuspension Homogeneity Assessment Of Ethylbenzene In Representative Dosing Formulations 12
4.7. Stability Of Ethylbenzene In Dosing Formulations 14
4.8. Concentration Analysis Of Dosing Formulations 14
5. Experimental - Purity Assessments **15**
5.1. Gas Chromatography (Purity And Stability Assessments) 15
5.2. Preparation Of Samples For Purity And Stability Analyses 15
5.3. Purity And Stability Assessments 16

Page

6. Conclusion 17

7. Key Study Personnel And Report Approval 18

INDEX OF FIGURES

Page

Figure 1: Representative Chromatogram Of A 1.0 µg Ethylbenzene/mL Calibration Sample 8

Figure 2: Representative Chromatogram Of A Processed 15.0 mg Ethylbenzene/mL QC Sample 9

Figure 3: Representative Chromatogram Of A Processed 207 mg Ethylbenzene/mL Formulation Sample 9

Figure 4: Representative Chromatogram Of A Processed Untreated Vehicle (Corn Oil) Sample 10

Figure 5: Representative Chromatogram Of A Commercially Available (Aldrich Chemical Company) Ethylbenzene Reference Standard (99.8% Pure) 16

Figure 6: Representative Chromatogram Of A Test Article Bottle Sample (99.91% Pure) 17

INDEX OF TABLES

Page

Table 1: Calculated Concentrations Of Validation Calibration Samples 20

Table 2: Calculated Concentrations Of Validation Quality Control Samples 21

Table 3: Peak Areas Of Validation Calibration Samples 22

Table 4: Peak Areas Of Validation Quality Control Samples 23

Page

Table 5: 3-Day Room Temperature Processed Sample Stability 24

Table 6: Homogeneity Analysis Of The 10/14/2002 Formulations 25

Table 7: 1-Day Room Temperature Re-Suspension Homogeneity Analysis Of The 10/14/02 Formulations 28

Table 8: 10-Day Room Temperature Re-Suspension Homogeneity Analysis Of The 10/14/02 Formulations 29

Table 9: Room Temperature Stability Analysis Of The 10/14/02 Formulations 30

Table 10: Concentration Analysis Of The 10/21/02 Formulations 31

Table 11: Concentration Analysis Of The 10/28/02 Formulations 32

Table 12: Purity Assessments 33

INDEX OF ATTACHMENTS

I: Supporting Data 39

1. INTRODUCTION

This report provides the detailed description and validation of an assay for the determination of ethylbenzene in corn oil formulations utilizing gas chromatography (GC) with mass spectrometry detection (MS). The validity of the assay procedure was established through a careful study of the assay specificity/selectivity, calibration reproducibility, accuracy and precision, ruggedness, and stability of ethylbenzene in processed samples. Ethylbenzene homogeneity, resuspension homogeneity, stability and concentrations in corn oil formulations were also assessed.

Samples of the test article (ethylbenzene) were analyzed to determine test article purity by gas chromatography with flame ionization detection (GC/FID). Retention samples (taken prior to initial use of each bottle on the study) and residual samples (taken after final use of each bottle on the study) were analyzed to assess purity and stability.

2. SUMMARY

Quantitation was performed utilizing ethylbenzene in hexane calibration samples in the range of 1.0 to 10.0 µg/mL. Precision and accuracy were verified with the analysis of quality control (QC) samples prepared as fortified corn oil at final ethylbenzene concentrations of 15.0, 150 and 350 mg/mL.

The dosing formulations were homogeneous with respect to ethylbenzene. The overall mean concentrations for samples taken from the top, middle and bottom strata ranged from 93.6% to 99.4% of the target dose concentrations. The relative standard deviations (RSDs) were 0.91%, 0.74%, and 3.1% for the 30.0 mg/mL, 114 mg/mL, and 207 mg/mL formulations, respectively. These data indicated uniform dispersal of ethylbenzene in the corn oil formulations.

To assess stability, dose formulations were analyzed after 1 and 10 days of room temperature storage. The mean concentrations of the stored formulations were ≥ 90% of the Time Zero concentrations, therefore the formulations were considered to be stable

over the periods and conditions of storage used during the study. Subsequent formulations used for dose administration were analyzed and the resulting concentrations were within acceptable limits (%RE within ± 15%).

3. EXPERIMENTAL - DOSING FORMULATIONS

3.1. GAS CHROMATOGRAPHY

Instrument:	Varian CP-3800 GC, Saturn 2000 GC/MS/MS, CP-8400 autosampler, Saturn Workstation or equivelent
Column:	Rtx-1, 30 m x 0.25 mm ID (0.25 µm film thickness) or equivelant
Temperature Program:	50°C for 3.0 minutes ramp at 20°C/minute to 90°C , ramp at 50°C/minute to 200°C
Carrier Gas:	Helium constant flow 1.0 mL/minute
Injector Temperature:	250°C
Injection Volume:	1.0 µL, split 50:1
Retention Time:	Approximately 4.2 minutes for Ethylbenzene
Run Time:	Approximately 7.2 minutes

Mass Spectrometry Parameters

Ion Trap:	150° C, EI ionization
Transfer Line:	200 ° C
Manifold Temp:	50° C
Solvent Delay:	3 minutes
Ions for Quantitation:	[m/z]+ = 91 and 106

3.2. PREPARATION OF CALIBRATION STOCK SOLUTION AND STANDARDS

A stock solution of the test article was prepared by accurately transferring approximately 11.6 µL of ethylbenzene (d=0.867) into a Falcon tube containing 10 mL hexane to yield an ethylbenzene concentration of approximately 1.0 mg/mL. This stock solution was used to prepare the calibration standards by transferring appropriate aliquots from this stock into Falcon tubes containing 10 mL hexane to yield concentrations of 1 - 10 µg/mL.

3.3. PREPARATION OF QUALITY CONTROL (QC) STOCK SOLUTION

The QC samples were prepared as described in the table below.

QC (mg/mL)	Ethylbenzene Aliquot (µL)	Corn oil (mL)	Hexane (mL)	Dilution Aliquot (µL)	Hexane (mL)
15	17.3	1	24	50	5
150	173	1	24	20	25
350	404	1	24	20	40

3.4. PROCESSING OF FORMULATION SAMPLES

Formulation samples were processed by adding an aliquot (1 mL) of each formulation to 24 mL of hexane in a 50-mL Falcon tube. Secondary dilutions in hexane, in the calibration range of 1-10 µg/mL, were prepared from these samples and transferred to autosampler vials.

3.5. CALIBRATION AND QUANTITATION

Single injections were made of each standard and sample. A calibration curve was constructed for each set of analyses. The ethylbenzene peak areas (y) and the theoretical concentrations of the calibration standards (x) were fit with a least-squares regression analysis to the ln quadratic function:

$$\ln(y) = a \times [\ln(x)]^2 + b \times \ln(x) + c$$

Concentrations were calculated from the regression equation using a PC spreadsheet program (Microsoft® Excel). The concentration data were transferred to another Excel spreadsheet, where appropriate summary statistics, that is, mean, standard deviation (SD), relative standard deviation (RSD), and percent relative error (%RE) were calculated and presented in tabular form. The concentrations of the dosing formulations and QC samples were calculated by applying any necessary multiplication factors.

4. RESULTS AND DISCUSSION

Under the described chromatographic conditions, the retention time of ethylbenzene was approximately 4.2 minutes. Figures 1, 2, 3 and 4 are typical chromatograms of a 1.0-µg

ethylbenzene/mL calibration sample, a processed 15.0-mg ethylbenzene/mL QC sample, a processed 207-mg ethylbenzene/mL formulation sample, and a processed untreated vehicle (corn oil) sample, respectively. The total analysis time required for each run was approximately 7.2 minutes. The validity of the assay procedure was established through a careful study of the assay specificity/selectivity, calibration reproducibility, accuracy and precision, ruggedness, ethylbenzene stability in processed samples, and the homogeneity and stability of ethylbenzene in dosing formulations.



Figure 1: Representative Chromatogram Of A 1.0-µg Ethylbenzene/mL Calibration Sample



Figure 2: Representative Chromatogram Of A Processed 15.0-mg Ethylbenzene/mL QC Sample



Figure 3: Representative Chromatogram Of A Processed 207-mg Ethylbenzene/mL Formulation Sample



Figure 4: Representative Chromatogram Of A Processed Untreated Vehicle (Corn Oil) Sample

4.1. SPECIFICITY/SELECTIVITY

As shown in Figure 4 (and in contrast to the chromatograms shown in Figures 1-3), assay specificity/selectivity was confirmed when GC/FID analysis of control formulations revealed that there were no significant peaks at or near the retention time for ethylbenzene (4.2 minutes).

4.2. CALIBRATION REPRODUCIBILITY

During each of three validation sessions, triplicate calibration samples at five concentration levels were prepared and analyzed as previously described. Single injections were made of each calibration sample. The resulting peak area-concentration data were fit to the ln-quadratic function using the least-squares regression analysis. The results of the regression analyses were used to back-calculate from the peak area data the corresponding concentrations. The reproducibility of the calibration curve data was considered valid when 1) the inter-session variability (RSD) of the back-calculated

concentrations at each concentration level were ≤ 15%, except at the lowest calibration concentration where an RSD ± 20% was acceptable; and 2) the mean back-calculated concentrations at each concentration level were within 15% of the theoretical values (%RE within ± 15%), except at the lowest concentration level where %RE within ± 20% was acceptable.

The back-calculated concentration values and the associated intra- and inter-session statistics for the ethylbenzene calibration samples are summarized in Table 1. The inter-session variability (RSD) of the back-calculated concentrations at each level ranged from -1.4% to 1.9%.

Based on these criteria and the resulting validation data, the reproducibility of the calibration data was acceptable.

4.3. PRECISION AND ACCURACY

During each of three validation sessions, triplicate QC samples at three concentration levels were prepared and analyzed as described above. Single injections were made of each processed QC sample. The results of the regression analyses were used to calculate the corresponding concentrations from these QC peak area data. The variability (RSD) of these calculated QC concentration data was used as a measure of assay precision. The precision of the method was considered acceptable when the inter-session RSD of the calculated concentrations at each QC concentration level was ≤ 15%. The difference from theoretical of the calculated QC concentration means (%RE) was used as a measure of assay accuracy. The accuracy of the method was considered acceptable when the inter-session concentration means of the calculated concentrations at each QC concentration level had %RE values within ± 15%.

The calculated concentration values and the associated intra- and inter-session statistics for the ethylbenzene assay QC samples are summarized in Table 2. The inter-session variability (RSD) of the calculated concentrations at each level (precision) ranged from

4.4% to 6.5%. The inter-session concentration means had %RE values (accuracy) ranging from -4.1% to 4.9%.

Based on the criteria mentioned above, the precision and accuracy of the ethylbenzene assay were acceptable. The integrated peak area data from both the calibration and QC sample analyses are summarized in Tables 3 and 4, respectively.

4.4. ASSAY RUGGEDNESS

There are several assay concerns in the category of assay ruggedness. In this assay validation, ruggedness was defined as the ability of another analyst to successfully perform the procedure as described. Assay ruggedness was demonstrated when two or more different analysts successfully conducted at least one of the required three validation sessions. Assay ruggedness was successfully demonstrated for this procedure.

4.5. PROCESSED SAMPLE STABILITY

The QC samples prepared for the third validation session and initially analyzed on 10/4/02, were stored at room temperature for 3 days and reanalyzed on 10/7/02. The concentration means of the re-analyses ranged from 103% to 106% of their corresponding time-zero concentrations (Table 5) and therefore met the WIL standard operating procedure requirement for stability, *i.e.*, the mean analyte concentration was not less than 90% of the time zero concentration.

4.6. HOMOGENEITY AND RESUSPENSION HOMOGENEITY ASSESSMENT OF ETHYLBENZENE IN REPRESENTATIVE DOSING FORMULATIONS

Homogeneity samples were collected from the top, middle, and bottom strata of the representative formulations prepared on 10/14/02. Aliquots (at approximate volumes necessary for one day of dosing) were stored at room temperature for 1 and 10 days, at which time they were resuspended with stirring, and samples taken from the top and bottom strata were analyzed to assess resuspension homogeneity. The results of the homogeneity and resuspension homogeneity assessments are presented in Tables 6 through 8, with the mean concentrations and overall statistics summarized as follows:

Ethylbenzene Homogeneity in Representative Dosing Formulations

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	29.5	111	196
Middle	30.0	113	199
Bottom	29.9	112	187
Group Mean (ppm)	29.8	112	194
SD	0.27	0.83	6.1
RSD(%)	0.91	0.74	3.1
Mean % of Target	99.4	98.3	93.6

1-Day Ethylbenzene Resuspension Homogeneity in Dosing Formulation Aliquots

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	34.9	132	215
Bottom	31.6	126	226
Group Mean (ppm)	33.3	129	220
SD	2.3	4.8	8.2
RSD(%)	7.0	3.8	3.7
Mean % of Target	111	113	106

10-Day Ethylbenzene Resuspension Homogeneity in Dosing Formulation Aliquots

Homogeneity	Group 2 (30 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
Top	29.0	106	221
Bottom	27.6	112	230
Group Mean (ppm)	28.3	109	226
SD	0.95	4.1	6.0
RSD(%)	3.3	3.8	2.6
Mean % of Target	94.3	95.4	109

All groups initially analyzed met the WIL standard operating procedure requirement for homogeneity, that is, the RSD for the overall mean concentration was 10% or less at a concentration that was within the acceptable limits (%RE within ± 15%).

4.7. STABILITY OF ETHYLBENZENE IN DOSING FORMULATIONS

The concentration data from the homogeneity and 1- and 10-day resuspension homogeneity analyses were used to assess ethylbenzene stability in dosing formulations stored at room temperature for 1 and 10 days (Table 9). These data, including mean ethylbenzene concentrations, % of target concentration values, and % of time zero concentrations are summarized in the table below.

1- and 10-Day Room Temperature Stability of Ethylbenzene in Corn Oil Formulations

		Group 2	Group 3	Group 4
	Target Concentration (mg/mL)	30.0	114	207
Time Zero	Mean Concentration (mg/mL)	29.8	112	194
	% of Target Concentration	99.4	98.3	93.6
	% of Time Zero Concentration	100	100	100
1-Day Storage	Mean Concentration (mg/mL)	33.3	129	220
	% of Target Concentration	111	113	106
	% of Time Zero Concentration	112	115	113
10-Day Storage	Mean Concentration (mg/mL)	28.3	109	226
	% of Target Concentration	94.3	95.4	109
	% of Time Zero Concentration	95.0	97.3	116

4.8. CONCENTRATION ANALYSIS OF DOSING FORMULATIONS

The results of the periodic concentration analyses of the dosing formulations are presented in Tables 10 through 11, and the mean concentration (and % of target) values are summarized below.

Periodic Concentration Analyses of the Dosing Formulations

Formulation Date	Group 1 (0 mg/mL)	Group 2 (30.0 mg/mL)	Group 3 (114 mg/mL)	Group 4 (207 mg/mL)
10/21/02	ND	33.7 (112)	122 (107)	231 (111)
10/28/02	ND	29.9 (100)	112 (98.5)	205 (99.1)

5. EXPERIMENTAL - PURITY ASSESSMENTS

5.1. GAS CHROMATOGRAPHY (PURITY AND STABILITY ASSESSMENTS)

Instrument: Hewlett Packard 6890A (series II) gas chromatograph equipped with a flame ionization detector (FID), an HP7673 autosampler, and an HP ChemStation data system, or equivalent system

Column: J & W Scientific DB-wax, 30 m × 0.25 mm ID, 0.25 µm film thickness, or equivalent

Temperature Program: 50°C for 2.0 minutes, ramp at 10°C/min to 200°C hold 1.0 minute

Carrier gas: 1.0 mL/minute

Injector temperature: 250°C

Injection volume: 1 µL split (50:1)

Detector: FID at 250°C

Retention time: Approximately 6.5 minutes

5.2. PREPARATION OF SAMPLES FOR PURITY AND STABILITY ANALYSES

Samples (5 mL) of the test article (ethylbenzene) were received from the WIL Inhalation Department for determination of test article purity by gas chromatography with flame ionization detection (GC/FID). Samples were analyzed by transferring approximately 1 mL of test article into an amber autosampler vial. The vial was capped and an aliquot (1 µL) injected for GC/FID analysis.

5.3. PURITY AND STABILITY ASSESSMENTS

A sample was collected at the beginning and end of use from each drum of ethylbenzene. The sample was transferred to the WIL Analytical Chemistry Department where they were stored at approximately -20°C until GC/FID analysis. Triplicate 1 µL injections were made from each sample, with the area percent results from the second and third injections used to assess purity and stability.

Purity assessment results are presented in Table 12. These data indicate that the test article used in this study was at least 99.91% pure. Representative chromatograms of a commercially available (Aldrich Chemical Co.) ethylbenzene reference standard (ARS 0260A 99.8% pure) and test article bottle sample (WIL Log No. 5478A; 99.91% pure) are shown in Figures 5 and 6, respectively.

Comparisons of the beginning- and end-of-use purity assessments for the test article indicate that there was no significant loss of purity during storage and use on this study.



Figure 5: Representative Chromatogram Of A Commercially Available (Aldrich Chemical Company) Ethylbenzene Reference Standard (99.8% Pure)



Figure 6: Representative Chromatogram Of A Test Article Bottle Sample (99.91% Pure)

6. CONCLUSION

A precise and accurate method for the quantitation of ethylbenzene in corn oil dosing formulations was validated. The test article was mixed with corn oil to produce homogeneous formulations. Assessment of the resuspension homogeneity of dosing formulation aliquots (at approximate volumes necessary for one day of dosing) after 1 and 10 days of room temperature storage indicated successful re-establishment of homogeneity. There was insignificant loss of ethylbenzene in these corn oil formulations after 1 and 10 days of room temperature storage. The analyzed dosing formulations had concentrations within the required 15% of the target dose concentrations.

The test article samples that were analyzed and used for inhalation exposures were greater than 99.91% pure. Comparison of the purity of samples taken at the beginning and end of use of each drum demonstrated that the test article was stable for the duration of use on this study.

7. KEY STUDY PERSONNEL AND REPORT APPROVAL

Study Personnel:

Wm Clue Nethero, B.S.	Chemist
Cathline L. Shay	Project Leader, Analytical Chemistry
Daniel Collings, B.A.S.	Associate Study Analyst
Robert A. Wally, B.S.	Senior Group Supervisor, Study Analysis and Reports

Report Prepared By:

Cathline L. Shay — 8-1-03
Cathline L. Shay
Project Leader, Analytical Chemistry
Date

Report Reviewed By:

Philip L. Stetson, M.D.,Ph.D. — 8/1/03
Philip L. Stetson, M.D.,Ph.D.
Associate Director, Analytical Chemistry
Date

Report Approved By:

Doanld G. Stump — 8/1/03
Doanld G. Stump, Ph.D., D.A.B.T.
Associate Director, Developmental and Reproductive Toxicology
Study Director
Date

TABLES 1-12

Table 1: Calculated Concentrations Of Validation Calibration Samples

mg/mL	1.00	3.00	5.00	7.00	10.0
Set 1 (10/2/02)	1.01	3.21	4.56	7.02	9.77
	0.968	2.83	5.13	7.68	9.75
	1.02	2.97	5.01	7.02	10.1
Mean	1.00	3.00	4.90	7.24	9.87
SD	0.030	0.19	0.30	0.38	0.20
RSD	3.0	6.2	6.1	5.3	2.0
%RE	0.14	0.15	-2.0	3.4	-1.3
Set 2 (10/2/02)	1.03	3.05	4.74	6.74	9.29
	0.942	2.89	5.14	7.44	10.0
	1.03	3.05	4.91	7.36	10.4
Mean	1.00	3.00	4.93	7.18	9.91
SD	0.052	0.094	0.20	0.39	0.57
RSD	5.2	3.1	4.1	5.4	5.7
%RE	0.19	-0.06	-1.4	2.5	-0.89
Set 3 (10/4/02)	1.01	2.83	5.00	6.50	10.1
	0.916	3.09	4.75	7.00	9.55
	1.08	3.19	5.10	7.43	10.5
Mean	1.00	3.04	4.95	6.97	10.1
SD	0.081	0.18	0.18	0.47	0.50
RSD	8.1	6.1	3.7	6.7	5.0
%RE	0.048	1.2	-1.0	-0.37	0.74
Interset Statistics					
n	9	9	9	9	9
Mean	1.00	3.01	4.93	7.13	9.95
SD	0.050	0.14	0.20	0.38	0.40
RSD	5.0	4.7	4.1	5.3	4.0
%RE	0.13	0.44	-1.4	1.9	-0.49

186028.xls Summary 1
Printed: 12/23/02 10:58

Table 2: Calculated Concentrations Of Validation Quality Control Samples

mg/mL	15	150	350
Set 1 (10/2/02)	14.8	159	359
	15.6	142	350
	15.0	147	341
Mean	15.1	149	350
SD	0.42	9.0	8.8
RSD	2.8	6.0	2.5
%RE	0.63	-0.38	0.0064
Set 2 (10/2/02)	16.0	138	368
	16.3	146	327
	17.0	144	336
Mean	16.4	143	344
SD	0.51	4.5	21
RSD	3.1	3.2	6.2
%RE	9.6	-5.0	-1.8
Set 3 (10/4/02)	15.5	151	331
	15.4	142	305
	16.0	153	304
Mean	15.6	148	313
SD	0.3	5.9	15.3
RSD	2.2	4.0	4.9
%RE	4.3	-1.0	-11
Interset Statistics			
n	9	9	9
Mean	15.7	147	336
SD	0.69	6.7	22
RSD	4.4	4.5	6.5
%RE	4.9	-2.1	-4.1

186028.xls Summary 2
Printed: 12/23/02 11:03

Table 3: Peak Areas Of Validation Calibration Samples

mg/mL	1.00	3.00	5.00	7.00	10.0
Set 1 (10/2/02)	7581	23193	33076	51374	72384
	7268	20528	37250	56357	72238
	7674	21521	36344	51345	74935
Set 2 (10/2/02)	9462	25524	38888	54852	75605
	8708	24231	42106	60547	81638
	9420	25522	40273	59852	84756
Set 3 (10/4/02)	6978	21662	39165	51054	79208
	6259	23751	37154	55027	74827
	7523	24553	39983	58368	82420

186028.xls Summary3
Printed: 12/23/02 11:05

Table 4: Peak Areas Of Validation Quality Control Samples

mg/mL	15	150	350
Set 1 (10/2/02)	42965	37035	52548
	45389	32946	51186
	43595	34045	49890
Set 2 (10/2/02)	52251	36221	59839
	53077	38458	53248
	55403	37734	54794
Set 3 (10/4/02)	48699	37732	52006
	48449	35429	47889
	50412	38309	47752

186028.xls Summary 4
Printed: 3/21/03 10:18

Table 5: 3-Day Room Temperature Processed Sample Stability

(Analyzed 10/7/02)

QC	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)	Percent of Time Zero (%)
1	15	23 - 1	114	16	106	16.2	0.38	2.3	108	104
		23 - 2	115	16	107					
		23 - 3	116	17	111					
2	150	23 - 4	117	149	99.3	153	4.0	2.6	102	103
		23 - 5	118	153	102					
		23 - 6	119	157	105					
3	350	23 - 7	120	354	101	333	18	5.4	95.2	106
		23 - 8	121	323	92.3					
		23 - 9	122	323	92.3					

* All run numbers are to be identified with an "a" following the run number to create a unique number

Time Zero Conc	(mg/mL)
15	15.6
150	148
350	313

186028.xls 5
Printed: 3/20/03 9:07

Table 6: Homogeneity Analysis Of The 10/14/2002 Formulations

(Analyzed 10/14/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
1	0	31 - 19	159	---------- Not Detected ----------					
2 Top	30	31 - 1	141	30.5	102	29.5	1.4	4.7	98.3
		31 - 2	142	28.5	95.1				
2 Mid	30	31 - 3	143	29.9	99.7	30.0	0.13	0.43	100
		31 - 4	144	30.1	100				
2 Btm	30	31 - 5	145	30.5	102	29.9	0.83	2.8	99.8
		31 - 6	146	29.4	97.8				

186028.xls 6
Printed: 12/23/02 11:14

Table 6: Homogeneity Analysis Of The 10/14/2002 Formulations (continued)

(Analyzed 10/14/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
3 Top	114	31 - 7	147	113	99.1	111	2.5	2.3	97.5
		31 - 8	148	109	95.9				
3 Mid	114	31 - 9	149	112	97.8	113	1.7	1.5	98.9
		31 - 10	150	114	100				
3 Btm	114	31 - 11	151	110	96.8	112	2.8	2.5	98.5
		31 - 12	152	114	100				

186028.xls 6
Printed: 12/23/02 11:20

Table 6: Homogeneity Analysis Of The 10/14/2002 Formulations (Continued)

(Analyzed 10/14/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
4 Top	207	31 - 13	153	194	93.8	196	2.3	1.2	94.6
		31 - 14	154	197	95.4				
4 Mid	207	31 - 15	155	189	91.3	199	14	6.9	95.9
		31 - 16	156	208	101				
4 Btm	207	31 - 17	157	187	90.4	187	0.21	0.11	90.3
		31 - 18	158	187	90.2				

186028.xls 6
Printed: 12/23/02 11:22

Table 7: 1-Day Room Temperature Re-Suspension Homogeneity Analysis Of The 10/14/02 Formulations

(Analyzed 10/15/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
2 Top	30	32 - 1	178	34.7	116	34.9	0.29	0.82	116
		32 - 2	179	35.1	117				
2 Btm	30	32 - 5	180	33.2	111	31.6	2.3	7.3	105
		32 - 6	181	30.0	100				
3 Top	114	32 - 7	182	132	116	132	0.59	0.44	116
		32 - 8	183	133	116				
3 Btm	114	32 - 11	184	122	107	126	4.7	3.7	110
		32 - 12	185	129	113				
4 Top	207	32 - 13	186	213	103	215	2.2	1.0	104
		32 - 14	187	216	104				
4 Btm	207	32 - 17	188	226	109	226	12	5.1	109
		32 - 18	189	210	101				

186028.xls 7
Printed: 12/23/02 11:23

Table 8: 10-Day Room Temperature Re-Suspension Homogeneity Analysis Of The 10/14/02 Formulations

10/24 & 25/2002

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
2 Top	30	54 - 1	232	28.6	95.3	29.0	0.54	1.9	96.5
		54 - 2	233	29.3	97.8				
2 Btm	30	54 - 5	180	28.5	95.0	27.6	1.3	4.5	92.1
		54 - 6	181	26.7	89.1				
3 Top	114	54 - 7	182	109	95.6	106	4.4	4.2	92.8
		54 - 8	183	103	90.1				
3 Btm	114	54 - 11	184	113	99.4	112	2.4	2.2	97.9
		54 - 12	185	110	96.4				
4 Top	207	54 - 13	186	227	110	221	7.5	3.4	107
		54 - 14	187	216	104				
4 Btm	207	54 - 17	188	230	111	230	11	5.0	111
		54 - 18	189	214	103				

186028.xls 8
Printed: 3/20/03 9:07

Table 9: Room Temperature Stability Analysis Of The 10/14/02 Formulations

Conc (mg/mL)		Analyzed Conc Time Zero	Analyzed Conc 1-Day	% of Time Zero	Analyzed Conc 10-Day	% of Time Zero
30.0	Top	29.5	34.9	118	29.0	98.3
	Btm	29.9	31.6	106	27.6	92.3
114	Top	111	132	119	106	95.5
	Btm	112	126	113	112	100
207	Top	196	215	110	221	113
	Btm	187	226	121	230	123

186028.xls 9
Printed: 12/23/02 11:27

Table 10: Concentration Analysis Of The 10/21/02 Formulations

(Analyzed 10/21/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
1	0	43 - 7	216	---------- Not Detected ----------					
2	30	43 - 1	210	34.6	115	34	1.3	3.7	112
		43 - 2	211	32.8	109				
3	114	43 - 3	212	124	108	122	2.8	2.3	107
		43 - 4	213	120	105				
4	207	43 - 5	214	225	109	231	8.1	3.5	111
		43 - 6	215	237	114				

186028.xls 10
Printed: 12/23/02 11:28

Table 11: Concentration Analysis Of The 10/28/02 Formulations

(Analyzed 10/28/02)

Group	Dose Conc (mg/mL)	Ref # (186028 -)	Run #	Analyzed Conc (mg/mL)	Percent of Target (%)	Mean Conc (mg/mL)	SD	RSD (%)	Mean Conc % of Target (%)
1	0	65 - 7	262	---------- Not Detected ----------					
2	30	65 - 1	261	30.1	100	29.9	0.39	1.3	100
		65 - 2	262	29.6	98.6				
3	114	65 - 3	263	111	97.6	112	1.4	1.2	98.5
		65 - 4	264	113	99.3				
4	207	65 - 5	265	197	95.3	205	11	5.4	99.1
		65 - 6	266	213	103				

186028.xls 11
Printed: 12/23/02 11:28

Table 12: Purity Assessments

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
08/06/2002	09/06/2002	(2-1)	5478A#1	7	2.711423	5.98268	0.00327	**99.91**
		Drum - beginning of use			2.917656	6.268926	0.00343	
					3.123523	5.213807	0.00285	
					3.409962	26.275122	0.01438	
					3.897737	38.06366	0.02084	
					4.359343	3.667321	0.00201	
					4.984481	3.274393	0.00179	
					5.086939	32.532608	0.01781	
					6.634102	**182529.69**	**99.91428**	
					7.061027	8.02707	0.00439	
					7.558275	5.15732	0.00282	
					7.785835	2.495452	0.00137	
					8.014593	2.651332	0.00145	
					8.134647	5.044788	0.00276	
					8.870699	2.02737	0.00111	
					13.429071	7.951958	0.00435	
					15.146688	1.964525	0.00108	

186028.xls purity assay 12
Printed: 3/20/03 9:41

Table 12: Purity Assessments (Continued)

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
08/06/2002	09/06/2002	(2-1)	5478A#1	8	2.711517	6.63165	0.00329	
		Drum - beginning of use			2.917901	6.900122	0.00342	
					3.123748	5.658282	0.00281	
					3.410477	29.12306	0.01444	
					3.897815	42.792351	0.02122	
					4.372937	3.754936	0.00186	
					5.00056	3.53478	0.00175	
					5.087614	36.404327	0.01805	
					6.650377	**201499.55**	**99.91389**	
					7.066809	8.852339	0.00439	
					7.561721	5.739807	0.00285	
					7.789414	2.754107	0.00137	
					8.017316	2.856421	0.00142	
					8.136481	5.566246	0.00276	
					8.871601	2.233625	0.00111	
					13.429648	8.749722	0.00434	
					15.147553	2.112108	0.00105	

186028.xls purity assay 12
Printed: 3/20/03 9:41

Table 12: Purity Assessments (Continued)

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
08/06/2002	09/06/2002	(2-2)	5478A#1	11	2.711375	5.579626	0.00327	**99.91**
		Drum - beginning of use			2.917361	5.875445	0.00344	
					3.123464	4.859771	0.00285	
					3.409965	24.452515	0.01434	
					3.897683	35.846466	0.02102	
					4.350902	3.69442	0.00217	
					4.972477	3.273101	0.00192	
					5.087176	30.304375	0.01777	
					6.62267	**170418.83**	**99.91358**	
					7.056819	7.559545	0.00443	
					7.555912	4.904139	0.00288	
					7.784864	2.302898	0.00135	
					8.013204	2.473817	0.00145	
					8.133306	4.809875	0.00282	
					8.869012	1.93855	0.00114	
					13.426006	7.682477	0.00450	
					15.146304	1.846493	0.00108	

186028.xls purity assay 12
Printed: 3/20/03 9:41

Table 12: Purity Assessments (Continued)

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
08/06/2002	09/06/2002	(2-2)	5478A#1	12	2.710883	5.44895	0.00329	
		Drum - beginning of use			2.916958	5.722741	0.00346	
					3.123012	4.768764	0.00288	
					3.409086	23.632627	0.01429	
					3.897211	34.77478	0.02102	
					4.346218	3.459921	0.00209	
					4.967479	3.11865	0.00189	
					5.086627	29.377718	0.01776	
					6.616831	**165273.73**	**99.91396**	
					7.054683	7.31943	0.00442	
					7.554741	4.716537	0.00285	
					7.783494	2.158784	0.00131	
					8.011359	2.356402	0.00142	
					8.132483	4.540479	0.00274	
					8.868167	1.81912	0.00110	
					13.428266	7.363625	0.00445	
					15.146001	1.745767	0.00106	

186028.xls purity assay 12
Printed: 3/20/03 9:41

Table 12: Purity Assessments (Continued)

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
12/05/2002	12/06/2002	(74-1)	5478A#1	277	2.680	2.94958	0.00307	**99.91**
		Drum - end of use			2.902	3.20297	0.00334	
					3.128	2.26344	0.00236	
					3.419	13.37419	0.01393	
					3.947	19.00739	0.01980	
					4.226	2.29497	0.00239	
					4.314	2.64867	0.00276	
					4.630	1.05674	0.00110	
					4.940	2.22289	0.00232	
					5.168	17.40657	0.01813	
					6.620	**95917.8**	**99.90544**	
					6.702	1.83527	0.00191	
					7.124	4.88048	0.00508	
					7.642	3.16249	0.00329	
					7.878	1.77332	0.00185	
					8.105	1.70323	0.00177	
					8.228	3.38153	0.00352	
					8.968	1.35178	0.00141	
					13.539	4.42698	0.00461	
					15.263	1.84027	0.00192	

186028.xls purity assay 12
Printed: 3/20/03 9:41

Table 12: Purity Assessments (Continued)

Collected Date	Analyzed Date	Reference # (186028-)	Sample ID	Run Number	Retention Time	Area Response	Area (%)	Mean Area %
12/05/2002	12/06/2002	(74-1)	5478A#1	278	2.688	1.94593	0.00307	
		Drum - end of use			2.901	2.13736	0.00337	
					3.127	1.4337	0.00226	
					3.416	8.81472	0.01391	
					3.946	13.19666	0.02083	
					4.221	1.69923	0.00268	
					4.291	1.80276	0.00285	
					4.912	1.49702	0.00236	
					5.166	11.55893	0.01825	
					6.578	**63290.7**	99.9094	
					6.676	1.07318	0.00169	
					7.115	3.25552	0.00514	
					7.638	2.1122	0.00333	
					7.875	0.889219	0.00140	
					8.101	1.14262	0.00180	
					8.225	2.21677	0.00350	
					8.966	0.918834	0.00145	
					13.540	0.343145	0.000542	
					15.263	1.38341	0.00218	

186028.xls purity assay 12
Printed: 3/20/03 9:41

ATTACHMENT I

Supporting Data

Table 1a: Calibration Standard Data
(Analyzed 10/2/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	SD	RSD (%)	Response Factor (Mean Area/Conc.)
1	12 - 3	42	7581	7508	213	2.8	7.51E+03
	12 - 4	43	7268				
	12 - 5	44	7674				
3	12 - 6	45	23193	21747	1347	6.2	7.25E+03
	12 - 7	46	20528				
	12 - 8	47	21521				
5	12 - 9	48	33076	35557	2196	6.2	7.11E+03
	12 - 10	49	37250				
	12 - 11	50	36344				
7	12 - 12	51	51374	53025	2885	5.4	7.58E+03
	12 - 13	52	56357				
	12 - 14	53	51345				
10	12 - 15	54	72384	73186	1517	2.07	7.32E+03
	12 - 16	55	72238				
	12 - 17	56	74935				
						Overall Mean	7.35E+03
						SD	1.9E+02
						RSD (%)	2.6

186028.xls val 1
Printed: 12/23/02 11:28

Table 1b: Calibration Curve Data
(Analyzed 10/2/02)

Ref # 186028- -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
12 - 3	8.93340	0.000000	0.000000	1	1.2
12 - 4	8.89124	0.000000	0.000000	1	-3.2
12 - 5	8.94559	0.000000	0.000000	1	2.5
12 - 6	10.05161	1.098612	1.206949	3	6.8
12 - 7	9.92955	1.098612	1.206949	3	-5.5
12 - 8	9.97678	1.098612	1.206949	3	-0.90
12 - 9	10.40656	1.609438	2.590290	5	-8.7
12 - 10	10.52541	1.609438	2.590290	5	2.6
12 - 11	10.50078	1.609438	2.590290	5	0.18
12 - 12	10.84689	1.945910	3.786566	7	0.32
12 - 13	10.93946	1.945910	3.786566	8	9.7
12 - 14	10.84632	1.945910	3.786566	7	0.27
12 - 15	11.18974	2.302585	5.301898	10	-2.3
12 - 16	11.18772	2.302585	5.301898	10	-2.5
12 - 17	11.22438	2.302585	5.301898	10	0.95

A	B	C	R^2
0.0228	0.9429	8.922	0.9969



186028.xls val 1
Printed: 3/20/03 9:57

Table 1c: Calibration Standards, Quality Controls
(Analyzed 10/2/02)

Ref #	Run #	Theo.	Area	ln Area	Conc.	Mean	SD	RSD	% RE
)		(µg/mL)			µg/mL				
Calibration Standards									
12 - 3	42	1.00	7581	8.93	1.01	1.0	0.030	3.0	0.142
12 - 4	43		7268	8.89	0.968				
12 - 5	44		7674	8.95	1.02				
12 - 6	45	3.00	23193	10.1	3.21	3.0	0.19	6.2	0.15
12 - 7	46		20528	9.93	2.83				
12 - 8	47		21521	9.98	2.97				
12 - 9	48	5.00	33076	10.41	4.56	4.9	0.30	6.1	-2.0
12 - 10	49		37250	10.53	5.13				
12 - 11	50		36344	10.50	5.01				
12 - 12	51	7.00	51374	10.85	7.02	7.2	0.38	5.3	3.4
12 - 13	52		56357	10.94	7.68				
12 - 14	53		51345	10.85	7.02				
12 - 15	54	10.0	72384	11.19	9.77	10	0.20	2.0	-1.3
12 - 16	55		72238	11.19	9.75				
12 - 17	56		74935	11.22	10.1				
		Conc.			Conc.				
Quality Control Sam		mg/mL			mg/mL				
13 - 1	58	15	42965	10.7	14.8	15	0.4	2.8	-1.6
13 - 2	59		45389	10.7	15.6				3.8
13 - 3	60		43595	10.7	15.0				-0.23
13 - 4	61	150	37035	10.5	159	149	9.0	6.0	6.3
13 - 5	62		32946	10.4	142				-5.3
13 - 6	63		34045	10.4	147				-2.2
13 - 7	64	350	52548	10.9	359	350	8.8	2.5	2.5
13 - 8	65		51186	10.8	350				-0.034
13 - 9	66		49890	10.8	341				-2.5

186028.xls val 1
Printed: 3/20/03 10:26

Table 2a: Calibration Standard Data
(Analyzed 10/2/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	SD	RSD (%)	Response Factor Mean Area/Conc.
1	14 - 3	68	9462	9197	424	4.6	9.20E+03
	14 - 4	69	8708				
	14 - 5	70	9420				
3	14 - 6	71	25524	25092	746	3.0	8.36E+03
	14 - 7	72	24231				
	14 - 8	73	25522				
5	14 - 9	74	38888	40422	1614	4.0	8.08E+03
	14 - 10	75	42106				
	14 - 11	76	40273				
7	14 - 12	78	54852	58417	3107	5.3	8.35E+03
	14 - 13	79	60547				
	14 - 14	80	59852				
10	14 - 15	81	75605	80666	4652	5.77	8.07E+03
	14 - 16	82	81638				
	14 - 17	83	84756				
						Overall Mean	8.41E+03
						SD	4.6E+02
						RSD (%)	5.5

186028.xls val 2
Printed: 3/20/03 10:26

Table 2b: Calibration Curve Data
(Analyzed 10/2/02)

Ref # 186028- -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
14 - 3	9.15504	0.000000	0.000000	1.0	3.4
14 - 4	9.07200	0.000000	0.000000	0.94	-5.8
14 - 5	9.15059	0.000000	0.000000	1.0	2.9
14 - 6	10.14737	1.098612	1.206949	3.1	1.8
14 - 7	10.09539	1.098612	1.206949	2.9	-3.7
14 - 8	10.14730	1.098612	1.206949	3.1	1.8
14 - 9	10.56844	1.609438	2.590290	4.7	-5.2
14 - 10	10.64795	1.609438	2.590290	5.1	2.9
14 - 11	10.60344	1.609438	2.590290	4.9	-1.7
14 - 12	10.91239	1.945910	3.786566	6.7	-3.8
14 - 13	11.01118	1.945910	3.786566	7.4	6.3
14 - 14	10.99963	1.945910	3.786566	7.4	5.1
14 - 15	11.23328	2.302585	5.301898	9.3	-7.1
14 - 16	11.31005	2.302585	5.301898	10.0	0.30
14 - 17	11.34753	2.302585	5.301898	10.4	4.09

A	B	C	R^2
0.0266	0.8863	9.125	0.9972



186028.xls val 2
Printed: 3/20/03 14:38

Table 2c: Calibration Standards, Quality Controls
(Analyzed 10/2/02)

Ref #)	Run #	Theo. (µg/mL)	Area	ln Area	Conc. µg/mL	Mean	SD	RSD	% RE
Calibration Standards									
14 - 3	68	1.00	9462	9.16	1.03	1.0	0.052	5.2	0.19
14 - 4	69		8708	9.07	0.942				
14 - 5	70		9420	9.15	1.03				
14 - 6	71	3.00	25524	10.1	3.05	3.0	0.094	3.1	-0.057
14 - 7	72		24231	10.10	2.89				
14 - 8	73		25522	10.15	3.05				
14 - 9	74	5.00	38888	10.57	4.74	4.9	0.20	4.1	-1.4
14 - 10	75		42106	10.65	5.14				
14 - 11	76		40273	10.60	4.91				
14 - 12	78	7.00	54852	10.91	6.74	7.2	0.39	5.4	2.5
14 - 13	79		60547	11.01	7.44				
14 - 14	80		59852	11.00	7.36				
14 - 15	81	10.0	75605	11.23	9.29	10	0.57	5.7	-0.89
14 - 16	82		81638	11.31	10.0				
14 - 17	83		84756	11.35	10.4				
		Conc.			Conc.				
Quality Control Sam		mg/mL			mg/mL				
15 - 1	85	15	52251	10.9	16.0	16	0.51	3.1	6.9
15 - 2	86		53077	10.9	16.3				8.6
15 - 3	87		55403	10.9	17.0				13
15 - 4	88	150	36221	10.5	138	143	4.5	3.2	-8.3
15 - 5	89		38458	10.6	146				-2.4
15 - 6	90		37734	10.5	144				-4.3
15 - 7	91	350	59839	11.0	368	344	21.4	6.2	5.1
15 - 8	92		53248	10.9	327				-6.6
15 - 9	93		54794	10.9	336				-3.9

186028.xls val 2
Printed: 3/20/03 14:42

Table 3a: Calibration Standard Data
(Analyzed 10/4/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	SD	RSD (%)	Response Factor (Mean Area/Conc.)
1	22 - 3	99	6978	6920	634	9.2	6.92E+03
	22 - 4	100	6259				
	22 - 5	100a	7523				
3	22 - 6	101	21662	23322	1492	6.4	7.77E+03
	22 - 7	102	23751				
	22 - 8	103	24553				
5	22 - 9	104	39165	38767	1456	3.8	7.75E+03
	22 - 10	105	37154				
	22 - 11	106	39983				
7	22 - 12	107	51054	54816	3662	6.7	7.83E+03
	22 - 13	108	55027				
	22 - 14	109	58368				
10	22 - 15	110	79208	78818	3811	4.84	7.88E+03
	22 - 16	111	74827				
	22 - 17	112	82420				
						Overall Mean	7.63E+03
						SD	4.0E+02
						RSD (%)	5.3

186028.xls val 3
Printed: 12/23/02 11:28

Table 3b: Calibration Curve Data
(Analyzed 10/4/02)

Ref # (186028- -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
22 - 3	8.85052	0.000000	0.000000	1.0	0.80
22 - 4	8.74178	0.000000	0.000000	0.92	-8.4
22 - 5	8.92572	0.000000	0.000000	1.1	7.7
22 - 6	9.98331	1.098612	1.206949	2.8	-5.6
22 - 7	10.07538	1.098612	1.206949	3.1	3.0
22 - 8	10.10859	1.098612	1.206949	3.2	6.3
22 - 9	10.57554	1.609438	2.590290	5.0	0.018
22 - 10	10.52283	1.609438	2.590290	4.8	-5.0
22 - 11	10.59621	1.609438	2.590290	5.1	2.1
22 - 12	10.84064	1.945910	3.786566	6.5	-7.2
22 - 13	10.91558	1.945910	3.786566	7.0	-0.00035
22 - 14	10.97452	1.945910	3.786566	7.4	6.1
22 - 15	11.27983	2.302585	5.301898	10.1	1.2
22 - 16	11.22293	2.302585	5.301898	9.6	-4.5
22 - 17	11.31958	2.302585	5.301898	10.5	5.5

A	B	C	R^2
-0.0340	1.1321	8.841	0.9960



186028.xls val 3
Printed: 3/20/03 14:42

Table 3c: Calibration Standards, Quality Controls
(Analyzed 10/4/02)

Ref #	Run #	Theo.	Area	ln Area	Conc.	Mean	SD	RSD	% RE
(186028 -)		(µg/mL)			µg/mL				
Calibration Standards									
22 - 3	99	1.00	6978	8.85	1.01	1.0	0.081	8.1	0.048
22 - 4	100		6259	8.74	0.916				
22 - 5	100a		7523	8.93	1.08				
22 - 6	101	3.00	21662	10.0	2.83	3.0	0.184	6.1	1.2
22 - 7	102		23751	10.08	3.09				
22 - 8	103		24553	10.11	3.19				
22 - 9	104	5.00	39165	10.58	5.00	5.0	0.18	3.7	-1.0
22 - 10	105		37154	10.52	4.75				
22 - 11	106		39983	10.60	5.10				
22 - 12	107	7.00	51054	10.84	6.50	7.0	0.47	6.7	-0.37
22 - 13	108		55027	10.92	7.00				
22 - 14	109		58368	10.97	7.43				
22 - 15	110	10.0	79208	11.28	10.1	10	0.50	5.0	0.74
22 - 16	111		74827	11.22	9.55				
22 - 17	112		82420	11.32	10.5				

		Conc.			Conc.				
Quality Control Sample		mg/mL			mg/mL				
23 - 1	114	15	48699	10.8	15.5	15.6	0.34	2.2	3.3
23 - 2	115		48449	10.8	15.4				2.8
23 - 3	116		50412	10.8	16.0				6.9
23 - 4	117	150	37732	10.5	151	148	5.9	4.0	0.46
23 - 5	118		35429	10.5	142				-5.5
23 - 6	119		38309	10.6	153				2.0
23 - 7	120	350	52006	10.9	331	313	15.3	4.9	-5.5
23 - 8	121		47889	10.8	305				-13
23 - 9	122		47752	10.8	304				-13

186028.xls val 3
Printed: 3/20/03 14:49

Table 4a: Calibration Standard Data
(Analyzed 10/7/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #*	Area	Mean Area	SD	RSD (%)	Response Factor (Mean Area/Conc.)
1	22 - 3	99	5974	6571	546	8.3	6.57E+03
	22 - 4	100	6695				
	22 - 5	101	7045				
3	22 - 6	102	22957	23455	722	3.1	7.82E+03
	22 - 7	103	24283				
	22 - 8	104	23124				
5	22 - 9	105	37703	37186	1698	4.6	7.44E+03
	22 - 10	106	35290				
	22 - 11	107	38565				
7	22 - 12	108	50803	50849	1180	2.3	7.26E+03
	22 - 13	109	52051				
	22 - 14	110	49692				
10	22 - 15	111	75082	78557	3255	4.14	7.86E+03
	22 - 16	112	79052				
	22 - 17	113	81536				
						Overall Mean	7.39E+03
						SD	5.2E+02
						RSD (%)	7.1

* All run numbers are to be identified with an "a" following the run number to create a unique number

186028.xls 4 processed samp stab
Printed: 12/23/02 11:28

Table 4b: Calibration Curve Data
(Analyzed 10/7/02)

Ref # 186028- -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
22 - 3	8.69517	0.000000	0.000000	0.9	-8.45
22 - 4	8.80912	0.000000	0.000000	1.01	1.0
22 - 5	8.86007	0.000000	0.000000	1.1	5.6
22 - 6	10.04138	1.098612	1.206949	3.1	2.4
22 - 7	10.09753	1.098612	1.206949	3.2	8.0
22 - 8	10.04863	1.098612	1.206949	3.1	3.1
22 - 9	10.53749	1.609438	2.590290	5.0	-0.987
22 - 10	10.47135	1.609438	2.590290	4.6	-7.2
22 - 11	10.56010	1.609438	2.590290	5.1	1.2
22 - 12	10.83571	1.945910	3.786566	6.7	-4.9
22 - 13	10.85998	1.945910	3.786566	6.8	-2.6
22 - 14	10.81360	1.945910	3.786566	6.5	-7.0
22 - 15	11.22634	2.302585	5.301898	9.9	-0.82
22 - 16	11.27786	2.302585	5.301898	10.5	4.7
22 - 17	11.30880	2.302585	5.301898	10.8	8.1

A	B	C	R^2
-0.0421	1.1551	8.797	0.9959



186028.xls 4 processed samp stab
Printed: 3/20/03 14:57

Table 4c: Calibration Standards, 3-day Processed Sample Stability
(Analyzed 10/7/02)

Ref #	Run # *	Theo.	Area	ln Area	Conc.	Mean	SD	RSD	% RE
(186028 -)		(µg/mL)			µg/mL				
Calibration Standards									
22 - 3	99	1.00	5974	8.70	0.92	1.0	0.072	7.2	-0.620
22 - 4	100		6695	8.81	1.010				
22 - 5	101		7045	8.86	1.06				
22 - 6	102	3.00	22957	10.0	3.07	3.1	0.091	2.9	4.5
22 - 7	103		24283	10.10	3.24				
22 - 8	104		23124	10.05	3.09				
22 - 9	105	5.00	37703	10.54	4.95	4.9	0.22	4.5	-2.3
22 - 10	106		35290	10.47	4.64				
22 - 11	107		38565	10.56	5.06				
22 - 12	108	7.00	50803	10.84	6.65	6.7	0.16	2.3	-4.85
22 - 13	109		52051	10.86	6.82				
22 - 14	110		49692	10.81	6.51				
22 - 15	111	10.0	75082	11.23	9.9	10	0.45	4.3	3.98
22 - 16	112		79052	11.28	10.5				
22 - 17	113		81536	11.31	10.8				
		Conc.			Conc.				
Quality Control Samples		mg/mL			mg/mL				
23 - 1	114	15	48633	10.8	15.9	16	0.38	2.4	6.2
23 - 2	115		48751	10.8	16.0				6.4
23 - 3	116		50709	10.8	16.6				11
23 - 4	117	150	36352	10.5	149	153	3.7	2.4	-0.48
23 - 5	118		37234	10.5	153				1.9
23 - 6	119		38182	10.6	157				4.4
23 - 7	120	350	54021	10.9	354	333	17.7	5.3	1.1
23 - 8	121		49389	10.8	323				-7.6
23 - 9	122		49331	10.8	323				-7.7

* All run numbers are to be identified with an "a" following the run number to create a unique number

186028.xls 4 processed samp stab
Printed: 12/23/02 11:28

Table 5a: Calibration Standard Data
(Analyzed 10/14/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	Response Factor (Mean Area/Conc.)
1	29 3*	126	21274	21274	2.13E+04
3	29 - 4	127	22778	22778	7.59E+03
5	29 - 5	128	38469	38469	7.69E+03
7	29 - 6	129	57258	57258	8.18E+03
10	29 - 7	130	97864	97864	9.79E+03
				Overall Mean	8.31E+03
				SD	1.0E+03
				RSD (%)	12.2

* Possible preperation error, not included in calculations

186028.xls 5a
Printed: 12/23/02 11:28

Table 5b: Calibration Curve Data
(Analyzed 10/14/02)

Ref # (186028 -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
29 - 4	10.03355	1.098612	1.206949	3.0	-0.3
29 - 5	10.55761	1.609438	2.590290	5.0	0.928
29 - 6	10.95532	1.945910	3.786566	6.9	-0.9
29 - 7	11.49133	2.302585	5.301898	10.0	0.3
29 3*	9.96524	0.000000	0.000000	2.8	175.31

A	B	C	R^2
0.2957	0.1994	9.460	0.9997



* Possible preperation error, not included in calculations

186028.xls 5a
Printed: 3/20/03 15:09

Table 5c: Calibration Standards, Quality Controls
(Analyzed 10/14/02)

Ref # (186028 -)	Run #	Theo. (µg/mL)	Area	ln Area	Conc. µg/mL	Mean	SD	RSD	% RE
Calibration Standards									
29 3*	126	1.00	21274	9.97	2.75	2.8			175
29 - 4	127	3.00	22778	10.0	2.99	3.0			-0.29
29 - 5	128	5.00	38469	10.56	5.05	5.0			0.93
29 - 6	129	7.00	57258	10.96	6.94	6.9			-0.92
29 - 7	130	10.0	97864	11.49	10.0	10			0.27
Quality Control Samples		Theo. Conc. mg/mL			Conc. mg/mL				
30 - 1	132	15	49011	10.8	15.4	16	0.43	2.7	2.6
30 - 2	133		52579	10.9	16.3				8.4
30 - 3	134		51212	10.8	15.9				6.2
30 - 4	135	150	39746	10.6	162	163	1.9	1.2	8.1
30 - 5	136		39817	10.6	162				8.3
30 - 6	137		40749	10.6	166				10
30 - 7	138	350	57625	11.0	348	345	6.4	1.9	-0.45
30 - 8	139		57942	11.0	350				-0.046
30 - 9	140		55345	10.9	338				-3.4

* Possible preperation error, not included in calculations

186028.xls 5a
Printed: 12/23/02 11:28

Table 5d: Homogeneity Samples
(Analyzed 10/14/02)

Ref # (186028 -)	Run #	Target mg/mL	Area	ln Area	Conc. mg/mL	Mean	SD	RSD	% of Target
Homogeneity Samples									
31 - 1	141	30	48362	10.79	30.5	29	1.4	4.7	102
31 - 2	142		44527	10.70	28.5				95.1
31 - 3	143	30	47215	10.76	29.9	30	0.1	0.4	99.7
31 - 4	144		47580	10.77	30.1				100
31 - 5	145	30	48473	10.79	30.5	30	0.8	2.8	102
31 - 6	146		46140	10.74	29.4				97.8
31 - 7	147	114	43979	10.69	113	111	2.5	2.3	99.1
31 - 8	148		42290	10.65	109				95.9
31 - 9	149	114	43312	10.68	112	113	1.7	1.5	97.8
31 - 10	150		44467	10.70	114				100.0
31 - 11	151	114	42756	10.66	110	112	2.8	2.5	96.8
31 - 12	152		44642	10.71	114				100
31 - 13	153	207	36804	10.51	194	196	2.3	1.2	93.8
31 - 14	154		37495	10.53	197				95.4
31 - 15	155	207	35686	10.48	189	199	13.6	6.9	91.3
31 - 16	156		39893	10.59	208				101
31 - 17	157	207	35295	10.47	187	187	0.2	0.1	90.4
31 - 18	158		35233	10.47	187				90.2
31 - 19	159	0	0.00000	-----	-----	----	----	----	----

186028.xls 5a
Printed: 12/23/02 11:28

Table 6a: Calibration Standard Data
(Analyzed 10/15/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	Response Factor (Mean Area/Conc.)
1	33 - 3	163	6641	6641	6.64E+03
3	33 - 4	164	23828	23828	7.94E+03
5	33 - 5	165	39116	39116	7.82E+03
7	33 - 6	166	50930	50930	7.28E+03
10	33 - 7	167	78223	78223	7.82E+03

Overall Mean	7.50E+03
SD	5.5E+02
RSD (%)	7.3

186028.xls 6a
Printed: 12/23/02 11:28

Table 6b: Calibration Curve Data
(Analyzed 10/15/02)

Ref # (186028 -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
33 - 3	8.80102	0.000000	0.000000	1.0	-0.59
33 - 4	10.07862	1.098612	1.206949	3.1	2.9
33 - 5	10.57429	1.609438	2.590290	5.0	0.19
33 - 6	10.83821	1.945910	3.786566	6.6	-6.2
33 - 7	11.26732	2.302585	5.301898	10	4.1

A	B	C	R^2
-0.0633	1.1980	8.808	0.9983



186028.xls 6a
Printed: 3/20/03 15:09

Table 6c: Calibration Standards, Quality Controls
(Analyzed 10/15/02)

Ref # (186028 -)	Run #	Theo. (µg/mL)	Area	ln Area	Conc. µg/mL	Mean	SD	RSD	% RE
Calibration Standards									
33 - 3	163	1.00	6641	8.80	0.99	1.0			-0.59
33 - 4	164	3.00	23828	10.1	3.09	3.1			2.9
33 - 5	165	5.00	39116	10.57	5.01	5.0			0.19
33 - 6	166	7.00	50930	10.84	6.56	6.6			-6.2
33 - 7	167	10.0	78223	11.27	10.4	10			4.1
Quality Control Samples		Theo. Conc. mg/mL			Conc. mg/mL				
34 - 1	168	15	47042	10.8	15.1	15	0.20	1.3	0.75
34 - 2	169		47011	10.8	15.1				0.68
34 - 3	170		48085	10.8	15.5				3.1
34 - 4	171	150	35384	10.5	142	135	7.2	5.4	-5.6
34 - 5	172		33997	10.4	136				-9.3
34 - 6	173		31750	10.4	127				-15
34 - 7	191	350	52671	10.9	340	357	26.7	7.5	-3
34 - 8	192		53294	10.9	344				-2
34 - 9	193		59720	11.0	388				11

186028.xls 6a
Printed: 12/23/02 11:28

Table 6d: 1-Day Re-Suspension Homogeneity Samples
(Analyzed 10/15/02)

Ref # (186028 -)	Run #	Target mg/mL	Area	ln Area	Conc. mg/mL	Mean	SD	RSD	% of Target
1-Day Re-Suspension Homogeneity Samples									
32 - 1	178	30	53724	10.89	34.7	35	0.29	0.82	116
32 - 2	179		54324	10.90	35.1				117
32 - 3	180	30	51551	10.85	33.2	32	2.29	7.25	111
32 - 4	181		46688	10.75	30.0				100
32 - 5	182	114	51186	10.84	132	132	0.6	0.4	116
32 - 6	183		51494	10.85	133				116
32 - 7	184	114	47543	10.77	122	126	4.7	3.7	107
32 - 8	185		50020	10.82	129				113
32 - 9	186	207	41565	10.64	213	215	2.2	1.0	103
32 - 10	187		42173	10.65	216				104
32 - 11	188	207	44087	10.69	226	218	11.6	5.3	109
32 - 12	189		40954	10.62	210				101

186028.xls 6a
Printed: 12/23/02 11:28

Table 7a: Calibration Standard Data
(Analyzed 10/21/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	Response Factor Mean Area/Conc
1	41 - 3	194	10464	10464	1.05E+04
3	41 - 4	195	23788	23788	7.93E+03
5	41 - 5	196	38613	38613	7.72E+03
7	41 - 6	197	54321	54321	7.76E+03
10	41 - 7	198	81359	81359	8.14E+03
				Overall Mean	8.40E+03
				SD	1.2E+03
				RSD (%)	13.9

186028.xls 7a
Printed: 3/20/03 15:09

Table 7b: Calibration Curve Data
10/21/2002

Ref # (186028 -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
41 - 3	9.25570	0.000000	0.000000	1.0	0.02
41 - 4	10.07694	1.098612	1.206949	3.0	-0.2
41 - 5	10.56134	1.609438	2.590290	5.0	0.40
41 - 6	10.90267	1.945910	3.786566	7.0	-0.4
41 - 7	11.30663	2.302585	5.301898	10	0.1

A	B	C	R^2
0.1175	0.6198	9.256	1.0000



186028.xls 7a
Printed: 3/20/03 15:09

Table 7c: Calibration Standards, Quality Controls
10/21/2002

Ref # (186028 -)	Run #	Theo. (µg/mL)	Area	ln Area	Conc. µg/mL	Mean	SD	RSD	% RE
Calibration Standards									
41 - 3	194	1.00	10464	9.26	1.00	1.0			0.016
41 - 4	195	3.00	23788	10.1	3.00	3.0			-0.15
41 - 5	196	5.00	38613	10.56	5.02	5.0			0.40
41 - 6	197	7.00	54321	10.90	6.98	7.0			-0.35
41 - 7	198	10.0	81359	11.31	10.0	10			0.094
Quality Control Samples		Theo. Conc. mg/mL			Conc. mg/mL				
42 - 1	199	15	53651	10.9	17.2	16	0.90	5.6	15
42 - 2	200		47872	10.8	15.5				3.2
42 - 3	201		49503	10.8	16.0				6.6
42 - 4	202	150	40363	10.6	164	159	4.5	2.8	9.3
42 - 5	203		38149	10.5	155				3.3
42 - 6	204		39190	10.6	159				6.1
42 - 7	205	350	56828	10.9	364	360	4.5	1.2	3.9
42 - 8	206		55334	10.9	355				1.4
42 - 9	207		56290	10.9	360				3.0

186028.xls 7a
Printed: 3/21/03 10:18

Table 7d: Concentration Analysis of the 10/21/02 Formulations
10/21/2002

Ref # (186028 -)	Run #	Target mg/mL	Area	ln Area	Conc. mg/mL	Mean	SD	RSD	% of Target
Concentration Analysis of the 10/21/02 Formulations									
32 - 1	210	30	53882	10.89	34.6	34	1.25	3.71	115
32 - 2	211		50941	10.84	32.8				109
32 - 3	212	114	47797	10.77	124	122	2.75	2.26	108
32 - 4	213		46227	10.74	120				105
32 - 5	214	207	43333	10.68	225	231	8.1	3.5	109
32 - 6	215		45618	10.73	237				114
32 - 7	216	0	0						

186028.xls 7a
Printed: 3/21/03 10:18

Table 8a: Calibration Standard Data
(Analyzed on 10/24 & 25/2002)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	Response Factor (Mean Area/Conc.)
1	52 - 3	218	8747	8747	8.75E+03
3	52 - 4	219	24677	24677	8.23E+03
5	52 - 5	220	41513	41513	8.30E+03
7	52 - 6	221	53285	53285	7.61E+03
10	52 - 7	222	79534	79534	7.95E+03
				Overall Mean	8.17E+03
				SD	4.2E+02
				RSD (%)	5.2

186028.xls 8a
Printed: 12/23/02 11:28

Table 8b: Calibration Curve Data
(Analyzed on 10/24 & 25/2002)

Ref # (186028 -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
52 - 3	9.07647	0.000000	0.000000	1.0	-0.088
52 - 4	10.11363	1.098612	1.206949	3.0	-0.34
52 - 5	10.63376	1.609438	2.590290	5.2	3.20
52 - 6	10.88341	1.945910	3.786566	6.7	-4.3
52 - 7	11.28394	2.302585	5.301898	10	1.7

A	B	C	R^2
0.0042	0.9416	9.077	0.9990



186028.xls 8a
Printed: 3/20/03 15:42

Table 8c: Calibration Standards, Quality Controls
(Analyzed on 10/24 & 25/2002)

Ref # (186028 -)	Run #	Theo. (µg/mL)	Area	ln Area	Conc. µg/mL	Mean	SD	RSD	% RE
Calibration Standards									
52 - 3	218	1.00	8747	9.08	1.00	1.0			-0.088
52 - 4	219	3.00	24677	10.1	2.99	3.0			-0.34
52 - 5	220	5.00	41513	10.63	5.16	5.2			3.2
52 - 6	221	7.00	53285	10.88	6.70	6.7			-4.3
52 - 7	222	10.0	79534	11.28	10.2	10			1.7
Quality Control Samples		Theo. Conc. mg/mL			Conc. mg/mL				
53 - 1	223	15	44346	10.7	13.8	14	0.36	2.6	-7.9
53 - 2	224		43236	10.7	13.5				-10
53 - 3	225		45435	10.7	14.2				-5.5
53 - 4	226	150	35629	10.5	137	143	4.9	3.4	-8.4
53 - 5	227		37827	10.5	146				-2.5
53 - 6	228		37573	10.5	145				-3.2
53 - 7	229	350	49123	10.8	308	313	5.6	1.8	-12
53 - 8	230		50811	10.8	319				-8.9
53 - 9	231		49693	10.8	311				-11

186028.xls 8a
Printed: 12/23/02 11:28

Table 8d: 10-Day Re-Suspension Homogeneity Samples
(Analyzed on 10/24 & 25/2002)

Ref # (186028 -)	Run #	Target mg/mL	Area	ln Area	Conc. mg/mL	Mean	SD	RSD	% of Target
10-Day Re-Suspension Homogeneity Samples									
54 - 1	232	30	45778	10.73	28.6	29.0	0.54	1.86	95.3
54 - 2	233		46942	10.76	29.3				97.8
54 - 3	234	30	45672	10.73	28.5	27.6	1.3	4.55	95.0
54 - 4	235		42949	10.67	26.7				89.1
54 - 5	236	114	43723	10.69	109	106	4.4	4.2	95.6
54 - 6	237		41320	10.63	103				90.1
54 - 7	238	114	45387	10.72	113	112	2.4	2.2	99.4
54 - 8	239		44082	10.69	110				96.4
54 - 9	240	207	45405	10.72	227	221	7.5	3.4	110
54 - 10	241		43369	10.68	216				104
54 - 11	242	207	46000	10.74	230	222	11	5.1	111
54 - 12	243		42908	10.67	214				103

186028.xls 8a
Printed: 3/20/03 15:42

Table 9a: Calibration Standard Data
(Analyzed 10/28/02)

Ethylbenzene (µg/mL)	Ref # (186028 -)	Run #	Area	Mean Area	Response Factor Mean Area/Conc
1	63 - 3	245	13097	13097	1.31E+04
3	63 - 4	246	38285	38285	1.28E+04
5	63 - 5	247	62222	62222	1.24E+04
7	63 - 6	248	91967	91967	1.31E+04
10	63 - 7	249	137493	137493	1.37E+04
12	63 - 8	250	156379	156379	1.30E+04
				Overall Mean	1.30E+04
				SD	4.4E+02
				RSD (%)	3.3

186028.xls 9a
Printed: 3/20/03 15:42

Table 9b: Calibration Curve Data
(Analyzed 10/28/02)

Ref # (186028 -)	ln Response	ln Conc (µg/mL)	ln Conc^2	Back-Calc. Conc. (µg/mL)	% RE
63 - 3	9.48014	0.000000	0.000000	1.0	0.075
63 - 4	10.55281	1.098612	1.206949	3.0	0.61
63 - 5	11.03846	1.609438	2.590290	4.9	-2.6
63 - 6	11.42919	1.945910	3.786566	7.1	1.3
63 - 7	11.83133	2.302585	5.301898	10	3.6
63 - 8	11.96004	2.484907	6.174761	12	-2.7

A	B	C	R^2
0.0280	0.9408	9.479	0.9992



186028.xls 9a
Printed: 3/20/03 15:47

Table 9c: Calibration Standards, Quality Controls
(Analyzed 10/28/02)

Ref #	Run #	Theo.	Area	ln Area	Conc.	Mean	SD	RSD	% RE
(186028 -)		(µg/mL)			µg/mL				
Calibration Standards									
63 - 3	245	1.00	13097	9.48	1.00	1.0			0.075
63 - 4	246	3.00	38285	10.6	3.02	3.0			0.61
63 - 5	247	5.00	62222	11.04	4.87	4.9			-2.6
63 - 6	248	7.00	91967	11.43	7.09	7.1			1.3
63 - 7	249	10.0	137493	11.83	10.4	10			3.6
63 - 8	250	12.0	156379	11.96	11.7	12			-3.3
		Theo. Conc.			Conc.				
Quality Control Samples		mg/mL			mg/mL				
64 - 1	251	15	71733	11.2	14.0	15	0.56	3.8	-6.9
64 - 2	252		76671	11.2	14.9				-0.73
64 - 3	253		77148	11.3	15.0				-0.13
64 - 4	254	150	63687	11.1	156	160	3.5	2.2	3.7
64 - 5	255		66315	11.1	162				7.9
64 - 6	256		66114	11.1	161				7.6
66 - 1	271	350	81632	11.3	316	339	20.4	6.0	-9.6
66 - 2	272		92059	11.4	355				1.4
66 - 3	273		89980	11.4	347				-0.82

186028.xls 9a
Printed: 3/20/03 16:22

Table 9d: 10-Day Re-Suspension Homogeneity Samples
(Analyzed 10/28/02)

Ref # (186028 -)	Run #	Target mg/mL	Area	ln Area	Conc. mg/mL	Mean	SD	RSD	% of Target
Concentration Analysis of the 10/21/02 Formulations									
65 - 1	261	30	77628	11.26	30.1	30	0.39	1.3	100
65 - 2	262		76158	11.24	29.6				98.6
65 - 3	263	114	71417	11.18	111	112	1.4	1.2	97.6
65 - 4	264		72717	11.19	113				99.3
65 - 5	265	207	63087	11.05	197	205	11	5.4	95.3
65 - 6	266		68292	11.13	213				103
65 - 7	267	0	0						

186028.xls 9a
Printed: 3/20/03 16:24

APPENDIX C

Inhalation Report (WIL Research Laboratories, Inc.)

A Pilot Inhalation Study for
Reproductive Toxicity and Developmental
Neurotoxicity Studies of Ethylbenzene in Rats

TABLE OF CONTENTS

Page

Table Of Contents 1010
Index Of Figures 1011
Index Of Tables 1011
1. Exposure Methods 1012
1.1. Exposure Regimen 1012
1.2. Inhalation Exposure Systems Description 1013
1.3. Animal Transport And Placement 1013
1.4. Exposure Environmental Conditions 1013
2. Test Atmosphere Generation Methods 1014
3. Methods Of Characterization Of Exposure Atmospheres 1016
3.1. Nominal Exposure Concentrations 1016
3.2. Analyzed Exposure Concentrations 1017
3.2.1. Analytical Methods 1017
3.2.2. Gas Chromatograph Calibration 1018
3.3. Determination Of Homogeneity Of Exposure Atmospheres 1020
4. Results Of Characterization Of Exposure Atmospheres 1021
4.1. Nominal Exposure Concentrations 1021
4.2. Analyzed Exposure Concentrations 1021

A Pilot Inhalation Study for
Reproductive Toxicity and Developmental
Neurotoxicity Studies of Ethylbenzene in Rats

INDEX OF FIGURES

Page

1. Schematic Diagram of Generation and Exposure System 1022

INDEX OF TABLES

1. Daily Mean Chamber Temperature (Degrees Celsius) 1024
2. Daily Mean Chamber Relative Humidity (%) 1028
3. Daily Mean Chamber Ventilation Rate (SLPM) 1032
4. Test Atmosphere Homogeneity Determination 1036
5. Daily Chamber Nominal Concentrations (F_0 Generation) 1039
6. Daily Chamber Nominal Concentrations (F_1 Generation) 1042
7. Daily Mean Test Atmosphere Concentrations (F_0 Generation) 1043
8. Daily Mean Test Atmosphere Concentrations (F_1 Generation) 1060

1. EXPOSURE METHODS

1.1. EXPOSURE REGIMEN

The test article or filtered air (control group) was administered as a daily six-hour exposure. Exposures were conducted seven days per week at approximately the same time each day according to the following regimen. F_0 males were exposed for a minimum of 4 weeks. F_0 females were exposed 2 weeks premating, during mating and gestation. At that time the females were divided into 2 subgroups (Inhalation Only Females and Inhalation and Gavage Females).

The Inhalation Only Females were exposed prior to mating, during mating and gestation through gestation day (GD) 20 and on lactation days (LD) 5-27. To avoid confounding effects on nesting and nursing behavior, exposures for the F_0 dams were suspended on GD 21 through LD 4 inclusive; exposures were re-initiated on LD 5 and continued through LD 27. Females that did not deliver were exposed until one day prior to euthanasia.

The Inhalation and Gavage Females were exposed via inhalation as described above. In addition, these dams received test article or vehicle control (corn oil) on LD 1-4 by gavage.

The F_1 generation was potentially exposed *in utero*, and through nursing during lactation. The day following weaning (on PND 21 and PND 28), one F_1 weanling per sex per litter from each of the weaning date cohorts were directly exposed to the same concentration of the test article as their dam through PND 33. Animals in the filtered-air control group were subjected to the identical exposure regimen.

1.2. INHALATION EXPOSURE SYSTEMS DESCRIPTION

Exposures were conducted in four 2.0 m^3 stainless steel and glass whole-body inhalation chambers (NYU-style). One chamber was dedicated for each group for the duration of the study. Chamber supply air was provided from a HEPA- and charcoal-filtered, temperature- and humidity-controlled source.

1.3. ANIMAL TRANSPORT AND PLACEMENT

Animals were individually housed in stainless steel, wire-mesh caging with the following exception. The F_1 weanlings were group housed with their littermates during exposure. Food and water were not available during exposure periods.

Animals were housed in a normal colony room during the non-exposure hours. For each day's exposure, the animals were transferred to exposure caging, transported to the exposure chamber room, exposed for the requisite duration and returned to their home cages.

The cage batteries were rotated on a daily basis through six battery positions in the chambers to help ensure a similar exposure for all animals within each group over the duration of the exposure period.

1.4. EXPOSURE ENVIRONMENTAL CONDITIONS

Temperature, relative humidity, chamber ventilation rate, and negative pressure within the chambers were continually monitored and recorded approximately every 35 minutes through the use of a data acquisition program written in LabVIEW® for Windows® from National Instruments, Inc. (Austin, TX) and a Pentium®-based computer with appropriate hardware.

Chamber temperature and relative humidity were monitored by Omega model no. HX94C temperature and humidity transmitter probes (Omega Engineering, Inc., Stamford, CT). Protocol-defined ranges for daily mean temperature and relative humidity were 18°-26°C and 30-70%, respectively. Airflow through the chamber was monitored by the pressure

drop across a sharp-edge orifice plate as measured by differential pressure gauges (Magnehelic® Indicating Transmitter, Dwyer, Michigan City, IN) and was set such that there were 12-15 air changes per hour. These gauges had been calibrated under the conditions of exposure for conversion from pressure to airflow in liters per minute (LPM) through the use of a FM Series Axial Turbine Flow Transducer and a 915 BATRT Indicator (Flowmetrics, Inc., Chatsworth, CA). Oxygen content was to be at least 19% and was measured during the pre-exposure method development phase with a calibrated oxygen sensor. Oxygen content was at least 21% for all exposure chambers.

Daily means for chamber temperature, relative humidity, and chamber ventilation rate over the study period are presented in Tables 1 through 3. The actual ranges from daily mean temperature and relative humidity were 19-26°C and 38-61%, respectively. The following table summarizes the grand means for environmental conditions for all four-study groups:

	Group 1	Group 2	Group 3	Group 4
Temperature Mean (ºC):	22	22	22	24
Standard Deviation:	0.7	1.2	0.8	0.9
Number of days:	81	81	85	81
Relative Humidity Mean (%):	45	49	52	46
Standard Deviation:	3.0	4.4	4.6	2.8
Number of days:	81	81	85	81
Chamber Ventilation Rate Mean (SLPM):	465	460	492	511
Standard Deviation:	17.3	9.2	13.9	15.7
Number of days:	81	81	85	81

2. TEST ATMOSPHERE GENERATION METHODS

The test atmosphere generation and exposure system is shown schematically in Figure 1. The generation system was operated as follows: Vapors of the test article were generated using a bead column. The test article was introduced to the top of the column, while

nitrogen entering the bottom of the column served as the carrier gas. For groups 2 and 3 the column was 2.4 cm in diameter (ID), 40 cm long and filled with various sized glass beads. For group 4, the column was five cm in diameter (ID), 68 cm long and filled with various sized glass beads. The columns were wrapped with heat tapes (Omega Engineering) that were set to approximately 90-100°C and controlled using an Omega CN370 temperature controller. The test article was vaporized as it dripped from a 1/16-inch Teflon® tubing onto the glass beads contained within each heated column.

The test article was metered from an amber glass reservoir to the capillary tube using a FMI pump (Fluid Metering, Inc., Oyster Bay, NY). Calibrated FMI pumps included a model no. QG-6 pump with a 1/4-inch piston for chambers 2 and 3. A model no. QG-20 pump with a 1/4-inch piston was used for chamber 4. Vaporization nitrogen was delivered from the facility nitrogen generation system and was controlled using calibrated rotameter-type flowmeters (Gilmont Instruments, Barrington, Illinois). The vaporization nitrogen carried the ethylbenzene vapor through Teflon® delivery lines (3/8-inch O.D. tubing) to the chamber inlet where the concentration was reduced to the desired level with chamber ventilation air. The animal exposure was initiated by switching the FMI pumps and the compressed nitrogen on simultaneously. The following table indicates generation and exposure system operating parameters for each exposure group.

Chamber Number	Target Concentration (ppm)	FMI Pump Setting (% Scale)	Test Article Flow Rate (ml/min.)	Nitrogen Flow Rate (LPM)	Nitrogen Regulator Setting (IND.)	Chamber Ventilation (LPM)
1	0	NA	NA	28.2	25	~450
2	100	5-10	0.38-0.48	21.3	20	~450
3	500	55-60	1.3-1.4	19.3	20	~450
4	1000	40-45	2.9-3.2	24.1	25	~450

3. METHODS OF CHARACTERIZATION OF EXPOSURE ATMOSPHERES

3.1. NOMINAL EXPOSURE CONCENTRATIONS

A nominal exposure concentration was calculated for each daily exposure for each chamber from the total amount of test article used during the exposure and the total volume of air passed through the chamber during that day's exposure. The amount of test article used was obtained by weighing the reservoir containing the test article for each chamber prior to and after each day's exposure. The total volume of air passed through each chamber was calculated from the daily average chamber ventilation flow rate in liters per minute (LPM) and the exposure duration. The nominal concentration was calculated as follows:

$$\text{PPM Ethylbenzene} = \frac{\text{Wt. Ethylbenzene} \bullet \text{Mol. Vol.} \bullet 10^6}{\text{MW} \bullet \text{Ch. Flow} \bullet \text{Exp. Dur.}}$$

Where:

Wt. Ethylbenzene	=	Weight of test article in grams
Mol. Vol.	=	Molar volume at 730 mm Hg and 21ºC, 25.11 L/mol
10^6	=	ppm conversion factor
MW	=	Ethylbenzene molecular weight, 106.17 g/mol
Ch. Flow	=	Daily average chamber flowrate for a given day, in LPM
Exp. Dur.	=	Duration of a given day's exposure in minutes

3.2. ANALYZED EXPOSURE CONCENTRATIONS

3.2.1. ANALYTICAL METHODS

Analyzed exposure concentrations were obtained using a gas chromatograph (GC). Samples of the exposure atmospheres were automatically collected at approximately 35-minute intervals using a sample loop and a computer-controlled multiposition valve. The PC-based LabVIEW® data acquisition program also controlled the GC sampling (i.e., the multiposition valve) and acquired peak area values from the GC for the concentration analyses. Except as described below, the program calculated exposure concentrations from the peak area values using a quadratic equation representing the standard curve for the GC calibration (see Section 3.2.2). From the study start on September 6, 2002 through September 27, 2002 (21 days), the exposure concentrations were calculated using two methods, the LabVIEW® program as described above and "manually" by entering the peak area values into a standard EXCEL spreadsheet setup to use the identical calibration quadratic equation. This double calculation was performed to validate the calculations made by the automated data acquisition program. The exposure concentrations reported for September 6 – 27 were calculated using the manual method. However, these values matched those calculated by the automated method. Daily concentration averages were to be within ± 10% of the target concentration, and any individual sample was to be ± 15% of the target concentration. All sampling lines were 1/8-inch stainless steel and were heated to approximately 30ºC using laboratory heating tapes controlled by an Omega CN370 temperature controller. The following table summarizes the GC conditions:

GC Manufacturer ..... Hewlett –Packard
Model No. ..... 5890 Series II

Detector Type ..... FID
Detector Temperature 300ºC

Column Diameter X Length ..... 5 m x 0.25 mm ID
Column Type ..... J & W DB-WAX Narrowbore

Fuel Gas ..... Hydrogen
Fuel Pressure ..... 15 psig
Fuel Flowrate ..... 30 mL/min.

Air Pressure ..... 35 psig
Air Flowrate ..... 310 mL/min.

Carrier Gas ..... Helium
Carrier Gas Pressure ..... 75 psig
Carrier Gas Flowrate ..... 10 mL/min

Injector Temperature 250ºC
Injection Volume ..... 0.25 mL
Retention Time ..... Approx. 1.16 min.

Integrator Manufacturer: HP Model 3396A Series II
Chart Zero Offset 0
Chart Attenuation 9
Chart Speed ..... 1.5 cm/min
Peak Area Rejection Value 0
Peak Threshold 8
Peak Width 0.04

3.2.2. GAS CHROMATOGRAPH CALIBRATION

The GC was standardized using 40-liter Tedlar® gas bags prepared to contain a known concentration of the test article. The standard bags were prepared by metering a known volume of air into the bag using a dry test meter (Model DTM-200A, American Meter Co., Nebraska City, PA). A known volume of test article was injected into the bag using gastight syringes. Using an ordinary household hair dryer, the bag was warmed until total

volatilization was visually observed. A sample was then collected from the bag. Concentrations of the gas-phase standards were calculated as follows:

$$\text{Concentration} = \frac{VOL \bullet R \bullet T \bullet D \bullet 10^{-3} \bullet 10^{6}}{L \bullet GMW \bullet P}$$

Where:
Conc. is in ppm

VOL	=	Volume of test article vaporized into bag in µL
R	=	Universal gas constant, $\frac{62.36 \text{ L mmHg}}{\text{mole K}}$
T	=	Nominal laboratory temperature in K (273 + 21ºC = 294 K)
D	=	Density of the test article, 0.9075 g/ml
L	=	Volume of air used to prepare bag, 30 liters
GMW	=	Gram molecular weight, 106.17 g/mole
P	=	Nominal laboratory barometric pressure, 730 mm Hg
10^{-3}	=	µL to mL conversion factor
10^{6}	=	Conversion factor to ppm

Prior to initiation of dosing, the GC was calibrated using a standard curve constructed by a Quadratic equation developed with the use of five standards. Each standard was prepared in triplicate prior to the exposure period and analyzed with the GC. On October 24, 2002, the GC was re-calibrated and put into use on 10/29/02. The following table defines the standards prepared for this study:

Standard Concentration (ppm)	Volume of Test Article Used (µL)	Volume of Air Used (L)
68	10	30
239	35	30
506	74	30
752	110	30
1196	175	30

On a daily basis, the integrity of the prime calibration curve was checked by analyzing one freshly prepared standard. On a rotational basis, a different one of the five standards was used each day. If the analyzed concentration was within ± 10% of the known concentration, the GC was considered within calibration specifications.

3.3. DETERMINATION OF HOMOGENEITY OF EXPOSURE ATMOSPHERES

Evaluation of the homogeneity of exposure concentrations was accomplished during the method development phase of the study prior to animal exposures. Four test locations and a reference location were used for these determinations. The test locations were Right Upper Front, Left Lower Front, Left Upper Rear and Right Lower Rear identified as 1, 2, 3 and 4, respectively. Samples were collected as rapidly as possible, always collecting a sample from the reference location and then from one of the four test locations. For each test location, the measured concentration was calculated as a percent difference from the reference location. The homogeneity determination was performed in triplicate for each test article exposure chamber. The results are presented in Table 4 of this appendix. The following table summarizes these data as the mean of the replicates for each chamber.

Chamber Number	Test Location	Mean % From Reference
2	1	-4.32
	2	-0.88
	3	-5.64
	4	-2.38
3	1	-4.67
	2	-0.57
	3	-2.20
	4	-3.42
4	1	-2.80
	2	-3.49
	3	-3.26
	4	-2.80

These data indicate that homogeneity of exposure atmospheres were adequate for the purpose of this study.

4. RESULTS OF CHARACTERIZATION OF EXPOSURE ATMOSPHERES

4.1. NOMINAL EXPOSURE CONCENTRATIONS

The overall mean nominal concentrations for the F_0 generation were 107 ppm, 510 ppm and 1015 ppm for groups 2, 3 and 4, respectively. The overall mean nominal concentrations for the F_1 generation were 108 ppm, 515 ppm and 992 ppm for groups 2, 3 and 4, respectively. Daily mean nominal concentrations for each generation are presented in Tables 5 and 6 of this appendix.

4.2. ANALYZED EXPOSURE CONCENTRATIONS

The overall mean analyzed concentrations for the F_0 generation were 99 ppm, 500 ppm and 1008 ppm for groups 2, 3 and 4, respectively. The overall mean analyzed concentrations for the F_1 generation were 101 ppm, 498 ppm and 1002 ppm for groups 2, 3 and 4, respectively. Daily mean test atmosphere concentrations for each generation are presented in Tables 7 and 8 of this appendix.

Prepared by:

G. Matt Candlish, B.S. — 8/1/03 Date
Biologist, Inhalation Toxicology

Reviewed by:

Daniel T. Kirkpatrick, Ph.D., D.A.B.T. — 8/1/03 Date
Director, Inhalation Toxicology

Donald G. Stump, Ph.D., D.A.B.T. — 8/1/03 Date
Study Director

Figure 1. Schematic Diagram Of Generation And Exposure System



TABLES 1 - 8

INHALATION TABLE 1

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN CHAMBER TEMPERATURE [DEGREES CELSIUS]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
09/06/02	24.	22.	24.	25.
09/07/02	22.	23.	23.	24.
09/08/02	22.	22.	22.	24.
09/09/02	22.	22.	22.	24.
09/10/02	22.	22.	22.	24.
09/11/02	23.	22.	22.	25.
09/12/02	23.	22.	23.	25.
09/13/02	22.	23.	23.	24.
09/14/02	24.	24.	24.	26.
09/15/02	23.	22.	23.	24.
09/16/02	22.	22.	22.	24.
09/17/02	23.	22.	23.	25.
09/18/02	23.	21.	23.	24.
09/19/02	22.	23.	22.	24.
09/20/02	22.	23.	22.	24.
09/21/02	22.	22.	23.	24.
09/22/02	22.	22.	22.	24.
09/23/02	23.	22.	22.	24.
09/24/02	23.	22.	23.	25.
09/25/02	22.	23.	23.	24.
09/26/02	22.	22.	22.	24.
09/27/02	22.	22.	23.	24.
09/28/02	22.	22.	23.	24.
09/29/02	23.	22.	23.	25.
09/30/02	23.	21.	23.	25.
10/01/02	22.	23.	23.	24.
10/02/02	22.	22.	22.	24.

DAILY MEAN CHAMBER TEMPERATURE [DEGREES CELSIUS]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/03/02	22.	22.	22.	24.
10/04/02	22.	23.	23.	24.
10/05/02	23.	22.	23.	25.
10/06/02	23.	22.	23.	25.
10/07/02	21.	23.	23.	24.
10/08/02	22.	21.	21.	23.
10/09/02	21.	21.	21.	23.
10/10/02	21.	21.	21.	23.
10/11/02	22.	21.	21.	23.
10/12/02	22.	21.	22.	23.
10/13/02	21.	22.	21.	22.
10/14/02	21.	20.	21.	22.
10/15/02	21.	21.	21.	23.
10/16/02	22.	21.	22.	23.
10/17/02	20.	19.	20.	22.
10/18/02	22.	21.	22.	24.
10/19/02	21.	21.	21.	23.
10/20/02	20.	21.	21.	22.
10/21/02	21.	21.	21.	22.
10/22/02	22.	21.	21.	23.
10/23/02	22.	21.	22.	23.
10/24/02	22.	21.	23.	23.
10/25/02	22.	22.	23.	24.
10/26/02	22.	21.	22.	23.
10/27/02	22.	21.	22.	23.
10/28/02	22.	22.	23.	24.
10/29/02	21.	21.	22.	23.

DAILY MEAN CHAMBER TEMPERATURE [DEGREES CELSIUS]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/30/02	22.	21.	23.	24.
10/31/02	21.	22.	22.	23.
11/01/02	22.	23.	22.	23.
11/02/02	22.	23.	23.	23.
11/03/02	21.	23.	22.	23.
11/04/02	22.	24.	22.	24.
11/05/02	22.	24.	23.	24.
11/06/02	22.	23.	23.	23.
11/07/02	22.	23.	22.	23.
11/08/02	22.	24.	23.	24.
11/09/02	22.	24.	23.	24.
11/10/02	23.	25.	24.	25.
11/11/02	23.	24.	23.	24.
11/12/02	22.	24.	23.	24.
11/13/02	22.	23.	23.	24.
11/14/02	22.	24.	22.	24.
11/15/02	23.	24.	24.	24.
11/16/02	22.	24.	23.	24.
11/17/02	22.	23.	23.	25.
11/18/02	23.	24.	23.	24.
11/19/02	22.	24.	22.	23.
11/21/02	22.	24.	22.	23.
11/20/02	21.	23.	22.	24.
11/22/02	22.	23.	22.	23.
11/23/02	22.	23.	22.	23.
11/24/02	22.	20.	22.	21.
11/25/02	22.	20.	22.	21.

DAILY MEAN CHAMBER TEMPERATURE [DEGREES CELSIUS]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
11/26/02	NA	NA	22.	NA
11/27/02	NA	NA	22.	NA
11/28/02	NA	NA	22.	NA
11/29/02	NA	NA	22.	NA
GRAND MEAN	22.	22.	22.	24.
S.D.	0.7	1.2	0.8	0.9
C.V.(%)	3.3	5.4	3.6	3.9
N	81	81	85	81

PINHv4.02
03/20/2003

INHALATION TABLE 2

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN CHAMBER RELATIVE HUMIDITY [%]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
09/06/02	42.	51.	53.	46.
09/07/02	46.	53.	58.	48.
09/08/02	46.	48.	53.	45.
09/09/02	47.	49.	55.	47.
09/10/02	45.	47.	53.	45.
09/11/02	41.	50.	49.	42.
09/12/02	44.	51.	60.	47.
09/13/02	44.	51.	60.	46.
09/14/02	43.	47.	51.	43.
09/15/02	48.	49.	60.	49.
09/16/02	46.	51.	58.	46.
09/17/02	42.	52.	51.	47.
09/18/02	44.	50.	58.	49.
09/19/02	48.	58.	61.	50.
09/20/02	47.	50.	53.	47.
09/21/02	50.	50.	56.	50.
09/22/02	48.	53.	56.	46.
09/23/02	45.	55.	53.	49.
09/24/02	48.	54.	58.	52.
09/25/02	49.	56.	58.	51.
09/26/02	46.	50.	53.	46.
09/27/02	47.	49.	53.	49.
09/28/02	49.	50.	52.	47.
09/29/02	44.	52.	52.	46.
09/30/02	47.	55.	57.	50.
10/01/02	47.	53.	55.	49.
10/02/02	48.	52.	53.	48.

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/03/02	50.	53.	56.	52.
10/04/02	51.	50.	52.	46.
10/05/02	43.	52.	50.	46.
10/06/02	45.	53.	54.	48.
10/07/02	53.	55.	56.	50.
10/08/02	47.	52.	53.	48.
10/09/02	48.	51.	53.	48.
10/10/02	47.	49.	51.	46.
10/11/02	42.	48.	49.	43.
10/12/02	41.	48.	50.	43.
10/13/02	44.	51.	51.	45.
10/14/02	46.	50.	51.	45.
10/15/02	46.	49.	51.	45.
10/16/02	46.	49.	49.	44.
10/17/02	52.	59.	54.	49.
10/18/02	44.	48.	49.	41.
10/19/02	41.	45.	46.	40.
10/20/02	49.	47.	48.	44.
10/21/02	47.	49.	50.	47.
10/22/02	46.	48.	52.	46.
10/23/02	45.	51.	51.	46.
10/24/02	44.	51.	51.	45.
10/25/02	48.	55.	57.	49.
10/26/02	48.	50.	51.	48.
10/27/02	45.	49.	53.	47.
10/28/02	50.	55.	56.	48.
10/29/02	43.	50.	49.	45.

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/30/02	44.	49.	50.	45.
10/31/02	46.	49.	56.	46.
11/01/02	44.	42.	50.	46.
11/02/02	44.	40.	49.	45.
11/03/02	43.	40.	48.	42.
11/04/02	43.	43.	50.	46.
11/05/02	45.	43.	54.	46.
11/06/02	46.	44.	55.	47.
11/07/02	46.	44.	49.	47.
11/08/02	50.	47.	58.	52.
11/09/02	45.	45.	51.	46.
11/10/02	42.	42.	50.	44.
11/11/02	44.	44.	54.	48.
11/12/02	45.	45.	54.	47.
11/13/02	46.	46.	50.	44.
11/14/02	46.	45.	61.	46.
11/15/02	46.	45.	53.	46.
11/16/02	44.	43.	51.	43.
11/17/02	43.	44.	50.	42.
11/18/02	44.	43.	50.	44.
11/19/02	44.	44.	49.	44.
11/21/02	43.	42.	47.	43.
11/20/02	49.	47.	45.	40.
11/22/02	39.	38.	42.	39.
11/23/02	38.	38.	42.	38.
11/24/02	38.	47.	42.	43.
11/25/02	39.	48.	44.	46.

INHALATION TABLE 2

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 4

SPONSOR:ACC DAILY MEAN CHAMBER RELATIVE HUMIDITY [%]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
11/26/02	NA	NA	46.	NA
11/27/02	NA	NA	42.	NA
11/28/02	NA	NA	41.	NA
11/29/02	NA	NA	43.	NA
GRAND MEAN	45.	49.	52.	46.
S.D.	3.0	4.4	4.6	2.8
C.V.(%)	6.6	9.0	8.8	6.2
N	81	81	85	81

PINHv4.02
03/20/2003

INHALATION TABLE 3

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN CHAMBER VENTILATION RATE [SLPM]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
09/06/02	450.	472.	464.	476.
09/07/02	450.	476.	468.	481.
09/08/02	449.	475.	468.	480.
09/09/02	448.	474.	467.	484.
09/10/02	446.	472.	465.	480.
09/11/02	446.	472.	466.	482.
09/12/02	443.	479.	465.	485.
09/13/02	447.	468.	464.	482.
09/14/02	444.	463.	461.	480.
09/15/02	445.	467.	461.	482.
09/16/02	448.	468.	462.	483.
09/17/02	449.	469.	484.	495.
09/18/02	452.	468.	497.	503.
09/19/02	451.	464.	489.	497.
09/20/02	450.	463.	494.	505.
09/21/02	450.	471.	495.	506.
09/22/02	451.	474.	488.	507.
09/23/02	450.	466.	490.	504.
09/24/02	449.	465.	495.	503.
09/25/02	436.	461.	487.	504.
09/26/02	436.	458.	502.	504.
09/27/02	436.	460.	498.	503.
09/28/02	438.	463.	501.	504.
09/29/02	436.	466.	501.	506.
09/30/02	435.	466.	500.	507.
10/01/02	435.	466.	498.	505.
10/02/02	435.	465.	498.	505.

SLPM = STANDARD LITERS PER MINUTE

DAILY MEAN CHAMBER VENTILATION RATE [SLPM]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/03/02	436.	468.	503.	508.
10/04/02	435.	470.	495.	505.
10/05/02	469.	467.	501.	518.
10/06/02	470.	461.	504.	522.
10/07/02	470.	461.	504.	524.
10/08/02	463.	456.	504.	527.
10/09/02	462.	455.	502.	514.
10/10/02	462.	455.	497.	519.
10/11/02	462.	456.	499.	524.
10/12/02	460.	454.	499.	523.
10/13/02	468.	457.	501.	519.
10/14/02	476.	464.	502.	521.
10/15/02	474.	462.	501.	521.
10/16/02	475.	464.	499.	523.
10/17/02	481.	472.	505.	524.
10/18/02	482.	466.	506.	516.
10/19/02	484.	456.	506.	513.
10/20/02	485.	448.	519.	520.
10/21/02	486.	448.	516.	521.
10/22/02	485.	448.	516.	518.
10/23/02	484.	462.	512.	517.
10/24/02	485.	464.	513.	520.
10/25/02	480.	458.	507.	516.
10/26/02	479.	459.	507.	515.
10/27/02	480.	458.	509.	525.
10/28/02	478.	456.	504.	522.
10/29/02	477.	466.	502.	528.

SLPM = STANDARD LITERS PER MINUTE

DAILY MEAN CHAMBER VENTILATION RATE [SLPM]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
10/30/02	480.	475.	506.	530.
10/31/02	482.	462.	498.	524.
11/01/02	480.	461.	498.	527.
11/02/02	480.	440.	497.	529.
11/03/02	480.	460.	497.	525.
11/04/02	478.	458.	495.	523.
11/05/02	475.	455.	490.	519.
11/06/02	471.	453.	494.	529.
11/07/02	478.	452.	497.	533.
11/08/02	477.	450.	489.	532.
11/09/02	476.	450.	488.	534.
11/10/02	474.	448.	487.	532.
11/11/02	478.	453.	489.	538.
11/12/02	478.	452.	489.	511.
11/13/02	478.	450.	487.	509.
11/14/02	479.	451.	488.	506.
11/15/02	480.	451.	485.	508.
11/16/02	480.	450.	487.	502.
11/17/02	478.	448.	485.	513.
11/18/02	479.	451.	488.	518.
11/19/02	480.	450.	486.	514.
11/21/02	483.	455.	490.	518.
11/20/02	483.	456.	491.	522.
11/22/02	481.	454.	489.	516.
11/23/02	484.	454.	489.	516.
11/24/02	484.	435.	482.	485.
11/25/02	484.	434.	482.	484.

SLPM = STANDARD LITERS PER MINUTE

DAILY MEAN CHAMBER VENTILATION RATE [SLPM]

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
11/26/02	NA	NA	484.	NA
11/27/02	NA	NA	474.	NA
11/28/02	NA	NA	475.	NA
11/29/02	NA	NA	474.	NA
GRAND MEAN	465.	460.	492.	511.
S.D.	17.3	9.2	13.9	15.7
C.V.(%)	3.7	2.0	2.8	3.1
N	81	81	85	81

SLPM = STANDARD LITERS PER MINUTE

PINHv4.02
03/20/2003

TARGET: 100 PPM CHAMBER #2 2.0 m3

DATE	SAMPLING LOCATION	CONC.(PPM)	% FROM REFERENCE	MEAN %
8/21/02	REFERENCE PORT	90		
	LEFT LOWER FRONT	94	(+)4.44	
	REFERENCE PORT	97		
	LEFT LOWER FRONT	94	(-)3.09	
	REFERENCE PORT	100		
	LEFT LOWER FRONT	96	(-)4.00	(-)0.88
	REFERENCE PORT	98		
	LEFT UPPER REAR	92	(-)6.12	
	REFERENCE PORT	102		
	LEFT UPPER REAR	98	(-)3.92	
	REFERENCE PORT	102		
	LEFT UPPER REAR	95	(-)6.86	(-)5.64
	REFERENCE PORT	97		
	RIGHT LOWER REAR	94	(-)3.09	
	REFERENCE PORT	99		
	RIGHT LOWER REAR	95	(-)4.04	
	REFERENCE PORT	100		
	RIGHT LOWER REAR	100	0.00	(-)2.38
	REFERENCE PORT	96		
	RIGHT UPPER FRONT	93	(-)3.13	
	REFERENCE PORT	93		
	RIGHT UPPER FRONT	91	(-)2.15	
	REFERENCE PORT	104		
	RIGHT UPPER FRONT	96	(-)7.69	(-)4.32

CONC. = CONCENTRATION PPM = PARTS PER MILLION

TARGET: 500 PPM CHAMBER #3 2.0 m3

DATE	SAMPLING LOCATION	CONC.(PPM)	% FROM REFERENCE	MEAN %
8/22/02	REFERENCE PORT	544		
	LEFT LOWER FRONT	524	(-)3.68	
	REFERENCE PORT	550		
	LEFT LOWER FRONT	536	(-)2.55	
	REFERENCE PORT	511		
	LEFT LOWER FRONT	534	(+)4.50	(-)0.57
	REFERENCE PORT	528		
	LEFT UPPER REAR	530	(+)0.38	
	REFERENCE PORT	546		
	LEFT UPPER REAR	521	(-)4.58	
	REFERENCE PORT	544		
	LEFT UPPER REAR	531	(-)2.39	(-)2.20
	REFERENCE PORT	547		
	RIGHT LOWER REAR	530	(-)3.11	
	REFERENCE PORT	546		
	RIGHT LOWER REAR	527	(-)3.48	
	REFERENCE PORT	544		
	RIGHT LOWER REAR	524	(-)3.68	(-)3.42
	REFERENCE PORT	533		
	RIGHT UPPER FRONT	518	(-)2.81	
	REFERENCE PORT	547		
	RIGHT UPPER FRONT	539	(-)1.46	
	REFERENCE PORT	545		
	RIGHT UPPER FRONT	492	(-)9.72	(-)4.67

CONC. = CONCENTRATION PPM = PARTS PER MILLION

TARGET: 1000 PPM CHAMBER #4 2.0 m3

DATE	SAMPLING LOCATION	CONC.(PPM)	% FROM REFERENCE	MEAN %
8/23/02	REFERENCE PORT	1040		
	LEFT LOWER FRONT	1003	(-)3.56	
	REFERENCE PORT	1044		
	LEFT LOWER FRONT	999	(-)4.31	
	REFERENCE PORT	1037		
	LEFT LOWER FRONT	1010	(-)2.60	(-)3.49
	REFERENCE PORT	1019		
	LEFT UPPER REAR	988	(-)3.04	
	REFERENCE PORT	1038		
	LEFT UPPER REAR	1002	(-)3.47	
	REFERENCE PORT	1040		
	LEFT UPPER REAR	1006	(-)3.27	(-)3.26
	REFERENCE PORT	1023		
	RIGHT LOWER REAR	997	(-)2.54	
	REFERENCE PORT	1042		
	RIGHT LOWER REAR	1007	(-)3.36	
	REFERENCE PORT	1037		
	RIGHT LOWER REAR	1011	(-)2.51	(-)2.80
	REFERENCE PORT	1034		
	RIGHT UPPER FRONT	1005	(-)2.80	
	REFERENCE PORT	1038		
	RIGHT UPPER FRONT	1007	(-)2.99	
	REFERENCE PORT	1040		
	RIGHT UPPER FRONT	1013	(-)2.60	(-)2.80

CONC. = CONCENTRATION PPM = PARTS PER MILLION

INHALATION TABLE 5

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY CHAMBER NOMINAL CONCENTRATIONS (F0 GENERATION)

DATE GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
09/06/02	0.	113.	544.	1310.
09/07/02	0.	112.	538.	1275.
09/08/02	0.	115.	536.	1279.
09/09/02	0.	115.	537.	1092.
09/10/02	0.	115.	540.	1055.
09/11/02	0.	115.	539.	1124.
09/12/02	0.	102.	541.	1025.
09/13/02	0.	114.	541.	1020.
09/14/02	0.	118.	546.	1035.
09/15/02	0.	120.	545.	1016.
09/16/02	0.	122.	554.	1089.
09/17/02	0.	104.	518.	1043.
09/18/02	0.	104.	505.	1029.
09/19/02	0.	105.	513.	1040.
09/20/02	0.	102.	506.	1025.
09/21/02	0.	107.	500.	1008.
09/22/02	0.	102.	512.	1023.
09/23/02	0.	102.	510.	1025.
09/24/02	0.	102.	505.	1029.
09/25/02	0.	104.	521.	1039.
09/26/02	0.	104.	497.	1017.
09/27/02	0.	104.	503.	1020.
09/28/02	0.	104.	497.	1014.
09/29/02	0.	104.	500.	1013.
09/30/02	0.	102.	501.	999.
10/01/02	0.	104.	501.	1012.
10/02/02	0.	102.	504.	1013.

DATE GROUP:	0 PPM	100 PPM	250 PPM	1000 PPM
10/03/02	0.	101.	499.	1007.
10/04/02	0.	101.	507.	1013.
10/05/02	0.	103.	501.	989.
10/06/02	0.	107.	502.	983.
10/07/02	0.	108.	504.	980.
10/08/02	0.	107.	503.	975.
10/09/02	0.	107.	501.	998.
10/10/02	0.	107.	508.	989.
10/11/02	0.	105.	506.	979.
10/12/02	0.	103.	503.	979.
10/13/02	0.	122.	504.	987.
10/14/02	0.	101.	500.	982.
10/15/02	0.	100.	501.	984.
10/16/02	0.	99.	504.	979.
10/17/02	0.	99.	498.	978.
10/18/02	0.	99.	497.	992.
10/19/02	0.	101.	496.	996.
10/20/02	0.	107.	487.	983.
10/21/02	0.	106.	488.	985.
10/22/02	0.	109.	493.	989.
10/23/02	0.	105.	493.	991.
10/24/02	0.	105.	491.	987.
10/25/02	0.	105.	496.	991.
10/26/02	0.	106.	496.	993.
10/27/02	0.	106.	488.	985.
10/28/02	0.	108.	498.	982.
10/29/02	0.	110.	500.	974.

DATE GROUP:	0 PPM	100 PPM	250 PPM	1000 PPM
10/30/02	0.	106.	496.	968.
10/31/02	0.	112.	507.	978.
11/01/02	0.	113.	504.	977.
11/02/02	0.	97.	504.	970.
11/03/02	0.	109.	508.	980.
11/04/02	0.	106.	506.	985.
11/05/02	0.	105.	514.	996.
11/06/02	0.	107.	508.	976.
11/07/02	0.	108.	505.	970.
11/08/02	0.	108.	512.	971.
11/09/02	0.	107.	518.	961.
11/10/02	0.	107.	517.	971.
11/11/02	0.	106.	505.	960.
11/12/02	0.	108.	505.	1008.
11/13/02	0.	108.	507.	1012.
11/14/02	0.	109.	508.	1018.
11/15/02	0.	108.	516.	1015.
11/16/02	0.	NA	513.	NA
11/17/02	0.	NA	515.	NA
11/18/02	0.	NA	514.	NA
11/19/02	0.	NA	515.	NA
11/20/02	NA	NA	510.	NA
11/21/02	NA	NA	511.	NA
11/22/02	NA	NA	511.	NA
11/23/02	NA	NA	530.	NA
GRAND MEAN	0.	107.	510.	1015.
S.D.	0.0	5.4	14.9	65.4
C.V.(%)	0.00	5.02	2.93	6.44
N	75	71	79	71

NA = NOT APPLICABLE

INHALATION TABLE 6

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS PAGE 1

SPONSOR:ACC DAILY CHAMBER NOMINAL CONCENTRATIONS (F1 GENERATION)

DATE GROUP:	0 PPM	100 PPM	250 PPM	1000 PPM
11/05/02	NA	105.	NA	996.
11/06/02	0.	107.	508.	976.
11/07/02	0.	108.	505.	970.
11/08/02	0.	108.	512.	971.
11/09/02	0.	107.	518.	961.
11/10/02	0.	107.	517.	971.
11/11/02	0.	106.	505.	960.
11/12/02	0.	108.	505.	1008.
11/13/02	0.	108.	507.	1012.
11/14/02	0.	109.	508.	1018.
11/15/02	0.	108.	516.	1015.
11/16/02	0.	108.	513.	1023.
11/17/02	0.	107.	515.	1001.
11/18/02	0.	109.	514.	994.
11/19/02	0.	109.	515.	1003.
11/20/02	0.	108.	510.	987.
11/21/02	0.	110.	511.	994.
11/22/02	0.	109.	511.	994.
11/23/02	0.	110.	515.	1002.
11/24/02	0.	NA	521.	NA
11/25/02	0.	NA	522.	NA
11/26/02	NA	NA	520.	NA
11/27/02	NA	NA	532.	NA
11/28/02	NA	NA	527.	NA
11/29/02	NA	NA	530.	NA
GRAND MEAN	0.	108.	515.	992.
S.D.	0.0	1.3	7.6	19.4
C.V.(%)	0.00	1.17	1.47	1.96
N	20	19	24	19

NA = NOT APPLICABLE

MANUALv1.0
04/12/2001
R:03/21/2003

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 06-SEP-02				
MEAN	0.	100.	499.	1061.
SD	0.0	2.2	4.7	24.6
CV(%)	0.00	2.22	0.95	2.32
N	10	10	10	10
EXPOSURE ON 07-SEP-02				
MEAN	0.	96.	493.	995.
SD	0.0	2.8	7.7	15.3
CV(%)	0.00	2.95	1.56	1.54
N	10	10	10	10
EXPOSURE ON 08-SEP-02				
MEAN	0.	98.	482.	974.
SD	0.0	2.8	8.2	12.8
CV(%)	0.00	2.87	1.70	1.32
N	10	10	10	10
EXPOSURE ON 09-SEP-02				
MEAN	0.	99.	490.	1056.
SD	0.0	1.6	5.8	73.6
CV(%)	0.00	1.66	1.19	6.98
N	10	10	10	10
EXPOSURE ON 10-SEP-02				
MEAN	0.	101.	492.	1023.
SD	0.0	3.5	9.8	13.3
CV(%)	0.00	3.47	1.99	1.30
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 11-SEP-02				
MEAN	0.	102.	496.	1011.
SD	0.0	3.0	5.4	6.0
CV(%)	0.00	2.94	1.09	0.60
N	10	10	10	10
EXPOSURE ON 12-SEP-02				
MEAN	0.	104.	493.	998.
SD	0.0	11.9	4.7	7.2
CV(%)	0.00	11.46	0.96	0.72
N	10	10	10	10
EXPOSURE ON 13-SEP-02				
MEAN	0.	96.	485.	990.
SD	0.0	8.6	5.9	8.2
CV(%)	0.00	8.90	1.21	0.82
N	10	10	10	10
EXPOSURE ON 14-SEP-02				
MEAN	0.	101.	488.	998.
SD	0.0	4.0	7.6	8.4
CV(%)	0.00	3.93	1.57	0.84
N	10	10	10	10
EXPOSURE ON 15-SEP-02				
MEAN	0.	100.	480.	977.
SD	0.0	5.1	11.6	11.5
CV(%)	0.00	5.13	2.42	1.17
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 16-SEP-02				
MEAN	0.	99.	472.	963.
SD	0.0	6.4	19.8	111.9
CV(%)	0.00	6.43	4.20	11.62
N	10	10	10	10
EXPOSURE ON 17-SEP-02				
MEAN	0.	103.	524.	1047.
SD	0.0	2.7	5.5	12.6
CV(%)	0.00	2.61	1.06	1.20
N	10	10	10	10
EXPOSURE ON 18-SEP-02				
MEAN	0.	99.	502.	1029.
SD	0.0	2.1	3.7	4.4
CV(%)	0.00	2.11	0.74	0.43
N	10	10	10	10
EXPOSURE ON 19-SEP-02				
MEAN	0.	102.	515.	1045.
SD	0.0	2.3	3.1	4.0
CV(%)	0.00	2.30	0.59	0.38
N	10	10	10	10
EXPOSURE ON 20-SEP-02				
MEAN	0.	99.	509.	1045.
SD	0.0	0.6	7.7	9.9
CV(%)	0.00	0.64	1.51	0.95
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 21-SEP-02				
MEAN	0.	97.	505.	1031.
SD	0.0	1.0	2.7	5.3
CV(%)	0.00	1.01	0.54	0.51
N	10	10	10	10
EXPOSURE ON 22-SEP-02				
MEAN	0.	98.	511.	1029.
SD	0.0	1.3	4.6	5.4
CV(%)	0.00	1.27	0.91	0.52
N	10	10	10	10
EXPOSURE ON 23-SEP-02				
MEAN	0.	98.	510.	1025.
SD	0.0	1.9	5.2	4.5
CV(%)	0.00	1.97	1.01	0.44
N	10	10	10	10
EXPOSURE ON 24-SEP-02				
MEAN	0.	97.	500.	1022.
SD	0.0	1.5	3.4	9.9
CV(%)	0.00	1.54	0.69	0.96
N	10	10	10	10
EXPOSURE ON 25-SEP-02				
MEAN	0.	98.	509.	1025.
SD	0.0	1.4	5.4	2.1
CV(%)	0.00	1.42	1.06	0.20
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 26-SEP-02				
MEAN	0.	99.	487.	1022.
SD	0.0	1.5	47.4	5.8
CV(%)	0.00	1.56	9.74	0.57
N	10	10	10	10
EXPOSURE ON 27-SEP-02				
MEAN	0.	98.	505.	1024.
SD	0.0	1.4	4.5	4.9
CV(%)	0.00	1.39	0.89	0.48
N	10	10	10	10
EXPOSURE ON 28-SEP-02				
MEAN	0.	99.	501.	1020.
SD	0.0	0.7	6.4	11.5
CV(%)	0.00	0.75	1.27	1.12
N	10	10	10	10
EXPOSURE ON 29-SEP-02				
MEAN	0.	98.	502.	1020.
SD	0.0	1.9	3.2	14.5
CV(%)	0.00	1.96	0.64	1.42
N	10	10	10	10
EXPOSURE ON 30-SEP-02				
MEAN	0.	98.	502.	1015.
SD	0.0	1.2	6.9	8.7
CV(%)	0.00	1.18	1.37	0.85
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 01-OCT-02				
MEAN	0.	99.	508.	1015.
SD	0.0	1.0	4.1	10.9
CV(%)	0.00	1.02	0.80	1.07
N	10	10	10	10
EXPOSURE ON 02-OCT-02				
MEAN	0.	99.	514.	1026.
SD	0.0	1.1	5.5	10.4
CV(%)	0.00	1.09	1.06	1.01
N	10	10	10	10
EXPOSURE ON 03-OCT-02				
MEAN	0.	98.	509.	1014.
SD	0.0	1.8	3.1	5.3
CV(%)	0.00	1.80	0.62	0.52
N	10	10	10	10
EXPOSURE ON 04-OCT-02				
MEAN	0.	98.	512.	1021.
SD	0.0	2.8	4.1	8.2
CV(%)	0.00	2.89	0.80	0.80
N	10	10	10	10
EXPOSURE ON 05-OCT-02				
MEAN	0.	98.	505.	1001.
SD	0.0	1.4	4.7	9.7
CV(%)	0.00	1.45	0.94	0.97
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 06-OCT-02				
MEAN	0.	99.	501.	993.
SD	0.0	1.2	3.4	7.5
CV(%)	0.00	1.17	0.68	0.75
N	10	10	10	10
EXPOSURE ON 07-OCT-02				
MEAN	0.	99.	506.	995.
SD	0.0	1.2	3.7	8.4
CV(%)	0.00	1.18	0.72	0.85
N	10	10	10	10
EXPOSURE ON 08-OCT-02				
MEAN	0.	100.	506.	996.
SD	0.0	1.0	4.4	15.0
CV(%)	0.00	1.00	0.86	1.50
N	10	10	10	10
EXPOSURE ON 09-OCT-02				
MEAN	0.	98.	506.	1011.
SD	0.0	0.8	5.2	12.5
CV(%)	0.00	0.84	1.02	1.24
N	10	10	10	10
EXPOSURE ON 10-OCT-02				
MEAN	0.	99.	510.	1010.
SD	0.0	0.7	3.0	9.4
CV(%)	0.00	0.72	0.59	0.93
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 11-OCT-02				
MEAN	0.	98.	506.	1000.
SD	0.0	1.1	5.0	1.7
CV(%)	0.00	1.07	0.99	0.17
N	10	10	10	10
EXPOSURE ON 12-OCT-02				
MEAN	0.	99.	507.	998.
SD	0.0	0.6	1.7	2.9
CV(%)	0.00	0.63	0.33	0.29
N	10	10	10	10
EXPOSURE ON 13-OCT-02				
MEAN	0.	99.	503.	1002.
SD	0.0	1.2	4.9	5.9
CV(%)	0.00	1.17	0.97	0.59
N	10	10	10	10
EXPOSURE ON 14-OCT-02				
MEAN	0.	97.	502.	989.
SD	0.0	0.9	6.4	8.3
CV(%)	0.00	0.97	1.29	0.84
N	10	10	10	10
EXPOSURE ON 15-OCT-02				
MEAN	0.	97.	507.	1005.
SD	0.0	0.9	4.0	2.2
CV(%)	0.00	0.96	0.79	0.22
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 16-OCT-02				
MEAN	0.	106.	513.	989.
SD	0.0	26.9	1.7	7.0
CV(%)	0.00	25.40	0.33	0.71
N	10	10	10	10
EXPOSURE ON 17-OCT-02				
MEAN	0.	97.	506.	992.
SD	0.0	0.9	3.5	8.4
CV(%)	0.00	0.97	0.68	0.84
N	10	10	10	10
EXPOSURE ON 18-OCT-02				
MEAN	0.	95.	505.	1005.
SD	0.0	5.8	3.9	8.5
CV(%)	0.00	6.03	0.78	0.85
N	10	10	10	10
EXPOSURE ON 19-OCT-02				
MEAN	0.	99.	502.	1007.
SD	0.0	2.1	3.5	8.5
CV(%)	0.00	2.12	0.69	0.84
N	10	10	10	10
EXPOSURE ON 20-OCT-02				
MEAN	0.	102.	498.	1011.
SD	0.0	1.8	6.7	8.3
CV(%)	0.00	1.77	1.35	0.82
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 21-OCT-02				
MEAN	0.	101.	499.	1001.
SD	0.0	1.3	4.4	6.5
CV(%)	0.00	1.28	0.88	0.65
N	10	10	10	10
EXPOSURE ON 22-OCT-02				
MEAN	0.	102.	497.	1006.
SD	0.0	0.9	2.8	3.9
CV(%)	0.00	0.83	0.55	0.39
N	10	10	10	10
EXPOSURE ON 23-OCT-02				
MEAN	0.	100.	499.	997.
SD	0.0	2.8	3.2	12.4
CV(%)	0.00	2.78	0.64	1.25
N	10	10	10	10
EXPOSURE ON 24-OCT-02				
MEAN	0.	100.	502.	1000.
SD	0.0	2.0	6.2	10.0
CV(%)	0.00	1.98	1.24	1.00
N	10	10	10	10
EXPOSURE ON 25-OCT-02				
MEAN	0.	100.	504.	1002.
SD	0.0	1.1	3.2	9.6
CV(%)	0.00	1.13	0.64	0.96
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 26-OCT-02				
MEAN	0.	100.	502.	1002.
SD	0.0	1.0	3.6	6.3
CV(%)	0.00	0.98	0.72	0.63
N	10	10	10	10
EXPOSURE ON 27-OCT-02				
MEAN	0.	101.	506.	1010.
SD	0.0	1.3	3.8	7.7
CV(%)	0.00	1.25	0.75	0.76
N	10	10	10	10
EXPOSURE ON 28-OCT-02				
MEAN	0.	99.	504.	1001.
SD	0.0	4.0	5.8	9.4
CV(%)	0.00	4.04	1.15	0.93
N	10	10	10	10
EXPOSURE ON 29-OCT-02				
MEAN	0.	100.	494.	1002.
SD	0.0	2.4	3.5	7.9
CV(%)	0.00	2.34	0.71	0.79
N	10	10	10	10
EXPOSURE ON 30-OCT-02				
MEAN	0.	98.	494.	989.
SD	0.0	1.1	5.2	5.4
CV(%)	0.00	1.11	1.05	0.54
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 31-OCT-02				
MEAN	0.	101.	499.	998.
SD	0.0	1.2	3.5	8.6
CV(%)	0.00	1.23	0.70	0.86
N	10	10	10	10
EXPOSURE ON 01-NOV-02				
MEAN	0.	102.	504.	1006.
SD	0.0	1.7	5.9	12.7
CV(%)	0.00	1.68	1.18	1.27
N	10	10	10	10
EXPOSURE ON 02-NOV-02				
MEAN	0.	92.	500.	996.
SD	0.0	17.5	4.6	4.1
CV(%)	0.00	18.95	0.91	0.41
N	10	10	10	10
EXPOSURE ON 03-NOV-02				
MEAN	0.	99.	494.	996.
SD	0.0	1.9	3.6	8.3
CV(%)	0.00	1.95	0.73	0.83
N	9	9	9	9
EXPOSURE ON 04-NOV-02				
MEAN	0.	100.	498.	1004.
SD	0.0	1.8	9.9	2.2
CV(%)	0.00	1.75	1.99	0.22
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 05-NOV-02				
MEAN	0.	100.	501.	1004.
SD	0.0	0.7	6.1	8.2
CV(%)	0.00	0.75	1.23	0.82
N	10	10	10	10
EXPOSURE ON 06-NOV-02				
MEAN	0.	103.	504.	1004.
SD	0.0	1.5	7.3	18.8
CV(%)	0.00	1.49	1.45	1.87
N	10	10	10	10
EXPOSURE ON 07-NOV-02				
MEAN	0.	102.	494.	994.
SD	0.0	1.7	7.5	10.0
CV(%)	0.00	1.69	1.51	1.00
N	10	10	10	10
EXPOSURE ON 08-NOV-02				
MEAN	0.	102.	503.	994.
SD	0.0	1.6	6.0	11.4
CV(%)	0.00	1.60	1.20	1.14
N	10	10	10	10
EXPOSURE ON 09-NOV-02				
MEAN	0.	100.	503.	978.
SD	0.0	2.2	10.3	9.3
CV(%)	0.00	2.15	2.05	0.96
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 10-NOV-02				
MEAN	0.	100.	507.	990.
SD	0.0	2.3	3.3	3.5
CV(%)	0.00	2.26	0.66	0.35
N	10	10	10	10
EXPOSURE ON 11-NOV-02				
MEAN	0.	97.	492.	979.
SD	0.0	5.8	4.6	15.8
CV(%)	0.00	5.97	0.94	1.61
N	10	11	10	10
EXPOSURE ON 12-NOV-02				
MEAN	0.	102.	495.	1015.
SD	0.0	1.8	5.2	11.1
CV(%)	0.00	1.72	1.06	1.09
N	10	10	10	10
EXPOSURE ON 13-NOV-02				
MEAN	0.	102.	490.	1019.
SD	0.0	1.8	4.7	7.5
CV(%)	0.00	1.78	0.96	0.74
N	10	10	10	10
EXPOSURE ON 14-NOV-02				
MEAN	0.	102.	496.	1027.
SD	0.0	1.5	3.1	4.3
CV(%)	0.00	1.47	0.62	0.42
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 15-NOV-02				
MEAN	0.	101.	498.	1022.
SD	0.0	1.7	8.8	10.0
CV(%)	0.00	1.72	1.76	0.98
N	10	10	10	10
EXPOSURE ON 16-NOV-02				
MEAN	0.	NA	497.	NA
SD	0.0		5.0	
CV(%)	0.00		1.00	
N	10		10	
EXPOSURE ON 17-NOV-02				
MEAN	0.	NA	501.	NA
SD	0.0		8.3	
CV(%)	0.00		1.65	
N	10		10	
EXPOSURE ON 18-NOV-02				
MEAN	0.	NA	485.	NA
SD	0.0		4.6	
CV(%)	0.00		0.96	
N	10		10	
EXPOSURE ON 19-NOV-02				
MEAN	0.	NA	498.	NA
SD	0.0		8.7	
CV(%)	0.00		1.74	
N	10		10	

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 20-NOV-02				
MEAN	NA	NA	490.	NA
SD			9.2	
CV(%)			1.89	
N			9	
EXPOSURE ON 21-NOV-02				
MEAN	NA	NA	504.	NA
SD			6.9	
CV(%)			1.37	
N			10	
EXPOSURE ON 22-NOV-02				
MEAN	NA	NA	504.	NA
SD			3.1	
CV(%)			0.62	
N			10	
EXPOSURE ON 23-NOV-02				
MEAN	NA	NA	490.	NA
SD			10.0	
CV(%)			2.03	
N			10	

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 7

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F0 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
ALL STUDY DAYS COMBINED				
MEAN	0.	99.	500.	1008.
SD	0.0	2.4	8.5	18.6
CV(%)	0.00	2.40	1.71	1.84
N	75	71	79	71

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

PCHCSUv4.04
03/20/2003
R:03/20/2003

INHALATION TABLE 8

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F1 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 05-NOV-02				
MEAN	NA	100.	NA	1004.
SD		0.7		8.2
CV(%)		0.75		0.82
N		10		10
EXPOSURE ON 06-NOV-02				
MEAN	0.	103.	504.	1004.
SD	0.0	1.5	7.3	18.8
CV(%)	0.00	1.49	1.45	1.87
N	10	10	10	10
EXPOSURE ON 07-NOV-02				
MEAN	0.	102.	494.	994.
SD	0.0	1.7	7.5	10.0
CV(%)	0.00	1.69	1.51	1.00
N	10	10	10	10
EXPOSURE ON 08-NOV-02				
MEAN	0.	102.	503.	994.
SD	0.0	1.6	6.0	11.4
CV(%)	0.00	1.60	1.20	1.14
N	10	10	10	10
EXPOSURE ON 09-NOV-02				
MEAN	0.	100.	503.	978.
SD	0.0	2.2	10.3	9.3
CV(%)	0.00	2.15	2.05	0.96
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 8

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F1 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 10-NOV-02				
MEAN	0.	100.	507.	990.
SD	0.0	2.3	3.3	3.5
CV(%)	0.00	2.26	0.66	0.35
N	10	10	10	10
EXPOSURE ON 11-NOV-02				
MEAN	0.	97.	492.	979.
SD	0.0	5.8	4.6	15.8
CV(%)	0.00	5.97	0.94	1.61
N	10	11	10	10
EXPOSURE ON 12-NOV-02				
MEAN	0.	102.	495.	1015.
SD	0.0	1.8	5.2	11.1
CV(%)	0.00	1.72	1.06	1.09
N	10	10	10	10
EXPOSURE ON 13-NOV-02				
MEAN	0.	102.	490.	1019.
SD	0.0	1.8	4.7	7.5
CV(%)	0.00	1.78	0.96	0.74
N	10	10	10	10
EXPOSURE ON 14-NOV-02				
MEAN	0.	102.	496.	1027.
SD	0.0	1.5	3.1	4.3
CV(%)	0.00	1.47	0.62	0.42
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 8

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F1 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 15-NOV-02				
MEAN	0.	101.	498.	1022.
SD	0.0	1.7	8.8	10.0
CV(%)	0.00	1.72	1.76	0.98
N	10	10	10	10
EXPOSURE ON 16-NOV-02				
MEAN	0.	101.	497.	1027.
SD	0.0	1.8	5.0	9.3
CV(%)	0.00	1.79	1.00	0.90
N	10	10	10	10
EXPOSURE ON 17-NOV-02				
MEAN	0.	101.	501.	1000.
SD	0.0	3.7	8.3	17.0
CV(%)	0.00	3.64	1.65	1.70
N	10	10	10	10
EXPOSURE ON 18-NOV-02				
MEAN	0.	101.	485.	1012.
SD	0.0	0.9	4.6	8.5
CV(%)	0.00	0.91	0.96	0.84
N	10	10	10	10
EXPOSURE ON 19-NOV-02				
MEAN	0.	102.	498.	984.
SD	0.0	1.0	8.7	9.5
CV(%)	0.00	1.02	1.74	0.96
N	10	10	10	10

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 8

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F1 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 20-NOV-02				
MEAN	0.	100.	490.	977.
SD	0.0	2.0	9.2	12.8
CV(%)	0.00	2.06	1.89	1.31
N	9	9	9	9
EXPOSURE ON 21-NOV-02				
MEAN	0.	101.	504.	994.
SD	0.0	2.8	6.9	6.3
CV(%)	0.00	2.80	1.37	0.64
N	10	10	10	10
EXPOSURE ON 22-NOV-02				
MEAN	0.	101.	504.	1005.
SD	0.0	1.2	3.1	7.1
CV(%)	0.00	1.20	0.62	0.70
N	10	10	10	10
EXPOSURE ON 23-NOV-02				
MEAN	0.	102.	490.	1006.
SD	0.0	1.0	10.0	10.6
CV(%)	0.00	0.96	2.03	1.06
N	10	10	10	10
EXPOSURE ON 24-NOV-02				
MEAN	0.	NA	496.	NA
SD	0.0		7.9	
CV(%)	0.00		1.60	
N	10		10	

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
EXPOSURE ON 25-NOV-02				
MEAN	0.	NA	495.	NA
SD	0.0		3.1	
CV(%)	0.00		0.62	
N	10		10	
EXPOSURE ON 26-NOV-02				
MEAN	NA	NA	495.	NA
SD			3.5	
CV(%)			0.70	
N			10	
EXPOSURE ON 27-NOV-02				
MEAN	NA	NA	506.	NA
SD			4.4	
CV(%)			0.87	
N			10	
EXPOSURE ON 28-NOV-02				
MEAN	NA	NA	501.	NA
SD			2.1	
CV(%)			0.42	
N			10	
EXPOSURE ON 29-NOV-02				
MEAN	NA	NA	502.	NA
SD			3.9	
CV(%)			0.77	
N			10	

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

INHALATION TABLE 8

PROJECT NO.:WIL-186028I PILOT INH. STUDY FOR REPRO. TOX. STUDY OF ETHYLBENZENE IN RATS

SPONSOR:ACC DAILY MEAN TEST ATMOSPHERE CONCENTRATIONS (F1 GENERATION)

GROUP:	0 PPM	100 PPM	500 PPM	1000 PPM
	CH. NO. 1 2.0M3 CONC.	CH. NO. 2 2.0M3 CONC.	CH. NO. 3 2.0M3 CONC.	CH. NO. 4 2.0M3 CONC.
ALL STUDY DAYS COMBINED				
MEAN	0.	101.	498.	1002.
SD	0.0	1.3	5.8	16.0
CV(%)	0.00	1.30	1.17	1.60
N	20	19	24	19

CH. = CHAMBER, NO. = NUMBER, CONC. = CONCENTRATION
CONCENTRATION IN: PPM

PCHCSUv4.04
03/20/2003
R:03/20/2003

APPENDIX D

Estimation of Oral Doses Report (Sponsor-Provided Data)

Estimation of Oral Doses for Use

in a Preliminary Reproduction Study of Ethylbenzene in the Rat

September 13, 2002

Dr. Kannan Krishnan
Universite de Montreal
Medicine Du Travail Et Hygiene Du Milieu
2375 Cote Ste-Catherine
Montreal, Quebec H3T 1A8 Canada

Estimation of Oral Doses for Use in a Preliminary Reproduction Study of Ethylbenzene in the Rat.

The gavage doses to be administered to dams during LD1-4 were determined using a physiologically-based pharmacokinetic (PBPK) modeling approach. An inhalation PBPK model for ethylbenzene (EBZ) was extended to facilitate the simulation of kinetics following gavage doses. For this purpose, the rate constant of oral absorption was estimated (0.18 hr^{-1}) following a single oral dose of 180 mg/kg (in 1 mg/kg corn oil) in adult female rats. Figure 1 shows the comparison of simulations of the PBPK model (using a rate constant for oral absorption of 0.18 hr^{-1}) with the experimental data collected in rats receiving a single oral EBZ dose of 180 mg/kg. Using this PBPK model then, the oral doses required to produce the same AUC as the inhalation exposures were determined by iterative simulation. These results presented in Table 1 indicate that three doses of 29.5 mg/kg per day during four days would give a cumulative AUC comparable to that associated with 6-hr inhalation exposure to 100 ppm during four days. Similarly, the oral doses of 114 and 206.5 mg/kg were determined to represent equivalent doses for the 500 ppm and 1000 ppm exposure groups. It should be noted that at the equivalent oral doses, the AUC were equivalent to those of the inhalation values whereas the Cmax were within the inhalation values (Figure 2). As a limited validation effort, the PBPK model prediction of the kinetics of EBZ following three gavage doses of 206.5 mg/kg was compared with the experimental data (Figure 3). The PBPK model-derived oral doses (206.5 mg/kg, 114 mg/kg, and 29.5 mg/kg) equivalent to the 1000 ppm, 500 ppm and 100 ppm inhalation exposures, were then rounded off and administered as outlined in the protocol.



Figure 1 Comparison of the experimental data (symbol) and PBPK model simulation (line) of venous blood concentration of ethybenzene in female rats, following a single oral dose (180 mg/kg, in 1 ml/kg corn oil)

Table 1. Comparison of maximal blood concentration (CV max) and AUC of ethylbenzene for different inhalation and oral doses in female rats (0.25kg).

	Treatment	Absorption constants (h^{-1})	Dose (mg)	CV max (mg/L)	AUC 0-96h h*(mg/l)
Inhalation	100 ppm x 6 h x 4 days	—	50.4	3.88	88.3
Oral dose	3 x 29.5 mg/kg x 4 days	0.18	88.5	2.70	88.1
Inhalation	500 ppm x 6 h. x 4 days	—	210.8	46.1	1265.1
Oral dose	3 x 114 mg/kg x 4 days	0.18	342	26.7	1263.0
Inhalation	1000 ppm x 6h x 4 days	—	402	104.6	3388.1
Oral dose	3 x 206.5 mg/kg x 4 days	0.18	619.5	61.0	3384.7



Figure 2 Comparison of the kinetic profile of EBZ during inhalation and oral exposures. The duration of inhalation exposures is 6 hr/d for 4 d. The oral dose was given three times/day at two-hour intervals for 4 d.



Figure 3 Comparison of the experimental data (symbol) and PBPK model predictions (solid line) of venous blood concentration of ethybenzene in female rats, following three oral doses (206.5mg/kg) given at two hour intervals.

Kannan Krishnan, Ph.D.

APPENDIX E

Nesting Material Analysis (Provided by the Manufacturer)

SILLIKER, Inc.
Ohio Laboratory
2057 Builders Place
Columbus, OH 43204
614/ 486 0150 Fax 614/ 486 0151

CERTIFICATE OF ANALYSIS

COA No:	OHI-23064437-0
Supersedes:	OHI-23064014-0
COA Date	12/11/02
Page 1 of 5	

TO:
Mr. Ted A. Weaver
Sales Manager
The Andersons, Inc.
480 West Dussel Drive
P.O. Box 119
Maumee, OH 43537

Received From:	Maumee, OH
Received Date:	11/18/02
P.O.# / ID:	Maumee, Oh
Location of Test: (except where noted)	Columbus, OH

Analytical Results

Desc. 1: bed-o' cobs **Desc. 4:** Maumee **Laboratory ID:** 230426686
Desc. 2: 1/8" & 1/4" **Condition Rec'd:** NORMAL
Desc. 3: Annual Test **Temp Rec'd (°C):** 20.0

Analyte	Result	Units	Method Reference	Test Date	Loc.
Aflatoxin - HPLC			HPLC	11/25/02	TAL
Aflatoxin B1	<1	ppb			
Aflatoxin B2	<1	ppb			
Aflatoxin G1	<1	ppb			
Aflatoxin G2	<1	ppb			
Arsenic	<0.20	mg/100g		11/25/02	MID
Cadmium	<0.05	ppm		11/25/02	MID
Fumonisin			HPLC	11/25/02	TAL
Fumonisin B1	0.4	ppm			
Fumonisin B2	<0.1	ppm			
Fumonisin B3	<0.1	ppm			
Lead	<0.10	mg/100g		11/25/02	MID
Mercury	<0.05	mg/100g		11/25/02	MID
Organochlorine Pesticide Screen			CDFA Method	11/25/02	EMA
a, b, d - BHC	< 0.010	ppm			
Alachlor, (Lasso)	< 0.020	ppm			
Alert, (Pirate)	< 0.040	ppm			
Aldrin	< 0.010	ppm			
Benfluralin, (Balan, Benefin)	< 0.020	ppm			
BHC, (Benzahex)	< 0.010	ppm			
Bifenox, (Modown)	< 0.050	ppm			
Bifenthrin	< 0.040	ppm			
Bromacil	< 0.040	ppm			
Captafol	< 0.040	ppm			
Captan	< 0.020	ppm			
Chlordane	< 0.250	ppm			
Chlorobenzilate, (Acaraben)	< 0.400	ppm			
Chlorthalonil, (Bravo)	< 0.010	ppm			
Cyanazine	< 0.100	ppm			
Cyfluthrin	< 0.050	ppm			
Cypermethrin	< 0.050	ppm			
Dacthal, (Chlorthal)	< 0.020	ppm			
DDD	< 0.020	ppm			
DDE	< 0.020	ppm			
DDT	< 0.020	ppm			

The results of these tests relate only to the samples tested. This report shall not be reproduced except in full, without the written approval of the laboratory.

SILLIKER, Inc.
Ohio Laboratory
2057 Builders Place
Columbus, OH 43204
614/ 486 0150 Fax 614/ 486 0151

CERTIFICATE OF ANALYSIS

COA No:	OHI-23064437-0
Supersedes:	OHI-23064014-0
COA Date	12/11/02
Page 2 of 5	

TO:
Mr. Ted A. Weaver
Sales Manager
The Andersons, Inc.
480 West Dussel Drive
P.O. Box 119
Maumee, OH 43537

Received From:	Maumee, OH
Received Date:	11/18/02
P.O.# / ID:	Maumee, Oh
Location of Test: (except where noted)	Columbus, OH

Analytical Results

Desc. 1: bad-o' cobs
Desc. 2: 1/8" & 1/4"
Desc. 3: Annual Test
Desc. 4: Maumee

Laboratory ID: 230426686
Condition Rec'd: NORMAL
Temp Rec'd (°C): 20.0

Analyte	Result	Units	Method Reference	Test Date	Loc.
Dichlobenil, (Casoron)	< 0.030	ppm			
Dichlone, (Phygon)	< 0.050	ppm			
Dicloran, (Botran)	< 0.020	ppm			
Dicofol, (Kelthane)	< 0.050	ppm			
Dieldrin	< 0.010	ppm			
Dyrene, (Anilazine)	< 0.100	ppm			
Endosulfan alpha	< 0.010	ppm			
Endosulfan beta	< 0.010	ppm			
Endosulfan sulfate	< 0.010	ppm			
Endrin	< 0.010	ppm			
Esfenvalerate, (Asana)	< 0.020	ppm			
Ethalfluralin, (Sonalan)	< 0.030	ppm			
Fluvalinate	< 0.050	ppm			
Folpet	< 0.050	ppm			
Heptachlor	< 0.010	ppm			
Heptachlor epoxide	< 0.020	ppm			
Iprodione, (Rovral)	< 0.050	ppm			
Lindane, (gamma-BHC)	< 0.010	ppm			
Linuron	< 0.020	ppm			
Methoxychlor	< 0.050	ppm			
Metribuzin	< 0.020	ppm			
Mirex	< 0.020	ppm			
Myclobutanil, (Rally)	< 0.050	ppm			
Nitrofen, (TOK)	< 0.050	ppm			
Oxadiazon, (Ronstar)	< 0.050	ppm			
Oxyfluorfen, (Goal)	< 0.040	ppm			
Pendamethalin	< 0.050	ppm			
Pentachloronitrobenzene (PCNB)	< 0.020	ppm			
Permethrin	< 0.100	ppm			
Perthane, (Ethylan)	< 0.100	ppm			
Polychlorinated Biphenyls	< 0.250	ppm			
Profluralin, (Tolban)	< 0.020	ppm			
Pronamide, (Kerb, Propyzamide)	< 0.050	ppm			
Pyrethrins, (Total)	< 0.100	ppm			
Toxaphene, (Attac, Strobane)	< 0.250	ppm			

The results of these tests relate only to the samples tested. This report shall not be reproduced except in full, without the written approval of the laboratory.

SILLIKER, Inc.
Ohio Laboratory
2057 Builders Place
Columbus, OH 43204
614/ 486 0150 Fax 614/ 486 0151

CERTIFICATE OF ANALYSIS

COA No:	OHI-23064437-0
Supersedes:	OHI-23064014-0
COA Date	12/11/02
Page 3 of 5	

TO:
Mr. Ted A. Weaver
Sales Manager
The Andersons, Inc.
480 West Dussel Drive
P.O. Box 119
Maumee, OH 43537

Received From:	Maumee, OH
Received Date:	11/18/02
P.O.# / ID:	Maumee, Oh
Location of Test: (except where noted)	Columbus, OH

Analytical Results

Desc. 1: bed-o' cobs
Desc. 2: 1/8" & 1/4"
Desc. 3: Annual Test
Desc. 4: Maumee

Laboratory ID: 230426686
Condition Rec'd: NORMAL
Temp Rec'd (°C): 20.0

Analyte	Result	Units	Method Reference	Test Date	Loc.
Tridimefon, (Bayleton)	< 0.020	ppm			
Trifluralin, (Treflan)	< 0.020	ppm			
Vegadex, (Diethyldithiocarb. acid)	< 0.050	ppm			
Vinclozolin, (Ronilan)	< 0.020	ppm			
Tetradifon (Tedion)	<0.020	ppm			
Organophosphate/Organonitrogen			CDFA Method	11/25/02	EMA
Acephate, (Orthene)	<0.050	ppm			
Ametryn	<0.050	ppm			
Atrazine	<0.050	ppm			
Azinphos-methyl, (Guthion)	<0.050	ppm			
Benthiocarb	<0.10	ppm			
Bolstar, (Sulprofos)	<0.050	ppm			
Carbophenothion, (Trithion)	<0.050	ppm			
Chlorfenvinphos, (Supona)	<0.050	ppm			
Chloropropham	<0.050	ppm			
Chlorpyrifos, (Dursban)	<0.03	ppm			
Chlorpyrifos-methyl	<0.050	ppm			
Ciodrin, (Crotophos)	<0.050	ppm			
Cyanazine, (Bladex)	<0.050	ppm			
DEF	<0.050	ppm			
Demeton, (Systox)	<0.050	ppm			
Diazinon	<0.03	ppm			
Dibrom, (Naled)	<0.050	ppm			
Dicrotophos, (Didrin)	<0.050	ppm			
Dimethoate, (Cygon)	<0.03	ppm			
Dioxathion, (Delnav)	<0.050	ppm			
Diphenyl Amine	<0.10	ppm			
Disulfoton, (Disyston)	<0.050	ppm			
EPN	<0.050	ppm			
Ethion	<0.050	ppm			
Ethoprop, (Mocap)	<0.050	ppm			
Fenamiphos, (Nemacur)	<0.050	ppm			
Fenitrothion, (Sumithion)	<0.050	ppm			
Fenthion, (Baytex)	<0.050	ppm			
Fonofos, (Dyfonate)	<0.050	ppm			

The results of these tests relate only to the samples tested. This report shall not be reproduced except in full, without the written approval of the laboratory.

SILLIKER, Inc.
Ohio Laboratory
2057 Builders Place
Columbus, OH 43204
614/ 486 0150 Fax 614/ 486 0151

CERTIFICATE OF ANALYSIS

COA No:	OHI-23064437-0
Supersedes:	OHI-23064014-0
COA Date	12/11/02
Page 4 of 5	

TO:
Mr. Ted A. Weaver
Sales Managar
The Andersons, Inc.
480 West Dussel Drive
P.O. Box 119
Maumee, OH 43537

Received From:	Maumee, OH
Received Date:	11/18/02
P.O.# / ID:	Maumee, Oh
Location of Test: (except where noted)	Columbus, OH

Analytical Results

Desc. 1:	bed-o' cobs	Desc. 4:	Maumee	Laboratory ID:	230426686
Desc. 2:	1/8" & 1/4"			Condition Rec'd:	NORMAL
Desc. 3:	Annual Test			Temp Rec'd (°C):	20.0

Analyte	Result	Units	Method Reference	Test Date	Loc.
Hexazinone	<0.050	ppm			
Hostathion, (Triazaophos)	<0.050	ppm			
Imazalil	<0.050	ppm			
Imidan, (Phosmet)	<0.050	ppm			
Isofenphos, (Oftanol)	<0.050	ppm			
Malathion + o-analogue	<0.050	ppm			
Metalaxyl	<0.050	ppm			
Methamidophos, (Monitor)	<0.050	ppm			
Methidathion, (Supracide)	<0.050	ppm			
Methyl Parathion	<0.050	ppm			
Metolachlor, (Dual)	<0.050	ppm			
Metribuzin, (Sencor)	<0.050	ppm			
Mevinphos, (Phosdrin)	<0.050	ppm			
Molinate, (Ordram)	<0.050	ppm			
Myclobutanil	<0.050	ppm			
Parathion	<0.04	ppm			
Phorate, (Thimet)	<0.050	ppm			
Phosalone, (Zolone)	<0.030	ppm			
Phosphamidon, (Dimecron)	<0.08	ppm			
Primiphos-methyl	<0.050	ppm			
Prometryne	<0.050	ppm			
Propetamphos, (Safrotin)	<0.050	ppm			
Ronnel, (Fenchlorfos)	<0.050	ppm			
Simazine	<0.050	ppm			
Terbacil	<0.500	ppm			
Thiobendazole	<0.050	ppm			
Thionazin, (Zinophos)	<0.050	ppm			
Coumaphos, (Co-Ral)	<0.050	ppm			
Tetrachlorvinphos (Gardona)	<0.050	ppm			
Profenofos (Curacron)	<0.050	ppm			
Vomitoxin	1.1	ppm	HPLC	11/25/02	TAL
Coliforms - 3 tube MPN	>1100	/g	AOAC 966.23	12/5/02	
Salmonella - ELFA	Negative	/25g	AOAC 996.08	11/20/02	
Shigella species	Negative	/25g	FDA-BAM, 8th ed.	11/21/02	

The results of these tests relate only to the samples tested. This report shall not be reproduced except in full, without the written approval of the laboratory.

SILLIKER, Inc.
Ohio Laboratory
2057 Builders Place
Columbus, OH 43204
614/ 486 0150 Fax 614/ 486 0151

CERTIFICATE OF ANALYSIS

COA No:	OHI-23064437-0
Supersedes:	OHI-23064014-0
COA Date	12/11/02
Page 5 of 5	

TO:
Mr. Ted A. Weaver
Sales Manager
The Andersons, Inc.
480 West Dussel Drive
P.O. Box 119
Maumee, OH 43537

Received From:	Maumee, OH
Received Date:	11/18/02
P.O.# / ID:	Maumee, Oh
Location of Test: (except where noted) Columbus, OH	

Analytical Results

Stephanie Campbell, Laboratory Director

Noted Test Locations: TAL-Trilogy Analytical Laboratories, Inc., 111 West Fourth Street, Washington, MO 63090
Noted Test Locations: MID-Midwest Laboratories, Inc., 13611 B Street, Omaha, NE 68144-3693
Noted Test Locations: EMA-Environmental Micro Analyses, Inc., 40 N. East Street, Suite B, Woodland, CA 95776

The results of these tests relate only to the samples tested. This report shall not be reproduced except in full, without the written approval of the laboratory.

APPENDIX F

Certified Feed Analysis (Provided by the Manufacturer)

LabDiet PMI NUTRITION INTERNATIONAL

Return to Certified Analysis Retrieval

Product Code: 5002M
Product Desc: CERTIFIED RODENT DIET MEAL
Lab Number: L0219103-2
Lot Code: JUL 01 02 2B
Entered: 7/2/2002

Assay	Analysis	Units
PROTEIN	21.5	%
FAT ACID (HYDRO.)	5.16	%
FIBER (CRUDE)	4.52	%
ARSENIC	LESS THAN 0.2	PPM
CADMIUM	0.059	PPM
CALCIUM	0.921	%
LEAD	0.217	PPM
MERCURY	LESS THAN 0.025	PPM
PHOSPHORUS	0.702	%
SELENIUM	0.304	PPM

ORGANOPHOSPHATES	PPM	ORGANOPHOSPHATES	PPM
Diazinon	LESS THAN 0.02	Disulfoton	LESS THAN 0.02
Ethion	LESS THAN 0.02	Malathion	0.03
Methyl Parathion	LESS THAN 0.02	Parathion	LESS THAN 0.02
Thimet	LESS THAN 0.02	Thiodan	LESS THAN 0.02
Trithion	LESS THAN 0.02		

PESTICIDES AND PCB	PPM	PESTICIDES AND PCB	PPM
Aldrin	LESS THAN 0.02	Alpha-BHC	LESS THAN 0.02
Beta-BHC	LESS THAN 0.02	Chlordane	LESS THAN 0.02
DDE	LESS THAN 0.02	DDT	LESS THAN 0.02
Delta-BHC	LESS THAN 0.02	Dieldrin	LESS THAN 0.02
Endrin	LESS THAN 0.02	HCB	LESS THAN 0.02
Heptachlor	LESS THAN 0.02	Heptachlor Epoxide	LESS THAN 0.02
Lindane	LESS THAN 0.02	Methoxychlor	LESS THAN 0.02
Mirex	LESS THAN 0.02	PCB	LESS THAN 0.15

Aflatoxin	Aflatoxins	LESS THAN 5 PPB

No notes.

-- for nutritional interpretation
3) Richmond, IN Manufacturing Plant at (765) 962- -- all other questions

The term "Less Than" is used to signify the lower limit of quantitation of the procedure under the conditions employed.
The use of the term "Less Than" does not imply that traces of analyte were present.

LabDiet PMI NUTRITION INTERNATIONAL

Return to Certified Analysis Retrieval

Product Code: 5002M
Product Desc: CERTIFIED RODENT DIET MEAL
Lab Number: L0219103-3
Lot Code: JUL 01 02 2C
Entered: 7/2/2002

Assay	Analysis	Units
PROTEIN	21.4	%
FAT ACID (HYDRO.)	5.16	%
FIBER (CRUDE)	4.7	%
ARSENIC	LESS THAN 0.2	PPM
CADMIUM	0.062	PPM
CALCIUM	0.966	%
LEAD	0.212	PPM
MERCURY	LESS THAN 0.025	PPM
PHOSPHORUS	0.724	%
SELENIUM	0.277	PPM

ORGANOPHOSPHATES	PPM	ORGANOPHOSPHATES	PPM
Diazinon	LESS THAN 0.02	Disulfoton	LESS THAN 0.02
Ethion	LESS THAN 0.02	Malathion	0.03
Methyl Parathion	LESS THAN 0.02	Parathion	LESS THAN 0.02
Thimet	LESS THAN 0.02	Thiodan	LESS THAN 0.02
Trithion	LESS THAN 0.02		

PESTICIDES AND PCB	PPM	PESTICIDES AND PCB	PPM
Aldrin	LESS THAN 0.02	Alpha-BHC	LESS THAN 0.02
Beta-BHC	LESS THAN 0.02	Chlordane	LESS THAN 0.02
DDE	LESS THAN 0.02	DDT	LESS THAN 0.02
Delta-BHC	LESS THAN 0.02	Dieldrin	LESS THAN 0.02
Endrin	LESS THAN 0.02	HCB	LESS THAN 0.02
Heptachlor	LESS THAN 0.02	Heptachlor Epoxide	LESS THAN 0.02
Lindane	LESS THAN 0.02	Methoxychlor	LESS THAN 0.02
Mirex	LESS THAN 0.02	PCB	LESS THAN 0.15

Aflatoxin	Aflatoxins	LESS THAN 5 PPB

No notes.

-- for nutritional interpretation
3) Richmond, IN Manufacturing Plant at (765) 962- -- all other questions

The term "Less Than" is used to signify the lower limit of quantitation of the procedure under the conditions employed.
The use of the term "Less Than" does not imply that traces of analyte were present.

LabDiet PMI NUTRITION INTERNATIONAL

Return to Certified Analysis Retrieval

Product Code: 5002M
Product Desc: CERTIFIED RODENT DIET MEAL
Lab Number: L0219670-1
Lot Code: JUL 10 02 3A
Entered: 7/12/2002

Assay	Analysis	Units
PROTEIN	21.5	%
FAT ACID (HYDRO.)	5.77	%
FIBER (CRUDE)	5.38	%
ARSENIC	LESS THAN 0.2	PPM
CADMIUM	0.135	PPM
CALCIUM	0.908	%
LEAD	0.177	PPM
MERCURY	LESS THAN 0.025	PPM
PHOSPHORUS	0.636	%
SELENIUM	0.309	PPM

ORGANOPHOSPHATES	PPM	ORGANOPHOSPHATES	PPM
Diazinon	LESS THAN 0.02	Disulfoton	LESS THAN 0.02
Ethion	LESS THAN 0.02	Malathion	0.02
Methyl Parathion	LESS THAN 0.02	Parathion	LESS THAN 0.02
Thimet	LESS THAN 0.02	Thiodan	LESS THAN 0.02
Trithion	LESS THAN 0.02		

PESTICIDES AND PCB	PPM	PESTICIDES AND PCB	PPM
Aldrin	LESS THAN 0.02	Alpha-BHC	LESS THAN 0.02
Beta-BHC	LESS THAN 0.02	Chlordane	LESS THAN 0.02
DDE	LESS THAN 0.02	DDT	LESS THAN 0.02
Delta-BHC	LESS THAN 0.02	Dieldrin	LESS THAN 0.02
Endrin	LESS THAN 0.02	HCB	LESS THAN 0.02
Heptachlor	LESS THAN 0.02	Heptachlor Epoxide	LESS THAN 0.02
Lindane	LESS THAN 0.02	Methoxychlor	LESS THAN 0.02
Mirex	LESS THAN 0.02	PCB	LESS THAN 0.15

No notes.

-- for nutritional interpretation
3) Richmond, IN Manufacturing Plant at (765) 962- -- all other questions

The term "Less Than" is used to signify the lower limit of quantitation of the procedure under the conditions employed.
The use of the term "Less Than" does not imply that traces of analyte were present.

LabDiet PMI NUTRITION INTERNATIONAL

Return to Certified Analysis Retrieval

Product Code: 5002M
Product Desc: CERTIFIED RODENT DIET MEAL
Lab Number: L0222607-1
Lot Code: SEP 08 02 3A
Entered: 9/24/2002

Assay	Analysis	Units
PROTEIN	21.2	%
FAT ACID (HYDRO.)	5.86	%
FIBER (CRUDE)	4.31	%
ARSENIC	LESS THAN 0.2	PPM
CADMIUM	LESS THAN 0.05	PPM
CALCIUM	0.881	%
LEAD	0.165	PPM
MERCURY	LESS THAN 0.025	PPM
PHOSPHORUS	0.617	%
SELENIUM	0.196	PPM

ORGANOPHOSPHATES	PPM	ORGANOPHOSPHATES	PPM
Diazinon	LESS THAN 0.02	Disulfoton	LESS THAN 0.02
Ethion	LESS THAN 0.02	Malathion	LESS THAN 0.02
Methyl Parathion	LESS THAN 0.02	Parathion	LESS THAN 0.02
Thimet	LESS THAN 0.02	Thiodan	LESS THAN 0.02
Trithion	LESS THAN 0.02		

PESTICIDES AND PCB	PPM	PESTICIDES AND PCB	PPM
Aldrin	LESS THAN 0.02	Alpha-BHC	LESS THAN 0.02
Beta-BHC	LESS THAN 0.02	Chlordane	LESS THAN 0.02
DDE	LESS THAN 0.02	DDT	LESS THAN 0.02
Delta-BHC	LESS THAN 0.02	Dieldrin	LESS THAN 0.02
Endrin	LESS THAN 0.02	HCB	LESS THAN 0.02
Heptachlor	LESS THAN 0.02	Heptachlor Epoxide	LESS THAN 0.02
Lindane	LESS THAN 0.02	Methoxychlor	LESS THAN 0.02
Mirex	LESS THAN 0.02	PCB	LESS THAN 0.15

Aflatoxin	Aflatoxins	LESS THAN 5 PPB

No notes.

-- for nutritional interpretation
3) Richmond, IN Manufacturing Plant at (765) 962- -- all other questions

The term "Less Than" is used to signify the lower limit of quantitation of the procedure under the conditions employed.
The use of the term "Less Than" does not imply that traces of analyte were present.

LabDiet PMI NUTRITION INTERNATIONAL

Return to Certified Analysis Retrieval

Product Code: 5002M
Product Desc: CERTIFIED RODENT DIET MEAL
Lab Number: L0222607-2
Lot Code: SEP 08 02 3B
Entered: 9/24/2002

Assay	Analysis	Units
PROTEIN	21.2	%
FAT ACID (HYDRO.)	5.86	%
FIBER (CRUDE)	4.14	%
ARSENIC	0.235	PPM
CADMIUM	LESS THAN 0.05	PPM
CALCIUM	0.820	%
LEAD	0.166	PPM
MERCURY	LESS THAN 0.025	PPM
PHOSPHORUS	0.587	%
SELENIUM	0.185	%

ORGANOPHOSPHATES	PPM	ORGANOPHOSPHATES	PPM
Diazinon	LESS THAN 0.02	Disulfoton	LESS THAN 0.02
Ethion	LESS THAN 0.02	Malathion	LESS THAN 0.02
Methyl Parathion	LESS THAN 0.02	Parathion	LESS THAN 0.02
Thimet	LESS THAN 0.02	Thiodan	LESS THAN 0.02
Trithion	LESS THAN 0.02		

PESTICIDES AND PCB	PPM	PESTICIDES AND PCB	PPM
Aldrin	LESS THAN 0.02	Alpha-BHC	LESS THAN 0.02
Beta-BHC	LESS THAN 0.02	Chlordane	LESS THAN 0.02
DDE	LESS THAN 0.02	DDT	LESS THAN 0.02
Delta-BHC	LESS THAN 0.02	Dieldrin	LESS THAN 0.02
Endrin	LESS THAN 0.02	HCB	LESS THAN 0.02
Heptachlor	LESS THAN 0.02	Heptachlor Epoxide	LESS THAN 0.02
Lindane	LESS THAN 0.02	Methoxychlor	LESS THAN 0.02
Mirex	LESS THAN 0.02	PCB	LESS THAN 0.15

Aflatoxin	Aflatoxins	LESS THAN 5 PPB

No notes.

-- for nutritional interpretation
3) Richmond, IN Manufacturing Plant at (765) 962- -- all other questions

The term "Less Than" is used to signify the lower limit of quantitation of the procedure under the conditions employed.
The use of the term "Less Than" does not imply that traces of analyte were present.

APPENDIX G

Water Analysis

DIVISION OF WATER TREATMENT & SUPPLY
206 Claremont Avenue
Ashland, Ohio 44805

Bruce Wiser
~~ROBERT XXSWINGHART~~
Director

January 28, 2002

Debbie Little
Wil Research
1407 Twp Rd 805
Ashland, OH 44805

Re: Water Regulations

Dear Ms. Little:

Enclosed you will find a listing of the most recent data on Primary, Secondary Water Regulation and Bacteriological testing for the City of Ashland, Water Treatment Plant.

The following are parameters that we test for each day and guidelines for those parameters:

PARAMETER	AVERAGE	GUIDELINES
pH	9.1	7.0 - 10.5 STATE
Alkalinity Phenol	6	NA
Alkalinity Total	28	20 - 40 OWN
Alkalinity Stability	28	0 - positive no. OWN
Hardness	126	<150 FOR DOMESTIC USE
Phosphate as Total P	2.29	< 1.0
Chlorine Free	1.3	0.5 - 2.0 OWN
Chlorine Combined	0.1	1.0 - 2.0 OWN
Chlorine Free Dist. System	1.1	MIN 0.2 STATE
Chlorine Combined Dist. System	0.1	MIN 1.0 STATE
Fluoride Plant Tap	1.1	0.8 - 2.0 FEDERAL
Fluoride Dist. System	0.94	0.8 - 2.0 FEDERAL

The above parameters are in mg/l except for pH which is in standard units.

If you have any questions or need additional information, please contact our office at 281-7041.

Yours very truly,

Bruce Wiser
Director, Water/Wastewater Treatment Facilities

Enclosures

PRIMARY DRINKING WATER REGULATIONS

PARAMETER	RESULTS	UNITS	DATE TESTED
ANTIMONY	<3.0	ug/L	1/21/99
ARSENIC	<3.0	ug/L	1/22/99
BARIUM	25	ug/L	5/21/93
BERYLLIUM	<0.5	ug/L	1/22/99
CADMIUM	<0.5	ug/L	1/21/99
CHROMIUM	<20	ug/L	1/28/99
CYANIDE	<0.010	mg/L	5/21/93
FLUORIDE	0.93	mg/L	2/4/99
MERCURY	<0.2	ug/L	5/21/93
NICKEL	<10	ug/L	1/28/99
NITRATE (as N)	0.13	mg/L	2/5/01
NITRITE	<0.05	mg/L	5/21/93
SELENIUM	<3.0	ug/L	5/21/93
THALLIUM	<1.0	ug/L	1/21/99

SOC's (18) see attached sheet 2/10/97
VOC's (58) see attached sheet 6/28/99
TOTAL TRIHOLOMETHANES Running annual avg. of 4 quarterly samples 0.04 mg/l
COLIFORM Safe <1/100 ML
TOTAL ALPHA <3 pCi/L 1/29/99
ASBESTOS <0.2 mf/l.>10 um 5/25/93

SECONDARY DRINKING WATER REGULATIONS

CHLORIDE	32 mg/l 3/27/01
COLOR	Not required at this time
CORROSIVENESS	Mildly Depositing
FOAMING AGENTS	Not required at this time
IRON	Not required at this time
MANGANESE	Not required at this time
ODOR	Not required at this time
pH	8.5 to 9.5 Standard Units
SULFATE	91 mg/L 3/27/01
ZINC	Not required at this time
T.D.S.	240 mg/l

BACTERIOLOGICAL
State approved bacteriological lab. Samples collected and analyzed on a daily basis from distribution system. We have had no violations of the Safe Drinking Water Requirements.

ATEL

Aqua Tech Environmental Laboratories, Inc.

- CERTIFICATE OF ANALYSIS -

Client #: I0043
Wil Research Laboratories
1407 George Road
Ashland, OH 44805

Report Date: *31-May-02*

Phone: (419) 289-8700 **Ext:**
FAX: (419) 289-3650

Attn:

Our Lab #: MAR02-09589 **Your Sample ID:** B=Prior to RD-E
Date Logged-In: 5/23/02 **Sample Source:** Other/Undefined
Matrix: Aqueous **Client Project #:** **PO#:** 12689
Project #: **Date Submitted to Lab:** 5/23/2002

- COLLECTION INFORMATION -

Date/Time/By: 5/22/02 11:53 AM

Test Group	EPA Method	Test	Result	Units	Analysis Date	Analyst	WS#
AS-MS	200.8/6020	Arsenic, As	< 3.0	UG/L	5/29/02	RCM	29996
BA-ICP	200.7/6010B	Barium, Ba	22	UG/L	5/24/02	RJA	29960
CD-MS	200.8/6020	Cadmium, Cd	< 0.5	UG/L	5/29/02	RCM	29996
CR-ICP	200.7/6010B	Chromium, Cr	< 20	UG/L	5/24/02	RJA	29960
PB-MS	200.8/6020	Lead, Pb	3.0	UG/L	5/29/02	RCM	29996
HG	245.1/7470A	Mercury, Hg	< 0.2	UG/L	5/29/02	RJA	30010
NO3+NO2	SM4500-NO3-F	Nitrogen, Nitrate + Nitrite (as N)	0.11	MG/L	5/24/02	JEL	29947
SE-MS	200.8	Selenium, Se	< 3.0	UG/L	5/29/02	RCM	29996
AG-GFAA	3113B/7761	Silver, Ag	< 1.0	UG/L	5/24/02	SPM	29957
NA-ICP	200.7/6010B	Sodium, Na	28	MG/L	5/24/02	RJA	29960

End of Report

Report Approved By: Lana L Jackson
Lana L. Jackson

This report shall not be reproduced, except in its entirety, without the written approval of the laboratory.

CERTIFICATIONS: NCDWQ263,NCDEH39700,AZ0071,OH4053,NY11071,A2LA102325

1776 MARION-WALDO RD. • P.O. BOX 436 • MARION, OH 43301-0436
PHONE 740-389-5991 • 1-800-873-2835 • FAX 740-389-1481

APPENDIX H

Animal Room Environmental Conditions

PROJECT NO.:WIL- 186028 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: ACC

STUDY SPECIFICATIONS: 186028 DATE IN: 08/20/02 TIME IN: 10:00
DATE OUT: 11/30/02 TIME OUT: 10:00

ROOM SPECIFICATIONS: B ROOM 33 LOW TEMPERATURE ºF: 66.0 HIGH TEMPERATURE ºF: 76.0 LOW HUMIDITY: 30.0
SPECIES: RAT LOW TEMPERATURE ºC: 18.9 HIGH TEMPERATURE ºC: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (ºF)	MEAN (ºC)	MEAN (%RH)
20-Aug-02	70.8	21.5	46.5
21-Aug-02	70.7	21.5	47.3
22-Aug-02	70.7	21.5	48.3
23-Aug-02	70.8	21.5	48.0
24-Aug-02	70.8	21.6	47.5
25-Aug-02	70.8	21.6	47.3
26-Aug-02	70.7	21.5	48.1
27-Aug-02	70.8	21.5	47.8
28-Aug-02	70.7	21.5	47.8
29-Aug-02	70.8	21.6	47.0
30-Aug-02	70.8	21.5	47.1
31-Aug-02	70.8	21.6	48.1
01-Sep-02	70.7	21.5	47.4
02-Sep-02	70.8	21.5	47.7
03-Sep-02	70.8	21.5	48.1
04-Sep-02	70.9	21.6	46.7
05-Sep-02	70.8	21.5	48.1
06-Sep-02	70.8	21.5	48.4
07-Sep-02	70.7	21.5	48.5
08-Sep-02	70.7	21.5	48.1
09-Sep-02	70.7	21.5	48.6
10-Sep-02	70.6	21.5	48.5
11-Sep-02	70.7	21.5	45.9

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.07
01/27/2003 09:59

PROJECT NO.:WIL- 186028 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: ACC

STUDY SPECIFICATIONS: 186028 DATE IN: 08/20/02 TIME IN: 10:00
DATE OUT: 11/30/02 TIME OUT: 10:00

ROOM SPECIFICATIONS: B ROOM 33 LOW TEMPERATURE ºF: 66.0 HIGH TEMPERATURE ºF: 76.0 LOW HUMIDITY: 30.0
SPECIES: RAT LOW TEMPERATURE ºC: 18.9 HIGH TEMPERATURE ºC: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (ºF)	MEAN (ºC)	MEAN (%RH)
12-Sep-02	70.7	21.5	41.7
13-Sep-02	70.7	21.5	41.1
14-Sep-02	70.7	21.5	47.4
15-Sep-02	70.7	21.5	48.0
16-Sep-02	70.7	21.5	48.7
17-Sep-02	70.7	21.5	48.0
18-Sep-02	70.7	21.5	48.8
19-Sep-02	70.7	21.5	50.1
20-Sep-02	70.7	21.5	51.1
21-Sep-02	70.7	21.5	49.3
22-Sep-02	70.8	21.5	49.0
23-Sep-02	70.8	21.5	42.3
24-Sep-02	70.7	21.5	41.5
25-Sep-02	70.8	21.6	44.2
26-Sep-02	70.7	21.5	48.9
27-Sep-02	70.7	21.5	49.2
28-Sep-02	70.8	21.6	48.0
29-Sep-02	70.8	21.6	48.3
30-Sep-02	70.6	21.5	48.8
01-Oct-02	70.7	21.5	48.8
02-Oct-02	70.6	21.5	48.5
03-Oct-02	70.6	21.5	48.8
04-Oct-02	70.7	21.5	49.4

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.07
01/27/2003 09:59

PROJECT NO.:WIL- 186028 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: ACC

STUDY SPECIFICATIONS: 186028 DATE IN: 08/20/02 TIME IN: 10:00
DATE OUT: 11/30/02 TIME OUT: 10:00

ROOM SPECIFICATIONS: B ROOM 33 LOW TEMPERATURE ºF: 66.0 HIGH TEMPERATURE ºF: 76.0 LOW HUMIDITY: 30.0
SPECIES: RAT LOW TEMPERATURE ºC: 18.9 HIGH TEMPERATURE ºC: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (ºF)	MEAN (ºC)	MEAN (%RH)
05-Oct-02	70.7	21.5	44.4
06-Oct-02	70.7	21.5	43.3
07-Oct-02	70.8	21.6	39.3
08-Oct-02	70.8	21.6	38.8
09-Oct-02	70.8	21.6	37.6
10-Oct-02	70.7	21.5	41.8
11-Oct-02	70.7	21.5	47.8
12-Oct-02	70.7	21.5	48.9
13-Oct-02	70.8	21.5	41.6
14-Oct-02	70.9	21.6	37.7
15-Oct-02	70.8	21.5	40.3
16-Oct-02	70.9	21.6	41.2
17-Oct-02	70.9	21.6	39.0
18-Oct-02	70.8	21.5	37.3
19-Oct-02	70.7	21.5	40.4
20-Oct-02	70.7	21.5	37.9
21-Oct-02	70.8	21.6	39.0
22-Oct-02	70.8	21.5	43.2
23-Oct-02	70.8	21.5	51.6
24-Oct-02	70.8	21.6	51.2
25-Oct-02	70.8	21.5	52.2
26-Oct-02	70.8	21.5	52.7
27-Oct-02	70.8	21.5	51.4

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.07
01/27/2003 09:59

PROJECT NO.:WIL- 186028 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: ACC

STUDY SPECIFICATIONS: 186028 DATE IN: 08/20/02 TIME IN: 10:00
DATE OUT: 11/30/02 TIME OUT: 10:00

ROOM SPECIFICATIONS: B ROOM 33 LOW TEMPERATURE ºF: 66.0 HIGH TEMPERATURE ºF: 76.0 LOW HUMIDITY: 30.0
SPECIES: RAT LOW TEMPERATURE ºC: 18.9 HIGH TEMPERATURE ºC: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (ºF)	MEAN (ºC)	MEAN (%RH)
28-Oct-02	70.7	21.5	51.0
29-Oct-02	70.8	21.6	51.7
30-Oct-02	70.8	21.5	51.4
31-Oct-02	70.8	21.6	47.0
01-Nov-02	70.8	21.5	42.1
02-Nov-02	70.7	21.5	41.8
03-Nov-02	70.8	21.5	41.6
04-Nov-02	70.8	21.5	43.1
05-Nov-02	70.8	21.6	42.2
06-Nov-02	70.8	21.6	42.7
07-Nov-02	70.8	21.5	42.4
08-Nov-02	70.8	21.5	40.6
09-Nov-02	70.7	21.5	41.8
10-Nov-02	70.8	21.5	49.9
11-Nov-02	70.7	21.5	45.8
12-Nov-02	70.8	21.5	42.3
13-Nov-02	70.8	21.6	41.3
14-Nov-02	70.8	21.6	41.0
15-Nov-02	70.8	21.6	42.2
16-Nov-02	70.8	21.5	41.9
17-Nov-02	70.8	21.5	41.6
18-Nov-02	70.7	21.5	41.8
19-Nov-02	70.8	21.6	41.0

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.07
01/27/2003 09:59

PROJECT NO.:WIL- 186028 TEMPERATURE/HUMIDITY - DAILY SUMMARY REPORT BY STUDY
SPONSOR: ACC

STUDY SPECIFICATIONS: 186028 DATE IN: 08/20/02 TIME IN: 10:00
DATE OUT: 11/30/02 TIME OUT: 10:00

ROOM SPECIFICATIONS: B ROOM 33 LOW TEMPERATURE ºF: 66.0 HIGH TEMPERATURE ºF: 76.0 LOW HUMIDITY: 30.0
SPECIES: RAT LOW TEMPERATURE ºC: 18.9 HIGH TEMPERATURE ºC: 24.4 HIGH HUMIDITY: 70.0

	TEMPERATURE		HUMIDITY
DATE	MEAN (ºF)	MEAN (ºC)	MEAN (%RH)
20-Nov-02	70.7	21.5	39.3
21-Nov-02	70.8	21.6	39.5
22-Nov-02	70.8	21.6	41.1
23-Nov-02	70.7	21.5	40.1
24-Nov-02	70.8	21.5	40.3
25-Nov-02	70.8	21.6	39.8
26-Nov-02	70.8	21.6	40.6
27-Nov-02	70.8	21.5	39.8
28-Nov-02	70.8	21.5	39.6
29-Nov-02	70.8	21.5	39.6
30-Nov-02	70.9	21.6	39.9

GRAND STATS	MEAN	MIN	MAX
TEMPERATURE ºF	70.8	70.6	70.9
TEMPERATURE ºC	21.5	21.5	21.6
HUMIDITY (%RH)	45.0	37.3	52.7
N DAYS	103		

NOTE: + = VALUE WAS GREATER THAN HIGH RANGE
- = VALUE WAS LESS THAN LOW RANGE
NOTE: MEANS REPRESENT THE MEAN OF THE DAILY VALUES

REPORT 4
VERSION 1.07
01/27/2003 09:59

ROOM SPECIFICATIONS:	B ROOM 33		
SPECIES:	RAT		
LOW TEMPERATURE:	66.0	DATE IN:	08/20/02
HIGH TEMPERATURE:	76.0	TIME IN:	10:00
LOW HUMIDITY:	30.0	DATE OUT:	11/30/02
HIGH HUMIDITY:	70.0	TIME OUT:	10:00

ROOM B ROOM 33 SUMMARY

	TEMPERATURE	HUMIDITY
MEAN	70.8	45.0
MIN	69.8	32.0
MAX	72.1	60.6
SD	0.23	4.69
N SAMPLES	2439	2439
FIRST DAY	08/20/02	
LAST DAY	11/30/02	
N DAYS	103	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
HUMIDITY UNITS = % RELATIVE HUMIDITY
NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

REPORT 5
VERSION 1.10
01/27/2003 10:00

STUDY 186028 SUMMARY

MEAN	70.8	45.0
MIN	69.8	32.0
MAX	72.1	60.6
SD	0.23	4.69
N SAMPLES	2439	2439
FIRST DAY	08/20/02	
LAST DAY	11/30/02	
N DAYS	103	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
HUMIDITY UNITS = % RELATIVE HUMIDITY
NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

APPENDIX I

WIL Reproductive Historical Control Data [Crl:CD®(SD)IGS BR Rats]

GRAND MEAN SUMMARY
PARENTAL AND NEONATAL OBSERVATIONS

ENDPOINT	Total	Mean	SD	Min	Max	25th Quartile	75th Quartile
TOTAL NO. MALES IN CONTROL GROUP	684	28.5	3.50	24	40	25	30
MALE MATING INDEX (%)		96.0	6.62	72.0	100.0	95.3	100.0
MALE FERTILITY (%)		89.3	10.03	56.7	100.0	87.7	95.9
TOTAL NO. FEMALES IN CONTROL GROUP	881	27.5	3.50	22	40	25	30
FEMALE MATING INDEX (%)		97.0	4.02	84.0	100.0	96.0	100.0
FEMALE FERTILITY (%)		90.4	8.80	56.7	100.0	87.9	95.9
TOTAL NO. FEMALES SELECTED TO DELIVER	879						
NO. WHICH DELIVERED	812	25.4	3.57	17	38	23.0	27.3
NO. WHICH DID NOT DELIVER	73	2.3	2.51	0	13	1	3
NO. DIED	2						
NO. OF DAMS WITH TOTAL LITTER LOSS	6	0.2	0.40	0	1	0.0	0.0
MEAN PRECOITAL INTERVAL (DAYS)		2.7	0.41	2	3.5	2.4	2.9
MEAN GESTATION LENGTH (DAYS)		21.8	0.17	21.6	22.3	21.7	21.8
MEAN NO. PUPS BORN		14.2	1.02	12.0	16.3	13.4	15.0
MEAN VIABLE LITTER SIZE PND 0		13.9	1.01	11.6	15.9	13	14.7
MEAN NO. DEAD PUPS PND 0		0.3	0.15	0.04	0.68	0	0.38
% DEAD PUPS PND 0		2.0	1.03	0.3	4.5	1.1	2.7
PUP SEX RATIO							
% MALE		50.0	2.54	44	56.4	48.6	51.6
% FEMALE		50.0	2.54	43.6	56	48.5	51.4
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING		15.2	0.86	13.7	16.7	14.2	15.9
MEAN NO. OF SITES UNACCOUNTED FOR AT WEANING		0.8	0.17	0.5	1.2	0.7	0.9
MEAN ESTROUS CYCLE LENGTH (DAYS)		4.3	0.29	4.1	5.1	4.2	4.4
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM		86.6	16.61	54.4	98.1	86.1	96.9

DATE OF INITIATION OF FIRST STUDY ENTERED 6/17/96
DATE OF TERMINATION OF LAST STUDY ENTERED 1/11/00

GRAND MEAN SUMMARY
PARENTAL AND NEONATAL OBSERVATIONS

ENDPOINT	Mean	SD	Min	Max	25th Quartile	75th Quartile
MEAN NO. PUPS BORN	14.2	1.02	12.0	16.3	13.4	15.0
PUP SURVIVAL INDICES (PND)						
BIRTH-4 (BEFORE SELECTION)	96.2	2.05	91.3	99.3	95.3	97.6
DAYS 4-21 (AFTER SELECTION)	98.9	1.45	95.4	100	98.7	100.0
MEAN PUP WEIGHTS (g) MALE (PND)						
DAY 1	7.0	0.23	6.5	7.4	6.8	7.1
DAY 4 (BEFORE SELECTION)	9.9	0.57	8.6	10.7	9.5	10.4
DAY 7	15.4	1.67	11.7	17.8	15.1	16.6
DAY 14	31.0	3.91	22.5	36.5	28.0	33.6
DAY 21	48.6	6.05	34.9	58	45.3	52.9
MEAN PUP WEIGHTS (g) FEMALE (PND)						
DAY 1	6.6	0.22	6.1	6.9	6.4	6.7
DAY 4 (BEFORE SELECTION)	9.3	0.54	8.1	10	9.0	9.7
DAY 7	14.6	1.60	11	16.8	14.1	15.9
DAY 14	29.7	3.82	21.2	34.7	26.6	32.2
DAY 21	46.4	5.70	33.3	54.8	43.6	50.7
ANOGENITAL DISTANCE (PND 1)						
MALE	5.3	0.32	4.8	5.7	5.3	5.3
FEMALE	3.2	0.43	2.7	3.9	3.1	3.3
MEAN BALANOPREPUTIAL SEPARATION (PND)	44.7	2.18	41.6	49	43.2	46.4
MEAN BODY WEIGHT AT ACQUISITION	227.8	11.70	210.5	248	221.7	230.8
MEAN VAGINAL PATENCY (PND)	33.3	1.68	31.9	38.8	32.5	33.3
MEAN BODY WEIGHT AT ACQUISITION	111.5	6.36	102.8	119.5	106.5	118.0

ENDPOINT	Mean	SD	Min	Max	25th Quartile	75th Quartile
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	2.40	0.368	1.76	2.80	2.05	2.70
MEAN RIGHT TESTIS WEIGHT (G)	1.75	0.065	1.65	1.86	1.71	1.79
MEAN LEFT TESTIS WEIGHT (G)	1.76	0.067	1.67	1.88	1.71	1.81
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	0.72	0.030	0.64	0.75	0.71	0.74
MEAN LEFT EPIDIDYMIS WEIGHT (G)	0.72	0.032	0.64	0.76	0.70	0.74
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	0.3179	0.01399	0.2807	0.3364	0.3160	0.3266
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	0.3210	0.01409	0.2943	0.3423	0.3197	0.3280
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)						
LEFT TESTIS	90.2	7.92	72.9	104.8	86.7	95.4
LEFT EPIDIDYMIS	444.4	47.91	343.6	534.3	414.2	464.9
MEAN SPERM PRODUCTION RATE						
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	14.8	1.30	11.9	17.2	14.2	15.6
% MOTILE SPERM	83.2	3.51	75.4	87.6	80.8	85.8
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)						
NORMAL	99.0	0.97	96.4	99.9	98.6	99.7
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.6	0.54	0.03	2.0	0.2	0.8
HEAD ABSENT WITH NORMAL FLAGELLUM	0.4	0.44	0.03	1.6	0.1	0.6
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.03	0.0	0.1	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.01	0.0	0.02	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.00	0.0	0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.00	0.0	0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.00	0.0	0	0.0	0.0
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)						
NORMAL	198.0	1.92	192.8	199.9	197.3	199.3
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	1.2	1.08	0.07	4	0.3	1.6
HEAD ABSENT WITH NORMAL FLAGELLUM	0.8	0.86	0.07	3.2	0.2	1.1
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.03	0.0	0.1	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.03	0.0	0.1	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.00	0.0	0.0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.00	0.0	0.0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.00	0.0	0.0	0.0	0.0

STUDY NO.	1	2	3	4	5
TOTAL NO. MALES IN CONTROL GROUP	30	30	30	30	30
MALE MATING INDEX (%)	100.0	93.3	100.0	90.0	100.0
MALE FERTILITY (%)	83.3	56.7	93.3	90.0	93.3
TOTAL NO. FEMALES IN CONTROL GROUP	30	30	30	30	30
FEMALE MATING INDEX (%)	100.0	93.3	100.0	90.0	100.0
FEMALE FERTILITY (%)	83.3	56.7	93.3	90.0	93.3
TOTAL NO. FEMALES SELECTED TO DELIVER	30	30	30	30	30
NO. WHICH DELIVERED	25	17	26	27	28
NO. WHICH DID NOT DELIVER	5	11	2	0	2
NO. DIED	0	0	0	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	1	0	0	0	0
MEAN PRECOITAL INTERVAL (DAYS)	3.2	3.0	2.3	2.4	2.2
MEAN GESTATION LENGTH (DAYS)	22.3	22.0	21.8	21.8	21.8
MEAN NO. PUPS BORN	12.0	12.9	13.6	13.5	13.0
MEAN VIABLE LITTER SIZE PND 0	11.6	12.5	13.5	13.4	13.0
TOTAL NO. DEAD PUPS PND 0	10	6	3	4	2
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	3.32	2.74	0.79	1.10	0.55
MEAN DEAD PUPS/LITTER	0.40	0.35	0.11	0.15	0.70
PUP SEX RATIO					
MALES (% PER LITTER)	49.7	52.1	51.1	51.8	52.1
FEMALES (% PER LITTER)	50.3	47.9	48.9	48.2	47.9
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	---	---	14.5	14.2	14.2
MEAN NO. OF SITES UNACCOUNTED FOR AT WEANING	---	---	0.9	0.7	1.2
MEAN ESTROUS CYCLE LENGTH (DAYS)	---	---	4.2	4.1	4.2
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	---	---	---	---	---
DATE OF STUDY INITIATION	11/19/97	2/23/98	11/3/98	2/3/99	9/24/98
DATE OF STUDY TERMINATION	4/7/98	8/18/98	3/16/99	7/23/99	2/5/99
VEHICLE	Basal Feed	Basal Feed	Basal Feed	Basal Feed	Filtered Air
ROUTE	Diet	Diet	Diet	Diet	Inhalation

STUDY NO.	6	7	8	9	10
TOTAL NO. MALES IN CONTROL GROUP	30	30	30	30	30
MALE MATING INDEX (%)	100.0	93.3	100.0	100.0	100.0
MALE FERTILITY (%)	96.7	80.0	89.7	93.3	93.3
TOTAL NO. FEMALES IN CONTROL GROUP	30	30	30	30	30
FEMALE MATING INDEX (%)	100.0	93.3	100.0	100.0	100.0
FEMALE FERTILITY (%)	96.7	80.0	89.7	93.3	93.3
TOTAL NO. FEMALES SELECTED TO DELIVER	30	30	29	30	30
NO. WHICH DELIVERED	29	24	26	28	28
NO. WHICH DID NOT DELIVER	1	4	3	2	2
NO. DIED	0	0	1	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	1	1	0	0	0
MEAN PRECOITAL INTERVAL (DAYS)	3.5	2.6	2.7	2.7	2.8
MEAN GESTATION LENGTH (DAYS)	21.7	22.0	21.8	22.1	21.8
MEAN NO. PUPS BORN	13.4	15.0	13.2	13.2	13.3
MEAN VIABLE LITTER SIZE PND 0	13.1	14.5	12.9	12.9	13.1
TOTAL NO. DEAD PUPS PND 0	7	12	8	7	7
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	1.80	3.34	2.33	1.90	1.88
MEAN DEAD PUPS/LITTER	0.24	0.50	0.31	0.25	0.25
PUP SEX RATIO					
MALES (% PER LITTER)	48.6	49.2	48.6	44.0	45.0
FEMALES (% PER LITTER)	51.4	50.8	51.4	56.0	55.0
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	14.0	15.7	14.0	13.7	14.2
MEAN NO. OF SITES UNACCOUNTED FOR	0.7	0.8	0.8	0.6	0.9
MEAN ESTROUS CYCLE LENGTH (DAYS)	5.1	4.2	4.3	4.5	4.4
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	96.7	54.4	98.1	---	85.5
DATE OF STUDY INITIATION	12/24/98	2/9/99	5/27/99	11/23/98	2/25/99
DATE OF STUDY TERMINATION	6/11/99	7/9/99	11/12/99	4/7/99	8/19/99
VEHICLE	Filtered Air	Deionized Water	Deionized Water	Basal Feed	Basal Feed
ROUTE	Inhalation	Gavage	Gavage	Diet	Diet

STUDY NO.	11	12	13	14	15
TOTAL NO. MALES IN CONTROL GROUP	30	30	30	30	---
MALE MATING INDEX (%)	96.6	96.7	93.3	100.0	---
MALE FERTILITY (%)	89.7	96.7	86.7	100.0	---
TOTAL NO. FEMALES IN CONTROL GROUP	30	30	30	30	25
FEMALE MATING INDEX (%)	96.7	96.7	93.3	100.0	100.0
FEMALE FERTILITY (%)	90.0	96.7	86.7	100.0	---
TOTAL NO. FEMALES SELECTED TO DELIVER	30	30	30	30	25
NO. WHICH DELIVERED	27	29	26	30	24
NO. WHICH DID NOT DELIVER	2	0	2	0	0
NO. DIED	0	0	0	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	1	0	0	0	1
MEAN PRECOITAL INTERVAL (DAYS)	2.7	3.3	2.6	2.0	---
MEAN GESTATION LENGTH (DAYS)	21.9	21.6	21.8	21.6	21.8
MEAN NO. PUPS BORN	13.7	13.4	13.5	14.9	15.1
MEAN VIABLE LITTER SIZE PND 0	13.3	13.1	13.2	14.4	14.4
TOTAL NO. DEAD PUPS PND 0	10	8	8	15	17
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	2.70	2.06	2.29	3.36	4.50
MEAN DEAD PUPS/LITTER	0.37	0.28	0.31	0.50	0.68
PUP SEX RATIO					
MALES (% PER LITTER)	56.4	50.6	51.3	50.0	49.0
FEMALES (% PER LITTER)	43.6	49.4	48.7	50.0	51.0
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	---	---	---	15.6	15.9
MEAN NO. OF SITES UNACCOUNTED FOR	---	---	---	0.8	0.8
MEAN ESTROUS CYCLE LENGTH (DAYS)	---	---	---	---	---
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	87.8	96.9	---	---	---
DATE OF STUDY INITIATION	1/14/97	4/15/97	4/15/97	11/4/97	8/31/98
DATE OF STUDY TERMINATION	6/3/97	11/29/97	11/29/97	11/25/97	10/9/98
VEHICLE	Filtered Air	Filtered Air	Filtered Air	Filtered Air	0.4% Methyl-cellulose
ROUTE	Inhalation	Inhalation	Inhalation	Inhalation	Gavage

STUDY NO.	16	17	18	19	20
TOTAL NO. MALES IN CONTROL GROUP	25	24	---	25	25
MALE MATING INDEX (%)	100.0	100.0	---	100.0	100.0
MALE FERTILITY (%)	92.0	95.8	---	100.0	96.0
TOTAL NO. FEMALES IN CONTROL GROUP	25	24	25	25	25
FEMALE MATING INDEX (%)	100.0	100.0	---	100.0	100.0
FEMALE FERTILITY (%)	92.0	95.8	---	100.0	96.0
TOTAL NO. FEMALES SELECTED TO DELIVER	25	24	25	25	25
NO. WHICH DELIVERED	23	23	23	25	24
NO. WHICH DID NOT DELIVER	2	1	0	0	1
NO. DIED	0	0	0	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	0	0	0	0	0
MEAN PRECOITAL INTERVAL (DAYS)	2.4	2.4	---	2.8	2.7
MEAN GESTATION LENGTH (DAYS)	21.8	21.6	21.8	---	---
MEAN NO. PUPS BORN	14.3	15.5	14.8	---	---
MEAN VIABLE LITTER SIZE PND 0	13.9	15.0	14.7	---	---
TOTAL NO. DEAD PUPS PND 0	9	10	3	---	---
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	2.74	2.81	0.88	---	---
MEAN DEAD PUPS/LITTER	0.39	0.43	0.13	---	---
PUP SEX RATIO					
MALES (% PER LITTER)	52.1	49.7	51.9	---	---
FEMALES (% PER LITTER)	47.9	50.3	48.1	---	---
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	15.1	15.9	15.7	---	---
MEAN NO. OF SITES UNACCOUNTED FOR	0.8	0.9	1.0	---	---
MEAN ESTROUS CYCLE LENGTH (DAYS)	---	---	---	---	---
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	---	---	---	---	---
DATE OF STUDY INITIATION	9/14/98	7/7/98	9/23/98	10/27/98	3/29/99
DATE OF STUDY TERMINATION	2/1/99	10/1/98	11/23/98	3/1/99	5/4/99
VEHICLE	0.4% Methyl-cellulose	Basal Feed	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80
ROUTE	Gavage	Diet	Gavage	Gavage	Gavage

STUDY NO.	21	22	23	24	25
TOTAL NO. MALES IN CONTROL GROUP	---	25	---	25	---
MALE MATING INDEX (%)	---	96.0	---	72.0	---
MALE FERTILITY (%)	---	88.0	---	72.0	---
TOTAL NO. FEMALES IN CONTROL GROUP	25	25	22	25	25
FEMALE MATING INDEX (%)	---	96.0	---	84.0	---
FEMALE FERTILITY (%)	---	88.0	---	84.0	---
TOTAL NO. FEMALES SELECTED TO DELIVER	25	25	22	25	25
NO. WHICH DELIVERED	25	22	21	21	25
NO. WHICH DID NOT DELIVER	0	3	0	0	0
NO. DIED	0	0	0	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	0	0	0	0	0
MEAN PRECOITAL INTERVAL (DAYS)	---	2.2	---	3.5	---
MEAN GESTATION LENGTH (DAYS)	21.6	21.8	21.8	---	22.0
MEAN NO. PUPS BORN	14.1	15.0	14.8	---	14.8
MEAN VIABLE LITTER SIZE PND 0	13.8	14.9	14.6	---	14.7
TOTAL NO. DEAD PUPS PND 0	8	5	3	---	1
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	2.27	1.51	0.97	---	0.27
MEAN DEAD PUPS/LITTER	0.32	0.23	0.14	---	0.04
PUP SEX RATIO					
MALES (% PER LITTER)	47.7	49.8	47.7	---	47.7
FEMALES (% PER LITTER)	52.3	50.2	52.3	---	52.3
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	15.2	15.9	15.4	---	15.7
MEAN NO. OF SITES UNACCOUNTED FOR	1.0	0.8	0.7	---	0.9
MEAN ESTROUS CYCLE LENGTH (DAYS)	---	---	---	4.2	---
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	---	---	---	---	---
DATE OF STUDY INITIATION	10/26/98	11/17/98	1/12/99	2/3/99	7/27/98
DATE OF STUDY TERMINATION	12/13/98	4/13/98	3/1/99	6/15/99	9/12/98
VEHICLE	20 mM Na-Phosphate	21 mM Na-Phosphate	Sponsor Supplied	Sponsor Supplied	0.75% Methyl-cellulose
ROUTE	SubQ	SubQ	SubQ	SubQ	Gavage

STUDY NO.	26	27	28	29	30
TOTAL NO. MALES IN CONTROL GROUP	25	---	---	25	---
MALE MATING INDEX (%)	96.0	---	---	96.0	---
MALE FERTILITY (%)	92.0	---	---	96.0	---
TOTAL NO. FEMALES IN CONTROL GROUP	25	25	25	25	25
FEMALE MATING INDEX (%)	96.0	---	---	96.0	---
FEMALE FERTILITY (%)	92.0	---	---	96.0	---
TOTAL NO. FEMALES SELECTED TO DELIVER	25	25	25	25	25
NO. WHICH DELIVERED	23	22	23	24	25
NO. WHICH DID NOT DELIVER	1	3	1	1	0
NO. DIED	0	0	0	0	0
NO. OF DAMS WITH TOTAL LITTER LOSS	0	1	0	0	0
MEAN PRECOITAL INTERVAL (DAYS)	2.4	---	---	2.9	---
MEAN GESTATION LENGTH (DAYS)	---	21.7	21.7	21.7	21.7
MEAN NO. PUPS BORN	---	15.2	16.3	14.8	15.1
MEAN VIABLE LITTER SIZE PND 0	---	14.9	15.9	14.7	15.0
TOTAL NO. DEAD PUPS PND 0	---	6	9	4	2
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	---	1.80	2.41	1.12	0.53
MEAN DEAD PUPS/LITTER	---	0.27	0.39	0.17	0.08
PUP SEX RATIO					
MALES (% PER LITTER)	---	50.8	54.0	50.8	48.5
FEMALES (% PER LITTER)	---	49.2	46.0	49.2	51.5
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	---	15.8	16.7	---	16.0
MEAN NO. OF SITES UNACCOUNTED FOR	---	0.6	0.5	---	1.0
MEAN ESTROUS CYCLE LENGTH (DAYS)	---	---	---	4.1	---
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	---	---	---	---	---
DATE OF STUDY INITIATION	8/18/98	9/13/99	8/2/99	8/17/99	8/9/99
DATE OF STUDY TERMINATION	12/29/98	10/31/99	9/12/99	1/10/00	9/25/99
VEHICLE	0.75% Methyl-cellulose	0.1 M Na-Phosphate	0.4% Methyl Cellulose	0.4% Methyl cellulose	Methyl-cellulose
ROUTE	Gavage	Gavage	Gavage	Gavage	Intranasal

STUDY NO.	31	32
TOTAL NO. MALES IN CONTROL GROUP	25	40
MALE MATING INDEX (%)	82.6	97.5
MALE FERTILITY (%)	73.9	95.0
TOTAL NO. FEMALES IN CONTROL GROUP	25	40
FEMALE MATING INDEX (%)	95.8	97.5
FEMALE FERTILITY (%)	87.5	95.0
TOTAL NO. FEMALES SELECTED TO DELIVER	24	40
NO. WHICH DELIVERED	21	38
NO. WHICH DID NOT DELIVER	3	2
NO. DIED	1	0
NO. OF DAMS WITH TOTAL LITTER LOSS	0	0
MEAN PRECOITAL INTERVAL (DAYS)	3.2	2.8
MEAN GESTATION LENGTH (DAYS)	---	21.6
MEAN NO. PUPS BORN	---	15.4
MEAN VIABLE LITTER SIZE PND 0	---	15.2
TOTAL NO. DEAD PUPS PND 0	---	9
% DEAD PUPS PND 0 [(DEAD PUPS/TOTAL NO. OF PUPS)*100]	---	1.54
MEAN DEAD PUPS/LITTER	---	0.24
PUP SEX RATIO		
MALES (% PER LITTER)	---	48.8
FEMALES (% PER LITTER)	---	51.2
MEAN NO. OF FORMER IMPLANTATION SITES AT WEANING	---	15.9
MEAN NO. OF SITES UNACCOUNTED FOR	---	0.5
MEAN ESTROUS CYCLE LENGTH (DAYS)	4.2	---
MEAN PRIMORDIAL FOLLICLE COUNT/10 SECTIONS/DAM	---	---
DATE OF STUDY INITIATION	8/31/99	6/17/96
DATE OF STUDY TERMINATION	1/11/00	11/15/96
VEHICLE	Methyl-cellulose	Filtered Air
ROUTE	Intranasal	Inhalation

STUDY NO.	1	2	3	4	5
MEAN NO. PUPS BORN	12.0	12.9	13.6	13.5	13.0
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	92.3	95.9	97.8	98.7	97.9
DAYS 4-21 (AFTER SELECTION)	99.5	98.5	100.0	99.1	99.6
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	7.4	7.1	7.2	7.0	7.2
DAY 4 (BEFORE SELECTION)	10.6	10.6	10.1	10.2	10.4
DAY 7	17.2	17.2	16.4	16.8	15.1
DAY 14	33.7	35.8	29.9	35.0	27.8
DAY 21	53.8	58.0	45.4	53.1	44.7
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	6.9	6.8	6.8	6.6	6.7
DAY 4 (BEFORE SELECTION)	10.0	10.0	9.5	9.7	9.7
DAY 7	16.1	16.3	15.5	16.2	14.1
DAY 14	32.1	34.3	28.9	33.9	26.3
DAY 21	51.6	54.8	44.1	51.0	42.2
ANOGENITAL DISTANCE (PND 1)					
MALE	---	---	---	---	---
FEMALE	---	---	---	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	---	43.3	---	46.7	---
MEAN BODY WEIGHT AT ACQUISITION	---	---	---	230.4	---
MEAN VAGINAL PATENCY (PND)	---	32.2	---	33.1	---
MEAN BODY WEIGHT AT ACQUISITION	---	---	---	106.9	---
VEHICLE	Basal Feed	Basal Feed	Basal Feed	Basal Feed	Filtered Air
ROUTE	Diet	Diet	Diet	Diet	Inhalation

STUDY NO.	6	7	8	9	10
MEAN NO. PUPS BORN	13.4	15.0	13.2	13.2	13.3
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	96.0	91.3	95.2	97.7	97.4
DAYS 4-21 (AFTER SELECTION)	96.1	100.0	99.5	100.0	96.0
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	7.1	6.8	6.8	7.3	7.1
DAY 4 (BEFORE SELECTION)	10.2	9.6	9.6	10.5	10.4
DAY 7	15.3	15.3	15.4	16.4	16.6
DAY 14	28.5	31.1	31.8	33.1	33.4
DAY 21	45.3	51.0	49.5	50.6	52.1
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	6.7	6.5	6.3	6.9	6.7
DAY 4 (BEFORE SELECTION)	9.5	9.1	9.0	10.0	9.7
DAY 7	14.3	14.5	14.6	15.7	15.6
DAY 14	27.5	29.7	30.8	32.2	31.2
DAY 21	43.5	47.9	47.7	49.2	49.0
ANOGENITAL DISTANCE (PND 1)					
MALE	---	5.3	5.7	---	---
FEMALE	---	3.2	3.9	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	45.0	---	44.6	---	44.6
MEAN BODY WEIGHT AT ACQUISITION	217.9	---	223.0	---	232.0
MEAN VAGINAL PATENCY (PND)	33.4	---	34.4	---	32.6
MEAN BODY WEIGHT AT ACQUISITION	105.1	---	118.9	---	112.2
VEHICLE	Filtered Air	Deionized Water	Deionized Water	Basal Feed	Basal Feed
ROUTE	Inhalation	Gavage	Gavage	Diet	Diet

STUDY NO.	11	12	13	14	15
MEAN NO. PUPS BORN	13.7	13.4	13.5	14.9	15.1
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	97.5	96.2	96.4	95.4	94.0
DAYS 4-21 (AFTER SELECTION)	95.4	98.5	---	---	99.5
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	6.9	6.6	7.0	6.9	7.1
DAY 4 (BEFORE SELECTION)	9.1	8.9	9.3	9.5	10.0
DAY 7	11.7	12.3	---	---	---
DAY 14	22.5	24.6	---	---	32.5
DAY 21	34.9	38.2	---	---	51.4
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	6.4	6.2	6.5	6.4	6.7
DAY 4 (BEFORE SELECTION)	8.5	8.4	8.8	9.0	9.5
DAY 7	11.0	11.5	---	---	15.4
DAY 14	21.2	23.4	---	---	31.7
DAY 21	33.3	37.0	---	---	49.1
ANOGENITAL DISTANCE (PND 1)					
MALE	5.3	5.3	---	---	---
FEMALE	3.3	3.1	---	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	---	47.0	47.5	---	---
MEAN BODY WEIGHT AT ACQUISITION	---	---	---	---	---
MEAN VAGINAL PATENCY (PND)	---	38.8	32.5	---	---
MEAN BODY WEIGHT AT ACQUISITION	---	---	---	---	---
VEHICLE	Filtered Air	Filtered Air	Filtered Air	Filtered Air	0.4% Methyl-cellulose
ROUTE	Inhalation	Inhalation	Inhalation	Inhalation	Gavage

STUDY NO.	16	17	18	19	20
MEAN NO. PUPS BORN	14.3	15.5	14.8	---	---
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	96.9	94.9	97.5	---	---
DAYS 4-21 (AFTER SELECTION)	---	100.0	100.0	---	---
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	7.2	6.7	7.1	---	---
DAY 4 (BEFORE SELECTION)	10.3	9.2	10.2	---	---
DAY 7	---	13.1	16.5	---	---
DAY 14	---	25.1	34.9	---	---
DAY 21	---	39.5	54.7	---	---
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	6.7	6.3	6.7	---	---
DAY 4 (BEFORE SELECTION)	9.8	8.7	9.7	---	---
DAY 7	---	12.6	15.9	---	---
DAY 14	---	24.1	33.7	---	---
DAY 21	---	38.0	52.4	---	---
ANOGENITAL DISTANCE (PND 1)					
MALE	---	4.8	---	---	---
FEMALE	---	2.7	---	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	41.6	---	41.8	---	---
MEAN BODY WEIGHT AT ACQUISITION	210.5	---	212.2	---	---
MEAN VAGINAL PATENCY (PND)	32.5	---	33.0	---	---
MEAN BODY WEIGHT AT ACQUISITION	107.4	---	117.7	---	---
VEHICLE	0.4% Methyl-cellulose	Basal Feed	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80
ROUTE	Gavage	Diet	Gavage	Gavage	Gavage

STUDY NO.	21	22	23	24	25
MEAN NO. PUPS BORN	14.1	15.0	14.8	---	14.8
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	97.4	97.5	97.8	---	99.3
DAYS 4-21 (AFTER SELECTION)	99.5	---	100.0	---	100.0
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	7.1	7.1	7.4	---	6.8
DAY 4 (BEFORE SELECTION)	10.2	10.4	10.7	---	9.6
DAY 7	16.7	---	17.8	---	15.7
DAY 14	34.8	---	36.5	---	32.4
DAY 21	53.3	---	55.3	---	52.4
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	6.8	6.7	6.9	---	6.5
DAY 4 (BEFORE SELECTION)	9.7	9.7	10.0	---	9.1
DAY 7	16.1	---	16.8	---	14.9
DAY 14	33.5	---	34.7	---	31.2
DAY 21	50.9	---	53.1	---	50.1
ANOGENITAL DISTANCE (PND 1)					
MALE	---	---	---	---	---
FEMALE	---	---	---	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	---	43.0	---	42.4	---
MEAN BODY WEIGHT AT ACQUISITION	---	227.1	---	229.0	---
MEAN VAGINAL PATENCY (PND)	---	32.4	---	31.9	---
MEAN BODY WEIGHT AT ACQUISITION	---	115.2	---	109.9	---
VEHICLE	20 mM Sodium Phosphate	21 mM Sodium Phosphate	Sponsor Supplied	Sponsor Supplied	0.75% Methyl-cellulose
ROUTE	SubQ	SubQ	SubQ	SubQ	Gavage

STUDY NO.	26	27	28	29	30
MEAN NO. PUPS BORN	---	15.2	16.3	14.8	15.1
PUP SURVIVAL INDICES (PND)					
BIRTH-4 (BEFORE SELECTION)	---	92.1	93.8	96.0	98.0
DAYS 4-21 (AFTER SELECTION)	---	99.3	100.0	---	97.0
MEAN PUP WEIGHTS (g) MALE (PND)					
DAY 1	---	6.8	6.7	7.1	6.5
DAY 4 (BEFORE SELECTION)	---	9.4	9.4	9.8	8.6
DAY 7	---	15.1	15.1	---	13.0
DAY 14	---	31.3	32.9	---	27.1
DAY 21	---	48.1	50.9	---	41.3
MEAN PUP WEIGHTS (g) FEMALE (PND)					
DAY 1	---	6.4	6.4	6.6	6.1
DAY 4 (BEFORE SELECTION)	---	8.9	8.8	9.1	8.1
DAY 7	---	14.1	14.3	---	12.2
DAY 14	---	29.4	31.2	---	25.7
DAY 21	---	45.0	48.0	---	39.4
ANOGENITAL DISTANCE (PND 1)					
MALE	---	---	---	---	---
FEMALE	---	---	---	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	44.3	46.1	---	43.8	---
MEAN BODY WEIGHT AT ACQUISITION	226.6	247.9	---	229.2	---
MEAN VAGINAL PATENCY (PND)	33.2	31.9	---	33.2	---
MEAN BODY WEIGHT AT ACQUISITION	119.1	103.8	---	119.5	---
VEHICLE	0.75% Methyl-cellulose	0.1 M Sodium Phosphate	0.4% Methyl Cellulose	0.4% Methyl cellulose	Methyl-cellulose
ROUTE	Gavage	Gavage	Gavage	Gavage	Intranasal

STUDY NO.	31	32
MEAN NO. PUPS BORN	---	15.4
PUP SURVIVAL INDICES (PND)		
BIRTH-4 (BEFORE SELECTION)	---	97.2
DAYS 4-21 (AFTER SELECTION)	---	99.3
MEAN PUP WEIGHTS (g) MALE (PND)		
DAY 1	---	7.1
DAY 4 (BEFORE SELECTION)	---	10.1
DAY 7	---	14.8
DAY 14	---	27.2
DAY 21	---	45.5
MEAN PUP WEIGHTS (g) FEMALE (PND)		
DAY 1	---	6.7
DAY 4 (BEFORE SELECTION)	---	9.6
DAY 7	---	14.0
DAY 14	---	26.3
DAY 21	---	43.8
ANOGENITAL DISTANCE (PND 1)		
MALE	---	---
FEMALE	---	---
MEAN BALANOPREPUTIAL SEPARATION (PND)	49.0	---
MEAN BODY WEIGHT AT ACQUISITION	248.0	---
MEAN VAGINAL PATENCY (PND)	33.7	---
MEAN BODY WEIGHT AT ACQUISITION	102.8	---
VEHICLE	Methyl-cellulose	Filtered Air
ROUTE	Intranasal	Inhalation

STUDY NO.	1	2	3	4	5
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	2.55	2.64	2.73	1.95	2.7
MEAN RIGHT TESTIS WEIGHT (G)	1.7	1.85	1.72	1.84	1.71
MEAN LEFT TESTIS WEIGHT (G)	1.71	1.88	1.74	1.85	1.71
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	0.71	0.75	0.74	0.74	0.71
MEAN LEFT EPIDIDYMIS WEIGHT (G)	0.72	0.76	0.72	0.75	0.72
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	0.3266	0.3293	0.3185	0.3164	0.3022
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	0.3197	0.3423	0.328	0.3295	0.327
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	85.2	89.1	99.3	87.0	87.3
LEFT EPIDIDYMIS	449.0	407.9	436.1	413.4	343.6
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	14.0	14.6	16.3	14.3	14.3
% MOTILE SPERM	84.9	82.4	85.5	87.6	80.0
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	98.6	99.4	99.9	99.6	99.0
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.7	0.5	0.0	0.3	0.5
HEAD ABSENT WITH NORMAL FLAGELLUM	0.6	0.1	0.0	0.1	0.5
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.1	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	197.2	198.8	199.9	199.1	198.0
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	1.4	0.9	0.1	0.6	1.1
HEAD ABSENT WITH NORMAL FLAGELLUM	1.3	0.3	0.1	0.3	0.9
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.1	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
VEHICLE	Basal Feed	Basal Feed	Basal Feed	Basal Feed	Filtered Air
ROUTE	Diet	Diet	Diet	Diet	Inhalation

STUDY NO.	6	7	8	9	10
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	2.05	1.88	---	2.8	1.76
MEAN RIGHT TESTIS WEIGHT (G)	1.7	1.72	---	1.73	1.79
MEAN LEFT TESTIS WEIGHT (G)	1.71	1.73	---	1.75	1.81
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	0.74	0.75	---	0.71	0.73
MEAN LEFT EPIDIDYMIS WEIGHT (G)	0.73	0.7	---	0.74	0.76
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	0.3269	0.3364	---	0.3157	0.321
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	0.3225	0.3242	---	0.328	0.3271
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	86.6	81.7	104.8	90.8	95.8
LEFT EPIDIDYMIS	517.5	410.6	534.3	452.1	416.4
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	14.2	13.4	17.2	14.9	15.7
% MOTILE SPERM	80.8	85.3	82.3	87.6	85.9
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	98.7	99.8	99.0	99.8	96.4
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.8	0.1	0.7	0.2	2.0
HEAD ABSENT WITH NORMAL FLAGELLUM	0.5	0.1	0.3	0.1	1.6
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	197.4	199.6	198.0	199.5	192.8
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	1.6	0.3	1.5	0.3	4.0
HEAD ABSENT WITH NORMAL FLAGELLUM	1.0	0.1	0.5	0.2	3.2
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	0.0	0.0	0.0
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	0.0	0.0	0.0
VEHICLE	Filtered Air	Deionized Water	Deionized Water	Basal Feed	Basal Feed
ROUTE	Inhalation	Gavage	Gavage	Diet	Diet

STUDY NO.	11	12	13	14	15
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	2.64	2.73	---	---	---
MEAN RIGHT TESTIS WEIGHT (G)	1.76	1.73	---	---	---
MEAN LEFT TESTIS WEIGHT (G)	1.71	1.76	---	---	---
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	0.7	0.72	---	---	---
MEAN LEFT EPIDIDYMIS WEIGHT (G)	0.7	0.7	---	---	---
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	0.3262	0.3174	---	---	---
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	0.3064	0.295	---	---	---
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	72.9	94.1	---	---	---
LEFT EPIDIDYMIS	456.0	467.9	---	---	---
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	11.9	15.4	---	---	---
% MOTILE SPERM	80.2	75.4	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	98.5	99.6	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.9	0.1	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	0.6	0.3	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.0	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	0.0	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	197.0	199.2	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	1.9	0.2	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	1.1	0.6	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	0.0	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.1	0.0	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	0.0	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	0.0	---	---	---
VEHICLE	Filtered Air	Filtered Air	Filtered Air	Filtered Air	0.4% Methyl-cellulose
ROUTE	Inhalation	Inhalation	Inhalation	Inhalation	Gavage

STUDY NO.	16	17	18	19	20
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	---	2.3	---	---	---
MEAN RIGHT TESTIS WEIGHT (G)	---	1.65	---	---	---
MEAN LEFT TESTIS WEIGHT (G)	---	1.67	---	---	---
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	---	0.64	---	---	---
MEAN LEFT EPIDIDYMIS WEIGHT (G)	---	0.64	---	---	---
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	---	0.2807	---	---	---
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	---	0.2943	---	---	---
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	---	96.6	---	---	---
LEFT EPIDIDYMIS	---	438.8	---	---	---
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	---	15.8	---	---	---
% MOTILE SPERM	---	80.9	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	---	97.8	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	1.2	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	1.0	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	0.0	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	0.0	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	0.0	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	0.0	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	0.0	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	---	195.7	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	2.4	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	1.9	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	0.0	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	0.0	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	0.0	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	0.0	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	0.0	---	---	---
VEHICLE	0.4% Methyl-cellulose	Basal Feed	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80	1% Avicel-5% Tween 80
ROUTE	Gavage	Diet	Gavage	Gavage	Gavage

STUDY NO.	21	22	23	24	25
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	2.45	---	---	---	---
MEAN RIGHT TESTIS WEIGHT (G)	1.86	---	---	---	---
MEAN LEFT TESTIS WEIGHT (G)	1.86	---	---	---	---
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	0.74	---	---	---	---
MEAN LEFT EPIDIDYMIS WEIGHT (G)	0.73	---	---	---	---
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	0.316	---	---	---	---
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	0.3293	---	---	---	---
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	91.7	---	---	---	---
LEFT EPIDIDYMIS	478.5	---	---	---	---
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	15.0	---	---	---	---
% MOTILE SPERM	86.2	---	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	99.7	---	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.2	---	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	0.1	---	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	---	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	---	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	---	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	---	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	---	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	199.3	---	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	0.4	---	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	0.2	---	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	0.0	---	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	0.0	---	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	0.0	---	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	---	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	0.0	---	---	---	---
VEHICLE	20 mM Sodium Phosphate	21 mM Sodium Phosphate	Sponsor Supplied	Sponsor Supplied	0.75% Methyl-cellulose
ROUTE	SubQ	SubQ	SubQ	SubQ	Gavage

STUDY NO.	26	27	28	29	30
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	---	---	---	---	---
MEAN RIGHT TESTIS WEIGHT (G)	---	---	---	---	---
MEAN LEFT TESTIS WEIGHT (G)	---	---	---	---	---
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	---	---	---	---	---
MEAN LEFT EPIDIDYMIS WEIGHT (G)	---	---	---	---	---
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	---	---	---	---	---
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	---	---	---	---	---
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)					
LEFT TESTIS	---	---	---	---	---
LEFT EPIDIDYMIS	---	---	---	---	---
MEAN SPERM PRODUCTION RATE					
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	---	---	---	---	---
% MOTILE SPERM	---	---	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)					
NORMAL	---	---	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	---	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	---	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	---	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	---	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	---	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---	---	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	---	---	---	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	---	---	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	---	---	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	---	---	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	---	---	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	---	---	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---	---	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---	---	---	---
VEHICLE	0.75% Methyl-cellulose	0.1 M Sodium Phosphate	0.4% Methyl-cellulose	0.4% Methyl-cellulose	Methyl-cellulose
ROUTE	Gavage	Gavage	Gavage	Gavage	Intranasal

STUDY NO.	31	32
MEAN SEMINAL VESICLE/COAGULATING GLAND WEIGHTS (G)	---	---
MEAN RIGHT TESTIS WEIGHT (G)	---	---
MEAN LEFT TESTIS WEIGHT (G)	---	---
MEAN RIGHT EPIDIDYMIS WEIGHT (G)	---	---
MEAN LEFT EPIDIDYMIS WEIGHT (G)	---	---
MEAN RIGHT CAUDA EPIDIDYMIS WEIGHT (G)	---	---
MEAN LEFT CAUDA EPIDIDYMIS WEIGHT (G)	---	---
MEAN SPERM COUNT (NO. SPERM IN MILLIONS/GRAM OF TISSUE)		
LEFT TESTIS	---	---
LEFT EPIDIDYMIS	---	---
MEAN SPERM PRODUCTION RATE		
(NO. SPERM IN MILLIONS/GRAM OF TISSUE/DAY)	---	---
% MOTILE SPERM	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (%)		
NORMAL	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---
SPERM MORPHOLOGY DIFFERENTIAL COUNT (ABSOLUTE NUMBER)	---	---
NORMAL SHAPED HEAD SEPARATED FROM FLAGELLUM	---	---
HEAD ABSENT WITH NORMAL FLAGELLUM	---	---
HEAD ABSENT WITH ABNORMAL FLAGELLUM	---	---
MISSHAPEN HEAD WITH NORMAL FLAGELLUM	---	---
MISSHAPEN HEAD WITH ABNORMAL FLAGELLUM	---	---
DEGENERATIVE FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---
OTHER FLAGELLAR DEFECTS WITH NORMAL HEAD	---	---
VEHICLE	Methyl-cellulose	Filtered Air
ROUTE	Intranasal	Inhalation

APPENDIX J

Study Protocol

Study Number: WIL-186028

PROTOCOL AMENDMENT III

Sponsor: American Chemistry Council Ethylbenzene Panel

A. Title of Study:

A Pilot Inhalation Study for a Reproductive Toxicity Study of Ethylbenzene in Rats

B. Protocol Modifications:

1) The study title is changed to:

"A Pilot Inhalation Study for a Reproductive Toxicity Study of Ethylbenzene in Rats"

C. Reasons for Protocol Modification:

1) To change the title to more closely reflect the objectives of the study.

Approved By:

American Chemistry Council

Elizabeth J. Moran, Ph.D., D.A.B.T.
Sponsor Representative

Jan 8, 2003
Date

Prepared By:

WIL Research Laboratories, Inc.

Donald G. Stump, Ph.D., D.A.B.T.
Study Director

12/19/02
Date

Mark D. Nemec, B.S., D.A.B.T.
Director, Developmental and
Reproductive Toxicology

12/19/2002
Date

Study Number: WIL-186028

PROTOCOL AMENDMENT II

Sponsor: American Chemistry Council
Ethylbenzene Panel

A. Title of Study:

A Pilot Inhalation Study for Reproductive Toxicity and Developmental Neurotoxicity Studies of Ethylbenzene in Rats

B. Protocol Modifications:

1) **IV. Test Article Data:**

F. Storage Conditions:

Bulk material will be stored under refrigerated conditions.

C. Reasons for Protocol Modification:

1) To change the storage conditions due to the low flash point of the test article.

Approved By:

American Chemistry Council

Elizabeth J. Moran, Ph.D., D.A.B.T. — 11/23/02 Date
Sponsor Representative

Prepared By:

WIL Research Laboratories, Inc.

Donald G. Stump, Ph.D., D.A.B.T. — 11/14/02 Date
Study Director

Mark D. Nemec, B.S., D.A.B.T. — 12/5/2002 Date
Director, Developmental and
Reproductive Toxicology

Study Number: WIL-186028

PROTOCOL AMENDMENT I

Sponsor: American Chemistry Council
Ethylbenzene Panel

A. Title of Study:

A Pilot Inhalation Study for Reproductive Toxicity and Developmental Neurotoxicity Studies of Ethylbenzene in Rats

B. Protocol Modifications:

1) **II. Personnel Involved in the Study:**

A. Sponsor's Representative:

Elizabeth J. Moran, Ph.D., D.A.B.T.
American Chemistry Council
Manager, Ethylbenzene Panel

VII. Experimental Design:

I. Organization of Test Groups, Dosage Levels and Treatment Regimen:

2) **1. Organization of Test Groups:**

The following table presents the study group arrangement:

Group Number	Test Article	Inhalation Exposure Level (ppm)	Gavage Dose Level[a] (mg/kg/day)	Gavage Dose Concentration (mg/mL)	Number of Males	Number of Females	
						Inhalation Only	Inhalation and Gavage
1	Control	0	0	0	20	10	10
2	Ethylbenzene	100	90	30	20	10	10
3	Ethylbenzene	500	342	114	20	10	10
4	Ethylbenzene	1000	621	207	20	10	10

[a] - The daily gavage dose will be divided into three equal doses administered at approximately two-hour intervals.

3) **2. Treatment Regimen:**

b. Inhalation and Gavage Females:

The following is added to the protocol.

On LD 1-4, inclusive, the dams will receive the test article or vehicle control by gavage three times per day at approximately two-hour intervals with a dose volume of 1 mL/kg/dose. The vehicle will be corn oil.

4) **M. General Observations During the Experimental Period:**

4. Examination of Offspring:

a. Nonexposure Period Appearance and Behavior:

The following change is made to the protocol.

All significant clinical observations noted for pups on PND 0 will be recorded. However, a detailed physical examination will not be recorded for each pup on PND 0.

C. Reasons for Protocol Modifications:

1) The Sponsor has assigned a new Sponsor Representative.

2) Gavage dose levels have been added to the protocol.

3) The dosing regimen and vehicle for the gavage phase of the study have been added to the protocol.

4) According to the protocol, the day of parturition is designated as day 0 of lactation (PND 0). Because of this definition and the length of the parturition process, it is possible that some pups will not be available for a detailed physical on PND 0. Therefore, the protocol has been revised to state that any significant pup observations will be recorded on PND 0 but detailed physical examinations will not be recorded for each pup on PND 0.

Approved By:

American Chemistry Council

Elizabeth J. Moran, Ph.D., D.A.B.T.
Sponsor Representative

10/31/02
Date

Prepared By:

WIL Research Laboratories, Inc.

Donald G. Stump, Ph.D., D.A.B.T.
Study Director

10/21/02
Date

Mark D. Nemec, B.S., D.A.B.T.
Director, Developmental
and Reproductive Toxicology

10/21/2002
Date

① correction of page ② ~~pagenumber~~ DDS 11/12/02
② spelling correction DDS 11/12/02

PROTOCOL

A PILOT INHALATION STUDY FOR REPRODUCTIVE TOXICITY AND DEVELOPMENTAL NEUROTOXICITY STUDIES OF ETHYLBENZENE IN RATS

Submitted To:

American Chemistry Council
Ethylbenzene Panel
1300 Wilson Boulevard
Arlington, VA 22209

WIL Research Laboratories, Inc.
1407 George Road
Ashland, OH 44805-9281

I. Objective: To determine the atmospheric concentrations of ethylbenzene that will generate minimal maternal and weanling toxicity but allow complete gestation, parturition and successful lactation.

This study is not subject to the applicable regulations of the United States Environmental Protection Agency (EPA) Health Effects Test Guidelines OPPTS 870.3800, EPA-C-98-239, August 1998 as it is a pilot (dose range-finding) study designed for setting appropriate exposure concentrations for additional studies.

II. Personnel Involved in the Study:

A. Sponsor's Representative:

Patricia A. Messenger, American Chemistry Council
Manager, CHEMSTAR Ethylbenzene Panel

B. Sponsor's Study Monitors:

Stephen S. Dimond, B.S., General Electric Company
Toxicologist

Judy Buelke-Sam, M.A., Toxicology Services
Toxicology Consultant

C. WIL Study Director:

Donald G. Stump, Ph.D., D.A.B.T.
Associate Director, Developmental
and Reproductive Toxicology
Telephone: (419) 289-8700
Fax: (419) 289-3650
Email: dstump@wilresearch.com

D. WIL Deputy Directors:

Bennett J. Varsho, B.S., L.A.T.G.
Staff Toxicologist, Developmental
and Reproductive Toxicology

Daniel T. Kirkpatrick, Ph.D., D.A.B.T.
Director, Inhalation Toxicology

III. Study Schedule:

Proposed Animal Receipt Date:	August 20, 2002
Proposed Experimental Start Date:	September 6, 2002
Proposed Experimental Termination Date:	December 1, 2002
Proposed Audited Report Date:	March 21, 2003

IV. Test Article Data:

A. Identification: Ethylbenzene: CAS Number 100-41-4

B. Lot Number: C2A0E01423

C. Purity: 99.903%. A 1-L aliquot of the test article will be collected and sent to the following address for characterization:

Michelle Gilles
The Dow Chemical Company
Toxicology Environmental Research and Consulting (TERC)
Building 1803
Midland, MI 48674
Phone: (989) 636-7784

D. Stability: The test article is considered to be stable under the storage conditions provided by the Sponsor.

E. Physical Description: To be documented by WIL Research Laboratories, Inc.

F. Storage Conditions: Bulk material will be stored at room temperature.

G. Reserve Samples: Reserve samples of each lot of the test article will be taken in accordance with WIL standard operating procedures and stored refrigerated in the Archives at WIL Research Laboratories, Inc. indefinitely, unless otherwise specified.

H. Personnel Safety Data: A material safety data sheet (MSDS) has been supplied by the Sponsor to WIL Research Laboratories, Inc.

V. Test System:

A. Species: Rat

B. Strain: Sprague-Dawley Crl:CD®(SD)IGS BR

C. Source: Charles River Laboratories, Inc.
Raleigh, North Carolina

D. Number of Animals: At randomization: 80 Males and 80 Females (maximum of 95 of each sex purchased). Animals not assigned to the study will be transferred to the stock animal colony or euthanized by carbon dioxide inhalation and discarded.

E. Body Weight Range: At start of in-life: Males 350-550 g
Females 220-300g

F. Approximate Age: At start of in-life phase: 11-12 weeks.

G. Identification System: The F_0 animals will be uniquely identified by a Monel® metal eartag displaying the animal number. Individual cage cards will be affixed to each cage and will display the animal number, group number, study number, dosage level and sex of the animal. All pups will be individually identified at the completion of parturition by application of tattoo markings to the digits. All weaning offspring will be identified by a Monel®metal eartag.

H. Justification for Selection: This species and strain of animal is recognized as appropriate for reproduction studies. WIL Research Laboratories, Inc. has reproductive historical control data in this species and strain of rat. This animal model has been proven to be susceptible to the effects of reproductive toxicants.

VI. Specific Maintenance Schedule (Non-Exposure Period):

A. Animal Housing:

F_0 animals will be housed 1 per cage, in clean suspended wire-mesh cages in an environmentally controlled room during quarantine and continuing until mating. The cages will be elevated above cage-board or other suitable material, which will be changed at least three times each week. During cohabitation, the females will be paired (1 male:1 female) with a male from the same exposure group in a suspended wire-mesh cage. Following successful mating, the females will be housed individually in a plastic maternity cage containing ground corncob nesting material (Bed-O'Cobs®, The Andersons, Inc.) and will remain in these cages until euthanasia. After weaning, F_1 offspring exposed to the test article on postnatal days (PND) 22-33 or 29-33 will be group housed with their litter mate in plastic cages with nesting material through termination. When housed with nesting material, clean material will be provided at least twice per week, clean cages will be provided each week. The facilities at WIL Research Laboratories, Inc. are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

B. Environmental Conditions:

Controls will be set to maintain an average daily temperature of 71 ± 5°F (22 ± 3°C) and an average daily relative humidity of 50 ± 20%. Temperature and relative humidity will be monitored continuously. Data for these two parameters will be scheduled for automatic collection on an hourly basis. Fluorescent lighting controlled by light timers will provide illumination for a 12-hour light/dark photoperiod. Temporary adjustments to the light/dark cycles may be made to accommodate protocol-specified activities. The ventilation rate will be set at a minimum of 10 room air changes per hour, 100% fresh air.

C. Drinking Water:

Reverse osmosis purified water will be available *ad libitum* during the study except during test article exposure. Filters servicing the automatic watering system are changed regularly according to WIL standard operating procedures. The municipal water supplying the laboratory is analyzed according to WIL standard operating procedures on a routine basis to assure that contaminants are not present in concentrations that would be expected to affect the outcome of the study.

D. Basal Diet:

PMI Nutrition International, Inc. Certified Rodent LabDiet® 5002 will be offered *ad libitum* during the study except during test article exposure. Periodic analyses of the certified feed are performed by the manufacturer to ensure that heavy metals and pesticides are not present at concentrations that would be expected to affect the outcome of the study. Results of the analyses are provided to WIL Research Laboratories, Inc. by the manufacturer. Feeders will be changed and sanitized once per week.

VII. Experimental Design:

A. Animal Receipt and Quarantine:

Each animal will be inspected by a qualified technician upon receipt. Rats judged to be in good health and suitable as test animals will be immediately placed in quarantine for a minimum of 10 days and animals judged to be unacceptable will be euthanized by carbon dioxide asphyxiation and discarded. All rats will be initially weighed and permanently identified with a metal eartag. During the quarantine period, each rat will be observed twice daily for changes in general appearance and behavior. If the shipment contains excess unsatisfactory animals a new batch of animals will be obtained. Prior to the start of the in-life phase, those animals judged to be suitable test subjects will be identified.

B. Randomization:

At the conclusion of the quarantine period, rats judged to be suitable test subjects and meeting acceptable body weight requirements will be assigned to groups using a computer program which assigns animals based on body weight stratification. At this time, the animal numbers and corresponding body weights will be entered into the WIL Toxicology Data Management System (WTDMS™). A printout containing the animal numbers and individual group assignments will be generated based on body weight stratification into a block design. Animals will then be arranged into the groups according to the printout. The F_0 control group and three test article groups will consist of 20 males and 20 females each. Ten females in each group will be assigned to the Inhalation Only Phase, and the remaining 10 females in each group will be assigned to the Inhalation and Gavage Phase.

C. Route and Rationale of Test Article Administration:

The route of administration will be whole body inhalation exposure as this would be a likely route of human exposure. One-half the females in each treatment group will be dosed by gavage on lactation days 1-4. This will be done because significant neurological development occurs in pups during this time period, when females typically are not removed from the pups in inhalation studies due to concerns for the effect of such stress on the pups.

D. Inhalation Exposure Methods:

Exposures will be conducted in four 2 m^3 stainless steel and glass exposure chambers. Three chambers will be dedicated for the test article exposure groups, while the fourth chamber will be dedicated for the control group. The chambers will be operated under dynamic conditions, at a slight negative pressure (ca 0.5 in of water) with at least 12 air changes per hour. Oxygen content of the exposure atmosphere will be at least 19% and will be documented during the pre-study methods development phase and approximately monthly during the exposure phase. Temperature and relative humidity during exposures will be measured at approximately 35-minute intervals for each chamber and the daily average will be between 18°C and 26°C, and 30% to 70%, respectively.

All animals will be housed in normal animal colony rooms during non-exposure hours. For each day's exposure, the animals will be transferred to exposure caging, transported to the exposure chamber room, exposed for the requisite duration and returned to their home cages. Exposure cage batteries will consist of 24 individual compartments with dimensions of 11x3.8x8 inches (LxWxH). This compartment size is acceptable for the 6-hour exposure period.

Animal exposure cage batteries will be rotated through the six possible chamber locations on a daily basis. Individual animals will be placed in the same cage battery compartment for all exposures.

E. Generation of Inhalation Exposure Atmospheres:

Appropriate equipment and procedures for generation of ethylbenzene vapor test atmospheres at the required concentrations will be determined during pre-study method development. At maximum, five days of pre-exposure chamber validation data will be collected prior to initiation of animal exposure. Although generation of the required concentrations of ethylbenzene vapor may require heating of liquid ethylbenzene, the lowest suitable temperature will be used. Regardless of the vaporization method selected, test

atmospheres will be evaluated for the presence of aerosols (during method development).

If appropriate for ethylbenzene, vapors will be generated using a glass-bead column-type vaporization system. Test article and nitrogen carrier gas are metered to the column with nitrogen entering below the glass beads while the test article is deposited on the beads. The beads may be heated using a heat tape wrapped around the bead column. An electric-controller and a thermocouple (positioned inside the bead column) will be used to provide a stable temperature and avoid overheating. Vaporization occurs as the test article flows down over the beads and nitrogen moves up through the beads. The concentrated vapors are piped to the chamber inlet where the concentration is reduced by mixing with chamber ventilation air. Tubing and/or pipes between the vaporization column and the chamber inlet may also be minimally heated to avoid condensation of the vapor.

F. Characterization of Exposure Atmospheres:

1. Nominal Exposure Concentrations:

Nominal exposure concentrations will be calculated for each day's exposure using the following formula:

$$\text{ppm Ethylbenzene} = \frac{\text{Wt.} \bullet \text{Mol. Vol.} \bullet 10^6}{\text{MW} \bullet \text{Ch. Flow} \bullet \text{Exp. Dur.}}$$

Where:

Wt. Ethylbenzene =	the weight of ethylbenzene used during a given day's exposure, grams
Mol. Vol. =	Molar volume at 730 mm Hg and 21°C, 25.11 L/mole
10^6 =	ppm conversion factor
MW =	Ethylbenzene molecular weight, 106 g/mole
Ch. Flow =	Daily average chamber flowrate for a given day, in L/min
Exp. Dur. =	Duration of a given day's exposure, in minutes

2. Analyzed Exposure Concentrations:

Actual concentrations of the test article in the exposure atmospheres will be determined at least 10 times each exposure day for each chamber by gas chromatography.

The analytical instrument will be under the control of a LabVIEW® data acquisition virtual instrument device (DAVID) such that all chamber concentration data will be collected automatically. Measurements of ethylbenzene concentration will commence after the t_{90} start-up period. At each sampling, chamber temperature, relative humidity, negative pressure and airflow will be recorded. Daily results will show the mean analyzed concentration ± standard deviation and the calculated nominal concentration.

3. Concentration Specifications:

Daily mean analyzed concentrations of ethylbenzene will be maintained within ± 10% of the target concentrations. During any given day, chamber concentration should vary by no more than 15%. Adjustments to the generating system will be made based on analyzed concentrations, not nominal concentrations. Circumstances beyond the control of the laboratory which prevent the satisfactory completion of exposure on a specific day will be brought to the attention of the sponsor immediately for a decision on its impact on the successful completion of the study.

4. Evaluation of Homogeneity of Exposure Atmospheres:

Evaluation of the homogeneity of exposure concentrations will be accomplished during the methods development phase of the study prior to animal exposures. Four test locations and a reference location will be used for these determinations. The test locations will be Right Upper Rear, Left Lower Rear, Right Lower Front, Left Upper Front, identified as 1, 2, 3 and 4, respectively. Samples will be collected as rapidly as possible in the following order: reference location, test location 1, reference location, test location 2, reference location, test location 3, reference location and test location 4. For each test location, the measured concentration will be calculated as a percent difference from the reference location. The homogeneity determination will be performed in triplicate for each test article exposure chamber. The spatial homogeneity for a chamber will be considered acceptable if the mean percent from reference (for triplicate determinations) for each test location is ≤ 10%.

G. Test Article Preparation for Gavage:

1. Method and Frequency of Preparation:

Based on the physical characteristics of the test article, appropriate methods will be used to ensure the best possible formulations of the test article in the vehicle. Dosing formulations will be stored at room

temperature for a period not to exceed one week in duration. The study director, deputy director or designee will visually inspect the formulations prior to initiation of dosing. This visual inspection will be performed to assure that the formulations are visibly homogeneous and acceptable for dosing. If any special procedures are required for formulation, these procedures will be documented according to Good Laboratory Practices and presented in the final report of this study. The dosing formulations will be aliquoted into appropriate volumes for daily dosing and chemical analyses.

2. **Homogeneity and Stability of Test Article Formulations:**

Homogeneity in bulk preparations and aliquots will be established on the first preparation. Representative batches of dosing formulations at each dosage level will be prepared. One 10-ml sample from the control formulation and one 10-ml sample from the top, middle and bottom of each of the test article formulations will be withdrawn. These samples will be analyzed to confirm homogeneity of the test article formulations. The aliquots dispensed for homogeneity will be representative of the size of aliquots dispensed for daily dosing procedures, and will include resuspension analyses over the longest period of aliquot storage (10 days). One 10-ml sample from the control formulation and one 10-ml sample from the top and bottom strata will be withdrawn from the aliquots dispensed for the first day of administration and for the tenth day after formulation to confirm stability and resuspension homogeneity of test article formulations. Samples collected from the bulk preparation and the aliquot dispensed for the first day of dose administration will be analyzed on the day collected.

3. **Concentration Analysis:**

One 10-ml sample will be taken from the middle of each dosing formulation prepared during the in-life phase of the study. These samples will be analyzed to verify the concentration of the test article in the dosing formulations.

H. Test Article Characterization:

1. **Purity Analysis:**

A 5-mL sample of the test article will be collected from each test article container prior to initial use. The samples will be analyzed by gas chromatography to determine purity of the test article. Purity will be expressed as area percent of ethylbenzene.

2. Stability Analysis:

The same procedure used for the purity analysis will be followed for the stability analysis except the samples will be collected at the end of use of each drum. The resulting concentrations will be compared to the time zero values.

I. Organization of Test Groups, Dosage Levels and Treatment Regimen:

1. Organization of Test Groups:

The exposure levels were determined from the results of previous studies and were provided by the Sponsor Representative. The following table presents the study group arrangement.

Group Number	Test Article	Inhalation Exposure Level (ppm)	Gavage Dose Level (mg/kg/day)	Gavage Dose Concentration (mg/mL)	Number of Males	Number of Females	
						Inhalation Only	Inhalation and Gavage
1	Control	0	0	0	20	10	10
2	Ethylbenzene	100	a	a	20	10	10
3	Ethylbenzene	500	a	a	20	10	10
4	Ethylbenzene	1000	a	a	20	10	10

a = To be added by protocol amendment.

2. Treatment Regimen:

The test article will be administered daily for six hours by whole-body vapor inhalation. All animals will be exposed at approximately the same time each day. Exposures will be conducted seven days per week. Oral gavage exposures will be administered on lactation days 1-4, inclusive. Males will be exposed for a minimum of 4 weeks. Females will be exposed 2 weeks premating, during mating and gestation. At this time, the females will be divided into 2 subgroups to be utilized per the following subsections entitled VII.I.2.a. and VII.I.2.b.

a. Inhalation Only Females:

The dams will be exposed prior to mating, during mating and gestation through gestation day (GD) 20 and on lactation days (LD) 5-27. During lactation, the dams will be removed from their litters during the daily 6-hour exposure period. To avoid confounding effects on nesting and nursing behavior, exposure for the F_0 dams will be suspended on GD 21 through LD 4 inclusive; exposures will be

re-initiated on LD 5 and continue through LD 27. Females that do not deliver will be exposed until one day prior to euthanasia.

b. Inhalation and Gavage Females:

During the inhalation period (prior to mating, during mating, GD 0-20 and LD 5-27), dams will be exposed as described above in section VII.I.2.a. Dams will not be exposed on the day of parturition because initiation of gavage dosing on GD 21 or GD 22 (either of which could be the day of delivery) was judged to be too stressful on the dams; therefore, initiation of gavage dosing will start on LD 1. On LD 1-4, inclusive, the dams will receive the test article or vehicle control by gavage. The vehicle identification will be added by protocol amendment.

The gavage dose levels and number of doses administered per day will be chosen based on physiologic based pharmacokinetic (PBPK) modeling.

c. F_1 Generation (F_0 offspring):

The F_1 generation will potentially be exposed to the test article *in utero*, and through nursing during lactation. The pups will remain with their dams through weaning on postnatal (PND) 28, with the exception a subgroup of one male and one female from each litter, which will be weaned on PND 21. The day following weaning (on PND 21 and PND 28), one male and one female pup per litter from each of the weaning date cohorts will be directly exposed to the same concentration of the test article as their dam through PND 33. The offspring will be randomly selected for either postweaning exposure regimen. Direct inhalation exposure periods for the selected pups will be either PND 22-33 or PND 29-33.

J. Breeding Procedures:

Following a minimum of two weeks of exposure, one treated female will be cohabitated with one treated male from the same exposure group, during non-exposure hours. Detection of mating will be confirmed by evidence of sperm in the vaginal smear or by the appearance of a vaginal copulatory plug. After confirmation of mating, the female will be returned to an individual suspended plastic cage containing nesting material (Bed-O'Cobs®) and the day designated as gestation day 0.

A maximum of 14 days will be allowed for mating. If no evidence of copulation is obtained after 14 days, the animals will be separated without further opportunity for mating. The females will be placed in a plastic cage containing nesting material (Bed-O'Cobs®) and remain in these cages until euthanasia.

K. F_0 Parturition and Lactation and F_1 Litters:

Gestation day 20 will be the last day of inhalation exposure prior to delivery. One-half of the dams in each group will be exposed to the test article on LD1-4 by gavage, while the other half will not be exposed until inhalation exposures resume on LD 5. The day parturition is initiated will be designated as day 0 of lactation. Any difficulties at the time of parturition will be recorded. When parturition is judged complete, litters will be sexed, examined for gross malformations and the number of stillbirths and live pups will be recorded. Any changes or abnormalities in nesting and nursing behavior will be recorded. The dam and litter will remain together until weaning on LD 28, except that one pup per sex per litter will be weaned on LD 21.

L. Reduction of F_1 Litter Size and Identification:

Upon completion of delivery, all pups will be individually identified by tattoo markings applied to the digits. To reduce variability among the litters, ten pups from each litter will be randomly selected of equal sex distribution on lactation day 4 (4:6; 5:5; 6:4; male:female, as necessary). The remaining pups will be weighed, euthanized by intraperitoneal injection of sodium pentobarbital, and discarded on PND 4.

M. General Observations During the Experimental Period:

1. Parental Appearance and Behavior:

The parental rats will be observed twice daily at least 7 hours apart for moribundity, mortality, appearance, behavior and pharmacotoxic signs (prior to exposure and within approximately one hour after completion of exposure). During exposure, animals that are visible through the chamber windows will be observed for appearance and behavior. A detailed physical examination will be conducted weekly. The observations shall include, but are not limited to, evaluation for changes in appearance of skin and fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system function, somatomotor activity and behavior patterns. Special attention will be paid to the degree of salivation and lacrimation, presence or absence of urination and defecation (including

polyuria and diarrhea), pupil size, degree of palpebral closure, presence of convulsions, tremors or abnormal movements, presence of posture and gait abnormalities, the presence of any unusual or abnormal behaviors and any repetitive actions (stereotypies). During the period of expected parturition, the dams will be observed twice daily for dystocia, prolonged labor, delayed labor or other difficulties at parturition. Animals not expected to survive to the next observation period (moribund) will be euthanized and subject to a gross necropsy.

2. **Parental Body Weights:**

   a. **Males:**

   Recorded prior to treatment on the first day of exposure, weekly thereafter and at termination prior to euthanasia.

   b. **Females:**

   Recorded prior to treatment on the first day of exposure and weekly thereafter until GD 0. Body weights will also be recorded on GD 0, 3, 6, 9, 12, 15, 18 and 20 on LD 1, 4, 5 (pre-exposure), 7, 14, 21 and 28.

3. **Parental Food Consumption:**

   Food consumption will be recorded on the same days as body weights are recorded. Individual food consumption measurement will be suspended during periods of mating as the animals are cohabitated at that time.

4. **Examination of Offspring:**

   a. **Non-Exposure Period Appearance and Behavior:**

   All pups will be observed daily for general appearance, behavior and survival during lactation. A detailed physical examination will be recorded for each pup on PND 0, 1, 4, 7, 14, 21 and 28. Any abnormalities in nesting and nursing behavior will be recorded. The pups will be sexed on PND 0, 4, 7, 14, 21 and 28.

   b. **Exposure Period Appearance and Behavior:**

   The offspring will be observed twice daily at least 7 hours apart for moribundity, mortality, appearance, behavior and pharmacotoxic signs (prior to exposure and within approximately one hour after completion of exposure). During exposure, animals that are visible through he

chamber windows will be observed for appearance and behavior. A detailed physical examination will be conducted weekly. The observations shall include, but are not limited to, evaluation for changes in appearance of skin and fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system function, somatomotor activity and behavior patterns. Special attention will be paid to the degree of salivation and lacrimation, presence or absence of urination and defecation (including polyuria and diarrhea), pupil size, degree of palpebral closure, presence of convulsions, tremors or abnormal movements, presence of posture and gait abnormalities, the presence of any unusual or abnormal behaviors and any repetitive actions (stereotypies). Animals not expected to survive to the next observation period (moribund) will be euthanized and subject to a gross necropsy.

c. Body Weights:

Each pup will be weighed on PND 1, 4, 7, 14, 21 and 28. Pups exposed to the test article by inhalation will be weighed daily during the exposure periods (PND 22-33 and PND 29-33). Body weights will be recorded on the day of euthanasia following the exposure periods (PND 34).

N. Euthanasia of F_0 Generation:

1. Males:

The F_0 males will be euthanized by carbon dioxide inhalation following completion of the mating period and subjected to a gross necropsy as described in Section VIII. No organs/tissues will be preserved.

2. Females:

a. Females Which Deliver:

On lactation day 28 the F_0 females that delivered will be euthanized by carbon dioxide inhalation. The abdominal and thoracic cavities will be opened and the contents examined. The number of former implantation sites will be recorded. The carcass of each dam will be discarded. Necropsy procedures are further described in Section VIII.

b. Females Which Fail to Deliver:

On post-mating day 25 or post-cohabitation day 25, the F_0 females which have not delivered will be euthanized by carbon dioxide inhalation. The abdominal and thoracic cavities of the dams will be opened and the contents examined. Nongravid uteri will be opened and placed in 10% ammonium sulfide solution for detection of implantation sites as described by Salewski[1]. If evidence of macroscopic implantations are present, the number of implantation sites and corpora lutea will be recorded. The carcass of each dam will be discarded. No organs/tissues will be preserved.

c. Females with Total Litter Loss:

Females with total litter loss will be euthanized by carbon dioxide inhalation within 24 hours of litter loss. The abdominal and thoracic cavities will be opened and the contents examined. The number of former implantation sites will be recorded. The carcass of each dam will be discarded. No organs/tissues will be preserved.

3. F_0 Deaths and Animals Euthanized *in Extremis*:

Animals not surviving until the scheduled euthanasia will be subjected to a complete necropsy and the cause of death recorded, if possible. Animals not expected to survive to the next observation period (moribund) will be euthanized by carbon dioxide inhalation and subjected to a gross necropsy as described in Section VIII. The carcass of each dam will be discarded. No organs/tissues will be preserved.

In addition, for females dying and euthanized during gestation, the number and location of implantation sites or scars will be recorded. Corpora lutea will be counted and recorded. Recognizable fetuses will be examined externally and discarded.

O. Euthanasia of F_1 Generation:

1. Pup Deaths:

a. Pups 0-4 Days of Age:

Stillborn pups and pups dying between birth and PND 4 will be dissected (including the heart and the brain examined by a mid-coronal slice) by a technique described by Stuckhardt and Poppe.[2] The carcasses will be discarded.

b. Pups 5 Days of Age to Weaning:

A gross necropsy will be performed and the carcasses discarded.

2. Pups Euthanized *in Extremis*:

Moribund pups will be euthanized by intraperitoneal injection of sodium pentobarbital (PND 0-10) or by carbon dioxide inhalation (PND 11-34) and necropsied as described above.

3. Terminal Procedures for F_1 Pups:

Pups will be euthanized by carbon dioxide inhalation. Pups exposed to the test article on PND 22-33 or PND 29-33 will be euthanized on PND 34 and receive a gross external exam prior to being discarded. All other remaining pups will be euthanized on PND 28 and will receive a gross external exam prior to being discarded. Pups that were exposed by inhalation during the postweaning period that die or are euthanized in extremis will undergo a necropsy procedure described in Section VIII.

VIII. Anatomic Pathology:

A. Macroscopic Examination:

A complete necropsy will be conducted on all F_0 animals dying spontaneously, euthanized *in extremis* or at termination. In addition, all F_1 animals (that receive an direct postweaning inhalation exposure) dying spontaneously or euthanized *in extremis* will also receive a complete necropsy. This will include examination of the external surface, all orifices, the cranial cavity, the external surface of the brain and spinal cord, the thoracic, abdominal and pelvic cavities including viscera and lymph nodes, thyroid glands and mammary glands.

B. Organ Weights:

The following organs from all F_0 males and females euthanized at scheduled termination will be weighed:

Kidneys Liver

Organ-to-body-weight ratios will be calculated.

IX. Duration of Study:

The conduct of this study will require approximately four months for acclimation, pre-mating, mating, gestation, and lactation of the F_0 generation and growth of the F_1 generation until euthanasia.

X. Statistical Methods:

All analyses will be two-tailed for a minimum significance level of 5% and performed separately by sex. All means will be presented with standard deviations. All statistical tests will be performed by a computer with appropriate programming as referenced below. The litter, rather than the pup, will be considered as the experimental unit.

Continuous data variables (mean body weights, body weight gains and food consumption at each interval), gestation length, number of pups born, live litter size and organ weights will be analyzed for heterogeneity of variance[3] and normality.[4] If the data are homogeneous and normal, a parametric one-way analysis of variance (ANOVA)[5] will be used to determine intergroup difference. If the results of the ANOVA are significant ($p<0.05$), Dunnett's test[6] will be applied to the data to compare the treated groups to the control group. If the data are not homogeneous and normal, a Kruskal-Wallis nonparametric ANOVA[7] will be used to determine intergroup difference. If the results of the ANOVA are significant ($p<0.05$), the Mann-Whitney U-Test[7] will be applied to the data to compare the treated groups to the control group. Data generated during gestation will be analyzed combined (N = 20/group). Parental mating and fertility indices of the treated groups will be compared to the control group using the Chi-square test with Yates' correction factor.[8]

Pup weights will be analyzed by a nested analysis of covariance (pup weight nested within dams nested within groups with litter size as covariant).[9] Male and female pup weights will be analyzed separately.

Sex ratios at birth (% males per litter) and postnatal survival will be analyzed by Kruskal-Wallis[7] test to determine intergroup difference. If the results of the ANOVA are significant, the Mann-Whitney U Test[7] will be applied to the data to compare the treated groups to the control group.

XI. Quality Assurance:

The study will be audited by the WIL Quality Assurance Unit while in progress to assure compliance with the study protocol and protocol amendments, WIL standard operating procedures and the appropriate provisions of EPA TSCA Good Laboratory Practice Standards published in the Federal Register (40 CFR Part

792), the OECD Good Laboratory Practice Regulations, November 26, 1997 [C(97) 186/Final] and the Japanese Ministry of International Trade and Industry Directive 31, March 1984, Kanpogyo No. 39 Environmental Agency, Kikoyoko No 85 (MITI). The raw data and draft report will be audited by the WIL Quality Assurance Unit prior to submission to the Sponsor Representative to assure that the final report accurately describes the conduct and the findings of the study.

This study will be included on the WIL master list of regulated studies.

XII. Records to be Maintained:

All original raw data records, as defined by WIL SOPs and the applicable GLPs, will be stored as described in Section XIII. in the Archives at WIL Research Laboratories, Inc.

XIII. Work Product:

The Sponsor will have title to all documentation records, raw data, slides, specimens and other work product generated during the performance of the study. All work product, including raw paper data, pertinent electronic storage media and specimens, will be retained for a period of ten years following issuance of the final report in the Archives at WIL Research Laboratories, Inc. Thereafter, WIL Research Laboratories, Inc. will charge a monthly archiving fee for retention of all work product. All work product will be stored in compliance with regulatory requirements.

Any work product, including documents, specimens, and samples, that are required by this protocol, its amendments, or other written instructions of the Sponsor, to be shipped by WIL Research Laboratories, Inc. to another location will be appropriately packaged and labeled as defined by WIL's SOPs and delivered to a common carrier for shipment. WIL Research Laboratories, Inc. will not be responsible for shipment following delivery to the common carrier.

XIV. Reports:

The final report will contain a summary, test article data, methods and procedures, maternal and pup data and an interpretation and discussion of the study results. The final report will be comprehensive and shall define level(s) inducing toxic effects as well as no-effect level(s) under the conditions of this investigation.

WIL Research Laboratories will provide two hard copies and an electronic copy (Adobe® Acrobat.pdf type file) of an Audited Draft Report, submitted in a timely manner upon completion of the study prior to issuance of the final report. One revision will be permitted as part of the cost of the study, from which the

Sponsor's revisions and suggestions will be incorporated into the Final Report, as appropriate. Additional changes or revisions may be made, at extra cost. It is expected that the Sponsor will review the draft report and provide comments to WIL within a two-month time frame following submission. WIL will submit the Final Report within one month following receipt of comments. Two hard copies of the Final Report (1 bound, 1 unbound) and an electronic copy (Adobe® .pdf type file) will be provided; requests for additional copies of the Final Report may result in additional charges.

Appendices:

A. WIL Historical Control Data [Charles River Crl:CD®(SD)IGS BR Rats]
B. Analytical Chemistry Report
C. Protocol and Protocol Amendments
D. Water, Diet and Nesting Material Analyses

XV. Animal Welfare Act Compliance:

This study will comply with all applicable sections of the Final Rules of the Animal Welfare Act regulations (9 CFR Parts 1, 2 and 3). The Sponsor should make particular note of the following:

- The Sponsor Representative's signature on this protocol documents for the Study Director the Sponsor's assurance that the study described in this protocol does not unnecessarily duplicate previous experiments.

- Whenever possible, procedures used in this study have been designed to avoid or minimize discomfort, distress or pain to animals. All methods are described in this study protocol or in written laboratory standard operating procedures.

- Animals that experience severe or chronic pain or distress that cannot be relieved will be painlessly euthanized as deemed appropriate by the veterinary staff and Study Director. The Sponsor will be advised by the Study Director of all circumstances which could lead to this action in as timely a manner as possible.

- Methods of euthanasia used during this study are in conformance with the above-referenced regulation.

XVI. Protocol Modification:

Modification of the protocol may be accomplished during the course of this investigation. However, no changes will be made in the study design without the verbal or written permission of the Sponsor. In the event that the Sponsor verbally requests or approves a change in the protocol, such changes will be made by appropriate documentation in the form of protocol amendment. All alterations of the protocol and reasons for the modification(s) will be signed by the Study Director and the Sponsor Representative.

XVII. References:

1. Salewski, E. (1964) Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. Naunyn - Schm. Archiv. für Exper. Pathologie und Pharm. 247:367.

2. Stuckhardt, J.L. and Poppe, S.M. (1984) Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratogenesis, Carcinogenesis and Mutagenesis 4:181-188.

3. Levene, H. (1960) Robust tests for equality of variances. In: Contributions to Probability and Statistics. Stanford University Press, Palo Alto, CA, pp. 278-292.

4. Royston, J.P. (1982) An extension of Shapiro and Wilk's W Test for normality to large samples. Applied Statistics 31:115-124.

5. Snedecor, G.W. and Cochran, W.G. (1980) One way classifications; analysis of variance. In: *Statistical Methods*, Seventh Edition. Iowa State University Press, Ames, IA, pp. 215-237.

6. Dunnett, C.W. (1964) New tables for multiple comparisons with a control. Biometrics 20:482-491.

7. Kruskal, W.H. and Wallis, W.A. (1952) Use of ranks in one-criterion variance analysis. Journal of the American Statistical Association. 47:583-621.

8. Hollander, M. and Wolfe, D.A. (1990) Nonparametric Statistical Methods, Second Edition. John Wiley and Sons, Inc., New York, NY, p.468.

9. SAS Institute, Inc. (1999) SAS/STAT® User's Guide, Version 8. SAS Institute, Inc., Cary, NC.

XVIII. Protocol Approval:

Sponsor approval received via NA on NA.
Date

American Chemistry Council (CHEMSTAR)

Patricia A. Messenger
Sponsor Representative

8/26/02
Date

WIL Research Laboratories, Inc.

Donald G. Stump, Ph.D., D.A.B.T.
Study Director

8/27/02
Date

Mark D. Nemec, B.S., D.A.B.T.
Director, Developmental and
Reproductive Toxicology

8/27/2002
Date